<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Mol Cancer</journal-id><journal-id journal-id-type="iso-abbrev">Mol Cancer</journal-id><journal-title-group><journal-title>Molecular Cancer</journal-title></journal-title-group><issn pub-type="epub">1476-4598</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC12093937</article-id><article-id pub-id-type="publisher-id">2289</article-id><article-id pub-id-type="doi">10.1186/s12943-025-02289-8</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Double-sided niche regulation in skin stem cell and cancer: mechanisms and clinical applications</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Pham</surname><given-names>Trang Thao Quoc</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Kuo</surname><given-names>Yung-Che</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Chang</surname><given-names>Wei-Ling</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Weng</surname><given-names>Hao-Jui</given-names></name><address><email>wenghaojui@tmu.edu.tw</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Huang</surname><given-names>Yen-Hua</given-names></name><address><email>rita1204@tmu.edu.tw</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff6">6</xref><xref ref-type="aff" rid="Aff7">7</xref><xref ref-type="aff" rid="Aff8">8</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05031qk94</institution-id><institution-id institution-id-type="GRID">grid.412896.0</institution-id><institution-id institution-id-type="ISNI">0000 0000 9337 0481</institution-id><institution>International Ph.D. Program in Cell Therapy and Regenerative Medicine, College of Medicine, </institution><institution>Taipei Medical University, </institution></institution-wrap>Taipei, 11031 Taiwan </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05031qk94</institution-id><institution-id institution-id-type="GRID">grid.412896.0</institution-id><institution-id institution-id-type="ISNI">0000 0000 9337 0481</institution-id><institution>TMU Research Center for Cell Therapy and Regeneration Medicine, </institution><institution>Taipei Medical University, </institution></institution-wrap>250 Wuxing Street, Taipei, 11031 Taiwan </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04k9dce70</institution-id><institution-id institution-id-type="GRID">grid.412955.e</institution-id><institution-id institution-id-type="ISNI">0000 0004 0419 7197</institution-id><institution>Department of Dermatology, </institution><institution>Taipei Medical University-Shuang Ho Hospital, </institution></institution-wrap>New Taipei City, 23561 Taiwan </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05031qk94</institution-id><institution-id institution-id-type="GRID">grid.412896.0</institution-id><institution-id institution-id-type="ISNI">0000 0000 9337 0481</institution-id><institution>Department of Dermatology, School of Medicine, College of Medicine, </institution><institution>Taipei Medical University, </institution></institution-wrap>Taipei, 11031 Taiwan </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05031qk94</institution-id><institution-id institution-id-type="GRID">grid.412896.0</institution-id><institution-id institution-id-type="ISNI">0000 0000 9337 0481</institution-id><institution>Graduate Institute of Clinical Medicine, College of Medicine, </institution><institution>Taipei Medical University, </institution></institution-wrap>Taipei, 11031 Taiwan </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05031qk94</institution-id><institution-id institution-id-type="GRID">grid.412896.0</institution-id><institution-id institution-id-type="ISNI">0000 0000 9337 0481</institution-id><institution>Department of Biochemistry and Molecular Cell Biology, School of Medicine, College of Medicine, </institution><institution>Taipei Medical University, </institution></institution-wrap>Taipei, 11031 Taiwan </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05031qk94</institution-id><institution-id institution-id-type="GRID">grid.412896.0</institution-id><institution-id institution-id-type="ISNI">0000 0000 9337 0481</institution-id><institution>Graduate Institute of Medical Sciences, College of Medicine, </institution><institution>Taipei Medical University, </institution></institution-wrap>Taipei, 11031 Taiwan </aff><aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03k0md330</institution-id><institution-id institution-id-type="GRID">grid.412897.1</institution-id><institution-id institution-id-type="ISNI">0000 0004 0639 0994</institution-id><institution>Center for Reproductive Medicine, </institution><institution>Taipei Medical University Hospital, Taipei Medical University, </institution></institution-wrap>Taipei, 11031 Taiwan </aff></contrib-group><pub-date pub-type="epub"><day>21</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>21</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>24</volume><elocation-id>147</elocation-id><history><date date-type="received"><day>19</day><month>12</month><year>2024</year></date><date date-type="accepted"><day>3</day><month>3</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><p id="Par12">The niche microenvironment plays a crucial role in regulating the fate of normal skin stem cells (SSCs) and cancer stem cells (CSCs). Therapeutically targeting the CSC niche holds promise as an effective strategy; however, the dual effects of shared SSC niche signaling in CSCs have contributed to the aggressive characteristics of tumors and poor survival rates in skin cancer patients. The lack of a clear underlying mechanism has significantly hindered drug development for effective treatment. This article explores recent advances in understanding how niche factors regulate cell fate determination between skin stem cells and skin CSCs, along with their clinical implications. The dual roles of key components of the adhesive niche, including the dermo-epidermal junction and adherens junction, various cell types&#x02014;especially immune cells and fibroblasts&#x02014;as well as major signaling pathways such as Sonic hedgehog (Shh), Wingless-related integration site (Wnt)/&#x003b2;-catenin, YAP (Yes-associated protein)/TAZ (transcriptional coactivator with PDZ-binding motif), and Notch, are highlighted. Additionally, recent advances in clinical trials and drug development targeting these pathways are discussed. Overall, this review provides valuable insights into the complex interactions between skin cancer stem cells and their microenvironment, laying the groundwork for future research and clinical strategies.</p></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Niche regulation</kwd><kwd>Skin stem cell</kwd><kwd>Cancer stem cell</kwd><kwd>Drug resistance</kwd><kwd>Shh/Wnt/YAP/Notch signaling</kwd><kwd>Therapeutic targeting</kwd><kwd>Clinical trial</kwd></kwd-group><funding-group><award-group><funding-source><institution>National Science and Technology Council, Taiwan</institution></funding-source><award-id>110-2314-B-038-028-MY3</award-id><award-id>111-2314-B-038-089-MY3</award-id><principal-award-recipient><name><surname>Weng</surname><given-names>Hao-Jui</given-names></name><name><surname>Huang</surname><given-names>Yen-Hua</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/100020595</institution-id><institution>National Science and Technology Council</institution></institution-wrap></funding-source><award-id>113-2314-B-038-136</award-id><principal-award-recipient><name><surname>Huang</surname><given-names>Yen-Hua</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; BioMed Central Ltd., part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par48">The epidermis is a mechanically responsive tissue that possesses continuous regenerative potential, serving as a dynamic barrier against environmental challenges [<xref ref-type="bibr" rid="CR1">1</xref>]. The integrity of the epidermis is sustained by the ongoing self-renewal of long-lived basal-layer skin stem cells (SSCs). Additionally, short-lived transient-amplifying cells (TACs), arising from the mitotic division of stem cells (SCs), detach from the basal layer and undergo terminal differentiation as they move toward the outermost surface. Maintaining a balanced epidermal development is crucial for preserving the protective barrier function and preventing excessive hyperproliferative disorders or skin neoplasms.</p><p id="Par49">The global incidence of skin cancer, including both cutaneous melanoma and nonmelanoma skin cancer (NMSCs), is on the rise [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>]. Among these, melanoma is the most lethal, accounting for approximately 75% of skin cancer-related deaths [<xref ref-type="bibr" rid="CR3">3</xref>] and ranked as the 22nd leading cause of cancer-related deaths worldwide, according to GLOBOCAN 2022 [<xref ref-type="bibr" rid="CR4">4</xref>]. Melanoma is characterized by a high tendency for metastasis, treatment resistance, and genetic instability. Late-stage melanoma patients exhibit a poor chemotherapy response, with the 5-year survival rate for stage IV melanoma at just 22.5% [<xref ref-type="bibr" rid="CR5">5</xref>]. In 2022, melanoma ranked as the 17th most common cancer worldwide, with approximately 331,722 new diagnoses and 58,667 fatalities [<xref ref-type="bibr" rid="CR6">6</xref>]. By 2040, the global incidence of melanoma is projected to increase by 50%, with new cases reaching 510,000 and deaths rising by 68% to 96,000, compared to 2020 [<xref ref-type="bibr" rid="CR7">7</xref>]. Notably, a significant proportion of melanoma cases (85.6%) and related deaths (67.2%) occurs in countries with a very high human development index [<xref ref-type="bibr" rid="CR7">7</xref>].</p><p id="Par50">Nonmelanoma skin cancers (NMSCs) primarily consist of two major types: basal cell carcinoma (BCC) and squamous cell carcinoma (SCC). BCC is the most common type, accounting for approximately 70% of cases, while SCC represents about 25% [<xref ref-type="bibr" rid="CR8">8</xref>]. NMSCs continue to be a significant public health concern, with data indicating that the incidence of BCC has increased by 20% to 80%, and SCC incidence has risen by 3% to 10% annually over the past 30&#x000a0;years [<xref ref-type="bibr" rid="CR9">9</xref>]. As of 2022, NMSCs accounted for 1,234,533 cancer cases and 69,416 fatalities, according to the GLOBOCAN report [<xref ref-type="bibr" rid="CR6">6</xref>]. Skin SCC is a highly aggressive form of NMSC that contributed to 56,000 deaths in 2019, according to a global survey [<xref ref-type="bibr" rid="CR2">2</xref>]. Invasive skin SCC can progress to advanced stages, with a dismal 10-year survival rate of less than 20% [<xref ref-type="bibr" rid="CR10">10</xref>]. In 2019, there were 2,402,221 global cases of cutaneous SCC, and the death rate increased by 6.1% between 1990 and 2019 [<xref ref-type="bibr" rid="CR11">11</xref>]. Projections for 2035 estimate an incidence of 3,637,626 cases, reflecting a 51.4% increase from 2019 [<xref ref-type="bibr" rid="CR11">11</xref>].</p><p id="Par51">The persistent self-renewal and expansion of cancer stem cells (CSCs) in aggressive skin cancer contribute to poor prognosis, significant treatment resistance, and advanced invasion, posing a major challenge in skin cancer treatment [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR13">13</xref>]. Research has shown that variations in chemoresistance and virulence of melanoma are attributed to the presence of CSCs in tumors, including CD133 (Cluster of differentiation 133) [<xref ref-type="bibr" rid="CR13">13</xref>], ABCB5 (ATP-binding cassette sub-family B member 5) [<xref ref-type="bibr" rid="CR14">14</xref>], ALDH (Aldehyde dehydrogenase) [<xref ref-type="bibr" rid="CR15">15</xref>], CD20 [<xref ref-type="bibr" rid="CR16">16</xref>], CD271 [<xref ref-type="bibr" rid="CR17">17</xref>], and SOX10 (SRY-Box transcription factor) [<xref ref-type="bibr" rid="CR18">18</xref>]. Subpopulations of cells exhibiting CSC properties in SCCs and BCCs are implicated in tumor initiation, progression, and resistance [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR20">20</xref>].</p><p id="Par52">The fate of both normal skin SSCs and CSCs is predominantly determined by the regulatory influence of the niche microenvironment [<xref ref-type="bibr" rid="CR21">21</xref>&#x02013;<xref ref-type="bibr" rid="CR23">23</xref>]. Notably, certain components of the SSC niche, including core signaling pathways, contribute to the formation and maintenance of the CSC niche. In the normal SSC niche, pathways such as Sonic Hedgehog (Shh), Wingless-related integration site (Wnt)/&#x003b2;-catenin, Notch, and YAP (Yes-associated protein)/TAZ (Transcriptional co-activator with PDZ-binding motif) are vital for maintaining the self-renewal and differentiation of SSCs within tissues [<xref ref-type="bibr" rid="CR24">24</xref>]. Regulated signaling, in conjunction with other niche components like the adhesion niche, dermal-epidermal interface, and cellular compartments, is essential for preserving SSC homeostasis by preventing uncontrolled proliferation and excessive differentiation [<xref ref-type="bibr" rid="CR24">24</xref>&#x02013;<xref ref-type="bibr" rid="CR26">26</xref>]. In contrast, signaling dysregulation, in collaboration with oncogenic pathways such as phosphoinositide 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) and Janus kinase (JAK)/ signal transducer and activator of transcription 3 (STAT3), characterizes the CSC niche, particularly in refractory skin cancers [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR27">27</xref>&#x02013;<xref ref-type="bibr" rid="CR29">29</xref>]. The aberrant activation of key signaling pathways or their specific components has been shown to sustain the CSC population and contribute to alternative mechanisms of cancer resistance. In addition to the intrinsic resistance developed by CSCs, these factors complicate the effective elimination of skin cancers.</p><p id="Par53">Patients with aggressive skin tumors often face a poor prognosis, marked by significant treatment resistance and advanced invasion. However, the development of effective therapies for these tumors remains challenging. Targeting the CSC niche offers a promising strategy, particularly for refractory skin cancers. This review provides an overview of the latest updates on the niche regulation of skin SSCs (Figs.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref> and&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>) and skin CSCs (Figs.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref> and&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>), focusing on the underlying mechanisms and current clinical trials that target CSC niche signaling for the treatment of skin cancers, including SCCs, BCCs, and melanoma (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref> and Tables <xref rid="Tab1" ref-type="table">1</xref> and <xref rid="Tab2" ref-type="table">2</xref>). The insights presented in this review will facilitate future research and advance clinical strategies, carrying significant implications for the treatment of skin cancer.<fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>The niche for normal and cancer skin stem cells. The illustration delineates the distinguishing characteristics between niche factors supporting normal SSC and skin CSC. The intricate and heterogeneous nature of the skin CSC niche is depicted through five primary features. <bold>1</bold>&#x000a0;Epidermal homeostasis is disrupted by the redistribution of integrins (&#x003b1;6&#x003b2;4 and &#x003b1;3&#x003b2;1), resulting in elevated suprabasal integrin levels, and dysregulated maturation of LM332, which presents as unprocessed LM332, remaining the LG4&#x02013;5 domain&#x000a0;and&#x000a0;full length of the &#x003b2;3 chain, or its subunit &#x003b3;2&#x000a0;fragments. The Notch signaling pathway can become dysfunctional, in which Notch is downregulated, leading to the release of its inhibitory effects on stem cell proliferation, thereby inducing skin tumorigenesis. However, Notch1 and its ligands, DLL1 and JAG1/2, are highly expressed in tumor cells during skin cancer metastasis. These opposing functions of Notch signaling may be associated with the ectopic presence of DLL1 in tumor cells, which are typically confined to the SSCs of the epidermal basal layer, and increased expression of JAG1/2. Additionally, alterations in the affinity of Notch1 receptor for its ligands could further contribute to this complexity. This may result from reduced LFNG expression, which reinforces DLL1-Notch cis-inhibition (<italic>indicated by the light grey arrow</italic>) and inhibits JAG-Notch cis-inhibition in the physiological SSC niche (<italic>indicated by the light grey line</italic>), in progressive tumors. <bold>2</bold>&#x000a0;Disruption of basement membrane integrity occurs through uncoupling of integrin from unprocessed LM332, breakdown of cadherin-mediated adhesion during EMT, and impairment of collagen IV, possibly induced by MMPs or miRNA-135b. Elevated MMP activity is sustained by CSCs, dysfunctional ECM proteins, and malignant cellular compartments, including CAFs, TAMs and TANs. The enhanced stiffness of the dermal matrix prompts the aberrant expression of integrins, which contribute to sustaining the stemness of CSCs. <bold>3</bold>&#x000a0;Factors secreted by CSCs and tumor-associated cells, particularly CAFs, TANs, and TAMs, include molecules like VEGF and MMPs, which promote angiogenesis. <bold>4</bold>&#x000a0;The continuous conversion of fibroblasts, monocytes, and neutrophils into CAFs, TAMs, and TANs, respectively, is imperative for maintaining the CSC niche. Concurrently, factors secreted by CSCs, fibrous ECM, and hypoxic conditions perpetuate the malignant traits of fibroblasts, macrophages, and neutrophils. Additionally, the transition from E-cadherin to N-cadherin in adherens junctions, driven by the increased expression of <italic>SNAIL</italic>, <italic>SLUG</italic>, <italic>TWIST1</italic>, <italic>ZEB1/2</italic>, <italic>SIP1</italic>, and <italic>TCF3</italic>, as well as secreted factors from CSCs or tumor-associated cells like TGF-&#x003b2;, promotes metastasis and facilitates the recruitment of CAFs into the CSC niche. <bold>5</bold>&#x000a0;The CSC niche sustains the survival of CSCs and tumor cells through multiple mechanisms. Cellular constituents within the CSC niche, including CAFs, TAMs, TANs, and Tregs, orchestrate an immunosuppressive TME, thereby inhibiting cytotoxic T cell function. Notably, soluble factors secreted by these immunosuppressive cells and CSCs, such as IL-10, CCL12, CXCR2 and IL-1&#x003b2;, promote Treg accumulation within the CSC niche and upregulate the expression of PD-1 and PD-L1 in both CSCs and tumor cells. CAFs can impair T cell function and increase T cell apoptosis by binding their FASL and PD-L1/2 to FAS and PD-1 receptors on T cells. CSCs further contribute to immune evasion by elevating PD-1 expression and downregulating MHC I/II expression&#x000a0;on their surfaces. Endothelial cells (ECs) not only facilitate angiogenesis to nourish the CSC niche but also promote skin cancer metastasis through interactions with adhesive proteins on CSCs. <italic>SC, Stem cell; TA, Transamplifying cell; KC, Keratinocytes; CSC-TA, Cancer stem cell-transamplifying cell; CA; Cancer cell;</italic>
<italic>SSC, skin stem cell; CSC, cancer stem cell; LM332, Laminin 332;&#x000a0;LG4-5, Laminin globular 4-5; DLL1, Delta-like ligand 1; JAG1/2, Jagged1/2; LFNG, Lunatic Fringe; EMT, Epithelial-mesenchymal transition; MMP, Matrix metalloproteinase, ECM, Extracellular matrix; CAF, Cancer-associated Fibroblast; TAMs, Tumor-associated Macrophage; TANs, Tumor-associated Neutrophil; VEGF, Vascular Endothelial Growth Factor; SNAIL, Snail Family Transcriptional Repressor 1; SLUG, Snail Family Transcriptional Repressor 2; TWIST1, Twist family bHLH transcription factor 1; ZEB1/2, Zinc finger E-box binding homeobox 1/2; SIP1, Smad interacting protein 1; TCF3, Transcription factor 3, EC, Endothelial cell; Treg, Regulatory T cells; FAS, Fas cell surface death receptor,; FASL, FAS ligand; MHC I, Major Histocompatibility Complex 1; PD-1, Programmed Cell Death Protein 1; PD-L1,&#x000a0;Programmed cell death ligand 1; IL-10, Interleukin 10;&#x000a0;CCL12, C&#x02013;C Motif Chemokine Ligand 12; CXCR2, C-X-C Motif Chemokine Receptor 2; VCAM, Vascular Cell Adhesion Molecule; E-cad, E-cadherin; N-cad, N-cadherin.</italic> Some figure components were created in BioRender. Pham, Q. (2025) <ext-link ext-link-type="uri" xlink:href="https://BioRender.com/z83f047">https://BioRender.com/z83f047</ext-link></p></caption><graphic xlink:href="12943_2025_2289_Fig1_HTML" id="MO1"/></fig><fig id="Fig2"><label>Fig.&#x000a0;2</label><caption><p>Core signaling pathways in skin stem cell niche. The schematic diagram emphasizes the core signaling pathways, demonstrating their role in orchestrating the physiological development of skin stem cells. Notably, Notch signaling promotes epidermal differentiation while also exerting negative control on Wnt and Shh signaling pathways to prevent unregulated epidermal proliferation. Under normal circumstances, the activity of YAP/TAZ is constrained by the Hippo pathway, accompanied by adherens junctions, which enhance the formation of the 14&#x02013;3-3-YAP complex, leading to proteasomal degradation of YAP. Furthermore, &#x003b1;-catenin in adherens junctions binds to &#x003b2;-catenin, impeding its nuclear translocation of &#x003b2;-catenin, consequently inhibiting skin stem cell differentiation and maintaining the skin stem cell compartment. <italic>SMO, smoothened; PTCH, Patched; Gli, Glioma-associated oncogene homolog; NICD, Notch intracellular domain; TCF/LEF, T-cell factor/lymphoid enhancer-binding factor; LATS1/2, Large tumor suppressor 1 and 2; MST1/2, Mammalian sterile20-like 1 and 2;&#x000a0;YAP/TAZ, Yes-associated protein/Transcriptional coactivator with PDZ-binding motif; TEAD, TEA domain transcription factor; FAK, Focal adhesion kinase; ECM, Extracellular matrix; PI3K/AKT/mTOR, Phosphoinositide 3-kinase/AKT/Mammalian target of rapamycin; JAK/STAT3, Signal transducer and activator of transcription 3</italic>. Some figure components were created in BioRender. Pham, Q. (2025) <ext-link ext-link-type="uri" xlink:href="https://BioRender.com/z83f047">https://BioRender.com/z83f047</ext-link></p></caption><graphic xlink:href="12943_2025_2289_Fig2_HTML" id="MO2"/></fig><fig id="Fig3"><label>Fig.&#x000a0;3</label><caption><p>Signaling network in skin cancer stem cell niche. Overactivation of core signaling pathways, encompassing Shh, Wnt, YAP/ TAZ, and Notch, augments the expression of molecules associated with proliferation, thereby fostering the expansion and persistence of CSCs. Dysregulated expression of E-cadherin and &#x003b1;-catenin disrupts the cytoplasmic sequestration of &#x003b2;-catenin, potentiating Wnt signaling, while concurrently diminishing the association between 14&#x02013;3-3 and YAP, thereby attenuating YAP proteasomal degradation. Stimulation of integrin-SRC signaling by stiff ECM promotes CSC proliferation by upregulating the PI3K/AKT/mTOR and JAK/STAT3 signaling pathways. Subsequently, these pathways facilitate the upregulation of YAP/TAZ and cell-cycle gene expression, disrupt adherens junctions, and prevent apoptosis in tumor cells. Within the CSC niche, modulation of inflammation, attenuation of Hippo signaling, and stimulation of Notch and JAK/STAT3 pathways potentiate the activity of YAP/TAZ. Hyperactivation of YAP/TAZ signaling induces cis-inhibition of Notch signaling, thereby impeding CSC differentiation. The maintenance of CSC quiescence by Notch signaling is reinforced by HIF-1&#x003b1;, which is stabilized within the hypoxic tumor microenvironment, along with regulatory crosstalk involving the Wnt/&#x003b2;-catenin, Shh, and YAP/TAZ signaling pathways. The migration and metastasis of skin cancers are facilitated by EMT, which is initiated by the switch from E-cadherin to N-cadherin. This shift is enhanced by factors secreted from CSCs and cellular compartments within the ECM, alongside the hyperactivation of key signaling pathways in the CSC niche. Notable pathways involved include Wnt/&#x003b2;-catenin, Notch, Shh/GLI, PTEN/PI3K, and JAK/STAT3 pathways. These pathways contribute to the upregulation of mesenchymal phenotype markers, such as <italic>SNAIL</italic>, <italic>SLUG</italic>, <italic>TWIST1</italic>, <italic>ZEB1/2</italic>, <italic>SIP1</italic>, and <italic>TCF3</italic>, facilitating the transition to a more invasive phenotype of skin tumors. <italic>CSC, cancer stem cell; SMO, smoothened; PTCH, Patched; Gli, Glioma-associated oncogene homolog; NICD, Notch intracellular domain; TCF/LEF, T-cell factor/lymphoid enhancer-binding factor; LATS1/2, Large tumor suppressor 1 and 2; MST1/2, Mammalian sterile20-like 1 and 2;&#x000a0;YAP/TAZ, Yes-associated protein/Transcriptional coactivator with PDZ-binding motif; TEAD, TEA domain transcription factor; FAK, Focal adhesion kinase; ECM, Extracellular matrix; PI3K/AKT/mTOR, Phosphoinositide 3-kinase/AKT/Mammalian target of rapamycin; JAK/STAT3, Signal transducer and activator of transcription 3; HIF, hypoxia-inducible factor; EMT, Epithelial-mesenchymal transition; SNAIL, Snail Family Transcriptional Repressor 1; SLUG, Snail Family Transcriptional Repressor 2; TWIST1, Twist family bHLH transcription factor 1; ZEB1/2, Zinc finger E-box binding homeobox 1/2; SIP1, Smad interacting protein 1; TCF3, Transcription factor 3;&#x000a0;NF-&#x003ba;B, Nuclear factor-kappa B; MITF, Microphthalmia-associated transcription factor; PAX3, Paired box gene 3.</italic> Some figure components were created in BioRender. Pham, Q. (2025) <ext-link ext-link-type="uri" xlink:href="https://BioRender.com/z83f047">https://BioRender.com/z83f047</ext-link></p></caption><graphic xlink:href="12943_2025_2289_Fig3_HTML" id="MO3"/></fig><fig id="Fig4"><label>Fig.&#x000a0;4</label><caption><p>Drug targeting on skin cancer stem cell niche. The figure depicts the principal signaling pathways involved in the regulation of the skin cancer stem cell niche, alongside an overview of FDA-approved drugs and those currently undergoing clinical trials for the treatment of skin cancer. These therapeutic agents encompass: <bold>A</bold> inhibitors targeting SMO and GLI expression within the Shh signaling pathway; <bold>B</bold> suppressors of porcupine and promoters of &#x003b2;-catenin degradation complex activity within the Wnt/&#x003b2;-catenin signaling cascade; <bold>C</bold> inhibitors targeting YAP/TAZ signaling activity; <bold>D</bold> &#x003b3;-secretase inhibitors targeting Notch signaling; and <bold>E</bold> inhibitors blocking integrin-related signaling pathways, such as FAK/Src,&#x000a0;PI3K/AKT/mTOR and JAK/STAT3 signaling pathways, and those targeting integrins, which are typically absent in the skin stem cell niche. <italic>FDA, Food and Drug Administration; SMO, Smoothened; PTCH, Patched; Gli, Glioma-associated oncogene homolog; NICD, Notch intracellular domain; TCF/LEF, T-cell factor/lymphoid enhancer-binding factor; HIF, hypoxia-inducible factor;&#x000a0;YAP/TAZ, Yes-associated protein/Transcriptional coactivator with PDZ-binding motif; TEAD, TEA domain transcription factor;&#x000a0;ECM, Extracellular matrix; FAK, Focal adhesion kinase;&#x000a0;PI3K/AKT/mTOR, Phosphoinositide 3-kinase/AKT/Mammalian target of rapamycin; JAK/STAT3, Signal transducer and activator of transcription 3;&#x000a0;NF-&#x003ba;B, Nuclear factor-kappa B; PAX3, Paired Box 3</italic><italic>; MITF, Microphthalmia-Associated Transcription Factor</italic>. Some figure components were created in BioRender. Pham, Q. (2025) <ext-link ext-link-type="uri" xlink:href="https://BioRender.com/z83f047">https://BioRender.com/z83f047</ext-link></p></caption><graphic xlink:href="12943_2025_2289_Fig4_HTML" id="MO4"/></fig><table-wrap id="Tab1"><label>Table 1</label><caption><p>Targeting signaling pathways associated with skin cancer stem cells</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Pathway</th><th align="left">Drug</th><th align="left">Mechanism of action</th><th align="left">Combined treatment</th><th align="left">Conditions</th><th align="left">Clinical trial phase</th><th align="left">NCT Number</th></tr></thead><tbody><tr><td align="left" rowspan="56"><bold>Sonic Hedgehog </bold><bold>pathway</bold></td><td align="left" rowspan="21">GDC-0449 (Vismodegib/Erivedge) Approved by FDA 2012</td><td align="left" rowspan="21">SMO inhibitor</td><td align="left">-</td><td align="left">Resectable, or treated (recurrent, or failed other chemotherapy) BCC</td><td align="left" rowspan="3">Phase I</td><td align="left">NCT01631331</td></tr><tr><td align="left">Photodynamic therapy</td><td align="left">Multiple BCCs</td><td align="left">NCT02639117</td></tr><tr><td align="left">-</td><td align="left">Metastatic or locally advanced BCC</td><td align="left">NCT00607724</td></tr><tr><td align="left">-</td><td align="left">Resectable BCC</td><td align="left" rowspan="11">Phase II</td><td align="left">NCT01543581</td></tr><tr><td align="left">-</td><td align="left">Metastatic or locally advanced BCC</td><td align="left">NCT00833417</td></tr><tr><td align="left">-</td><td align="left">New (not recurrent or previously treated) nodular BCC</td><td align="left">NCT01201915</td></tr><tr><td align="left">-</td><td align="left">Large and/or recurrent resectable BCC</td><td align="left">NCT03035188</td></tr><tr><td align="left">-</td><td align="left">BCC with surgery stage A, B or C</td><td align="left">NCT02667574</td></tr><tr><td align="left">-</td><td align="left">Multiple BCCs</td><td align="left">NCT01815840</td></tr><tr><td align="left">-</td><td align="left">Metastatic or locally advanced BCC</td><td align="left">NCT01367665</td></tr><tr><td align="left">-</td><td align="left">Clinically suspicious or locally advanced BCC</td><td align="left">NCT01700049</td></tr><tr><td align="left">-</td><td align="left">Locally advanced BCC</td><td align="left">NCT01835626</td></tr><tr><td align="left">Topical aminolevulinic acid 20% (photosensitizing agents)</td><td align="left">Multiple BCCs</td><td align="left">NCT01556009</td></tr><tr><td align="left">FOLFOX (folinic acid [leucovorin], fluorouracil [anti-metabolite], and oxaliplatin [OX]), FOLFIRI (Folinic acid [leucovorin], fluorouracil [anti-metabolite], and irinotecan [TOP1 inhibitor]) and Bevacizumab (antiangiogenic agent)</td><td align="left">Metastatic or locally advanced BCC</td><td align="left">NCT00959647</td></tr><tr><td align="left">Pembrolizumab (PD-1 inhibitor)</td><td align="left">Metastatic or unresectable BCC</td><td align="left">Phase I/II</td><td align="left">NCT02690948</td></tr><tr><td align="left">-</td><td align="left">Locally advanced or recurrent BCC</td><td align="left">Phase IV</td><td align="left">NCT02436408</td></tr><tr><td align="left">-</td><td align="left">Metastatic or locally advanced BCC</td><td align="left" rowspan="5">-</td><td align="left">NCT01160250</td></tr><tr><td align="left">-</td><td align="left">Advanced BCC</td><td align="left">NCT02371967</td></tr><tr><td align="left">-</td><td align="left">Locally advanced BCC</td><td align="left">NCT02781389</td></tr><tr><td align="left">-</td><td align="left">Locally advanced BCC</td><td align="left">NCT02674009</td></tr><tr><td align="left">-</td><td align="left">Metastatic or locally advanced BCC</td><td align="left">NCT02438644</td></tr><tr><td align="left" rowspan="8"><p>LDE225 (Erismodegib/ Sonidegib/ Odomzo)</p><p>Approved by FDA 2015</p></td><td align="left" rowspan="8">SMO inhibitor</td><td align="left">-</td><td align="left">Advanced BCC</td><td align="left" rowspan="2">Phase I</td><td align="left">NCT01208831</td></tr><tr><td align="left">-</td><td align="left">Advanced BCC</td><td align="left">NCT00880308</td></tr><tr><td align="left">-</td><td align="left">Locally advanced and metastatic BCC</td><td align="left" rowspan="4">Phase II</td><td align="left">NCT01327053</td></tr><tr><td align="left">Imiquimod</td><td align="left">Resectable and invasive BCC</td><td align="left">NCT03534947</td></tr><tr><td align="left">-</td><td align="left">Multiple BCCs</td><td align="left">NCT00961896</td></tr><tr><td align="left">-</td><td align="left">Multiple BCCs</td><td align="left">NCT01350115</td></tr><tr><td align="left">-</td><td align="left">Locally advanced or metastatic BCC (previously received a non-LDE225 Smo inhibitor)</td><td align="left">-</td><td align="left">NCT01529450</td></tr><tr><td align="left">Pembrolizumab (PD-1 inhibitor)</td><td align="left">Unresectable or metastatic&#x000a0;melanoma and stage IV SCC</td><td align="left">Phase I</td><td align="left">NCT04007744</td></tr><tr><td align="left" rowspan="5">IPI-926 (Saridegib/ Patidegib)</td><td align="left" rowspan="5">SMO inhibitor</td><td align="left">-</td><td align="left">BCC</td><td align="left">-</td><td align="left">NCT01609179</td></tr><tr><td align="left">-</td><td align="left">Advanced and/or metastatic BCC</td><td align="left">Phase I</td><td align="left">NCT00761696</td></tr><tr><td align="left">-</td><td align="left">Sporadic nodular BCC</td><td align="left" rowspan="2">Phase II</td><td align="left">NCT02828111</td></tr><tr><td align="left">-</td><td align="left">Surgically eligible BCCs</td><td align="left">NCT02762084</td></tr><tr><td align="left">-</td><td align="left">Basal cell nevus syndrome</td><td align="left">Phase III</td><td align="left">NCT03703310</td></tr><tr><td align="left" rowspan="2">Itraconazole</td><td align="left" rowspan="2">SMO inhibitor</td><td align="left">-</td><td align="left" rowspan="2">BCC</td><td align="left">Early phase I</td><td align="left">NCT02120677</td></tr><tr><td align="left">-</td><td align="left">Phase II</td><td align="left">NCT01108094</td></tr><tr><td align="left">BMS-833923 (XL139)</td><td align="left">SMO inhibitor</td><td align="left">-</td><td align="left">Advanced or metastatic BCC</td><td align="left">Phase I</td><td align="left">NCT00670189</td></tr><tr><td align="left">Taladegib (LY2940680)</td><td align="left">SMO inhibitor</td><td align="left">-</td><td align="left">Advanced or metastatic BCC</td><td align="left">Phase I</td><td align="left">NCT01226485</td></tr><tr><td align="left">LEQ506</td><td align="left">SMO inhibitor</td><td align="left">-</td><td align="left">Metastatic or locally advanced BCC</td><td align="left">Phase I</td><td align="left">NCT01106508</td></tr><tr><td align="left" rowspan="2">Vitamin D3 (calcitriol)</td><td align="left" rowspan="2">SMO inhibitor</td><td align="left">Temozolomide (alkylating agent)</td><td align="left">Malignant melanoma</td><td align="left">Phase I/II</td><td align="left">NCT00301067</td></tr><tr><td align="left">Diclofenac (NSAID)</td><td align="left">Nodular or superficial BCC</td><td align="left">Phase II</td><td align="left">NCT01358045</td></tr><tr><td align="left">ZSP1602</td><td align="left">SMO inhibitor</td><td align="left">-</td><td align="left">Advanced BCC</td><td align="left">Phase I</td><td align="left">NCT03734913</td></tr><tr><td align="left">TAK-441</td><td align="left">SMO inhibitor</td><td align="left">-</td><td align="left">Advanced BCC</td><td align="left">Phase I</td><td align="left">NCT01204073</td></tr><tr><td align="left">Arsenic trioxide</td><td align="left" rowspan="13">Gli inhibitor</td><td align="left">-</td><td align="left">BCC</td><td align="left">Phase I/II</td><td align="left">NCT01791894</td></tr><tr><td align="left" rowspan="2">Nicotinamide</td><td align="left">-</td><td align="left" rowspan="2">SCC, BCC</td><td align="left">Phase II</td><td align="left">NCT03769285</td></tr><tr><td align="left">-</td><td align="left">Phase III</td><td align="left">ACTRN12612000625875</td></tr><tr><td align="left">CX-4945 (CK2 inhibitor; silmitasertib)</td><td align="left">-</td><td align="left">Metastatic BCC&#x000a0;or locally advanced BCC</td><td align="left">Phase I</td><td align="left">NCT03897036</td></tr><tr><td align="left" rowspan="9">Imiquimod Approved by FDA 2004</td><td align="left">Cryosurgery</td><td align="left" rowspan="9">Superficial and nodular BCC</td><td align="left">-</td><td align="left">NCT01212562</td></tr><tr><td align="left">-</td><td align="left" rowspan="5">Phase III</td><td align="left">NCT00066872</td></tr><tr><td align="left">-</td><td align="left">NCT00129519</td></tr><tr><td align="left">-</td><td align="left">NCT00189241</td></tr><tr><td align="left">-</td><td align="left">NCT00189306</td></tr><tr><td align="left">Cryosurgery</td><td align="left">NCT01212549</td></tr><tr><td align="left">-</td><td align="left" rowspan="3">Phase IV</td><td align="left">NCT00204555</td></tr><tr><td align="left">-</td><td align="left">NCT00314756</td></tr><tr><td align="left">Interferon alpha-2&#x003b2; (Intron-A)</td><td align="left">NCT00581425</td></tr><tr><td align="left" rowspan="4"><bold>Wnt pathway</bold></td><td align="left">LGK974 (WNT974)</td><td align="left">Porcupine inhibitor</td><td align="left">&#x02009;&#x000b1;&#x02009;PDR001 (PD-1 inhibitor)</td><td align="left">Locally advanced or metastatic melanoma</td><td align="left">Phase I</td><td align="left">NCT01351103</td></tr><tr><td align="left">E7449</td><td align="left">Axin stabilization</td><td align="left"><p>&#x02009;&#x000b1;&#x02009;Temozolomide (alkylating agent)</p><p>or&#x02009;&#x000b1;&#x02009;Carboplatin (alkylating agent) and Paclitaxel (mitotic inhibitor)</p></td><td align="left">Advanced or metastatic melanoma</td><td align="left">Phase I/II</td><td align="left">NCT01618136</td></tr><tr><td align="left">Aspirin</td><td align="left" rowspan="2">&#x003b2;-catenin degradation by increasing phosphorylation of GSK3&#x003b2;</td><td align="left">Pembrolizumab (PD-1 inhibitor) and Ipilimumab (CTLA-4 inhibitor)</td><td align="left">Metastatic or unresectable melanoma</td><td align="left">Phase II</td><td align="left">NCT03396952</td></tr><tr><td align="left">Sulindac</td><td align="left">Epirubicin (cytotoxic antibiotic)</td><td align="left">Metastatic malignant melanoma</td><td align="left">Phase II</td><td align="left">NCT00755976</td></tr><tr><td align="left"><bold>Notch pathway</bold></td><td align="left">RO4929097</td><td align="left">&#x003b3;-secretase inhibitor</td><td align="left">Cisplatin (alkylating agent), Vinblastine (alkaloid agent), and Temozolomide (alkylating agent)</td><td align="left">Recurrent or metastatic melanoma</td><td align="left">Phase I/II</td><td align="left">NCT01196416</td></tr><tr><td align="left" rowspan="16"><bold>YAP/TAZ pathway</bold></td><td align="left" rowspan="3">Vorinostat (HDAC inhibitor)</td><td align="left" rowspan="3"><italic>YAP</italic> transcription suppressor</td><td align="left">Doxorubicin (cytotoxic antibiotic)</td><td align="left">Melanoma</td><td align="left">Phase I</td><td align="left">NCT00331955</td></tr><tr><td align="left">-</td><td align="left">Advanced melanoma with BRAF V600 mutation and progression of disease, while on treatment with BRAFi or a combination of BRAF&#x000a0;and MEK inhibitors</td><td align="left">Phase I/II</td><td align="left">NCT02836548</td></tr><tr><td align="left">-</td><td align="left">Metastatic or unresectable melanoma</td><td align="left">Phase II</td><td align="left">NCT00121225</td></tr><tr><td align="left" rowspan="5">Dasatinib</td><td align="left" rowspan="10">Src inhibitor</td><td align="left">Dacarbazine (alkylating agent)</td><td align="left">Stage IV or unresectable stage III&#x000a0;melanoma</td><td align="left">Phase I/II</td><td align="left">NCT00597038</td></tr><tr><td align="left">-</td><td align="left">Unresectable locally advanced or metastatic melanoma</td><td align="left">Phase II</td><td align="left">NCT00700882</td></tr><tr><td align="left">-</td><td align="left">Unresectable locally advanced or metastatic melanoma</td><td align="left" rowspan="2">Phase II</td><td align="left">NCT00436605</td></tr><tr><td align="left">Dendritic cell vaccines</td><td align="left">Stage IV or unresectable stage IIIB/C melanoma</td><td align="left">NCT01876212</td></tr><tr><td align="left">-</td><td align="left">Unresectable or metastatic SCC</td><td align="left">Phase II</td><td align="left">NCT00563290</td></tr><tr><td align="left" rowspan="4">Nilotinib</td><td align="left">Dabrafenib (BRAF inhibitor) and Trametinib (MEK inhibitor)</td><td align="left">Unresectable melanoma with BRAF V600 mutation and failed or have stable disease on any BRAFi/MEKi regimen</td><td align="left">Phase I</td><td align="left">NCT04903119</td></tr><tr><td align="left">-</td><td align="left">Metastatic melanoma</td><td align="left" rowspan="3">Phase II</td><td align="left">NCT00788775</td></tr><tr><td align="left">-</td><td align="left">Unresectable locally advanced or metastatic melanoma with c-KIT mutation</td><td align="left">NCT01395121</td></tr><tr><td align="left">Dacarbazine (alkylating agent)</td><td align="left">Unresectable or&#x000a0;metastatic melanoma with c-KIT mutation</td><td align="left">NCT01028222</td></tr><tr><td align="left">Saracatinib</td><td align="left">-</td><td align="left">Metastatic melanoma</td><td align="left">Phase II</td><td align="left">NCT00669019</td></tr><tr><td align="left" rowspan="3">Pazopanib</td><td align="left" rowspan="3">Inhibition of nuclear YAP translocation by enhancing proteasomal degradation</td><td align="left">Alisertib (AURKA inhibitor)</td><td align="left">Advanced melanoma</td><td align="left">Phase I</td><td align="left">NCT01639911</td></tr><tr><td align="left">-</td><td align="left">Unresectable malignant melanoma</td><td align="left" rowspan="2">Phase II</td><td align="left">NCT00861913</td></tr><tr><td align="left">Paclitaxel (mitotic inhibitor)</td><td align="left">Stage IV or unresectable stage III melanoma</td><td align="left">NCT01107665</td></tr><tr><td align="left" rowspan="22"><bold>PI3K/AKT/ mTOR pathway</bold></td><td align="left">Voxtalisib (SAR245409)</td><td align="left"><p>pan-PI3K</p><p>mTOR inhibitor</p></td><td align="left">Pimasertib (MEK inhibitor)</td><td align="left">Locally&#x000a0;advanced or metastatic melanoma</td><td align="left">Phase I</td><td align="left">NCT01390818</td></tr><tr><td align="left" rowspan="3">Buparlisib (BKM120)</td><td align="left" rowspan="3">pan-PI3K inhibitor</td><td align="left">Vemurafenib (BRAF inhibitor)</td><td align="left">Unresectable stage III and stage IV melanoma with BRAFV600E/K mutation</td><td align="left">Phase I/II</td><td align="left">NCT01512251</td></tr><tr><td align="left">MEK162 (MEK inhibitor)</td><td align="left">Advanced unresectable melanoma</td><td align="left">Phase I</td><td align="left">NCT01363232</td></tr><tr><td align="left">LGX818 (BRAF inhibitor) and MEK162 (MEK inhibitor)</td><td align="left">Unresectable stage III or metastatic melanoma with BRAF V600 mutation</td><td align="left">Phase II</td><td align="left">NCT02159066</td></tr><tr><td align="left">Pictilisib (GDC-0941)</td><td align="left">PI3K inhibitor</td><td align="left">-</td><td align="left">Locally advanced or metastatic melanoma</td><td align="left">Phase I</td><td align="left">NCT00876122</td></tr><tr><td align="left">Alpelisib (BYL719)</td><td align="left">PI3K&#x003b1; inhibitor</td><td align="left"><p>MEK162</p><p>(MEK inhibitor)</p></td><td align="left">Advanced melanoma</td><td align="left">Phase I</td><td align="left">NCT01449058</td></tr><tr><td align="left">GSK2636771</td><td align="left">PI3K&#x003b2; inhibitor</td><td align="left">Pembrolizumab (PD-1 inhibitor)</td><td align="left">Refractory, unresectable stage III or stage IV metastatic melanoma with PTEN loss</td><td align="left">Phase I/II</td><td align="left">NCT03131908</td></tr><tr><td align="left">Eganelisib (IPI-549)</td><td align="left">PI3K&#x003b3; inhibitor</td><td align="left">Nivolumab (PD-1 inhibitor)</td><td align="left">Advanced and/or metastatic melanoma</td><td align="left">Phase I</td><td align="left">NCT02637531</td></tr><tr><td align="left" rowspan="2">Temsirolimus (CCI-779)</td><td align="left" rowspan="7">mTOR inhibitor</td><td align="left">HCQ (autophagy inhibitor)</td><td align="left">Refractory, metastatic melanoma</td><td align="left">Phase I</td><td align="left">NCT00909831</td></tr><tr><td align="left">-</td><td align="left">Metastatic melanoma</td><td align="left">Phase II</td><td align="left">NCT00022464</td></tr><tr><td align="left" rowspan="5">Everolimus (RAD001)</td><td align="left">Bevacizumab (antiangiogenic agent)</td><td align="left">Unresectable stage IV melanoma, or recurrent melanoma with metastases</td><td align="left" rowspan="3">Phase II</td><td align="left">NCT00591734</td></tr><tr><td align="left">Paclitaxel (mitotic inhibitor) and Carboplatin (alkylating agent)</td><td align="left">Unresectable, stage IV melanoma</td><td align="left">NCT01014351</td></tr><tr><td align="left">&#x02009;&#x000b1;&#x02009;Carboplatin (alkylating agent), Paclitaxel (mitotic inhibitor), and Bevacizumab (antiangiogenic agent)</td><td align="left">Unresectable, stage IV melanoma</td><td align="left">NCT00976573</td></tr><tr><td align="left">-</td><td align="left">Stage IV melanoma</td><td align="left" rowspan="2">Phase II</td><td align="left">NCT00098553</td></tr><tr><td align="left">Temozolomide (alkylating agent)</td><td align="left">Stage IV melanoma and unresectable metastatic melanoma</td><td align="left">NCT00521001</td></tr><tr><td align="left" rowspan="3">Uprosertib (GSK 2141795)</td><td align="left" rowspan="6">Akt inhibitor</td><td align="left"><p>GSK1120212</p><p>(MEK inhibitor)</p></td><td align="left">BRAF wild-type melanoma</td><td align="left">Phase I</td><td align="left">NCT01138085</td></tr><tr><td align="left"><p>Trametinib</p><p>(MEK inhibitor)</p></td><td align="left">Unresectable stage III or stage IV melanoma</td><td align="left">Phase II</td><td align="left">NCT01941927</td></tr><tr><td align="left"><p>Trametinib</p><p>(MEK inhibitor)</p><p>Dabrafenib</p><p>(BRAF inhibitor)</p></td><td align="left">Stage IIIC-IV melanoma</td><td align="left">Phase I/II</td><td align="left">NCT01902173</td></tr><tr><td align="left" rowspan="2">MK-2206</td><td align="left"><p>Carboplatin (alkylating agent) and paclitaxel (mitotic inhibitor)</p><p>or Docetaxel (mitotic inhibitor)</p><p>or Erlotinib (EGFR inhibitor)</p></td><td align="left">Locally advanced or metastatic melanoma</td><td align="left" rowspan="2">Phase I</td><td align="left">NCT00848718</td></tr><tr><td align="left">HCQ (autophagy inhibitor)</td><td align="left">Advanced melanoma</td><td align="left">NCT01480154</td></tr><tr><td align="left">Ipatasertib (GDC-0068)</td><td align="left"><p>Atezolizumab</p><p>(PD-L1 inhibitor)</p></td><td align="left">Melanoma post progression on immune-checkpoint inhibitors</td><td align="left">Phase I/II</td><td align="left">NCT03673787</td></tr><tr><td align="left">Afuresertib (GSK2110183)</td><td align="left"/><td align="left"><p>Trametinib</p><p>(MEK inhibitor)</p></td><td align="left">Melanoma</td><td align="left">Phase I</td><td align="left">NCT01476137</td></tr><tr><td align="left" rowspan="2"><bold>JAK/STAT3 pathway</bold></td><td align="left">TTI-101</td><td align="left" rowspan="2">STAT3 inhibitor</td><td align="left">-</td><td align="left">Locally advanced, inoperable, metastatic and/or treatment refractory melanoma</td><td align="left" rowspan="2">Phase I</td><td align="left">NCT03195699</td></tr><tr><td align="left">OPB-31121</td><td align="left">-</td><td align="left">Advanced melanoma</td><td align="left">NCT00657176</td></tr><tr><td align="left" rowspan="4"><bold>Integrin</bold></td><td align="left" rowspan="2">MEDI-522 (Etaracizumab, Abegrin, or Vitaxin)</td><td align="left" rowspan="2">&#x003b1;v&#x003b2;3 integrin inhibitor</td><td align="left">-</td><td align="left">Unresectable, stage IV or recurrent malignant melanoma</td><td align="left">Phase I</td><td align="left">NCT00111696</td></tr><tr><td align="left">&#x02009;&#x000b1;&#x02009;Dacarbazine (alkylating agent)</td><td align="left">Unresectable, stage IV metastatic&#x000a0;melanoma</td><td align="left">Phase II</td><td align="left">NCT00066196</td></tr><tr><td align="left">Volociximab</td><td align="left">&#x003b1;5&#x003b2;1 inhibitor</td><td align="left">Dacarbazine (alkylating agent)</td><td align="left">Stage IV or unresectable stage III melanoma</td><td align="left">Phase II</td><td align="left">NCT00099970</td></tr><tr><td align="left">Intetumumab</td><td align="left">&#x003b1;v integrin inhibitor</td><td align="left">&#x02009;&#x000b1;&#x02009;Dacarbazine (alkylating agent)</td><td align="left">Stage IV or unresectable stage III&#x000a0;melanoma</td><td align="left">Phase I/II</td><td align="left">NCT00246012</td></tr><tr><td align="left" colspan="7">The clinical trial information was accessed at US National Library of Medicine, <italic>ClinicalTrials.gov</italic>, <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov">https://clinicaltrials.gov</ext-link> with the National clinical trial number (NCT number) and <ext-link ext-link-type="uri" xlink:href="https://www.anzctr.org.au">https://www.anzctr.org.au</ext-link> with ONTRAC Australian New Zealand clinical trials registry number (ACTRN)</td></tr></tbody></table><table-wrap-foot><p><italic>CK2&#x000a0;casein kinase,&#x000a0;HCQ Hydroxychloroquine, EGFR Epidermal Growth Factor Receptor, PD-1 Programmed Cell Death Protein 1, CTLA-4 Cytotoxic T-Lymphocyte Antigen 4, MEK Mitogen-Activated Protein Kinase Kinase, AURKA Aurora kinase A, NSAID Non-Steroidal Anti-Inflammatory Drug, TOP1 Topoisomerase 1</italic></p></table-wrap-foot></table-wrap></p></sec><sec id="Sec2"><title>The dermal&#x02013;epidermal niche in SSC and CSC maintenance</title><p id="Par54">SSCs, which primarily include interfollicular epidermal stem cells (IFESCs), hair follicle stem cells (HFSCs), and melanocyte stem cells (MSCs), are widely recognized for their roles in maintaining the skin epidermis through self-regeneration and terminal differentiation [<xref ref-type="bibr" rid="CR1">1</xref>]. In the epidermal basal layer, IFESCs are located and function in regulating the regeneration of the interfollicular epidermis (IFE) [<xref ref-type="bibr" rid="CR30">30</xref>]. HFSCs are crucial for driving HF growth and are predominantly found in the hair follicle (HF) bulge region. During the physiological anagen phase, the outer root sheath and sebaceous ducts are formed by differentiated keratinocytes originating from HFSCs. In wound healing, however, HFSCs contribute to maintaining the IFESC population [<xref ref-type="bibr" rid="CR31">31</xref>&#x02013;<xref ref-type="bibr" rid="CR33">33</xref>]. Skin pigmentation is regulated by melanin, synthesized by melanocytes originating from MSCs in the IFE. MSCs in the lower bulge of the HF generate melanocytes, which are essential for hair shaft pigmentation [<xref ref-type="bibr" rid="CR34">34</xref>]. Hair pigmentation is continuously maintained through the cyclical activation of HFSCs, which is regulated by paracrine signals from the bulge and dermal papilla (DP). This process is closely synchronized with the activation of MSCs [<xref ref-type="bibr" rid="CR35">35</xref>].</p><p id="Par55">
<table-wrap id="Tab2"><label>Table 2</label><caption><p>The dual roles of core signaling pathway in SSC and CSC niche</p></caption><graphic position="anchor" xlink:href="12943_2025_2289_Tab2_HTML" id="MO5"/><table-wrap-foot><p>Key signaling pathways that regulate SSC differentiation, proliferation and stemness are essential for the maintenance and expansion of CSCs. Dysregulation and imbalance of these pathways are observed in the CSC niche, promoting cancer metastasis while sustaining the CSC population. Positive regulation of signaling pathways is represented by an upward-pointing arrow, while inhibition of these pathways, affecting SSC and CSC differentiation, proliferation or quiescence, is indicated by a downward-pointing arrow. A green arrow indicates the altered function of a signaling pathway in the SSC and CSC niche. A red arrow denotes the dual function of the signaling pathway, which can either activate or inhibit cellular processes</p></table-wrap-foot></table-wrap></p><p id="Par56">It has been demonstrated that the survival of SSCs relies heavily on the niche environment, which comprises the dermal-epidermal basement membrane (dermal-epidermal BM), cell&#x02013;cell adhesive contacts, cellular compartments, and signaling pathways. Considering the critical roles of IFESCs and HFSCs in maintaining epidermal homeostasis and their involvement as key sources of common nonmelanoma skin cancers (SCC and BCC) [<xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR37">37</xref>], as well as their regulation of melanoma cell origins in the normal SSC niche [<xref ref-type="bibr" rid="CR35">35</xref>], this review will primarily focus on the IFESC and HFSC populations of SSCs. The term &#x0201c;SSCs&#x0201d; will be discussed in relation to these specific stem cell populations throughout the review.</p><sec id="Sec3"><title>Dermal&#x02013;epidermal basement membrane (Dermal-epidermal BM)</title><p id="Par57">To maintain a balance in epidermal development during regeneration, the connection between the dermis and epidermis, known as the dermal-epidermal BM, provides an adhesive scaffold and mechanical forces to stem cells or facilitates important signaling processes involving growth factors and extracellular matrix (ECM) proteins [<xref ref-type="bibr" rid="CR38">38</xref>]. In the skin&#x02019;s structure, the dermal-epidermal BM contains a wealth of ECM and various molecules that promote communication and separation between the epidermis and dermis [<xref ref-type="bibr" rid="CR38">38</xref>]. Key ECM proteins in the BM, such as laminin (LM) and collagen IV, bind to integrin receptors on basal SSCs, forming anchoring complexes that orchestrate the coordination of actin and microtubule networks within these cells [<xref ref-type="bibr" rid="CR38">38</xref>]. This interaction influences the behavior of both normal SSCs and CSCs.</p><sec id="Sec4"><title>Laminin-integrin interaction in SSC and CSC regulation</title><p id="Par58">
<list list-type="alpha-lower"><list-item><p id="Par59">Laminin-integrin interaction in SSC niche</p></list-item></list>
</p><sec id="FPar1"><title>Laminin 332 (LM332) and laminin 511 (LM511), and their integrin receptors</title><p id="Par60">Laminins (LMs) are multifunctional non-collagenous components of BM which mainly contribute to the skin anchorage structure and maintain SSC homeostasis. LM332 and LM511 are the most abundant laminins in the BM. LM332 is primarily located beneath IFESCs and less abundant in the upper HF [<xref ref-type="bibr" rid="CR39">39</xref>], playing a key role in regulating epidermal differentiation [<xref ref-type="bibr" rid="CR40">40</xref>]. In contrast, LM511 is predominantly found in deeper regions of the HF, with lower presence around basal IFESCs. It is integral to sustaining HFSCs and facilitating the progression of HF development [<xref ref-type="bibr" rid="CR39">39</xref>].</p><p>LM332 and LM511 differ in their structure, distribution, and interaction with integrin receptors, resulting in their distinct roles in maintaining skin homeostasis. LM332 and LM511 share similar primary integrin receptors (&#x003b1;6&#x003b2;4 and &#x003b1;3&#x003b2;1) [<xref ref-type="bibr" rid="CR40">40</xref>]. The skin integrins &#x003b1;6&#x003b2;4 and &#x003b1;3&#x003b2;1 serve as the main cell surface receptors on SSCs, interacting with LMs in the BM to enhance proliferation and maintain the quiescence of SSCs [<xref ref-type="bibr" rid="CR41">41</xref>]. These transmembrane receptors are dual-direction signal transmitters, conveying information between the external environment and cell interior [<xref ref-type="bibr" rid="CR42">42</xref>]. To ensure stable connections between SSCs and the ECM, they aggregate with intracellular adaptor proteins that bind to the cytoskeleton or actin filaments in SSCs [<xref ref-type="bibr" rid="CR42">42</xref>]. In intact skin, the interaction of LM332 with the &#x003b1;6&#x003b2;4 integrin is more prominent than its binding to &#x003b1;3&#x003b2;1 integrin [<xref ref-type="bibr" rid="CR43">43</xref>]. Conversely, the interaction between LM511 and &#x003b1;3&#x003b2;1 is regarded as dominant [<xref ref-type="bibr" rid="CR44">44</xref>].</p><p>Integrin &#x003b1;6&#x003b2;4 and &#x003b1;3&#x003b2;1 receptors have distinct distribution patterns on the SSC membrane, facilitating their interaction with LMs to maintain SSC quiescence. &#x003b1;3&#x003b2;1 integrin, present on both the basolateral and apical surfaces of basal SSCs [<xref ref-type="bibr" rid="CR43">43</xref>], interacts with LM332 and LM511 to constitute focal adhesions (FAs) [<xref ref-type="bibr" rid="CR44">44</xref>]. In contrast, &#x003b1;6&#x003b2;4 is concentrated on the membrane surface of SSCs adjacent to the BM [<xref ref-type="bibr" rid="CR43">43</xref>]. This arrangement enables &#x003b1;6&#x003b2;4 integrin to effectively bind to processed LM332, stabilizing basal SSCs in the BM through hemidesmosome formation [<xref ref-type="bibr" rid="CR43">43</xref>]. Moreover, the expression of &#x003b1;6&#x003b2;4 and &#x003b1;3&#x003b2;1 is confined to the basal epidermal layer, where SSCs show high levels of these integrins, whereas TACs exhibit considerably lower levels [<xref ref-type="bibr" rid="CR45">45</xref>, <xref ref-type="bibr" rid="CR46">46</xref>].</p></sec><sec id="FPar2"><title>LM332 and &#x003b1;6&#x003b2;4 integrin: SSC population maintenance</title><p id="Par63">LM332 and its primary receptor, &#x003b1;6&#x003b2;4 integrin, help maintain the SSC pool by preserving the integrity of the epidermal-dermal junction [<xref ref-type="bibr" rid="CR40">40</xref>]. To perform its functions, LM332, unlike LM511, is secreted by keratinocytes as a precursor containing full-length &#x003b1;3, &#x003b2;3, and &#x003b3;2 chains. It undergoes extensive proteolytic processing after secretion and deposition, which is required for its interactions with surface receptors and other ECM components [<xref ref-type="bibr" rid="CR47">47</xref>]. The matured or processed LM332, resulting from these maturation events, is the primary form found in the BM of normal skin [<xref ref-type="bibr" rid="CR47">47</xref>]. The laminin globular (LG)4&#x02013;5 fragment is released when the 190&#x02013;200&#x000a0;kDa &#x003b1;3 subunit is cleaved within the C-terminal region between the LG3 and LG4 subdomains. Meanwhile, a 105&#x000a0;kDa subunit is generated following cleavage of the 160&#x000a0;kDa &#x003b3;2 subunit at its N-terminus [<xref ref-type="bibr" rid="CR48">48</xref>, <xref ref-type="bibr" rid="CR49">49</xref>]. Following the initial partial proteolytic cleavage, LM332 self-organizes into polymer networks in the BM by indirectly connecting to the keratin intermediate filaments of basal SSCs through its &#x003b1;6&#x003b2;4 integrin receptors and to anchoring fibrils in the dermis via collagen VII, thereby forming stable hemidesmosomes [<xref ref-type="bibr" rid="CR50">50</xref>, <xref ref-type="bibr" rid="CR51">51</xref>]. Therefore, hemidesmosomes act as a bridge to stabilize SSC-matrix adhesion and maintain BM assembly [<xref ref-type="bibr" rid="CR49">49</xref>, <xref ref-type="bibr" rid="CR52">52</xref>]. The interaction between &#x003b1;6&#x003b2;4 integrin and processed LM332, embedded in stable hemidesmosome complexes, primarily restricts migration by ensuring basal SSC adhesion in the BM niche [<xref ref-type="bibr" rid="CR52">52</xref>]. During epidermal regeneration, the dissociation of hemidesmosomes facilitates the detachment of basal keratinocytes from the BM, thereby promoting their differentiation. The &#x003b3;2 subunit of LM332 may undergo further N-terminal cleavage by MMPs (Matrix metalloproteinases) during epidermal differentiation, resulting in a smaller protein EGF-like segment [<xref ref-type="bibr" rid="CR53">53</xref>, <xref ref-type="bibr" rid="CR54">54</xref>]. EGFR (Epidermal growth factor receptor)-induced serine phosphorylation of the intracellular &#x003b2;4 tail is initiated by the EGF-like fragment [<xref ref-type="bibr" rid="CR55">55</xref>, <xref ref-type="bibr" rid="CR56">56</xref>]. As a result, the interaction between &#x003b1;6&#x003b2;4 integrin and its adaptor protein plectin is disrupted, potentially destabilizing hemidesmosomes and enhancing cell migration [<xref ref-type="bibr" rid="CR55">55</xref>, <xref ref-type="bibr" rid="CR57">57</xref>].</p><p>LM332 not only serves a structural role in stable hemidesmosomes but also modulates SSC behavior by participating in signaling through &#x003b1;6&#x003b2;4 integrins in hemidesmosomes and &#x003b1;3&#x003b2;1 integrins in FAs [<xref ref-type="bibr" rid="CR52">52</xref>]. Tyrosine phosphorylation of &#x003b2;4 integrin in its intracellular tail occurs when &#x003b1;6&#x003b2;4 binds to the mature extracellular LM332 ligand [<xref ref-type="bibr" rid="CR58">58</xref>]. This phosphorylated form of &#x003b2;4 can sequentially recruit and attach to the Src homology 2 domain containing (SHC) adaptor protein, and growth factor receptor-bound protein 2 (GRB2) [<xref ref-type="bibr" rid="CR58">58</xref>&#x02013;<xref ref-type="bibr" rid="CR60">60</xref>]. The association of &#x003b1;6&#x003b2;4 with these adaptor proteins potentially links &#x003b1;6&#x003b2;4 to RAS (Rat sarcoma virus) and activates two distinct MAPK (Mitogen-activated protein kinase) signaling pathways, both RAS/ERK (Extracellular signal-regulated kinase) and RAC (Ras-related C3 botulinum toxin substrate)/JNK (c-Jun NH2-terminal kinase) signaling pathways, which control cell division in response to mitogens [<xref ref-type="bibr" rid="CR59">59</xref>, <xref ref-type="bibr" rid="CR60">60</xref>]. Concurrently, &#x003b1;6&#x003b2;4 integrin-mediated quiescent SSCs may be reinforced by RAC1 (Rac family small GTPase 1), which exerts a negative regulatory effect on c-MYC stability [<xref ref-type="bibr" rid="CR61">61</xref>]. Furthermore, c-MYC activation in keratinocytes causes a marked reduction in &#x003b1;6&#x003b2;4 integrin localization at the cell surface and hemidesmosomal junctions, impairing hemidesmosome assembly [<xref ref-type="bibr" rid="CR62">62</xref>]. Overexpression of c-MYC transcriptionally results in the downregulation of integrin genes &#x003b1;6 (<italic>ITGA6</italic>), &#x003b2;1 (<italic>ITGB1</italic>), and &#x003b2;4 (<italic>ITGB4</italic>), causing stem cells to exit their BM niche and undergo premature terminal differentiation [<xref ref-type="bibr" rid="CR63">63</xref>]. These findings point to the critical involvement of LM332 and integrin &#x003b1;6&#x003b2;4 in sustaining SSC populations.</p></sec><sec id="FPar3"><title>LM332 and &#x003b1;3&#x003b2;1 integrin: SSC quiescence and migration</title><p id="Par65">The interaction between LM332 and integrin &#x003b1;3&#x003b2;1 contributes to the dynamic dimensions of FAs, which are crucial for preserving quiescent SSCs. FAs in the basal epidermal layer not only transmit cytoskeletal forces but also act as key hubs for converting external signals into intracellular pathways [<xref ref-type="bibr" rid="CR64">64</xref>]. FAs are initiated through the linkage of &#x003b1;3&#x003b2;1 integrins to LM332, with adaptor proteins such as talin, vinculin, and integrin-linked kinase (ILK) providing structural connections between the cytoplasmic &#x003b2;1 domain and the actin cytoskeleton [<xref ref-type="bibr" rid="CR65">65</xref>]. The &#x003b1;3&#x003b2;1-LM332 interaction activates the MAPK pathway, essential for SSC proliferation, while also triggering focal adhesion kinase (FAK)/SRC/RAC1 signaling, which facilitates SSC differentiation and migration [<xref ref-type="bibr" rid="CR66">66</xref>, <xref ref-type="bibr" rid="CR67">67</xref>]. Notably, MAPK is downstream of LM332-&#x003b1;6&#x003b2;4 integrin in hemidesmosomes and LM332-&#x003b1;3&#x003b2;1 integrin in FAs. However, the activation of MAPK by &#x003b1;3&#x003b2;1-LM332 occurs independently of RAS/SHC, as evidenced in studies involving &#x003b1;6&#x003b2;4-LM332 [<xref ref-type="bibr" rid="CR59">59</xref>, <xref ref-type="bibr" rid="CR67">67</xref>]. MAPK activation via RAS, induced by &#x003b1;6&#x003b2;4-mediated anchorage, promotes cell cycle progression in response to mitogenic signals [<xref ref-type="bibr" rid="CR59">59</xref>]. Conversely, the MAPK cascade, downstream of &#x003b1;3&#x003b2;1-mediated adhesion, plays a critical role in preserving the SSC pool [<xref ref-type="bibr" rid="CR66">66</xref>, <xref ref-type="bibr" rid="CR68">68</xref>]. Moreover, the capacity of &#x003b1;3&#x003b2;1-LM332 to sustain the SSC compartment through MAPK activation may be associated with its downstream target gene, p53, which preserves the proliferative potential of SSCs and interrupts the cell cycle [<xref ref-type="bibr" rid="CR69">69</xref>]. The p53 homolog p51/p63 enhances the transcription of &#x003b1;3&#x003b2;1 and &#x003b1;6&#x003b2;4 integrins in SSCs, supporting SC preservation by ensuring proper BM attachment and inhibiting Notch1 activity [<xref ref-type="bibr" rid="CR70">70</xref>, <xref ref-type="bibr" rid="CR71">71</xref>]. Nonetheless, it is still uncertain whether MAPK activation by &#x003b1;3&#x003b2;1-LM332 plays a role in sustaining SSC immaturity via p53 or through other distinct downstream effectors. Interestingly, the activity of &#x003b1;3&#x003b2;1 integrin can be negatively modulated by MAPK signaling triggered by EGF or by &#x003b1;6&#x003b2;4 integrin [<xref ref-type="bibr" rid="CR72">72</xref>]. This negative regulatory mechanism may be essential for preventing SSC hyperproliferation.</p><p>The interaction between LM332 and &#x003b1;3&#x003b2;1 integrin at FA sites promotes SSC migration. FAs regulate cell movement by anchoring to the actin cytoskeleton, enabling dynamic interactions essential for motility [<xref ref-type="bibr" rid="CR52">52</xref>]. The binding of LM332 to &#x003b1;3&#x003b2;1 integrin activates FAK autophosphorylation, which then facilitates its interaction with the Src-homology 2 (SH2) domain of SRC [<xref ref-type="bibr" rid="CR73">73</xref>]. The recruited SRC phosphorylates other tyrosine residues on FAK, activating the RAC1 downstream pathway, which drives cellular polarization and initiates cell spreading [<xref ref-type="bibr" rid="CR67">67</xref>, <xref ref-type="bibr" rid="CR74">74</xref>]. The engagement of LM332 with &#x003b1;3&#x003b2;1 integrin induces actin cytoskeleton rearrangement and enhances cell movement by preferentially activating RAC1 and CDC42 (Cell division cycle 42), while concurrently weakening RAS homolog family member A (RHOA)/ Rho-associated protein kinase (ROCK) [<xref ref-type="bibr" rid="CR75">75</xref>, <xref ref-type="bibr" rid="CR76">76</xref>]. In addition, inhibition of RHOA and ROCK activity correlates with reduced assembly and stabilization of FAs, reducing cell&#x02013;matrix attachment and facilitating cell motility [<xref ref-type="bibr" rid="CR77">77</xref>].</p></sec><sec id="FPar4"><title>LM332 and LM511: antagonistic roles during HF cycle</title><p id="Par67">LM511 is well recognized for its primary role in hair growth and maintenance of HFSC populations, although its functions in IFESCs have been less explored. During the normal HF cycle, LM332 antagonizes LM511-driven hair growth. LM511 encourages the proliferation of HFSCs stimulated by transforming growth factor (TGF)-&#x003b2;2, whereas LM332 inhibits the Wingless-related integration site (Wnt)/&#x003b2;-catenin pathway-induced differentiation of HFSCs [<xref ref-type="bibr" rid="CR39">39</xref>]. Epidermal progenitor cell (EPC) adhesion to LM511 triggers SMAD2 (SMAD family member 2) phosphorylation, upregulating TGF-&#x003b2; expression without affecting &#x003b2;-catenin stability or Wnt target gene expression [<xref ref-type="bibr" rid="CR39">39</xref>]. In contrast, adhesion of EPCs to LM332 suppresses &#x003b2;-catenin levels and downregulates Wnt target gene expression, without affecting TGF-&#x003b2; signaling [<xref ref-type="bibr" rid="CR39">39</xref>]. Normally, a balanced gradient of LM332 and LM511 expression is maintained, with lower LM332 and higher LM511 levels around the bulge niche and hair germ, and the reverse around the basal IFE. This gradient is crucial for sustaining HFSC and IFSC homeostasis. Indeed, reduced levels of LM332 and elevated expression of LM511 enhance EPC assembly into LM511, accompanied by the unrestrained upregulation of Wnt and TGF-&#x003b2; signaling in EPCs [<xref ref-type="bibr" rid="CR39">39</xref>]. This imbalance in the LM332/LM511 ratio occurs in the absence of actin-binding regulatory protein ILK, which is crucial for laminin-integrin interactions in FA complexes [<xref ref-type="bibr" rid="CR78">78</xref>]. Accordingly, ILK-depleted mice exhibit hyperproliferation and elevated Wnt gene expression in IFESCs, increasing the risk of carcinogenesis and leading to a loss of quiescent SCs [<xref ref-type="bibr" rid="CR39">39</xref>]. However, the exact contribution of ILK in modulating the deposition of LM332 and LM511, as well as its interaction with related signaling pathways during HF cycles, remains unclear. Furthermore, LM511 inhibits the proliferation and motility of basal keratinocytes, without significantly affecting their differentiation [<xref ref-type="bibr" rid="CR79">79</xref>]. The absence of LM511 in the epidermal BM leads to a hyperproliferative phenotype in basal keratinocytes [<xref ref-type="bibr" rid="CR79">79</xref>]. Moreover, LM511 supports basal cells by sustaining stem and progenitor cells, including melanoma-associated chondroitin sulphate proteoglycan (MCSP) and keratin 15 (K15)-positive cells [<xref ref-type="bibr" rid="CR80">80</xref>].</p><p>
<list list-type="simple"><list-item><label>b.</label><p id="Par69">Laminin-integrin interaction in skin CSC niche</p></list-item></list>
</p><p>While LMs and integrins are crucial for maintaining the SSC niche, they have also been implicated in tumorigenesis and invasiveness of skin cancers. LM332 overexpression at the invasive edges of SCCs is associated with poor prognosis [<xref ref-type="bibr" rid="CR81">81</xref>, <xref ref-type="bibr" rid="CR82">82</xref>]. Numerous studies demonstrate that &#x003b1;3&#x003b2;1 or &#x003b1;6&#x003b2;4 integrins are indispensable for the tumorigenesis and invasiveness of SCC, BCC, and melanoma [<xref ref-type="bibr" rid="CR83">83</xref>&#x02013;<xref ref-type="bibr" rid="CR88">88</xref>]. Depletion of &#x003b1;3&#x003b2;1 [<xref ref-type="bibr" rid="CR87">87</xref>&#x02013;<xref ref-type="bibr" rid="CR89">89</xref>] or &#x003b1;6&#x003b2;4 integrin [<xref ref-type="bibr" rid="CR84">84</xref>] in the epidermis reduces both cutaneous SCC size and incidence, whereas its overexpression is associated with poor prognosis [<xref ref-type="bibr" rid="CR86">86</xref>, <xref ref-type="bibr" rid="CR87">87</xref>]. These observations may be attributed to the abnormal forms and localization of LM332 and its integrin receptors in the CSC niche.</p></sec><sec id="FPar5"><title>LM332 maturation disorder: abnormal variants and malignant behavior</title><p id="Par71">The promotive role of LM332 and integrins in the CSC niche is attributed to disruptions in the proteolytic processing of LM332. Disorders in the maturation process of the LM332 precursor induce dysfunctional variants and malignant behavior in LM332-integrin interactions [<xref ref-type="bibr" rid="CR90">90</xref>, <xref ref-type="bibr" rid="CR91">91</xref>]. Physiologically, LM332 undergoes maturation, during which smaller &#x003b2;3 LG4-5 and &#x003b3;2 EGF-like fragments are released and removed from the ECM in the BM [<xref ref-type="bibr" rid="CR47">47</xref>]. However, LM332 appears as an independent biologically active &#x003b1;3 LG4&#x02013;5 or &#x003b3;2 EGF-like fragment, or contains full-length &#x003b1;3 in the BM, as reported in the microenvironment of aggressive forms of melanoma, SCC, and BCC [<xref ref-type="bibr" rid="CR92">92</xref>&#x02013;<xref ref-type="bibr" rid="CR94">94</xref>]. These abnormal LM332 patterns do not attach well to the ECM, resulting in the breakdown of the BM assembly by destabilizing hemidesmosomes [<xref ref-type="bibr" rid="CR93">93</xref>].</p><p>Abnormal variants of LM332 impair normal function in SSC development, promoting malignant cell behavior. The cleaved component LM332-&#x003b3;2, comprising EGF-like fragments, is a distinctive marker of metastatic potential of tumors. This recognition is attributed to its prominent expression as a monomer at invasive tumor borders and its increased prevalence in more aggressive subtypes of BCC, SCC, and melanoma [<xref ref-type="bibr" rid="CR92">92</xref>&#x02013;<xref ref-type="bibr" rid="CR96">96</xref>]. Overexpression of LM332-&#x003b3;2 fragments in skin cancer has been associated with several MMPs, including MMP-2 [<xref ref-type="bibr" rid="CR94">94</xref>], MMP-7 [<xref ref-type="bibr" rid="CR97">97</xref>, <xref ref-type="bibr" rid="CR98">98</xref>], MMP-13 [<xref ref-type="bibr" rid="CR99">99</xref>], MMP-19 [<xref ref-type="bibr" rid="CR100">100</xref>], and membrane-type 1 (MT1)-MMP [<xref ref-type="bibr" rid="CR94">94</xref>]. Additionally, significant co-localization of these MMPs with LM332-&#x003b3;2 chains was observed at the invasive margins of skin tumor cells [<xref ref-type="bibr" rid="CR98">98</xref>, <xref ref-type="bibr" rid="CR100">100</xref>]. Approximately 96.2% of BCC cases (50 out of 52) were positive for LM332-&#x003b3;2, exhibiting a prominently diffuse pattern in the cytoplasm of infiltrating tumor cells. Furthermore, aggressive BCC demonstrated significantly higher levels of LM332-&#x003b3;2 compared to non-aggressive BCC [<xref ref-type="bibr" rid="CR96">96</xref>]. In addition, the inhibition of LM332-&#x003b3;2 substantially decreased the migratory potential of SCC cells in vitro [<xref ref-type="bibr" rid="CR92">92</xref>]. The supportive role of monomeric LM332-&#x003b3;2 in skin cancer may be attributed to its EGF-like chain, which activates EGF/MAPK/ERK signaling pathways upon interacting with EGFR in cancer cells [<xref ref-type="bibr" rid="CR55">55</xref>]. The resultant disassembly of hemidesmosomes, induced by tyrosine/serine phosphorylation of the &#x003b2;4 tail, facilitates the migration and scattering of tumor cells [<xref ref-type="bibr" rid="CR56">56</xref>,&#x000a0;<xref ref-type="bibr" rid="CR57">57</xref>]. Hyperactivation of oncogenic RAS, stimulated by the &#x003b1;6&#x003b2;4 integrin-LM332 in an EGFR-dependent manner, is observed in SCC progression and invasion [<xref ref-type="bibr" rid="CR84">84</xref>]. Additional proteolytic cleavage of the &#x003b3;2 domain has been proposed to inhibit the deposition and integration of LM332 into the ECM of the BM [<xref ref-type="bibr" rid="CR51">51</xref>]. However, further research is required to fully understand the nature of this association.</p><p>A distinct abnormal form of LM332, either a full-length &#x003b1;3 chain or a monomeric LG4&#x02013;5 chain, is proposed to contribute to skin cancer invasion. The LG4&#x02013;5 segment, cleaved from the LM332 precursor on the &#x003b1;3 subunit and absent in the normal epidermis, is exclusively found in tumor tissue and facilitates the formation and progression of SCC [<xref ref-type="bibr" rid="CR101">101</xref>]. Moderate to strong levels of &#x003b1;3 LG4&#x02013;5 segments were found in 75% of 75 cutaneous SCC tumors and 56 non-cutaneous SCC tumors [<xref ref-type="bibr" rid="CR101">101</xref>]. The LM332 harboring the full-length &#x003b1;3 chain exhibits a higher affinity for FA components, such as &#x003b1;3&#x003b2;1 integrin and syndecan-1, compared to &#x003b1;6&#x003b2;4 [<xref ref-type="bibr" rid="CR102">102</xref>, <xref ref-type="bibr" rid="CR103">103</xref>]. Consequently, a transition in the main adhesion structure for the attachment of basal epidermal cells to the BM niche, evolving from reliance on hemidesmosome-dependent regulation to FA-dependent mediation, is observed [<xref ref-type="bibr" rid="CR102">102</xref>]. Moreover, the activation of the MAPK/ERK/IL-1&#x003b2; pathway by &#x003b1;3 LG4 interaction with syndecan promotes the expression of MMP-1 [<xref ref-type="bibr" rid="CR104">104</xref>] and MMP-9 [<xref ref-type="bibr" rid="CR105">105</xref>]. MMP-1 and MMP-9 activity in invasive SCC, mediated by MAPK and PI3K pathways, necessitates the presence of LM332 containing &#x003b1;3 LG4&#x02013;5 [<xref ref-type="bibr" rid="CR101">101</xref>]. Notably, these MMPs are capable of cleaving LM332, releasing the LM332-&#x003b3;2 fragment, which contributes to the progression of BCC, SCC, and melanoma [<xref ref-type="bibr" rid="CR94">94</xref>&#x02013;<xref ref-type="bibr" rid="CR96">96</xref>]. As a result, LM332 &#x003b1;3 LG4&#x02013;5 may facilitate and amplify the release of LM332-&#x003b3;2, further driving tumor growth. However, the direct interactions of these altered LM332 fragments in the skin CSC niche are yet to be fully investigated. Future investigation into these interactions may offer critical understanding of the mechanisms underlying skin CSC resistance.</p></sec><sec id="FPar6"><title>Abnormal interactions of aberrant LM332 variants with integrins</title><p id="Par74">The aberrant variants of LM332 interfere with the interaction between LM332 and integrins. Unprocessed LM332 preferentially attaches to integrin &#x003b1;3&#x003b2;1 over &#x003b1;6&#x003b2;4, which triggers FAK phosphorylation and activates the RAS/MAPK pathway. This cascade subsequently enhances RAC1- and CDC42-mediated cell migration [<xref ref-type="bibr" rid="CR103">103</xref>, <xref ref-type="bibr" rid="CR106">106</xref>]. The clustering of unprocessed LM332 is predominantly localized at the FA sites on the cell membrane, potentially enhancing FA formation through efficient binding to &#x003b1;3&#x003b2;1 [<xref ref-type="bibr" rid="CR102">102</xref>]. This contrasts with the typical form of LM332, which is predominantly recruited to &#x003b1;6&#x003b2;4 sites. The atypical interaction redefines the role of LM and integrin, shifting from the maintenance of cell&#x02013;matrix adhesion to acting as a cell signaling hub in the skin CSC niche, which facilitates BM disruption and accelerates cell migration. Furthermore, SCC tumors exhibit extensive cell death, along with markedly impaired proliferation and invasion, in the absence of LM332 &#x003b1;3 LG4&#x02013;5. These defects are attributed to inactive PI3K/AKT signaling and reduced levels of MMPs, such as MMP-1 and MMP-9, following specific inhibition of the &#x003b1;3 LG4&#x02013;5 domain [<xref ref-type="bibr" rid="CR101">101</xref>].</p><p>Integrin &#x003b1;6&#x003b2;4 and integrin &#x003b1;3&#x003b2;1, which exhibit ectopic expression in the epidermis, can contribute to dysregulated signaling in skin cancer progression, independent of their LM ligands. Rudimentary hemidesmosomes are critical early factors that promote skin tumor cell movement and invasion [<xref ref-type="bibr" rid="CR102">102</xref>]. Disruption of integrin-hemidesmosome interactions subsequently promotes malignant transformation within the SSC niche. Integrin &#x003b1;6&#x003b2;4 shifts from primarily facilitating cell&#x02013;matrix adhesion to interacting with signaling proteins when not confined to hemidesmosomes. Altered integrin expression, characterized by abnormal basal or suprabasal expression instead of its typical restriction to the epidermal basal layer, contributes to the progression and invasion of skin cancers [<xref ref-type="bibr" rid="CR107">107</xref>&#x02013;<xref ref-type="bibr" rid="CR110">110</xref>]. Suprabasal integrin &#x003b1;6&#x003b2;4 expression increases throughout SCC progression, with elevated levels associated with early relapse [<xref ref-type="bibr" rid="CR109">109</xref>,&#x000a0;<xref ref-type="bibr" rid="CR111">111</xref>]. Additionally, &#x003b1;6&#x003b2;4 integrin receptors redistribute diffusely on cell membranes&#x000a0;in BCC and SCC, contrasting with their typical localization in the basal epidermal cells [<xref ref-type="bibr" rid="CR108">108</xref>, <xref ref-type="bibr" rid="CR112">112</xref>]. In the normal epidermis, integrin &#x003b1;3&#x003b2;1 is primarily localized to the lateral membranes of basal SSCs. In contrast, integrin &#x003b1;3&#x003b2;1 is aberrantly expressed throughout the epidermis in SCC and BCC tumors, with a higher concentration on the basal membrane of basal keratinocytes [<xref ref-type="bibr" rid="CR112">112</xref>, <xref ref-type="bibr" rid="CR113">113</xref>]. Notably, epithelial (E)-cadherin-mediated adhesion and PI3K activity are essential for the suprabasal activity of &#x003b1;6&#x003b2;4 integrin in SCC formation, thereby facilitating TGF-&#x003b2;-mediated epidermal hyperproliferation [<xref ref-type="bibr" rid="CR114">114</xref>]. Additionally, the inflammatory milieu established by suprabasal &#x003b1;3&#x003b2;1 integrin through the MAPK/ERK pathway induces the unrestrained hyperproliferation of keratinocytes [<xref ref-type="bibr" rid="CR115">115</xref>, <xref ref-type="bibr" rid="CR116">116</xref>].</p><p>Moreover, non-ligand-bound integrins can initiate oncogenic signaling pathways in the CSC niche. Signaling initiated by non-ligand integrins is contingent on their activation mechanism and the interacting molecules involved, which can generate distinct responses in SSCs&#x000a0;and CSCs. Integrin &#x003b1;3&#x003b2;1, independent of its binding to LM332, engages FAK/SRC signaling and activates the downstream AKT/STAT3 cascade in basal keratinocytes, mediated through its membrane-associated protein, CD151 [<xref ref-type="bibr" rid="CR117">117</xref>&#x02013;<xref ref-type="bibr" rid="CR119">119</xref>]. This mechanistic pathway enhances basal cell proliferation mediated by cyclin D [<xref ref-type="bibr" rid="CR120">120</xref>, <xref ref-type="bibr" rid="CR121">121</xref>]. Simultaneously, the integrin &#x003b1;3&#x003b2;1-CD151 interaction at the cell&#x02013;cell junctions of suprabasal keratinocytes activates AKT and STAT3 signaling, conferencing protection to differentiating cells by preventing apoptosis [<xref ref-type="bibr" rid="CR117">117</xref>]. Subsequently, the retention of proliferating and&#x000a0;differentiating&#x000a0;cells due to impaired terminal differentiation facilitates tumor outgrowth and skin carcinogenesis. In contrast, the absence of integrin &#x003b1;3&#x003b2;1 diminishes FAK/SRC activation and attenuates STAT3/AKT signaling, which in turn expedites the depletion of slow-cycling stem cells and the terminal differentiation of suprabasal keratinocytes, ultimately preventing skin tumorigenesis [<xref ref-type="bibr" rid="CR117">117</xref>,&#x000a0;<xref ref-type="bibr" rid="CR122">122</xref>]. On the other hand, in the absence of its LM332 ligand, the interaction between &#x003b1;6&#x003b2;4 integrin and its co-receptor syndecan-1 facilitates the self-association of &#x003b2;4 cytoplasmic tails. Phosphorylated &#x003b2;4 engages Erb-B2 receptor tyrosine kinase 2 (ErbB2), a member of the EGFR kinase family [<xref ref-type="bibr" rid="CR123">123</xref>]. This process initiates a cascade of Fyn-dependent phosphorylation of &#x003b2;4, which is associated with the disruption of hemidesmosomes and the subsequent activation of downstream PI3K/AKT signaling pathways [<xref ref-type="bibr" rid="CR123">123</xref>]. The resulting PI3K/AKT signaling cascade elicits actin reorganization, facilitating tumor cell migration [<xref ref-type="bibr" rid="CR124">124</xref>]. Although certain factors associated with the emergence of unconventional integrins have been identified, the precise mechanisms governing the interaction between ectopic integrin expression and signaling pathways in skin tumorigenesis warrant further investigation.</p><p>&#x0feff;The activation of integrins &#x003b1;6&#x003b2;4 and &#x003b1;3&#x003b2;1 is essential for the tumorigenic properties of CSCs. &#x003b1;6&#x003b2;4 integrin expression is upregulated in CSCs that also express Transglutaminase 2 (TG2), a multifunctional protein essential for CSC survival in SCC tumors [<xref ref-type="bibr" rid="CR125">125</xref>]. Binding of integrin &#x003b1;6&#x003b2;4 to TG2 activates FAK/SRC/PI3K, which subsequently triggers phosphoinositide-dependent kinase 1 (PDK1) signaling [<xref ref-type="bibr" rid="CR126">126</xref>]. PDK1, by inhibiting LATS1 activity, dampens the Hippo pathway [<xref ref-type="bibr" rid="CR127">127</xref>], promoting nuclear accumulation of YAP1. This nuclear YAP1 then stabilizes &#x00394;Np63&#x003b1; (Delta Np63 alpha), subsequently strengthening CSC stemness and promoting invasion of SCCs. Inhibition of &#x003b1;6&#x003b2;4 disrupts PI3K/PDK1 signaling and decreases &#x00394;Np63&#x003b1; activity, which impairs CSC properties and SCC formation [<xref ref-type="bibr" rid="CR126">126</xref>]. Knockout of integrin &#x003b1;3&#x003b2;1 in HFSCs residing in the bulge niche significantly impairs papilloma development, a type of skin tumor. In the early stages of tumorigenesis, the onset of epidermal tumors is facilitated by &#x003b1;3&#x003b2;1 in HFSCs through the upregulation of HFSC-derived CCN2 (Cellular communication network factor 2) expression [<xref ref-type="bibr" rid="CR122">122</xref>]. The significant involvement of common integrins in SSCs in the initiation of skin tumors driven by CSCs has been recognized. However, the precise impact of these integrins on CSCs in the context of skin cancers remains largely unexplored. Investigating the functions of these integrins and their associated signaling pathways in the CSC niche may provide deeper insights into the mechanisms that sustain CSCs within their niche.</p></sec></sec><sec id="Sec11"><title>Collagen IV</title><p id="Par78">
<list list-type="alpha-lower"><list-item><p id="Par79">Collagen type IV in SSC niche</p></list-item></list>
</p><p id="Par80">Collagen IV, another major BM component, primarily functions as a scaffold that supports the attachment of basal epidermal cells to the BM. Collagen IV not only preserves the structural integrity of the BM but also contributes to its durability [<xref ref-type="bibr" rid="CR38">38</xref>]. Collagen IV forms intermolecular covalent linkages and tightly aggregates with LM and other BM proteins, generating a stable meshwork that provides the BM with the ability to withstand mechanical forces [<xref ref-type="bibr" rid="CR50">50</xref>]. Basal SSC attachment to the BM is strengthened by the direct binding of collagen IV to integrin &#x003b1;2&#x003b2;1 on these SCs [<xref ref-type="bibr" rid="CR46">46</xref>]. Additionally, collagen IV in the BM contributes to SSC maintenance. Epidermal cells rapidly adhering to collagen IV demonstrate significant proliferative potential in vitro and form fully differentiated epidermis in vivo [<xref ref-type="bibr" rid="CR46">46</xref>]. Collagen IV is thought to be crucial for maintaining basal keratinocyte proliferation as a target of miR-135b [<xref ref-type="bibr" rid="CR128">128</xref>]. In the absence of miR-135b, collagen IV expression in the SSC niche increased, whereas miR-135b reintroduction reversed this effect and promoted early keratinocyte differentiation [<xref ref-type="bibr" rid="CR128">128</xref>]. Moreover, inhibition of miR-135b consistently elevated p63 levels, a recognized marker of SSCs [<xref ref-type="bibr" rid="CR129">129</xref>], and enhanced proliferation in normal keratinocytes [<xref ref-type="bibr" rid="CR128">128</xref>]. These findings underscore that restoring collagen IV in the BM may be essential for SSC proliferation and preservation. This aligns with the role of collagen IV in maintaining BM integrity, which supports SSCs within their niche and sustains their stemness properties [<xref ref-type="bibr" rid="CR38">38</xref>]. Additional research is needed to uncover the mechanisms driving the interaction between collagen IV and miR-135b and their roles in sustaining the quiescent state of normal SSCs.</p><p id="Par81">
<list list-type="simple"><list-item><label>b.</label><p id="Par82">Collagen type IV in skin CSC niche</p></list-item></list>
</p><p id="Par83">During skin cancer progression, the ECM composition surrounding CSCs and tumor cells varies, with collagen being the most abundant matrix protein. Disorganization of collagen IV is a common feature in skin cancers, closely associated with enhanced tumor invasion and progression. In aggressive skin cancers, such as melanoma and SCC, structural disintegration of collagen IV and the absence of an intact BM are often prominent features [<xref ref-type="bibr" rid="CR112">112</xref>, <xref ref-type="bibr" rid="CR130">130</xref>&#x02013;<xref ref-type="bibr" rid="CR132">132</xref>]. During epithelial&#x02013;mesenchymal transition (EMT), a key process in cancer progression, MMP-1 and MMP-2 secretion is significantly upregulated, leading to collagen IV fragmentation and destruction of the BM niche in invasive skin cancers [<xref ref-type="bibr" rid="CR131">131</xref>]. Furthermore, the degradation of collagen IV in skin cancer may correlate with the aberrant expression of its regulatory factors. Notably, miR-135b, which inhibits collagen IV expression in normal SSCs [<xref ref-type="bibr" rid="CR128">128</xref>], is overexpressed in human melanoma and aggressive SCCs. This microRNA promotes tumor growth by targeting LATS2 (Large tumor suppressor kinase 2) [<xref ref-type="bibr" rid="CR133">133</xref>] and enhances invasiveness by inhibiting LZTS1 (Leucine zipper tumor suppressor 1) [<xref ref-type="bibr" rid="CR134">134</xref>]. In addition, degradation of collagen IV in melanoma and SCCs is frequently observed [<xref ref-type="bibr" rid="CR112">112</xref>, <xref ref-type="bibr" rid="CR130">130</xref>&#x02013;<xref ref-type="bibr" rid="CR132">132</xref>], suggesting a potential relationship between miR-135b and collagen IV expression in skin cancers. Therefore, targeting miR-135b may provide a novel approach for restoring BM integrity and inhibiting skin cancer progression.</p><p id="Par84">When collagen IV is cleaved proteolytically, it unveils hidden binding sites that may influence integrin specificity and alter its cellular functions. Proteolytic cleavage of collagen IV denatures its triple helical structure by MMPs such as MMP-2, revealing a cryptic site that is typically obscured [<xref ref-type="bibr" rid="CR135">135</xref>]. This shift in structure alters the integrin binding specificity from &#x003b2;1 integrin to &#x003b1;v&#x003b2;3 integrin, which promotes angiogenesis in melanoma [<xref ref-type="bibr" rid="CR136">136</xref>]. Thus, this alteration in integrin-mediated interactions may serve as a key regulatory mechanism for activating critical signaling pathways involved in invasive cellular behavior. However, the &#x003b1;v&#x003b2;3 integrin inhibits vascular endothelial cell (EC) and melanoma cell proliferation when engaging with the &#x003b1;3 chain of collagen IV [&#x003b1;3(IV)] [<xref ref-type="bibr" rid="CR136">136</xref>, <xref ref-type="bibr" rid="CR137">137</xref>]. Melanoma cell adhesion is enhanced by the coupling of &#x003b1;v&#x003b2;3 integrin with the &#x003b1;3(IV) chain, which simultaneously reduces cancer spread by suppressing MMP-2 expression [<xref ref-type="bibr" rid="CR138">138</xref>]. These findings suggest that modulating the &#x003b1;3 chain in the non-collagenous 1 fragment of collagen IV could offer novel strategies for inhibiting angiogenesis and tumor progression in melanoma.</p></sec></sec><sec id="Sec12"><title>Adherens junction (AJ)-mediated cell&#x02013;cell contact niche</title><sec id="Sec13"><title>Adherens junctions (AJ) in SSC niche</title><p id="Par85">Adherens junctions (AJs), formed by cadherin&#x02013;catenin complexes, are instrumental in maintaining cell-to-cell cohesion and preserving quiescent SSCs. Transmembrane E-cadherin is essential to AJs, facilitating lateral cell attachment through calcium-dependent binding in its extracellular regions [<xref ref-type="bibr" rid="CR139">139</xref>]. E-cadherin levels are high in AJs of quiescent bulge stem cells. However, during anagen, as HFSCs experience enhanced cell division and decreased FOXC1 (Forkhead box C1) expression, E-cadherin levels drop accordingly [<xref ref-type="bibr" rid="CR140">140</xref>]. This implies a negative correlation between the junction stability and SC proliferation.</p><p id="Par86">AJs are reinforced by intracellular associations with cytosolic &#x003b1;-, &#x003b2;-, and p120-catenin. &#x003b1;-Catenin connects AJs to the actin filament network, either through direct interaction or through actin-binding molecules such as vinculin [<xref ref-type="bibr" rid="CR141">141</xref>]. By stabilizing force transduction between actin and &#x003b1;-catenin, vinculin reinforces &#x003b1;-catenin interactions with both actin and &#x003b2;-catenin [<xref ref-type="bibr" rid="CR141">141</xref>]. &#x003b2;-catenin is both a critical component of AJs and a transcriptional activator in the canonical Wnt pathway [<xref ref-type="bibr" rid="CR142">142</xref>]. p120-catenin binds to the membrane-proximal portion of cadherins, recruiting microtubules to the cadherin-catenin junction. This interaction reinforces intercellular adhesion by stabilizing the junctional structure and enhancing cytoskeletal connections [<xref ref-type="bibr" rid="CR143">143</xref>]. p120-catenin regulates basal epidermal cell behavior by modulating the RAS homolog (RHO) GTPase activity. The cytosolic domain of p120-catenin inhibits RHOA activation by binding to p190RHOGAP (Rho GTPase activating protein 19), preventing RHO&#x02013;GDP (guanosine diphosphate) dissociation and its subsequent activity [<xref ref-type="bibr" rid="CR144">144</xref>, <xref ref-type="bibr" rid="CR145">145</xref>]. Integrin-activated RAC recruits p190RHOGAP to p120-catenin in AJs, leading to RHOA inactivation and regulation of cytoskeletal dynamics [<xref ref-type="bibr" rid="CR144">144</xref>]. This interaction partly elucidates the crosstalk between integrins and the RAC inhibition of RHOA in FAs.</p><p id="Par87">AJ components are critical for maintaining the SSC pool and facilitating differentiation in response to mechanical cues. In proliferating basal epidermal cells, AJs extend beyond the lateral sides to encompass the cortical surface, functioning as a crucial cell&#x02013;cell interface. In differentiating cells, AJs undergo remodeling, marked by a reduction in E-cadherin expression, which decreases adhesion forces and cortical tension in the early stages of differentiation [<xref ref-type="bibr" rid="CR146">146</xref>]. This reduction in cell interface tension and cell&#x02013;matrix contact enhances cell polarity and promotes delamination of basal keratinocytes. Upon detachment from the BM, differentiated keratinocytes lose cell&#x02013;matrix adhesion, including FAs, while concurrently reorganizing and potentially enhancing E-cadherin-mediated adhesion. This transition results in an elevated cortical tension state, which is correlated with a decrease in actomyosin contractility [<xref ref-type="bibr" rid="CR146">146</xref>, <xref ref-type="bibr" rid="CR147">147</xref>]. Thus, the re-establishment of AJs stabilizes the positioning of the suprabasal delaminated keratinocytes. Correspondingly, E-cadherin is expressed in basal SSCs, and its expression increases in the suprabasal layers [<xref ref-type="bibr" rid="CR147">147</xref>].</p><p id="Par88">The RHO family of small GTPases regulates AJ remodeling through modulation of actin dynamics and junctional integrity [<xref ref-type="bibr" rid="CR148">148</xref>]. Activated RAC1 specifically disrupts cadherin receptor localization without affecting integrins, resulting in disassembly of cadherin-mediated contacts in keratinocytes [<xref ref-type="bibr" rid="CR148">148</xref>], possibly by inducing E-cadherin endocytosis [<xref ref-type="bibr" rid="CR149">149</xref>]. These observations align with the initiation of SSC differentiation, during which &#x003b1;3&#x003b2;1 integrin-LM332 ligation in FAs activates RAC1-mediated cell migration [<xref ref-type="bibr" rid="CR67">67</xref>, <xref ref-type="bibr" rid="CR74">74</xref>]. This process coincides with actin polymerization and reduction of cell&#x02013;cell AJs [<xref ref-type="bibr" rid="CR149">149</xref>]. Further research is required to clarify how integrin and cadherin adhesion crosstalk regulates SSC behavior during epidermal regeneration.</p><p id="Par89">Cadherins serve as mechanical sensors, actively responding to mechanical signals from both the extracellular and intracellular mechanical signals. Through interactions with their intracellularly bound proteins, cadherins modulate actomyosin connections and signaling pathways, thereby facilitating SSC adaptation to sustained mechanical stimuli [<xref ref-type="bibr" rid="CR64">64</xref>]. Specifically, E-cadherin&#x02013;&#x003b1;-catenin (E&#x003b1;) complexes maintain the quiescent SSC population by inhibiting core signaling pathways involved in cell cycle activation, such as Wnt/&#x003b2;-catenin and YAP/TAZ pathways. Mechanical strain activates nuclear YAP and &#x003b2;-catenin, which enables quiescent SSCs to rapidly enter the cell cycle. This response relies on E-cadherin-mediated adhesion, which facilitates proliferation under mechanical stress [<xref ref-type="bibr" rid="CR150">150</xref>]. In keratinocytes, tensile force applied to E-cadherin-based contacts inhibits cell proliferation by impairing the translocation of &#x003b2;-catenin and YAP to the nucleus [<xref ref-type="bibr" rid="CR151">151</xref>]. E-cadherin stabilizes &#x003b2;-catenin, a crucial transcriptional co-activator of the lymphoid enhancer-binding factor 1 (LEF1)/ T-cell factor (TCF), by binding to it intracellularly and releasing it when necessary [<xref ref-type="bibr" rid="CR142">142</xref>]. This interaction prevents &#x003b2;-catenin from entering the nucleus and inhibits transcriptional &#x003b2;-catenin/LEF1 activity, thereby regulating Wnt signaling pathway. Conversely, destabilization of the cadherin complex releases &#x003b2;-catenin, which initiates Wnt signaling pathway and promotes SSC terminal differentiation [<xref ref-type="bibr" rid="CR142">142</xref>].</p><p id="Par90">&#x003b1;-catenin, a force-responsive component of AJs, preserves quiescent SSCs by maintaining AJ integrity and modulating intracellular YAP/TAZ signaling [<xref ref-type="bibr" rid="CR141">141</xref>, <xref ref-type="bibr" rid="CR152">152</xref>, <xref ref-type="bibr" rid="CR153">153</xref>]. The establishment of an intercellular bridge, which connects cytoskeletal actin filaments between adjacent cells via AJs, generates tensile forces across these junctions. Sequentially, tension-dependent conformational changes in &#x003b1;-catenin facilitate the exposure of previously concealed domains [<xref ref-type="bibr" rid="CR141">141</xref>]. This &#x003b1;-catenin variant, in conjunction with vinculin, is thought to locally reorganize actomyosin, reinforcing AJs and maintaining &#x003b1;-catenin in the extended conformation [<xref ref-type="bibr" rid="CR141">141</xref>]. This conformation stabilizes &#x003b1;-catenin through its association with actin, effectively sequestering YAP1 from &#x003b1;-catenin [<xref ref-type="bibr" rid="CR152">152</xref>]. Interestingly, an intermediate force generated during actomyosin binding at the AJ cell&#x02013;cell junctions stabilizes E&#x003b1; complexes. However, excessive force causes vinculin to dissociate from the &#x003b1;-catenin-actin complex, shifting &#x003b1;-catenin to an inhibited state and liberating YAP1 [<xref ref-type="bibr" rid="CR141">141</xref>]. By restricting YAP nuclear translocation, &#x003b1;-catenin serves as both an upstream modulator of YAP and an anti-oncogenic factor in the skin, ultimately inhibiting SC expansion [<xref ref-type="bibr" rid="CR153">153</xref>]. Additionally, &#x003b1;-catenin indirectly regulates YAP/TAZ activity by interacting with protein 14&#x02013;3-3, which retains YAP1 in cytoplasm [<xref ref-type="bibr" rid="CR153">153</xref>]. The E-cadherin-&#x003b1;-catenin-&#x003b2;-catenin complex can phosphorylate the Ser127 residue of YAP independently of the Hippo kinase cascades (mammalian sterile20-like 1 [MST1/2]-LATS1/2), thereby exposing its binding site for 14&#x02013;3-3 proteins [<xref ref-type="bibr" rid="CR152">152</xref>, <xref ref-type="bibr" rid="CR153">153</xref>]. Another alternative non-canonical Hippo pathway mechanism through which &#x003b1;-catenin regulates YAP/TAZ involves the suppression of &#x003b2;4 integrin-mediated SRC activation [<xref ref-type="bibr" rid="CR154">154</xref>]. In the absence of &#x003b1;-catenin, &#x003b2;4 integrin-mediated SRC becomes hyperactive, promoting YAP1/ TEA domain transcription factors (TEAD) transcriptional activity [<xref ref-type="bibr" rid="CR154">154</xref>]. Therefore, &#x003b1;-catenin exerts an inhibitory effect on SSC proliferation by directly or indirectly downregulating YAP1.</p></sec><sec id="Sec14"><title>Adherens junctions (AJ) in skin CSC niche</title><p id="Par91">Disruption of AJ integrity in skin epidermal cells, including impaired function or deficiency of E-cadherin or &#x003b1;-catenin, can trigger uncontrolled cell growth and tumorigenesis [<xref ref-type="bibr" rid="CR153">153</xref>, <xref ref-type="bibr" rid="CR155">155</xref>, <xref ref-type="bibr" rid="CR156">156</xref>]. Skin cancers, particularly aggressive variants with poor prognosis, frequently exhibit reduced E-cadherin and &#x003b1;-catenin expression [<xref ref-type="bibr" rid="CR155">155</xref>&#x02013;<xref ref-type="bibr" rid="CR159">159</xref>]. The expansion of proliferating SOX9-expressing stem cells occurs following inducible depletion of &#x003b1;-catenin in HFSCs, culminating in SCC tumor development in vivo [<xref ref-type="bibr" rid="CR152">152</xref>].</p><p id="Par92">The E-cadherin-&#x003b1;-catenin complex performs its oncosuppressive function by regulating multiple mechanisms, including inhibition of &#x003b2;-catenin signaling [<xref ref-type="bibr" rid="CR157">157</xref>], YAP/TAZ signaling [<xref ref-type="bibr" rid="CR150">150</xref>, <xref ref-type="bibr" rid="CR152">152</xref>, <xref ref-type="bibr" rid="CR153">153</xref>], FAK&#x02013;SRC signaling [<xref ref-type="bibr" rid="CR160">160</xref>], and the nuclear factor-kappa B (NF-&#x003ba;B) pathway [<xref ref-type="bibr" rid="CR155">155</xref>]. The elevated expression of neural (N)-cadherin adhesion and the downregulation of E-cadherin, which trigger EMT, coincide with the release of AJ-mediated inhibition of these signaling pathways. In melanoma, the abundance of cytoplasmic and nuclear &#x003b2;-catenin results from the downregulation of E-cadherin, promoting tumorigenic signaling, whereas in normal SSCs, E-cadherin sequesters &#x003b2;-catenin [<xref ref-type="bibr" rid="CR157">157</xref>]. Moreover, SRC activates N-cadherin phosphorylation, disrupting the &#x003b2;-catenin-cadherin binding and promoting &#x003b2;-catenin accumulation in the cytoplasm and nucleus during melanoma cell transendothelial migration [<xref ref-type="bibr" rid="CR161">161</xref>]. The increased transcriptional activity of nuclear &#x003b2;-catenin subsequently stimulates the upregulation of target genes essential for the progression and metastasis of skin cancers. These targets are <italic>c-MYC</italic>, <italic>VEGF</italic> (Vascular endothelial growth factor), <italic>TWIST-1</italic> (Twist-related protein-1), <italic>Wnt5a</italic> (Wnt family member 5a), <italic>SOX9</italic>, and <italic>MMPs</italic> [<xref ref-type="bibr" rid="CR162">162</xref>, <xref ref-type="bibr" rid="CR163">163</xref>]. Moreover, down-regulation of &#x003b1;-catenin correlates with increased nuclear phosphorylated NF-&#x003ba;B and STAT3, inducing inflammatory gene expression and aligning with typical features of human skin SCCs [<xref ref-type="bibr" rid="CR155">155</xref>]. Additionally, the YAP/TAZ signaling pathway involved in skin cancer progression evades AJ surveillance upon &#x003b1;-catenin reduction. Dysregulation of three independent pathways by which E-cadherin and &#x003b1;-catenin mediate YAP/TAZ activity has been observed during skin oncogenic transformation. The resultant increase in nuclear YAP/TAZ localization can be attributed to impaired sequestration of YAP/TAZ by &#x003b1;-catenin or its effector 14&#x02013;3-3 protein [<xref ref-type="bibr" rid="CR152">152</xref>]. Enhanced YAP/TAZ transcriptional activity, induced by &#x003b2;4 integrin-mediated SRC activation, may also contribute to the increased &#x003b1;-catenin-mediated YAP/TAZ activity [<xref ref-type="bibr" rid="CR154">154</xref>].</p><p id="Par93">Hyperproliferation and tumorigenesis in the skin are induced by p120-catenin loss, similar to the effects of &#x003b1;-catenin and E-cadherin depletion. E-cadherin loss disrupts the tumor suppressive role of p120-catenin, promoting cellular proliferation by enhancing NF-&#x003ba;B-mediated inflammation and aberrant RHOA hyperactivity in SCC [<xref ref-type="bibr" rid="CR164">164</xref>]. In melanoma, RAS/MAPK signaling activates p90 ribosomal S6 kinases (RSKs), which phosphorylate and reorganize p120-catenin, leading to a direct disruption of AJ integrity [<xref ref-type="bibr" rid="CR165">165</xref>]. Additionally, the reduction of cadherin-mediated adhesion may promote cell migration by activating RHO GTPases via p120-catenin reduction [<xref ref-type="bibr" rid="CR166">166</xref>]. However, the exact mechanisms and direct interactions involved in these processes in skin CSC niche remain unclear.</p><p id="Par94">Loss of E-cadherin coupled with upregulation of N-cadherin defines the &#x02018;cadherin switch&#x02019;, a critical driver of EMT and skin cancer metastasis. This shift in adhesive properties correlates with more aggressive behavior and progression of advanced-stage SCC [<xref ref-type="bibr" rid="CR167">167</xref>], BCC [<xref ref-type="bibr" rid="CR156">156</xref>, <xref ref-type="bibr" rid="CR168">168</xref>], and melanoma [<xref ref-type="bibr" rid="CR169">169</xref>]. For instance, E-cadherin loss stabilizes c-JUN protein and upregulates target genes [<xref ref-type="bibr" rid="CR170">170</xref>], such as MMP-9, MMP-14 and MMP-2 [<xref ref-type="bibr" rid="CR171">171</xref>, <xref ref-type="bibr" rid="CR172">172</xref>], key factors in driving melanoma metastasis. N-cadherin on melanoma cell surfaces enables selective binding to tumor-associated cells, such as vascular ECs and cancer-associated fibroblasts (CAFs), which naturally express N-cadherin [<xref ref-type="bibr" rid="CR169">169</xref>, <xref ref-type="bibr" rid="CR173">173</xref>, <xref ref-type="bibr" rid="CR174">174</xref>]. The intercellular connections formed by N-cadherin molecules are less stable than those formed by E-cadherin molecules, leading to increased motility in N-cadherin-expressing cells. Additionally, N-cadherin enhances melanoma cell persistence by activating the AKT pathway, thereby preventing apoptosis [<xref ref-type="bibr" rid="CR175">175</xref>]. Consequently, skin tumor cells acquire a mesenchymal phenotype during EMT, facilitating invasion into the dermis and promoting metastasis [<xref ref-type="bibr" rid="CR173">173</xref>, <xref ref-type="bibr" rid="CR176">176</xref>].</p><p id="Par95">Cadherin switching is triggered by various mechanisms in skin cancer progression, notably through transcriptional regulation of cadherin gene expression. Microenvironmental factors from tumor or stromal cells such as tumor-associated macrophages (TAMs) [<xref ref-type="bibr" rid="CR177">177</xref>], CAFs [<xref ref-type="bibr" rid="CR178">178</xref>], including fibroblast growth factors (FGF), TGF-&#x003b2;, EGF, and hepatocyte growth factor (HGF), contribute to cadherin switching [<xref ref-type="bibr" rid="CR179">179</xref>, <xref ref-type="bibr" rid="CR180">180</xref>]. Secreted factors and oncogenic pathways, including PTEN/PI3K and JAK/STAT3 activate EMT-related regulators such as Snail family transcriptional repressor 2 (SLUG), Zinc finger E-box binding homeobox (ZEB) 1/2, Snail family transcriptional repressor (SNAIL), TWIST1, Smad interacting protein (SIP) 1 and Transcription factor 3 (TCF3) [<xref ref-type="bibr" rid="CR176">176</xref>, <xref ref-type="bibr" rid="CR181">181</xref>, <xref ref-type="bibr" rid="CR182">182</xref>]. These transcriptional regulators enhance N-cadherin expression while downregulating E-cadherin in skin cancers [<xref ref-type="bibr" rid="CR168">168</xref>, <xref ref-type="bibr" rid="CR179">179</xref>, <xref ref-type="bibr" rid="CR183">183</xref>&#x02013;<xref ref-type="bibr" rid="CR186">186</xref>]. In particular, Snail-induced cylindromatosis lysine 63 deubiquitinase (CYLD) loss in melanoma promotes B cell lymphoma 3 (BCL3) ubiquitination, inducing N-cadherin expression [<xref ref-type="bibr" rid="CR187">187</xref>]. TWIST further facilitates EMT by directly repressing E-cadherin transcription through binding to the E-cadherin promoter at the E-box, or indirectly by activating SNAIL [<xref ref-type="bibr" rid="CR176">176</xref>, <xref ref-type="bibr" rid="CR188">188</xref>].</p><p id="Par96">Signaling pathways such as Notch, Wnt/&#x003b2;-catenin, Shh/GLI&#x000a0;(Glioma-associated oncogene homolog), PTEN/PI3K, and FAK/SRC are essential regulatory components for the conversion of E-cadherin to N-cadherin during cancer development. Activation of Notch1 enhances N-cadherin expression, thereby facilitating melanoma cell adhesion through N-cadherin interaction [<xref ref-type="bibr" rid="CR179">179</xref>, <xref ref-type="bibr" rid="CR189">189</xref>]. Loss of PTEN activity or hyperactivation of PI3K during melanoma progression correlates with the transition from E-cadherin to N-cadherin, coupled with upregulation of the transcription factors SNAIL and TWIST [<xref ref-type="bibr" rid="CR176">176</xref>]. Moreover, invasive cutaneous SCCs exhibit markedly reduced E-cadherin expression, accompanied by enhanced activity of the PI3K/AKT signaling pathway [<xref ref-type="bibr" rid="CR181">181</xref>]. Pharmacological AKT inhibition attenuates EMT progression by decreasing the mesenchymal marker SLUG and restoring E-cadherin, suggesting its potential as a therapeutic target in skin SCC [<xref ref-type="bibr" rid="CR181">181</xref>]. GLI2, a key mediator of Shh signaling, contributes to E-cadherin downregulation by inducing <italic>SNAIL</italic> in melanoma cells [<xref ref-type="bibr" rid="CR190">190</xref>]. The p38/NF-&#x003ba;B signaling cascade, activated by free &#x003b2;-catenin accumulating in the cytoplasm following E-cadherin loss, upregulates N-cadherin expression in melanoma cells [<xref ref-type="bibr" rid="CR191">191</xref>]. The upregulation of &#x003b2;1 integrin-mediated FAK/SRC signaling activates ERK1/2 and STAT3 pathways, which enhance the endocytosis of E-cadherin [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR192">192</xref>]. Inhibition of the FAK/SRC pathway with SRC inhibitors preserves membranous E-cadherin localization and effectively reduces melanoma cell migration [<xref ref-type="bibr" rid="CR192">192</xref>, <xref ref-type="bibr" rid="CR193">193</xref>]. Despite the proposed mechanisms underlying EMT, the precise regulatory pathways driving the cadherin switch in the skin CSC niche remain unclear.</p></sec></sec><sec id="Sec15"><title>Cellular compartments in SSC and CSC niche</title><p id="Par97">In addition to the epidermis&#x02019;s role in maintaining skin homeostasis, the dermis is a multifaceted layer of skin that provides structural support through its ECM and houses a variety of cells, including immune cells, fibroblasts, adipocytes, and endothelial cells. These cellular components play a significant role in regulating SSC behavior. The interaction between the cellular niche and SSCs is particularly important for HF development and epidermal regeneration [<xref ref-type="bibr" rid="CR194">194</xref>]. These cells undergo dynamic changes throughout the hair growth cycle, responding to signals from the epidermis in both normal and pathological conditions, such as wound healing.</p><p id="Par98">The roles of CSCs in self-renewal, tumor maintenance, and resistance to therapy are shaped by their interactions with surrounding cells, including immune cells, fibroblasts, adipocytes, and endothelial cells. Molecular signals secreted by CSCs in SCC, BCC, and melanoma can drive a malignant phenotype in adjacent cells, sustaining the TME. In turn, the surrounding cellular niche supports tumor survival, aggressiveness, and treatment resistance.</p><sec id="Sec16"><title>Fibroblasts</title><p id="Par99">
<list list-type="alpha-lower"><list-item><p id="Par100">Fibroblasts in SSC niche</p></list-item></list>
</p><p id="Par101">Human skin dermis contains heterogeneous fibroblast subpopulations, each with distinct structural and functional characteristics that play a role in regulating SSC fate and HF growth [<xref ref-type="bibr" rid="CR194">194</xref>, <xref ref-type="bibr" rid="CR195">195</xref>]. Apart from supporting HF regeneration, dermal fibroblasts also contribute to the maintenance of BM integrity through the synthesis of ECM proteins and collagen [<xref ref-type="bibr" rid="CR196">196</xref>, <xref ref-type="bibr" rid="CR197">197</xref>].</p><p id="Par102">Dermal fibroblasts play a dual role in promoting and inhibiting HFSC activation, thereby influencing HF development and maintaining the SSC pool. Papillary fibroblasts, located immediately beneath the epidermis, are essential for HF formation. In contrast, reticular fibroblasts, residing in the deeper dermis, primarily contribute to the synthesis of major constitutive components of the ECM [<xref ref-type="bibr" rid="CR196">196</xref>, <xref ref-type="bibr" rid="CR198">198</xref>]. Notably, the composition of the dermal fibroblast population shifts across the different stages of the HF cycle. During telogen, reticular fibroblasts dominate the dermis, while papillary fibroblasts become more prevalent during anagen [<xref ref-type="bibr" rid="CR198">198</xref>]. Stabilizing &#x003b2;-catenin in papillary fibroblasts prolongs the anagen phase, whereas its stabilization in reticular fibroblasts does not affect HF cycling [<xref ref-type="bibr" rid="CR199">199</xref>].</p><p id="Par103">Distinct fibroblast subsets exhibit differential responses to signals from SSCs throughout the HF cycle. Activated Wnt/&#x003b2;-catenin signaling in the epidermis increases the number of papillary and reticular fibroblasts [<xref ref-type="bibr" rid="CR198">198</xref>, <xref ref-type="bibr" rid="CR200">200</xref>]. Subsequently, Wnt/&#x003b2;-catenin-mediated enhancement of Shh signaling potentiates fibroblast proliferation in the papillary dermis, promoting HF growth. Epidermal TGF-&#x003b2; signaling, activated through Wnt/&#x003b2;-catenin, drives reticular fibroblasts to orchestrate ECM remodeling [<xref ref-type="bibr" rid="CR198">198</xref>]. However, when Shh signaling in fibroblasts is suppressed, both papillary and reticular fibroblasts fail to respond to epidermal &#x003b2;-catenin activation [<xref ref-type="bibr" rid="CR198">198</xref>]. This finding underscores the paramount role of dynamic Shh regulation in Wnt/&#x003b2;-catenin signaling during physiological HF cycling, ensuring the selective accumulation of fibroblasts in the anagen HF while curbing the aberrant hyperproliferation of quiescent HFSCs in the bulge [<xref ref-type="bibr" rid="CR33">33</xref>]. Meanwhile, paracrine TGF-&#x003b2;1 signaling acts as a trigger for reticular fibroblast proliferation and ECM protein synthesis, promoting collagen maturation [<xref ref-type="bibr" rid="CR198">198</xref>]. Activation of epidermal Wnt/&#x003b2;-catenin signaling enhances ECM-related gene expression, such as <italic>COL11A1</italic>, in dermal fibroblasts [<xref ref-type="bibr" rid="CR201">201</xref>]. Furthermore, by functioning as a negative feedback mechanism, dermal fibroblasts help preserve stem cell reservoir. During the telogen phase, these fibroblasts amplify the BMP (Bone morphogenetic protein) signaling pathway by releasing BMP4, which suppresses HFSC activation and preserves the SSC pool [<xref ref-type="bibr" rid="CR202">202</xref>]. In addition, the TGF-&#x003b2;2 signaling pathway, activated after Shh induction by Wnt/&#x003b2;-catenin, suppresses ECM production, collagen maturation, and fibroblast proliferation in the reticular dermis [<xref ref-type="bibr" rid="CR198">198</xref>]. This may act as a negative feedback mechanism, preventing ectopic HF formation and excessive ECM protein accumulation. However, the underlying mechanisms of these processes are not fully understood and warrant further investigation.</p><p id="Par104">
<list list-type="simple"><list-item><label>b.</label><p id="Par105">Fibroblasts in skin CSC niche</p></list-item></list>
</p><p id="Par106">CAFs are crucial for tumor progression, immune suppression, and treatment resistance in melanoma, SCC, and BCC [<xref ref-type="bibr" rid="CR203">203</xref>&#x02013;<xref ref-type="bibr" rid="CR205">205</xref>]. CAFs, characterized by &#x003b1;SMA (Alpha smooth muscle actin) upregulation, modulate the CSC niche by engaging various signaling pathways, promoting dermal fibroblast expansion and increasing ECM stiffness [<xref ref-type="bibr" rid="CR206">206</xref>]. The secretion of MMPs, such as MMP-2, MMP-11 and MMP-14, by these cells accelerates ECM degradation, promoting cancer cell invasion [<xref ref-type="bibr" rid="CR203">203</xref>, <xref ref-type="bibr" rid="CR204">204</xref>]. Notably, hyperactivation of YAP1 in CAFs enhances tumor cell adhesion to CAFs via N-cadherin. Furthermore, YAP-silenced CAFs fail to activate the PI3K/AKT signaling pathway when attaching to N-cadherin-expressing melanoma cells [<xref ref-type="bibr" rid="CR207">207</xref>]. In the melanoma microenvironment, N-cadherin-expressing fibroblasts and ECs can produce growth factors such as FGF, IGF-1 (Insulin-like growth factor), HIF (hypoxia-inducible factor), VEGF, and TGF-&#x003b2;. These factors foster MSLC&#x000a0;(melanoma stem-like cell) proliferation, contributing to melanoma progression [<xref ref-type="bibr" rid="CR208">208</xref>].</p><p id="Par107">CAFs are recognized as key factors limiting immunotherapy effectiveness, exhibiting a distinct profile of immunomodulatory proteins and secreted factors that influence both innate and adaptive immune mechanisms against tumors [<xref ref-type="bibr" rid="CR209">209</xref>]. For instance, CAFs can promote the infiltration and activity of immunosuppressive cells, including TAMs, myeloid-derived suppressor cells (MDSCs), and regulatory T cells (Tregs) in the melanoma microenvironment [<xref ref-type="bibr" rid="CR209">209</xref>, <xref ref-type="bibr" rid="CR210">210</xref>]. Additionally, CAFs can weaken the proliferation, survival, and cytotoxic capabilities of cytotoxic T cells (CTLs) [<xref ref-type="bibr" rid="CR211">211</xref>, <xref ref-type="bibr" rid="CR212">212</xref>] and natural killer (NK) cells [<xref ref-type="bibr" rid="CR213">213</xref>, <xref ref-type="bibr" rid="CR214">214</xref>]. Additionally, therapies targeting CAFs can enhance CTL and NK cell-mediated tumor elimination, while preventing the recruitment of MDSCs and Tregs [<xref ref-type="bibr" rid="CR210">210</xref>].</p><p id="Par108">T cell dysfunction in melanoma, which contributes to resistance to CTL treatment, is partially influenced by CAFs. Melanoma-derived fibroblasts secrete factors such as C&#x02013;C motif chemokine ligand 5 (CCL5), CCL2, and C-X-C motif chemokine ligand 12 (CXCL12), which induce immune checkpoint (ICP) ligand expression in melanoma cells, thereby compromising CD8<sup>+</sup> T cell function [<xref ref-type="bibr" rid="CR211">211</xref>, <xref ref-type="bibr" rid="CR212">212</xref>]. Notably, CAFs can shield tumor cells from immune attack by promoting the elimination of tumor antigen-specific CD8<sup>+</sup> T cells. Melanoma-derived CAFs engulf antigens and exhibit delayed antigen processing, acquiring features similar to those of antigen-presenting cells (APCs). This enhances their ability to present cross-priming antigens to T cells, thereby distracting and diverting T cell attention from tumor cells [<xref ref-type="bibr" rid="CR215">215</xref>]. Additionally, the simultaneous upregulation of FAS (Fas cell surface death receptor)/PD-1 (Programmed cell death protein 1) on T cells and FASL (Fas ligand)/PD-L2&#x000a0;(Programmed cell death ligand 2) on CAFs impairs the function and survival of tumor antigen-specific T cells, ultimately facilitating melanoma survival and progression [<xref ref-type="bibr" rid="CR215">215</xref>]. Conversely, enhanced infiltration of tumor antigen-specific CD8<sup>+</sup> T cells and reduced tumor volume are observed when the activity of PD-L2 or FASL on CAFs is blocked [<xref ref-type="bibr" rid="CR215">215</xref>]. Collectively, targeting CAFs could be a strategy to counteract immune evasion in skin cancers.</p><p id="Par109">In addition, CAFs can hinder the efficacy of immunotherapy through multiple mechanisms. Secreted factors like IL-6 and TGF-&#x003b2; from CAFs reduce the expression of major histocompatibility complex (MHC) I and II molecules in melanoma cells, promoting resistance to CTL-based therapies [<xref ref-type="bibr" rid="CR216">216</xref>, <xref ref-type="bibr" rid="CR217">217</xref>]. By disrupting NF-&#x003ba;B and ERK1/2 signaling, melanoma-associated CAFs restrict CTL function, reducing granzyme B secretion and impairing their capacity to kill melanoma cells [<xref ref-type="bibr" rid="CR218">218</xref>]. Furthermore, CAFs can reduce the effectiveness of anti-PD-1/PD-L1 therapy by concealing PD-1 molecules expressed on melanoma cells. Increased CAF accumulation within melanoma is associated with a reduced success rate of PD-1-targeted treatment [<xref ref-type="bibr" rid="CR219">219</xref>]. CAF-derived MMP-9 may contribute to resistance against anti-PD-1 therapy by cleaving PD-L1 from melanoma cell surfaces, potentially impairing immune system recognition [<xref ref-type="bibr" rid="CR220">220</xref>].</p><p id="Par110">CAFs can protect tumor cells from immune destruction by significantly altering the NK&#x000a0;cell-dependent anti-tumor immune response. CAFs decreased melanoma cell sensitivity to NK cell-mediated cytotoxicity by secreting high levels of MMPs, such as MMP-1, -2, -3, and -9. These MMPs promote the detachment of MHC class I polypeptide-related sequence A and B (MICA/B), ligands of NKG2D (Natural killer group 2 member D), from the surface of melanoma cells, weakening the NKG2D-mediated cytotoxic response of NK cells against tumor cells [<xref ref-type="bibr" rid="CR213">213</xref>]. Furthermore, MMP inhibitor restored the presence of MICA/B on the melanoma cell membrane, thereby enhancing their susceptibility to NK cell-mediated destruction [<xref ref-type="bibr" rid="CR213">213</xref>]. However, blocking MMP activity in CAF-conditioned media did not fully reinstate melanoma cell vulnerability to NK cell assault, indicating that MMPs are not the only contributors involved [<xref ref-type="bibr" rid="CR213">213</xref>]. Further investigation is required to ascertain whether MMP inhibitors can augment NK cell-mediated tumor surveillance or whether additional CAF-derived factors contribute to facilitating cancer resistance. Additionally, CAFs secrete prostaglandin E2, which inhibits the upregulation of natural killer cell p44 (NKp44) and NKp30 expression on NK cells, thereby impeding NK cell activation [<xref ref-type="bibr" rid="CR214">214</xref>]. These receptors enhance NK cell cytotoxicity by identifying and attaching to their specific ligands on tumor cells. Consequently, NK cells with low expression of these receptors impair their capacity to effectively target and eliminate tumor cells.</p><p id="Par111">CAFs contribute to the progression of SCC by inhibiting anti-tumor immunity and facilitating tumor invasion via ECM remodeling. These fibroblasts are scarce in pre-cancerous lesions, but their abundance increases in established SCC tumors, emphasizing their involvement in tumor advancement [<xref ref-type="bibr" rid="CR204">204</xref>]. Recurrent SCC shows an association between CAFs and upregulation of EMT markers, including TGF-&#x003b2;1 and vimentin. This is coupled with immunosuppressive traits in recurrent SCC, characterized by reduced inflammation and increased exhausted CD8<sup>+</sup> T cells [<xref ref-type="bibr" rid="CR221">221</xref>]. CAFs in relapsed SCC exhibit oncogenic properties, including impaired phagocytosis, reduced inflammation, and increased angiogenic potential, which collectively drive tumor proliferation and metastasis [<xref ref-type="bibr" rid="CR221">221</xref>].</p><p id="Par112">The interaction between CAFs and CSCs in the TME has been observed, but the precise role of CAFs in the CSC niche remains unclear. Melanoma cells attract dermal fibroblasts to the TME, inducing SOX2 expression in them and driving their transformation into CAFs [<xref ref-type="bibr" rid="CR222">222</xref>]. Additionally, melanoma cells persuade fibroblasts to adopt a CAF phenotype by secreting soluble factors such as platelet-derived growth factor (PDGF), FGF, and TGF-&#x003b2; [<xref ref-type="bibr" rid="CR217">217</xref>]. A heterogeneous population of fibroblasts, including cells with CAF-like properties, presented when dermal fibroblasts were cultured with melanoma spheroids [<xref ref-type="bibr" rid="CR223">223</xref>]. CAFs in melanoma stroma contribute significantly to tumor progression by interacting directly with tumor cells and secreting a variety of factors. These include ECM proteins like collagen, MMPs (MMP-2, -9, and -13), angiogenesis-related factors (VEGF), growth factors (TGF-&#x003b2;, HGF), and&#x000a0;chemokines such as CXCL-8 and IL-6, which affect tumor cell growth, metastatic potential, drug resistance, and CSC self-renewal [<xref ref-type="bibr" rid="CR212">212</xref>, <xref ref-type="bibr" rid="CR223">223</xref>&#x02013;<xref ref-type="bibr" rid="CR225">225</xref>].</p><p id="Par113">Moreover, CAFs have been demonstrated to modulate CSC behavior. CD44-expressing CAFs support the preservation of MSLC stemness and self-renewal capabilities through direct cellular interactions. However, the exact mechanistic pathways governing these interactions between CAFs and CSCs remain elusive. Interestingly, CD44<sup>+</sup> CAFs can sustain MSLC survival in avascular environments [<xref ref-type="bibr" rid="CR226">226</xref>]. Moreover, the abundance of CD44<sup>+</sup> CAFs in tumor tissues was exacerbated following angiogenesis suppression using anti-VEGF neutralizing antibodies [<xref ref-type="bibr" rid="CR226">226</xref>]. A synergistic approach targeting both CAFs and angiogenesis may potentiate therapeutic efficacy against malignant melanoma. These findings indicate that CAFs are implicated in the drug resistance mechanisms of malignant melanoma, particularly in relation to CSCs.</p><p id="Par114">Although CSCs and adjacent CAFs in the tumor stroma interact pathologically, the exact molecular and biological processes remain poorly understood. Furthermore, key signaling pathways, such as the YAP/TAZ signaling pathway, in regulating normal SSC and CSC development, are associated with drug resistance when activated in CAFs. Thus, investigating the interactions between CSCs and CAFs could offer valuable insights for overcoming resistance in skin cancer therapies.</p></sec><sec id="Sec17"><title>Immune cells</title><p id="Par115">
<list list-type="alpha-lower"><list-item><p id="Par116">Immune cells in SSC niche</p></list-item></list>
</p><p id="Par117">Immune cells in the epidermis and dermis, including innate and memory cells, are crucial for skin function and epidermal homeostasis. Although the specific molecules mediating the interactions between SSCs and immune cells are still being identified, it is evident that these cells mutually regulate their behavior and functions.</p><p id="Par118">Dendritic epidermal T cells (DETCs; &#x003b3;&#x003b4; T cells) and Langerhans cells are found in the epidermis, functioning as T cells and APCs, respectively [<xref ref-type="bibr" rid="CR227">227</xref>]. Despite their presence in the IFE and outer root sheath of HFs, the exact role these immune cells play in regulating SSC functions remains largely unknown [<xref ref-type="bibr" rid="CR227">227</xref>, <xref ref-type="bibr" rid="CR228">228</xref>]. Their influence on HFSCs has been observed particularly in wound healing scenarios. Activated DETCs stimulate HFSC proliferation for HF growth and the healing process [<xref ref-type="bibr" rid="CR229">229</xref>].</p><p id="Par119">Immune cells residing in the dermis, including macrophages, CD4<sup>+</sup>&#x02009;T cells, and Tregs, contribute to SSC development. These cells influence the natural process of HF regeneration by directly affecting the HFSC behavior [<xref ref-type="bibr" rid="CR230">230</xref>, <xref ref-type="bibr" rid="CR231">231</xref>]. Immune cells influence HFSC differentiation and activation through signaling pathways like Wnt/&#x003b2;-catenin, JAK/STAT, and JAGGED1/Notch within the SSC niche [<xref ref-type="bibr" rid="CR232">232</xref>]. Their distribution and function vary during hair development and growth phases [<xref ref-type="bibr" rid="CR231">231</xref>, <xref ref-type="bibr" rid="CR232">232</xref>].</p><p id="Par120">In the dermis, resident Tregs, especially CD4<sup>+</sup>&#x02009;Tregs, are the most prevalent immune cells, constituting approximately 20% of the total resident T cells. Tregs are predominantly localized in the vicinity of HFs, enabling dynamic interactions with bulge-derived HFSCs [<xref ref-type="bibr" rid="CR233">233</xref>]. When Tregs are depleted, there is a significant reduction in HF regeneration, emphasizing their critical function in modulating stem cell proliferation and maturation [<xref ref-type="bibr" rid="CR231">231</xref>]. The number and functional state of Tregs in the skin are tightly associated with distinct stages of the HF cycle. In the telogen phase, the abundance and activation of local Tregs drive the shift to anagen by promoting HFSC proliferation and differentiation. In contrast, Treg numbers decline throughout the anagen period [<xref ref-type="bibr" rid="CR231">231</xref>]. Most skin-resident Tregs, which express high levels of JAGGED1, rely on the Notch signaling pathway to activate HFSCs and modulate efficient hair regeneration [<xref ref-type="bibr" rid="CR231">231</xref>,&#x000a0;<xref ref-type="bibr" rid="CR234">234</xref>]. Absence of JAGGED1 on Tregs results in a substantial decrease in HFSC population and downregulation of critical epidermal differentiation genes, such as <italic>SOX7</italic>, <italic>SOX4</italic>, and <italic>CCND1</italic> (Cyclin D1) [<xref ref-type="bibr" rid="CR231">231</xref>]. The depletion of CD4<sup>+</sup>CD25<sup>+</sup>FOXP3<sup>+</sup> Tregs hampers CD34<sup>+</sup> HFSC proliferation, inhibiting their progression to the anagen phase [<xref ref-type="bibr" rid="CR231">231</xref>]. In addition to HF regeneration, Tregs aid in the regeneration of IFESCs. This role becomes apparent during epidermal repair following injury, where a particular population of Tregs enhances EGFR expression to promote wound healing [<xref ref-type="bibr" rid="CR235">235</xref>]. Overall, Tregs in the SSC niche primarily carry out non-immune functions, playing a role in supporting both epidermal and HF regeneration.</p><p id="Par121">HFSCs and IFESCs exhibit contrasting immunogenic profiles, facilitating their distinct physiological functions. While HFSCs can evade detection by T cells, IFESCs are recognized and eliminated by T cells promptly. Upon activation, local T cells expand and efficiently kill KRT14<sup>+</sup> IFESCs, which express high levels of MHC I [<xref ref-type="bibr" rid="CR236">236</xref>]. In contrast to IFESCs, LGR5<sup>+</sup> bulge HFSCs exhibit a downregulation of MHC I, which helps them avoid detection and destruction by T cells [<xref ref-type="bibr" rid="CR236">236</xref>]. Moreover, IFESCs are in close proximity to a dense population of resident immune cells, such as &#x003b3;&#x003b4; T cells and memory CD8<sup>+</sup> T cells, which serve as crucial immune effector cells in the initial response to both inflammation and cancer progression [<xref ref-type="bibr" rid="CR237">237</xref>, <xref ref-type="bibr" rid="CR238">238</xref>]. This supports the role of IFSCs and their differentiated cells as the primary defense against pathogens. The highly immunogenic IFESCs act as detectors of inflammatory signals and produce cytokines to sustain immune balance and a healthy physical barrier.</p><p id="Par122">In contrast, the HF region is characterized by immune privilege, which supports the maintenance of SSCs for both epidermal and HF regeneration. The dynamic activity of HFs and their signaling pathways during physical injury and the HF cycle recruit various immune cells. This recruitment increases the risk of immune activation and inflammation, putting HFSCs in the bulge niche at greater vulnerability. Therefore, the attenuated immunogenicity of the HFSC niche ensures the preservation of its population. HFSCs, situated in a Treg-dense niche, express the immunoinhibitory molecule CD200 [<xref ref-type="bibr" rid="CR239">239</xref>] and resist T-cell destruction, potentially resulting from reduced MHC I expression on their surfaces [<xref ref-type="bibr" rid="CR236">236</xref>]. In the telogen phase, high levels of MHC I protein are observed across the IFE and isthmus region of the HF, with the bulge being the only area showing low MHC I expression [<xref ref-type="bibr" rid="CR236">236</xref>]. This reduces their visibility to T cells, along with the high presence of resident Tregs, safeguarding the stem cell reservoir essential for lifelong skin regeneration.</p><p id="Par123">Macrophages are also crucial for regulating SSC activity. HFSC proliferation and hair growth are enhanced due to the depletion of TREM2<sup>+</sup> macrophages, which are present around the HF during the quiescent phase. These macrophages maintain HFSC dormancy during the telogen phase, preserving HF quiescence [<xref ref-type="bibr" rid="CR240">240</xref>]. Removal of skin-resident macrophages triggers premature HF growth, driven by the Wnt/&#x003b2;-catenin pathway in HFSCs [<xref ref-type="bibr" rid="CR230">230</xref>]. Additionally, the increase in macrophages expressing Wnt10a and Wnt7b coincides with the activation of bulge HFSCs before the onset of anagen [<xref ref-type="bibr" rid="CR230">230</xref>]. Thus, under normal conditions, macrophages act as key regulators of HFSC activity.</p><p id="Par124">
<list list-type="simple"><list-item><label>b.</label><p id="Par125">Immune cells in the skin CSC niche</p></list-item></list>
</p><p id="Par126">Recent research and current immunotherapy approaches have shown the clinical potential of targeting immune cells within the CSC niche for treating skin cancers, particularly melanoma [<xref ref-type="bibr" rid="CR241">241</xref>&#x02013;<xref ref-type="bibr" rid="CR243">243</xref>] and SCC [<xref ref-type="bibr" rid="CR244">244</xref>]. However, resistance, both primary and acquired, is commonly observed in advanced melanoma and SCC patients treated with immunotherapies like CTLs and ICP inhibitors [<xref ref-type="bibr" rid="CR245">245</xref>, <xref ref-type="bibr" rid="CR246">246</xref>]. This resistance is often associated with CSCs and other components of the CSC niche.</p><sec id="FPar7"><title>Decreased function of anti-tumor immune cells in CSC niche</title><p id="Par127">The immune cell niche typically helps eliminate malignant cells, but in the CSC niche, these responses turn immunosuppressive. The impaired anti-tumor functions of immune cells contribute to tumor cell evasion of immune surveillance by promoting inhibitory receptor expression and pro-inflammatory cytokine secretion in melanoma and SCC [<xref ref-type="bibr" rid="CR241">241</xref>&#x02013;<xref ref-type="bibr" rid="CR243">243</xref>, <xref ref-type="bibr" rid="CR247">247</xref>]. CD8<sup>+</sup> T cells are key effectors in cancer immune surveillance, leveraging their ability to identify and eliminate target cells through T-cell receptor (TCR) recognition of antigens displayed by MHC I molecules [<xref ref-type="bibr" rid="CR248">248</xref>]. However, despite their cytotoxic potential, CD8<sup>+</sup> T cells, especially those associated with CSCs, fail to mount a sustained and effective anti-tumor response in refractory melanoma and SCC.</p><p>MSLCs evade immune detection by downregulating melanoma-associated antigens (MAAs), preventing effective anti-tumor immune responses [<xref ref-type="bibr" rid="CR249">249</xref>, <xref ref-type="bibr" rid="CR250">250</xref>]. In melanoma, tumor cells typically express MAAs such as gp100, MAGE-A (Melanoma antigen family A), MART-1 (Melanoma antigen recognized by T cells 1), and CTAG1B (Cancer/testis antigen 1B), which attract MAA-specific CTLs for targeted destruction [<xref ref-type="bibr" rid="CR250">250</xref>]. CD133<sup>+</sup> CSCs in melanoma, which display elevated levels of MAAs like CTAG1B, are particularly susceptible to recognition by specific T cells [<xref ref-type="bibr" rid="CR251">251</xref>]. Nevertheless, a distinct subset of MSLCs suppresses MAA expression on their surfaces, thereby maintaining their immune privilege and protecting them from immune attack. Specifically, MSLCs expressing ABCB5 and CD271 demonstrate a marked attenuation in the levels of MAAs such as MART-1, CTAG1B, and MAGE-A [<xref ref-type="bibr" rid="CR249">249</xref>, <xref ref-type="bibr" rid="CR252">252</xref>, <xref ref-type="bibr" rid="CR253">253</xref>]. Moreover, CTL therapy can induce melanoma cell dedifferentiation, marked by increased CD271 (NGFR [Nerve growth factor receptor]) expression and reduced MAA levels, including gp100 and MART-1. Such changes contribute to resistance against CTLs and are associated with increased levels of TNF-&#x003b1;, an inflammatory mediator released by activated T cells [<xref ref-type="bibr" rid="CR254">254</xref>, <xref ref-type="bibr" rid="CR255">255</xref>]. Additionally, inhibition of CD271 can reverse melanoma resistance, restoring its vulnerability to T cell-mediated attacks. The presence of the CD271 signature in melanoma cells may predict resistance to anti-PD-1 treatment [<xref ref-type="bibr" rid="CR256">256</xref>].</p><p>MSLCs and their secreted factors impair cytotoxic T cell function. MSLCs expressing ABCB5 significantly reduce or completely lack MHC I expression [<xref ref-type="bibr" rid="CR249">249</xref>]. Melanoma cells lacking MHC I expression are unable to be recognized by CD8<sup>+</sup> T cells, impairing the anti-tumor immune response. Even when MAAs are present, the absence of functional MHC I molecules blocks CTL activation, further enabling immune evasion. Moreover, overexpression of PD-1, PD-L1, CD86, and B7-2 in ABCB5<sup>+</sup> MSLCs suppresses immune function by inducing T cell anergy, recruiting Tregs, and enhancing the secretion of immunosuppressive cytokines, such as IL-10 [<xref ref-type="bibr" rid="CR249">249</xref>, <xref ref-type="bibr" rid="CR257">257</xref>, <xref ref-type="bibr" rid="CR258">258</xref>]. On the other hand, ABCB5<sup>+</sup> MSLCs can release TGF-&#x003b2; family members, including TGFB2 and TGFB3, into the CSC niche, thereby reinforcing immunosuppression through the promotion of Treg activation [<xref ref-type="bibr" rid="CR249">249</xref>]. However, it remains unresolved whether this resistance is primarily driven by the inflammatory microenvironment, or if other factors within the CSC niche contribute significantly to the amplification of melanoma resistance to CTLs and various immunotherapeutic approaches.</p><p>Although T cells heavily infiltrate SCC, the presence of CSCs fosters resistance to T cell immunotherapy, preventing these immune cells from successfully eliminating the tumor in advanced stages of SCC [<xref ref-type="bibr" rid="CR259">259</xref>, <xref ref-type="bibr" rid="CR260">260</xref>]. A subset of CSCs in SCC preferentially evades T cells by upregulating CD80 in response to TGF-&#x003b2;, which promotes T cell exhaustion and contributes to tumor relapse [<xref ref-type="bibr" rid="CR261">261</xref>]. CD80 overexpression on CSCs within the SCC niche binds to cytotoxic T-lymphocyte antigen 4 (CTLA-4) on T cells, effectively suppressing T cell activity [<xref ref-type="bibr" rid="CR261">261</xref>]. Moreover, Tregs are implicated in SCC metastasis and may serve as important prognostic markers. The SCC microenvironment, especially in metastatic cases, shows significant accumulation of CD4<sup>+</sup>FOXP3<sup>+</sup> and CD8<sup>+</sup>FOXP3<sup>+</sup> Tregs [<xref ref-type="bibr" rid="CR262">262</xref>&#x02013;<xref ref-type="bibr" rid="CR264">264</xref>]. These tumor-infiltrating Tregs suppress the expansion of effector CD4<sup>+</sup> and CD8<sup>+</sup> T cells and their secretion of interferon gamma (IFN&#x003b3;) [<xref ref-type="bibr" rid="CR259">259</xref>]. However, it remains uncertain whether the elevated presence of Tregs or other immunosuppressive factors is directly associated with CSCs in the SCC microenvironment. Investigating the relationship between CSCs and immune system interactions may provide deeper insights into SCC progression.</p></sec><sec id="FPar8"><title>Increased immunosuppressive cells in CSC niche</title><p id="Par131">In addition to exhausted T cells in resistant tumors, immunosuppressive cells, such as Tregs, TAMs and tumor-associated neutrophils (TANs), are frequently observed and associated with drug resistance in the CSC niche.</p><p>
<bold>Tumor-associated macrophages (TAMs)</bold>
</p><p>TAMs, transitioning from M1 to M2 forms, are present in melanoma, SCC, and BCC, contributing to drug resistance and poor clinical outcomes [<xref ref-type="bibr" rid="CR265">265</xref>&#x02013;<xref ref-type="bibr" rid="CR271">271</xref>]. In SCC, IL-10, IL-4, and VEGF-A drive TAM polarization to the M2 type, promoting neovascularization [<xref ref-type="bibr" rid="CR272">272</xref>]. In BCC, an abundance of M2 macrophages has been linked to more aggressive disease, marked by deeper invasion and elevated microvessel density [<xref ref-type="bibr" rid="CR268">268</xref>]. Furthermore, co-culturing BCC cell lines with M2 macrophages significantly augments the invasiveness and angiogenic potential of tumor cells [<xref ref-type="bibr" rid="CR268">268</xref>]. In melanoma, M2 macrophages are primarily found in the early inflammatory infiltrate, whereas M1 macrophages, known for their anti-cancer activity, are present in much smaller numbers within the tumor [<xref ref-type="bibr" rid="CR273">273</xref>]. Moreover, melanoma cell-derived PD-L1 promotes macrophage polarization toward the TAM phenotype, exacerbating the immunosuppressive landscape of the TME [<xref ref-type="bibr" rid="CR274">274</xref>]. The secreted products from TAMs contribute to various processes, such as ECM remodeling, angiogenesis, pro-inflammatory cytokine production, and the promotion of local invasion and metastasis in melanoma, SCC, and BCC [<xref ref-type="bibr" rid="CR266">266</xref>, <xref ref-type="bibr" rid="CR268">268</xref>&#x02013;<xref ref-type="bibr" rid="CR270">270</xref>, <xref ref-type="bibr" rid="CR275">275</xref>]. TAM-secreted factors include a range of chemokines, including IL-2, IL-10, IL-1, TNF-&#x003b1;, IFN&#x003b3;, angiotensin, cyclooxygenase-2, CCL12, CCL17 and IL-1&#x003b2;. These chemokines recruit immunosuppressive cells, including Tregs, MDSCs, and T-helper 2 (Th2) cells, which are essential for sustaining the immunosuppressive TME [<xref ref-type="bibr" rid="CR265">265</xref>, <xref ref-type="bibr" rid="CR268">268</xref>, <xref ref-type="bibr" rid="CR269">269</xref>, <xref ref-type="bibr" rid="CR276">276</xref>&#x02013;<xref ref-type="bibr" rid="CR280">280</xref>]. TAMs also secrete VEGF and MMPs, such as MMP-9 and MMP-11 [<xref ref-type="bibr" rid="CR266">266</xref>, <xref ref-type="bibr" rid="CR268">268</xref>], which are crucial for tumor dissemination.</p><p>TAMs influence the TME by releasing chemokines that recruit immunosuppressive cells and cytokines that stimulate fibroblasts to release additional chemokines. For instance, IL-1&#x003b2; released by TAMs prompts fibroblasts to generate CXCR2 ligands, which are crucial for attracting MDSCs to melanoma tumors [<xref ref-type="bibr" rid="CR281">281</xref>, <xref ref-type="bibr" rid="CR282">282</xref>]. Additionally, the combined use of anti-CD115 antibodies, which significantly reduce TAMs by targeting CSF1R (Colony stimulating factor 1 receptor), and CXCR2 antagonists has demonstrated potent antitumor effects in vivo. This approach not only prevents the recruitment of granulocytic MDSCs via CXCR2 blockade but also depletes TAMs through CSF1R inhibition, thereby disrupting immune evasion mechanisms within the melanoma microenvironment [<xref ref-type="bibr" rid="CR282">282</xref>].</p><p>TAMs contribute to the failure of the immunomodulatory effects of chemotherapeutic agents in skin cancers. Increased TAMs and PD-L1 are associated with melanoma resistance to the single-agent BRAF (Serine/threonine-protein kinase B-raf) inhibitor dabrafenib or in combination with MEK (Mitogen-activated protein kinase) inhibitor trametinib [<xref ref-type="bibr" rid="CR283">283</xref>]. TAMs are associated with poorer prognosis, likely by facilitating immune evasion in melanoma [<xref ref-type="bibr" rid="CR273">273</xref>]. Similarly, improvements in treatment are associated with a reduction in TAM infiltration within SCC tumor tissues. Peplomycin enhances cytotoxic T lymphocyte presence and reduces TAM and Treg levels, potentially enhancing immune response and defense against SCC [<xref ref-type="bibr" rid="CR284">284</xref>]. TAMs in malignant melanoma exhibit elevated PD-L1 expression [<xref ref-type="bibr" rid="CR285">285</xref>], which impairs macrophage phagocytosis and diminishes their tumoricidal functions [<xref ref-type="bibr" rid="CR286">286</xref>]. The therapeutic efficacy of cytotoxic agents such as dacarbazine, vincristine, and nimustine hydrochloride relies on their ability to modulate TAM activity, notably through the suppression of PD-L1 expression and a decrease in CCL22 chemokine levels [<xref ref-type="bibr" rid="CR287">287</xref>]. These drugs, commonly used in adjuvant treatment for advanced melanoma, exert anti-TAM effects as a key aspect of their therapeutic action [<xref ref-type="bibr" rid="CR287">287</xref>]. Notably, circadian modulation of PD-1 expression on TAMs significantly affects the response to PD-1 inhibitors in melanoma treatment. The therapeutic impact of PD-1 inhibitors is considerably attenuated when TAMs exhibit minimal PD-1 expression on their surface during the daytime, thereby impairing the immune response [<xref ref-type="bibr" rid="CR288">288</xref>]. Intriguingly, DEC2 (differentiated embryo-chondrocyte expressed gene 2) transcriptionally regulates diurnal PD-1 expression on TAMs by inhibiting the time-dependent activation of <italic>PDCD1</italic> (Programmed cell death 1) through p65. Downregulation of DEC2 in macrophages increases <italic>PDCD1</italic> expression, encoding PD-1, which in turn enhances tumor cell clearance by anti-PD-1 therapy [<xref ref-type="bibr" rid="CR288">288</xref>]. Therefore, therapeutic interventions that modulate or block PD-L1 expression on TAMs can potentiate anti-tumor immunity.</p><p>In malignant skin tumors, CSC niches are intricately regulated by immune cells, particularly TAMs. SCC, originating from oncogenic mutations in IFESCs, exhibits infiltration of TAMs, which secrete VEGF within the CSC niche, thus fostering tumor growth [<xref ref-type="bibr" rid="CR246">246</xref>]. TAMs can support the survival of CD34-negative tumor-initiating cells and promote melanoma progression [<xref ref-type="bibr" rid="CR289">289</xref>]. TGF-&#x003b2; released from TAMs and Tregs in the hypoxic melanoma microenvironment induces glucosylceramide synthase (GCS) expression in melanoma cells, crucial for sustaining and expanding MSLCs [<xref ref-type="bibr" rid="CR290">290</xref>]. Inhibition of GCS effectively eliminates the immunosuppressive functions of Tregs and TAMs [<xref ref-type="bibr" rid="CR290">290</xref>]. The microphthalmia-associated transcription factor (MITF)-low melanoma, typically characterized by high stemness, produces a CCL2-rich secretome&#x000a0;[<xref ref-type="bibr" rid="CR291">291</xref>], which promotes the recruitment of TAMs. These observations imply that TAMs are crucial in the skin CSC niche and may become potential targets for future molecular therapies. However, the complex interplay between skin CSCs and TAMs, which underpins the maintenance and tumorigenic potential of CSCs, is yet to be fully understood.</p><p>
<bold>Tumor-associated neutrophils (TANs)</bold>
</p><p>The interplay between TANs and CSCs fosters sustained viability of CSCs, thereby driving the continued progression of skin cancer. Neutrophils initially act as the first line of defense in early inflammation, promoting immunostimulatory effects. However, they rapidly transform into TANs within the immunosuppressive TME of skin cancers. Melanoma [<xref ref-type="bibr" rid="CR292">292</xref>, <xref ref-type="bibr" rid="CR293">293</xref>] and SCC [<xref ref-type="bibr" rid="CR294">294</xref>] patients with abundant TAN infiltration often exhibit poorer therapeutic outcomes and advanced disease stages. The secretome of MSLCs, including IL-6, IL-8, GM-CSF (Granulocyte&#x02013;macrophage colony-stimulating factor), CCL2, and TGF-&#x003b2;, not only recruits neutrophils but also induces their polarization toward the protumor phenotype [<xref ref-type="bibr" rid="CR292">292</xref>, <xref ref-type="bibr" rid="CR295">295</xref>]. The activation of the STAT3/ERK and IL-8/CXCR2/NF-&#x003ba;B pathways in TANs is triggered by exposure to MSLC-conditioned medium [<xref ref-type="bibr" rid="CR295">295</xref>]. Moreover, MSLC-conditioned medium enhances ROS (Reactive oxygen species) production, cytokine release, MMP-9 secretion, and NET (neutrophil extracellular trap) formation in neutrophils, which collectively bolster the immunosuppressive and protumor functions of TANs. MSLC-activated neutrophils impart unique stem cell characteristics to melanoma cells, enhancing ABCG2 (ATP-binding cassette sub-family G member 2) expression and capacity to form melanospheres [<xref ref-type="bibr" rid="CR295">295</xref>]. The reciprocal interaction between CSCs and neutrophils in melanoma underscores the need for further research on tumor-promoting TANs in the skin CSC niche to better understand the mechanisms driving resistance in skin cancers.</p></sec></sec><sec id="Sec20"><title>Adipocytes</title><p id="Par139">
<list list-type="alpha-lower"><list-item><p id="Par140">Adipocytes in SSC niche</p></list-item></list>
</p><p id="Par141">Adipocytes, in conjunction with dermal fibroblasts, are crucial for epidermal integrity and HF cycling regulation. During anagen, intradermal adipose tissue regenerates, increasing the adipose layer thickness and enhancing adipocyte proliferation [<xref ref-type="bibr" rid="CR296">296</xref>]. Adipocytes and preadipocytes in the skin have contrasting roles in regulating HFSC activity during the physiological hair cycle [<xref ref-type="bibr" rid="CR297">297</xref>].</p><p id="Par142">Mature adipocytes in the dermis regulate the duration of the hair cycle&#x02019;s resting phase. Upon the activation of HFSCs for anagen, these adipocytes secrete BMP proteins [<xref ref-type="bibr" rid="CR298">298</xref>, <xref ref-type="bibr" rid="CR299">299</xref>]. As hair growth progresses, the increased in mature adipocytes enhances BMP ligand expression in the dermis [<xref ref-type="bibr" rid="CR298">298</xref>]. The expression of BMP2 in these adipocytes aligns with telogen phase, promoting HFSC quiescence and preventing overactivation. As the hair cycle shifts from telogen to anagen, preadipocytes release PDGF-&#x003b1;, which activates PDGF signaling in the dermal papilla, thereby stimulating HFSCs [<xref ref-type="bibr" rid="CR296">296</xref>]. The communication between adipocytes and HFs underscores the critical role of cellular&#x000a0;niche in supporting proper SSC development. When adipocyte precursor formation is blocked, the resulting loss of adipocytes disrupts HFSC activation and delays the onset of hair growth [<xref ref-type="bibr" rid="CR296">296</xref>]. The activation of HFSCs by preadipocytes is regulated by PPAR&#x003b3; (Peroxisome proliferator-activated receptor gamma), an adipogenic transcription factor predominantly expressed in preadipocytes. Inhibiting PPAR&#x003b3; before the onset of anagen disrupts the regrowth of adipose tissue in dermis by disrupting preadipocyte function [<xref ref-type="bibr" rid="CR296">296</xref>]. Furthermore, PPAR&#x003b3; antagonists did not impact epidermal proliferation or preadipocyte formation but effectively inhibited the development of PPAR&#x003b3;<sup>+</sup> preadipocytes [<xref ref-type="bibr" rid="CR296">296</xref>].</p><p id="Par143">The dynamic process of adipogenesis and its impact on HF growth are influenced by epidermal signals, particularly Shh and Wnt/&#x003b2;-catenin signaling [<xref ref-type="bibr" rid="CR300">300</xref>, <xref ref-type="bibr" rid="CR301">301</xref>]. Activation of Wnt/&#x003b2;-catenin in the epidermis stimulates HF growth and regulates adipogenesis, driving adipose tissue expansion and dermal adipocyte differentiation [<xref ref-type="bibr" rid="CR198">198</xref>,&#x000a0;<xref ref-type="bibr" rid="CR300">300</xref>]. The precise mechanism is not fully understood, but keratinocytes are thought to release proadipogenic factors like BMP2, BMP6, and IGF2, which promote adipocyte differentiation [<xref ref-type="bibr" rid="CR300">300</xref>]. The persistence of Wnt/&#x003b2;-catenin activation in the epidermis triggers abnormal HF growth and thickens the adipose tissue layer. This also causes an abnormal accumulation of adipocytes in the deeper dermis and their unusual presence in the superficial dermis, a region in which they are typically absent [<xref ref-type="bibr" rid="CR300">300</xref>]. Once anagen is initiated, TACs in HFs increase Shh production, promoting the proliferation and differentiation of preadipocytes through PPAR&#x003b3;, and enabling TACs to generate both their progeny and neighboring stromal lineages [<xref ref-type="bibr" rid="CR301">301</xref>].</p><p id="Par144">The functional roles of adipocytes in the HFSC niche have previously been identified. However, the role of adipocytes in other aspects of SSC development remains unclear. Future studies are required to uncover the molecular pathways through which adipocytes regulate SSC behavior and to determine whether SSCs can modulate adipocyte function.</p><p id="Par145">
<list list-type="simple"><list-item><label>b.</label><p id="Par146">Adipocytes in the skin CSC niche</p></list-item></list>
</p><p id="Par147">Although the involvement of cancer-associated adipocytes (CAAs) is well-documented in various cancers, their exact role in the skin CSC niche remains largely unexplored. In melanoma, the adipose tissue surrounding the tumor shows significant macrophage infiltration with TAM-like properties [<xref ref-type="bibr" rid="CR302">302</xref>]. The influx of macrophages prompts melanoma cells to secrete angiogenic factors like VEGF and pro-inflammatory cytokines such as MCSF (Macrophage colony-stimulating factor) and CCL2 [<xref ref-type="bibr" rid="CR303">303</xref>]. Considering the spatial proximity of adipose tissue to melanoma and SCC lesions, further investigation is imperative to elucidate their potential interactions and subsequent influence on tumorigenesis and progression [<xref ref-type="bibr" rid="CR302">302</xref>, <xref ref-type="bibr" rid="CR304">304</xref>].</p><p id="Par148">Adipose tissue in the skin cancer niche can influence the anti-cancer immune response. Secreted proteins from adipose tissue-derived macrophages, such as YKL-40 (chitinase-3-like protein 1), have been correlated with poor survival rates in melanoma patients [<xref ref-type="bibr" rid="CR305">305</xref>, <xref ref-type="bibr" rid="CR306">306</xref>]. This may be due to a TAM-related reduction in NK cell accumulation, which promotes pulmonary metastasis in melanoma [<xref ref-type="bibr" rid="CR307">307</xref>]. Adipocyte-derived TNF-&#x003b1; and IL-6 are positively associated with PD-L1 expression in melanoma [<xref ref-type="bibr" rid="CR308">308</xref>]. On the other hand, reduced adiponectin levels, commonly downregulated in cancer, foster melanoma progression while hindering the recruitment of tumor-suppressive macrophages to the TME [<xref ref-type="bibr" rid="CR309">309</xref>].</p><p id="Par149">Despite being abundant in the TME, the role of adipocytes in skin cancers and CSC development remains poorly understood. In cancers such as prostate cancer and breast cancer, adipocytes undergo differentiation into CAAs, exhibiting distinct characteristics from their normal counterparts [<xref ref-type="bibr" rid="CR310">310</xref>]. These CAAs contribute to tumorigenesis and protect tumor cells from therapeutic treatments. Consequently, exploring the interplay between the skin CSC niche and CAAs is crucial for devising more effective approaches to targeting and eradicating resistant skin cancers.</p></sec><sec id="Sec21"><title>Endothelial cells (ECs)</title><p id="Par150">
<list list-type="alpha-lower"><list-item><p id="Par151">Endothelial cells in SSC niche</p></list-item></list>
</p><p id="Par152">The epidermis and HFs are avascular and rely on nearby dermal blood vessels to supply nutrients. ECs support HF regeneration by promoting angiogenesis during the anagen phase and undergoing apoptosis in the catagen phase [<xref ref-type="bibr" rid="CR311">311</xref>]. As HFSCs in the hair germ prepare for activation during the transition from late catagen to telogen, the skin vasculature undergoes morphological changes [<xref ref-type="bibr" rid="CR311">311</xref>]. It becomes more horizontal, forming a distinct plexus with tightly packed blood vessels beneath the hair germ. This vascular network briefly aligns with the region where HFSC activation occurs during the telogen phase [<xref ref-type="bibr" rid="CR311">311</xref>]. During the resting phase, EGFL6 (Epidermal growth factor-like domain 6), an angiogenic factor expressed by K15-negative HFSCs above the bulge, may attract ECs to telogen HFs [<xref ref-type="bibr" rid="CR312">312</xref>]. As activated HFSCs proliferate from telogen to early anagen, the vascular plexus progressively disperses away from the proliferating hair germ [<xref ref-type="bibr" rid="CR311">311</xref>].</p><p id="Par153">ECs play a role in maintaining the SSC source. When angiogenesis is suppressed, anagen onset is delayed [<xref ref-type="bibr" rid="CR313">313</xref>]. However, during the late catagen and early telogen phases, an expanded vascular network near the hair germ generates BMP4 signals that sustain HFSC quiescence prior to activation and the initiation of hair growth [<xref ref-type="bibr" rid="CR311">311</xref>, <xref ref-type="bibr" rid="CR314">314</xref>]. Moreover, an enhanced density of the vascular network surrounding the hair germ during the telogen phase is concomitant with extended HFSC quiescence and a delayed transition into the anagen phase [<xref ref-type="bibr" rid="CR311">311</xref>]. These findings suggest that EC compartments may influence the timing of HFSC awakening from the resting state, ensuring proper skin homeostasis. Further studies are essential to elucidate the interactions between skin ECs and SSCs in epidermal regeneration.</p><p id="Par154">
<list list-type="simple"><list-item><label>b.</label><p id="Par155">Endothelial cells in skin CSC niche</p></list-item></list>
</p><p id="Par156">Neoangiogenesis in ECs is a critical driver of CSC development and tumor progression in melanoma, SCC, and BCC, providing essential support for tumor growth and metastasis [<xref ref-type="bibr" rid="CR315">315</xref>&#x02013;<xref ref-type="bibr" rid="CR317">317</xref>]. Several angiogenic growth factors and signaling pathways, including the VEGF family (VEGF-A, VEGF-B, VEGF-C, VEGF-D, and PLGF [Placental growth factor]), are increased in melanoma. The VEGF and its receptor can activate critical intracellular pathways, such as FAK, PI3K/ERK, PKC, and MAPK/ERK, which facilitate melanoma cell movement and tumor progression [<xref ref-type="bibr" rid="CR318">318</xref>]. Highly proliferative MSLCs, particularly at the tumor margins, produce crucial factors for angiogenesis and are closely associated with the early onset of vascularization [<xref ref-type="bibr" rid="CR319">319</xref>]. Particularly, MSLCs expressing ABCB5, CD133, and ABCG2 secrete proangiogenic factors, including TIE2 (Tyrosine kinase with immunoglobulin and epidermal growth factor homology domains 2), VEGF and its receptor VEGFR-2, MMP-2/&#x02212;9, and angiopoietin [<xref ref-type="bibr" rid="CR320">320</xref>&#x02013;<xref ref-type="bibr" rid="CR323">323</xref>]. Integrin &#x003b1;5&#x003b2;1 activation in melanoma cells highly expressing CD271 triggers the MAPK/ERK pathway, which activates STAT and HIF1&#x003b1; pathways. These signaling pathways reinforce the proangiogenic secretome of MSLCs by enhancing the production of angiogenic VEGF and IGF2 activators, while attenuating the levels of angiogenic inhibitors such as TIMP1 (tissue inhibitor of metalloproteinases 1) [<xref ref-type="bibr" rid="CR324">324</xref>]. Inhibition of integrin &#x003b1;5&#x003b2;1 or ERK1/2 signaling reduces both MSLC characteristics and its ability to promote angiogenesis [<xref ref-type="bibr" rid="CR324">324</xref>]. Overexpression of ALDH1A1 in melanoma cells stimulates the secretion of proangiogenic factors, including IL-8, activating the DLL4-dependent Notch signaling pathway in ECs and promoting angiogenesis. Moreover, there is a noticeable increase in the recruitment of ECs to melanomaspheres [<xref ref-type="bibr" rid="CR325">325</xref>].</p><p id="Par157">Vasculogenic mimicry (VM) refers to tumor cells adopting endothelial-like traits, reflecting the aggressiveness and plasticity of melanoma [<xref ref-type="bibr" rid="CR326">326</xref>, <xref ref-type="bibr" rid="CR327">327</xref>]. The CD133<sup>+</sup> and ABCB5<sup>+</sup> MSLCs in perivascular niches, expressing VE-cadherin, TIE2, VEGF, and VEGFR, possess the ability to acquire the VM phenotype and contribute to melanoma drug resistance [<xref ref-type="bibr" rid="CR322">322</xref>, <xref ref-type="bibr" rid="CR327">327</xref>]. Under hypoxia, endothelin-1 synthesis is induced, sustaining HIF-1&#x003b1;/2&#x003b1;-driven VEGF-A and VEGF-C expression in tumor cells and ECs, thereby promoting angiogenesis and melanoma cell migration&#x000a0;[<xref ref-type="bibr" rid="CR328">328</xref>]. The vasculogenic capacity and acquisition of MSLC traits are influenced by EC-derived signals, which are modulated through the endothelin B receptor (ETBR) and VEGFR [<xref ref-type="bibr" rid="CR328">328</xref>].</p><p id="Par158">MSLCs facilitate melanoma metastasis through their interaction with ECs. MSLCs engage their &#x003b1;4&#x003b2;1 integrin and E-selectin ligands with VCAM-1 and E-selectin on ECs, thereby enhancing migration along the endothelial surface [<xref ref-type="bibr" rid="CR329">329</xref>] (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). MSLCs can traverse EC junctions by binding their upregulated &#x003b1;5&#x003b2;1 and &#x003b1;6&#x003b2;4 integrins to fibronectin and laminin, respectively, which are present in endothelial and basement membranes [<xref ref-type="bibr" rid="CR329">329</xref>]. Given that the attachment of MSLCs to ECs initiates transendothelial navigation, targeting the adhesion proteins involved offers a promising therapeutic strategy for impeding cancer cell extravasation.</p><p id="Par159">ECs are integral in modulating the TME and constructing a vascular niche for CSCs in SCCs. As tumors advance, angiogenesis becomes increasingly pronounced, facilitating the progression of malignancy [<xref ref-type="bibr" rid="CR316">316</xref>, <xref ref-type="bibr" rid="CR330">330</xref>]. Angiogenesis progressively intensifies as SCC progresses to a malignant and invasive state. The enhanced density of the microvascular network in the TME strongly correlates with the upregulation of VEGF and its VEGFR2 receptors [<xref ref-type="bibr" rid="CR331">331</xref>]. Conversely, SCC regression correlates with a reduction in EC proliferation and vasculature density [<xref ref-type="bibr" rid="CR330">330</xref>]. Moreover, the VEGF/VEGFR2 signaling is instrumental in advancing SCC progression by establishing a supportive vascular niche for CSCs [<xref ref-type="bibr" rid="CR330">330</xref>]. The overexpression of VEGF in the epidermis promotes the expansion of the CD34<sup>+</sup> CSC pool in SCC. These cells exhibit significantly higher VEGF expression compared to CD34<sup>&#x02212;</sup> tumor cells or normal keratinocytes [<xref ref-type="bibr" rid="CR330">330</xref>]. In contrast, deficiency of VEGF or VEGFR2 in the epidermis impairs CSC proliferation and results in a remarkable reduction in SCC establishment. Neuropilin-1 (NRP1), a co-receptor of VEGF found in melanoma and SCC tumor cells, mediates the role of VEGF in maintaining CSC self-renewal. VEGF signaling activates NRP1 in CSCs, which enhances stemness and proliferative gene expression, sustaining tumor growth and CSC maintenance [<xref ref-type="bibr" rid="CR330">330</xref>]. The deletion of NRP1 and/or NRP2 specifically in ECs profoundly hampers melanoma progression and disrupts the angiogenic processes crucial for tumor vascularization [<xref ref-type="bibr" rid="CR332">332</xref>].</p><p id="Par160">EC activity in the skin CSC niche evidently contributes to the dynamic aggressiveness of CSCs. Elucidating the mechanisms of their interactions could provide crucial insights to develop targeted therapies against malignant skin cancers.</p></sec></sec></sec><sec id="Sec22"><title>Signaling regulation of SSCs and CSCs</title><sec id="Sec23"><title>Signaling regulation of skin stem cell niche</title><p id="Par161">The balance between SSC maintenance and lineage specification is mainly regulated by four core pathways, including the Shh, Wnt/&#x003b2;-catenin, YAP/TAZ, and Notch signaling pathways (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>).</p><sec id="Sec24"><title>Sonic Hedgehog signaling pathway</title><p id="Par162">Shh signaling is a crucial factor in the regeneration and preservation of IFESCs and HFSCs [<xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR333">333</xref>]. Shh pathway effectors, including GLI2 and GLI3, are expressed in the outer root sheath during the active stage and in the hair germ and bulge during the resting stage of the hair cycle [<xref ref-type="bibr" rid="CR33">33</xref>]. Hair growth regulation is influenced by GLI1 expression in the epidermis&#x000a0;layer and dermal papillae [<xref ref-type="bibr" rid="CR33">33</xref>]. Notably, GLI1 and GLI2 drive the activation of the Shh pathway, whereas GLI3 functions as a repressive modulator, attenuating its signaling [<xref ref-type="bibr" rid="CR334">334</xref>, <xref ref-type="bibr" rid="CR335">335</xref>]. GLI1 and SOX2, key target genes of Shh signaling, serve as distinct markers for the stem cell-like subpopulation in the dermal papilla, essential for its maintenance and HF regeneration [<xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR336">336</xref>]. Shh signaling inhibition disrupts HF cycle initiation and slows HFSC proliferation, preventing de novo HF formation [<xref ref-type="bibr" rid="CR333">333</xref>]. The enhanced Shh levels promote the renewal of SSCs by directly activating cell cycle regulators such as cyclin E, cyclin D, N-MYC, and c-MYC [<xref ref-type="bibr" rid="CR335">335</xref>, <xref ref-type="bibr" rid="CR337">337</xref>].</p><p id="Par163">The Shh signaling pathway holds a crucial function in HFSC regeneration and IFESC proliferation.&#x000a0;Patched 1 (<italic>PTCH1)</italic>, which encodes the PTCH1 receptor, is the main Shh transcriptional suppressor gene in the epidermis. The attenuated Shh transcriptional repressors, <italic>PTCH1</italic> and <italic>PTCH2</italic>, enhance SSC proliferation while suppressing cell differentiation [<xref ref-type="bibr" rid="CR338">338</xref>]. <italic>PTCH</italic> forms a crucial negative feedback loop that dampens Shh pathway activity by sequestering the Shh ligand [<xref ref-type="bibr" rid="CR339">339</xref>]. When Shh ligands are absent, PTCH1 receptor inhibits Smoothened (SMO) activity through a ligand-independent mechanism [<xref ref-type="bibr" rid="CR339">339</xref>]. When Shh binds to PTCH1, it triggers degradation of the SMO-PTCH complex, which enables the phosphorylation and activation of SMO. This activated SMO then initiates the canonical Shh signaling pathway, leading to GLI-dependent transcription of crucial targets for cell proliferation, such as cyclin D, <italic>PTCH1</italic>, <italic>SOX2</italic>, <italic>GLI1</italic>, and <italic>GLI2</italic> [<xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR336">336</xref>, <xref ref-type="bibr" rid="CR337">337</xref>]. In developing HFs, the expression of PTCH1 and GLI1 is highest at the proximal base and progressively decreases toward the IFE [<xref ref-type="bibr" rid="CR340">340</xref>]. During HF maturation, the hair germ at the HF base continues to express high levels of PTCH1 transcripts in response to increased Shh ligand production [<xref ref-type="bibr" rid="CR340">340</xref>]. Shh signaling weakens as the HF elongates and moves farther from the Shh source. In the quiescent basal IFE, low GLI1 transcriptional activity is observed in both basal IFESCs and those above the future HF bulge [<xref ref-type="bibr" rid="CR340">340</xref>]. Therefore, a gradient of Shh levels is mainly established by <italic>PTCH1</italic> across different SSC regions, with hair germ HFSCs exhibiting high Shh activity, while basal IFESCs exhibit low Shh expression [<xref ref-type="bibr" rid="CR340">340</xref>]. This is important for ensuring normal HF growth and IFESC maintenance.</p><p id="Par164">The Shh pathway interacts with Wnt/&#x003b2;-catenin and Notch in HF formation. In the epidermis, enhanced &#x003b2;-catenin activity elevates Shh and its receptor Patched (PTCH) levels [<xref ref-type="bibr" rid="CR341">341</xref>]. HES1 (Hairy and enhancer of split-1) stabilizes the GLI1<sup>+</sup> population in the lower bulge or hair germ, independent of canonical Notch signaling, promoting anagen initiation [<xref ref-type="bibr" rid="CR342">342</xref>]. Simultaneously, GLI1 activity promotes the inactivation of glycogen synthase kinase 3 beta (GSK3&#x003b2;) in anagen HF, resulting in increased nuclear &#x003b2;-catenin activation and stimulating SSC proliferation during the anagen phase of HF growth [<xref ref-type="bibr" rid="CR335">335</xref>]. However, Shh signalling can activate Wnt5a in human dermal papillae, which reduces LEF-1 levels and subsequently suppresses Wnt/&#x003b2;-catenin signaling [<xref ref-type="bibr" rid="CR343">343</xref>]. Therefore, the Shh/Wnt5a signaling promotes mature, differentiated HF formation by inhibiting proliferation and promoting differentiation of cells in human dermal papillae [<xref ref-type="bibr" rid="CR344">344</xref>]. Collectively, the interplay of these pathways precisely controls SSC proliferation and orchestrates the dynamics of hair growth.</p></sec><sec id="Sec25"><title>WNT/&#x003b2;-catenin signaling pathway</title><p id="Par165">The Wnt/&#x003b2;-catenin pathway is integral to maintaining, regenerating, and determining the fate of SSCs during skin development. Wnt ligands bind to frizzled (FZD) and low-density lipoprotein receptor-related protein (LRP) receptors, initiating signaling that disrupts the adenomatous polyposis coli (APC)/AXIN/Glycogen synthase kinase (GSK-3&#x003b2;) complex, preventing &#x003b2;-catenin degradation [<xref ref-type="bibr" rid="CR345">345</xref>]. Activated Wnt signaling upregulates &#x003b2;-catenin and LEF1, initiating a new HF growth cycle [<xref ref-type="bibr" rid="CR333">333</xref>]. Conversely, Wnt/&#x003b2;-catenin deficiency accelerates the premature differentiation of IFESCs and promotes HFSC quiescence in the bulge and hair germ during the telogen phase [<xref ref-type="bibr" rid="CR346">346</xref>]. Moreover, the Wnt3a subtype enhances SSC stemness by upregulating key factors in the BM niche, including <italic>COL4A1</italic>, <italic>ITGB4</italic>, <italic>ITGB1</italic> and <italic>ITGA6</italic> [<xref ref-type="bibr" rid="CR347">347</xref>].</p><p id="Par166">IFESCs and HFSCs rely on Wnt/&#x003b2;-catenin signaling to sustain quiescent SSCs and facilitate hair growth. SSCs that express <italic>AXIN2</italic> (Axin homolog 2), a Wnt target gene, are predominant in the basal epidermal layer and bulge niche [<xref ref-type="bibr" rid="CR346">346</xref>, <xref ref-type="bibr" rid="CR348">348</xref>]. These cells can secrete Wnt gene products, including <italic>Wnt1</italic>, <italic>Wnt3</italic>, <italic>Wnt4</italic>, <italic>Wnt6</italic>, <italic>Wnt10a</italic>, <italic>Wnt10b,</italic> and <italic>Wnt7b</italic>, to sustain their proliferative cycle renewal and release Wnt inhibitors to modulate IFESC proliferation [<xref ref-type="bibr" rid="CR346">346</xref>, <xref ref-type="bibr" rid="CR348">348</xref>]. Wnt ligands are predominantly localized in the basal layers, while elevated concentrations of Wnt inhibitors, such as DKK, are found in the suprabasal layers adjacent to AXIN2<sup>+</sup> SSCs [<xref ref-type="bibr" rid="CR346">346</xref>]. This distribution pattern may inhibit Wnt signaling in IFESCs, prompting these SCs to depart from the basal layer and trigger differentiation. AXIN2 is expressed exclusively in the outer bulge during the growth phase of the hair cycle, while the Wnt-inactive inner bulge, containing differentiated cells, expresses Dickkopf 3 (DKK3) [<xref ref-type="bibr" rid="CR348">348</xref>]. Moreover, Wnt suppressors such as SFRP1 (Secreted frizzled related protein 1) and DKK3 secreted by AXIN2<sup>+</sup> HFSCs are predominantly found in the outer regions of the bulge niche during the resting stage [<xref ref-type="bibr" rid="CR346">346</xref>, <xref ref-type="bibr" rid="CR348">348</xref>]. This finding provides insight into how Wnt/&#x003b2;-catenin activation is suppressed during the transition of HFs into the resting phase. Consequently, AXIN2<sup>+</sup> IFESCs and HFSCs can maintain their stemness while still being capable of committing to differentiation in an autocrine Wnt/&#x003b2;-catenin signaling manner.</p><p id="Par167">Wnt signaling not only regulates skin development but also governs melanocyte stem cell (MSC) development. Its activation in MSCs promotes pigmented hair formation by driving the commitment to melanocyte fate. Wnt/&#x003b2;-catenin signaling directs the differentiation of neural crest stem cells (NCSCs) into melanocytes during embryonic development by regulating the homeobox gene MITF [<xref ref-type="bibr" rid="CR349">349</xref>]. Conversely, a shortage of melanocytes occurs when &#x003b2;-catenin is deficient in NCSCs [<xref ref-type="bibr" rid="CR35">35</xref>].</p></sec><sec id="Sec26"><title>YAP/TAZ signaling pathway</title><p id="Par168">Mechanosensitive signaling pathways, such as YAP/TAZ, are responsible for sensing biomechanical pressures and regulating cell fate in SSCs [<xref ref-type="bibr" rid="CR350">350</xref>]. In proliferating basal epidermal cells, YAP is mainly nuclear, while its levels decline and it relocates to the cytoplasm during the differentiation of suprabasal cells [<xref ref-type="bibr" rid="CR153">153</xref>, <xref ref-type="bibr" rid="CR351">351</xref>]. Therefore, YAP facilitates the proliferation of SSCs, keeping them in an undifferentiated state, while reduced YAP activity is crucial for epidermal cell terminal differentiation [<xref ref-type="bibr" rid="CR351">351</xref>, <xref ref-type="bibr" rid="CR352">352</xref>]. The fate determination of SSCs is influenced by mechanical cues, such as tensile and compressive forces within their niche. Cell proliferation is enhanced by increased matrix stiffness through EGFR signaling activation via FA feedback [<xref ref-type="bibr" rid="CR353">353</xref>]. Meanwhile, increased contractility reduces E-cadherin expression in SSCs, which subsequently activates YAP1 and &#x003b2;-catenin signaling [<xref ref-type="bibr" rid="CR354">354</xref>]. Low mechanical pressure inactivates YAP/TAZ signaling, reducing SSC stemness and activating Notch signaling [<xref ref-type="bibr" rid="CR350">350</xref>]. Accordingly, keratinocytes on soft substrates stop proliferating and undergo differentiation [<xref ref-type="bibr" rid="CR355">355</xref>]. Furthermore, YAP/TAZ signaling is upregulated in a fibrous and rigid ECM environment but downregulated in a soft ECM environment [<xref ref-type="bibr" rid="CR350">350</xref>]. Therefore, ECM mechanical properties regulate SSC behavior and fate through the modulation of YAP/TAZ signaling.</p><p id="Par169">YAP/TAZ is crucial for preserving the quiescent SSC pool, which is contingent on adhesive proteins. In normal keratinocytes, the integrity of the hemidesmosome complex, which mainly consists of LM332 and integrin &#x003b1;6&#x003b2;4, regulates YAP signaling [<xref ref-type="bibr" rid="CR352">352</xref>, <xref ref-type="bibr" rid="CR356">356</xref>]. Disruption of the LM332-&#x003b1;6&#x003b2;4 connection caused by harmful mutations in <italic>LAMB3</italic> elevates cytoplasmic YAP level [<xref ref-type="bibr" rid="CR352">352</xref>]. The expansion of SSCs dependent on YAP/TAZ is mediated by the integrin-SRC interaction, which phosphorylates YAP directly or indirectly through PI3K stimulation, suppressing the MST-LATS in the Hippo kinase cascade [<xref ref-type="bibr" rid="CR356">356</xref>]. This activation of YAP/TAZ subsequently suppresses Notch signaling during SSC differentiation [<xref ref-type="bibr" rid="CR40">40</xref>]. LM332 regulates the balance between differentiation and proliferation of IFESCs by modulating YAP activity. Increased YAP/TAZ signaling and suppression of Notch activity, both associated with LM332 depletion, promote the regeneration of IFESCs [<xref ref-type="bibr" rid="CR40">40</xref>]. In <italic>LAMB3</italic>-deficient junctional epidermolysis bullosa, enhanced YAP expression effectively reinstates the clonogenic potential and proliferative capacity of IFESCs [<xref ref-type="bibr" rid="CR352">352</xref>].</p><p id="Par170">Skin cell density also regulates YAP signaling via &#x003b1;-catenin in AJs. &#x003b1;-catenin prevents YAP activation by promoting YAP/TAZ-14&#x02013;3-3 interaction [<xref ref-type="bibr" rid="CR153">153</xref>]. The &#x003b1;-catenin-mediated sequestration of YAP1 in the cytoplasm by 14&#x02013;3-3 proteins under high cell density conditions facilitates YAP1 phosphorylation [<xref ref-type="bibr" rid="CR153">153</xref>]. This process prevents nuclear localization and enhances the proteasomal degradation of YAP, thereby ensuring proper regulation. Nuclear YAP activity increases with the loss of 14&#x02013;3-3&#x003c3; function, inhibiting differentiation and stimulating basal epidermal progenitor expansion [<xref ref-type="bibr" rid="CR357">357</xref>].</p><p id="Par171">The YAP/TAZ pathway interacts with other core signaling pathways to sustain the SSC niche. Notch signaling regulates YAP/TAZ activity, which, in turn, also influences Notch signaling. Abnormal hyperactivity of YAP/TAZ can hinder SC differentiation by inhibiting Notch signaling, specifically through enhancing cis-inhibition by delta-like ligand 1 (DLL1) in SSCs [<xref ref-type="bibr" rid="CR350">350</xref>]. Conversely, weak mechanical forces generally suppress the transcriptional activity of YAP/TAZ by activating Notch signaling. This leads to the terminal differentiation of SSCs and loss of their stemness properties [<xref ref-type="bibr" rid="CR350">350</xref>]. Overexpression of GLI2/Shh, which is linked to YAP/TAZ transcriptional activity, is critical for SSC development [<xref ref-type="bibr" rid="CR358">358</xref>]. Additionally, YAP activation promotes SSC proliferation via the classical Wnt/&#x003b2;-catenin pathway by upregulating the downstream effector WNT16 [<xref ref-type="bibr" rid="CR359">359</xref>]. YAP-driven &#x003b2;-catenin expression enhances mitotic activity in basal epidermal cells [<xref ref-type="bibr" rid="CR360">360</xref>].</p><p id="Par172">In summary, YAP/TAZ signaling in the SSC niche acts as a critical intrinsic regulator of skin homeostasis, primarily by driving cell division and preserving the stemness of SSCs.</p></sec><sec id="Sec27"><title>Notch signaling pathway</title><p id="Par173">Notch signaling regulates SSCs by controlling their epidermal differentiation, proliferation, and fate determination. Activated Notch signaling coincides with increased differentiation markers, including spinous-specific genes like keratin 1/10, involucrin and the negative cell cycle regulator p21 [<xref ref-type="bibr" rid="CR361">361</xref>], which represses Wnt4 expression [<xref ref-type="bibr" rid="CR362">362</xref>]. Consequently, keratinocytes commit to leaving the SSC compartment, leading to their detachment from the BM and commence differentiation.</p><p id="Par174">The differentiation of SSCs and MSCs is driven by Notch signaling, mediated by Notch1&#x02013;4 receptors and ligands such as DLL1 and JAGGED1/2 within the SSC niche [<xref ref-type="bibr" rid="CR363">363</xref>, <xref ref-type="bibr" rid="CR364">364</xref>]. Notch1, the most active receptor in the epidermis, is expressed across both basal and suprabasal layers, and is found in SSCs, TACs, and differentiated keratinocytes [<xref ref-type="bibr" rid="CR363">363</xref>, <xref ref-type="bibr" rid="CR364">364</xref>]. In contrast, Notch2 and Notch3 are mainly expressed in the suprabasal layers, particularly in the spinous and granular cells, with Notch4 being nearly absent [<xref ref-type="bibr" rid="CR363">363</xref>&#x02013;<xref ref-type="bibr" rid="CR365">365</xref>]. While inactivation of Notch2 and Notch3 impairs terminal differentiation, knockdown of Notch1 predominantly accelerates cell proliferation, with a negligible impact on differentiation [<xref ref-type="bibr" rid="CR363">363</xref>]. JAGGED1/2 and DLL1 are predominantly expressed in the basal layer, where JAGGED1/2 promotes terminal differentiation, while DLL1 counteracts this effect [<xref ref-type="bibr" rid="CR363">363</xref>, <xref ref-type="bibr" rid="CR364">364</xref>]. Ligation of Notch ligands (DLL1 or JAGGED1/2) to Notch1 receptors in sender cells induces a cis-inhibition process. This enhances the binding of Notch receptors in neighboring receiver cells to ligands in sender cells, a phenomenon known as transactivation [<xref ref-type="bibr" rid="CR363">363</xref>]. Consequently, this activates Notch signaling in adjacent receiver cells by promoting paracrine Notch-ligand interactions. Activation of the Notch receptor leads to cleavage of its intracellular domain, which then translocates to the nucleus. In the nucleus, it associates with RBPJ (transcription factor C promoter-binding factor 1/recombination signal binding protein J/&#x003ba;), a transcription factor, to regulate the expression of genes such as <italic>HEY1</italic> (hairy/enhancer-of-split related with YRPW motif 1) and <italic>HES1</italic> [<xref ref-type="bibr" rid="CR365">365</xref>].</p><p id="Par175">Second, Notch signaling induces SSC differentiation by influencing the cohesion and formation of boundaries within the epidermis. Notch signaling induces basal keratinocyte detachment from the BM by downregulating &#x003b1;3&#x003b2;1 and &#x003b1;6&#x003b2;4 integrins and upregulating differentiation markers such as involucrin and keratin 1 [<xref ref-type="bibr" rid="CR361">361</xref>]. Additionally, activated Notch in human epidermal cells and SCC tumor cells inhibits the expression of ROCK2 and MRCK&#x003b1; (myotonic dystrophy kinase-related Cdc42-binding kinase), impairing cell migration&#x000a0;and&#x000a0;favoring the development of&#x000a0;well-differentiated tumors&#x000a0;by disrupting the expression of integrin &#x003b1;6&#x003b2;4 and Wnt7a [<xref ref-type="bibr" rid="CR366">366</xref>]. In contrast, increased activity of these molecules suppresses cell differentiation and enlarges the stem cell pool in SCC [<xref ref-type="bibr" rid="CR366">366</xref>]. Therefore, Notch1 functions as a tumor-suppressive regulator within the homeostatic SSC niche by preventing hyperproliferation.</p><p id="Par176">Thirdly, Notch signaling facilitates differentiation by downregulating p63 through a non-canonical pathway. p63 is prominently expressed in proliferative SSCs, with a marked reduction as cells undergo differentiation into suprabasal layers [<xref ref-type="bibr" rid="CR367">367</xref>]. Notch activation suppresses p63 expression by selectively influencing the interferon regulatory factors (IRFs), leading to decreased levels of IRF3 and IRF7 [<xref ref-type="bibr" rid="CR367">367</xref>], while increasing IRF6 [<xref ref-type="bibr" rid="CR368">368</xref>]. However, the reduction in p63 and its downstream effectors creates a negative feedback loop, which prevents excessive differentiation and maintains the SSC pool by inhibiting the Notch target gene <italic>HES1</italic> through p63 [<xref ref-type="bibr" rid="CR367">367</xref>]. Therefore, the interplay between Notch signaling and p63 is crucial for regulating SSC development.</p><p id="Par177">Fourthly, Notch signaling governs MSC development and differentiation, as evidenced by the elevated expression of Notch1 and its transcription factor HES1 in MSCs of the bulge niche [<xref ref-type="bibr" rid="CR369">369</xref>]. Deletion of Notch1 and Notch2 increases <italic>HES1</italic>-mediated apoptosis of MSCs and hair pigmentation disorders [<xref ref-type="bibr" rid="CR369">369</xref>]. Maintenance of the immature state and migration of melanoblasts are primarily regulated by Notch signaling. Notch inactivation leads to a graying hair phenotype, which can be reversed by overexpression of HES1 in the melanocyte lineage [<xref ref-type="bibr" rid="CR369">369</xref>].</p><p id="Par178">Finally, in addition to Notch-mediated SSC differentiation, intrinsic signaling helps sustain the SSC population. Notch ligand-mediated cis-inhibition of Notch in SSCs, driven by YAP/TAZ or Fringe enzymes, preserves the undifferentiated state of SSCs [<xref ref-type="bibr" rid="CR363">363</xref>]. Fringe proteins, known for binding to the EGF repeats of the Notch extracellular domain (NECD), can modify the affinity of the NECD for ligands in neighboring or the same cells [<xref ref-type="bibr" rid="CR370">370</xref>]. The most prominent of these is the lunatic fringe (LFNG), which is highly expressed in basal epidermal cells rich in DLL1 [<xref ref-type="bibr" rid="CR364">364</xref>]. LFNG enhances the affinity of Notch for DLL1 while simultaneously inhibiting signals from JAGGED [<xref ref-type="bibr" rid="CR371">371</xref>]. In cells overexpressing LFNG, reduced differentiation is reflected by decreased Notch downstream differentiation markers and HES1, while increased proliferation is indicated by elevated p63 levels [<xref ref-type="bibr" rid="CR364">364</xref>]. In contrast, JAGGED ligands induce differentiation in keratinocytes, selectively downregulating LFNG expression [<xref ref-type="bibr" rid="CR364">364</xref>]. Elevated levels of DLL1 enhance keratinocyte adhesion independently of Notch signaling, while impairing Notch activity, which inhibits the terminal differentiation of epidermal cells [<xref ref-type="bibr" rid="CR371">371</xref>]. Thus, DLL1, despite being present at lower concentrations than other Notch ligands and localized in SSCs, significantly contributes to sustaining stemness, with LFNG expression amplifying its function [<xref ref-type="bibr" rid="CR364">364</xref>].</p><p id="Par179">In summary, Notch signaling has significant effects on SSC differentiation, with its ability to either promote or inhibit differentiation determined by its engaging ligands. When this pathway is disrupted, Notch can adopt opposing roles, either promoting tumor suppression or driving oncogenesis.</p></sec><sec id="Sec28"><title>PI3K/AKT/mTOR and JAK/STAT3 signaling pathway</title><p id="Par180">The PI3K/AKT/mTOR and JAK/STAT3 signaling pathways play key roles in survival, proliferation, and regeneration of SSCs. In the SSC niche, PI3K/AKT/mTOR facilitates epidermal differentiation, while JAK/STAT3 helps maintain the resting state of SSCs. The positive impact of these pathways on cell proliferation and HF growth is particularly noticeable during epidermal regeneration following injury, inflammation, and cancer development [<xref ref-type="bibr" rid="CR372">372</xref>&#x02013;<xref ref-type="bibr" rid="CR376">376</xref>].</p><p id="Par181">The survival and proper differentiation of cells depend on PI3K/AKT signaling [<xref ref-type="bibr" rid="CR372">372</xref>]. During SSC differentiation, this pathway can be activated by EGFR, SRC family tyrosine kinases, and E-cadherin-mediated adhesion [<xref ref-type="bibr" rid="CR114">114</xref>, <xref ref-type="bibr" rid="CR356">356</xref>, <xref ref-type="bibr" rid="CR377">377</xref>]. Extracellular ligands bind to tyrosine kinase receptors, activating PI3K phosphorylation. This leads to the conversion of phosphatidylinositol (4,5)-bisphosphate (PIP2) to phosphatidylinositol (3,4,5)-trisphosphate (PIP3), which recruits AKT to the plasma membrane and activates mTORC1. This cascade then activates downstream effectors essential for survival, cell proliferation, and metabolism [<xref ref-type="bibr" rid="CR378">378</xref>, <xref ref-type="bibr" rid="CR379">379</xref>]. Active AKT is mainly found in post-mitotic suprabasal keratinocytes and in a subset of basal SSCs, which are loosely anchored to the BM and begin to migrate toward the spinous layer [<xref ref-type="bibr" rid="CR372">372</xref>]. AKT activation causes growth arrest in keratinocytes and initiates their differentiation. In contrast, the majority of proliferating basal SSCs do not exhibit AKT activation [<xref ref-type="bibr" rid="CR372">372</xref>]. In addition, PI3K signaling is crucial for preventing premature cell death in differentiating keratinocytes. Inhibition of this pathway activates selective caspase-3 and apoptosis in differentiating keratinocytes, while proliferating keratinocytes remain unaffected [<xref ref-type="bibr" rid="CR372">372</xref>]. Consequently, the PI3K signaling pathway governs epidermal cell differentiation and prevents apoptosis-driven cell death during this process.</p><p id="Par182">JAK/STAT3 signaling helps prevent SSC exhaustion and depletion by inhibiting their proliferative and activating capacity. JAK/STAT3 is implicated in anti-hair growth signaling [<xref ref-type="bibr" rid="CR380">380</xref>]. Inhibition of this pathway prompts HFSCs to exit their resting state and re-enter the hair cycle [<xref ref-type="bibr" rid="CR380">380</xref>]. In aged skin, inhibition of JAK/STAT3 signaling increases SSC proliferation in the IFE and bulge niche [<xref ref-type="bibr" rid="CR381">381</xref>]. On the other hand, hyperactive JAK/STAT3 signaling in aged mice is closely tied to impaired HFSC function [<xref ref-type="bibr" rid="CR381">381</xref>].</p><p id="Par183">STAT3 activation, a key component of JAK/STAT signaling, helps prevent programmed cell death and promotes proliferation of SSCs during skin regeneration, particularly in wound healing and HF growth [<xref ref-type="bibr" rid="CR375">375</xref>, <xref ref-type="bibr" rid="CR376">376</xref>]. The absence of STAT3 profoundly impairs the HF cycle activation, affecting the healing process [<xref ref-type="bibr" rid="CR375">375</xref>]. Cytokine receptors (e.g., IL-6, IL-11, CCL2), receptor tyrosine kinases (e.g., EGFR), and non-receptor tyrosine kinases like SRC can activate STAT3 [<xref ref-type="bibr" rid="CR382">382</xref>, <xref ref-type="bibr" rid="CR383">383</xref>]. Phosphorylated STAT3 dimerizes and moves to the nucleus, and modulates its targets such as cyclin D1, Bcl-xL (B-cell lymphoma-extra large), c-MYC, and TWIST [<xref ref-type="bibr" rid="CR384">384</xref>].</p><p id="Par184">STAT3 promotes epidermal cell differentiation and HF maturation. Its activation is evident in differentiating keratinocytes, whereas the abrogation of STAT3 activation results in a concomitant diminution in the expression of the differentiation marker keratin 1 [<xref ref-type="bibr" rid="CR385">385</xref>]. Moreover, keratinocytes lacking STAT3 exhibit increased adhesiveness and impaired migratory capacity [<xref ref-type="bibr" rid="CR386">386</xref>]. Conversely, the constitutively active STAT3C variant of STAT3, facilitates HFSC maturation within the bulge region and promotes their egress from the niche [<xref ref-type="bibr" rid="CR387">387</xref>].</p></sec></sec><sec id="Sec29"><title>Signaling regulation of skin cancer stem cell niche</title><p id="Par185">Signaling regulation in the normal SSC niche operates as a tightly woven network, where each signaling pathway and niche factor is precisely positioned to interact with surrounding elements, ensuring balanced epidermal homeostasis. Dysregulation of these fundamental signaling pathways, whether through pro-oncogenic events, latent mutations, or SC niche disturbance, can trigger uncontrolled proliferation and differentiation, thereby initiating and sustaining CSC populations. This complexity presents a significant challenge for effective skin cancer treatment. In the following sections, we will focus on how core signaling pathways in the SSC niche contribute to the CSC niche (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>), with particular emphasis on melanoma, SCC, and BCC.</p><sec id="Sec30"><title>Sonic Hedgehog signaling pathway</title><p id="Par186">Shh signaling is crucial for preserving the SSC pool, and its overactivation drives the continuous growth and expansion of CSCs. Shh signaling is a critical pathway involved in maintaining CSC properties in melanoma. MSLCs express pluripotency factors (<italic>OCT4, SOX2</italic>, and <italic>NANOG</italic>) and genes related to Shh downstream signaling (<italic>SHH</italic>, <italic>GLI2</italic>, <italic>GLI3, SMO</italic>, and <italic>PTCH1</italic>) [<xref ref-type="bibr" rid="CR388">388</xref>]. Blocking both <italic>SMO</italic> and <italic>GLI1</italic> significantly inhibits ALDH<sup>+</sup> MSLC self-renewal and tumorigenesis [<xref ref-type="bibr" rid="CR388">388</xref>]. The oncogenic gene <italic>WIP1</italic> positively regulates Shh activity in melanoma, and its silencing limits melanosphere formation by impairing <italic>GLI1</italic> and Shh signaling activation [<xref ref-type="bibr" rid="CR389">389</xref>].</p><p id="Par187">Abnormal Shh signaling is a prominent mechanism in BCC. PTCH1-mediated Shh repression is relieved through enhanced Shh binding to PTCH1 or mutational inactivation of <italic>PTCH1</italic>, resulting in unregulated SMO activation [<xref ref-type="bibr" rid="CR390">390</xref>]. Hyperactivation of the Shh pathway enhances the CSC population in the epidermis, driving epidermal hyperproliferation and facilitating oncogenic progression of BCC [<xref ref-type="bibr" rid="CR384">384</xref>]. GLI1 and GLI2 expression are tightly associated with the HFSC markers LGR4 and LGR5 in BCC [<xref ref-type="bibr" rid="CR391">391</xref>]. Furthermore, cells expressing GLI1 are predominantly localized in the hair bulb, a critical reservoir of CSCs involved in BCC formation, with their localization largely overlapping the region expressing LGR5 [<xref ref-type="bibr" rid="CR391">391</xref>, <xref ref-type="bibr" rid="CR392">392</xref>]. In addition, GLI1 is significantly upregulated and is necessary for the CD200<sup>+</sup> cells in BCC tumors to function properly [<xref ref-type="bibr" rid="CR20">20</xref>]. CD200<sup>+</sup>CD45<sup>&#x02212;</sup> cells in BCC display stem cell-like properties and chemotherapy resistance, with sustained Shh activation [<xref ref-type="bibr" rid="CR20">20</xref>]. These findings propose a potential BCC treatment strategy combining anti-CD200 neutralizing antibodies and SMO inhibitors.</p></sec><sec id="Sec31"><title>Wnt/&#x003b2;-catenin signaling pathway</title><p id="Par188">In the CSC niche, dysregulation of the Wnt/&#x003b2;-catenin pathway disrupts its ability to prevent CSC hyperproliferation. Silencing &#x003b2;-catenin depletes CD34<sup>+&#x000a0;</sup>CSCs and suppresses SCCs, whereas overexpression of nuclear &#x003b2;-catenin results in SCC-like tumors and an expanded CSC pool in the bulge [<xref ref-type="bibr" rid="CR393">393</xref>]. Furthermore, diminished Wnt/&#x003b2;-catenin correlates with reduced levels of its effector SOX9 and impaired tumor cell proliferation in metastatic SCCs [<xref ref-type="bibr" rid="CR394">394</xref>].</p><p id="Par189">Wnt/&#x003b2;-catenin signaling is crucial for melanoma initiation and metastasis, regulating the functional and biological traits of MSLCs. Its activation promotes EMT and fosters the acquisition of stem-like properties in melanoma [<xref ref-type="bibr" rid="CR395">395</xref>]. For instance, it enhances the prometastatic properties of MSLCs that express CD133 [<xref ref-type="bibr" rid="CR396">396</xref>]. Disruption of Wnt/&#x003b2;-catenin signaling in MSLCs diminishes stemness features, impairs migration, and limits proangiogenesis [<xref ref-type="bibr" rid="CR397">397</xref>]. Targeting the Wnt/&#x003b2;-catenin pathway to eliminate CSCs could significantly enhance the effectiveness of melanoma treatments.</p><p id="Par190">EMT enhancement and accelerated skin cancer metastasis are driven by the Wnt/&#x003b2;-catenin signaling cascade. A critical event in melanoma, EMT initiation, involves the disruption of &#x003b2;-catenin/E-cadherin complexes. This process liberates &#x003b2;-catenin, which in turn hyperactivates the Wnt pathway, driving the progression and metastatic potential of melanoma [<xref ref-type="bibr" rid="CR398">398</xref>]. Additionally, Wnt5a overexpression in melanoma cells activates PKC, upregulating MMP-2 and promoting cell spread [<xref ref-type="bibr" rid="CR399">399</xref>]. This process decreases E-cadherin expression and simultaneously upregulates EMT markers such as vimentin and SNAIL [<xref ref-type="bibr" rid="CR399">399</xref>]. SNAIL and SLUG promote &#x003b2;-catenin/LEF1 transcription during EMT by downregulating E-cadherin, which allows &#x003b2;-catenin to translocate to the nucleus [<xref ref-type="bibr" rid="CR400">400</xref>].</p></sec><sec id="Sec32"><title>YAP/TAZ signaling pathway</title><p id="Par191">YAP/TAZ hyperactivation enhances the growth and survival of melanoma, SCC, and BCC tumors in a fibrotic and dysregulated signaling niche. High YAP/TAZ activity contributes to BCC and SCC development. The knockout of YAP/TAZ in epidermal basal cells inhibits BCC and SCC tumor formation [<xref ref-type="bibr" rid="CR28">28</xref>]. Enhanced expression of YAP/TAZ has been implicated in melanoma progression and may significantly affect postoperative survival outcomes in patients [<xref ref-type="bibr" rid="CR401">401</xref>].</p><p id="Par192">Condensed ECM activates YAP/TAZ signaling, maintaining stemness in tumor cells within the CSC niche. The stiff ECM surrounding the SCC tumor stimulates YAP/TAZ signaling through Hippo-independent pathways, including PI3K/AKT and ERK [<xref ref-type="bibr" rid="CR402">402</xref>]. Ectopic expression of YAP in BCC is influenced and promoted by the stiffness of the tumor niche. Shh/GLI2 signaling, which mediates the c-JUN/AP1&#x000a0;(Activator protein 1) axis, may promote YAP function [<xref ref-type="bibr" rid="CR358">358</xref>, <xref ref-type="bibr" rid="CR403">403</xref>]. Furthermore, hyperactivation of YAP and its downstream molecules, such as connective tissue growth factor (CTGF) and cysteine-rich protein 61 (Cyr61), was observed in BCC [<xref ref-type="bibr" rid="CR404">404</xref>]. Notably, Cyr61 can induce aberrant proliferation of epidermal basal cells and CTGF can remodel the tumor microenvironment [<xref ref-type="bibr" rid="CR404">404</xref>].</p><p id="Par193">YAP/TAZ plays a key role in determining MSLC fate within various ECM environments in the CSC niche. In a collagen-induced stiff matrix, nuclear YAP/TAZ signaling is triggered by enhanced FAK/SRC phosphorylation, regulated by FAs [<xref ref-type="bibr" rid="CR405">405</xref>]. This activation promotes a differentiated/proliferative MITF-high phenotype in melanoma cells, which exhibit enhanced spreading in a rigid collagen matrix [<xref ref-type="bibr" rid="CR405">405</xref>]. This contrasts with the canonical YAP/TAZ pathway via YAP/TEAD signaling, which promotes the resting state of SSCs and CSCs. YAP/TAZ-induced differentiation of melanoma cells occurs through a transcriptional interaction with PAX3 (Paired box 3), which activates MITF gene expression in these cells [<xref ref-type="bibr" rid="CR405">405</xref>, <xref ref-type="bibr" rid="CR406">406</xref>]. Nevertheless, YAP/TAZ suppresses MITF expression and induces a de-differentiated melanoma phenotype in a fibroblast-rich matrix. This effect is attributed to fibroblast-secreted TGF-&#x003b2;, which activates YAP/TEAD transcription while inhibiting YAP/PAX3-driven MITF expression [<xref ref-type="bibr" rid="CR405">405</xref>]. Mechanistically, TGF-&#x003b2; downregulates PAX3 expression [<xref ref-type="bibr" rid="CR407">407</xref>], limiting the availability of PAX3 for YAP binding. Moreover, PAX3 depletion decreases YAP association with the MITF promoter and increases its interaction with the CTGF (connective-tissue growth factor) promoter [<xref ref-type="bibr" rid="CR405">405</xref>], which is responsive to TGF-&#x003b2; [<xref ref-type="bibr" rid="CR408">408</xref>]. In summary, YAP/TAZ promotes melanoma cell proliferation and invasion while preserving MSLC stemness. Therefore, combining treatments that target stromal components to modulate various aspects of YAP/TAZ activity may help overcome resistance in melanoma and other skin cancers.</p></sec><sec id="Sec33"><title>Notch signaling pathway</title><p id="Par194">In skin cancers, Notch signaling plays dual roles as both an oncogene and tumor suppressor, contrasting its tumor-suppressive function in the SSC niche. Loss-of-function mutations that inactivate Notch contribute to cutaneous SCC formation by disrupting its role in differentiation and preventing hyperproliferation [<xref ref-type="bibr" rid="CR409">409</xref>]. Alterations in <italic>NOTCH1</italic> and <italic>NOTCH2</italic> genes, leading to their inactivation, are frequently observed in both SCC and BCC. Among 88 SCC tumors, <italic>NOTCH1</italic> mutations were found in 55.4% of cases, and <italic>NOTCH2</italic> mutations in 36.1% [<xref ref-type="bibr" rid="CR410">410</xref>]. Of the 293 BCC tumors analyzed, 25%&#x000a0;of 85 BCCs and 30% of 76 BCCs exhibit&#x000a0;loss of function mutations in <italic>NOTCH1</italic> and <italic>NOTCH2</italic>, respectively&#x000a0;[<xref ref-type="bibr" rid="CR411">411</xref>]. These findings align with the role of Notch signaling in restraining cancer progression in skin malignancies [<xref ref-type="bibr" rid="CR412">412</xref>]. These loss of function&#x000a0;mutations impair receptor-ligand interactions, thereby disrupting signaling pathways [<xref ref-type="bibr" rid="CR410">410</xref>, <xref ref-type="bibr" rid="CR411">411</xref>, <xref ref-type="bibr" rid="CR413">413</xref>, <xref ref-type="bibr" rid="CR414">414</xref>]. In SCC patients, mutations in the EGF-repeat region, such as D469G (missense) in <italic>NOTCH1</italic> and Q610* and W330* (nonsense) in <italic>NOTCH1</italic> and <italic>NOTCH2</italic>, respectively, impair the binding of the Notch receptor to DLL1 [<xref ref-type="bibr" rid="CR415">415</xref>], effectively blocking DLL1-dependent signaling. Another type of mutation that impairs Notch function involves disruption of Notch/RBPJ complex formation. For example, the P1770S mutation in the RAM (RBPJk&#x02013;associated molecule) domain of <italic>NOTCH1</italic> interferes with its binding to RBPJ, preventing the assembly of functional Notch transcription complexes [<xref ref-type="bibr" rid="CR416">416</xref>]. This disruption blocks the activation of downstream gene expression mediated by Notch signaling. A novel mechanism driving <italic>NOTCH</italic> inactivation in SCC is through mutations in its transcriptional regulator, EP300 (p300) [<xref ref-type="bibr" rid="CR410">410</xref>]. The histone acetyltransferase domain of EP300, essential for its function as a transcriptional co-activator of <italic>NOTCH1</italic>, harbors hotspot mutations [<xref ref-type="bibr" rid="CR417">417</xref>]. Additionally, the expression of HES1, HEY1, and the canonical Notch transcription factor RBPJ is downregulated in CD133<sup>+</sup> stem-like&#x000a0;subsets&#x000a0;in SCC tumors [<xref ref-type="bibr" rid="CR418">418</xref>]. Despite the high&#x000a0;frequency of <italic>NOTCH</italic> driver mutations in skin cancers, their direct relationship with CSCs is yet to be explored.</p><p id="Par195">On the other hand, suppressing Notch1 diminishes tumor growth, likely due to its non-canonical functions. Inhibition of Notch1 signaling reduces the number and tumorigenicity of CD133<sup>+</sup> CSCs [<xref ref-type="bibr" rid="CR418">418</xref>]. This observation pertains specifically to the impairment of the IKK&#x003b1;/NF-&#x003ba;B axis, a non-canonical Notch pathway that induces tumor cell death. In CD133<sup>+</sup> CSCs from SCCs, upregulation is seen in genes associated with the Notch (<italic>JAGGED2</italic>, <italic>NOTCH1</italic>), Shh (<italic>GLI2</italic>, <italic>PTCH1</italic>, <italic>SUFU</italic>), and Wnt (<italic>CTNNB1</italic>, <italic>WNT3</italic>) pathways [<xref ref-type="bibr" rid="CR418">418</xref>]. Notch signaling promotes melanoma cell survival and invasiveness by post-translationally stimulating the PI3K/AKT pathway [<xref ref-type="bibr" rid="CR189">189</xref>]. Conversely, stabilized HIF-1&#x003b1;, in conjunction with PI3K/AKT activation, enhances Notch signaling in melanoma [<xref ref-type="bibr" rid="CR419">419</xref>]. These findings suggest that dysregulated Notch signaling, skewed toward a non-canonical pathway and hindering classical Notch function, may redirect Notch from its anti-tumor role to a tumorigenic promoter.</p><p id="Par196">Notch signaling is critical for sustaining CSC populations. In melanoma, Notch activity enhances melanoblast proliferation and CD133 expression, thereby facilitating MSLC expansion [<xref ref-type="bibr" rid="CR321">321</xref>]. Inhibition of &#x003b3;-secretase and tumor necrosis factor-alpha converting enzyme (TACE) prevents melanosphere establishment by downregulating NICD2 and HES1 [<xref ref-type="bibr" rid="CR420">420</xref>]. Additionally, Notch signaling promotes cyclin D1 expression, driving the G1 to S phase transition [<xref ref-type="bibr" rid="CR421">421</xref>]. Mechanistically, Notch signaling activation supports the preservation of MSLCs by either inducing its downstream effector HES1 [<xref ref-type="bibr" rid="CR369">369</xref>] or activating HIF1&#x003b1;/&#x003b2;, promoting the upregulation of tumor-related genes such as <italic>VEGF</italic> [<xref ref-type="bibr" rid="CR422">422</xref>]. Deletion of Notch1 or CD133 leads to the downregulation of SNAIL and SLUG, while E-cadherin expression is upregulated [<xref ref-type="bibr" rid="CR321">321</xref>]. Additionally, CD133 activation initiates the MAPK pathway, increasing MMP-2, MMP-9, and VEGF expression, thereby promoting angiogenesis and tumor development [<xref ref-type="bibr" rid="CR321">321</xref>]. Furthermore, Notch1 enhances the proangiogenic properties of melanoma cells that overexpress ALDH1A1, thereby facilitating tumor vascularization and progression [<xref ref-type="bibr" rid="CR325">325</xref>].</p><p id="Par197">Notch3 and Notch4 are elevated and crucial for maintaining the plasticity of MSLCs [<xref ref-type="bibr" rid="CR423">423</xref>, <xref ref-type="bibr" rid="CR424">424</xref>]. Silencing Notch3 results in a reduction of stemness markers such as CD133 and CD271, depletes the melanoma CSC population, and weakens their proangiogenic activity [<xref ref-type="bibr" rid="CR424">424</xref>]. Inhibition of VM and tumor blood vessel formation due to Notch3 inactivation destabilizes MSLC homeostasis [<xref ref-type="bibr" rid="CR424">424</xref>]. Notch4 drives the aggressive behavior of melanoma, promoting processes such as VM and growth independently of attachment [<xref ref-type="bibr" rid="CR425">425</xref>]. Targeting Notch3 or Notch4 could disrupt the vascular niche and suppress stemness markers, thereby eliminating established MSLCs and preventing the formation of new MSLC subsets [<xref ref-type="bibr" rid="CR423">423</xref>, <xref ref-type="bibr" rid="CR424">424</xref>].</p></sec><sec id="Sec34"><title>PI3K/AKT/mTOR and JAK/STAT3 signaling pathway</title><p id="Par198">The PI3K/AKT/mTOR and JAK/STAT3 signaling cascades are commonly aberrant in skin malignancies, facilitating tumor persistence by exerting anti-apoptotic effects and driving proliferative expansion [<xref ref-type="bibr" rid="CR374">374</xref>, <xref ref-type="bibr" rid="CR379">379</xref>, <xref ref-type="bibr" rid="CR384">384</xref>, <xref ref-type="bibr" rid="CR426">426</xref>&#x02013;<xref ref-type="bibr" rid="CR429">429</xref>].</p><p id="Par199">The PI3K/AKT/mTOR axis is crucial for SCC progression. Aberrant ECM components, such as LM332, in the SCC microenvironment trigger the PI3K/AKT pathway. The &#x003b2;3 domain of LM332 (V-III), which is highly enriched during SCC invasion, interacts with collagen VII rather than with integrins, activating the PI3K pathway and driving SCC progression [<xref ref-type="bibr" rid="CR430">430</xref>]. Moreover, oncogenic RAS initiates SSC tumorigenesis through the activation of the PI3K/AKT/mTOR pathway as a downstream effector [<xref ref-type="bibr" rid="CR431">431</xref>].</p><p id="Par200">Maintaining the stemness of MSLCs and enhancing their resistance to drugs are both regulated by the PI3K/AKT/mTOR pathway. PI3K activation subsequently activates downstream pathways, such as PI3K/MDM2 (Mouse double minute 2) and PI3K/AKT/MKP-1 (Mitogen-activated protein kinase phosphatase 1), which drive self-renewal, sustain stemness, and contribute to treatment resistance in CD133<sup>+</sup> MSLCs [<xref ref-type="bibr" rid="CR432">432</xref>]. The PI3K/AKT/MDM2 pathway destabilizes p53, whereas the PI3K/AKT/MKP-1 pathway suppresses JNK and p38-MAPK activity [<xref ref-type="bibr" rid="CR432">432</xref>]. Both PI3K/AKT/MKP-1 and PI3K/AKT/MDM2 pathways are instrumental in blocking apoptosis. Additionally, MSLCs rely on the PI3K/AKT pathway for their VM formation and angiogenesis, processes essential for tumor spread and metastasis [<xref ref-type="bibr" rid="CR433">433</xref>]. Blocking PI3K activity prevents MSLCs from forming VM structures [<xref ref-type="bibr" rid="CR433">433</xref>].</p><p id="Par201">JAK/STAT3 signaling plays a pivotal role in the oncogenesis, progression, and maintenance of CSCs in skin cancers, with its activation being crucial for the formation of SCC [<xref ref-type="bibr" rid="CR428">428</xref>, <xref ref-type="bibr" rid="CR434">434</xref>], BCC [<xref ref-type="bibr" rid="CR384">384</xref>], and melanoma [<xref ref-type="bibr" rid="CR429">429</xref>]. STAT3 activation facilitates the growth and persistence of tumor cells during SCC carcinogenesis [<xref ref-type="bibr" rid="CR435">435</xref>]. Conversely, STAT3 deletion in the basal epidermal layer prevents epidermal hyperproliferation during SCC progression [<xref ref-type="bibr" rid="CR428">428</xref>]. Mechanistically, STAT3 deletion lowers the levels of cell cycle mediators (c-MYC, cyclin D1, and cyclin E) and survival proteins (Bcl-xL) in tumor cells [<xref ref-type="bibr" rid="CR120">120</xref>, <xref ref-type="bibr" rid="CR435">435</xref>]. STAT3 regulates HFSC behavior in the bulge niche during early skin tumorigenesis. STAT3 ablation at this stage significantly reduces tumor establishment and increases HFSC apoptosis [<xref ref-type="bibr" rid="CR436">436</xref>]. Furthermore, in the absence of STAT3, CSC proliferation in response to Shh signaling is significantly diminished, impairing the initiation of BCC tumorigenesis [<xref ref-type="bibr" rid="CR384">384</xref>]. STAT3 activation drives the upregulation of cyclin D1, which accelerates cellular proliferation, thereby facilitating CSC accumulation and BCC development [<xref ref-type="bibr" rid="CR384">384</xref>].</p><p id="Par202">Hyperactivation of STAT3 is crucial for the invasion and metastasis of skin cancers, including SCC [<xref ref-type="bibr" rid="CR437">437</xref>&#x02013;<xref ref-type="bibr" rid="CR440">440</xref>], BCC [<xref ref-type="bibr" rid="CR440">440</xref>, <xref ref-type="bibr" rid="CR441">441</xref>] and melanoma [<xref ref-type="bibr" rid="CR442">442</xref>, <xref ref-type="bibr" rid="CR443">443</xref>]. In melanoma, poor prognosis and unfavorable clinicopathological features are associated with STAT3 hyperactivation [<xref ref-type="bibr" rid="CR443">443</xref>]. STAT3 suppression triggers apoptosis, enhancing melanoma cell death [<xref ref-type="bibr" rid="CR429">429</xref>]. Disruption of the STAT3 pathway impedes tumor progression and suppresses the secretion of soluble factors by SCC tumor cells [<xref ref-type="bibr" rid="CR439">439</xref>, <xref ref-type="bibr" rid="CR444">444</xref>, <xref ref-type="bibr" rid="CR445">445</xref>]. STAT3 further potentiates the metastatic capability of SCCs by downregulating E-cadherin and activating TWIST, which drive EMT [<xref ref-type="bibr" rid="CR437">437</xref>, <xref ref-type="bibr" rid="CR444">444</xref>, <xref ref-type="bibr" rid="CR446">446</xref>]. Consequently, STAT3 is integral not only to the initiation of skin carcinogenesis but also to its metastatic advancement. </p><p id="Par203">JAK/STAT3 maintains survival and reinforces the CSC phenotype in the skin CSC niche. In SCC tumors, SNAIL overexpression preserves the undifferentiated state of CSCs during metastasis [<xref ref-type="bibr" rid="CR447">447</xref>], which is associated with the increased activation of STAT3 [<xref ref-type="bibr" rid="CR448">448</xref>]. Inhibition of STAT3 phosphorylation disrupts self-renewal in SNAIL-expressing CSCs and downregulates stem cell markers, such as OCT4, SOX2, NANOG, and CD44 [<xref ref-type="bibr" rid="CR447">447</xref>]. Consistently, the absence of STAT3 in SNAIL-driven SCC tumors results in diminished tumor size and growth. Notably, SNAIL-expressing CSCs can sustain STAT3 activation in an autocrine manner. This is mediated by the secretion of Mindin (Spondin-2), a protein in the SNAIL-expressing epidermal cell secretome [<xref ref-type="bibr" rid="CR449">449</xref>] that is required for SSC stemness preservation and engages SRC to activate the STAT3 signaling cascade [<xref ref-type="bibr" rid="CR447">447</xref>]. Furthermore, STAT3 is essential for sustaining the Shh-driven CSC population during the formation and progression of BCC [<xref ref-type="bibr" rid="CR384">384</xref>]. These findings emphasize the need for deeper exploration of the ECM in the CSC niche and the secreted factors from CSCs, which engage with signaling pathways to sustain skin cancer progression.</p></sec></sec><sec id="Sec35"><title>Crosstalk between signaling pathways in the SSC and CSC niche</title><p id="Par204">Signaling regulation within the normal SSC niche operates as an intricately connected network, where each signaling pathway and niche factor is strategically placed to interact with surrounding elements, ensuring the maintenance of balanced epidermal and HF development. Pro-oncogenic events and latent malignant risks, such as mutations, can induce dysregulated proliferation and differentiation by disrupting the critical regulation of fundamental signaling pathways. For instance, disruption of regulatory control over cell growth signals from the Wnt and Shh pathways in the SC compartment occurs through loss-of-function mutations in <italic>NOTCH1</italic> or Shh inhibitor <italic>PTCH</italic> [<xref ref-type="bibr" rid="CR390">390</xref>, <xref ref-type="bibr" rid="CR412">412</xref>]. Furthermore, the Shh and Wnt signaling pathways mutually enhance each other in skin cancers, amplifying tumor cell proliferation [<xref ref-type="bibr" rid="CR450">450</xref>, <xref ref-type="bibr" rid="CR451">451</xref>]. In the CSC niche, reduced DKK levels [<xref ref-type="bibr" rid="CR452">452</xref>] and increased nuclear &#x003b2;-catenin [<xref ref-type="bibr" rid="CR359">359</xref>] contribute to the hyperactivation of Wnt signaling. Additionally, enhanced metastatic and proliferative capabilities in tumor cells are promoted by the overexpression of Notch and its ligands [<xref ref-type="bibr" rid="CR189">189</xref>, <xref ref-type="bibr" rid="CR453">453</xref>]. YAP/ TAZ hyperactivation in the CSC niche, crucial for maintaining CSC stemness, is driven by a stiff ECM and disrupted cell adhesion [<xref ref-type="bibr" rid="CR126">126</xref>, <xref ref-type="bibr" rid="CR153">153</xref>]. These dysregulated signaling pathways and their crosstalk facilitate the accumulation of oncogenic mutations and help sustain CSC populations.</p><p id="Par205">The interplay between Shh and Wnt signaling may complicate melanoma treatment. Loss of <italic>PTCH</italic> function releases SMO inhibition, leading to excessive Shh activity and enhanced expression of downstream Wnt proteins [<xref ref-type="bibr" rid="CR454">454</xref>]. Wnt5a, a main target of the Shh pathway, can activate both canonical and non-canonical Wnt signaling [<xref ref-type="bibr" rid="CR455">455</xref>]. In melanoma, Wnt5a promotes tumor cell proliferation by activating ADP-ribosylation factor 6 (ARF6) through interaction with FZD4 or LRP6, which in turn facilitates &#x003b2;-catenin nuclear translocation [<xref ref-type="bibr" rid="CR456">456</xref>]. Additionally, Wnt5a drives tumor cell invasion via the non-canonical Wnt pathway, engaging PKC [<xref ref-type="bibr" rid="CR399">399</xref>], CDC42 [<xref ref-type="bibr" rid="CR457">457</xref>] or JNK/c-JUN [<xref ref-type="bibr" rid="CR458">458</xref>, <xref ref-type="bibr" rid="CR459">459</xref>] signaling cascades. Wnt5a activation induces an invasive phenotype in melanoma by promoting SNAIL-mediated downregulation of E-cadherin, thus facilitating EMT during tumor progression [<xref ref-type="bibr" rid="CR399">399</xref>]. Moreover, canonical Wnt signaling can interact with Shh through its downstream genes, <italic>LGR4</italic> and <italic>LGR5</italic>, in BCC. The ablation of <italic>PTCH1</italic> in LGR5<sup>+</sup> SSCs promotes the formation of BCC-like tumors [<xref ref-type="bibr" rid="CR460">460</xref>]. Overexpression of SSC markers <italic>LGR4</italic> and <italic>LGR5</italic>, which enhance <italic>GLI1/2</italic> gene expression, was observed in BCCs [<xref ref-type="bibr" rid="CR391">391</xref>]. GLI proteins induce the expression of <italic>SNAIL</italic>, promoting nuclear &#x003b2;-catenin accumulation and facilitating EMT in BCCs [<xref ref-type="bibr" rid="CR461">461</xref>].</p><p id="Par206">The interaction between Shh and YAP/TAZ or Notch signaling is critical for BCC initiation and progression. Generally, Shh drives oncogenesis in BCC, whereas Notch acts to prevent tumor formation. Notch1 loss in the skin sustains GLI2 and &#x003b2;-catenin activation, fostering BCC-like tumor formation [<xref ref-type="bibr" rid="CR412">412</xref>]. In contrast, YAP transcriptional activity exerts a synergistic effect with the Shh signaling pathway in enhancing CSC proliferation. Epidermal YAP activation stimulates &#x003b2;-catenin signaling in basal SSCs, facilitating substantial nuclear expression of GLI2 in BCC [<xref ref-type="bibr" rid="CR358">358</xref>] and promoting epidermal hyperproliferation [<xref ref-type="bibr" rid="CR360">360</xref>]. This YAP/&#x003b2;-catenin-induced GLI2 hyperactivation is concomitant with enhanced RHOA/ROCK signaling and elevated ECM fibrous deposition in human BCC [<xref ref-type="bibr" rid="CR358">358</xref>].</p><p id="Par207">The mechano-transduction pathway, increased by elevated protein deposition and increased stiffness of the ECM, drives the hyperactivation of multiple signaling pathways and their crosstalk, ultimately promoting the expansion of CSCs. The mechanical forces present in the CSC niche promote &#x003b2;-catenin nuclear accumulation and stimulate oncogenic pathways, including integrin-mediated FAK and PI3K/AKT signaling pathway [<xref ref-type="bibr" rid="CR462">462</xref>]. Aberrant integrin-FAK-SRC signaling contributes to an aggressive SCC variant [<xref ref-type="bibr" rid="CR463">463</xref>] and sustains the CSC population [<xref ref-type="bibr" rid="CR19">19</xref>]. Increased ECM density can stimulate the integrin-FAK signaling pathway, resulting in PI3K/AKT activation in hyperproliferative and invasive SCC tumors. Nuclear &#x003b2;-catenin accumulation is enhanced by AKT-mediated GSK3&#x003b2; phosphorylation, which prevents its degradation [<xref ref-type="bibr" rid="CR462">462</xref>, <xref ref-type="bibr" rid="CR463">463</xref>].</p><p id="Par208">In the skin CSC niche, STAT3 activation is facilitated by SRC, a non-receptor tyrosine kinase. SRC kinase inhibition impedes STAT3 signaling, thereby attenuating the proliferative capacity of melanoma cells [<xref ref-type="bibr" rid="CR429">429</xref>]. Blocking STAT3 or SRC signaling decreases key cell survival proteins, including Bcl-xL and Mcl-1 (Myeloid cell leukemia-1), precipitating apoptosis in melanoma cells [<xref ref-type="bibr" rid="CR429">429</xref>]. These findings underscore the indispensable functions of STAT3 and SRC signaling in sustaining tumor cell viability and facilitating malignant progression in melanoma. Moreover, the STAT3 signaling pathway is pivotal in conferring stem-like properties and tumorigenic capabilities to SCC cells. Notably, this effect is mitigated in the absence of SRC within SCC tumors that express SNAIL [<xref ref-type="bibr" rid="CR447">447</xref>]. In addition, STAT3 signaling activation is frequently observed in Shh signaling-driven BCCs. Ablation of STAT3 results in a marked reduction in both tumor volume and proliferation mediated by Shh signaling. Additionally, Shh-induced expansion of CSCs is significantly attenuated in the absence of STAT3 in BCC tumors [<xref ref-type="bibr" rid="CR384">384</xref>].</p><p id="Par209">The intricate interplay between the signaling pathways in the CSC niche warrants further exploration. A deeper understanding of these interactions could enhance therapeutic efficacy by targeting and reducing the CSC population in skin cancers.</p></sec></sec><sec id="Sec36"><title>Drug targeting and clinical implications</title><p id="Par210">A promising therapeutic strategy for addressing drug resistance and recurrence involves targeting skin CSC niche. Various strategies have been designed to target CSC niche and eliminate the CSC population in skin tumors. The core signaling pathways, namely Shh, Wnt/&#x003b2;-catenin, YAP/TAZ, Notch, PI3K/AKT/mTOR, and JAK/STAT3 have been reported to stimulate the expansion of skin CSCs (as shown in Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">3</xref> and Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). The potential signaling pathways targeted in both current and ongoing clinical trials (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref> and&#x000a0;Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>) are summarized below.</p><sec id="Sec37"><title>Targeting Shh signaling pathway</title><p id="Par211">Targeting the Shh signaling pathway can be achieved through the use of inhibitors targeting Shh, GLI, and SMO (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>A). For the treatment of advanced BCC, vismodegib and sonidegib received approval from the US Food and Drug Administration (FDA) in 2012 and 2015, respectively [<xref ref-type="bibr" rid="CR464">464</xref>]. Clinical studies have shown that vismodegib (GDC-0449, a SMO inhibitor) is effective in treating late-stage BCC [<xref ref-type="bibr" rid="CR465">465</xref>, <xref ref-type="bibr" rid="CR466">466</xref>]. The objective response rates (ORRs) for metastatic BCC (mBCC) and locally advanced BCC (laBCC) patients were 30%&#x02013;30.8% and 43%&#x02013;46.4%, respectively [<xref ref-type="bibr" rid="CR465">465</xref>, <xref ref-type="bibr" rid="CR467">467</xref>]. For mBCC and laBCC patients, overall response rates ranged from 30.3% to 50% and 42.9% to 60%, respectively, with median response durations between 7.6 and 8.8&#x000a0;months [<xref ref-type="bibr" rid="CR466">466</xref>, <xref ref-type="bibr" rid="CR468">468</xref>]. For individuals affected by nevoid basal cell carcinoma syndrome, vismodegib reduced tumor burden and prevented the development of new BCCs [<xref ref-type="bibr" rid="CR469">469</xref>]. Furthermore, a clinical trial showed that sonidegib treatment resulted in ORRs for 194&#x000a0;laBCC and 36&#x000a0;mBCC patients ranging from 46.1% to 56% and 8% to 17%, respectively [<xref ref-type="bibr" rid="CR470">470</xref>]. This trial also had a long-term 42-month follow-up on safety and efficacy [<xref ref-type="bibr" rid="CR470">470</xref>].</p><p id="Par212">Despite the significant effects of vismodegib and sonidegib on shrinking tumors and delayed progression, some patients experienced BCC recurrence upon discontinuation of the drugs [<xref ref-type="bibr" rid="CR469">469</xref>, <xref ref-type="bibr" rid="CR471">471</xref>, <xref ref-type="bibr" rid="CR472">472</xref>]. The main reasons for treatment failures may involve refractory quiescent CSCs and SMO mutations [<xref ref-type="bibr" rid="CR473">473</xref>&#x02013;<xref ref-type="bibr" rid="CR476">476</xref>]. The ERIVANCE phase II clinical trial identified concerns regarding the safety profile of vismodegib, with disease progression cited as the reason for treatment discontinuation in 27.9% of the 104 advanced BCC patients [<xref ref-type="bibr" rid="CR477">477</xref>]. A retrospective review found that 21% of 28 advanced BCC patients who received vismodegib treatment experienced tumor recurrence within 56&#x000a0;weeks [<xref ref-type="bibr" rid="CR478">478</xref>]. Similarly, trials of sonidegib also reported continuous tumor progression in some patients [<xref ref-type="bibr" rid="CR470">470</xref>, <xref ref-type="bibr" rid="CR479">479</xref>]. Notably, patients with a history of resistance to an SMO inhibitor exhibited a secondary resistance event when treated with another SMO inhibitor [<xref ref-type="bibr" rid="CR480">480</xref>]. Additionally, a contentious association has been observed between vismodegib treatment for BCC and a high susceptibility to developing SCC [<xref ref-type="bibr" rid="CR481">481</xref>, <xref ref-type="bibr" rid="CR482">482</xref>].</p><p id="Par213">Other SMO antagonists have been evaluated in phase I and II trials for treating advanced or metastatic BCC and melanoma. These include IPI-926 (NCT00761696, NCT02828111, NCT01609179, and NCT02762084), itraconazole (NCT01108094 and NCT02120677) [<xref ref-type="bibr" rid="CR483">483</xref>, <xref ref-type="bibr" rid="CR484">484</xref>], BMS-833923 (XL139; NCT00670189), taladegib (NCT01226485), LEQ506 (NCT01106508), vitamin D3 (calcitriol; NCT00301067 and NCT01358045), and ZSP1602 (NCT03734913). Oral IPI-926 (saridegib/patidegib) was well-tolerated and demonstrated efficacy in BCC patients, showing anti-tumor activity in those previously untreated with vismodegib [<xref ref-type="bibr" rid="CR485">485</xref>]. Topical application of patidegib (IPI-926) has shown promising results in reducing tumor size and decreasing <italic>GLI1</italic> mRNA levels after 12&#x000a0;weeks in phase II trials (NCT02828111) [<xref ref-type="bibr" rid="CR486">486</xref>]. The topical variant of IPI-926 has also been shown to be safe and effective, with minimal risks of systemic adverse events [<xref ref-type="bibr" rid="CR486">486</xref>]. Itraconazole, an antifungal agent that can inhibit the Shh pathway, has demonstrated some efficacy in BCC patients (NCT01108094). However, congestive heart failure and fatigue were reported as complications in two patients [<xref ref-type="bibr" rid="CR487">487</xref>], emphasizing the need for further research to assess the safety of this treatment over time.</p><p id="Par214">In populations resistant to SMO inhibitors, alternative compounds have been investigated to target other molecules in the Shh signaling pathway. For instance, arsenic trioxide (ATO; NCT01791894), nicotinamide (NCT03769285 and ACTRN12612000625875 [<xref ref-type="bibr" rid="CR488">488</xref>]), and casein kinase 2 inhibitor&#x000a0;(CX-4945, silmitasertib) (NCT03897036) have been studied for their ability to target <italic>GLI</italic> transcription factors. Nicotinamide is thought to suppress GLI activity by increasing cytoplasmic sirtuin 1 (SIRT1) level [<xref ref-type="bibr" rid="CR489">489</xref>]. A phase III trial involving oral administration of nicotinamide (500&#x000a0;mg twice per day) demonstrated a safe and effective regimen for preventing new BCC and SCC development [<xref ref-type="bibr" rid="CR488">488</xref>]. Furthermore, topical imiquimod (Aldara), FDA-approved in 2004 for primary superficial BCC&#x000a0;treatment, inhibits the Shh pathway by inducing protein kinase A-mediated GLI phosphorylation [<xref ref-type="bibr" rid="CR490">490</xref>].</p></sec><sec id="Sec38"><title>Targeting Wnt/&#x003b2;-catenin signaling pathway</title><p id="Par215">Suppressors of Wnt/&#x003b2;-catenin activation in skin cancers include &#x003b2;-catenin destruction complex enhancers and porcupine inhibitors like WNT974 (NCT01351103) (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>B). The initial results of this trial indicated reduced AXIN2 expression, a marker of Wnt/&#x003b2;-catenin activity, in melanoma patients [<xref ref-type="bibr" rid="CR491">491</xref>]. With only 4% of 94 patients encountering dose-limiting toxicities&#x000a0;during the first course of treatment, WNT974 demonstrated good tolerance [<xref ref-type="bibr" rid="CR491">491</xref>]. In a phase I/II clinical trial, the tankyrase inhibitor E7449, which stabilizes Axin protein and suppresses &#x003b2;-catenin, is being assessed for its potential in treating solid tumors, including advanced melanoma (NCT01618136) [<xref ref-type="bibr" rid="CR492">492</xref>]. Sulindac (NCT00755976) and aspirin (NCT03396952) are also being investigated as treatments for melanoma in phase II clinical trials, due to their ability to increase GSK3&#x003b2; phosphorylation and &#x003b2;-catenin degradation [<xref ref-type="bibr" rid="CR493">493</xref>, <xref ref-type="bibr" rid="CR494">494</xref>].</p></sec><sec id="Sec39"><title>Targeting YAP/TAZ signaling pathway</title><p id="Par216">SRC inhibitors have shown potential as drugs that inhibit YAP/TAZ activity in skin cancers (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>C). The efficacy of SRC inhibitors, such as dasatinib, nilotinib, and saracatinib, has been evaluated in clinical trials for melanoma. In trial NCT00597038, the dasatinib-dacarbazine combination yielded a 72.4% clinical benefit rate in 29 metastatic melanoma patients [<xref ref-type="bibr" rid="CR495">495</xref>]. A phase II study (NCT00700882) found that KIT-positive melanoma had a higher partial response rate (18% or 4/22&#x000a0;tumors) than KIT-negative melanoma (5.9% or 3/51&#x000a0;tumors) [<xref ref-type="bibr" rid="CR496">496</xref>]. Notably, KIT-mutated metastatic melanoma patients treated with nilotinib showed stable disease for more than six weeks in 47.6% of cases (<italic>n</italic>&#x02009;=&#x02009;42), without noticeable side effects [<xref ref-type="bibr" rid="CR497">497</xref>]. Overall, phase I/II trials in advanced melanoma have also observed partial and minor responses to SRC inhibitors [<xref ref-type="bibr" rid="CR495">495</xref>&#x02013;<xref ref-type="bibr" rid="CR498">498</xref>].</p><p id="Par217">Histone deacetylase (HDAC) inhibitors have been shown to effectively&#x000a0;block nuclear YAP translocation by suppressing its gene transcription [<xref ref-type="bibr" rid="CR499">499</xref>]. HDAC inhibitors specifically target cancer cells with hyperactive YAP expression. In phase I/II clinical trials for skin cancers, vorinostat, an HDAC inhibitor, was evaluated. Two melanoma patients in a phase I clinical trial (NCT00331955) maintained stable disease for at least 8&#x000a0;months following treatment with a combination of vorinostat and doxorubicin [<xref ref-type="bibr" rid="CR500">500</xref>]. A&#x000a0;phase II trial (NCT00121225)&#x000a0;in advanced melanoma patients reported that the major side effects of vorinostat included fatigue, nausea, lymphopenia, anemia, and hyperglycemia.</p><p id="Par218">Pazopanib, which promotes the degradation of YAP, has demonstrated beneficial effects in melanoma treatment. A clinical benefit rate of 91% was observed in 58 metastatic melanoma patients receiving pazopanib and paclitaxel [<xref ref-type="bibr" rid="CR501">501</xref>]. In terms of clinical outcomes, the median overall survival was 12.7&#x000a0;months, and 55% of the 58 patients had stable disease for a duration of 8&#x000a0;weeks or more [<xref ref-type="bibr" rid="CR501">501</xref>]. Notably, no severe side effects were reported. Although pazopanib shows promise as a treatment for advanced melanoma, further evaluation of this regimen is needed.</p></sec><sec id="Sec40"><title>Targeting Notch signaling pathway</title><p id="Par219">RO4929097, a small-molecule blocker of &#x003b3;-secretase, shows potential benefits for skin cancer treatment (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>D), although its efficacy remains mixed. In a phase I trial, RO4929097 demonstrated efficacy in treating melanoma patients [<xref ref-type="bibr" rid="CR502">502</xref>]. This drug showed nearly complete antitumor efficacy against cutaneous metastatic melanoma&#x000a0;in one patient. Additionally, individuals with different stages of melanoma maintained stable disease for a minimum of 3 to 6&#x000a0;months post-treatment [<xref ref-type="bibr" rid="CR502">502</xref>]. RO4929097 was evaluated in phase II trials on melanoma patients in stages IIIB&#x02013;IV, but these trials (NCT01216787 and NCT01120275) were withdrawn and terminated, respectively. Further evaluation is required to validate the safety and effectiveness of this agent, as well as to investigate other potential targets of the Notch signaling pathway or to consider combination therapies for skin cancer treatment.</p></sec><sec id="Sec41"><title>Targeting PI3K/AKT/mTOR and JAK/STAT3 signaling pathway</title><p id="Par220">Several PI3K inhibitors are under evaluation in clinical trials for skin cancer, yielding promising results (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>E). A trial combining the PI3K/mTOR inhibitor voxtalisib (SAR245409) with the MEK inhibitor pimasertib (NCT01390818) reported a complete response in one melanoma patient. Moreover, 46% of the 110-patient cohort with advanced solid tumors of various types exhibited stable disease with this combination&#x000a0;treatment [<xref ref-type="bibr" rid="CR503">503</xref>]. Another study on triple therapy including the PI3K inhibitor buparlisib, BRAF inhibitor, and MEK inhibitor, showed a low clinical benefit in advanced BRAF V600-mutated melanoma (NCT02159066) [<xref ref-type="bibr" rid="CR504">504</xref>]. Notably, buparlisib combined with a BRAF inhibitor (NCT01512251) did not yield a well-tolerated response in BRAF V600 melanoma patients [<xref ref-type="bibr" rid="CR505">505</xref>]. In addition, current and ongoing clinical trials have focused on agents targeting the PI3K/AKT/mTOR pathway in metastatic and BRAF-mutant melanoma. These include the PI3K-beta inhibitor GSK2636771 (NCT03131908), PI3K-gamma inhibitor eganelisib (IPI-549; NCT02637531), and mTORC1 inhibitors such as temsirolimus (CCI-779, NCT00909831 and NCT00022464), and everolimus (RAD001, NCT00591734, NCT00098553, NCT00521001, NCT01014351, and NCT00976573).</p><p id="Par221">AKT inhibitors have shown potential as therapies for advanced and refractory skin cancers, but there are inconsistent data regarding their toxicity and clinical advantages. In a phase I trial, BRAF-wildtype melanoma patients were treated with a combination of the AKT inhibitor uprosertib and trametinib [<xref ref-type="bibr" rid="CR506">506</xref>]. Disease progression was observed in 43% of 14 patients with melanoma undergoing this combined regimen [<xref ref-type="bibr" rid="CR506">506</xref>]. Another phase II trial found that no BRAF-wild type melanoma patients achieved a noticeable objective response when treated with the combined uprosertib-trametinib regimen (NCT01941927) [<xref ref-type="bibr" rid="CR507">507</xref>]<bold>.</bold> Common adverse effects like rash, diarrhea, and mucositis affected the patients&#x02019; quality of life with this regimen [<xref ref-type="bibr" rid="CR506">506</xref>, <xref ref-type="bibr" rid="CR507">507</xref>]. However, a SWOG S1221 clinical trial reported that uprosertib combined with dabrafenib or trametinib was well tolerated in melanoma patients [<xref ref-type="bibr" rid="CR508">508</xref>]. Other AKT inhibitors, such as MK-2206 (NCT00848718&#x000a0;and&#x000a0;NCT01480154), ipatasertib (NCT03673787), and afuresertib (NCT01476137), have also been studied in clinical trials targeting advanced melanoma. During a phase I trial, one melanoma patient showed a partial response when MK-2206 was administered alongside carboplatin/paclitaxel, docetaxel, or erlotinib [<xref ref-type="bibr" rid="CR509">509</xref>]. These combinations were well tolerated, with maculopapular rash and febrile neutropenia being the most common adverse events [<xref ref-type="bibr" rid="CR509">509</xref>]. A phase I study showed a 55% tumor size&#x000a0;reduction in a melanoma patient after 40&#x000a0;weeks of treatment with afuresertib and trametinib [<xref ref-type="bibr" rid="CR510">510</xref>]. While clinical improvement has been observed with AKT inhibitors, further investigation is required to assess their efficacy and toxicity in skin cancer treatment.</p><p id="Par222">The JAK/STAT3 signaling pathway, crucial in skin cancer progression, presents a potential target for enhancing treatments for advanced skin cancers [<xref ref-type="bibr" rid="CR117">117</xref>] (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>E). Inhibitors of JAK and STAT3 have shown strong preclinical antitumor activity against skin cancers. Oral STAT3 inhibitors, such as TTI-101 (NCT03195699) and OPB-31121 (NCT00657176), are currently being assessed in phase I/II clinical trials for their effectiveness and safety. Additionally, modulation of JAK/STAT3 signaling could potentially influence the YAP/TAZ pathway (Fig. <xref rid="Fig3" ref-type="fig">3</xref>). However, additional research is needed to evaluate the efficacy and risk profile of STAT3 inhibitors in skin cancer treatment.</p></sec></sec><sec id="Sec42"><title>Discussion of treatment challenges and future perspectives related to double-sided niche regulation</title><p id="Par223">The self-renewing epidermis maintains a balance between basal layer proliferation and a precisely regulated differentiation process, forming distinct suprabasal layers, while ensuring SSC preservation. Disruption or dysfunction within the normal SSC niche may serve as a catalyst for skin cancer initiation. The complexity of managing skin cancers arises from the dual functionality of key regulators, which are essential for sustaining both normal SSC and CSC niches (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). Additionally, CSCs can acquire intrinsic resistance while interacting with heterogeneous components of their niche, including critical signaling pathways, adhesion molecules, stromal cells, and immune cells. This multifaceted crosstalk sustains the CSC pool and resistance attributes, including immune evasion. A thorough understanding of how to modulate the components of the CSC niche, in conjunction with the intrinsic resistance mechanisms of CSCs, is essential for devising strategies that can efficiently target and eliminate tumors while sparing the normal developmental processes of SSCs.</p><sec id="Sec43"><title>Challenges presented by the shared regulation of signaling pathways in SSC and CSC niches</title><p id="Par224">A major concern when targeting shared regulators of both normal SSC and CSC niches is the potential for treatment failure, as well as the risk of secondary skin cancers arising as adverse outcomes. Notably, the involvement of Shh inhibitors in the formation of secondary SCC is contentious, as existing evidence has failed to demonstrate a clear causal relationship. Nonetheless, various potential pathways have been suggested to elucidate the predisposition to non-BCC secondary cancers following Shh inhibitor treatment [<xref ref-type="bibr" rid="CR511">511</xref>&#x02013;<xref ref-type="bibr" rid="CR513">513</xref>]. It has been reported that among 2,576 patients with BCC treated with vismodegib, there were 197 instances of cutaneous SCC [<xref ref-type="bibr" rid="CR514">514</xref>]. Invasive SCCs arising from post-BCC clearance with Shh inhibitors harbor new mutations in genes commonly implicated in metastatic SCC, including NOTCH1/2 [<xref ref-type="bibr" rid="CR515">515</xref>]. Remarkably, these invasive SCCs exhibit a similar mutation rate and approximately 90% genomic identity to the original BCC in a patient treated with vismodegib [<xref ref-type="bibr" rid="CR513">513</xref>]. These observations imply that mutations in these novel or primary BCC-like genes may drive the squamous transition during Shh pathway blockade. Additionally, SCCs may develop at the same site as previously treated BCCs following Shh inhibitor therapy [<xref ref-type="bibr" rid="CR513">513</xref>]. Although these cases show SCC-like pathological features, genetic analyses revealed shared tumor drivers between primary BCC and subsequent SCC, suggesting that Shh inhibitors may induce a phenotypic shift from BCC to other skin cancer types [<xref ref-type="bibr" rid="CR513">513</xref>, <xref ref-type="bibr" rid="CR516">516</xref>]. Some alternative oncogenic pathways have been proposed to contribute to the switch in cancer types or exacerbate latent skin cancers following Shh inhibition [<xref ref-type="bibr" rid="CR481">481</xref>, <xref ref-type="bibr" rid="CR517">517</xref>].</p><p id="Par225">The RAS/MAPK pathway has been reported to be activated as an alternative mechanism following Shh pathway inhibition, thereby promoting SCC progression. In Shh inhibitor-resistant BCC or secondary SCCs following BCC treatment, reduced Shh pathway activation is accompanied by increased RAS/MAPK activation [<xref ref-type="bibr" rid="CR517">517</xref>, <xref ref-type="bibr" rid="CR518">518</xref>]. Interestingly, Shh inhibitor-resistant melanoma cell lines show downregulation of Shh-GLI signaling and a shift toward alternative MAPK pathways, such as RAS/ Rapidly Accelerated Fibrosarcoma (RAF)/ERK and JNK/p38 pathways [<xref ref-type="bibr" rid="CR519">519</xref>], which are also crucial for sustaining CSC stemness and EMT-driven migration in SCC [<xref ref-type="bibr" rid="CR84">84</xref>, <xref ref-type="bibr" rid="CR431">431</xref>, <xref ref-type="bibr" rid="CR520">520</xref>]. Additionally, GLI1, a key downstream effector of Shh signaling in BCC, suppresses keratinocyte migration and hyperproliferation driven by EGFR/MEK/ERK signaling [<xref ref-type="bibr" rid="CR521">521</xref>]. Therefore, inhibition of GLI1 via Shh antagonist treatment may upregulate the EGFR/MEK/ERK signaling pathway, potentially activating the RAS/MAPK pathway in SCC development [<xref ref-type="bibr" rid="CR521">521</xref>]. Collectively, the potential risks of secondary skin cancers and enhanced tumor invasiveness from Shh pathway inhibitors emphasize the necessity for a deeper understanding of SSC and CSC niches to effectively manage skin cancer.</p><p id="Par226">The dual roles of certain factors in normal SSCs can complicate effective treatment strategies and raise concerns about their unintended effects on healthy tissues. For instance, Notch antagonists have demonstrated minimal antitumor activity in stage IV cutaneous melanoma and are not widely favored in research for skin cancer therapy [<xref ref-type="bibr" rid="CR522">522</xref>]. Reportedly, unlike Notch1, which promotes the E-cadherin to N-cadherin switch, Notch4 induces opposing changes in melanoma cells during EMT. It reverses this process by repressing the transcription of mesenchymal markers and enhancing E-cadherin expression [<xref ref-type="bibr" rid="CR523">523</xref>]. Upon activation, Notch4 specifically promotes the expression of HEY1 and HEY2, which suppresses SNAIL2 and TWIST1 transcription by directly binding to their promoter regions [<xref ref-type="bibr" rid="CR523">523</xref>]. Moreover, Notch is a tumor suppressor in BCC [<xref ref-type="bibr" rid="CR412">412</xref>] and SCC [<xref ref-type="bibr" rid="CR414">414</xref>]; however, its activation and DLL1 ligand expression are required for SCC [<xref ref-type="bibr" rid="CR524">524</xref>] and melanoma progression [<xref ref-type="bibr" rid="CR453">453</xref>]. DLL1 can promote melanoma expansion through canonical Notch activation or the non-canonical Notch pathway, such as through enhanced tumor cell adhesion or cadherin switch [<xref ref-type="bibr" rid="CR453">453</xref>, <xref ref-type="bibr" rid="CR525">525</xref>]. Interestingly, decreased LFNG levels coincided with elevated expression of DLL1, JAGGED1, and Notch downstream effectors such as HES1 in metastatic melanoma [<xref ref-type="bibr" rid="CR526">526</xref>]. Reduced LFNG levels in tumor cells may promote Notch trans-activation in adjacent cells through JAGGED ligands by weakening DLL1-Notch1 cis-inhibition and releasing constraints on JAGGED1-Notch1 cis-inhibition [<xref ref-type="bibr" rid="CR364">364</xref>] (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). This change can increase DLL1 ligand availability to activate Notch receptors in adjacent cells [<xref ref-type="bibr" rid="CR364">364</xref>] or promote TGF-&#x003b2;-mediated tumor spread via SMAD binding [<xref ref-type="bibr" rid="CR527">527</xref>]. Alternatively, manic and radical fringe enzymes may undergo compensatory changes due to the reduction in LFNG, sustaining high Notch affinity for DLL1 [<xref ref-type="bibr" rid="CR370">370</xref>]. However, direct evidence connecting reduced LFNG levels with DLL1 activation in melanoma development is still lacking. Collectively, the dual functions of Notch signaling in skin cancers likely contribute to the limited efficacy of Notch inhibitor-based therapies. This underscores the critical need for precise targeting of Notch components or intervention at optimal time points to enhance the effectiveness of skin cancer treatment.</p><p id="Par227">The Wnt signaling pathway can both inhibit and promote melanoma, depending on the context. Given the role of increased Wnt signaling in skin cancer progression, its inhibition has been shown to effectively halt tumor growth [<xref ref-type="bibr" rid="CR491">491</xref>, <xref ref-type="bibr" rid="CR492">492</xref>, <xref ref-type="bibr" rid="CR494">494</xref>]. However, recent findings indicate that improving melanoma treatment outcomes may involve the enhancement of Wnt/&#x003b2;-catenin pathway. This can be achieved either by using selective GSK3&#x003b1;/&#x003b2; inhibitors [<xref ref-type="bibr" rid="CR528">528</xref>] or by increasing Wnt3a levels [<xref ref-type="bibr" rid="CR529">529</xref>]. The dual roles of Wnt/&#x003b2;-catenin signaling in melanoma likely arise due to shifts between canonical and non-canonical mechanisms. Notably, Wnt5a, which activates Wnt signaling in both canonical and non-canonical processes, is typically upregulated in skin cancers [<xref ref-type="bibr" rid="CR399">399</xref>]. Wnt5a disrupts the classical Wnt/&#x003b2;-catenin signaling pathway by blocking Wnt3a binding to the FZD2 and LRP6 receptors [<xref ref-type="bibr" rid="CR530">530</xref>], or by interacting with ROR2 (receptor tyrosine kinase-like orphan receptor 2), either directly or through the upregulation of SIAH2 (Siah E3 ubiquitin protein ligase 2) [<xref ref-type="bibr" rid="CR455">455</xref>, <xref ref-type="bibr" rid="CR531">531</xref>]. These interactions sequester &#x003b2;-catenin in the cytoplasm, promoting its degradation and inhibiting &#x003b2;-catenin-dependent Wnt signaling [<xref ref-type="bibr" rid="CR455">455</xref>, <xref ref-type="bibr" rid="CR530">530</xref>, <xref ref-type="bibr" rid="CR531">531</xref>]. Interestingly, the Wnt5a/ROR2 interaction activates the Hippo suppressive pathway of YAP/TAZ signaling, thereby restraining melanoma growth [<xref ref-type="bibr" rid="CR532">532</xref>]. In contrast, the activation of PKC by non-canonical Wnt5a signaling initiates STAT3 activation, leading to the suppression of MITF expression. This&#x000a0;MITF downregulation subsequently suppresses melanocytic differentiation antigens, including MART-1 (melanoma antigen recognized by T-cells 1), while promoting a metastatic, low MITF, stem-like phenotype in invasive melanoma [<xref ref-type="bibr" rid="CR455">455</xref>]. Additionally, in melanoma cells with highly invasive signatures, increased expression of <italic>WNT5a</italic>, <italic>VEGF</italic>, <italic>TCF4</italic>, and EMT-related genes (fibronectin, <italic>SOX9</italic>, and <italic>MMPs</italic>) is observed, while levels of &#x003b2;-catenin, <italic>LEF1</italic>, <italic>MITF</italic>, E-cadherin, cyclin D1, and c<italic>-MYC</italic> are reduced [<xref ref-type="bibr" rid="CR162">162</xref>]. In contrast, Wnt3a protein, by activating the canonical Wnt pathway, increases the expression of MAAs such as MART1 and gp100, which helps CTLs target and kill melanoma cells. Furthermore, Wnt3a induces MITF expression in melanoma cells, potentially promoting the differentiation of MSLCs [<xref ref-type="bibr" rid="CR455">455</xref>, <xref ref-type="bibr" rid="CR533">533</xref>]. In addition, &#x003b2;-catenin-induced upregulation of MITF inhibits RHO/ROCK-mediated cell invasion and disrupts the &#x003b2;-catenin-induced expression of MT1-MMP, ultimately reducing tumor invasiveness [<xref ref-type="bibr" rid="CR534">534</xref>]. These findings suggest that targeting specific Wnt components, including ligands, receptors, and the &#x003b2;-catenin degradation complex, along with the associated signaling pathways, is key to modulating pathway activity and preventing resistance.</p></sec><sec id="Sec44"><title>The unique therapeutic targets in the CSC niche for resistant skin cancers</title><p id="Par228">Focusing on components with minimal impact on epidermal homeostasis or those rarely present in the normal SSC niche may help overcome the challenge posed by shared mediators in SSC and CSC niches. For instance, targeting aberrant integrin ligands, such as the &#x003b3;2 and LG4&#x02013;5 subunits of LM332, which are absent in the normal SSC niche, shows promise by blocking their integrin binding sites [<xref ref-type="bibr" rid="CR101">101</xref>]. Antibodies targeting the LM332 &#x003b1;3 chain at the LG4&#x02013;5 segment effectively induce SCC tumor apoptosis, inhibit tumor cell proliferation, and significantly impair tumorigenesis, while sparing normal tissue adhesion [<xref ref-type="bibr" rid="CR101">101</xref>]. In addition, the abundant accumulation of the LM332 &#x003b3;2 chain, coupled with its cleaving enzymes MT1-MMP and MMP-2, is indispensable for the establishment of VM by aggressive melanoma cells [<xref ref-type="bibr" rid="CR95">95</xref>]. The aberrant cleavage of LM332 &#x003b3;2 fragments in invasive melanoma generates pro-migratory segments, which significantly enhance VM-associated gene expression [<xref ref-type="bibr" rid="CR95">95</xref>]. Notably, PI3K facilitates melanoma migration and VM formation by driving MMP-2 and MT1-MMP production, which cleave LM332 &#x003b3;2 into migratory segments [<xref ref-type="bibr" rid="CR535">535</xref>]. Intriguingly, inhibiting PI3K with LY294002 significantly impairs the capacity of MSLCs to form VM [<xref ref-type="bibr" rid="CR535">535</xref>], but also substantially diminishes MT1-MMP and MMP-2 activity, thereby preventing the proteolytic degradation of the LM332 &#x003b3;2 chain [<xref ref-type="bibr" rid="CR536">536</xref>]. Therefore, effectively targeting stemness and invasiveness in aggressive skin cancers demands a thorough grasp of the complex relationships among signaling pathways and other components within the CSC niche, including dysregulated ECM elements.</p><p id="Par229">Similarly, integrins like &#x003b1;5&#x003b2;1, &#x003b1;v&#x003b2;6, &#x003b1;v&#x003b2;5, &#x003b1;4&#x003b2;1, and &#x003b1;v&#x003b2;3, which are barely detectable in normal epidermis, are significantly upregulated in CSCs and invasive skin cancers [<xref ref-type="bibr" rid="CR112">112</xref>, <xref ref-type="bibr" rid="CR180">180</xref>, <xref ref-type="bibr" rid="CR537">537</xref>&#x02013;<xref ref-type="bibr" rid="CR541">541</xref>]. Particularly, integrins &#x003b1;5&#x003b2;1,&#x000a0;&#x003b1;v&#x003b2;5, and &#x003b1;v&#x003b2;3 are overexpressed in melanoma and contribute to tumor progression. By inhibiting &#x003b1;5&#x003b2;1 [<xref ref-type="bibr" rid="CR542">542</xref>, <xref ref-type="bibr" rid="CR543">543</xref>] or &#x003b1;v&#x003b2;3 [<xref ref-type="bibr" rid="CR544">544</xref>], melanoma metastasis is reduced through decreased MMP (MMP-2,-7, and -9) expression and suppression of angiogenesis driven by FGF and VEGF [<xref ref-type="bibr" rid="CR545">545</xref>]. Additionally, ongoing phase I/II clinical trials are targeting integrin conformations (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>E), particularly &#x003b1;v&#x003b2;3 integrin antagonists like MEDI-522 (Etaracizumab, Abegrin, or Vitaxin) (NCT00066196, NCT00111696), Volociximab (&#x003b1;5&#x003b2;1 inhibitor, NCT00099970), and Intetumumab (anti-&#x003b1;v integrin antibody, NCT00246012). These trials have shown a favorable safety profile for targeting key integrins in skin cancers, which are absent in the normal SSC niche, reinforcing their potential for treatment.</p></sec><sec id="Sec45"><title>Intrinsic immune evasion mechanisms within CSC niche hinder the effectiveness of immunotherapy</title><p id="Par230">The inherent quiescence of SCs may serve as a defense mechanism, enabling them to evade immune detection. Specifically, long-lived CD34<sup>+</sup> SSCs located in the HF bulge can escape immune surveillance by T cells [<xref ref-type="bibr" rid="CR236">236</xref>]. Therefore,&#x000a0;CD34<sup>+</sup> CSCs may resist T cells because of their intrinsically reduced MHC I expression. In contrast, CD34<sup>&#x02212;</sup> cells, located outside the bulge, are more vulnerable to CD8<sup>+</sup> T cell-driven cytotoxicity and show elevated MHC I expression [<xref ref-type="bibr" rid="CR236">236</xref>]. Notably, CD34<sup>+</sup> CSCs are increasingly being recognized for their role in enhancing tumorigenicity and conferring resistance to treatments in skin cancers, including BCCs [<xref ref-type="bibr" rid="CR546">546</xref>], SCCs [<xref ref-type="bibr" rid="CR547">547</xref>], and melanoma [<xref ref-type="bibr" rid="CR548">548</xref>]. Investigating the mechanisms that sustain the stemness of CSCs within their niche, particularly those that contribute to immune evasion, could reveal new strategies for improving treatment efficacy in malignant skin cancers.</p><p id="Par231">MSLCs are crucial contributors to the CSC niche and resistance to immunotherapies, including CTL therapies and ICP inhibitors. Their stemness characteristics may provide a means to classify melanoma into distinct immune subtypes, which can help predict how these tumors will respond to immunotherapy. A correlation between stemness and the immune phenotype of melanoma cells was demonstrated through clustering analysis. By analyzing the composition of 28 immune cell populations in the melanoma TME, the study categorized melanoma into three immune groups: high (Im-H), medium (Im-M), and low (Im-L) [<xref ref-type="bibr" rid="CR549">549</xref>]. The Im-H subtype is distinguished by a pronounced anti-tumor immune landscape and minimal stemness. It also exhibits limited proliferative capacity, enhanced sensitivity to immunotherapy, and favorable clinical prognosis. Conversely, the Im-L subtype is marked by poor anti-tumor immune profiles, elevated stemness, enhanced proliferative potential, and reduced response to immunotherapy [<xref ref-type="bibr" rid="CR549">549</xref>]. Compared to other subtypes, the Im-H group exhibits higher expression of HLA (Human leukocyte antigen) genes, which are responsible for encoding MHC proteins, as well as elevated scores for both type I and II interferon responses. In contrast to the Im-L group, the Im-H group demonstrates a markedly elevated ratio of immunostimulatory markers, such as CD8<sup>+</sup>&#x02009;T cells, to immunosuppressive elements, including CD4<sup>+</sup>&#x02009;Treg cells and M2 macrophages [<xref ref-type="bibr" rid="CR549">549</xref>]. Notably, melanomas resistant to treatment display significantly augmented stemness attributes and reduced immune scores, particularly in cases treated with ICP inhibitors [<xref ref-type="bibr" rid="CR549">549</xref>]. The differentiated, proliferative phenotype, and its increased sensitivity to anti-melanoma immunotherapy, are associated with high MITF expression. In contrast, an invasive MSLC phenotype that resists apoptosis and is capable of immune evasion is correlated with low MITF expression [<xref ref-type="bibr" rid="CR550">550</xref>&#x02013;<xref ref-type="bibr" rid="CR552">552</xref>]. This aligns with the reduced MITF levels and upregulation of the mesenchymal marker TCF4 observed in ICP therapy non-responders [<xref ref-type="bibr" rid="CR552">552</xref>]. These findings indicate that the inherent traits of CSCs, along with the CSC niche that sustains their stemness, are critical factors in contributing to resistance to immunotherapy.</p></sec><sec id="Sec46"><title>Potential treatments targeting factors in the CSC niche sustaining immunoresistance</title><p id="Par232">Enhanced IFN&#x003b3; expression in the CSC niche can sensitize tumor cells to immunotherapy. During the telogen phase, HFSCs show low expression of interferon gamma receptor genes such as <italic>IFNGR1</italic>, which impedes the ability of activated T cells to upregulate MHC I levels through IFN&#x003b3; production [<xref ref-type="bibr" rid="CR236">236</xref>]. This lack of IFN&#x003b3; responsiveness is consistent with the observation that reduced IFN&#x003b3; levels correlate with a poorer prognosis in skin cancers. CD8<sup>+</sup> T cell infiltration and SCC regression were not observed when IFN&#x003b3; activity was blocked [<xref ref-type="bibr" rid="CR553">553</xref>]. In addition, a case of early mortality due to disseminated and recurrent SCC was reported in a patient with a deficiency in IFN&#x003b3;R2 [<xref ref-type="bibr" rid="CR554">554</xref>]. Conversely, elevated IFN&#x003b3; levels in the TME correlate with BCC tumor regression [<xref ref-type="bibr" rid="CR555">555</xref>]. Treatment with IFN&#x003b3; serves as an immuno-sensitizer, enhancing MHC-dependent antigen presentation across various cell types, including melanoma and cutaneous SCC cells [<xref ref-type="bibr" rid="CR553">553</xref>, <xref ref-type="bibr" rid="CR556">556</xref>]. Additionally, IFN&#x003b3; increases MHC I expression and enhances CD8<sup>+</sup> T cell migration into SCCs by upregulating chemokines such as CXCL10 and CCL5 [<xref ref-type="bibr" rid="CR553">553</xref>]. Systemic IFN&#x003b3; administration induced MHC I expression in MHC I-negative melanomas, as demonstrated in a phase II trial [<xref ref-type="bibr" rid="CR556">556</xref>]. In a phase Ib/II trial, IFN&#x003b3; supplementation was shown to improve the effectiveness of checkpoint blockade therapy in melanoma patients [<xref ref-type="bibr" rid="CR557">557</xref>]. Melanoma pretreatment with low-dose IFN&#x003b3; enhances tumor cell sensitivity to CD8<sup>+</sup> and CD4<sup>+</sup> T cell-mediated destruction [<xref ref-type="bibr" rid="CR558">558</xref>]. This suggests that combining IFN&#x003b3; with adoptive cell therapy (ACT) could enhance treatment efficacy, offering a promising approach for metastatic melanoma. However, IFN&#x003b3; is considered a double-edged sword due to its contrasting effects on tumor immunity [<xref ref-type="bibr" rid="CR558">558</xref>, <xref ref-type="bibr" rid="CR559">559</xref>]. While IFN&#x003b3; enhances tumor cell recognition by upregulating MHC I and II, crucial for effective CTL-mediated killing, it also induces the upregulation of immunosuppressive factors like PD-L1 and IDO (indoleamine 2,3-dioxygenase) in melanoma cells [<xref ref-type="bibr" rid="CR558">558</xref>]. Notably, transferred T cells that overexpress PD-1 following IFN&#x003b3; treatment may dampen the immune response, ultimately limiting the effectiveness of immunotherapy [<xref ref-type="bibr" rid="CR559">559</xref>]. In addition, IFN&#x003b3;-induced PD-L1 upregulation can trigger dedifferentiation in melanoma cells, which is characterized by reduced MITF expression, increased SOX10 expression, and elevated PD-L1 levels [<xref ref-type="bibr" rid="CR560">560</xref>, <xref ref-type="bibr" rid="CR561">561</xref>]. Through dedifferentiation, IFN&#x003b3; induces higher expression of immunomodulatory genes, upregulates PD-L1 protein, and promotes cytokine secretion [<xref ref-type="bibr" rid="CR561">561</xref>]. To enhance therapeutic efficacy, it is crucial to identify and target the various cellular pathways involved in CSC immunogenicity, thereby achieving a more precise and effective immune response.</p><p id="Par233">Integrating&#x000a0;targets involved in key signaling pathways in the CSC niche with immunotherapy could enhance treatment strategies for skin cancers. For example, by upregulating MHC I expression and boosting CD4<sup>+</sup> and CD8<sup>+</sup> T cell infiltration in BCC tumors [<xref ref-type="bibr" rid="CR562">562</xref>], Shh inhibitors may enhance adaptive immune responses, thereby potentially improving the effectiveness of anti-PD-1 therapy and increasing tumor response rates [<xref ref-type="bibr" rid="CR563">563</xref>]. Moreover, PD-L1 expression is elevated in tumor cells and lymphocytes in BCC after treatment with Shh inhibitors [<xref ref-type="bibr" rid="CR564">564</xref>]. As a result, combining Shh inhibitors with PD-L1 inhibitors could provide a promising strategy for advanced BCCs, potentially overcoming the immune resistance caused by increased PD-L1 expression. Anti-tumor T-cell activity is enhanced by cemiplimab, an FDA-approved treatment for adults with advanced or metastatic BCC that failed or cannot tolerate Shh inhibitors [<xref ref-type="bibr" rid="CR565">565</xref>]. This IgG4 human monoclonal antibody prevents PD-L1 and PD-L2 ligands from binding to the PD-1 receptor. In clinical trials, cemiplimab induced durable responses and exhibited substantial anti-tumor activity in metastatic BCC patients with disease progression or those unable to tolerate Shh inhibitors. A phase II multi-center study (NCT03132636) examined cemiplimab efficacy in 54 mBCC and 84 laBCC patients with prior Shh inhibitor failure or intolerance. The trial showed that cemiplimab yielded clinically meaningful anti-tumor activity and was well-tolerated in these patients. Notably, complete and partial responses were recorded in 5 patients (6%) and 21 patients (25%) experiencing laBCC, respectively [<xref ref-type="bibr" rid="CR566">566</xref>]. Among the 84 laBCC patients, 40 (48%) experienced emergent side effects with grade 3&#x02013;4, most commonly colitis and hypertension (both in 5% of patients). Progression-free survival in 54 mBCC patients ranged from 4 to 16&#x000a0;months, with a disease control rate of 63%, according to independent central examination [<xref ref-type="bibr" rid="CR567">567</xref>]. Importantly, no fatalities were attributed to treatment in this phase II trial [<xref ref-type="bibr" rid="CR566">566</xref>, <xref ref-type="bibr" rid="CR567">567</xref>]. However, a phase II trial comparing the combination of anti-PD-1 pembrolizumab with vismodegib to pembrolizumab monotherapy found no substantial enhancement in response rate [<xref ref-type="bibr" rid="CR568">568</xref>]. The overall response rate for pembrolizumab monotherapy (44% in 9 patients) surpassed that of the combination with vismodegib (29% in 7 patients). These results imply that targeting the signaling pathway and immunotherapy remain challenging in skin cancer treatment.</p><p id="Par234">In metastatic melanoma, combining Wnt/&#x003b2;-catenin antagonists with ICP inhibitors (anti-PD-1 pembrolizumab and anti-CTLA-4 ipilimumab) failed to yield a substantial therapeutic benefit in metastatic melanoma, while concomitantly increasing the risk of adverse effects [<xref ref-type="bibr" rid="CR569">569</xref>]. Aspirin functions both as a Wnt/&#x003b2;-catenin inhibitor, promoting &#x003b2;-catenin sequestration via GSK3&#x003b2;, and as an anti-inflammatory agent by inhibiting COX enzymes [<xref ref-type="bibr" rid="CR494">494</xref>]. Therefore, this combination may confer dual benefits in enhancing anti-PD-1 efficacy for several reasons. Reportedly, Wnt/&#x003b2;-catenin activation in melanoma cells impedes anti-PD-L1 efficacy by blocking T-cell recruitment into the TME. Mechanistically, when &#x003b2;-catenin is activated in melanoma cells, ATF3-mediated repression of CCL4 hinders T-cell infiltration in the melanoma microenvironment [<xref ref-type="bibr" rid="CR570">570</xref>]. Upregulated Wnt ligands (Wnt4 and Wnt5a) and positive modulators (DKK2 and SFRP2) were detected in non-responders to anti-PD-L1 therapy [<xref ref-type="bibr" rid="CR571">571</xref>]. Additionally, COX2 suppression by aspirin can impair the synthesis of prostaglandin E2 [<xref ref-type="bibr" rid="CR494">494</xref>], which is associated with a reduced accumulation of exhausted CD8<sup>+</sup> T cells, marked&#x000a0;by&#x000a0;TIM3&#x000a0;(T-cell immunoglobulin and mucin-domain containing-3) expression, in the melanoma TME [<xref ref-type="bibr" rid="CR572">572</xref>]. A retrospective analysis showed that combining ICP inhibitors (anti-CTLA-4 and/or anti-PD-1) with COX inhibitors (aspirin or selective COX2 inhibitors) significantly improved the overall response rate at 6&#x000a0;months in melanoma patients, compared to ICP monotherapy. Among 90 melanoma patients, combination therapy achieved an overall response rate of 58.6%, compared to 19.2% with ICP monotherapy (<italic>p</italic>&#x02009;=&#x02009;0.0005) [<xref ref-type="bibr" rid="CR573">573</xref>]. However, the trial (NCT03396952) examining the combination of aspirin and ICP inhibitors in melanoma has not yielded significant clinical benefits in metastatic melanoma [<xref ref-type="bibr" rid="CR569">569</xref>]. This trial reported a 62.9% objective response rate at 12 weeks&#x000a0;in 27 patients [<xref ref-type="bibr" rid="CR569">569</xref>], comparable to the 55%&#x02212;61% observed at approximately&#x000a0;16 months&#x000a0;in a clinical study using exclusive ICP treatment [<xref ref-type="bibr" rid="CR574">574</xref>]. In addition, a study found that PD-L1 expression inversely correlated with Wnt/&#x003b2;-catenin signaling activity in melanoma tumors [<xref ref-type="bibr" rid="CR575">575</xref>]. These findings suggest the presence of alternative mechanisms within the CSC niche, as well as in CSCs or tumor cells, which may sustain resistance to therapy after blocking oncogenic signaling pathways such as Wnt and Shh. Integrating immunotherapy and modulating other signaling pathways or CSC features associated with immune evasion could enhance therapeutic efficacy in refractory skin cancers.</p><p id="Par235">Currently, phase I/II clinical trials (NCT03673787, NCT02637531, NCT03131908) are investigating anti-PD-1/PD-L1 agents in combination with PI3K/AKT inhibitors for advanced melanoma. Additionally, targeting the YAP pathway has demonstrated potential in mitigating tumor-induced immune evasion. Melan-A-specific CD8<sup>+</sup> T cells failed to attack BRAFi-resistant melanoma cells with high nuclear YAP accumulation, which upregulated PD-L1 expression [<xref ref-type="bibr" rid="CR576">576</xref>]. Anti-PD-1 treatment or YAP depletion can mitigate T cell dysfunction and PD-L1 upregulation mediated by YAP in melanoma cells [<xref ref-type="bibr" rid="CR576">576</xref>]. Therefore, further investigation into how signaling pathways and immune responses interact within the CSC niche may uncover new combination strategies to overcome resistance in skin cancers.</p></sec><sec id="Sec47"><title>Shared signaling pathways in the CSC niche and tumor immunosuppression</title><p id="Par236">Signaling pathway activation or specific protein expression in CSCs, which overlap with those found in immunosuppressive cells such as CAFs and TAMs, may elevate the likelihood of treatment resistance in skin cancers. A&#x000a0;clinical trial with cilengitide has failed to show survival benefits in metastatic melanoma patients [<xref ref-type="bibr" rid="CR577">577</xref>]. Integrin &#x003b2;3 expression on TAMs contributes to cilengitide-mediated tumor-promoting effects. This may be attributed to their role in suppressing the tumor-promoting functions of TAMs [<xref ref-type="bibr" rid="CR578">578</xref>]. Integrin &#x003b2;3 in macrophages increases the M1/M2 macrophage ratio in the TME by activating STAT1 and suppressing STAT6 [<xref ref-type="bibr" rid="CR578">578</xref>]. Therefore, inhibiting &#x003b2;3 on TAMs can accelerate tumor growth, promote TAM accumulation, and diminish CD8<sup>+</sup> T&#x000a0;cell infiltration. Conversely, targeting macrophages can reduce the unexpected supportive effects of anti-integrin &#x003b2;3 treatment on tumor progression [<xref ref-type="bibr" rid="CR578">578</xref>]. Melanoma resistance to integrin &#x003b1;v&#x003b2;3 inhibitors is influenced by these opposing roles of integrin &#x003b2;3 in TAMs and MSLC. Therefore, a combination treatment of anti-macrophage might help reduce cancer resistance.</p><p id="Par237">The plasticity of metastatic melanoma cells is regulated by Notch1 signaling in CAFs. Melanosphere formation and the acquisition of Nestin- and CD271-positive melanoma stem/initiating cell phenotypes are suppressed by CAFs with Notch1 hyperactivation [<xref ref-type="bibr" rid="CR579">579</xref>]. In contrast, Notch1-silenced CAFs significantly expand the MSLC population by upregulating stemness markers such as SOX2, OCT4, and NANOG [<xref ref-type="bibr" rid="CR579">579</xref>]. Moreover, Notch1 preserves the stemness, oncogenic properties, and metastatic potential of MSLCs [<xref ref-type="bibr" rid="CR321">321</xref>, <xref ref-type="bibr" rid="CR325">325</xref>]. Therefore, the divergent effects of Notch1 signaling in CAFs and MSLCs may attenuate the therapeutic efficacy of targeting the Notch pathway.</p><p id="Par238">Gaining a comprehensive understanding of how core signaling pathways are intricately regulated within the CSC niche is crucial for effectively influencing CSC behavior. Targeting these pathways, in combination with other niche components, could offer a more efficient strategy to eradicate CSC populations in skin cancers.</p></sec></sec><sec id="Sec48"><title>Conclusion</title><p id="Par239">The niche microenvironment plays a crucial role in regulating the fate of normal SSCs and CSCs. Adhesive molecules within the niche are essential for normal epidermal differentiation; however, their excessive and abnormal expression can lead to the expansion of CSCs. The dual roles of key components of the adhesive niche&#x02014;including the dermo-epidermal junction, adherens junctions, various cell types (especially immune cells and fibroblasts), and major signaling pathways such as Shh, Wnt/&#x003b2;-catenin, YAP/TAZ, and Notch&#x02014;are critical for maintaining the balanced growth of SSCs. While their aberrant activation contributes to skin tumor progression and CSC formation, targeting specific signaling pathways regulated by the niche holds the potential for treating skin cancers with CSC properties and drug resistance, both in clinical practice and ongoing clinical trials. Nonetheless, the precise relationship between CSCs and their niche remains partially understood in certain contexts, and cases of resistance have been associated with the incomplete eradication of CSCs. Further research is needed to investigate the reciprocal interactions between cutaneous CSCs and their niche, which could provide valuable insights for addressing malignancy and drug resistance in skin cancers.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>SSCs</term><def><p id="Par13">Skin stem cells</p></def></def-item><def-item><term>TACs</term><def><p id="Par14">Transient-amplifying cells</p></def></def-item><def-item><term>SCs</term><def><p id="Par15">Stem cells</p></def></def-item><def-item><term>NMSC</term><def><p id="Par16">Nonmelanoma skin cancer</p></def></def-item><def-item><term>SCC</term><def><p id="Par17">Squamous cell carcinoma</p></def></def-item><def-item><term>CSCs</term><def><p id="Par18">Cancer stem cells</p></def></def-item><def-item><term>IFESCs</term><def><p id="Par19">Interfollicular epidermal stem cells</p></def></def-item><def-item><term>HFSCs</term><def><p id="Par20">Hair follicle stem cells</p></def></def-item><def-item><term>BM</term><def><p id="Par21">Basement membrane</p></def></def-item><def-item><term>ECM</term><def><p id="Par22">Extracellular matrix</p></def></def-item><def-item><term>LMs</term><def><p id="Par23">Laminins</p></def></def-item><def-item><term>EGFR</term><def><p id="Par24">Epidermal growth factor receptor</p></def></def-item><def-item><term>FAs</term><def><p id="Par25">Focal adhesions</p></def></def-item><def-item><term>TGF</term><def><p id="Par26">Transforming growth factor</p></def></def-item><def-item><term>Wnt</term><def><p id="Par27">Wingless-related integration site</p></def></def-item><def-item><term>BCC</term><def><p id="Par28">Basal cell carcinoma</p></def></def-item><def-item><term>MMPs</term><def><p id="Par29">Matrix metalloproteinases</p></def></def-item><def-item><term>MAPK/ERK</term><def><p id="Par30">Mitogen-activated protein kinase/Extracellular signal-regulated kinase</p></def></def-item><def-item><term>RAC1</term><def><p id="Par31">Rac family small GTPase 1</p></def></def-item><def-item><term>CDC42</term><def><p id="Par32">Cell division cycle 42</p></def></def-item><def-item><term>RAS</term><def><p id="Par33">Rat sarcoma virus</p></def></def-item><def-item><term>PI3K/AKT/mTOR</term><def><p id="Par34">Phosphoinositide 3-kinase/Protein kinase B (Akt)/Mammalian target of rapamycin</p></def></def-item><def-item><term>FAK</term><def><p id="Par35">Focal adhesion kinase</p></def></def-item><def-item><term>RHOA/ROCK</term><def><p id="Par36">Ras homolog family member A/ Rho-associated protein kinase</p></def></def-item><def-item><term>JAK/STAT3</term><def><p id="Par37">Janus kinase/ Signal transducer and activator of transcription 3</p></def></def-item><def-item><term>EMT</term><def><p id="Par38">Epithelial&#x02013;mesenchymal transition</p></def></def-item><def-item><term>AJs</term><def><p id="Par39">Adherens junctions</p></def></def-item><def-item><term>YAP/TAZ</term><def><p id="Par40">Yes-associated protein/transcriptional co-activator with pdz-binding motif</p></def></def-item><def-item><term>CAFs</term><def><p id="Par41">Cancer-associated fibroblasts</p></def></def-item><def-item><term>TAMs</term><def><p id="Par42">Tumor-associated macrophages</p></def></def-item><def-item><term>TANs</term><def><p id="Par43">Tumor-associated neutrophils</p></def></def-item><def-item><term>SHH</term><def><p id="Par44">Sonic hedgehog</p></def></def-item><def-item><term>MSCs</term><def><p id="Par45">Melanocyte stem cell</p></def></def-item><def-item><term>DLL1</term><def><p id="Par46">Delta-like ligand 1</p></def></def-item><def-item><term>LFNG</term><def><p id="Par47">Lunatic Fringe</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher&#x02019;s Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn><fn><p>Yung-Che Kuo and Wei-Ling Chang contributed equally to this work.</p></fn></fn-group><ack><title>Acknowledgements</title><p> Figures were designed in BioRender and Adobe Illustrator. The authors acknowledge the academic and science graphic illustration service partially supported by the Office of Research and Development at Taipei Medical University. This manuscript was edited by Wallace Academic Editing.</p></ack><notes notes-type="author-contribution"><title>Authors&#x02019; contributions
</title><p>Conception, design, writing, and figure preparation: Y.H.H. and Q.T.T.P. Review and/or revision of the manuscript and figures: Q.T.T.P., Y.C.K., W.L.C., H.J.W., and Y.H.H. Study supervision: H.J.W. and Y.H.H.. All authors reviewed the manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This study is supported by research grants from National Science and Technology Council, Taiwan (Grant numbers: MOST&#x000a0;111-2314-B-038-089-MY3, NSTC&#x000a0;113-2314-B-038-136 to YH Huang and MOST&#x000a0;110-2314-B-038-028-MY3 to HJ Weng).</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>No datasets were generated or analysed during the current study.</p></notes><notes><title>Declarations</title><notes id="FPar9"><title>Ethics approval and consent to participate</title><p id="Par240">Not applicable.</p></notes><notes id="FPar10"><title>Consent for publication</title><p id="Par241">Not applicable.</p></notes><notes id="FPar11" notes-type="COI-statement"><title>Competing interests
</title><p id="Par242">The authors declare no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References
</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name><surname>Blanpain</surname><given-names>C</given-names></name><name><surname>Fuchs</surname><given-names>E</given-names></name></person-group><article-title>Epidermal homeostasis: a balancing act of stem cells in the skin</article-title><source>Nat Rev Mol Cell Biol</source><year>2009</year><volume>10</volume><fpage>207</fpage><lpage>217</lpage><pub-id pub-id-type="doi">10.1038/nrm2636</pub-id><pub-id pub-id-type="pmid">19209183</pub-id>
</element-citation><mixed-citation id="mc-CR1" publication-type="journal">Blanpain C, Fuchs E. Epidermal homeostasis: a balancing act of stem cells in the skin. Nat Rev Mol Cell Biol. 2009;10:207&#x02013;17.<pub-id pub-id-type="pmid">19209183</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Zeng</surname><given-names>W</given-names></name><name><surname>Jiang</surname><given-names>A</given-names></name><name><surname>He</surname><given-names>Z</given-names></name><name><surname>Shen</surname><given-names>X</given-names></name><name><surname>Dong</surname><given-names>X</given-names></name><etal/></person-group><article-title>Global, regional and national incidence, mortality and disability-adjusted life-years of skin cancers and trend analysis from 1990 to 2019: An analysis of the global burden of disease study 2019</article-title><source>Cancer Med</source><year>2021</year><volume>10</volume><fpage>4905</fpage><lpage>4922</lpage><pub-id pub-id-type="doi">10.1002/cam4.4046</pub-id><pub-id pub-id-type="pmid">34105887</pub-id>
</element-citation><mixed-citation id="mc-CR2" publication-type="journal">Zhang W, Zeng W, Jiang A, He Z, Shen X, Dong X, et al. Global, regional and national incidence, mortality and disability-adjusted life-years of skin cancers and trend analysis from 1990 to 2019: An analysis of the global burden of disease study 2019. Cancer Med. 2021;10:4905&#x02013;22.<pub-id pub-id-type="pmid">34105887</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Qin</surname><given-names>YR</given-names></name></person-group><article-title>Health-related quality of life in stage III-IV melanoma treated with targeted therapy or immunotherapy: A systematic review on the adequacy of reporting and clinical issues in phase III randomized controlled trials</article-title><source>Cancer Med</source><year>2023</year><volume>12</volume><fpage>2262</fpage><lpage>2280</lpage><pub-id pub-id-type="doi">10.1002/cam4.5183</pub-id><pub-id pub-id-type="pmid">36030506</pub-id>
</element-citation><mixed-citation id="mc-CR3" publication-type="journal">Chen C, Wang Z, Qin YR. Health-related quality of life in stage III-IV melanoma treated with targeted therapy or immunotherapy: A systematic review on the adequacy of reporting and clinical issues in phase III randomized controlled trials. Cancer Med. 2023;12:2262&#x02013;80.<pub-id pub-id-type="pmid">36030506</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Bray</surname><given-names>F</given-names></name><name><surname>Laversanne</surname><given-names>M</given-names></name><name><surname>Sung</surname><given-names>H</given-names></name><name><surname>Ferlay</surname><given-names>J</given-names></name><name><surname>Siegel</surname><given-names>RL</given-names></name><name><surname>Soerjomataram</surname><given-names>I</given-names></name><etal/></person-group><article-title>Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries</article-title><source>CA Cancer J Clin</source><year>2024</year><volume>74</volume><fpage>229</fpage><lpage>263</lpage><pub-id pub-id-type="doi">10.3322/caac.21834</pub-id><pub-id pub-id-type="pmid">38572751</pub-id>
</element-citation><mixed-citation id="mc-CR4" publication-type="journal">Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229&#x02013;63.<pub-id pub-id-type="pmid">38572751</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Hamp</surname><given-names>A</given-names></name><name><surname>Anderson</surname><given-names>J</given-names></name><name><surname>Sivesind</surname><given-names>TE</given-names></name><name><surname>Szeto</surname><given-names>MD</given-names></name><name><surname>Hadjinicolaou</surname><given-names>A</given-names></name></person-group><article-title>From the Cochrane library: systemic treatments for metastatic cutaneous melanoma</article-title><source>JMIR Dermatol</source><year>2021</year><volume>4</volume><fpage>e30270</fpage><pub-id pub-id-type="doi">10.2196/30270</pub-id><pub-id pub-id-type="pmid">37632820</pub-id>
</element-citation><mixed-citation id="mc-CR5" publication-type="journal">Hamp A, Anderson J, Sivesind TE, Szeto MD, Hadjinicolaou A. From the Cochrane library: systemic treatments for metastatic cutaneous melanoma. JMIR Dermatol. 2021;4: e30270.<pub-id pub-id-type="pmid">37632820</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>M</given-names></name><name><surname>Gao</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name></person-group><article-title>Recent global patterns in skin cancer incidence, mortality, and prevalence</article-title><source>Chin Med J (Engl)</source><year>2025</year><volume>138</volume><fpage>185</fpage><lpage>192</lpage><pub-id pub-id-type="doi">10.1097/CM9.0000000000003416</pub-id><pub-id pub-id-type="pmid">39682020</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">Wang M, Gao X, Zhang L. Recent global patterns in skin cancer incidence, mortality, and prevalence. Chin Med J (Engl). 2025;138:185&#x02013;92.<pub-id pub-id-type="pmid">39682020</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Arnold</surname><given-names>M</given-names></name><name><surname>Singh</surname><given-names>D</given-names></name><name><surname>Laversanne</surname><given-names>M</given-names></name><name><surname>Vignat</surname><given-names>J</given-names></name><name><surname>Vaccarella</surname><given-names>S</given-names></name><name><surname>Meheus</surname><given-names>F</given-names></name><etal/></person-group><article-title>Global burden of cutaneous melanoma in 2020 and projections to 2040</article-title><source>JAMA Dermatol</source><year>2022</year><volume>158</volume><fpage>495</fpage><lpage>503</lpage><pub-id pub-id-type="doi">10.1001/jamadermatol.2022.0160</pub-id><pub-id pub-id-type="pmid">35353115</pub-id>
</element-citation><mixed-citation id="mc-CR7" publication-type="journal">Arnold M, Singh D, Laversanne M, Vignat J, Vaccarella S, Meheus F, et al. Global burden of cutaneous melanoma in 2020 and projections to 2040. JAMA Dermatol. 2022;158:495&#x02013;503.<pub-id pub-id-type="pmid">35353115</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Leiter</surname><given-names>U</given-names></name><name><surname>Keim</surname><given-names>U</given-names></name><name><surname>Garbe</surname><given-names>C</given-names></name><name><surname>Epidemiology of skin cancer: update, </surname></name></person-group><article-title>In Sunlight, Vitamin D and Skin</article-title><source>Cancer</source><year>2019</year><volume>2020</volume><fpage>123</fpage><lpage>139</lpage></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Leiter U, Keim U, Garbe C, Epidemiology of skin cancer: update,. In Sunlight, Vitamin D and Skin. Cancer. 2019;2020:123&#x02013;39.</mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>Eide</surname><given-names>MJ</given-names></name><name><surname>Krajenta</surname><given-names>R</given-names></name><name><surname>Johnson</surname><given-names>D</given-names></name><name><surname>Long</surname><given-names>JJ</given-names></name><name><surname>Jacobsen</surname><given-names>G</given-names></name><name><surname>Asgari</surname><given-names>MM</given-names></name><etal/></person-group><article-title>Identification of patients with nonmelanoma skin cancer using health maintenance organization claims data</article-title><source>Am J Epidemiol</source><year>2010</year><volume>171</volume><fpage>123</fpage><lpage>128</lpage><pub-id pub-id-type="doi">10.1093/aje/kwp352</pub-id><pub-id pub-id-type="pmid">19969529</pub-id>
</element-citation><mixed-citation id="mc-CR9" publication-type="journal">Eide MJ, Krajenta R, Johnson D, Long JJ, Jacobsen G, Asgari MM, et al. Identification of patients with nonmelanoma skin cancer using health maintenance organization claims data. Am J Epidemiol. 2010;171:123&#x02013;8.<pub-id pub-id-type="pmid">19969529</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>Hillen</surname><given-names>U</given-names></name><name><surname>Leiter</surname><given-names>U</given-names></name><name><surname>Haase</surname><given-names>S</given-names></name><name><surname>Kaufmann</surname><given-names>R</given-names></name><name><surname>Becker</surname><given-names>J</given-names></name><name><surname>Gutzmer</surname><given-names>R</given-names></name><etal/></person-group><article-title>Advanced cutaneous squamous cell carcinoma: A retrospective analysis of patient profiles and treatment patterns-Results of a non-interventional study of the DeCOG</article-title><source>Eur J Cancer</source><year>2018</year><volume>96</volume><fpage>34</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2018.01.075</pub-id><pub-id pub-id-type="pmid">29665511</pub-id>
</element-citation><mixed-citation id="mc-CR10" publication-type="journal">Hillen U, Leiter U, Haase S, Kaufmann R, Becker J, Gutzmer R, et al. Advanced cutaneous squamous cell carcinoma: A retrospective analysis of patient profiles and treatment patterns-Results of a non-interventional study of the DeCOG. Eur J Cancer. 2018;96:34&#x02013;43.<pub-id pub-id-type="pmid">29665511</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>A</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Cheng</surname><given-names>W</given-names></name><name><surname>Song</surname><given-names>Y</given-names></name></person-group><article-title>The global, regional, national burden of cutaneous squamous cell carcinoma (1990&#x02013;2019) and predictions to 2035</article-title><source>Eur J Cancer Care</source><year>2023</year><volume>2023</volume><fpage>5484597</fpage><pub-id pub-id-type="doi">10.1155/2023/5484597</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Guo A, Liu X, Li H, Cheng W, Song Y. The global, regional, national burden of cutaneous squamous cell carcinoma (1990&#x02013;2019) and predictions to 2035. Eur J Cancer Care. 2023;2023:5484597.</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Biddle</surname><given-names>A</given-names></name><name><surname>Liang</surname><given-names>X</given-names></name><name><surname>Gammon</surname><given-names>L</given-names></name><name><surname>Fazil</surname><given-names>B</given-names></name><name><surname>Harper</surname><given-names>LJ</given-names></name><name><surname>Emich</surname><given-names>H</given-names></name><etal/></person-group><article-title>Cancer stem cells in squamous cell carcinoma switch between two distinct phenotypes that are preferentially migratory or proliferative</article-title><source>Cancer Res</source><year>2011</year><volume>71</volume><fpage>5317</fpage><lpage>5326</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-11-1059</pub-id><pub-id pub-id-type="pmid">21685475</pub-id>
</element-citation><mixed-citation id="mc-CR12" publication-type="journal">Biddle A, Liang X, Gammon L, Fazil B, Harper LJ, Emich H, et al. Cancer stem cells in squamous cell carcinoma switch between two distinct phenotypes that are preferentially migratory or proliferative. Cancer Res. 2011;71:5317&#x02013;26.<pub-id pub-id-type="pmid">21685475</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>El-Khattouti</surname><given-names>A</given-names></name><name><surname>Selimovic</surname><given-names>D</given-names></name><name><surname>Ha&#x000ef;kel</surname><given-names>Y</given-names></name><name><surname>Megahed</surname><given-names>M</given-names></name><name><surname>Gomez</surname><given-names>CR</given-names></name><name><surname>Hassan</surname><given-names>M</given-names></name></person-group><article-title>Identification and analysis of CD133+ melanoma stem-like cells conferring resistance to taxol: An insight into the mechanisms of their resistance and response</article-title><source>Cancer Lett</source><year>2014</year><volume>343</volume><fpage>123</fpage><lpage>133</lpage><pub-id pub-id-type="doi">10.1016/j.canlet.2013.09.024</pub-id><pub-id pub-id-type="pmid">24080340</pub-id>
</element-citation><mixed-citation id="mc-CR13" publication-type="journal">El-Khattouti A, Selimovic D, Ha&#x000ef;kel Y, Megahed M, Gomez CR, Hassan M. Identification and analysis of CD133+ melanoma stem-like cells conferring resistance to taxol: An insight into the mechanisms of their resistance and response. Cancer Lett. 2014;343:123&#x02013;33.<pub-id pub-id-type="pmid">24080340</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>Schatton</surname><given-names>T</given-names></name><name><surname>Murphy</surname><given-names>GF</given-names></name><name><surname>Frank</surname><given-names>NY</given-names></name><name><surname>Yamaura</surname><given-names>K</given-names></name><name><surname>Waaga-Gasser</surname><given-names>AM</given-names></name><name><surname>Gasser</surname><given-names>M</given-names></name><etal/></person-group><article-title>Identification of cells initiating human melanomas</article-title><source>Nature</source><year>2008</year><volume>451</volume><fpage>345</fpage><lpage>349</lpage><pub-id pub-id-type="doi">10.1038/nature06489</pub-id><pub-id pub-id-type="pmid">18202660</pub-id>
</element-citation><mixed-citation id="mc-CR14" publication-type="journal">Schatton T, Murphy GF, Frank NY, Yamaura K, Waaga-Gasser AM, Gasser M, et al. Identification of cells initiating human melanomas. Nature. 2008;451:345&#x02013;9.<pub-id pub-id-type="pmid">18202660</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname><given-names>Y</given-names></name><name><surname>Dallaglio</surname><given-names>K</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Robinson</surname><given-names>WA</given-names></name><name><surname>Robinson</surname><given-names>SE</given-names></name><name><surname>McCarter</surname><given-names>MD</given-names></name><etal/></person-group><article-title>ALDH1A isozymes are markers of human melanoma stem cells and potential therapeutic targets</article-title><source>Stem Cells</source><year>2012</year><volume>30</volume><fpage>2100</fpage><lpage>2113</lpage><pub-id pub-id-type="doi">10.1002/stem.1193</pub-id><pub-id pub-id-type="pmid">22887839</pub-id>
</element-citation><mixed-citation id="mc-CR15" publication-type="journal">Luo Y, Dallaglio K, Chen Y, Robinson WA, Robinson SE, McCarter MD, et al. ALDH1A isozymes are markers of human melanoma stem cells and potential therapeutic targets. Stem Cells. 2012;30:2100&#x02013;13.<pub-id pub-id-type="pmid">22887839</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>Pinc</surname><given-names>A</given-names></name><name><surname>Somasundaram</surname><given-names>R</given-names></name><name><surname>Wagner</surname><given-names>C</given-names></name><name><surname>H&#x000f6;rmann</surname><given-names>M</given-names></name><name><surname>Karanikas</surname><given-names>G</given-names></name><name><surname>Jalili</surname><given-names>A</given-names></name><etal/></person-group><article-title>Targeting CD20 in melanoma patients at high risk of disease recurrence</article-title><source>Mol Ther</source><year>2012</year><volume>20</volume><fpage>1056</fpage><lpage>1062</lpage><pub-id pub-id-type="doi">10.1038/mt.2012.27</pub-id><pub-id pub-id-type="pmid">22354376</pub-id>
</element-citation><mixed-citation id="mc-CR16" publication-type="journal">Pinc A, Somasundaram R, Wagner C, H&#x000f6;rmann M, Karanikas G, Jalili A, et al. Targeting CD20 in melanoma patients at high risk of disease recurrence. Mol Ther. 2012;20:1056&#x02013;62.<pub-id pub-id-type="pmid">22354376</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name><surname>Civenni</surname><given-names>G</given-names></name><name><surname>Walter</surname><given-names>A</given-names></name><name><surname>Kobert</surname><given-names>N</given-names></name><name><surname>Mihic-Probst</surname><given-names>D</given-names></name><name><surname>Zipser</surname><given-names>M</given-names></name><name><surname>Belloni</surname><given-names>B</given-names></name><etal/></person-group><article-title>Human CD271-positive melanoma stem cells associated with metastasis establish tumor heterogeneity and long-term growth</article-title><source>Cancer Res</source><year>2011</year><volume>71</volume><fpage>3098</fpage><lpage>3109</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-10-3997</pub-id><pub-id pub-id-type="pmid">21393506</pub-id>
</element-citation><mixed-citation id="mc-CR17" publication-type="journal">Civenni G, Walter A, Kobert N, Mihic-Probst D, Zipser M, Belloni B, et al. Human CD271-positive melanoma stem cells associated with metastasis establish tumor heterogeneity and long-term growth. Cancer Res. 2011;71:3098&#x02013;109.<pub-id pub-id-type="pmid">21393506</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>Shakhova</surname><given-names>O</given-names></name><name><surname>Zingg</surname><given-names>D</given-names></name><name><surname>Schaefer</surname><given-names>SM</given-names></name><name><surname>Hari</surname><given-names>L</given-names></name><name><surname>Civenni</surname><given-names>G</given-names></name><name><surname>Blunschi</surname><given-names>J</given-names></name><etal/></person-group><article-title>Sox10 promotes the formation and maintenance of giant congenital naevi and melanoma</article-title><source>Nat Cell Biol</source><year>2012</year><volume>14</volume><fpage>882</fpage><lpage>890</lpage><pub-id pub-id-type="doi">10.1038/ncb2535</pub-id><pub-id pub-id-type="pmid">22772081</pub-id>
</element-citation><mixed-citation id="mc-CR18" publication-type="journal">Shakhova O, Zingg D, Schaefer SM, Hari L, Civenni G, Blunschi J, et al. Sox10 promotes the formation and maintenance of giant congenital naevi and melanoma. Nat Cell Biol. 2012;14:882&#x02013;90.<pub-id pub-id-type="pmid">22772081</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name><surname>Schober</surname><given-names>M</given-names></name><name><surname>Fuchs</surname><given-names>E</given-names></name></person-group><article-title>Tumor-initiating stem cells of squamous cell carcinomas and their control by TGF-&#x003b2; and integrin/focal adhesion kinase (FAK) signaling</article-title><source>Proc Natl Acad Sci U S A</source><year>2011</year><volume>108</volume><fpage>10544</fpage><lpage>10549</lpage><pub-id pub-id-type="doi">10.1073/pnas.1107807108</pub-id><pub-id pub-id-type="pmid">21670270</pub-id>
</element-citation><mixed-citation id="mc-CR19" publication-type="journal">Schober M, Fuchs E. Tumor-initiating stem cells of squamous cell carcinomas and their control by TGF-&#x003b2; and integrin/focal adhesion kinase (FAK) signaling. Proc Natl Acad Sci U S A. 2011;108:10544&#x02013;9.<pub-id pub-id-type="pmid">21670270</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name><surname>Colmont</surname><given-names>CS</given-names></name><name><surname>BenKetah</surname><given-names>A</given-names></name><name><surname>Reed</surname><given-names>SH</given-names></name><name><surname>Hawk</surname><given-names>NV</given-names></name><name><surname>Telford</surname><given-names>WG</given-names></name><name><surname>Ohyama</surname><given-names>M</given-names></name><etal/></person-group><article-title>CD200-expressing human basal cell carcinoma cells initiate tumor growth</article-title><source>Proc Natl Acad Sci U S A</source><year>2013</year><volume>110</volume><fpage>1434</fpage><lpage>1439</lpage><pub-id pub-id-type="doi">10.1073/pnas.1211655110</pub-id><pub-id pub-id-type="pmid">23292936</pub-id>
</element-citation><mixed-citation id="mc-CR20" publication-type="journal">Colmont CS, BenKetah A, Reed SH, Hawk NV, Telford WG, Ohyama M, et al. CD200-expressing human basal cell carcinoma cells initiate tumor growth. Proc Natl Acad Sci U S A. 2013;110:1434&#x02013;9.<pub-id pub-id-type="pmid">23292936</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><mixed-citation publication-type="other">Guasch G, The epithelial stem cell niche in skin, in Biology and engineering of stem cell niches, A.a.K. Vishwakarma, J.M., Editor. 2017, Elsevier. p. 127&#x02013;143.</mixed-citation></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>Gonzales</surname><given-names>KAU</given-names></name><name><surname>Fuchs</surname><given-names>E</given-names></name></person-group><article-title>Skin and its regenerative powers: an alliance between stem cells and their niche</article-title><source>Dev Cell</source><year>2017</year><volume>43</volume><fpage>387</fpage><lpage>401</lpage><pub-id pub-id-type="doi">10.1016/j.devcel.2017.10.001</pub-id><pub-id pub-id-type="pmid">29161590</pub-id>
</element-citation><mixed-citation id="mc-CR22" publication-type="journal">Gonzales KAU, Fuchs E. Skin and its regenerative powers: an alliance between stem cells and their niche. Dev Cell. 2017;43:387&#x02013;401.<pub-id pub-id-type="pmid">29161590</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name><surname>Box</surname><given-names>NF</given-names></name><name><surname>Torchia</surname><given-names>EC</given-names></name><name><surname>Roop</surname><given-names>DR</given-names></name></person-group><article-title>Are stem cell niches shared for skin cancers?</article-title><source>Pigment Cell Melanoma Res</source><year>2010</year><volume>23</volume><fpage>517</fpage><lpage>520</lpage><pub-id pub-id-type="doi">10.1111/j.1755-148X.2010.00727.x</pub-id><pub-id pub-id-type="pmid">20546533</pub-id>
</element-citation><mixed-citation id="mc-CR23" publication-type="journal">Box NF, Torchia EC, Roop DR. Are stem cell niches shared for skin cancers? Pigment Cell Melanoma Res. 2010;23:517&#x02013;20.<pub-id pub-id-type="pmid">20546533</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name><surname>Hsu</surname><given-names>Y-C</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Fuchs</surname><given-names>E</given-names></name></person-group><article-title>Emerging interactions between skin stem cells and their niches</article-title><source>Nat Med</source><year>2014</year><volume>20</volume><fpage>847</fpage><lpage>856</lpage><pub-id pub-id-type="doi">10.1038/nm.3643</pub-id><pub-id pub-id-type="pmid">25100530</pub-id>
</element-citation><mixed-citation id="mc-CR24" publication-type="journal">Hsu Y-C, Li L, Fuchs E. Emerging interactions between skin stem cells and their niches. Nat Med. 2014;20:847&#x02013;56.<pub-id pub-id-type="pmid">25100530</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name><surname>Boukamp</surname><given-names>P</given-names></name></person-group><article-title>Non-melanoma skin cancer: what drives tumor development and progression?</article-title><source>Carcinogenesis</source><year>2005</year><volume>26</volume><fpage>1657</fpage><lpage>1667</lpage><pub-id pub-id-type="doi">10.1093/carcin/bgi123</pub-id><pub-id pub-id-type="pmid">15905207</pub-id>
</element-citation><mixed-citation id="mc-CR25" publication-type="journal">Boukamp P. Non-melanoma skin cancer: what drives tumor development and progression? Carcinogenesis. 2005;26:1657&#x02013;67.<pub-id pub-id-type="pmid">15905207</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name><surname>Hasan</surname><given-names>N</given-names></name><name><surname>Nadaf</surname><given-names>A</given-names></name><name><surname>Imran</surname><given-names>M</given-names></name><name><surname>Jiba</surname><given-names>U</given-names></name><name><surname>Sheikh</surname><given-names>A</given-names></name><name><surname>Almalki</surname><given-names>WH</given-names></name><etal/></person-group><article-title>Skin cancer: understanding the journey of transformation from conventional to advanced treatment approaches</article-title><source>Mol Cancer</source><year>2023</year><volume>22</volume><fpage>168</fpage><pub-id pub-id-type="doi">10.1186/s12943-023-01854-3</pub-id><pub-id pub-id-type="pmid">37803407</pub-id>
</element-citation><mixed-citation id="mc-CR26" publication-type="journal">Hasan N, Nadaf A, Imran M, Jiba U, Sheikh A, Almalki WH, et al. Skin cancer: understanding the journey of transformation from conventional to advanced treatment approaches. Mol Cancer. 2023;22:168.<pub-id pub-id-type="pmid">37803407</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>D</given-names></name><name><surname>Gorain</surname><given-names>M</given-names></name><name><surname>Kundu</surname><given-names>G</given-names></name><name><surname>Kundu</surname><given-names>GC</given-names></name></person-group><article-title>Therapeutic implications of cellular and molecular biology of cancer stem cells in melanoma</article-title><source>Mol Cancer</source><year>2017</year><volume>16</volume><fpage>7</fpage><pub-id pub-id-type="doi">10.1186/s12943-016-0578-3</pub-id><pub-id pub-id-type="pmid">28137308</pub-id>
</element-citation><mixed-citation id="mc-CR27" publication-type="journal">Kumar D, Gorain M, Kundu G, Kundu GC. Therapeutic implications of cellular and molecular biology of cancer stem cells in melanoma. Mol Cancer. 2017;16:7.<pub-id pub-id-type="pmid">28137308</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name><surname>Debaugnies</surname><given-names>M</given-names></name><name><surname>S&#x000e1;nchez-Dan&#x000e9;s</surname><given-names>A</given-names></name><name><surname>Rorive</surname><given-names>S</given-names></name><name><surname>Rapha&#x000eb;l</surname><given-names>M</given-names></name><name><surname>Liagre</surname><given-names>M</given-names></name><name><surname>Parent</surname><given-names>MA</given-names></name><etal/></person-group><article-title>YAP and TAZ are essential for basal and squamous cell carcinoma initiation</article-title><source>EMBO Rep</source><year>2018</year><volume>19</volume><fpage>e45809</fpage><pub-id pub-id-type="doi">10.15252/embr.201845809</pub-id><pub-id pub-id-type="pmid">29875149</pub-id>
</element-citation><mixed-citation id="mc-CR28" publication-type="journal">Debaugnies M, S&#x000e1;nchez-Dan&#x000e9;s A, Rorive S, Rapha&#x000eb;l M, Liagre M, Parent MA, et al. YAP and TAZ are essential for basal and squamous cell carcinoma initiation. EMBO Rep. 2018;19: e45809.<pub-id pub-id-type="pmid">29875149</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name><surname>Pei</surname><given-names>G</given-names></name><name><surname>Lan</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>D</given-names></name><name><surname>Ji</surname><given-names>L</given-names></name><name><surname>Hua</surname><given-names>ZC</given-names></name></person-group><article-title>FAK regulates E-cadherin expression via p-SrcY416/p-ERK1/2/p-Stat3Y705 and PPAR&#x003b3;/miR-125b/Stat3 signaling pathway in B16F10 melanoma cells</article-title><source>Oncotarget</source><year>2017</year><volume>8</volume><fpage>13898</fpage><lpage>13908</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.14687</pub-id><pub-id pub-id-type="pmid">28108732</pub-id>
</element-citation><mixed-citation id="mc-CR29" publication-type="journal">Pei G, Lan Y, Chen D, Ji L, Hua ZC. FAK regulates E-cadherin expression via p-SrcY416/p-ERK1/2/p-Stat3Y705 and PPAR&#x003b3;/miR-125b/Stat3 signaling pathway in B16F10 melanoma cells. Oncotarget. 2017;8:13898&#x02013;908.<pub-id pub-id-type="pmid">28108732</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name><surname>Blanpain</surname><given-names>C</given-names></name><name><surname>Simons</surname><given-names>BD</given-names></name></person-group><article-title>Unravelling stem cell dynamics by lineage tracing</article-title><source>Nat Rev Mol Cell Biol</source><year>2013</year><volume>14</volume><fpage>489</fpage><lpage>502</lpage><pub-id pub-id-type="doi">10.1038/nrm3625</pub-id><pub-id pub-id-type="pmid">23860235</pub-id>
</element-citation><mixed-citation id="mc-CR30" publication-type="journal">Blanpain C, Simons BD. Unravelling stem cell dynamics by lineage tracing. Nat Rev Mol Cell Biol. 2013;14:489&#x02013;502.<pub-id pub-id-type="pmid">23860235</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name><surname>Hsu</surname><given-names>Y-C</given-names></name><name><surname>Pasolli</surname><given-names>HA</given-names></name><name><surname>Fuchs</surname><given-names>E</given-names></name></person-group><article-title>Dynamics between stem cells, niche, and progeny in the hair follicle</article-title><source>Cell</source><year>2011</year><volume>144</volume><fpage>92</fpage><lpage>105</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2010.11.049</pub-id><pub-id pub-id-type="pmid">21215372</pub-id>
</element-citation><mixed-citation id="mc-CR31" publication-type="journal">Hsu Y-C, Pasolli HA, Fuchs E. Dynamics between stem cells, niche, and progeny in the hair follicle. Cell. 2011;144:92&#x02013;105.<pub-id pub-id-type="pmid">21215372</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name><surname>Ito</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>Z</given-names></name><name><surname>Nguyen</surname><given-names>J</given-names></name><name><surname>Liang</surname><given-names>F</given-names></name><name><surname>Morris</surname><given-names>RJ</given-names></name><etal/></person-group><article-title>Stem cells in the hair follicle bulge contribute to wound repair but not to homeostasis of the epidermis</article-title><source>Nat Med</source><year>2005</year><volume>11</volume><fpage>1351</fpage><lpage>1354</lpage><pub-id pub-id-type="doi">10.1038/nm1328</pub-id><pub-id pub-id-type="pmid">16288281</pub-id>
</element-citation><mixed-citation id="mc-CR32" publication-type="journal">Ito M, Liu Y, Yang Z, Nguyen J, Liang F, Morris RJ, et al. Stem cells in the hair follicle bulge contribute to wound repair but not to homeostasis of the epidermis. Nat Med. 2005;11:1351&#x02013;4.<pub-id pub-id-type="pmid">16288281</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name><surname>Brownell</surname><given-names>I</given-names></name><name><surname>Guevara</surname><given-names>E</given-names></name><name><surname>Bai</surname><given-names>CB</given-names></name><name><surname>Loomis</surname><given-names>CA</given-names></name><name><surname>Joyner</surname><given-names>AL</given-names></name></person-group><article-title>Nerve-derived sonic hedgehog defines a niche for hair follicle stem cells capable of becoming epidermal stem cells</article-title><source>Cell Stem Cell</source><year>2011</year><volume>8</volume><fpage>552</fpage><lpage>565</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2011.02.021</pub-id><pub-id pub-id-type="pmid">21549329</pub-id>
</element-citation><mixed-citation id="mc-CR33" publication-type="journal">Brownell I, Guevara E, Bai CB, Loomis CA, Joyner AL. Nerve-derived sonic hedgehog defines a niche for hair follicle stem cells capable of becoming epidermal stem cells. Cell Stem Cell. 2011;8:552&#x02013;65.<pub-id pub-id-type="pmid">21549329</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name><surname>Dupin</surname><given-names>E</given-names></name><name><surname>Le Douarin</surname><given-names>NM</given-names></name></person-group><article-title>Development of melanocyte precursors from the vertebrate neural crest</article-title><source>Oncogene</source><year>2003</year><volume>22</volume><fpage>3016</fpage><lpage>3023</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1206460</pub-id><pub-id pub-id-type="pmid">12789276</pub-id>
</element-citation><mixed-citation id="mc-CR34" publication-type="journal">Dupin E, Le Douarin NM. Development of melanocyte precursors from the vertebrate neural crest. Oncogene. 2003;22:3016&#x02013;23.<pub-id pub-id-type="pmid">12789276</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name><surname>Rabbani</surname><given-names>P</given-names></name><name><surname>Takeo</surname><given-names>M</given-names></name><name><surname>Chou</surname><given-names>W</given-names></name><name><surname>Myung</surname><given-names>P</given-names></name><name><surname>Bosenberg</surname><given-names>M</given-names></name><name><surname>Chin</surname><given-names>L</given-names></name><etal/></person-group><article-title>Coordinated activation of Wnt in epithelial and melanocyte stem cells initiates pigmented hair regeneration</article-title><source>Cell</source><year>2011</year><volume>145</volume><fpage>941</fpage><lpage>955</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2011.05.004</pub-id><pub-id pub-id-type="pmid">21663796</pub-id>
</element-citation><mixed-citation id="mc-CR35" publication-type="journal">Rabbani P, Takeo M, Chou W, Myung P, Bosenberg M, Chin L, et al. Coordinated activation of Wnt in epithelial and melanocyte stem cells initiates pigmented hair regeneration. Cell. 2011;145:941&#x02013;55.<pub-id pub-id-type="pmid">21663796</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name><surname>Lapouge</surname><given-names>G</given-names></name><name><surname>Youssef</surname><given-names>KK</given-names></name><name><surname>Vokaer</surname><given-names>B</given-names></name><name><surname>Achouri</surname><given-names>Y</given-names></name><name><surname>Michaux</surname><given-names>C</given-names></name><name><surname>Sotiropoulou</surname><given-names>PA</given-names></name><etal/></person-group><article-title>Identifying the cellular origin of squamous skin tumors</article-title><source>Proc Natl Acad Sci U S A</source><year>2011</year><volume>108</volume><fpage>7431</fpage><lpage>7436</lpage><pub-id pub-id-type="doi">10.1073/pnas.1012720108</pub-id><pub-id pub-id-type="pmid">21502497</pub-id>
</element-citation><mixed-citation id="mc-CR36" publication-type="journal">Lapouge G, Youssef KK, Vokaer B, Achouri Y, Michaux C, Sotiropoulou PA, et al. Identifying the cellular origin of squamous skin tumors. Proc Natl Acad Sci U S A. 2011;108:7431&#x02013;6.<pub-id pub-id-type="pmid">21502497</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><mixed-citation publication-type="other">Becker JC and zur Hausen A. Cells of origin in skin cancer. J Invest Dermatol. 2014; 134:2491&#x02013;2493.</mixed-citation></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name><surname>Roig-Rosello</surname><given-names>E</given-names></name><name><surname>Rousselle</surname><given-names>P</given-names></name></person-group><article-title>The human epidermal basement membrane: A shaped and cell instructive platform that aging slowly alters</article-title><source>Biomolecules</source><year>2020</year><volume>10</volume><fpage>1607</fpage><pub-id pub-id-type="doi">10.3390/biom10121607</pub-id><pub-id pub-id-type="pmid">33260936</pub-id>
</element-citation><mixed-citation id="mc-CR38" publication-type="journal">Roig-Rosello E, Rousselle P. The human epidermal basement membrane: A shaped and cell instructive platform that aging slowly alters. Biomolecules. 2020;10:1607.<pub-id pub-id-type="pmid">33260936</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name><surname>Morgner</surname><given-names>J</given-names></name><name><surname>Ghatak</surname><given-names>S</given-names></name><name><surname>Jakobi</surname><given-names>T</given-names></name><name><surname>Dieterich</surname><given-names>C</given-names></name><name><surname>Aumailley</surname><given-names>M</given-names></name><name><surname>Wickstr&#x000f6;m</surname><given-names>SA</given-names></name></person-group><article-title>Integrin-linked kinase regulates the niche of quiescent epidermal stem cells</article-title><source>Nat Commun</source><year>2015</year><volume>6</volume><fpage>1</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1038/ncomms9198</pub-id></element-citation><mixed-citation id="mc-CR39" publication-type="journal">Morgner J, Ghatak S, Jakobi T, Dieterich C, Aumailley M, Wickstr&#x000f6;m SA. Integrin-linked kinase regulates the niche of quiescent epidermal stem cells. Nat Commun. 2015;6:1&#x02013;15.</mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name><surname>Yamada</surname><given-names>T</given-names></name><name><surname>Hasegawa</surname><given-names>S</given-names></name><name><surname>Miyachi</surname><given-names>K</given-names></name><name><surname>Date</surname><given-names>Y</given-names></name><name><surname>Inoue</surname><given-names>Y</given-names></name><name><surname>Yagami</surname><given-names>A</given-names></name><etal/></person-group><article-title>Laminin-332 regulates differentiation of human interfollicular epidermal stem cells</article-title><source>Mech Ageing Dev</source><year>2018</year><volume>171</volume><fpage>37</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1016/j.mad.2018.03.007</pub-id><pub-id pub-id-type="pmid">29555367</pub-id>
</element-citation><mixed-citation id="mc-CR40" publication-type="journal">Yamada T, Hasegawa S, Miyachi K, Date Y, Inoue Y, Yagami A, et al. Laminin-332 regulates differentiation of human interfollicular epidermal stem cells. Mech Ageing Dev. 2018;171:37&#x02013;46.<pub-id pub-id-type="pmid">29555367</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name><surname>Margadant</surname><given-names>C</given-names></name><name><surname>Charafeddine</surname><given-names>RA</given-names></name><name><surname>Sonnenberg</surname><given-names>A</given-names></name></person-group><article-title>Unique and redundant functions of integrins in the epidermis</article-title><source>FASEB J</source><year>2010</year><volume>24</volume><fpage>4133</fpage><lpage>4152</lpage><pub-id pub-id-type="doi">10.1096/fj.09-151449</pub-id><pub-id pub-id-type="pmid">20624931</pub-id>
</element-citation><mixed-citation id="mc-CR41" publication-type="journal">Margadant C, Charafeddine RA, Sonnenberg A. Unique and redundant functions of integrins in the epidermis. FASEB J. 2010;24:4133&#x02013;52.<pub-id pub-id-type="pmid">20624931</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name><surname>Huveneers</surname><given-names>S</given-names></name><name><surname>Danen</surname><given-names>EHJ</given-names></name></person-group><article-title>Adhesion signaling &#x02013; crosstalk between integrins</article-title><source>Src and Rho J Cell Sci</source><year>2009</year><volume>122</volume><fpage>1059</fpage><lpage>1069</lpage><pub-id pub-id-type="doi">10.1242/jcs.039446</pub-id><pub-id pub-id-type="pmid">19339545</pub-id>
</element-citation><mixed-citation id="mc-CR42" publication-type="journal">Huveneers S, Danen EHJ. Adhesion signaling &#x02013; crosstalk between integrins. Src and Rho J Cell Sci. 2009;122:1059&#x02013;69.<pub-id pub-id-type="pmid">19339545</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name><surname>Carter</surname><given-names>WG</given-names></name><name><surname>Kaur</surname><given-names>P</given-names></name><name><surname>Gil</surname><given-names>SG</given-names></name><name><surname>Gahr</surname><given-names>PJ</given-names></name><name><surname>Wayner</surname><given-names>EA</given-names></name></person-group><article-title>Distinct functions for integrins alpha 3 beta 1 in focal adhesions and alpha 6 beta 4/bullous pemphigoid antigen in a new stable anchoring contact (SAC) of keratinocytes: relation to hemidesmosomes</article-title><source>J Cell Biol</source><year>1990</year><volume>111</volume><fpage>3141</fpage><lpage>3154</lpage><pub-id pub-id-type="doi">10.1083/jcb.111.6.3141</pub-id><pub-id pub-id-type="pmid">2269668</pub-id>
</element-citation><mixed-citation id="mc-CR43" publication-type="journal">Carter WG, Kaur P, Gil SG, Gahr PJ, Wayner EA. Distinct functions for integrins alpha 3 beta 1 in focal adhesions and alpha 6 beta 4/bullous pemphigoid antigen in a new stable anchoring contact (SAC) of keratinocytes: relation to hemidesmosomes. J Cell Biol. 1990;111:3141&#x02013;54.<pub-id pub-id-type="pmid">2269668</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name><surname>Nishiuchi</surname><given-names>R</given-names></name><name><surname>Murayama</surname><given-names>O</given-names></name><name><surname>Fujiwara</surname><given-names>H</given-names></name><name><surname>Gu</surname><given-names>J</given-names></name><name><surname>Kawakami</surname><given-names>T</given-names></name><name><surname>Aimoto</surname><given-names>S</given-names></name><etal/></person-group><article-title>Characterization of the ligand-binding specificities of integrin alpha3beta1 and alpha6beta1 using a panel of purified laminin isoforms containing distinct alpha chains</article-title><source>J Biochem</source><year>2003</year><volume>134</volume><fpage>497</fpage><lpage>504</lpage><pub-id pub-id-type="doi">10.1093/jb/mvg185</pub-id><pub-id pub-id-type="pmid">14607975</pub-id>
</element-citation><mixed-citation id="mc-CR44" publication-type="journal">Nishiuchi R, Murayama O, Fujiwara H, Gu J, Kawakami T, Aimoto S, et al. Characterization of the ligand-binding specificities of integrin alpha3beta1 and alpha6beta1 using a panel of purified laminin isoforms containing distinct alpha chains. J Biochem. 2003;134:497&#x02013;504.<pub-id pub-id-type="pmid">14607975</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name><surname>Kaur</surname><given-names>P</given-names></name><name><surname>Li</surname><given-names>A</given-names></name></person-group><article-title>Adhesive properties of human basal epidermal cells: an analysis of keratinocyte stem cells, transit amplifying cells, and postmitotic differentiating cells</article-title><source>J Invest Dermatol</source><year>2000</year><volume>114</volume><fpage>413</fpage><lpage>420</lpage><pub-id pub-id-type="doi">10.1046/j.1523-1747.2000.00884.x</pub-id><pub-id pub-id-type="pmid">10692098</pub-id>
</element-citation><mixed-citation id="mc-CR45" publication-type="journal">Kaur P, Li A. Adhesive properties of human basal epidermal cells: an analysis of keratinocyte stem cells, transit amplifying cells, and postmitotic differentiating cells. J Invest Dermatol. 2000;114:413&#x02013;20.<pub-id pub-id-type="pmid">10692098</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>PH</given-names></name><name><surname>Harper</surname><given-names>S</given-names></name><name><surname>Watt</surname><given-names>FM</given-names></name></person-group><article-title>Stem cell patterning and fate in human epidermis</article-title><source>Cell</source><year>1995</year><volume>80</volume><fpage>83</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1016/0092-8674(95)90453-0</pub-id><pub-id pub-id-type="pmid">7813021</pub-id>
</element-citation><mixed-citation id="mc-CR46" publication-type="journal">Jones PH, Harper S, Watt FM. Stem cell patterning and fate in human epidermis. Cell. 1995;80:83&#x02013;93.<pub-id pub-id-type="pmid">7813021</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name><surname>Rousselle</surname><given-names>P</given-names></name><name><surname>Beck</surname><given-names>K</given-names></name></person-group><article-title>Laminin 332 processing impacts cellular behavior</article-title><source>Cell Adh Migr</source><year>2013</year><volume>7</volume><fpage>122</fpage><lpage>134</lpage><pub-id pub-id-type="doi">10.4161/cam.23132</pub-id><pub-id pub-id-type="pmid">23263634</pub-id>
</element-citation><mixed-citation id="mc-CR47" publication-type="journal">Rousselle P, Beck K. Laminin 332 processing impacts cellular behavior. Cell Adh Migr. 2013;7:122&#x02013;34.<pub-id pub-id-type="pmid">23263634</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name><surname>Tsubota</surname><given-names>Y</given-names></name><name><surname>Yasuda</surname><given-names>C</given-names></name><name><surname>Kariya</surname><given-names>Y</given-names></name><name><surname>Ogawa</surname><given-names>T</given-names></name><name><surname>Hirosaki</surname><given-names>T</given-names></name><name><surname>Mizushima</surname><given-names>H</given-names></name><etal/></person-group><article-title>Regulation of biological activity and matrix assembly of laminin-5 by COOH-terminal, LG4-5 domain of alpha3 chain</article-title><source>J Biol Chem</source><year>2005</year><volume>280</volume><fpage>14370</fpage><lpage>14377</lpage><pub-id pub-id-type="doi">10.1074/jbc.M413051200</pub-id><pub-id pub-id-type="pmid">15695818</pub-id>
</element-citation><mixed-citation id="mc-CR48" publication-type="journal">Tsubota Y, Yasuda C, Kariya Y, Ogawa T, Hirosaki T, Mizushima H, et al. Regulation of biological activity and matrix assembly of laminin-5 by COOH-terminal, LG4-5 domain of alpha3 chain. J Biol Chem. 2005;280:14370&#x02013;7.<pub-id pub-id-type="pmid">15695818</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name><surname>Goldfinger</surname><given-names>LE</given-names></name><name><surname>Stack</surname><given-names>MS</given-names></name><name><surname>Jones</surname><given-names>JC</given-names></name></person-group><article-title>Processing of laminin-5 and its functional consequences: role of plasmin and tissue-type plasminogen activator</article-title><source>J Cell Biol</source><year>1998</year><volume>141</volume><fpage>255</fpage><lpage>265</lpage><pub-id pub-id-type="doi">10.1083/jcb.141.1.255</pub-id><pub-id pub-id-type="pmid">9531563</pub-id>
</element-citation><mixed-citation id="mc-CR49" publication-type="journal">Goldfinger LE, Stack MS, Jones JC. Processing of laminin-5 and its functional consequences: role of plasmin and tissue-type plasminogen activator. J Cell Biol. 1998;141:255&#x02013;65.<pub-id pub-id-type="pmid">9531563</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR50"><label>50.</label><citation-alternatives><element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name><surname>Behrens</surname><given-names>DT</given-names></name><name><surname>Villone</surname><given-names>D</given-names></name><name><surname>Koch</surname><given-names>M</given-names></name><name><surname>Brunner</surname><given-names>G</given-names></name><name><surname>Sorokin</surname><given-names>L</given-names></name><name><surname>Robenek</surname><given-names>H</given-names></name><etal/></person-group><article-title>The epidermal basement membrane is a composite of separate laminin- or collagen IV-containing networks connected by aggregated perlecan, but not by nidogens</article-title><source>J Biol Chem</source><year>2012</year><volume>287</volume><fpage>18700</fpage><lpage>18709</lpage><pub-id pub-id-type="doi">10.1074/jbc.M111.336073</pub-id><pub-id pub-id-type="pmid">22493504</pub-id>
</element-citation><mixed-citation id="mc-CR50" publication-type="journal">Behrens DT, Villone D, Koch M, Brunner G, Sorokin L, Robenek H, et al. The epidermal basement membrane is a composite of separate laminin- or collagen IV-containing networks connected by aggregated perlecan, but not by nidogens. J Biol Chem. 2012;287:18700&#x02013;9.<pub-id pub-id-type="pmid">22493504</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR51"><label>51.</label><citation-alternatives><element-citation id="ec-CR51" publication-type="journal"><person-group person-group-type="author"><name><surname>Kariya</surname><given-names>Y</given-names></name><name><surname>Sato</surname><given-names>H</given-names></name><name><surname>Katou</surname><given-names>N</given-names></name><name><surname>Kariya</surname><given-names>Y</given-names></name><name><surname>Miyazaki</surname><given-names>K</given-names></name></person-group><article-title>Polymerized laminin-332 matrix supports rapid and tight adhesion of keratinocytes, suppressing cell migration</article-title><source>PLoS ONE</source><year>2012</year><volume>7</volume><fpage>e35546</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0035546</pub-id><pub-id pub-id-type="pmid">22563463</pub-id>
</element-citation><mixed-citation id="mc-CR51" publication-type="journal">Kariya Y, Sato H, Katou N, Kariya Y, Miyazaki K. Polymerized laminin-332 matrix supports rapid and tight adhesion of keratinocytes, suppressing cell migration. PLoS ONE. 2012;7: e35546.<pub-id pub-id-type="pmid">22563463</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR52"><label>52.</label><citation-alternatives><element-citation id="ec-CR52" publication-type="journal"><person-group person-group-type="author"><name><surname>Tsuruta</surname><given-names>D</given-names></name><name><surname>Hashimoto</surname><given-names>T</given-names></name><name><surname>Hamill</surname><given-names>KJ</given-names></name><name><surname>Jones</surname><given-names>JC</given-names></name></person-group><article-title>Hemidesmosomes and focal contact proteins: functions and cross-talk in keratinocytes, bullous diseases and wound healing</article-title><source>J Dermatol Sci</source><year>2011</year><volume>62</volume><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">21376539</pub-id>
</element-citation><mixed-citation id="mc-CR52" publication-type="journal">Tsuruta D, Hashimoto T, Hamill KJ, Jones JC. Hemidesmosomes and focal contact proteins: functions and cross-talk in keratinocytes, bullous diseases and wound healing. J Dermatol Sci. 2011;62:1&#x02013;7.<pub-id pub-id-type="pmid">21376539</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR53"><label>53.</label><citation-alternatives><element-citation id="ec-CR53" publication-type="journal"><person-group person-group-type="author"><name><surname>Koshikawa</surname><given-names>N</given-names></name><name><surname>Giannelli</surname><given-names>G</given-names></name><name><surname>Cirulli</surname><given-names>V</given-names></name><name><surname>Miyazaki</surname><given-names>K</given-names></name><name><surname>Quaranta</surname><given-names>V</given-names></name></person-group><article-title>Role of cell surface metalloprotease MT1-MMP in epithelial cell migration over laminin-5</article-title><source>J Cell Biol</source><year>2000</year><volume>148</volume><fpage>615</fpage><lpage>624</lpage><pub-id pub-id-type="doi">10.1083/jcb.148.3.615</pub-id><pub-id pub-id-type="pmid">10662785</pub-id>
</element-citation><mixed-citation id="mc-CR53" publication-type="journal">Koshikawa N, Giannelli G, Cirulli V, Miyazaki K, Quaranta V. Role of cell surface metalloprotease MT1-MMP in epithelial cell migration over laminin-5. J Cell Biol. 2000;148:615&#x02013;24.<pub-id pub-id-type="pmid">10662785</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR54"><label>54.</label><citation-alternatives><element-citation id="ec-CR54" publication-type="journal"><person-group person-group-type="author"><name><surname>Koshikawa</surname><given-names>N</given-names></name><name><surname>Minegishi</surname><given-names>T</given-names></name><name><surname>Sharabi</surname><given-names>A</given-names></name><name><surname>Quaranta</surname><given-names>V</given-names></name><name><surname>Seiki</surname><given-names>M</given-names></name></person-group><article-title>Membrane-type matrix metalloproteinase-1 (MT1-MMP) is a processing enzyme for human laminin gamma 2 chain</article-title><source>J Biol Chem</source><year>2005</year><volume>280</volume><fpage>88</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1074/jbc.M411824200</pub-id><pub-id pub-id-type="pmid">15525652</pub-id>
</element-citation><mixed-citation id="mc-CR54" publication-type="journal">Koshikawa N, Minegishi T, Sharabi A, Quaranta V, Seiki M. Membrane-type matrix metalloproteinase-1 (MT1-MMP) is a processing enzyme for human laminin gamma 2 chain. J Biol Chem. 2005;280:88&#x02013;93.<pub-id pub-id-type="pmid">15525652</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR55"><label>55.</label><citation-alternatives><element-citation id="ec-CR55" publication-type="journal"><person-group person-group-type="author"><name><surname>Schenk</surname><given-names>S</given-names></name><name><surname>Hintermann</surname><given-names>E</given-names></name><name><surname>Bilban</surname><given-names>M</given-names></name><name><surname>Koshikawa</surname><given-names>N</given-names></name><name><surname>Hojilla</surname><given-names>C</given-names></name><name><surname>Khokha</surname><given-names>R</given-names></name><etal/></person-group><article-title>Binding to EGF receptor of a laminin-5 EGF-like fragment liberated during MMP-dependent mammary gland involution</article-title><source>J Cell Biol</source><year>2003</year><volume>161</volume><fpage>197</fpage><lpage>209</lpage><pub-id pub-id-type="doi">10.1083/jcb.200208145</pub-id><pub-id pub-id-type="pmid">12695504</pub-id>
</element-citation><mixed-citation id="mc-CR55" publication-type="journal">Schenk S, Hintermann E, Bilban M, Koshikawa N, Hojilla C, Khokha R, et al. Binding to EGF receptor of a laminin-5 EGF-like fragment liberated during MMP-dependent mammary gland involution. J Cell Biol. 2003;161:197&#x02013;209.<pub-id pub-id-type="pmid">12695504</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR56"><label>56.</label><citation-alternatives><element-citation id="ec-CR56" publication-type="journal"><person-group person-group-type="author"><name><surname>Margadant</surname><given-names>C</given-names></name><name><surname>Frijns</surname><given-names>E</given-names></name><name><surname>Wilhelmsen</surname><given-names>K</given-names></name><name><surname>Sonnenberg</surname><given-names>A</given-names></name></person-group><article-title>Regulation of hemidesmosome disassembly by growth factor receptors</article-title><source>Curr Opin Cell Biol</source><year>2008</year><volume>20</volume><fpage>589</fpage><lpage>596</lpage><pub-id pub-id-type="doi">10.1016/j.ceb.2008.05.001</pub-id><pub-id pub-id-type="pmid">18583123</pub-id>
</element-citation><mixed-citation id="mc-CR56" publication-type="journal">Margadant C, Frijns E, Wilhelmsen K, Sonnenberg A. Regulation of hemidesmosome disassembly by growth factor receptors. Curr Opin Cell Biol. 2008;20:589&#x02013;96.<pub-id pub-id-type="pmid">18583123</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR57"><label>57.</label><citation-alternatives><element-citation id="ec-CR57" publication-type="journal"><person-group person-group-type="author"><name><surname>Frijns</surname><given-names>E</given-names></name><name><surname>Sachs</surname><given-names>N</given-names></name><name><surname>Kreft</surname><given-names>M</given-names></name><name><surname>Wilhelmsen</surname><given-names>K</given-names></name><name><surname>Sonnenberg</surname><given-names>A</given-names></name></person-group><article-title>EGF-induced MAPK signaling inhibits hemidesmosome formation through phosphorylation of the integrin beta4</article-title><source>J Biol Chem</source><year>2010</year><volume>285</volume><fpage>37650</fpage><lpage>37662</lpage><pub-id pub-id-type="doi">10.1074/jbc.M110.138818</pub-id><pub-id pub-id-type="pmid">20870721</pub-id>
</element-citation><mixed-citation id="mc-CR57" publication-type="journal">Frijns E, Sachs N, Kreft M, Wilhelmsen K, Sonnenberg A. EGF-induced MAPK signaling inhibits hemidesmosome formation through phosphorylation of the integrin beta4. J Biol Chem. 2010;285:37650&#x02013;62.<pub-id pub-id-type="pmid">20870721</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR58"><label>58.</label><citation-alternatives><element-citation id="ec-CR58" publication-type="journal"><person-group person-group-type="author"><name><surname>Mainiero</surname><given-names>F</given-names></name><name><surname>Pepe</surname><given-names>A</given-names></name><name><surname>Wary</surname><given-names>KK</given-names></name><name><surname>Spinardi</surname><given-names>L</given-names></name><name><surname>Mohammadi</surname><given-names>M</given-names></name><name><surname>Schlessinger</surname><given-names>J</given-names></name><etal/></person-group><article-title>Signal transduction by the alpha 6 beta 4 integrin: distinct beta 4 subunit sites mediate recruitment of Shc/Grb2 and association with the cytoskeleton of hemidesmosomes</article-title><source>EMBO J</source><year>1995</year><volume>14</volume><fpage>4470</fpage><lpage>4481</lpage><pub-id pub-id-type="doi">10.1002/j.1460-2075.1995.tb00126.x</pub-id><pub-id pub-id-type="pmid">7556090</pub-id>
</element-citation><mixed-citation id="mc-CR58" publication-type="journal">Mainiero F, Pepe A, Wary KK, Spinardi L, Mohammadi M, Schlessinger J, et al. Signal transduction by the alpha 6 beta 4 integrin: distinct beta 4 subunit sites mediate recruitment of Shc/Grb2 and association with the cytoskeleton of hemidesmosomes. EMBO J. 1995;14:4470&#x02013;81.<pub-id pub-id-type="pmid">7556090</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR59"><label>59.</label><citation-alternatives><element-citation id="ec-CR59" publication-type="journal"><person-group person-group-type="author"><name><surname>Mainiero</surname><given-names>F</given-names></name><name><surname>Murgia</surname><given-names>C</given-names></name><name><surname>Wary</surname><given-names>KK</given-names></name><name><surname>Curatola</surname><given-names>AM</given-names></name><name><surname>Pepe</surname><given-names>A</given-names></name><name><surname>Blumemberg</surname><given-names>M</given-names></name><etal/></person-group><article-title>The coupling of alpha6beta4 integrin to Ras-MAP kinase pathways mediated by Shc controls keratinocyte proliferation</article-title><source>EMBO J</source><year>1997</year><volume>16</volume><fpage>2365</fpage><lpage>2375</lpage><pub-id pub-id-type="doi">10.1093/emboj/16.9.2365</pub-id><pub-id pub-id-type="pmid">9171350</pub-id>
</element-citation><mixed-citation id="mc-CR59" publication-type="journal">Mainiero F, Murgia C, Wary KK, Curatola AM, Pepe A, Blumemberg M, et al. The coupling of alpha6beta4 integrin to Ras-MAP kinase pathways mediated by Shc controls keratinocyte proliferation. EMBO J. 1997;16:2365&#x02013;75.<pub-id pub-id-type="pmid">9171350</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR60"><label>60.</label><citation-alternatives><element-citation id="ec-CR60" publication-type="journal"><person-group person-group-type="author"><name><surname>Dans</surname><given-names>M</given-names></name><name><surname>Gagnoux-Palacios</surname><given-names>L</given-names></name><name><surname>Blaikie</surname><given-names>P</given-names></name><name><surname>Klein</surname><given-names>S</given-names></name><name><surname>Mariotti</surname><given-names>A</given-names></name><name><surname>Giancotti</surname><given-names>FG</given-names></name></person-group><article-title>Tyrosine phosphorylation of the beta 4 integrin cytoplasmic domain mediates Shc signaling to extracellular signal-regulated kinase and antagonizes formation of hemidesmosomes</article-title><source>J Biol Chem</source><year>2001</year><volume>276</volume><fpage>1494</fpage><lpage>1502</lpage><pub-id pub-id-type="doi">10.1074/jbc.M008663200</pub-id><pub-id pub-id-type="pmid">11044453</pub-id>
</element-citation><mixed-citation id="mc-CR60" publication-type="journal">Dans M, Gagnoux-Palacios L, Blaikie P, Klein S, Mariotti A, Giancotti FG. Tyrosine phosphorylation of the beta 4 integrin cytoplasmic domain mediates Shc signaling to extracellular signal-regulated kinase and antagonizes formation of hemidesmosomes. J Biol Chem. 2001;276:1494&#x02013;502.<pub-id pub-id-type="pmid">11044453</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR61"><label>61.</label><citation-alternatives><element-citation id="ec-CR61" publication-type="journal"><person-group person-group-type="author"><name><surname>Benitah</surname><given-names>SA</given-names></name><name><surname>Frye</surname><given-names>M</given-names></name><name><surname>Glogauer</surname><given-names>M</given-names></name><name><surname>Watt</surname><given-names>FM</given-names></name></person-group><article-title>Stem cell depletion through epidermal deletion of Rac1</article-title><source>Science</source><year>2005</year><volume>309</volume><fpage>933</fpage><lpage>935</lpage><pub-id pub-id-type="doi">10.1126/science.1113579</pub-id><pub-id pub-id-type="pmid">16081735</pub-id>
</element-citation><mixed-citation id="mc-CR61" publication-type="journal">Benitah SA, Frye M, Glogauer M, Watt FM. Stem cell depletion through epidermal deletion of Rac1. Science. 2005;309:933&#x02013;5.<pub-id pub-id-type="pmid">16081735</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR62"><label>62.</label><citation-alternatives><element-citation id="ec-CR62" publication-type="journal"><person-group person-group-type="author"><name><surname>Frye</surname><given-names>M</given-names></name><name><surname>Gardner</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>ER</given-names></name><name><surname>Arnold</surname><given-names>I</given-names></name><name><surname>Watt</surname><given-names>FM</given-names></name></person-group><article-title>Evidence that Myc activation depletes the epidermal stem cell compartment by modulating adhesive interactions with the local microenvironment</article-title><source>Development</source><year>2003</year><volume>130</volume><fpage>2793</fpage><lpage>2808</lpage><pub-id pub-id-type="doi">10.1242/dev.00462</pub-id><pub-id pub-id-type="pmid">12736221</pub-id>
</element-citation><mixed-citation id="mc-CR62" publication-type="journal">Frye M, Gardner C, Li ER, Arnold I, Watt FM. Evidence that Myc activation depletes the epidermal stem cell compartment by modulating adhesive interactions with the local microenvironment. Development. 2003;130:2793&#x02013;808.<pub-id pub-id-type="pmid">12736221</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR63"><label>63.</label><citation-alternatives><element-citation id="ec-CR63" publication-type="journal"><person-group person-group-type="author"><name><surname>Gebhardt</surname><given-names>A</given-names></name><name><surname>Frye</surname><given-names>M</given-names></name><name><surname>Herold</surname><given-names>S</given-names></name><name><surname>Benitah</surname><given-names>SA</given-names></name><name><surname>Braun</surname><given-names>K</given-names></name><name><surname>Samans</surname><given-names>B</given-names></name><etal/></person-group><article-title>Myc regulates keratinocyte adhesion and differentiation via complex formation with Miz1</article-title><source>J Cell Biol</source><year>2006</year><volume>172</volume><fpage>139</fpage><lpage>149</lpage><pub-id pub-id-type="doi">10.1083/jcb.200506057</pub-id><pub-id pub-id-type="pmid">16391002</pub-id>
</element-citation><mixed-citation id="mc-CR63" publication-type="journal">Gebhardt A, Frye M, Herold S, Benitah SA, Braun K, Samans B, et al. Myc regulates keratinocyte adhesion and differentiation via complex formation with Miz1. J Cell Biol. 2006;172:139&#x02013;49.<pub-id pub-id-type="pmid">16391002</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR64"><label>64.</label><citation-alternatives><element-citation id="ec-CR64" publication-type="journal"><person-group person-group-type="author"><name><surname>Noethel</surname><given-names>B</given-names></name><name><surname>Ramms</surname><given-names>L</given-names></name><name><surname>Dreissen</surname><given-names>G</given-names></name><name><surname>Hoffmann</surname><given-names>M</given-names></name><name><surname>Springer</surname><given-names>R</given-names></name><name><surname>R&#x000fc;bsam</surname><given-names>M</given-names></name><etal/></person-group><article-title>Transition of responsive mechanosensitive elements from focal adhesions to adherens junctions on epithelial differentiation</article-title><source>Mol Biol Cell</source><year>2018</year><volume>29</volume><fpage>2317</fpage><lpage>2325</lpage><pub-id pub-id-type="doi">10.1091/mbc.E17-06-0387</pub-id><pub-id pub-id-type="pmid">30044710</pub-id>
</element-citation><mixed-citation id="mc-CR64" publication-type="journal">Noethel B, Ramms L, Dreissen G, Hoffmann M, Springer R, R&#x000fc;bsam M, et al. Transition of responsive mechanosensitive elements from focal adhesions to adherens junctions on epithelial differentiation. Mol Biol Cell. 2018;29:2317&#x02013;25.<pub-id pub-id-type="pmid">30044710</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR65"><label>65.</label><citation-alternatives><element-citation id="ec-CR65" publication-type="journal"><person-group person-group-type="author"><name><surname>Stutchbury</surname><given-names>B</given-names></name><name><surname>Atherton</surname><given-names>P</given-names></name><name><surname>Tsang</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>DY</given-names></name><name><surname>Ballestrem</surname><given-names>C</given-names></name></person-group><article-title>Distinct focal adhesion protein modules control different aspects of mechanotransduction</article-title><source>J Cell Sci</source><year>2017</year><volume>130</volume><fpage>1612</fpage><lpage>1624</lpage><pub-id pub-id-type="doi">10.1242/jcs.195362</pub-id><pub-id pub-id-type="pmid">28302906</pub-id>
</element-citation><mixed-citation id="mc-CR65" publication-type="journal">Stutchbury B, Atherton P, Tsang R, Wang DY, Ballestrem C. Distinct focal adhesion protein modules control different aspects of mechanotransduction. J Cell Sci. 2017;130:1612&#x02013;24.<pub-id pub-id-type="pmid">28302906</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR66"><label>66.</label><citation-alternatives><element-citation id="ec-CR66" publication-type="journal"><person-group person-group-type="author"><name><surname>Gonzales</surname><given-names>M</given-names></name><name><surname>Haan</surname><given-names>K</given-names></name><name><surname>Baker</surname><given-names>SE</given-names></name><name><surname>Fitchmun</surname><given-names>M</given-names></name><name><surname>Todorov</surname><given-names>I</given-names></name><name><surname>Weitzman</surname><given-names>S</given-names></name><etal/></person-group><article-title>A cell signal pathway involving laminin-5, alpha3beta1 integrin, and mitogen-activated protein kinase can regulate epithelial cell proliferation</article-title><source>Mol Biol Cell</source><year>1999</year><volume>10</volume><fpage>259</fpage><lpage>270</lpage><pub-id pub-id-type="doi">10.1091/mbc.10.2.259</pub-id><pub-id pub-id-type="pmid">9950675</pub-id>
</element-citation><mixed-citation id="mc-CR66" publication-type="journal">Gonzales M, Haan K, Baker SE, Fitchmun M, Todorov I, Weitzman S, et al. A cell signal pathway involving laminin-5, alpha3beta1 integrin, and mitogen-activated protein kinase can regulate epithelial cell proliferation. Mol Biol Cell. 1999;10:259&#x02013;70.<pub-id pub-id-type="pmid">9950675</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR67"><label>67.</label><citation-alternatives><element-citation id="ec-CR67" publication-type="journal"><person-group person-group-type="author"><name><surname>Choma</surname><given-names>DP</given-names></name><name><surname>Milano</surname><given-names>V</given-names></name><name><surname>Pumiglia</surname><given-names>KM</given-names></name><name><surname>DiPersio</surname><given-names>CM</given-names></name></person-group><article-title>Integrin alpha3beta1-dependent activation of FAK/Src regulates Rac1-mediated keratinocyte polarization on laminin-5</article-title><source>J Invest Dermatol</source><year>2007</year><volume>127</volume><fpage>31</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1038/sj.jid.5700505</pub-id><pub-id pub-id-type="pmid">16917494</pub-id>
</element-citation><mixed-citation id="mc-CR67" publication-type="journal">Choma DP, Milano V, Pumiglia KM, DiPersio CM. Integrin alpha3beta1-dependent activation of FAK/Src regulates Rac1-mediated keratinocyte polarization on laminin-5. J Invest Dermatol. 2007;127:31&#x02013;40.<pub-id pub-id-type="pmid">16917494</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR68"><label>68.</label><citation-alternatives><element-citation id="ec-CR68" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>AJ</given-names></name><name><surname>Haase</surname><given-names>I</given-names></name><name><surname>Watt</surname><given-names>FM</given-names></name></person-group><article-title>Signaling via beta1 integrins and mitogen-activated protein kinase determines human epidermal stem cell fate in vitro</article-title><source>Proc Natl Acad Sci U S A</source><year>1999</year><volume>96</volume><fpage>6728</fpage><lpage>6733</lpage><pub-id pub-id-type="doi">10.1073/pnas.96.12.6728</pub-id><pub-id pub-id-type="pmid">10359780</pub-id>
</element-citation><mixed-citation id="mc-CR68" publication-type="journal">Zhu AJ, Haase I, Watt FM. Signaling via beta1 integrins and mitogen-activated protein kinase determines human epidermal stem cell fate in vitro. Proc Natl Acad Sci U S A. 1999;96:6728&#x02013;33.<pub-id pub-id-type="pmid">10359780</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR69"><label>69.</label><citation-alternatives><element-citation id="ec-CR69" publication-type="journal"><person-group person-group-type="author"><name><surname>Freije</surname><given-names>A</given-names></name><name><surname>Molinuevo</surname><given-names>R</given-names></name><name><surname>Ceballos</surname><given-names>L</given-names></name><name><surname>Cagigas</surname><given-names>M</given-names></name><name><surname>Alonso-Lecue</surname><given-names>P</given-names></name><name><surname>Rodriguez</surname><given-names>R</given-names></name><etal/></person-group><article-title>Inactivation of p53 in human keratinocytes leads to squamous differentiation and shedding via replication stress and mitotic slippage</article-title><source>Cell Rep</source><year>2014</year><volume>9</volume><fpage>1349</fpage><lpage>1360</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2014.10.012</pub-id><pub-id pub-id-type="pmid">25453755</pub-id>
</element-citation><mixed-citation id="mc-CR69" publication-type="journal">Freije A, Molinuevo R, Ceballos L, Cagigas M, Alonso-Lecue P, Rodriguez R, et al. Inactivation of p53 in human keratinocytes leads to squamous differentiation and shedding via replication stress and mitotic slippage. Cell Rep. 2014;9:1349&#x02013;60.<pub-id pub-id-type="pmid">25453755</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR70"><label>70.</label><mixed-citation publication-type="other">Kurata S-i, Okuyama T, Osada M, Watanabe T, Tomimori Y, Sato S, et al. p51/p63 controls subunit &#x003b1;3 of the major epidermis integrin anchoring the stem cells to the niche<italic>.</italic> J Biol Chem. 2004; 279:50069&#x02013;50077.</mixed-citation></ref><ref id="CR71"><label>71.</label><citation-alternatives><element-citation id="ec-CR71" publication-type="journal"><person-group person-group-type="author"><name><surname>Okuyama</surname><given-names>R</given-names></name><name><surname>Ogawa</surname><given-names>E</given-names></name><name><surname>Nagoshi</surname><given-names>H</given-names></name><name><surname>Yabuki</surname><given-names>M</given-names></name><name><surname>Kurihara</surname><given-names>A</given-names></name><name><surname>Terui</surname><given-names>T</given-names></name><etal/></person-group><article-title>p53 homologue, p51/p63, maintains the immaturity of keratinocyte stem cells by inhibiting Notch1 activity</article-title><source>Oncogene</source><year>2007</year><volume>26</volume><fpage>4478</fpage><lpage>4488</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1210235</pub-id><pub-id pub-id-type="pmid">17237812</pub-id>
</element-citation><mixed-citation id="mc-CR71" publication-type="journal">Okuyama R, Ogawa E, Nagoshi H, Yabuki M, Kurihara A, Terui T, et al. p53 homologue, p51/p63, maintains the immaturity of keratinocyte stem cells by inhibiting Notch1 activity. Oncogene. 2007;26:4478&#x02013;88.<pub-id pub-id-type="pmid">17237812</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR72"><label>72.</label><citation-alternatives><element-citation id="ec-CR72" publication-type="journal"><person-group person-group-type="author"><name><surname>Russell</surname><given-names>AJ</given-names></name><name><surname>Fincher</surname><given-names>EF</given-names></name><name><surname>Millman</surname><given-names>L</given-names></name><name><surname>Smith</surname><given-names>R</given-names></name><name><surname>Vela</surname><given-names>V</given-names></name><name><surname>Waterman</surname><given-names>EA</given-names></name><etal/></person-group><article-title>Alpha 6 beta 4 integrin regulates keratinocyte chemotaxis through differential GTPase activation and antagonism of alpha 3 beta 1 integrin</article-title><source>J Cell Sci</source><year>2003</year><volume>116</volume><fpage>3543</fpage><lpage>3556</lpage><pub-id pub-id-type="doi">10.1242/jcs.00663</pub-id><pub-id pub-id-type="pmid">12865436</pub-id>
</element-citation><mixed-citation id="mc-CR72" publication-type="journal">Russell AJ, Fincher EF, Millman L, Smith R, Vela V, Waterman EA, et al. Alpha 6 beta 4 integrin regulates keratinocyte chemotaxis through differential GTPase activation and antagonism of alpha 3 beta 1 integrin. J Cell Sci. 2003;116:3543&#x02013;56.<pub-id pub-id-type="pmid">12865436</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR73"><label>73.</label><citation-alternatives><element-citation id="ec-CR73" publication-type="journal"><person-group person-group-type="author"><name><surname>Schlaepfer</surname><given-names>DD</given-names></name><name><surname>Mitra</surname><given-names>SK</given-names></name></person-group><article-title>Multiple connections link FAK to cell motility and invasion</article-title><source>Curr Opin Genet Dev</source><year>2004</year><volume>14</volume><fpage>92</fpage><lpage>101</lpage><pub-id pub-id-type="doi">10.1016/j.gde.2003.12.002</pub-id><pub-id pub-id-type="pmid">15108811</pub-id>
</element-citation><mixed-citation id="mc-CR73" publication-type="journal">Schlaepfer DD, Mitra SK. Multiple connections link FAK to cell motility and invasion. Curr Opin Genet Dev. 2004;14:92&#x02013;101.<pub-id pub-id-type="pmid">15108811</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR74"><label>74.</label><citation-alternatives><element-citation id="ec-CR74" publication-type="journal"><person-group person-group-type="author"><name><surname>Hamelers</surname><given-names>IH</given-names></name><name><surname>Olivo</surname><given-names>C</given-names></name><name><surname>Mertens</surname><given-names>AE</given-names></name><name><surname>Pegtel</surname><given-names>DM</given-names></name><name><surname>van der Kammen</surname><given-names>RA</given-names></name><name><surname>Sonnenberg</surname><given-names>A</given-names></name><etal/></person-group><article-title>The Rac activator Tiam1 is required for (alpha)3(beta)1-mediated laminin-5 deposition, cell spreading, and cell migration</article-title><source>J Cell Biol</source><year>2005</year><volume>171</volume><fpage>871</fpage><lpage>881</lpage><pub-id pub-id-type="doi">10.1083/jcb.200509172</pub-id><pub-id pub-id-type="pmid">16330714</pub-id>
</element-citation><mixed-citation id="mc-CR74" publication-type="journal">Hamelers IH, Olivo C, Mertens AE, Pegtel DM, van der Kammen RA, Sonnenberg A, et al. The Rac activator Tiam1 is required for (alpha)3(beta)1-mediated laminin-5 deposition, cell spreading, and cell migration. J Cell Biol. 2005;171:871&#x02013;81.<pub-id pub-id-type="pmid">16330714</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR75"><label>75.</label><citation-alternatives><element-citation id="ec-CR75" publication-type="journal"><person-group person-group-type="author"><name><surname>Miao</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Hu</surname><given-names>YL</given-names></name><name><surname>Yuan</surname><given-names>S</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>BP</given-names></name><etal/></person-group><article-title>Differential regulation of Rho GTPases by beta1 and beta3 integrins: the role of an extracellular domain of integrin in intracellular signaling</article-title><source>J Cell Sci</source><year>2002</year><volume>115</volume><fpage>2199</fpage><lpage>2206</lpage><pub-id pub-id-type="doi">10.1242/jcs.115.10.2199</pub-id><pub-id pub-id-type="pmid">11973360</pub-id>
</element-citation><mixed-citation id="mc-CR75" publication-type="journal">Miao H, Li S, Hu YL, Yuan S, Zhao Y, Chen BP, et al. Differential regulation of Rho GTPases by beta1 and beta3 integrins: the role of an extracellular domain of integrin in intracellular signaling. J Cell Sci. 2002;115:2199&#x02013;206.<pub-id pub-id-type="pmid">11973360</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR76"><label>76.</label><citation-alternatives><element-citation id="ec-CR76" publication-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>BP</given-names></name><name><surname>Gil</surname><given-names>SG</given-names></name><name><surname>Carter</surname><given-names>WG</given-names></name></person-group><article-title>Deposition of laminin 5 by keratinocytes regulates integrin adhesion and signaling</article-title><source>J Biol Chem</source><year>2000</year><volume>275</volume><fpage>31896</fpage><lpage>31907</lpage><pub-id pub-id-type="doi">10.1074/jbc.M006379200</pub-id><pub-id pub-id-type="pmid">10926936</pub-id>
</element-citation><mixed-citation id="mc-CR76" publication-type="journal">Nguyen BP, Gil SG, Carter WG. Deposition of laminin 5 by keratinocytes regulates integrin adhesion and signaling. J Biol Chem. 2000;275:31896&#x02013;907.<pub-id pub-id-type="pmid">10926936</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR77"><label>77.</label><citation-alternatives><element-citation id="ec-CR77" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>H</given-names></name><name><surname>Kramer</surname><given-names>RH</given-names></name></person-group><article-title>Integrin engagement differentially modulates epithelial cell motility by RhoA/ROCK and PAK1</article-title><source>J Biol Chem</source><year>2005</year><volume>280</volume><fpage>10624</fpage><lpage>10635</lpage><pub-id pub-id-type="doi">10.1074/jbc.M411900200</pub-id><pub-id pub-id-type="pmid">15611088</pub-id>
</element-citation><mixed-citation id="mc-CR77" publication-type="journal">Zhou H, Kramer RH. Integrin engagement differentially modulates epithelial cell motility by RhoA/ROCK and PAK1. J Biol Chem. 2005;280:10624&#x02013;35.<pub-id pub-id-type="pmid">15611088</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR78"><label>78.</label><citation-alternatives><element-citation id="ec-CR78" publication-type="journal"><person-group person-group-type="author"><name><surname>Brakebusch</surname><given-names>C</given-names></name><name><surname>F&#x000e4;ssler</surname><given-names>R</given-names></name></person-group><article-title>The integrin-actin connection, an eternal love affair</article-title><source>EMBO J</source><year>2003</year><volume>22</volume><fpage>2324</fpage><lpage>2333</lpage><pub-id pub-id-type="doi">10.1093/emboj/cdg245</pub-id><pub-id pub-id-type="pmid">12743027</pub-id>
</element-citation><mixed-citation id="mc-CR78" publication-type="journal">Brakebusch C, F&#x000e4;ssler R. The integrin-actin connection, an eternal love affair. EMBO J. 2003;22:2324&#x02013;33.<pub-id pub-id-type="pmid">12743027</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR79"><label>79.</label><citation-alternatives><element-citation id="ec-CR79" publication-type="journal"><person-group person-group-type="author"><name><surname>Wegner</surname><given-names>J</given-names></name><name><surname>Loser</surname><given-names>K</given-names></name><name><surname>Apsite</surname><given-names>G</given-names></name><name><surname>Nischt</surname><given-names>R</given-names></name><name><surname>Eckes</surname><given-names>B</given-names></name><name><surname>Krieg</surname><given-names>T</given-names></name><etal/></person-group><article-title>Laminin &#x003b1;5 in the keratinocyte basement membrane is required for epidermal-dermal intercommunication</article-title><source>Matrix Biol</source><year>2016</year><volume>56</volume><fpage>24</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1016/j.matbio.2016.05.001</pub-id><pub-id pub-id-type="pmid">27234307</pub-id>
</element-citation><mixed-citation id="mc-CR79" publication-type="journal">Wegner J, Loser K, Apsite G, Nischt R, Eckes B, Krieg T, et al. Laminin &#x003b1;5 in the keratinocyte basement membrane is required for epidermal-dermal intercommunication. Matrix Biol. 2016;56:24&#x02013;41.<pub-id pub-id-type="pmid">27234307</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR80"><label>80.</label><citation-alternatives><element-citation id="ec-CR80" publication-type="journal"><person-group person-group-type="author"><name><surname>Iriyama</surname><given-names>S</given-names></name><name><surname>Yasuda</surname><given-names>M</given-names></name><name><surname>Nishikawa</surname><given-names>S</given-names></name><name><surname>Takai</surname><given-names>E</given-names></name><name><surname>Hosoi</surname><given-names>J</given-names></name><name><surname>Amano</surname><given-names>S</given-names></name></person-group><article-title>Decrease of laminin-511 in the basement membrane due to photoaging reduces epidermal stem/progenitor cells</article-title><source>Sci Rep</source><year>2020</year><volume>10</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1038/s41598-020-69558-y</pub-id><pub-id pub-id-type="pmid">31913322</pub-id>
</element-citation><mixed-citation id="mc-CR80" publication-type="journal">Iriyama S, Yasuda M, Nishikawa S, Takai E, Hosoi J, Amano S. Decrease of laminin-511 in the basement membrane due to photoaging reduces epidermal stem/progenitor cells. Sci Rep. 2020;10:1&#x02013;10.<pub-id pub-id-type="pmid">31913322</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR81"><label>81.</label><citation-alternatives><element-citation id="ec-CR81" publication-type="journal"><person-group person-group-type="author"><name><surname>Katayama</surname><given-names>S</given-names></name><name><surname>Koga</surname><given-names>K</given-names></name><name><surname>Fujimoto</surname><given-names>M</given-names></name><name><surname>Matsuzaki</surname><given-names>I</given-names></name><name><surname>Nabeshima</surname><given-names>K</given-names></name><name><surname>Imafuku</surname><given-names>S</given-names></name><etal/></person-group><article-title>Expression of laminin332 &#x003b3;2 at the invasive front is associated with tumor budding and poor prognosis in cutaneous squamous cell carcinoma</article-title><source>J Dermatol</source><year>2023</year><volume>50</volume><fpage>1585</fpage><lpage>1593</lpage><pub-id pub-id-type="doi">10.1111/1346-8138.16952</pub-id><pub-id pub-id-type="pmid">37752805</pub-id>
</element-citation><mixed-citation id="mc-CR81" publication-type="journal">Katayama S, Koga K, Fujimoto M, Matsuzaki I, Nabeshima K, Imafuku S, et al. Expression of laminin332 &#x003b3;2 at the invasive front is associated with tumor budding and poor prognosis in cutaneous squamous cell carcinoma. J Dermatol. 2023;50:1585&#x02013;93.<pub-id pub-id-type="pmid">37752805</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR82"><label>82.</label><citation-alternatives><element-citation id="ec-CR82" publication-type="journal"><person-group person-group-type="author"><name><surname>Siljam&#x000e4;ki</surname><given-names>E</given-names></name><name><surname>Rappu</surname><given-names>P</given-names></name><name><surname>Riihil&#x000e4;</surname><given-names>P</given-names></name><name><surname>Nissinen</surname><given-names>L</given-names></name><name><surname>K&#x000e4;h&#x000e4;ri</surname><given-names>VM</given-names></name><name><surname>Heino</surname><given-names>J</given-names></name></person-group><article-title>H-Ras activation and fibroblast-induced TGF-&#x003b2; signaling promote laminin-332 accumulation and invasion in cutaneous squamous cell carcinoma</article-title><source>Matrix Biol</source><year>2020</year><volume>87</volume><fpage>26</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1016/j.matbio.2019.09.001</pub-id><pub-id pub-id-type="pmid">31655292</pub-id>
</element-citation><mixed-citation id="mc-CR82" publication-type="journal">Siljam&#x000e4;ki E, Rappu P, Riihil&#x000e4; P, Nissinen L, K&#x000e4;h&#x000e4;ri VM, Heino J. H-Ras activation and fibroblast-induced TGF-&#x003b2; signaling promote laminin-332 accumulation and invasion in cutaneous squamous cell carcinoma. Matrix Biol. 2020;87:26&#x02013;47.<pub-id pub-id-type="pmid">31655292</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR83"><label>83.</label><citation-alternatives><element-citation id="ec-CR83" publication-type="journal"><person-group person-group-type="author"><name><surname>Oikawa</surname><given-names>Y</given-names></name><name><surname>Hansson</surname><given-names>J</given-names></name><name><surname>Sasaki</surname><given-names>T</given-names></name><name><surname>Rousselle</surname><given-names>P</given-names></name><name><surname>Domogatskaya</surname><given-names>A</given-names></name><name><surname>Rodin</surname><given-names>S</given-names></name><etal/></person-group><article-title>Melanoma cells produce multiple laminin isoforms and strongly migrate on &#x003b1;5 laminin(s) via several integrin receptors</article-title><source>Exp Cell Res</source><year>2011</year><volume>317</volume><fpage>1119</fpage><lpage>1133</lpage><pub-id pub-id-type="doi">10.1016/j.yexcr.2010.12.019</pub-id><pub-id pub-id-type="pmid">21195710</pub-id>
</element-citation><mixed-citation id="mc-CR83" publication-type="journal">Oikawa Y, Hansson J, Sasaki T, Rousselle P, Domogatskaya A, Rodin S, et al. Melanoma cells produce multiple laminin isoforms and strongly migrate on &#x003b1;5 laminin(s) via several integrin receptors. Exp Cell Res. 2011;317:1119&#x02013;33.<pub-id pub-id-type="pmid">21195710</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR84"><label>84.</label><citation-alternatives><element-citation id="ec-CR84" publication-type="journal"><person-group person-group-type="author"><name><surname>Dajee</surname><given-names>M</given-names></name><name><surname>Lazarov</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>JY</given-names></name><name><surname>Cai</surname><given-names>T</given-names></name><name><surname>Green</surname><given-names>CL</given-names></name><name><surname>Russell</surname><given-names>AJ</given-names></name><etal/></person-group><article-title>NF-kappaB blockade and oncogenic Ras trigger invasive human epidermal neoplasia</article-title><source>Nature</source><year>2003</year><volume>421</volume><fpage>639</fpage><lpage>643</lpage><pub-id pub-id-type="doi">10.1038/nature01283</pub-id><pub-id pub-id-type="pmid">12571598</pub-id>
</element-citation><mixed-citation id="mc-CR84" publication-type="journal">Dajee M, Lazarov M, Zhang JY, Cai T, Green CL, Russell AJ, et al. NF-kappaB blockade and oncogenic Ras trigger invasive human epidermal neoplasia. Nature. 2003;421:639&#x02013;43.<pub-id pub-id-type="pmid">12571598</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR85"><label>85.</label><citation-alternatives><element-citation id="ec-CR85" publication-type="journal"><person-group person-group-type="author"><name><surname>Tsuji</surname><given-names>T</given-names></name><name><surname>Kawada</surname><given-names>Y</given-names></name><name><surname>Kai-Murozono</surname><given-names>M</given-names></name><name><surname>Komatsu</surname><given-names>S</given-names></name><name><surname>Han</surname><given-names>SA</given-names></name><name><surname>Takeuchi</surname><given-names>K</given-names></name><etal/></person-group><article-title>Regulation of melanoma cell migration and invasion by laminin-5 and alpha3beta1 integrin (VLA-3)</article-title><source>Clin Exp Metastasis</source><year>2002</year><volume>19</volume><fpage>127</fpage><lpage>134</lpage><pub-id pub-id-type="doi">10.1023/A:1014573204062</pub-id><pub-id pub-id-type="pmid">11964076</pub-id>
</element-citation><mixed-citation id="mc-CR85" publication-type="journal">Tsuji T, Kawada Y, Kai-Murozono M, Komatsu S, Han SA, Takeuchi K, et al. Regulation of melanoma cell migration and invasion by laminin-5 and alpha3beta1 integrin (VLA-3). Clin Exp Metastasis. 2002;19:127&#x02013;34.<pub-id pub-id-type="pmid">11964076</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR86"><label>86.</label><citation-alternatives><element-citation id="ec-CR86" publication-type="journal"><person-group person-group-type="author"><name><surname>Stewart</surname><given-names>RL</given-names></name><name><surname>O&#x02019;connor</surname><given-names>KL</given-names></name></person-group><article-title>Clinical significance of the integrin &#x003b1;6&#x003b2;4 in human malignancies</article-title><source>Lab Invest</source><year>2015</year><volume>95</volume><fpage>976</fpage><lpage>986</lpage><pub-id pub-id-type="doi">10.1038/labinvest.2015.82</pub-id><pub-id pub-id-type="pmid">26121317</pub-id>
</element-citation><mixed-citation id="mc-CR86" publication-type="journal">Stewart RL, O&#x02019;connor KL. Clinical significance of the integrin &#x003b1;6&#x003b2;4 in human malignancies. Lab Invest. 2015;95:976&#x02013;86.<pub-id pub-id-type="pmid">26121317</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR87"><label>87.</label><citation-alternatives><element-citation id="ec-CR87" publication-type="journal"><person-group person-group-type="author"><name><surname>Longmate</surname><given-names>WM</given-names></name><name><surname>Varney</surname><given-names>S</given-names></name><name><surname>Power</surname><given-names>D</given-names></name><name><surname>Miskin</surname><given-names>RP</given-names></name><name><surname>Anderson</surname><given-names>KE</given-names></name><name><surname>DeFreest</surname><given-names>L</given-names></name><etal/></person-group><article-title>Integrin &#x003b1;3&#x003b2;1 on tumor keratinocytes is essential to maintain tumor growth and promotes a tumor-supportive keratinocyte secretome</article-title><source>J Invest Dermatol</source><year>2021</year><volume>141</volume><fpage>142</fpage><lpage>151.e6</lpage><pub-id pub-id-type="doi">10.1016/j.jid.2020.05.080</pub-id><pub-id pub-id-type="pmid">32454065</pub-id>
</element-citation><mixed-citation id="mc-CR87" publication-type="journal">Longmate WM, Varney S, Power D, Miskin RP, Anderson KE, DeFreest L, et al. Integrin &#x003b1;3&#x003b2;1 on tumor keratinocytes is essential to maintain tumor growth and promotes a tumor-supportive keratinocyte secretome. J Invest Dermatol. 2021;141:142-151.e6.<pub-id pub-id-type="pmid">32454065</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR88"><label>88.</label><citation-alternatives><element-citation id="ec-CR88" publication-type="journal"><person-group person-group-type="author"><name><surname>Sachs</surname><given-names>N</given-names></name><name><surname>Secades</surname><given-names>P</given-names></name><name><surname>van Hulst</surname><given-names>L</given-names></name><name><surname>Kreft</surname><given-names>M</given-names></name><name><surname>Song</surname><given-names>JY</given-names></name><name><surname>Sonnenberg</surname><given-names>A</given-names></name></person-group><article-title>Loss of integrin &#x003b1;3 prevents skin tumor formation by promoting epidermal turnover and depletion of slow-cycling cells</article-title><source>Proc Natl Acad Sci U S A</source><year>2012</year><volume>109</volume><fpage>21468</fpage><lpage>21473</lpage><pub-id pub-id-type="doi">10.1073/pnas.1204614110</pub-id><pub-id pub-id-type="pmid">23236172</pub-id>
</element-citation><mixed-citation id="mc-CR88" publication-type="journal">Sachs N, Secades P, van Hulst L, Kreft M, Song JY, Sonnenberg A. Loss of integrin &#x003b1;3 prevents skin tumor formation by promoting epidermal turnover and depletion of slow-cycling cells. Proc Natl Acad Sci U S A. 2012;109:21468&#x02013;73.<pub-id pub-id-type="pmid">23236172</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR89"><label>89.</label><citation-alternatives><element-citation id="ec-CR89" publication-type="journal"><person-group person-group-type="author"><name><surname>Missan</surname><given-names>DS</given-names></name><name><surname>Mitchell</surname><given-names>K</given-names></name><name><surname>Subbaram</surname><given-names>S</given-names></name><name><surname>DiPersio</surname><given-names>CM</given-names></name></person-group><article-title>Integrin &#x003b1;3&#x003b2;1 signaling through MEK/ERK determines alternative polyadenylation of the MMP-9 mRNA transcript in immortalized mouse keratinocytes</article-title><source>PLoS ONE</source><year>2015</year><volume>10</volume><fpage>e0119539</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0119539</pub-id><pub-id pub-id-type="pmid">25751421</pub-id>
</element-citation><mixed-citation id="mc-CR89" publication-type="journal">Missan DS, Mitchell K, Subbaram S, DiPersio CM. Integrin &#x003b1;3&#x003b2;1 signaling through MEK/ERK determines alternative polyadenylation of the MMP-9 mRNA transcript in immortalized mouse keratinocytes. PLoS ONE. 2015;10: e0119539.<pub-id pub-id-type="pmid">25751421</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR90"><label>90.</label><citation-alternatives><element-citation id="ec-CR90" publication-type="journal"><person-group person-group-type="author"><name><surname>Marinkovich</surname><given-names>MP</given-names></name></person-group><article-title>Laminin 332 in squamous-cell carcinoma</article-title><source>Nat Rev Cancer</source><year>2007</year><volume>7</volume><fpage>370</fpage><lpage>380</lpage><pub-id pub-id-type="doi">10.1038/nrc2089</pub-id><pub-id pub-id-type="pmid">17457303</pub-id>
</element-citation><mixed-citation id="mc-CR90" publication-type="journal">Marinkovich MP. Laminin 332 in squamous-cell carcinoma. Nat Rev Cancer. 2007;7:370&#x02013;80.<pub-id pub-id-type="pmid">17457303</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR91"><label>91.</label><citation-alternatives><element-citation id="ec-CR91" publication-type="journal"><person-group person-group-type="author"><name><surname>Chung</surname><given-names>H</given-names></name><name><surname>Suh</surname><given-names>EK</given-names></name><name><surname>Han</surname><given-names>IO</given-names></name><name><surname>Oh</surname><given-names>ES</given-names></name></person-group><article-title>Keratinocyte-derived laminin-332 promotes adhesion and migration in melanocytes and melanoma</article-title><source>J Biol Chem</source><year>2011</year><volume>286</volume><fpage>13438</fpage><lpage>13447</lpage><pub-id pub-id-type="doi">10.1074/jbc.M110.166751</pub-id><pub-id pub-id-type="pmid">21349841</pub-id>
</element-citation><mixed-citation id="mc-CR91" publication-type="journal">Chung H, Suh EK, Han IO, Oh ES. Keratinocyte-derived laminin-332 promotes adhesion and migration in melanocytes and melanoma. J Biol Chem. 2011;286:13438&#x02013;47.<pub-id pub-id-type="pmid">21349841</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR92"><label>92.</label><citation-alternatives><element-citation id="ec-CR92" publication-type="journal"><person-group person-group-type="author"><name><surname>Hamasaki</surname><given-names>H</given-names></name><name><surname>Koga</surname><given-names>K</given-names></name><name><surname>Aoki</surname><given-names>M</given-names></name><name><surname>Hamasaki</surname><given-names>M</given-names></name><name><surname>Koshikawa</surname><given-names>N</given-names></name><name><surname>Seiki</surname><given-names>M</given-names></name><etal/></person-group><article-title>Expression of laminin 5-&#x003b3;2 chain in cutaneous squamous cell carcinoma and its role in tumour invasion</article-title><source>Br J Cancer</source><year>2011</year><volume>105</volume><fpage>824</fpage><lpage>832</lpage><pub-id pub-id-type="doi">10.1038/bjc.2011.283</pub-id><pub-id pub-id-type="pmid">21829200</pub-id>
</element-citation><mixed-citation id="mc-CR92" publication-type="journal">Hamasaki H, Koga K, Aoki M, Hamasaki M, Koshikawa N, Seiki M, et al. Expression of laminin 5-&#x003b3;2 chain in cutaneous squamous cell carcinoma and its role in tumour invasion. Br J Cancer. 2011;105:824&#x02013;32.<pub-id pub-id-type="pmid">21829200</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR93"><label>93.</label><citation-alternatives><element-citation id="ec-CR93" publication-type="journal"><person-group person-group-type="author"><name><surname>Rousselle</surname><given-names>P</given-names></name><name><surname>Scoazec</surname><given-names>JY</given-names></name></person-group><article-title>Laminin 332 in cancer: when the extracellular matrix turns signals from cell anchorage to cell movement</article-title><source>Semin Cancer Biol</source><year>2020</year><volume>62</volume><fpage>149</fpage><lpage>165</lpage><pub-id pub-id-type="doi">10.1016/j.semcancer.2019.09.026</pub-id><pub-id pub-id-type="pmid">31639412</pub-id>
</element-citation><mixed-citation id="mc-CR93" publication-type="journal">Rousselle P, Scoazec JY. Laminin 332 in cancer: when the extracellular matrix turns signals from cell anchorage to cell movement. Semin Cancer Biol. 2020;62:149&#x02013;65.<pub-id pub-id-type="pmid">31639412</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR94"><label>94.</label><citation-alternatives><element-citation id="ec-CR94" publication-type="journal"><person-group person-group-type="author"><name><surname>Natarajan</surname><given-names>E</given-names></name><name><surname>Saeb</surname><given-names>M</given-names></name><name><surname>Crum</surname><given-names>CP</given-names></name><name><surname>Woo</surname><given-names>SB</given-names></name><name><surname>McKee</surname><given-names>PH</given-names></name><name><surname>Rheinwald</surname><given-names>JG</given-names></name></person-group><article-title>Co-expression of p16(INK4A) and laminin 5 gamma2 by microinvasive and superficial squamous cell carcinomas in vivo and by migrating wound and senescent keratinocytes in culture</article-title><source>Am J Pathol</source><year>2003</year><volume>163</volume><fpage>477</fpage><lpage>491</lpage><pub-id pub-id-type="doi">10.1016/S0002-9440(10)63677-2</pub-id><pub-id pub-id-type="pmid">12875969</pub-id>
</element-citation><mixed-citation id="mc-CR94" publication-type="journal">Natarajan E, Saeb M, Crum CP, Woo SB, McKee PH, Rheinwald JG. Co-expression of p16(INK4A) and laminin 5 gamma2 by microinvasive and superficial squamous cell carcinomas in vivo and by migrating wound and senescent keratinocytes in culture. Am J Pathol. 2003;163:477&#x02013;91.<pub-id pub-id-type="pmid">12875969</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR95"><label>95.</label><citation-alternatives><element-citation id="ec-CR95" publication-type="journal"><person-group person-group-type="author"><name><surname>Seftor</surname><given-names>RE</given-names></name><name><surname>Seftor</surname><given-names>EA</given-names></name><name><surname>Koshikawa</surname><given-names>N</given-names></name><name><surname>Meltzer</surname><given-names>PS</given-names></name><name><surname>Gardner</surname><given-names>LM</given-names></name><name><surname>Bilban</surname><given-names>M</given-names></name><etal/></person-group><article-title>Cooperative interactions of laminin 5 gamma2 chain, matrix metalloproteinase-2, and membrane type-1-matrix/metalloproteinase are required for mimicry of embryonic vasculogenesis by aggressive melanoma</article-title><source>Cancer Res</source><year>2001</year><volume>61</volume><fpage>6322</fpage><lpage>6327</lpage><pub-id pub-id-type="pmid">11522618</pub-id>
</element-citation><mixed-citation id="mc-CR95" publication-type="journal">Seftor RE, Seftor EA, Koshikawa N, Meltzer PS, Gardner LM, Bilban M, et al. Cooperative interactions of laminin 5 gamma2 chain, matrix metalloproteinase-2, and membrane type-1-matrix/metalloproteinase are required for mimicry of embryonic vasculogenesis by aggressive melanoma. Cancer Res. 2001;61:6322&#x02013;7.<pub-id pub-id-type="pmid">11522618</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR96"><label>96.</label><citation-alternatives><element-citation id="ec-CR96" publication-type="journal"><person-group person-group-type="author"><name><surname>Hamasaki</surname><given-names>H</given-names></name><name><surname>Koga</surname><given-names>K</given-names></name><name><surname>Hamasaki</surname><given-names>M</given-names></name><name><surname>Kiryu</surname><given-names>H</given-names></name><name><surname>Nakayama</surname><given-names>J</given-names></name><name><surname>Iwasaki</surname><given-names>H</given-names></name><etal/></person-group><article-title>Immunohistochemical analysis of laminin 5-&#x003b3;2 chain expression for differentiation of basal cell carcinoma from trichoblastoma</article-title><source>Histopathology</source><year>2011</year><volume>59</volume><fpage>159</fpage><lpage>161</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2559.2011.03871.x</pub-id><pub-id pub-id-type="pmid">21771037</pub-id>
</element-citation><mixed-citation id="mc-CR96" publication-type="journal">Hamasaki H, Koga K, Hamasaki M, Kiryu H, Nakayama J, Iwasaki H, et al. Immunohistochemical analysis of laminin 5-&#x003b3;2 chain expression for differentiation of basal cell carcinoma from trichoblastoma. Histopathology. 2011;59:159&#x02013;61.<pub-id pub-id-type="pmid">21771037</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR97"><label>97.</label><citation-alternatives><element-citation id="ec-CR97" publication-type="journal"><person-group person-group-type="author"><name><surname>Yamamoto</surname><given-names>K</given-names></name><name><surname>Miyazaki</surname><given-names>K</given-names></name><name><surname>Higashi</surname><given-names>S</given-names></name></person-group><article-title>Cholesterol sulfate alters substrate preference of matrix metalloproteinase-7 and promotes degradations of pericellular laminin-332 and fibronectin</article-title><source>J Biol Chem</source><year>2010</year><volume>285</volume><fpage>28862</fpage><lpage>28873</lpage><pub-id pub-id-type="doi">10.1074/jbc.M110.136994</pub-id><pub-id pub-id-type="pmid">20605794</pub-id>
</element-citation><mixed-citation id="mc-CR97" publication-type="journal">Yamamoto K, Miyazaki K, Higashi S. Cholesterol sulfate alters substrate preference of matrix metalloproteinase-7 and promotes degradations of pericellular laminin-332 and fibronectin. J Biol Chem. 2010;285:28862&#x02013;73.<pub-id pub-id-type="pmid">20605794</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR98"><label>98.</label><citation-alternatives><element-citation id="ec-CR98" publication-type="journal"><person-group person-group-type="author"><name><surname>Kivisaari</surname><given-names>AK</given-names></name><name><surname>Kallajoki</surname><given-names>M</given-names></name><name><surname>Mirtti</surname><given-names>T</given-names></name><name><surname>McGrath</surname><given-names>JA</given-names></name><name><surname>Bauer</surname><given-names>JW</given-names></name><name><surname>Weber</surname><given-names>F</given-names></name><etal/></person-group><article-title>Transformation-specific matrix metalloproteinases (MMP)-7 and MMP-13 are expressed by tumour cells in epidermolysis bullosa-associated squamous cell carcinomas</article-title><source>Br J Dermatol</source><year>2008</year><volume>158</volume><fpage>778</fpage><lpage>785</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2133.2008.08466.x</pub-id><pub-id pub-id-type="pmid">18284387</pub-id>
</element-citation><mixed-citation id="mc-CR98" publication-type="journal">Kivisaari AK, Kallajoki M, Mirtti T, McGrath JA, Bauer JW, Weber F, et al. Transformation-specific matrix metalloproteinases (MMP)-7 and MMP-13 are expressed by tumour cells in epidermolysis bullosa-associated squamous cell carcinomas. Br J Dermatol. 2008;158:778&#x02013;85.<pub-id pub-id-type="pmid">18284387</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR99"><label>99.</label><citation-alternatives><element-citation id="ec-CR99" publication-type="journal"><person-group person-group-type="author"><name><surname>Piril&#x000e4;</surname><given-names>E</given-names></name><name><surname>Sharabi</surname><given-names>A</given-names></name><name><surname>Salo</surname><given-names>T</given-names></name><name><surname>Quaranta</surname><given-names>V</given-names></name><name><surname>Tu</surname><given-names>H</given-names></name><name><surname>Heljasvaara</surname><given-names>R</given-names></name><etal/></person-group><article-title>Matrix metalloproteinases process the laminin-5 gamma 2-chain and regulate epithelial cell migration</article-title><source>Biochem Biophys Res Commun</source><year>2003</year><volume>303</volume><fpage>1012</fpage><lpage>1017</lpage><pub-id pub-id-type="doi">10.1016/S0006-291X(03)00452-2</pub-id><pub-id pub-id-type="pmid">12684035</pub-id>
</element-citation><mixed-citation id="mc-CR99" publication-type="journal">Piril&#x000e4; E, Sharabi A, Salo T, Quaranta V, Tu H, Heljasvaara R, et al. Matrix metalloproteinases process the laminin-5 gamma 2-chain and regulate epithelial cell migration. Biochem Biophys Res Commun. 2003;303:1012&#x02013;7.<pub-id pub-id-type="pmid">12684035</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR100"><label>100.</label><citation-alternatives><element-citation id="ec-CR100" publication-type="journal"><person-group person-group-type="author"><name><surname>Sadowski</surname><given-names>T</given-names></name><name><surname>Dietrich</surname><given-names>S</given-names></name><name><surname>Koschinsky</surname><given-names>F</given-names></name><name><surname>Ludwig</surname><given-names>A</given-names></name><name><surname>Proksch</surname><given-names>E</given-names></name><name><surname>Titz</surname><given-names>B</given-names></name><etal/></person-group><article-title>Matrix metalloproteinase 19 processes the laminin 5 gamma 2 chain and induces epithelial cell migration</article-title><source>Cell Mol Life Sci</source><year>2005</year><volume>62</volume><fpage>870</fpage><lpage>880</lpage><pub-id pub-id-type="doi">10.1007/s00018-005-4478-8</pub-id><pub-id pub-id-type="pmid">15868410</pub-id>
</element-citation><mixed-citation id="mc-CR100" publication-type="journal">Sadowski T, Dietrich S, Koschinsky F, Ludwig A, Proksch E, Titz B, et al. Matrix metalloproteinase 19 processes the laminin 5 gamma 2 chain and induces epithelial cell migration. Cell Mol Life Sci. 2005;62:870&#x02013;80.<pub-id pub-id-type="pmid">15868410</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR101"><label>101.</label><citation-alternatives><element-citation id="ec-CR101" publication-type="journal"><person-group person-group-type="author"><name><surname>Tran</surname><given-names>M</given-names></name><name><surname>Rousselle</surname><given-names>P</given-names></name><name><surname>Nokelainen</surname><given-names>P</given-names></name><name><surname>Tallapragada</surname><given-names>S</given-names></name><name><surname>Nguyen</surname><given-names>NT</given-names></name><name><surname>Fincher</surname><given-names>EF</given-names></name><etal/></person-group><article-title>Targeting a tumor-specific laminin domain critical for human carcinogenesis</article-title><source>Cancer Res</source><year>2008</year><volume>68</volume><fpage>2885</fpage><lpage>2894</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-07-6160</pub-id><pub-id pub-id-type="pmid">18413757</pub-id>
</element-citation><mixed-citation id="mc-CR101" publication-type="journal">Tran M, Rousselle P, Nokelainen P, Tallapragada S, Nguyen NT, Fincher EF, et al. Targeting a tumor-specific laminin domain critical for human carcinogenesis. Cancer Res. 2008;68:2885&#x02013;94.<pub-id pub-id-type="pmid">18413757</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR102"><label>102.</label><citation-alternatives><element-citation id="ec-CR102" publication-type="journal"><person-group person-group-type="author"><name><surname>Litjens</surname><given-names>SH</given-names></name><name><surname>de Pereda</surname><given-names>JM</given-names></name><name><surname>Sonnenberg</surname><given-names>A</given-names></name></person-group><article-title>Current insights into the formation and breakdown of hemidesmosomes</article-title><source>Trends Cell Biol</source><year>2006</year><volume>16</volume><fpage>376</fpage><lpage>383</lpage><pub-id pub-id-type="doi">10.1016/j.tcb.2006.05.004</pub-id><pub-id pub-id-type="pmid">16757171</pub-id>
</element-citation><mixed-citation id="mc-CR102" publication-type="journal">Litjens SH, de Pereda JM, Sonnenberg A. Current insights into the formation and breakdown of hemidesmosomes. Trends Cell Biol. 2006;16:376&#x02013;83.<pub-id pub-id-type="pmid">16757171</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR103"><label>103.</label><citation-alternatives><element-citation id="ec-CR103" publication-type="journal"><person-group person-group-type="author"><name><surname>Bachy</surname><given-names>S</given-names></name><name><surname>Letourneur</surname><given-names>F</given-names></name><name><surname>Rousselle</surname><given-names>P</given-names></name></person-group><article-title>Syndecan-1 interaction with the LG4/5 domain in laminin-332 is essential for keratinocyte migration</article-title><source>J Cell Physiol</source><year>2008</year><volume>214</volume><fpage>238</fpage><lpage>249</lpage><pub-id pub-id-type="doi">10.1002/jcp.21184</pub-id><pub-id pub-id-type="pmid">17579341</pub-id>
</element-citation><mixed-citation id="mc-CR103" publication-type="journal">Bachy S, Letourneur F, Rousselle P. Syndecan-1 interaction with the LG4/5 domain in laminin-332 is essential for keratinocyte migration. J Cell Physiol. 2008;214:238&#x02013;49.<pub-id pub-id-type="pmid">17579341</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR104"><label>104.</label><citation-alternatives><element-citation id="ec-CR104" publication-type="journal"><person-group person-group-type="author"><name><surname>Utani</surname><given-names>A</given-names></name><name><surname>Momota</surname><given-names>Y</given-names></name><name><surname>Endo</surname><given-names>H</given-names></name><name><surname>Kasuya</surname><given-names>Y</given-names></name><name><surname>Beck</surname><given-names>K</given-names></name><name><surname>Suzuki</surname><given-names>N</given-names></name><etal/></person-group><article-title>Laminin alpha 3 LG4 module induces matrix metalloproteinase-1 through mitogen-activated protein kinase signaling</article-title><source>J Biol Chem</source><year>2003</year><volume>278</volume><fpage>34483</fpage><lpage>34490</lpage><pub-id pub-id-type="doi">10.1074/jbc.M304827200</pub-id><pub-id pub-id-type="pmid">12826666</pub-id>
</element-citation><mixed-citation id="mc-CR104" publication-type="journal">Utani A, Momota Y, Endo H, Kasuya Y, Beck K, Suzuki N, et al. Laminin alpha 3 LG4 module induces matrix metalloproteinase-1 through mitogen-activated protein kinase signaling. J Biol Chem. 2003;278:34483&#x02013;90.<pub-id pub-id-type="pmid">12826666</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR105"><label>105.</label><citation-alternatives><element-citation id="ec-CR105" publication-type="journal"><person-group person-group-type="author"><name><surname>Momota</surname><given-names>Y</given-names></name><name><surname>Suzuki</surname><given-names>N</given-names></name><name><surname>Kasuya</surname><given-names>Y</given-names></name><name><surname>Kobayashi</surname><given-names>T</given-names></name><name><surname>Mizoguchi</surname><given-names>M</given-names></name><name><surname>Yokoyama</surname><given-names>F</given-names></name><etal/></person-group><article-title>Laminin&#x003b1;3 LG4 module induces keratinocyte migration: involvement of matrix metalloproteinase-9</article-title><source>J Recept Signal Transduct Res</source><year>2005</year><volume>25</volume><fpage>1</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1081/RRS-200047870</pub-id><pub-id pub-id-type="pmid">15960391</pub-id>
</element-citation><mixed-citation id="mc-CR105" publication-type="journal">Momota Y, Suzuki N, Kasuya Y, Kobayashi T, Mizoguchi M, Yokoyama F, et al. Laminin&#x003b1;3 LG4 module induces keratinocyte migration: involvement of matrix metalloproteinase-9. J Recept Signal Transduct Res. 2005;25:1&#x02013;17.<pub-id pub-id-type="pmid">15960391</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR106"><label>106.</label><citation-alternatives><element-citation id="ec-CR106" publication-type="journal"><person-group person-group-type="author"><name><surname>Katayama</surname><given-names>H</given-names></name></person-group><article-title>Mechanism of anchorage-independency and tumor formation of cancer cells: possible involvement of cell membrane-bound laminin-332</article-title><source>Cell Tissue Res</source><year>2020</year><volume>379</volume><fpage>255</fpage><lpage>259</lpage><pub-id pub-id-type="doi">10.1007/s00441-019-03114-7</pub-id><pub-id pub-id-type="pmid">31705213</pub-id>
</element-citation><mixed-citation id="mc-CR106" publication-type="journal">Katayama H. Mechanism of anchorage-independency and tumor formation of cancer cells: possible involvement of cell membrane-bound laminin-332. Cell Tissue Res. 2020;379:255&#x02013;9.<pub-id pub-id-type="pmid">31705213</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR107"><label>107.</label><citation-alternatives><element-citation id="ec-CR107" publication-type="journal"><person-group person-group-type="author"><name><surname>Owens</surname><given-names>DM</given-names></name><name><surname>Watt</surname><given-names>FM</given-names></name></person-group><article-title>Contribution of stem cells and differentiated cells to epidermal tumours</article-title><source>Nat Rev Cancer</source><year>2003</year><volume>3</volume><fpage>444</fpage><lpage>451</lpage><pub-id pub-id-type="doi">10.1038/nrc1096</pub-id><pub-id pub-id-type="pmid">12778134</pub-id>
</element-citation><mixed-citation id="mc-CR107" publication-type="journal">Owens DM, Watt FM. Contribution of stem cells and differentiated cells to epidermal tumours. Nat Rev Cancer. 2003;3:444&#x02013;51.<pub-id pub-id-type="pmid">12778134</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR108"><label>108.</label><citation-alternatives><element-citation id="ec-CR108" publication-type="journal"><person-group person-group-type="author"><name><surname>Stamp</surname><given-names>GW</given-names></name><name><surname>Pignatelli</surname><given-names>M</given-names></name></person-group><article-title>Distribution of beta 1, alpha 1, alpha 2 and alpha 3 integrin chains in basal cell carcinomas</article-title><source>J Pathol</source><year>1991</year><volume>163</volume><fpage>307</fpage><lpage>313</lpage><pub-id pub-id-type="doi">10.1002/path.1711630407</pub-id><pub-id pub-id-type="pmid">2033490</pub-id>
</element-citation><mixed-citation id="mc-CR108" publication-type="journal">Stamp GW, Pignatelli M. Distribution of beta 1, alpha 1, alpha 2 and alpha 3 integrin chains in basal cell carcinomas. J Pathol. 1991;163:307&#x02013;13.<pub-id pub-id-type="pmid">2033490</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR109"><label>109.</label><citation-alternatives><element-citation id="ec-CR109" publication-type="journal"><person-group person-group-type="author"><name><surname>Tennenbaum</surname><given-names>T</given-names></name><name><surname>Weiner</surname><given-names>AK</given-names></name><name><surname>Belanger</surname><given-names>AJ</given-names></name><name><surname>Glick</surname><given-names>AB</given-names></name><name><surname>Hennings</surname><given-names>H</given-names></name><name><surname>Yuspa</surname><given-names>SH</given-names></name></person-group><article-title>The suprabasal expression of alpha 6 beta 4 integrin is associated with a high risk for malignant progression in mouse skin carcinogenesis</article-title><source>Cancer Res</source><year>1993</year><volume>53</volume><fpage>4803</fpage><lpage>4810</lpage><pub-id pub-id-type="pmid">8402665</pub-id>
</element-citation><mixed-citation id="mc-CR109" publication-type="journal">Tennenbaum T, Weiner AK, Belanger AJ, Glick AB, Hennings H, Yuspa SH. The suprabasal expression of alpha 6 beta 4 integrin is associated with a high risk for malignant progression in mouse skin carcinogenesis. Cancer Res. 1993;53:4803&#x02013;10.<pub-id pub-id-type="pmid">8402665</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR110"><label>110.</label><citation-alternatives><element-citation id="ec-CR110" publication-type="journal"><person-group person-group-type="author"><name><surname>Owens</surname><given-names>DM</given-names></name><name><surname>Watt</surname><given-names>FM</given-names></name></person-group><article-title>Influence of of beta1 integrins on epidermal squamous cell carcinoma formation in a transgenic mouse model: alpha3beta1, but not alpha2beta1, suppresses malignant conversion</article-title><source>Cancer Res</source><year>2001</year><volume>61</volume><fpage>5248</fpage><lpage>5254</lpage><pub-id pub-id-type="pmid">11431366</pub-id>
</element-citation><mixed-citation id="mc-CR110" publication-type="journal">Owens DM, Watt FM. Influence of of beta1 integrins on epidermal squamous cell carcinoma formation in a transgenic mouse model: alpha3beta1, but not alpha2beta1, suppresses malignant conversion. Cancer Res. 2001;61:5248&#x02013;54.<pub-id pub-id-type="pmid">11431366</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR111"><label>111.</label><citation-alternatives><element-citation id="ec-CR111" publication-type="journal"><person-group person-group-type="author"><name><surname>Maalouf</surname><given-names>SW</given-names></name><name><surname>Theivakumar</surname><given-names>S</given-names></name><name><surname>Owens</surname><given-names>DM</given-names></name></person-group><article-title>Epidermal &#x003b1;6&#x003b2;4 integrin stimulates the influx of immunosuppressive cells during skin tumor promotion</article-title><source>J Dermatol Sci</source><year>2012</year><volume>66</volume><fpage>108</fpage><lpage>118</lpage><pub-id pub-id-type="doi">10.1016/j.jdermsci.2012.02.009</pub-id><pub-id pub-id-type="pmid">22464766</pub-id>
</element-citation><mixed-citation id="mc-CR111" publication-type="journal">Maalouf SW, Theivakumar S, Owens DM. Epidermal &#x003b1;6&#x003b2;4 integrin stimulates the influx of immunosuppressive cells during skin tumor promotion. J Dermatol Sci. 2012;66:108&#x02013;18.<pub-id pub-id-type="pmid">22464766</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR112"><label>112.</label><mixed-citation publication-type="other">Peltonen J, Larjava H, Jaakkola S, Gralnick H, Akiyama SK, Yamada SS, et al. Localization of integrin receptors for fibronectin, collagen, and laminin in human skin. Variable expression in basal and squamous cell carcinomas<italic>.</italic> J Clin Invest. 1989; 84:1916&#x02013;1923.</mixed-citation></ref><ref id="CR113"><label>113.</label><citation-alternatives><element-citation id="ec-CR113" publication-type="journal"><person-group person-group-type="author"><name><surname>De Luca</surname><given-names>M</given-names></name><name><surname>Pellegrini</surname><given-names>G</given-names></name><name><surname>Zambruno</surname><given-names>G</given-names></name><name><surname>Marchisio</surname><given-names>PC</given-names></name></person-group><article-title>Role of integrins in cell adhesion and polarity in normal keratinocytes and human skin pathologies</article-title><source>J Dermatol</source><year>1994</year><volume>21</volume><fpage>821</fpage><lpage>828</lpage><pub-id pub-id-type="doi">10.1111/j.1346-8138.1994.tb03296.x</pub-id><pub-id pub-id-type="pmid">7852642</pub-id>
</element-citation><mixed-citation id="mc-CR113" publication-type="journal">De Luca M, Pellegrini G, Zambruno G, Marchisio PC. Role of integrins in cell adhesion and polarity in normal keratinocytes and human skin pathologies. J Dermatol. 1994;21:821&#x02013;8.<pub-id pub-id-type="pmid">7852642</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR114"><label>114.</label><citation-alternatives><element-citation id="ec-CR114" publication-type="journal"><person-group person-group-type="author"><name><surname>Owens</surname><given-names>DM</given-names></name><name><surname>Romero</surname><given-names>MR</given-names></name><name><surname>Gardner</surname><given-names>C</given-names></name><name><surname>Watt</surname><given-names>FM</given-names></name></person-group><article-title>Suprabasal alpha6beta4 integrin expression in epidermis results in enhanced tumourigenesis and disruption of TGFbeta signalling</article-title><source>J Cell Sci</source><year>2003</year><volume>116</volume><fpage>3783</fpage><lpage>3791</lpage><pub-id pub-id-type="doi">10.1242/jcs.00725</pub-id><pub-id pub-id-type="pmid">12902406</pub-id>
</element-citation><mixed-citation id="mc-CR114" publication-type="journal">Owens DM, Romero MR, Gardner C, Watt FM. Suprabasal alpha6beta4 integrin expression in epidermis results in enhanced tumourigenesis and disruption of TGFbeta signalling. J Cell Sci. 2003;116:3783&#x02013;91.<pub-id pub-id-type="pmid">12902406</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR115"><label>115.</label><citation-alternatives><element-citation id="ec-CR115" publication-type="journal"><person-group person-group-type="author"><name><surname>Hobbs</surname><given-names>RM</given-names></name><name><surname>Silva-Vargas</surname><given-names>V</given-names></name><name><surname>Groves</surname><given-names>R</given-names></name><name><surname>Watt</surname><given-names>FM</given-names></name></person-group><article-title>Expression of activated MEK1 in differentiating epidermal cells is sufficient to generate hyperproliferative and inflammatory skin lesions</article-title><source>J Invest Dermatol</source><year>2004</year><volume>123</volume><fpage>503</fpage><lpage>515</lpage><pub-id pub-id-type="doi">10.1111/j.0022-202X.2004.23225.x</pub-id><pub-id pub-id-type="pmid">15304090</pub-id>
</element-citation><mixed-citation id="mc-CR115" publication-type="journal">Hobbs RM, Silva-Vargas V, Groves R, Watt FM. Expression of activated MEK1 in differentiating epidermal cells is sufficient to generate hyperproliferative and inflammatory skin lesions. J Invest Dermatol. 2004;123:503&#x02013;15.<pub-id pub-id-type="pmid">15304090</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR116"><label>116.</label><citation-alternatives><element-citation id="ec-CR116" publication-type="journal"><person-group person-group-type="author"><name><surname>Haase</surname><given-names>I</given-names></name><name><surname>Hobbs</surname><given-names>RM</given-names></name><name><surname>Romero</surname><given-names>MR</given-names></name><name><surname>Broad</surname><given-names>S</given-names></name><name><surname>Watt</surname><given-names>FM</given-names></name></person-group><article-title>A role for mitogen-activated protein kinase activation by integrins in the pathogenesis of psoriasis</article-title><source>J Clin Invest</source><year>2001</year><volume>108</volume><fpage>527</fpage><lpage>536</lpage><pub-id pub-id-type="doi">10.1172/JCI12153</pub-id><pub-id pub-id-type="pmid">11518726</pub-id>
</element-citation><mixed-citation id="mc-CR116" publication-type="journal">Haase I, Hobbs RM, Romero MR, Broad S, Watt FM. A role for mitogen-activated protein kinase activation by integrins in the pathogenesis of psoriasis. J Clin Invest. 2001;108:527&#x02013;36.<pub-id pub-id-type="pmid">11518726</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR117"><label>117.</label><citation-alternatives><element-citation id="ec-CR117" publication-type="journal"><person-group person-group-type="author"><name><surname>Ramovs</surname><given-names>V</given-names></name><name><surname>Krotenberg Garcia</surname><given-names>A</given-names></name><name><surname>Kreft</surname><given-names>M</given-names></name><name><surname>Sonnenberg</surname><given-names>A</given-names></name></person-group><article-title>Integrin &#x003b1;3&#x003b2;1 is a key regulator of several protumorigenic pathways during skin carcinogenesis</article-title><source>J Invest Dermatol</source><year>2021</year><volume>141</volume><fpage>732</fpage><lpage>741.e6</lpage><pub-id pub-id-type="doi">10.1016/j.jid.2020.07.024</pub-id><pub-id pub-id-type="pmid">32805217</pub-id>
</element-citation><mixed-citation id="mc-CR117" publication-type="journal">Ramovs V, Krotenberg Garcia A, Kreft M, Sonnenberg A. Integrin &#x003b1;3&#x003b2;1 is a key regulator of several protumorigenic pathways during skin carcinogenesis. J Invest Dermatol. 2021;141:732-741.e6.<pub-id pub-id-type="pmid">32805217</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR118"><label>118.</label><citation-alternatives><element-citation id="ec-CR118" publication-type="journal"><person-group person-group-type="author"><name><surname>Picco</surname><given-names>ME</given-names></name><name><surname>Castro</surname><given-names>MV</given-names></name><name><surname>Quezada</surname><given-names>MJ</given-names></name><name><surname>Barbero</surname><given-names>G</given-names></name><name><surname>Villanueva</surname><given-names>MB</given-names></name><name><surname>Fern&#x000e1;ndez</surname><given-names>NB</given-names></name><etal/></person-group><article-title>STAT3 enhances the constitutive activity of AGC kinases in melanoma by transactivating PDK1</article-title><source>Cell Biosci</source><year>2019</year><volume>9</volume><fpage>3</fpage><pub-id pub-id-type="doi">10.1186/s13578-018-0265-8</pub-id><pub-id pub-id-type="pmid">30622697</pub-id>
</element-citation><mixed-citation id="mc-CR118" publication-type="journal">Picco ME, Castro MV, Quezada MJ, Barbero G, Villanueva MB, Fern&#x000e1;ndez NB, et al. STAT3 enhances the constitutive activity of AGC kinases in melanoma by transactivating PDK1. Cell Biosci. 2019;9:3.<pub-id pub-id-type="pmid">30622697</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR119"><label>119.</label><citation-alternatives><element-citation id="ec-CR119" publication-type="journal"><person-group person-group-type="author"><name><surname>Vogt</surname><given-names>PK</given-names></name><name><surname>Hart</surname><given-names>JR</given-names></name></person-group><article-title>PI3K and STAT3: a new alliance</article-title><source>Cancer Discov</source><year>2011</year><volume>1</volume><fpage>481</fpage><lpage>486</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-11-0218</pub-id><pub-id pub-id-type="pmid">22348200</pub-id>
</element-citation><mixed-citation id="mc-CR119" publication-type="journal">Vogt PK, Hart JR. PI3K and STAT3: a new alliance. Cancer Discov. 2011;1:481&#x02013;6.<pub-id pub-id-type="pmid">22348200</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR120"><label>120.</label><citation-alternatives><element-citation id="ec-CR120" publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>KS</given-names></name><name><surname>Sano</surname><given-names>S</given-names></name><name><surname>Kiguchi</surname><given-names>K</given-names></name><name><surname>Anders</surname><given-names>J</given-names></name><name><surname>Komazawa</surname><given-names>N</given-names></name><name><surname>Takeda</surname><given-names>J</given-names></name><etal/></person-group><article-title>Disruption of Stat3 reveals a critical role in both the initiation and the promotion stages of epithelial carcinogenesis</article-title><source>J Clin Invest</source><year>2004</year><volume>114</volume><fpage>720</fpage><lpage>728</lpage><pub-id pub-id-type="doi">10.1172/JCI200421032</pub-id><pub-id pub-id-type="pmid">15343391</pub-id>
</element-citation><mixed-citation id="mc-CR120" publication-type="journal">Chan KS, Sano S, Kiguchi K, Anders J, Komazawa N, Takeda J, et al. Disruption of Stat3 reveals a critical role in both the initiation and the promotion stages of epithelial carcinogenesis. J Clin Invest. 2004;114:720&#x02013;8.<pub-id pub-id-type="pmid">15343391</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR121"><label>121.</label><citation-alternatives><element-citation id="ec-CR121" publication-type="journal"><person-group person-group-type="author"><name><surname>Segrelles</surname><given-names>C</given-names></name><name><surname>Lu</surname><given-names>J</given-names></name><name><surname>Hammann</surname><given-names>B</given-names></name><name><surname>Santos</surname><given-names>M</given-names></name><name><surname>Moral</surname><given-names>M</given-names></name><name><surname>Cascallana</surname><given-names>JL</given-names></name><etal/></person-group><article-title>Deregulated activity of Akt in epithelial basal cells induces spontaneous tumors and heightened sensitivity to skin carcinogenesis</article-title><source>Cancer Res</source><year>2007</year><volume>67</volume><fpage>10879</fpage><lpage>10888</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-07-2564</pub-id><pub-id pub-id-type="pmid">18006833</pub-id>
</element-citation><mixed-citation id="mc-CR121" publication-type="journal">Segrelles C, Lu J, Hammann B, Santos M, Moral M, Cascallana JL, et al. Deregulated activity of Akt in epithelial basal cells induces spontaneous tumors and heightened sensitivity to skin carcinogenesis. Cancer Res. 2007;67:10879&#x02013;88.<pub-id pub-id-type="pmid">18006833</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR122"><label>122.</label><citation-alternatives><element-citation id="ec-CR122" publication-type="journal"><person-group person-group-type="author"><name><surname>Ramovs</surname><given-names>V</given-names></name><name><surname>Krotenberg Garcia</surname><given-names>A</given-names></name><name><surname>Song</surname><given-names>JY</given-names></name><name><surname>de Rink</surname><given-names>I</given-names></name><name><surname>Kreft</surname><given-names>M</given-names></name><name><surname>Goldschmeding</surname><given-names>R</given-names></name><etal/></person-group><article-title>Integrin &#x003b1;3&#x003b2;1 in hair bulge stem cells modulates CCN2 expression and promotes skin tumorigenesis</article-title><source>Life Sci Alliance</source><year>2020</year><volume>3</volume><fpage>e202000645</fpage><pub-id pub-id-type="doi">10.26508/lsa.202000645</pub-id><pub-id pub-id-type="pmid">32423907</pub-id>
</element-citation><mixed-citation id="mc-CR122" publication-type="journal">Ramovs V, Krotenberg Garcia A, Song JY, de Rink I, Kreft M, Goldschmeding R, et al. Integrin &#x003b1;3&#x003b2;1 in hair bulge stem cells modulates CCN2 expression and promotes skin tumorigenesis. Life Sci Alliance. 2020;3: e202000645.<pub-id pub-id-type="pmid">32423907</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR123"><label>123.</label><citation-alternatives><element-citation id="ec-CR123" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Leavitt</surname><given-names>L</given-names></name><name><surname>Ramaswamy</surname><given-names>R</given-names></name><name><surname>Rapraeger</surname><given-names>AC</given-names></name></person-group><article-title>Interaction of syndecan and alpha6beta4 integrin cytoplasmic domains: regulation of ErbB2-mediated integrin activation</article-title><source>J Biol Chem</source><year>2010</year><volume>285</volume><fpage>13569</fpage><lpage>21357</lpage><pub-id pub-id-type="doi">10.1074/jbc.M110.102137</pub-id><pub-id pub-id-type="pmid">20181947</pub-id>
</element-citation><mixed-citation id="mc-CR123" publication-type="journal">Wang H, Leavitt L, Ramaswamy R, Rapraeger AC. Interaction of syndecan and alpha6beta4 integrin cytoplasmic domains: regulation of ErbB2-mediated integrin activation. J Biol Chem. 2010;285:13569&#x02013;21357.<pub-id pub-id-type="pmid">20181947</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR124"><label>124.</label><citation-alternatives><element-citation id="ec-CR124" publication-type="journal"><person-group person-group-type="author"><name><surname>Mercurio</surname><given-names>AM</given-names></name><name><surname>Rabinovitz</surname><given-names>I</given-names></name><name><surname>Shaw</surname><given-names>LM</given-names></name></person-group><article-title>The &#x003b1;6&#x003b2;4 integrin and epithelial cell migration</article-title><source>Curr Opin Cell Biol</source><year>2001</year><volume>13</volume><fpage>541</fpage><lpage>545</lpage><pub-id pub-id-type="doi">10.1016/S0955-0674(00)00249-0</pub-id><pub-id pub-id-type="pmid">11544021</pub-id>
</element-citation><mixed-citation id="mc-CR124" publication-type="journal">Mercurio AM, Rabinovitz I, Shaw LM. The &#x003b1;6&#x003b2;4 integrin and epithelial cell migration. Curr Opin Cell Biol. 2001;13:541&#x02013;5.<pub-id pub-id-type="pmid">11544021</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR125"><label>125.</label><citation-alternatives><element-citation id="ec-CR125" publication-type="journal"><person-group person-group-type="author"><name><surname>Fisher</surname><given-names>ML</given-names></name><name><surname>Keillor</surname><given-names>JW</given-names></name><name><surname>Xu</surname><given-names>W</given-names></name><name><surname>Eckert</surname><given-names>RL</given-names></name><name><surname>Kerr</surname><given-names>C</given-names></name></person-group><article-title>Transglutaminase is required for epidermal squamous cell carcinoma stem cell survival</article-title><source>Mol Cancer Res</source><year>2015</year><volume>13</volume><fpage>1083</fpage><lpage>1094</lpage><pub-id pub-id-type="doi">10.1158/1541-7786.MCR-14-0685-T</pub-id><pub-id pub-id-type="pmid">25934691</pub-id>
</element-citation><mixed-citation id="mc-CR125" publication-type="journal">Fisher ML, Keillor JW, Xu W, Eckert RL, Kerr C. Transglutaminase is required for epidermal squamous cell carcinoma stem cell survival. Mol Cancer Res. 2015;13:1083&#x02013;94.<pub-id pub-id-type="pmid">25934691</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR126"><label>126.</label><citation-alternatives><element-citation id="ec-CR126" publication-type="journal"><person-group person-group-type="author"><name><surname>Fisher</surname><given-names>ML</given-names></name><name><surname>Kerr</surname><given-names>C</given-names></name><name><surname>Adhikary</surname><given-names>G</given-names></name><name><surname>Grun</surname><given-names>D</given-names></name><name><surname>Xu</surname><given-names>W</given-names></name><name><surname>Keillor</surname><given-names>JW</given-names></name><etal/></person-group><article-title>Transglutaminase interaction with &#x003b1;6/&#x003b2;4-integrin stimulates YAP1-dependent &#x00394;Np63&#x003b1; stabilization and leads to enhanced cancer stem cell survival and tumor formation</article-title><source>Cancer Res</source><year>2016</year><volume>76</volume><fpage>7265</fpage><lpage>7276</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-16-2032</pub-id><pub-id pub-id-type="pmid">27780825</pub-id>
</element-citation><mixed-citation id="mc-CR126" publication-type="journal">Fisher ML, Kerr C, Adhikary G, Grun D, Xu W, Keillor JW, et al. Transglutaminase interaction with &#x003b1;6/&#x003b2;4-integrin stimulates YAP1-dependent &#x00394;Np63&#x003b1; stabilization and leads to enhanced cancer stem cell survival and tumor formation. Cancer Res. 2016;76:7265&#x02013;76.<pub-id pub-id-type="pmid">27780825</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR127"><label>127.</label><citation-alternatives><element-citation id="ec-CR127" publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>NG</given-names></name><name><surname>Gumbiner</surname><given-names>BM</given-names></name></person-group><article-title>Adhesion to fibronectin regulates Hippo signaling via the FAK-Src-PI3K pathway</article-title><source>J Cell Biol</source><year>2015</year><volume>210</volume><fpage>503</fpage><lpage>515</lpage><pub-id pub-id-type="doi">10.1083/jcb.201501025</pub-id><pub-id pub-id-type="pmid">26216901</pub-id>
</element-citation><mixed-citation id="mc-CR127" publication-type="journal">Kim NG, Gumbiner BM. Adhesion to fibronectin regulates Hippo signaling via the FAK-Src-PI3K pathway. J Cell Biol. 2015;210:503&#x02013;15.<pub-id pub-id-type="pmid">26216901</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR128"><label>128.</label><citation-alternatives><element-citation id="ec-CR128" publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>H-R</given-names></name><name><surname>Nam</surname><given-names>K-M</given-names></name><name><surname>Park</surname><given-names>S-J</given-names></name><name><surname>Kim</surname><given-names>D-S</given-names></name><name><surname>Huh</surname><given-names>C-H</given-names></name><name><surname>Park</surname><given-names>W-Y</given-names></name><etal/></person-group><article-title>Suppression of miR135b increases the proliferative potential of normal human keratinocytes</article-title><source>J Invest Dermatol</source><year>2014</year><volume>134</volume><fpage>1161</fpage><pub-id pub-id-type="doi">10.1038/jid.2013.427</pub-id><pub-id pub-id-type="pmid">24129066</pub-id>
</element-citation><mixed-citation id="mc-CR128" publication-type="journal">Choi H-R, Nam K-M, Park S-J, Kim D-S, Huh C-H, Park W-Y, et al. Suppression of miR135b increases the proliferative potential of normal human keratinocytes. J Invest Dermatol. 2014;134:1161.<pub-id pub-id-type="pmid">24129066</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR129"><label>129.</label><citation-alternatives><element-citation id="ec-CR129" publication-type="journal"><person-group person-group-type="author"><name><surname>Pellegrini</surname><given-names>G</given-names></name><name><surname>Dellambra</surname><given-names>E</given-names></name><name><surname>Golisano</surname><given-names>O</given-names></name><name><surname>Martinelli</surname><given-names>E</given-names></name><name><surname>Fantozzi</surname><given-names>I</given-names></name><name><surname>Bondanza</surname><given-names>S</given-names></name><etal/></person-group><article-title>p63 identifies keratinocyte stem cells</article-title><source>Proc Natl Acad Sci U S A</source><year>2001</year><volume>98</volume><fpage>3156</fpage><lpage>3161</lpage><pub-id pub-id-type="doi">10.1073/pnas.061032098</pub-id><pub-id pub-id-type="pmid">11248048</pub-id>
</element-citation><mixed-citation id="mc-CR129" publication-type="journal">Pellegrini G, Dellambra E, Golisano O, Martinelli E, Fantozzi I, Bondanza S, et al. p63 identifies keratinocyte stem cells. Proc Natl Acad Sci U S A. 2001;98:3156&#x02013;61.<pub-id pub-id-type="pmid">11248048</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR130"><label>130.</label><citation-alternatives><element-citation id="ec-CR130" publication-type="journal"><person-group person-group-type="author"><name><surname>Hasche</surname><given-names>D</given-names></name><name><surname>Stephan</surname><given-names>S</given-names></name><name><surname>Braspenning-Wesch</surname><given-names>I</given-names></name><name><surname>Mikulec</surname><given-names>J</given-names></name><name><surname>Niebler</surname><given-names>M</given-names></name><name><surname>Gr&#x000f6;ne</surname><given-names>HJ</given-names></name><etal/></person-group><article-title>The interplay of UV and cutaneous papillomavirus infection in skin cancer development</article-title><source>PLoS Pathog</source><year>2017</year><volume>13</volume><fpage>e1006723</fpage><pub-id pub-id-type="doi">10.1371/journal.ppat.1006723</pub-id><pub-id pub-id-type="pmid">29190285</pub-id>
</element-citation><mixed-citation id="mc-CR130" publication-type="journal">Hasche D, Stephan S, Braspenning-Wesch I, Mikulec J, Niebler M, Gr&#x000f6;ne HJ, et al. The interplay of UV and cutaneous papillomavirus infection in skin cancer development. PLoS Pathog. 2017;13: e1006723.<pub-id pub-id-type="pmid">29190285</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR131"><label>131.</label><mixed-citation publication-type="other">Bassi DE, Lopez De Cicco R, Cenna J, Litwin S, Cukierman E, and Klein-Szanto AJP. PACE4 expression in mouse basal keratinocytes results in basement membrane disruption and acceleration of tumor progression. Cancer Res. 2005; 65:7310&#x02013;7319.</mixed-citation></ref><ref id="CR132"><label>132.</label><citation-alternatives><element-citation id="ec-CR132" publication-type="journal"><person-group person-group-type="author"><name><surname>Schmoeckel</surname><given-names>C</given-names></name><name><surname>Stolz</surname><given-names>W</given-names></name><name><surname>Sakai</surname><given-names>LY</given-names></name><name><surname>Burgeson</surname><given-names>RE</given-names></name><name><surname>Timpl</surname><given-names>R</given-names></name><name><surname>Krieg</surname><given-names>T</given-names></name></person-group><article-title>Structure of basement membranes in malignant melanoma and nevocytic nevi</article-title><source>J Invest Dermatol</source><year>1989</year><volume>92</volume><fpage>663</fpage><lpage>668</lpage><pub-id pub-id-type="doi">10.1016/0022-202X(89)90179-6</pub-id><pub-id pub-id-type="pmid">2497191</pub-id>
</element-citation><mixed-citation id="mc-CR132" publication-type="journal">Schmoeckel C, Stolz W, Sakai LY, Burgeson RE, Timpl R, Krieg T. Structure of basement membranes in malignant melanoma and nevocytic nevi. J Invest Dermatol. 1989;92:663&#x02013;8.<pub-id pub-id-type="pmid">2497191</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR133"><label>133.</label><citation-alternatives><element-citation id="ec-CR133" publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Zhu</surname><given-names>XH</given-names></name></person-group><article-title>MiR-135b is a novel oncogenic factor in cutaneous melanoma by targeting LATS2</article-title><source>Melanoma Res</source><year>2019</year><volume>29</volume><fpage>119</fpage><lpage>125</lpage><pub-id pub-id-type="doi">10.1097/CMR.0000000000000524</pub-id><pub-id pub-id-type="pmid">30480622</pub-id>
</element-citation><mixed-citation id="mc-CR133" publication-type="journal">Hu Y, Wang Q, Zhu XH. MiR-135b is a novel oncogenic factor in cutaneous melanoma by targeting LATS2. Melanoma Res. 2019;29:119&#x02013;25.<pub-id pub-id-type="pmid">30480622</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR134"><label>134.</label><citation-alternatives><element-citation id="ec-CR134" publication-type="journal"><person-group person-group-type="author"><name><surname>Olasz</surname><given-names>EB</given-names></name><name><surname>Seline</surname><given-names>LN</given-names></name><name><surname>Schock</surname><given-names>AM</given-names></name><name><surname>Duncan</surname><given-names>NE</given-names></name><name><surname>Lopez</surname><given-names>A</given-names></name><name><surname>Lazar</surname><given-names>J</given-names></name><etal/></person-group><article-title>MicroRNA-135b regulates leucine zipper tumor suppressor 1 in cutaneous squamous cell carcinoma</article-title><source>PLoS ONE</source><year>2015</year><volume>10</volume><fpage>e0125412</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0125412</pub-id><pub-id pub-id-type="pmid">25938461</pub-id>
</element-citation><mixed-citation id="mc-CR134" publication-type="journal">Olasz EB, Seline LN, Schock AM, Duncan NE, Lopez A, Lazar J, et al. MicroRNA-135b regulates leucine zipper tumor suppressor 1 in cutaneous squamous cell carcinoma. PLoS ONE. 2015;10: e0125412.<pub-id pub-id-type="pmid">25938461</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR135"><label>135.</label><citation-alternatives><element-citation id="ec-CR135" publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Rodriguez</surname><given-names>D</given-names></name><name><surname>Petitclerc</surname><given-names>E</given-names></name><name><surname>Kim</surname><given-names>JJ</given-names></name><name><surname>Hangai</surname><given-names>M</given-names></name><name><surname>Moon</surname><given-names>YS</given-names></name><etal/></person-group><article-title>Proteolytic exposure of a cryptic site within collagen type IV is required for angiogenesis and tumor growth in vivo</article-title><source>J Cell Biol</source><year>2001</year><volume>154</volume><fpage>1069</fpage><lpage>1079</lpage><pub-id pub-id-type="doi">10.1083/jcb.200103111</pub-id><pub-id pub-id-type="pmid">11535623</pub-id>
</element-citation><mixed-citation id="mc-CR135" publication-type="journal">Xu J, Rodriguez D, Petitclerc E, Kim JJ, Hangai M, Moon YS, et al. Proteolytic exposure of a cryptic site within collagen type IV is required for angiogenesis and tumor growth in vivo. J Cell Biol. 2001;154:1069&#x02013;79.<pub-id pub-id-type="pmid">11535623</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR136"><label>136.</label><citation-alternatives><element-citation id="ec-CR136" publication-type="journal"><person-group person-group-type="author"><name><surname>Maeshima</surname><given-names>Y</given-names></name><name><surname>Colorado</surname><given-names>PC</given-names></name><name><surname>Kalluri</surname><given-names>R</given-names></name></person-group><article-title>Two RGD-independent alpha vbeta 3 integrin binding sites on tumstatin regulate distinct anti-tumor properties</article-title><source>J Biol Chem</source><year>2000</year><volume>275</volume><fpage>23745</fpage><lpage>23750</lpage><pub-id pub-id-type="doi">10.1074/jbc.C000186200</pub-id><pub-id pub-id-type="pmid">10837460</pub-id>
</element-citation><mixed-citation id="mc-CR136" publication-type="journal">Maeshima Y, Colorado PC, Kalluri R. Two RGD-independent alpha vbeta 3 integrin binding sites on tumstatin regulate distinct anti-tumor properties. J Biol Chem. 2000;275:23745&#x02013;50.<pub-id pub-id-type="pmid">10837460</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR137"><label>137.</label><citation-alternatives><element-citation id="ec-CR137" publication-type="journal"><person-group person-group-type="author"><name><surname>Maeshima</surname><given-names>Y</given-names></name><name><surname>Colorado</surname><given-names>PC</given-names></name><name><surname>Torre</surname><given-names>A</given-names></name><name><surname>Holthaus</surname><given-names>KA</given-names></name><name><surname>Grunkemeyer</surname><given-names>JA</given-names></name><name><surname>Ericksen</surname><given-names>MB</given-names></name><etal/></person-group><article-title>Distinct antitumor properties of a type IV collagen domain derived from basement membrane</article-title><source>J Biol Chem</source><year>2000</year><volume>275</volume><fpage>21340</fpage><lpage>21348</lpage><pub-id pub-id-type="doi">10.1074/jbc.M001956200</pub-id><pub-id pub-id-type="pmid">10766752</pub-id>
</element-citation><mixed-citation id="mc-CR137" publication-type="journal">Maeshima Y, Colorado PC, Torre A, Holthaus KA, Grunkemeyer JA, Ericksen MB, et al. Distinct antitumor properties of a type IV collagen domain derived from basement membrane. J Biol Chem. 2000;275:21340&#x02013;8.<pub-id pub-id-type="pmid">10766752</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR138"><label>138.</label><citation-alternatives><element-citation id="ec-CR138" publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>J</given-names></name><name><surname>Ohno</surname><given-names>N</given-names></name><name><surname>Pasco</surname><given-names>S</given-names></name><name><surname>Monboisse</surname><given-names>JC</given-names></name><name><surname>Borel</surname><given-names>JP</given-names></name><name><surname>Kefalides</surname><given-names>NA</given-names></name></person-group><article-title>A cell binding domain from the alpha3 chain of type IV collagen inhibits proliferation of melanoma cells</article-title><source>J Biol Chem</source><year>1997</year><volume>272</volume><fpage>20395</fpage><lpage>20401</lpage><pub-id pub-id-type="doi">10.1074/jbc.272.33.20395</pub-id><pub-id pub-id-type="pmid">9252346</pub-id>
</element-citation><mixed-citation id="mc-CR138" publication-type="journal">Han J, Ohno N, Pasco S, Monboisse JC, Borel JP, Kefalides NA. A cell binding domain from the alpha3 chain of type IV collagen inhibits proliferation of melanoma cells. J Biol Chem. 1997;272:20395&#x02013;401.<pub-id pub-id-type="pmid">9252346</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR139"><label>139.</label><citation-alternatives><element-citation id="ec-CR139" publication-type="journal"><person-group person-group-type="author"><name><surname>R&#x000fc;bsam</surname><given-names>M</given-names></name><name><surname>Broussard</surname><given-names>JA</given-names></name><name><surname>Wickstr&#x000f6;m</surname><given-names>SA</given-names></name><name><surname>Nekrasova</surname><given-names>O</given-names></name><name><surname>Green</surname><given-names>KJ</given-names></name><name><surname>Niessen</surname><given-names>CM</given-names></name></person-group><article-title>Adherens junctions and desmosomes coordinate mechanics and signaling to orchestrate tissue morphogenesis and function: an evolutionary perspective</article-title><source>Cold Spring Harb Perspect Biol</source><year>2018</year><volume>10</volume><fpage>a029207</fpage><pub-id pub-id-type="doi">10.1101/cshperspect.a029207</pub-id><pub-id pub-id-type="pmid">28893859</pub-id>
</element-citation><mixed-citation id="mc-CR139" publication-type="journal">R&#x000fc;bsam M, Broussard JA, Wickstr&#x000f6;m SA, Nekrasova O, Green KJ, Niessen CM. Adherens junctions and desmosomes coordinate mechanics and signaling to orchestrate tissue morphogenesis and function: an evolutionary perspective. Cold Spring Harb Perspect Biol. 2018;10: a029207.<pub-id pub-id-type="pmid">28893859</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR140"><label>140.</label><citation-alternatives><element-citation id="ec-CR140" publication-type="journal"><person-group person-group-type="author"><name><surname>Lay</surname><given-names>K</given-names></name><name><surname>Kume</surname><given-names>T</given-names></name><name><surname>Fuchs</surname><given-names>E</given-names></name></person-group><article-title>FOXC1 maintains the hair follicle stem cell niche and governs stem cell quiescence to preserve long-term tissue-regenerating potential</article-title><source>Proc Natl Acad Sci U S A</source><year>2016</year><volume>113</volume><fpage>E1506</fpage><lpage>E1515</lpage><pub-id pub-id-type="doi">10.1073/pnas.1601569113</pub-id><pub-id pub-id-type="pmid">26912458</pub-id>
</element-citation><mixed-citation id="mc-CR140" publication-type="journal">Lay K, Kume T, Fuchs E. FOXC1 maintains the hair follicle stem cell niche and governs stem cell quiescence to preserve long-term tissue-regenerating potential. Proc Natl Acad Sci U S A. 2016;113:E1506&#x02013;15.<pub-id pub-id-type="pmid">26912458</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR141"><label>141.</label><citation-alternatives><element-citation id="ec-CR141" publication-type="journal"><person-group person-group-type="author"><name><surname>Yao</surname><given-names>M</given-names></name><name><surname>Qiu</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>R</given-names></name><name><surname>Efremov</surname><given-names>AK</given-names></name><name><surname>Cong</surname><given-names>P</given-names></name><name><surname>Seddiki</surname><given-names>R</given-names></name><etal/></person-group><article-title>Force-dependent conformational switch of &#x003b1;-catenin controls vinculin binding</article-title><source>Nat Commun</source><year>2014</year><volume>5</volume><fpage>4525</fpage><pub-id pub-id-type="doi">10.1038/ncomms5525</pub-id><pub-id pub-id-type="pmid">25077739</pub-id>
</element-citation><mixed-citation id="mc-CR141" publication-type="journal">Yao M, Qiu W, Liu R, Efremov AK, Cong P, Seddiki R, et al. Force-dependent conformational switch of &#x003b1;-catenin controls vinculin binding. Nat Commun. 2014;5:4525.<pub-id pub-id-type="pmid">25077739</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR142"><label>142.</label><citation-alternatives><element-citation id="ec-CR142" publication-type="journal"><person-group person-group-type="author"><name><surname>Heuberger</surname><given-names>J</given-names></name><name><surname>Birchmeier</surname><given-names>W</given-names></name></person-group><article-title>Interplay of cadherin-mediated cell adhesion and canonical Wnt signaling</article-title><source>Cold Spring Harb Perspect Biol</source><year>2010</year><volume>2</volume><fpage>a002915</fpage><pub-id pub-id-type="doi">10.1101/cshperspect.a002915</pub-id><pub-id pub-id-type="pmid">20182623</pub-id>
</element-citation><mixed-citation id="mc-CR142" publication-type="journal">Heuberger J, Birchmeier W. Interplay of cadherin-mediated cell adhesion and canonical Wnt signaling. Cold Spring Harb Perspect Biol. 2010;2: a002915.<pub-id pub-id-type="pmid">20182623</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR143"><label>143.</label><citation-alternatives><element-citation id="ec-CR143" publication-type="journal"><person-group person-group-type="author"><name><surname>Davis</surname><given-names>MA</given-names></name><name><surname>Ireton</surname><given-names>RC</given-names></name><name><surname>Reynolds</surname><given-names>AB</given-names></name></person-group><article-title>A core function for p120-catenin in cadherin turnover</article-title><source>J Cell Biol</source><year>2003</year><volume>163</volume><fpage>525</fpage><lpage>534</lpage><pub-id pub-id-type="doi">10.1083/jcb.200307111</pub-id><pub-id pub-id-type="pmid">14610055</pub-id>
</element-citation><mixed-citation id="mc-CR143" publication-type="journal">Davis MA, Ireton RC, Reynolds AB. A core function for p120-catenin in cadherin turnover. J Cell Biol. 2003;163:525&#x02013;34.<pub-id pub-id-type="pmid">14610055</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR144"><label>144.</label><citation-alternatives><element-citation id="ec-CR144" publication-type="journal"><person-group person-group-type="author"><name><surname>Wildenberg</surname><given-names>GA</given-names></name><name><surname>Dohn</surname><given-names>MR</given-names></name><name><surname>Carnahan</surname><given-names>RH</given-names></name><name><surname>Davis</surname><given-names>MA</given-names></name><name><surname>Lobdell</surname><given-names>NA</given-names></name><name><surname>Settleman</surname><given-names>J</given-names></name><etal/></person-group><article-title>p120-catenin and p190RhoGAP regulate cell-cell adhesion by coordinating antagonism between Rac and Rho</article-title><source>Cell</source><year>2006</year><volume>127</volume><fpage>1027</fpage><lpage>1039</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2006.09.046</pub-id><pub-id pub-id-type="pmid">17129786</pub-id>
</element-citation><mixed-citation id="mc-CR144" publication-type="journal">Wildenberg GA, Dohn MR, Carnahan RH, Davis MA, Lobdell NA, Settleman J, et al. p120-catenin and p190RhoGAP regulate cell-cell adhesion by coordinating antagonism between Rac and Rho. Cell. 2006;127:1027&#x02013;39.<pub-id pub-id-type="pmid">17129786</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR145"><label>145.</label><citation-alternatives><element-citation id="ec-CR145" publication-type="journal"><person-group person-group-type="author"><name><surname>Anastasiadis</surname><given-names>PZ</given-names></name><name><surname>Moon</surname><given-names>SY</given-names></name><name><surname>Thoreson</surname><given-names>MA</given-names></name><name><surname>Mariner</surname><given-names>DJ</given-names></name><name><surname>Crawford</surname><given-names>HC</given-names></name><name><surname>Zheng</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Inhibition of RhoA by p120 catenin</article-title><source>Nat Cell Biol</source><year>2000</year><volume>2</volume><fpage>637</fpage><lpage>644</lpage><pub-id pub-id-type="doi">10.1038/35023588</pub-id><pub-id pub-id-type="pmid">10980705</pub-id>
</element-citation><mixed-citation id="mc-CR145" publication-type="journal">Anastasiadis PZ, Moon SY, Thoreson MA, Mariner DJ, Crawford HC, Zheng Y, et al. Inhibition of RhoA by p120 catenin. Nat Cell Biol. 2000;2:637&#x02013;44.<pub-id pub-id-type="pmid">10980705</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR146"><label>146.</label><citation-alternatives><element-citation id="ec-CR146" publication-type="journal"><person-group person-group-type="author"><name><surname>Miroshnikova</surname><given-names>YA</given-names></name><name><surname>Le</surname><given-names>HQ</given-names></name><name><surname>Schneider</surname><given-names>D</given-names></name><name><surname>Thalheim</surname><given-names>T</given-names></name><name><surname>R&#x000fc;bsam</surname><given-names>M</given-names></name><name><surname>Bremicker</surname><given-names>N</given-names></name><etal/></person-group><article-title>Adhesion forces and cortical tension couple cell proliferation and differentiation to drive epidermal stratification</article-title><source>Nat Cell Biol</source><year>2018</year><volume>20</volume><fpage>69</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1038/s41556-017-0005-z</pub-id><pub-id pub-id-type="pmid">29230016</pub-id>
</element-citation><mixed-citation id="mc-CR146" publication-type="journal">Miroshnikova YA, Le HQ, Schneider D, Thalheim T, R&#x000fc;bsam M, Bremicker N, et al. Adhesion forces and cortical tension couple cell proliferation and differentiation to drive epidermal stratification. Nat Cell Biol. 2018;20:69&#x02013;80.<pub-id pub-id-type="pmid">29230016</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR147"><label>147.</label><citation-alternatives><element-citation id="ec-CR147" publication-type="journal"><person-group person-group-type="author"><name><surname>Simpson</surname><given-names>CL</given-names></name><name><surname>Patel</surname><given-names>DM</given-names></name><name><surname>Green</surname><given-names>KJ</given-names></name></person-group><article-title>Deconstructing the skin: cytoarchitectural determinants of epidermal morphogenesis</article-title><source>Nat Rev Mol Cell Biol</source><year>2011</year><volume>12</volume><fpage>565</fpage><lpage>580</lpage><pub-id pub-id-type="doi">10.1038/nrm3175</pub-id><pub-id pub-id-type="pmid">21860392</pub-id>
</element-citation><mixed-citation id="mc-CR147" publication-type="journal">Simpson CL, Patel DM, Green KJ. Deconstructing the skin: cytoarchitectural determinants of epidermal morphogenesis. Nat Rev Mol Cell Biol. 2011;12:565&#x02013;80.<pub-id pub-id-type="pmid">21860392</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR148"><label>148.</label><citation-alternatives><element-citation id="ec-CR148" publication-type="journal"><person-group person-group-type="author"><name><surname>Braga</surname><given-names>VM</given-names></name><name><surname>Betson</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Lamarche-Vane</surname><given-names>N</given-names></name></person-group><article-title>Activation of the small GTPase Rac is sufficient to disrupt cadherin-dependent cell-cell adhesion in normal human keratinocytes</article-title><source>Mol Biol Cell</source><year>2000</year><volume>11</volume><fpage>3703</fpage><lpage>3721</lpage><pub-id pub-id-type="doi">10.1091/mbc.11.11.3703</pub-id><pub-id pub-id-type="pmid">11071901</pub-id>
</element-citation><mixed-citation id="mc-CR148" publication-type="journal">Braga VM, Betson M, Li X, Lamarche-Vane N. Activation of the small GTPase Rac is sufficient to disrupt cadherin-dependent cell-cell adhesion in normal human keratinocytes. Mol Biol Cell. 2000;11:3703&#x02013;21.<pub-id pub-id-type="pmid">11071901</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR149"><label>149.</label><citation-alternatives><element-citation id="ec-CR149" publication-type="journal"><person-group person-group-type="author"><name><surname>Akhtar</surname><given-names>N</given-names></name><name><surname>Hotchin</surname><given-names>NA</given-names></name></person-group><article-title>RAC1 regulates adherens junctions through endocytosis of E-cadherin</article-title><source>Mol Biol Cell</source><year>2001</year><volume>12</volume><fpage>847</fpage><lpage>862</lpage><pub-id pub-id-type="doi">10.1091/mbc.12.4.847</pub-id><pub-id pub-id-type="pmid">11294891</pub-id>
</element-citation><mixed-citation id="mc-CR149" publication-type="journal">Akhtar N, Hotchin NA. RAC1 regulates adherens junctions through endocytosis of E-cadherin. Mol Biol Cell. 2001;12:847&#x02013;62.<pub-id pub-id-type="pmid">11294891</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR150"><label>150.</label><mixed-citation publication-type="other">Benham-Pyle BW, Pruitt BL, and Nelson WJ. Cell adhesion. Mechanical strain induces E-cadherin-dependent Yap1 and &#x003b2;-catenin activation to drive cell cycle entry<italic>.</italic> Science. 2015; 348:1024&#x02013;1027.</mixed-citation></ref><ref id="CR151"><label>151.</label><citation-alternatives><element-citation id="ec-CR151" publication-type="journal"><person-group person-group-type="author"><name><surname>Hirata</surname><given-names>H</given-names></name><name><surname>Samsonov</surname><given-names>M</given-names></name><name><surname>Sokabe</surname><given-names>M</given-names></name></person-group><article-title>Actomyosin contractility provokes contact inhibition in E-cadherin-ligated keratinocytes</article-title><source>Sci Rep</source><year>2017</year><volume>7</volume><fpage>46326</fpage><pub-id pub-id-type="doi">10.1038/srep46326</pub-id><pub-id pub-id-type="pmid">28406163</pub-id>
</element-citation><mixed-citation id="mc-CR151" publication-type="journal">Hirata H, Samsonov M, Sokabe M. Actomyosin contractility provokes contact inhibition in E-cadherin-ligated keratinocytes. Sci Rep. 2017;7:46326.<pub-id pub-id-type="pmid">28406163</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR152"><label>152.</label><mixed-citation publication-type="other">Silvis MR, Kreger BT, Lien WH, Klezovitch O, Rudakova GM, Camargo FD, et al. &#x003b1;-catenin is a tumor suppressor that controls cell accumulation by regulating the localization and activity of the transcriptional coactivator Yap1<italic>.</italic> Sci Signal. 2011; 4:ra33.</mixed-citation></ref><ref id="CR153"><label>153.</label><citation-alternatives><element-citation id="ec-CR153" publication-type="journal"><person-group person-group-type="author"><name><surname>Schlegelmilch</surname><given-names>K</given-names></name><name><surname>Mohseni</surname><given-names>M</given-names></name><name><surname>Kirak</surname><given-names>O</given-names></name><name><surname>Pruszak</surname><given-names>J</given-names></name><name><surname>Rodriguez</surname><given-names>JR</given-names></name><name><surname>Zhou</surname><given-names>D</given-names></name><etal/></person-group><article-title>Yap1 acts downstream of &#x003b1;-catenin to control epidermal proliferation</article-title><source>Cell</source><year>2011</year><volume>144</volume><fpage>782</fpage><lpage>795</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2011.02.031</pub-id><pub-id pub-id-type="pmid">21376238</pub-id>
</element-citation><mixed-citation id="mc-CR153" publication-type="journal">Schlegelmilch K, Mohseni M, Kirak O, Pruszak J, Rodriguez JR, Zhou D, et al. Yap1 acts downstream of &#x003b1;-catenin to control epidermal proliferation. Cell. 2011;144:782&#x02013;95.<pub-id pub-id-type="pmid">21376238</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR154"><label>154.</label><citation-alternatives><element-citation id="ec-CR154" publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>P</given-names></name><name><surname>Silvis</surname><given-names>MR</given-names></name><name><surname>Honaker</surname><given-names>Y</given-names></name><name><surname>Lien</surname><given-names>WH</given-names></name><name><surname>Arron</surname><given-names>ST</given-names></name><name><surname>Vasioukhin</surname><given-names>V</given-names></name></person-group><article-title>&#x003b1;E-catenin inhibits a Src-YAP1 oncogenic module that couples tyrosine kinases and the effector of Hippo signaling pathway</article-title><source>Genes Dev</source><year>2016</year><volume>30</volume><fpage>798</fpage><lpage>811</lpage><pub-id pub-id-type="doi">10.1101/gad.274951.115</pub-id><pub-id pub-id-type="pmid">27013234</pub-id>
</element-citation><mixed-citation id="mc-CR154" publication-type="journal">Li P, Silvis MR, Honaker Y, Lien WH, Arron ST, Vasioukhin V. &#x003b1;E-catenin inhibits a Src-YAP1 oncogenic module that couples tyrosine kinases and the effector of Hippo signaling pathway. Genes Dev. 2016;30:798&#x02013;811.<pub-id pub-id-type="pmid">27013234</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR155"><label>155.</label><citation-alternatives><element-citation id="ec-CR155" publication-type="journal"><person-group person-group-type="author"><name><surname>Kobielak</surname><given-names>A</given-names></name><name><surname>Fuchs</surname><given-names>E</given-names></name></person-group><article-title>Links between alpha-catenin, NF-kappaB, and squamous cell carcinoma in skin</article-title><source>Proc Natl Acad Sci U S A</source><year>2006</year><volume>103</volume><fpage>2322</fpage><lpage>2327</lpage><pub-id pub-id-type="doi">10.1073/pnas.0510422103</pub-id><pub-id pub-id-type="pmid">16452166</pub-id>
</element-citation><mixed-citation id="mc-CR155" publication-type="journal">Kobielak A, Fuchs E. Links between alpha-catenin, NF-kappaB, and squamous cell carcinoma in skin. Proc Natl Acad Sci U S A. 2006;103:2322&#x02013;7.<pub-id pub-id-type="pmid">16452166</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR156"><label>156.</label><citation-alternatives><element-citation id="ec-CR156" publication-type="journal"><person-group person-group-type="author"><name><surname>Papanikolaou</surname><given-names>S</given-names></name><name><surname>Bravou</surname><given-names>V</given-names></name><name><surname>Gyftopoulos</surname><given-names>K</given-names></name><name><surname>Nakas</surname><given-names>D</given-names></name><name><surname>Repanti</surname><given-names>M</given-names></name><name><surname>Papadaki</surname><given-names>H</given-names></name></person-group><article-title>ILK expression in human basal cell carcinoma correlates with epithelial-mesenchymal transition markers and tumour invasion</article-title><source>Histopathology</source><year>2010</year><volume>56</volume><fpage>799</fpage><lpage>809</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2559.2010.03556.x</pub-id><pub-id pub-id-type="pmid">20546345</pub-id>
</element-citation><mixed-citation id="mc-CR156" publication-type="journal">Papanikolaou S, Bravou V, Gyftopoulos K, Nakas D, Repanti M, Papadaki H. ILK expression in human basal cell carcinoma correlates with epithelial-mesenchymal transition markers and tumour invasion. Histopathology. 2010;56:799&#x02013;809.<pub-id pub-id-type="pmid">20546345</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR157"><label>157.</label><citation-alternatives><element-citation id="ec-CR157" publication-type="journal"><person-group person-group-type="author"><name><surname>Tucci</surname><given-names>MG</given-names></name><name><surname>Lucarini</surname><given-names>G</given-names></name><name><surname>Brancorsini</surname><given-names>D</given-names></name><name><surname>Zizzi</surname><given-names>A</given-names></name><name><surname>Pugnaloni</surname><given-names>A</given-names></name><name><surname>Giacchetti</surname><given-names>A</given-names></name><etal/></person-group><article-title>Involvement of E-cadherin, beta-catenin, Cdc42 and CXCR4 in the progression and prognosis of cutaneous melanoma</article-title><source>Br J Dermatol</source><year>2007</year><volume>157</volume><fpage>1212</fpage><lpage>1216</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2133.2007.08246.x</pub-id><pub-id pub-id-type="pmid">17970806</pub-id>
</element-citation><mixed-citation id="mc-CR157" publication-type="journal">Tucci MG, Lucarini G, Brancorsini D, Zizzi A, Pugnaloni A, Giacchetti A, et al. Involvement of E-cadherin, beta-catenin, Cdc42 and CXCR4 in the progression and prognosis of cutaneous melanoma. Br J Dermatol. 2007;157:1212&#x02013;6.<pub-id pub-id-type="pmid">17970806</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR158"><label>158.</label><citation-alternatives><element-citation id="ec-CR158" publication-type="journal"><person-group person-group-type="author"><name><surname>Kreizenbeck</surname><given-names>GM</given-names></name><name><surname>Berger</surname><given-names>AJ</given-names></name><name><surname>Subtil</surname><given-names>A</given-names></name><name><surname>Rimm</surname><given-names>DL</given-names></name><name><surname>Gould Rothberg</surname><given-names>BE</given-names></name></person-group><article-title>Prognostic significance of cadherin-based adhesion molecules in cutaneous malignant melanoma</article-title><source>Cancer Epidemiol Biomarkers Prev</source><year>2008</year><volume>17</volume><fpage>949</fpage><lpage>958</lpage><pub-id pub-id-type="doi">10.1158/1055-9965.EPI-07-2729</pub-id><pub-id pub-id-type="pmid">18398036</pub-id>
</element-citation><mixed-citation id="mc-CR158" publication-type="journal">Kreizenbeck GM, Berger AJ, Subtil A, Rimm DL, Gould Rothberg BE. Prognostic significance of cadherin-based adhesion molecules in cutaneous malignant melanoma. Cancer Epidemiol Biomarkers Prev. 2008;17:949&#x02013;58.<pub-id pub-id-type="pmid">18398036</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR159"><label>159.</label><citation-alternatives><element-citation id="ec-CR159" publication-type="journal"><person-group person-group-type="author"><name><surname>Bosch</surname><given-names>FX</given-names></name><name><surname>Andl</surname><given-names>C</given-names></name><name><surname>Abel</surname><given-names>U</given-names></name><name><surname>Kartenbeck</surname><given-names>J</given-names></name></person-group><article-title>E-cadherin is a selective and strongly dominant prognostic factor in squamous cell carcinoma: a comparison of E-cadherin with desmosomal components</article-title><source>Int J Cancer</source><year>2005</year><volume>114</volume><fpage>779</fpage><lpage>790</lpage><pub-id pub-id-type="doi">10.1002/ijc.20782</pub-id><pub-id pub-id-type="pmid">15609307</pub-id>
</element-citation><mixed-citation id="mc-CR159" publication-type="journal">Bosch FX, Andl C, Abel U, Kartenbeck J. E-cadherin is a selective and strongly dominant prognostic factor in squamous cell carcinoma: a comparison of E-cadherin with desmosomal components. Int J Cancer. 2005;114:779&#x02013;90.<pub-id pub-id-type="pmid">15609307</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR160"><label>160.</label><citation-alternatives><element-citation id="ec-CR160" publication-type="journal"><person-group person-group-type="author"><name><surname>Livshits</surname><given-names>G</given-names></name><name><surname>Kobielak</surname><given-names>A</given-names></name><name><surname>Fuchs</surname><given-names>E</given-names></name></person-group><article-title>Governing epidermal homeostasis by coupling cell&#x02013;cell adhesion to integrin and growth factor signaling, proliferation, and apoptosis</article-title><source>Proc Natl Acad Sci U S A</source><year>2012</year><volume>109</volume><fpage>4886</fpage><lpage>4891</lpage><pub-id pub-id-type="doi">10.1073/pnas.1202120109</pub-id><pub-id pub-id-type="pmid">22411810</pub-id>
</element-citation><mixed-citation id="mc-CR160" publication-type="journal">Livshits G, Kobielak A, Fuchs E. Governing epidermal homeostasis by coupling cell&#x02013;cell adhesion to integrin and growth factor signaling, proliferation, and apoptosis. Proc Natl Acad Sci U S A. 2012;109:4886&#x02013;91.<pub-id pub-id-type="pmid">22411810</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR161"><label>161.</label><citation-alternatives><element-citation id="ec-CR161" publication-type="journal"><person-group person-group-type="author"><name><surname>Qi</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Romanyuk</surname><given-names>O</given-names></name><name><surname>Siu</surname><given-names>CH</given-names></name></person-group><article-title>Involvement of Src family kinases in N-cadherin phosphorylation and beta-catenin dissociation during transendothelial migration of melanoma cells</article-title><source>Mol Biol Cell</source><year>2006</year><volume>17</volume><fpage>1261</fpage><lpage>1272</lpage><pub-id pub-id-type="doi">10.1091/mbc.e05-10-0927</pub-id><pub-id pub-id-type="pmid">16371504</pub-id>
</element-citation><mixed-citation id="mc-CR161" publication-type="journal">Qi J, Wang J, Romanyuk O, Siu CH. Involvement of Src family kinases in N-cadherin phosphorylation and beta-catenin dissociation during transendothelial migration of melanoma cells. Mol Biol Cell. 2006;17:1261&#x02013;72.<pub-id pub-id-type="pmid">16371504</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR162"><label>162.</label><citation-alternatives><element-citation id="ec-CR162" publication-type="journal"><person-group person-group-type="author"><name><surname>Kovacs</surname><given-names>D</given-names></name><name><surname>Migliano</surname><given-names>E</given-names></name><name><surname>Muscardin</surname><given-names>L</given-names></name><name><surname>Silipo</surname><given-names>V</given-names></name><name><surname>Catrical&#x000e0;</surname><given-names>C</given-names></name><name><surname>Picardo</surname><given-names>M</given-names></name><etal/></person-group><article-title>The role of Wnt/&#x003b2;-catenin signaling pathway in melanoma epithelial-to-mesenchymal-like switching: evidences from patients-derived cell lines</article-title><source>Oncotarget</source><year>2016</year><volume>7</volume><fpage>43295</fpage><lpage>43314</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.9232</pub-id><pub-id pub-id-type="pmid">27175588</pub-id>
</element-citation><mixed-citation id="mc-CR162" publication-type="journal">Kovacs D, Migliano E, Muscardin L, Silipo V, Catrical&#x000e0; C, Picardo M, et al. The role of Wnt/&#x003b2;-catenin signaling pathway in melanoma epithelial-to-mesenchymal-like switching: evidences from patients-derived cell lines. Oncotarget. 2016;7:43295&#x02013;314.<pub-id pub-id-type="pmid">27175588</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR163"><label>163.</label><citation-alternatives><element-citation id="ec-CR163" publication-type="journal"><person-group person-group-type="author"><name><surname>Delgado-Bellido</surname><given-names>D</given-names></name><name><surname>Zamudio-Mart&#x000ed;nez</surname><given-names>E</given-names></name><name><surname>Fern&#x000e1;ndez-Cort&#x000e9;s</surname><given-names>M</given-names></name><name><surname>Herrera-Campos</surname><given-names>AB</given-names></name><name><surname>Olmedo-Pelayo</surname><given-names>J</given-names></name><name><surname>Perez</surname><given-names>CJ</given-names></name><etal/></person-group><article-title>VE-cadherin modulates &#x003b2;-catenin/TCF-4 to enhance vasculogenic mimicry</article-title><source>Cell Death Dis</source><year>2023</year><volume>14</volume><fpage>135</fpage><pub-id pub-id-type="doi">10.1038/s41419-023-05666-7</pub-id><pub-id pub-id-type="pmid">36797281</pub-id>
</element-citation><mixed-citation id="mc-CR163" publication-type="journal">Delgado-Bellido D, Zamudio-Mart&#x000ed;nez E, Fern&#x000e1;ndez-Cort&#x000e9;s M, Herrera-Campos AB, Olmedo-Pelayo J, Perez CJ, et al. VE-cadherin modulates &#x003b2;-catenin/TCF-4 to enhance vasculogenic mimicry. Cell Death Dis. 2023;14:135.<pub-id pub-id-type="pmid">36797281</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR164"><label>164.</label><citation-alternatives><element-citation id="ec-CR164" publication-type="journal"><person-group person-group-type="author"><name><surname>Perez-Moreno</surname><given-names>M</given-names></name><name><surname>Song</surname><given-names>W</given-names></name><name><surname>Pasolli</surname><given-names>HA</given-names></name><name><surname>Williams</surname><given-names>SE</given-names></name><name><surname>Fuchs</surname><given-names>E</given-names></name></person-group><article-title>Loss of p120 catenin and links to mitotic alterations, inflammation, and skin cancer</article-title><source>Proc Natl Acad Sci U S A</source><year>2008</year><volume>105</volume><fpage>15399</fpage><lpage>15404</lpage><pub-id pub-id-type="doi">10.1073/pnas.0807301105</pub-id><pub-id pub-id-type="pmid">18809907</pub-id>
</element-citation><mixed-citation id="mc-CR164" publication-type="journal">Perez-Moreno M, Song W, Pasolli HA, Williams SE, Fuchs E. Loss of p120 catenin and links to mitotic alterations, inflammation, and skin cancer. Proc Natl Acad Sci U S A. 2008;105:15399&#x02013;404.<pub-id pub-id-type="pmid">18809907</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR165"><label>165.</label><citation-alternatives><element-citation id="ec-CR165" publication-type="journal"><person-group person-group-type="author"><name><surname>M&#x000e9;ant</surname><given-names>A</given-names></name><name><surname>Gao</surname><given-names>B</given-names></name><name><surname>Lavoie</surname><given-names>G</given-names></name><name><surname>Nourreddine</surname><given-names>S</given-names></name><name><surname>Jung</surname><given-names>F</given-names></name><name><surname>Aubert</surname><given-names>L</given-names></name><etal/></person-group><article-title>Proteomic analysis reveals a role for RSK in p120-catenin phosphorylation and melanoma cell-cell adhesion</article-title><source>Mol Cell Proteomics</source><year>2020</year><volume>19</volume><fpage>50</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1074/mcp.RA119.001811</pub-id><pub-id pub-id-type="pmid">31678930</pub-id>
</element-citation><mixed-citation id="mc-CR165" publication-type="journal">M&#x000e9;ant A, Gao B, Lavoie G, Nourreddine S, Jung F, Aubert L, et al. Proteomic analysis reveals a role for RSK in p120-catenin phosphorylation and melanoma cell-cell adhesion. Mol Cell Proteomics. 2020;19:50&#x02013;64.<pub-id pub-id-type="pmid">31678930</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR166"><label>166.</label><citation-alternatives><element-citation id="ec-CR166" publication-type="journal"><person-group person-group-type="author"><name><surname>Yanagisawa</surname><given-names>M</given-names></name><name><surname>Anastasiadis</surname><given-names>PZ</given-names></name></person-group><article-title>p120 catenin is essential for mesenchymal cadherin-mediated regulation of cell motility and invasiveness</article-title><source>J Cell Biol</source><year>2006</year><volume>174</volume><fpage>1087</fpage><lpage>1096</lpage><pub-id pub-id-type="doi">10.1083/jcb.200605022</pub-id><pub-id pub-id-type="pmid">16982802</pub-id>
</element-citation><mixed-citation id="mc-CR166" publication-type="journal">Yanagisawa M, Anastasiadis PZ. p120 catenin is essential for mesenchymal cadherin-mediated regulation of cell motility and invasiveness. J Cell Biol. 2006;174:1087&#x02013;96.<pub-id pub-id-type="pmid">16982802</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR167"><label>167.</label><citation-alternatives><element-citation id="ec-CR167" publication-type="journal"><person-group person-group-type="author"><name><surname>Bozdogan</surname><given-names>O</given-names></name><name><surname>Vargel</surname><given-names>I</given-names></name><name><surname>Cavusoglu</surname><given-names>T</given-names></name><name><surname>Karabulut</surname><given-names>AA</given-names></name><name><surname>Karahan</surname><given-names>G</given-names></name><name><surname>Sayar</surname><given-names>N</given-names></name><etal/></person-group><article-title>Metastasis suppressor proteins in cutaneous squamous cell carcinoma</article-title><source>Pathol Res Pract</source><year>2016</year><volume>212</volume><fpage>608</fpage><lpage>615</lpage><pub-id pub-id-type="doi">10.1016/j.prp.2015.12.018</pub-id><pub-id pub-id-type="pmid">27215390</pub-id>
</element-citation><mixed-citation id="mc-CR167" publication-type="journal">Bozdogan O, Vargel I, Cavusoglu T, Karabulut AA, Karahan G, Sayar N, et al. Metastasis suppressor proteins in cutaneous squamous cell carcinoma. Pathol Res Pract. 2016;212:608&#x02013;15.<pub-id pub-id-type="pmid">27215390</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR168"><label>168.</label><citation-alternatives><element-citation id="ec-CR168" publication-type="journal"><person-group person-group-type="author"><name><surname>Majima</surname><given-names>Y</given-names></name><name><surname>Hirakawa</surname><given-names>S</given-names></name><name><surname>Kito</surname><given-names>Y</given-names></name><name><surname>Suzuki</surname><given-names>H</given-names></name><name><surname>Koide</surname><given-names>M</given-names></name><name><surname>Fukamizu</surname><given-names>H</given-names></name><etal/></person-group><article-title>Twist1 as a possible biomarker for metastatic basal cell carcinoma</article-title><source>Acta Derm Venereol</source><year>2012</year><volume>92</volume><fpage>621</fpage><lpage>622</lpage><pub-id pub-id-type="doi">10.2340/00015555-1422</pub-id><pub-id pub-id-type="pmid">22965800</pub-id>
</element-citation><mixed-citation id="mc-CR168" publication-type="journal">Majima Y, Hirakawa S, Kito Y, Suzuki H, Koide M, Fukamizu H, et al. Twist1 as a possible biomarker for metastatic basal cell carcinoma. Acta Derm Venereol. 2012;92:621&#x02013;2.<pub-id pub-id-type="pmid">22965800</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR169"><label>169.</label><citation-alternatives><element-citation id="ec-CR169" publication-type="journal"><person-group person-group-type="author"><name><surname>Kuphal</surname><given-names>S</given-names></name><name><surname>Bosserhoff</surname><given-names>AK</given-names></name></person-group><article-title>E-cadherin cell-cell communication in melanogenesis and during development of malignant melanoma</article-title><source>Arch Biochem Biophys</source><year>2012</year><volume>524</volume><fpage>43</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1016/j.abb.2011.10.020</pub-id><pub-id pub-id-type="pmid">22085498</pub-id>
</element-citation><mixed-citation id="mc-CR169" publication-type="journal">Kuphal S, Bosserhoff AK. E-cadherin cell-cell communication in melanogenesis and during development of malignant melanoma. Arch Biochem Biophys. 2012;524:43&#x02013;7.<pub-id pub-id-type="pmid">22085498</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR170"><label>170.</label><citation-alternatives><element-citation id="ec-CR170" publication-type="journal"><person-group person-group-type="author"><name><surname>Spangler</surname><given-names>B</given-names></name><name><surname>Kappelmann</surname><given-names>M</given-names></name><name><surname>Schittek</surname><given-names>B</given-names></name><name><surname>Meierjohann</surname><given-names>S</given-names></name><name><surname>Vardimon</surname><given-names>L</given-names></name><name><surname>Bosserhoff</surname><given-names>AK</given-names></name><etal/></person-group><article-title>ETS-1/RhoC signaling regulates the transcription factor c-Jun in melanoma</article-title><source>Int J Cancer</source><year>2012</year><volume>130</volume><fpage>2801</fpage><lpage>2811</lpage><pub-id pub-id-type="doi">10.1002/ijc.26277</pub-id><pub-id pub-id-type="pmid">21732343</pub-id>
</element-citation><mixed-citation id="mc-CR170" publication-type="journal">Spangler B, Kappelmann M, Schittek B, Meierjohann S, Vardimon L, Bosserhoff AK, et al. ETS-1/RhoC signaling regulates the transcription factor c-Jun in melanoma. Int J Cancer. 2012;130:2801&#x02013;11.<pub-id pub-id-type="pmid">21732343</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR171"><label>171.</label><citation-alternatives><element-citation id="ec-CR171" publication-type="journal"><person-group person-group-type="author"><name><surname>Hong</surname><given-names>IK</given-names></name><name><surname>Jin</surname><given-names>YJ</given-names></name><name><surname>Byun</surname><given-names>HJ</given-names></name><name><surname>Jeoung</surname><given-names>DI</given-names></name><name><surname>Kim</surname><given-names>YM</given-names></name><name><surname>Lee</surname><given-names>H</given-names></name></person-group><article-title>Homophilic interactions of Tetraspanin CD151 up-regulate motility and matrix metalloproteinase-9 expression of human melanoma cells through adhesion-dependent c-Jun activation signaling pathways</article-title><source>J Biol Chem</source><year>2006</year><volume>281</volume><fpage>24279</fpage><lpage>24292</lpage><pub-id pub-id-type="doi">10.1074/jbc.M601209200</pub-id><pub-id pub-id-type="pmid">16798740</pub-id>
</element-citation><mixed-citation id="mc-CR171" publication-type="journal">Hong IK, Jin YJ, Byun HJ, Jeoung DI, Kim YM, Lee H. Homophilic interactions of Tetraspanin CD151 up-regulate motility and matrix metalloproteinase-9 expression of human melanoma cells through adhesion-dependent c-Jun activation signaling pathways. J Biol Chem. 2006;281:24279&#x02013;92.<pub-id pub-id-type="pmid">16798740</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR172"><label>172.</label><citation-alternatives><element-citation id="ec-CR172" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Hu</surname><given-names>H</given-names></name><name><surname>Miao</surname><given-names>X</given-names></name><name><surname>Song</surname><given-names>X</given-names></name><etal/></person-group><article-title>Human hemokinin-1 promotes migration of melanoma cells and increases MMP-2 and MT1-MMP expression by activating tumor cell NK1 receptors</article-title><source>Peptides</source><year>2016</year><volume>83</volume><fpage>8</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1016/j.peptides.2016.07.004</pub-id><pub-id pub-id-type="pmid">27458061</pub-id>
</element-citation><mixed-citation id="mc-CR172" publication-type="journal">Zhang Y, Li X, Li J, Hu H, Miao X, Song X, et al. Human hemokinin-1 promotes migration of melanoma cells and increases MMP-2 and MT1-MMP expression by activating tumor cell NK1 receptors. Peptides. 2016;83:8&#x02013;15.<pub-id pub-id-type="pmid">27458061</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR173"><label>173.</label><citation-alternatives><element-citation id="ec-CR173" publication-type="journal"><person-group person-group-type="author"><name><surname>Hsu</surname><given-names>MY</given-names></name><name><surname>Meier</surname><given-names>FE</given-names></name><name><surname>Nesbit</surname><given-names>M</given-names></name><name><surname>Hsu</surname><given-names>JY</given-names></name><name><surname>Van Belle</surname><given-names>P</given-names></name><name><surname>Elder</surname><given-names>DE</given-names></name><etal/></person-group><article-title>E-cadherin expression in melanoma cells restores keratinocyte-mediated growth control and down-regulates expression of invasion-related adhesion receptors</article-title><source>Am J Pathol</source><year>2000</year><volume>156</volume><fpage>1515</fpage><lpage>1525</lpage><pub-id pub-id-type="doi">10.1016/S0002-9440(10)65023-7</pub-id><pub-id pub-id-type="pmid">10793063</pub-id>
</element-citation><mixed-citation id="mc-CR173" publication-type="journal">Hsu MY, Meier FE, Nesbit M, Hsu JY, Van Belle P, Elder DE, et al. E-cadherin expression in melanoma cells restores keratinocyte-mediated growth control and down-regulates expression of invasion-related adhesion receptors. Am J Pathol. 2000;156:1515&#x02013;25.<pub-id pub-id-type="pmid">10793063</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR174"><label>174.</label><citation-alternatives><element-citation id="ec-CR174" publication-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>T</given-names></name><name><surname>M&#x000e8;ge</surname><given-names>RM</given-names></name></person-group><article-title>N-cadherin and fibroblast growth factor receptors crosstalk in the control of developmental and cancer cell migrations</article-title><source>Eur J Cell Biol</source><year>2016</year><volume>95</volume><fpage>415</fpage><lpage>426</lpage><pub-id pub-id-type="doi">10.1016/j.ejcb.2016.05.002</pub-id><pub-id pub-id-type="pmid">27320194</pub-id>
</element-citation><mixed-citation id="mc-CR174" publication-type="journal">Nguyen T, M&#x000e8;ge RM. N-cadherin and fibroblast growth factor receptors crosstalk in the control of developmental and cancer cell migrations. Eur J Cell Biol. 2016;95:415&#x02013;26.<pub-id pub-id-type="pmid">27320194</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR175"><label>175.</label><citation-alternatives><element-citation id="ec-CR175" publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>G</given-names></name><name><surname>Satyamoorthy</surname><given-names>K</given-names></name><name><surname>Herlyn</surname><given-names>M</given-names></name></person-group><article-title>N-cadherin-mediated intercellular interactions promote survival and migration of melanoma cells</article-title><source>Cancer Res</source><year>2001</year><volume>61</volume><fpage>3819</fpage><lpage>3825</lpage><pub-id pub-id-type="pmid">11325858</pub-id>
</element-citation><mixed-citation id="mc-CR175" publication-type="journal">Li G, Satyamoorthy K, Herlyn M. N-cadherin-mediated intercellular interactions promote survival and migration of melanoma cells. Cancer Res. 2001;61:3819&#x02013;25.<pub-id pub-id-type="pmid">11325858</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR176"><label>176.</label><citation-alternatives><element-citation id="ec-CR176" publication-type="journal"><person-group person-group-type="author"><name><surname>Hao</surname><given-names>L</given-names></name><name><surname>Ha</surname><given-names>JR</given-names></name><name><surname>Kuzel</surname><given-names>P</given-names></name><name><surname>Garcia</surname><given-names>E</given-names></name><name><surname>Persad</surname><given-names>S</given-names></name></person-group><article-title>Cadherin switch from E- to N-cadherin in melanoma progression is regulated by the PI3K/PTEN pathway through Twist and Snail</article-title><source>Br J Dermatol</source><year>2012</year><volume>166</volume><fpage>1184</fpage><lpage>1197</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2133.2012.10824.x</pub-id><pub-id pub-id-type="pmid">22332917</pub-id>
</element-citation><mixed-citation id="mc-CR176" publication-type="journal">Hao L, Ha JR, Kuzel P, Garcia E, Persad S. Cadherin switch from E- to N-cadherin in melanoma progression is regulated by the PI3K/PTEN pathway through Twist and Snail. Br J Dermatol. 2012;166:1184&#x02013;97.<pub-id pub-id-type="pmid">22332917</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR177"><label>177.</label><citation-alternatives><element-citation id="ec-CR177" publication-type="journal"><person-group person-group-type="author"><name><surname>Takahara</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Kido</surname><given-names>M</given-names></name><name><surname>Takeuchi</surname><given-names>S</given-names></name><name><surname>Uchi</surname><given-names>H</given-names></name><name><surname>Tu</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Stromal CD10 expression, as well as increased dermal macrophages and decreased Langerhans cells, are associated with malignant transformation of keratinocytes</article-title><source>J Cutan Pathol</source><year>2009</year><volume>36</volume><fpage>668</fpage><lpage>674</lpage><pub-id pub-id-type="doi">10.1111/j.1600-0560.2008.01139.x</pub-id><pub-id pub-id-type="pmid">19515046</pub-id>
</element-citation><mixed-citation id="mc-CR177" publication-type="journal">Takahara M, Chen S, Kido M, Takeuchi S, Uchi H, Tu Y, et al. Stromal CD10 expression, as well as increased dermal macrophages and decreased Langerhans cells, are associated with malignant transformation of keratinocytes. J Cutan Pathol. 2009;36:668&#x02013;74.<pub-id pub-id-type="pmid">19515046</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR178"><label>178.</label><citation-alternatives><element-citation id="ec-CR178" publication-type="journal"><person-group person-group-type="author"><name><surname>Sasaki</surname><given-names>K</given-names></name><name><surname>Sugai</surname><given-names>T</given-names></name><name><surname>Ishida</surname><given-names>K</given-names></name><name><surname>Osakabe</surname><given-names>M</given-names></name><name><surname>Amano</surname><given-names>H</given-names></name><name><surname>Kimura</surname><given-names>H</given-names></name><etal/></person-group><article-title>Analysis of cancer-associated fibroblasts and the epithelial-mesenchymal transition in cutaneous basal cell carcinoma, squamous cell carcinoma, and malignant melanoma</article-title><source>Hum Pathol</source><year>2018</year><volume>79</volume><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/j.humpath.2018.03.006</pub-id><pub-id pub-id-type="pmid">29555579</pub-id>
</element-citation><mixed-citation id="mc-CR178" publication-type="journal">Sasaki K, Sugai T, Ishida K, Osakabe M, Amano H, Kimura H, et al. Analysis of cancer-associated fibroblasts and the epithelial-mesenchymal transition in cutaneous basal cell carcinoma, squamous cell carcinoma, and malignant melanoma. Hum Pathol. 2018;79:1&#x02013;8.<pub-id pub-id-type="pmid">29555579</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR179"><label>179.</label><citation-alternatives><element-citation id="ec-CR179" publication-type="journal"><person-group person-group-type="author"><name><surname>Murtas</surname><given-names>D</given-names></name><name><surname>Maxia</surname><given-names>C</given-names></name><name><surname>Diana</surname><given-names>A</given-names></name><name><surname>Pilloni</surname><given-names>L</given-names></name><name><surname>Corda</surname><given-names>C</given-names></name><name><surname>Minerba</surname><given-names>L</given-names></name><etal/></person-group><article-title>Role of epithelial-mesenchymal transition involved molecules in the progression of cutaneous melanoma</article-title><source>Histochem Cell Biol</source><year>2017</year><volume>148</volume><fpage>639</fpage><lpage>649</lpage><pub-id pub-id-type="doi">10.1007/s00418-017-1606-0</pub-id><pub-id pub-id-type="pmid">28828681</pub-id>
</element-citation><mixed-citation id="mc-CR179" publication-type="journal">Murtas D, Maxia C, Diana A, Pilloni L, Corda C, Minerba L, et al. Role of epithelial-mesenchymal transition involved molecules in the progression of cutaneous melanoma. Histochem Cell Biol. 2017;148:639&#x02013;49.<pub-id pub-id-type="pmid">28828681</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR180"><label>180.</label><citation-alternatives><element-citation id="ec-CR180" publication-type="journal"><person-group person-group-type="author"><name><surname>D&#x02019;Arcy</surname><given-names>C</given-names></name><name><surname>Kiel</surname><given-names>C</given-names></name></person-group><article-title>Cell adhesion molecules in normal skin and melanoma</article-title><source>Biomolecules</source><year>2021</year><volume>11</volume><fpage>1213</fpage><pub-id pub-id-type="doi">10.3390/biom11081213</pub-id><pub-id pub-id-type="pmid">34439879</pub-id>
</element-citation><mixed-citation id="mc-CR180" publication-type="journal">D&#x02019;Arcy C, Kiel C. Cell adhesion molecules in normal skin and melanoma. Biomolecules. 2021;11:1213.<pub-id pub-id-type="pmid">34439879</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR181"><label>181.</label><citation-alternatives><element-citation id="ec-CR181" publication-type="journal"><person-group person-group-type="author"><name><surname>Barrette</surname><given-names>K</given-names></name><name><surname>Van Kelst</surname><given-names>S</given-names></name><name><surname>Wouters</surname><given-names>J</given-names></name><name><surname>Marasigan</surname><given-names>V</given-names></name><name><surname>Fieuws</surname><given-names>S</given-names></name><name><surname>Agostinis</surname><given-names>P</given-names></name><etal/></person-group><article-title>Epithelial-mesenchymal transition during invasion of cutaneous squamous cell carcinoma is paralleled by AKT activation</article-title><source>Br J Dermatol</source><year>2014</year><volume>171</volume><fpage>1014</fpage><lpage>1021</lpage><pub-id pub-id-type="doi">10.1111/bjd.12967</pub-id><pub-id pub-id-type="pmid">24628329</pub-id>
</element-citation><mixed-citation id="mc-CR181" publication-type="journal">Barrette K, Van Kelst S, Wouters J, Marasigan V, Fieuws S, Agostinis P, et al. Epithelial-mesenchymal transition during invasion of cutaneous squamous cell carcinoma is paralleled by AKT activation. Br J Dermatol. 2014;171:1014&#x02013;21.<pub-id pub-id-type="pmid">24628329</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR182"><label>182.</label><citation-alternatives><element-citation id="ec-CR182" publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>H-H</given-names></name><name><surname>Chu</surname><given-names>J-H</given-names></name><name><surname>Kwan</surname><given-names>H-Y</given-names></name><name><surname>Su</surname><given-names>T</given-names></name><name><surname>Yu</surname><given-names>H</given-names></name><name><surname>Cheng</surname><given-names>C-Y</given-names></name><etal/></person-group><article-title>Inhibition of the STAT3 signaling pathway contributes to apigenin-mediated anti-metastatic effect in melanoma</article-title><source>Sci Rep</source><year>2016</year><volume>6</volume><fpage>21731</fpage><pub-id pub-id-type="doi">10.1038/srep21731</pub-id><pub-id pub-id-type="pmid">26911838</pub-id>
</element-citation><mixed-citation id="mc-CR182" publication-type="journal">Cao H-H, Chu J-H, Kwan H-Y, Su T, Yu H, Cheng C-Y, et al. Inhibition of the STAT3 signaling pathway contributes to apigenin-mediated anti-metastatic effect in melanoma. Sci Rep. 2016;6:21731.<pub-id pub-id-type="pmid">26911838</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR183"><label>183.</label><citation-alternatives><element-citation id="ec-CR183" publication-type="journal"><person-group person-group-type="author"><name><surname>Tsai</surname><given-names>JH</given-names></name><name><surname>Donaher</surname><given-names>JL</given-names></name><name><surname>Murphy</surname><given-names>DA</given-names></name><name><surname>Chau</surname><given-names>S</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name></person-group><article-title>Spatiotemporal regulation of epithelial-mesenchymal transition is essential for squamous cell carcinoma metastasis</article-title><source>Cancer Cell</source><year>2012</year><volume>22</volume><fpage>725</fpage><lpage>736</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2012.09.022</pub-id><pub-id pub-id-type="pmid">23201165</pub-id>
</element-citation><mixed-citation id="mc-CR183" publication-type="journal">Tsai JH, Donaher JL, Murphy DA, Chau S, Yang J. Spatiotemporal regulation of epithelial-mesenchymal transition is essential for squamous cell carcinoma metastasis. Cancer Cell. 2012;22:725&#x02013;36.<pub-id pub-id-type="pmid">23201165</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR184"><label>184.</label><citation-alternatives><element-citation id="ec-CR184" publication-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>S</given-names></name><name><surname>Holderness</surname><given-names>BM</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Seidel</surname><given-names>GD</given-names></name><name><surname>Gui</surname><given-names>J</given-names></name><name><surname>Fisher</surname><given-names>JL</given-names></name><etal/></person-group><article-title>Epithelial-mesenchymal expression phenotype of primary melanoma and matched metastases and relationship with overall survival</article-title><source>Anticancer Res</source><year>2016</year><volume>36</volume><fpage>6449</fpage><lpage>6456</lpage><pub-id pub-id-type="doi">10.21873/anticanres.11243</pub-id><pub-id pub-id-type="pmid">27919967</pub-id>
</element-citation><mixed-citation id="mc-CR184" publication-type="journal">Yan S, Holderness BM, Li Z, Seidel GD, Gui J, Fisher JL, et al. Epithelial-mesenchymal expression phenotype of primary melanoma and matched metastases and relationship with overall survival. Anticancer Res. 2016;36:6449&#x02013;56.<pub-id pub-id-type="pmid">27919967</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR185"><label>185.</label><citation-alternatives><element-citation id="ec-CR185" publication-type="journal"><person-group person-group-type="author"><name><surname>Wels</surname><given-names>C</given-names></name><name><surname>Joshi</surname><given-names>S</given-names></name><name><surname>Koefinger</surname><given-names>P</given-names></name><name><surname>Bergler</surname><given-names>H</given-names></name><name><surname>Schaider</surname><given-names>H</given-names></name></person-group><article-title>Transcriptional activation of ZEB1 by Slug leads to cooperative regulation of the epithelial-mesenchymal transition-like phenotype in melanoma</article-title><source>J Invest Dermatol</source><year>2011</year><volume>131</volume><fpage>1877</fpage><lpage>1885</lpage><pub-id pub-id-type="doi">10.1038/jid.2011.142</pub-id><pub-id pub-id-type="pmid">21593765</pub-id>
</element-citation><mixed-citation id="mc-CR185" publication-type="journal">Wels C, Joshi S, Koefinger P, Bergler H, Schaider H. Transcriptional activation of ZEB1 by Slug leads to cooperative regulation of the epithelial-mesenchymal transition-like phenotype in melanoma. J Invest Dermatol. 2011;131:1877&#x02013;85.<pub-id pub-id-type="pmid">21593765</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR186"><label>186.</label><mixed-citation publication-type="other">Moreno-Bueno G, Cubillo E, Sarri&#x000f3; D, Peinado Hc, Rodr&#x000ed;guez-Pinilla SMa, Villa S, et al. Genetic profiling of epithelial cells expressing E-cadherin repressors reveals a distinct role for Snail, Slug, and E47 factors in epithelial-mesenchymal transition. Cancer Res. 2006; 66:9543&#x02013;9556.</mixed-citation></ref><ref id="CR187"><label>187.</label><citation-alternatives><element-citation id="ec-CR187" publication-type="journal"><person-group person-group-type="author"><name><surname>Massoumi</surname><given-names>R</given-names></name><name><surname>Kuphal</surname><given-names>S</given-names></name><name><surname>Hellerbrand</surname><given-names>C</given-names></name><name><surname>Haas</surname><given-names>B</given-names></name><name><surname>Wild</surname><given-names>P</given-names></name><name><surname>Spruss</surname><given-names>T</given-names></name><etal/></person-group><article-title>Down-regulation of CYLD expression by Snail promotes tumor progression in malignant melanoma</article-title><source>J Exp Med</source><year>2009</year><volume>206</volume><fpage>221</fpage><lpage>232</lpage><pub-id pub-id-type="doi">10.1084/jem.20082044</pub-id><pub-id pub-id-type="pmid">19124656</pub-id>
</element-citation><mixed-citation id="mc-CR187" publication-type="journal">Massoumi R, Kuphal S, Hellerbrand C, Haas B, Wild P, Spruss T, et al. Down-regulation of CYLD expression by Snail promotes tumor progression in malignant melanoma. J Exp Med. 2009;206:221&#x02013;32.<pub-id pub-id-type="pmid">19124656</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR188"><label>188.</label><citation-alternatives><element-citation id="ec-CR188" publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Mani</surname><given-names>SA</given-names></name><name><surname>Donaher</surname><given-names>JL</given-names></name><name><surname>Ramaswamy</surname><given-names>S</given-names></name><name><surname>Itzykson</surname><given-names>RA</given-names></name><name><surname>Come</surname><given-names>C</given-names></name><etal/></person-group><article-title>Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis</article-title><source>Cell</source><year>2004</year><volume>117</volume><fpage>927</fpage><lpage>939</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2004.06.006</pub-id><pub-id pub-id-type="pmid">15210113</pub-id>
</element-citation><mixed-citation id="mc-CR188" publication-type="journal">Yang J, Mani SA, Donaher JL, Ramaswamy S, Itzykson RA, Come C, et al. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell. 2004;117:927&#x02013;39.<pub-id pub-id-type="pmid">15210113</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR189"><label>189.</label><citation-alternatives><element-citation id="ec-CR189" publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Z-J</given-names></name><name><surname>Xiao</surname><given-names>M</given-names></name><name><surname>Balint</surname><given-names>K</given-names></name><name><surname>Smalley</surname><given-names>KSM</given-names></name><name><surname>Brafford</surname><given-names>P</given-names></name><name><surname>Qiu</surname><given-names>R</given-names></name><etal/></person-group><article-title>Notch1 signaling promotes primary melanoma progression by activating mitogen-activated protein kinase/phosphatidylinositol 3-kinase-Akt pathways and up-regulating N-cadherin expression</article-title><source>Cancer Res</source><year>2006</year><volume>66</volume><fpage>4182</fpage><lpage>4190</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-05-3589</pub-id><pub-id pub-id-type="pmid">16618740</pub-id>
</element-citation><mixed-citation id="mc-CR189" publication-type="journal">Liu Z-J, Xiao M, Balint K, Smalley KSM, Brafford P, Qiu R, et al. Notch1 signaling promotes primary melanoma progression by activating mitogen-activated protein kinase/phosphatidylinositol 3-kinase-Akt pathways and up-regulating N-cadherin expression. Cancer Res. 2006;66:4182&#x02013;90.<pub-id pub-id-type="pmid">16618740</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR190"><label>190.</label><citation-alternatives><element-citation id="ec-CR190" publication-type="journal"><person-group person-group-type="author"><name><surname>Alexaki</surname><given-names>VI</given-names></name><name><surname>Javelaud</surname><given-names>D</given-names></name><name><surname>Van Kempen</surname><given-names>LC</given-names></name><name><surname>Mohammad</surname><given-names>KS</given-names></name><name><surname>Dennler</surname><given-names>S</given-names></name><name><surname>Luciani</surname><given-names>F</given-names></name><etal/></person-group><article-title>GLI2-mediated melanoma invasion and metastasis</article-title><source>J Natl Cancer Inst</source><year>2010</year><volume>102</volume><fpage>1148</fpage><lpage>1159</lpage><pub-id pub-id-type="doi">10.1093/jnci/djq257</pub-id><pub-id pub-id-type="pmid">20660365</pub-id>
</element-citation><mixed-citation id="mc-CR190" publication-type="journal">Alexaki VI, Javelaud D, Van Kempen LC, Mohammad KS, Dennler S, Luciani F, et al. GLI2-mediated melanoma invasion and metastasis. J Natl Cancer Inst. 2010;102:1148&#x02013;59.<pub-id pub-id-type="pmid">20660365</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR191"><label>191.</label><citation-alternatives><element-citation id="ec-CR191" publication-type="journal"><person-group person-group-type="author"><name><surname>Kuphal</surname><given-names>S</given-names></name><name><surname>Poser</surname><given-names>I</given-names></name><name><surname>Jobin</surname><given-names>C</given-names></name><name><surname>Hellerbrand</surname><given-names>C</given-names></name><name><surname>Bosserhoff</surname><given-names>AK</given-names></name></person-group><article-title>Loss of E-cadherin leads to upregulation of NF&#x003ba;B activity in malignant melanoma</article-title><source>Oncogene</source><year>2004</year><volume>23</volume><fpage>8509</fpage><lpage>8519</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1207831</pub-id><pub-id pub-id-type="pmid">15378016</pub-id>
</element-citation><mixed-citation id="mc-CR191" publication-type="journal">Kuphal S, Poser I, Jobin C, Hellerbrand C, Bosserhoff AK. Loss of E-cadherin leads to upregulation of NF&#x003ba;B activity in malignant melanoma. Oncogene. 2004;23:8509&#x02013;19.<pub-id pub-id-type="pmid">15378016</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR192"><label>192.</label><citation-alternatives><element-citation id="ec-CR192" publication-type="journal"><person-group person-group-type="author"><name><surname>Canel</surname><given-names>M</given-names></name><name><surname>Serrels</surname><given-names>A</given-names></name><name><surname>Miller</surname><given-names>D</given-names></name><name><surname>Timpson</surname><given-names>P</given-names></name><name><surname>Serrels</surname><given-names>B</given-names></name><name><surname>Frame</surname><given-names>MC</given-names></name><etal/></person-group><article-title>Quantitative in vivo imaging of the effects of inhibiting integrin signaling via Src and FAK on cancer cell movement: effects on E-cadherin dynamics</article-title><source>Cancer Res</source><year>2010</year><volume>70</volume><fpage>9413</fpage><lpage>9422</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-10-1454</pub-id><pub-id pub-id-type="pmid">21045155</pub-id>
</element-citation><mixed-citation id="mc-CR192" publication-type="journal">Canel M, Serrels A, Miller D, Timpson P, Serrels B, Frame MC, et al. Quantitative in vivo imaging of the effects of inhibiting integrin signaling via Src and FAK on cancer cell movement: effects on E-cadherin dynamics. Cancer Res. 2010;70:9413&#x02013;22.<pub-id pub-id-type="pmid">21045155</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR193"><label>193.</label><citation-alternatives><element-citation id="ec-CR193" publication-type="journal"><person-group person-group-type="author"><name><surname>Serrels</surname><given-names>A</given-names></name><name><surname>Canel</surname><given-names>M</given-names></name><name><surname>Brunton</surname><given-names>VG</given-names></name><name><surname>Frame</surname><given-names>MC</given-names></name></person-group><article-title>Src/FAK-mediated regulation of E-cadherin as a mechanism for controlling collective cell movement: insights from in vivo imaging</article-title><source>Cell Adh Migr</source><year>2011</year><volume>5</volume><fpage>360</fpage><lpage>365</lpage><pub-id pub-id-type="doi">10.4161/cam.5.4.17290</pub-id><pub-id pub-id-type="pmid">21836391</pub-id>
</element-citation><mixed-citation id="mc-CR193" publication-type="journal">Serrels A, Canel M, Brunton VG, Frame MC. Src/FAK-mediated regulation of E-cadherin as a mechanism for controlling collective cell movement: insights from in vivo imaging. Cell Adh Migr. 2011;5:360&#x02013;5.<pub-id pub-id-type="pmid">21836391</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR194"><label>194.</label><citation-alternatives><element-citation id="ec-CR194" publication-type="journal"><person-group person-group-type="author"><name><surname>Higgins</surname><given-names>CA</given-names></name><name><surname>Roger</surname><given-names>MF</given-names></name><name><surname>Hill</surname><given-names>RP</given-names></name><name><surname>Ali-Khan</surname><given-names>AS</given-names></name><name><surname>Garlick</surname><given-names>JA</given-names></name><name><surname>Christiano</surname><given-names>AM</given-names></name><etal/></person-group><article-title>Multifaceted role of hair follicle dermal cells in bioengineered skins</article-title><source>Br J Dermatol</source><year>2017</year><volume>176</volume><fpage>1259</fpage><lpage>1269</lpage><pub-id pub-id-type="doi">10.1111/bjd.15087</pub-id><pub-id pub-id-type="pmid">27679975</pub-id>
</element-citation><mixed-citation id="mc-CR194" publication-type="journal">Higgins CA, Roger MF, Hill RP, Ali-Khan AS, Garlick JA, Christiano AM, et al. Multifaceted role of hair follicle dermal cells in bioengineered skins. Br J Dermatol. 2017;176:1259&#x02013;69.<pub-id pub-id-type="pmid">27679975</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR195"><label>195.</label><citation-alternatives><element-citation id="ec-CR195" publication-type="journal"><person-group person-group-type="author"><name><surname>Hiraoka</surname><given-names>C</given-names></name><name><surname>Toki</surname><given-names>F</given-names></name><name><surname>Shiraishi</surname><given-names>K</given-names></name><name><surname>Sayama</surname><given-names>K</given-names></name><name><surname>Nishimura</surname><given-names>EK</given-names></name><name><surname>Miura</surname><given-names>H</given-names></name><etal/></person-group><article-title>Two clonal types of human skin fibroblasts with different potentials for proliferation and tissue remodeling ability</article-title><source>J Dermatol Sci</source><year>2016</year><volume>82</volume><fpage>84</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1016/j.jdermsci.2016.01.009</pub-id><pub-id pub-id-type="pmid">26867959</pub-id>
</element-citation><mixed-citation id="mc-CR195" publication-type="journal">Hiraoka C, Toki F, Shiraishi K, Sayama K, Nishimura EK, Miura H, et al. Two clonal types of human skin fibroblasts with different potentials for proliferation and tissue remodeling ability. J Dermatol Sci. 2016;82:84&#x02013;94.<pub-id pub-id-type="pmid">26867959</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR196"><label>196.</label><citation-alternatives><element-citation id="ec-CR196" publication-type="journal"><person-group person-group-type="author"><name><surname>Driskell</surname><given-names>RR</given-names></name><name><surname>Lichtenberger</surname><given-names>BM</given-names></name><name><surname>Hoste</surname><given-names>E</given-names></name><name><surname>Kretzschmar</surname><given-names>K</given-names></name><name><surname>Simons</surname><given-names>BD</given-names></name><name><surname>Charalambous</surname><given-names>M</given-names></name><etal/></person-group><article-title>Distinct fibroblast lineages determine dermal architecture in skin development and repair</article-title><source>Nature</source><year>2013</year><volume>504</volume><fpage>277</fpage><lpage>281</lpage><pub-id pub-id-type="doi">10.1038/nature12783</pub-id><pub-id pub-id-type="pmid">24336287</pub-id>
</element-citation><mixed-citation id="mc-CR196" publication-type="journal">Driskell RR, Lichtenberger BM, Hoste E, Kretzschmar K, Simons BD, Charalambous M, et al. Distinct fibroblast lineages determine dermal architecture in skin development and repair. Nature. 2013;504:277&#x02013;81.<pub-id pub-id-type="pmid">24336287</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR197"><label>197.</label><citation-alternatives><element-citation id="ec-CR197" publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>DY</given-names></name><name><surname>Cho</surname><given-names>KH</given-names></name></person-group><article-title>The effects of epidermal keratinocytes and dermal fibroblasts on the formation of cutaneous basement membrane in three-dimensional culture systems</article-title><source>Arch Dermatol Res</source><year>2005</year><volume>296</volume><fpage>296</fpage><lpage>302</lpage><pub-id pub-id-type="doi">10.1007/s00403-004-0529-5</pub-id><pub-id pub-id-type="pmid">15650892</pub-id>
</element-citation><mixed-citation id="mc-CR197" publication-type="journal">Lee DY, Cho KH. The effects of epidermal keratinocytes and dermal fibroblasts on the formation of cutaneous basement membrane in three-dimensional culture systems. Arch Dermatol Res. 2005;296:296&#x02013;302.<pub-id pub-id-type="pmid">15650892</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR198"><label>198.</label><citation-alternatives><element-citation id="ec-CR198" publication-type="journal"><person-group person-group-type="author"><name><surname>Lichtenberger</surname><given-names>BM</given-names></name><name><surname>Mastrogiannaki</surname><given-names>M</given-names></name><name><surname>Watt</surname><given-names>FM</given-names></name></person-group><article-title>Epidermal &#x003b2;-catenin activation remodels the dermis via paracrine signalling to distinct fibroblast lineages</article-title><source>Nat Commun</source><year>2016</year><volume>7</volume><fpage>10537</fpage><pub-id pub-id-type="doi">10.1038/ncomms10537</pub-id><pub-id pub-id-type="pmid">26837596</pub-id>
</element-citation><mixed-citation id="mc-CR198" publication-type="journal">Lichtenberger BM, Mastrogiannaki M, Watt FM. Epidermal &#x003b2;-catenin activation remodels the dermis via paracrine signalling to distinct fibroblast lineages. Nat Commun. 2016;7:10537.<pub-id pub-id-type="pmid">26837596</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR199"><label>199.</label><citation-alternatives><element-citation id="ec-CR199" publication-type="journal"><person-group person-group-type="author"><name><surname>Mastrogiannaki</surname><given-names>M</given-names></name><name><surname>Lichtenberger</surname><given-names>BM</given-names></name><name><surname>Reimer</surname><given-names>A</given-names></name><name><surname>Collins</surname><given-names>CA</given-names></name><name><surname>Driskell</surname><given-names>RR</given-names></name><name><surname>Watt</surname><given-names>FM</given-names></name></person-group><article-title>&#x003b2;-Catenin stabilization in skin fibroblasts causes fibrotic lesions by preventing adipocyte differentiation of the reticular dermis</article-title><source>J Invest Dermatol</source><year>2016</year><volume>136</volume><fpage>1130</fpage><lpage>1142</lpage><pub-id pub-id-type="doi">10.1016/j.jid.2016.01.036</pub-id><pub-id pub-id-type="pmid">26902921</pub-id>
</element-citation><mixed-citation id="mc-CR199" publication-type="journal">Mastrogiannaki M, Lichtenberger BM, Reimer A, Collins CA, Driskell RR, Watt FM. &#x003b2;-Catenin stabilization in skin fibroblasts causes fibrotic lesions by preventing adipocyte differentiation of the reticular dermis. J Invest Dermatol. 2016;136:1130&#x02013;42.<pub-id pub-id-type="pmid">26902921</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR200"><label>200.</label><citation-alternatives><element-citation id="ec-CR200" publication-type="journal"><person-group person-group-type="author"><name><surname>Ito</surname><given-names>M</given-names></name><name><surname>Yang</surname><given-names>Z</given-names></name><name><surname>Andl</surname><given-names>T</given-names></name><name><surname>Cui</surname><given-names>C</given-names></name><name><surname>Kim</surname><given-names>N</given-names></name><name><surname>Millar</surname><given-names>SE</given-names></name><etal/></person-group><article-title>Wnt-dependent de novo hair follicle regeneration in adult mouse skin after wounding</article-title><source>Nature</source><year>2007</year><volume>447</volume><fpage>316</fpage><lpage>320</lpage><pub-id pub-id-type="doi">10.1038/nature05766</pub-id><pub-id pub-id-type="pmid">17507982</pub-id>
</element-citation><mixed-citation id="mc-CR200" publication-type="journal">Ito M, Yang Z, Andl T, Cui C, Kim N, Millar SE, et al. Wnt-dependent de novo hair follicle regeneration in adult mouse skin after wounding. Nature. 2007;447:316&#x02013;20.<pub-id pub-id-type="pmid">17507982</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR201"><label>201.</label><citation-alternatives><element-citation id="ec-CR201" publication-type="journal"><person-group person-group-type="author"><name><surname>Collins</surname><given-names>CA</given-names></name><name><surname>Kretzschmar</surname><given-names>K</given-names></name><name><surname>Watt</surname><given-names>FM</given-names></name></person-group><article-title>Reprogramming adult dermis to a neonatal state through epidermal activation of &#x003b2;-catenin</article-title><source>Development</source><year>2011</year><volume>138</volume><fpage>5189</fpage><lpage>5199</lpage><pub-id pub-id-type="doi">10.1242/dev.064592</pub-id><pub-id pub-id-type="pmid">22031549</pub-id>
</element-citation><mixed-citation id="mc-CR201" publication-type="journal">Collins CA, Kretzschmar K, Watt FM. Reprogramming adult dermis to a neonatal state through epidermal activation of &#x003b2;-catenin. Development. 2011;138:5189&#x02013;99.<pub-id pub-id-type="pmid">22031549</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR202"><label>202.</label><citation-alternatives><element-citation id="ec-CR202" publication-type="journal"><person-group person-group-type="author"><name><surname>Daszczuk</surname><given-names>P</given-names></name><name><surname>Mazurek</surname><given-names>P</given-names></name><name><surname>Pieczonka</surname><given-names>TD</given-names></name><name><surname>Olczak</surname><given-names>A</given-names></name><name><surname>Bory&#x00144;</surname><given-names>&#x00141;M</given-names></name><name><surname>Kobielak</surname><given-names>K</given-names></name></person-group><article-title>An intrinsic oscillation of gene networks inside hair follicle stem cells: an additional layer that can modulate hair stem cell activities</article-title><source>Front Cell Dev Biol</source><year>2020</year><volume>8</volume><fpage>595178</fpage><pub-id pub-id-type="doi">10.3389/fcell.2020.595178</pub-id><pub-id pub-id-type="pmid">33363148</pub-id>
</element-citation><mixed-citation id="mc-CR202" publication-type="journal">Daszczuk P, Mazurek P, Pieczonka TD, Olczak A, Bory&#x00144; &#x00141;M, Kobielak K. An intrinsic oscillation of gene networks inside hair follicle stem cells: an additional layer that can modulate hair stem cell activities. Front Cell Dev Biol. 2020;8: 595178.<pub-id pub-id-type="pmid">33363148</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR203"><label>203.</label><citation-alternatives><element-citation id="ec-CR203" publication-type="journal"><person-group person-group-type="author"><name><surname>Mazurkiewicz</surname><given-names>J</given-names></name><name><surname>Simiczyjew</surname><given-names>A</given-names></name><name><surname>Dratkiewicz</surname><given-names>E</given-names></name><name><surname>Pietraszek-Gremplewicz</surname><given-names>K</given-names></name><name><surname>Majkowski</surname><given-names>M</given-names></name><name><surname>Kot</surname><given-names>M</given-names></name><etal/></person-group><article-title>Melanoma cells with diverse invasive potential differentially induce the activation of normal human fibroblasts</article-title><source>Cell Commun Signal</source><year>2022</year><volume>20</volume><fpage>63</fpage><pub-id pub-id-type="doi">10.1186/s12964-022-00871-x</pub-id><pub-id pub-id-type="pmid">35538545</pub-id>
</element-citation><mixed-citation id="mc-CR203" publication-type="journal">Mazurkiewicz J, Simiczyjew A, Dratkiewicz E, Pietraszek-Gremplewicz K, Majkowski M, Kot M, et al. Melanoma cells with diverse invasive potential differentially induce the activation of normal human fibroblasts. Cell Commun Signal. 2022;20:63.<pub-id pub-id-type="pmid">35538545</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR204"><label>204.</label><citation-alternatives><element-citation id="ec-CR204" publication-type="journal"><person-group person-group-type="author"><name><surname>Sch&#x000fc;tz</surname><given-names>S</given-names></name><name><surname>Sol&#x000e9;-Boldo</surname><given-names>L</given-names></name><name><surname>Lucena-Porcel</surname><given-names>C</given-names></name><name><surname>Hoffmann</surname><given-names>J</given-names></name><name><surname>Brobeil</surname><given-names>A</given-names></name><name><surname>Lonsdorf</surname><given-names>AS</given-names></name><etal/></person-group><article-title>Functionally distinct cancer-associated fibroblast subpopulations establish a tumor promoting environment in squamous cell carcinoma</article-title><source>Nat Commun</source><year>2023</year><volume>14</volume><fpage>5413</fpage><pub-id pub-id-type="doi">10.1038/s41467-023-41141-9</pub-id><pub-id pub-id-type="pmid">37669956</pub-id>
</element-citation><mixed-citation id="mc-CR204" publication-type="journal">Sch&#x000fc;tz S, Sol&#x000e9;-Boldo L, Lucena-Porcel C, Hoffmann J, Brobeil A, Lonsdorf AS, et al. Functionally distinct cancer-associated fibroblast subpopulations establish a tumor promoting environment in squamous cell carcinoma. Nat Commun. 2023;14:5413.<pub-id pub-id-type="pmid">37669956</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR205"><label>205.</label><citation-alternatives><element-citation id="ec-CR205" publication-type="journal"><person-group person-group-type="author"><name><surname>Omland</surname><given-names>SH</given-names></name><name><surname>Wettergren</surname><given-names>EE</given-names></name><name><surname>Mollerup</surname><given-names>S</given-names></name><name><surname>Asplund</surname><given-names>M</given-names></name><name><surname>Mourier</surname><given-names>T</given-names></name><name><surname>Hansen</surname><given-names>AJ</given-names></name><etal/></person-group><article-title>Cancer associated fibroblasts (CAFs) are activated in cutaneous basal cell carcinoma and in the peritumoural skin</article-title><source>BMC Cancer</source><year>2017</year><volume>17</volume><fpage>675</fpage><pub-id pub-id-type="doi">10.1186/s12885-017-3663-0</pub-id><pub-id pub-id-type="pmid">28987144</pub-id>
</element-citation><mixed-citation id="mc-CR205" publication-type="journal">Omland SH, Wettergren EE, Mollerup S, Asplund M, Mourier T, Hansen AJ, et al. Cancer associated fibroblasts (CAFs) are activated in cutaneous basal cell carcinoma and in the peritumoural skin. BMC Cancer. 2017;17:675.<pub-id pub-id-type="pmid">28987144</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR206"><label>206.</label><citation-alternatives><element-citation id="ec-CR206" publication-type="journal"><person-group person-group-type="author"><name><surname>Erdogan</surname><given-names>B</given-names></name><name><surname>Webb</surname><given-names>DJ</given-names></name></person-group><article-title>Cancer-associated fibroblasts modulate growth factor signaling and extracellular matrix remodeling to regulate tumor metastasis</article-title><source>Biochem Soc Trans</source><year>2017</year><volume>45</volume><fpage>229</fpage><lpage>236</lpage><pub-id pub-id-type="doi">10.1042/BST20160387</pub-id><pub-id pub-id-type="pmid">28202677</pub-id>
</element-citation><mixed-citation id="mc-CR206" publication-type="journal">Erdogan B, Webb DJ. Cancer-associated fibroblasts modulate growth factor signaling and extracellular matrix remodeling to regulate tumor metastasis. Biochem Soc Trans. 2017;45:229&#x02013;36.<pub-id pub-id-type="pmid">28202677</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR207"><label>207.</label><citation-alternatives><element-citation id="ec-CR207" publication-type="journal"><person-group person-group-type="author"><name><surname>Xiao</surname><given-names>Y</given-names></name><name><surname>Zhou</surname><given-names>L</given-names></name><name><surname>Andl</surname><given-names>T</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name></person-group><article-title>YAP1 controls the N-cadherin-mediated tumor-stroma interaction in melanoma progression</article-title><source>Oncogene</source><year>2024</year><volume>43</volume><fpage>884</fpage><lpage>898</lpage><pub-id pub-id-type="doi">10.1038/s41388-024-02953-1</pub-id><pub-id pub-id-type="pmid">38308096</pub-id>
</element-citation><mixed-citation id="mc-CR207" publication-type="journal">Xiao Y, Zhou L, Andl T, Zhang Y. YAP1 controls the N-cadherin-mediated tumor-stroma interaction in melanoma progression. Oncogene. 2024;43:884&#x02013;98.<pub-id pub-id-type="pmid">38308096</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR208"><label>208.</label><citation-alternatives><element-citation id="ec-CR208" publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>JT</given-names></name><name><surname>Herlyn</surname><given-names>M</given-names></name></person-group><article-title>Microenvironmental influences in melanoma progression</article-title><source>J Cell Biochem</source><year>2007</year><volume>101</volume><fpage>862</fpage><lpage>872</lpage><pub-id pub-id-type="doi">10.1002/jcb.21204</pub-id><pub-id pub-id-type="pmid">17171636</pub-id>
</element-citation><mixed-citation id="mc-CR208" publication-type="journal">Lee JT, Herlyn M. Microenvironmental influences in melanoma progression. J Cell Biochem. 2007;101:862&#x02013;72.<pub-id pub-id-type="pmid">17171636</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR209"><label>209.</label><citation-alternatives><element-citation id="ec-CR209" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>Q</given-names></name><name><surname>Jin</surname><given-names>X</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Tao</surname><given-names>M</given-names></name><name><surname>Cao</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Melanoma-associated fibroblasts in tumor-promotion flammation and antitumor immunity: novel mechanisms and potential immunotherapeutic strategies</article-title><source>Hum Mol Genet</source><year>2024</year><volume>33</volume><fpage>1186</fpage><lpage>1193</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddae056</pub-id><pub-id pub-id-type="pmid">38538564</pub-id>
</element-citation><mixed-citation id="mc-CR209" publication-type="journal">Zhou Q, Jin X, Zhao Y, Wang Y, Tao M, Cao Y, et al. Melanoma-associated fibroblasts in tumor-promotion flammation and antitumor immunity: novel mechanisms and potential immunotherapeutic strategies. Hum Mol Genet. 2024;33:1186&#x02013;93.<pub-id pub-id-type="pmid">38538564</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR210"><label>210.</label><citation-alternatives><element-citation id="ec-CR210" publication-type="journal"><person-group person-group-type="author"><name><surname>Ohshio</surname><given-names>Y</given-names></name><name><surname>Teramoto</surname><given-names>K</given-names></name><name><surname>Hanaoka</surname><given-names>J</given-names></name><name><surname>Tezuka</surname><given-names>N</given-names></name><name><surname>Itoh</surname><given-names>Y</given-names></name><name><surname>Asai</surname><given-names>T</given-names></name><etal/></person-group><article-title>Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine</article-title><source>Cancer Sci</source><year>2015</year><volume>106</volume><fpage>134</fpage><lpage>142</lpage><pub-id pub-id-type="doi">10.1111/cas.12584</pub-id><pub-id pub-id-type="pmid">25483888</pub-id>
</element-citation><mixed-citation id="mc-CR210" publication-type="journal">Ohshio Y, Teramoto K, Hanaoka J, Tezuka N, Itoh Y, Asai T, et al. Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine. Cancer Sci. 2015;106:134&#x02013;42.<pub-id pub-id-type="pmid">25483888</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR211"><label>211.</label><citation-alternatives><element-citation id="ec-CR211" publication-type="journal"><person-group person-group-type="author"><name><surname>Khalili</surname><given-names>JS</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Rodr&#x000ed;guez-Cruz</surname><given-names>TG</given-names></name><name><surname>Whittington</surname><given-names>M</given-names></name><name><surname>Wardell</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name><etal/></person-group><article-title>Oncogenic BRAF(V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma</article-title><source>Clin Cancer Res</source><year>2012</year><volume>18</volume><fpage>5329</fpage><lpage>5340</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-12-1632</pub-id><pub-id pub-id-type="pmid">22850568</pub-id>
</element-citation><mixed-citation id="mc-CR211" publication-type="journal">Khalili JS, Liu S, Rodr&#x000ed;guez-Cruz TG, Whittington M, Wardell S, Liu C, et al. Oncogenic BRAF(V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma. Clin Cancer Res. 2012;18:5329&#x02013;40.<pub-id pub-id-type="pmid">22850568</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR212"><label>212.</label><citation-alternatives><element-citation id="ec-CR212" publication-type="journal"><person-group person-group-type="author"><name><surname>Ziani</surname><given-names>L</given-names></name><name><surname>Buart</surname><given-names>S</given-names></name><name><surname>Chouaib</surname><given-names>S</given-names></name><name><surname>Thiery</surname><given-names>J</given-names></name></person-group><article-title>Hypoxia increases melanoma-associated fibroblasts immunosuppressive potential and inhibitory effect on T cell-mediated cytotoxicity</article-title><source>Oncoimmunology</source><year>2021</year><volume>10</volume><fpage>1950953</fpage><pub-id pub-id-type="doi">10.1080/2162402X.2021.1950953</pub-id><pub-id pub-id-type="pmid">34367731</pub-id>
</element-citation><mixed-citation id="mc-CR212" publication-type="journal">Ziani L, Buart S, Chouaib S, Thiery J. Hypoxia increases melanoma-associated fibroblasts immunosuppressive potential and inhibitory effect on T cell-mediated cytotoxicity. Oncoimmunology. 2021;10:1950953.<pub-id pub-id-type="pmid">34367731</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR213"><label>213.</label><citation-alternatives><element-citation id="ec-CR213" publication-type="journal"><person-group person-group-type="author"><name><surname>Ziani</surname><given-names>L</given-names></name><name><surname>Safta-Saadoun</surname><given-names>TB</given-names></name><name><surname>Gourbeix</surname><given-names>J</given-names></name><name><surname>Cavalcanti</surname><given-names>A</given-names></name><name><surname>Robert</surname><given-names>C</given-names></name><name><surname>Favre</surname><given-names>G</given-names></name><etal/></person-group><article-title>Melanoma-associated fibroblasts decrease tumor cell susceptibility to NK cell-mediated killing through matrix-metalloproteinases secretion</article-title><source>Oncotarget</source><year>2017</year><volume>8</volume><fpage>19780</fpage><lpage>19794</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.15540</pub-id><pub-id pub-id-type="pmid">28423623</pub-id>
</element-citation><mixed-citation id="mc-CR213" publication-type="journal">Ziani L, Safta-Saadoun TB, Gourbeix J, Cavalcanti A, Robert C, Favre G, et al. Melanoma-associated fibroblasts decrease tumor cell susceptibility to NK cell-mediated killing through matrix-metalloproteinases secretion. Oncotarget. 2017;8:19780&#x02013;94.<pub-id pub-id-type="pmid">28423623</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR214"><label>214.</label><citation-alternatives><element-citation id="ec-CR214" publication-type="journal"><person-group person-group-type="author"><name><surname>Balsamo</surname><given-names>M</given-names></name><name><surname>Scordamaglia</surname><given-names>F</given-names></name><name><surname>Pietra</surname><given-names>G</given-names></name><name><surname>Manzini</surname><given-names>C</given-names></name><name><surname>Cantoni</surname><given-names>C</given-names></name><name><surname>Boitano</surname><given-names>M</given-names></name><etal/></person-group><article-title>Melanoma-associated fibroblasts modulate NK cell phenotype and antitumor cytotoxicity</article-title><source>Proc Natl Acad Sci U S A</source><year>2009</year><volume>106</volume><fpage>20847</fpage><lpage>20852</lpage><pub-id pub-id-type="doi">10.1073/pnas.0906481106</pub-id><pub-id pub-id-type="pmid">19934056</pub-id>
</element-citation><mixed-citation id="mc-CR214" publication-type="journal">Balsamo M, Scordamaglia F, Pietra G, Manzini C, Cantoni C, Boitano M, et al. Melanoma-associated fibroblasts modulate NK cell phenotype and antitumor cytotoxicity. Proc Natl Acad Sci U S A. 2009;106:20847&#x02013;52.<pub-id pub-id-type="pmid">19934056</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR215"><label>215.</label><citation-alternatives><element-citation id="ec-CR215" publication-type="journal"><person-group person-group-type="author"><name><surname>Lakins</surname><given-names>MA</given-names></name><name><surname>Ghorani</surname><given-names>E</given-names></name><name><surname>Munir</surname><given-names>H</given-names></name><name><surname>Martins</surname><given-names>CP</given-names></name><name><surname>Shields</surname><given-names>JD</given-names></name></person-group><article-title>Cancer-associated fibroblasts induce antigen-specific deletion of CD8+T Cells to protect tumour cells</article-title><source>Nat Commun</source><year>2018</year><volume>9</volume><fpage>948</fpage><pub-id pub-id-type="doi">10.1038/s41467-018-03347-0</pub-id><pub-id pub-id-type="pmid">29507342</pub-id>
</element-citation><mixed-citation id="mc-CR215" publication-type="journal">Lakins MA, Ghorani E, Munir H, Martins CP, Shields JD. Cancer-associated fibroblasts induce antigen-specific deletion of CD8+T Cells to protect tumour cells. Nat Commun. 2018;9:948.<pub-id pub-id-type="pmid">29507342</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR216"><label>216.</label><citation-alternatives><element-citation id="ec-CR216" publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>JH</given-names></name><name><surname>Shklovskaya</surname><given-names>E</given-names></name><name><surname>Lim</surname><given-names>SY</given-names></name><name><surname>Carlino</surname><given-names>MS</given-names></name><name><surname>Menzies</surname><given-names>AM</given-names></name><name><surname>Stewart</surname><given-names>A</given-names></name><etal/></person-group><article-title>Transcriptional downregulation of MHC class I and melanoma de-differentiation in resistance to PD-1 inhibition</article-title><source>Nat Commun</source><year>2020</year><volume>11</volume><fpage>1897</fpage><pub-id pub-id-type="doi">10.1038/s41467-020-15726-7</pub-id><pub-id pub-id-type="pmid">32312968</pub-id>
</element-citation><mixed-citation id="mc-CR216" publication-type="journal">Lee JH, Shklovskaya E, Lim SY, Carlino MS, Menzies AM, Stewart A, et al. Transcriptional downregulation of MHC class I and melanoma de-differentiation in resistance to PD-1 inhibition. Nat Commun. 2020;11:1897.<pub-id pub-id-type="pmid">32312968</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR217"><label>217.</label><citation-alternatives><element-citation id="ec-CR217" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>L</given-names></name><name><surname>Yang</surname><given-names>K</given-names></name><name><surname>Andl</surname><given-names>T</given-names></name><name><surname>Wickett</surname><given-names>RR</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name></person-group><article-title>Perspective of targeting cancer-associated fibroblasts in melanoma</article-title><source>J Cancer</source><year>2015</year><volume>6</volume><fpage>717</fpage><lpage>726</lpage><pub-id pub-id-type="doi">10.7150/jca.10865</pub-id><pub-id pub-id-type="pmid">26185533</pub-id>
</element-citation><mixed-citation id="mc-CR217" publication-type="journal">Zhou L, Yang K, Andl T, Wickett RR, Zhang Y. Perspective of targeting cancer-associated fibroblasts in melanoma. J Cancer. 2015;6:717&#x02013;26.<pub-id pub-id-type="pmid">26185533</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR218"><label>218.</label><citation-alternatives><element-citation id="ec-CR218" publication-type="journal"><person-group person-group-type="author"><name><surname>&#x000c9;rsek</surname><given-names>B</given-names></name><name><surname>Sill&#x000f3;</surname><given-names>P</given-names></name><name><surname>Cakir</surname><given-names>U</given-names></name><name><surname>Moln&#x000e1;r</surname><given-names>V</given-names></name><name><surname>Bencsik</surname><given-names>A</given-names></name><name><surname>Mayer</surname><given-names>B</given-names></name><etal/></person-group><article-title>Melanoma-associated fibroblasts impair CD8+ T cell function and modify expression of immune checkpoint regulators via increased arginase activity</article-title><source>Cell Mol Life Sci</source><year>2021</year><volume>78</volume><fpage>661</fpage><lpage>673</lpage><pub-id pub-id-type="doi">10.1007/s00018-020-03517-8</pub-id><pub-id pub-id-type="pmid">32328671</pub-id>
</element-citation><mixed-citation id="mc-CR218" publication-type="journal">&#x000c9;rsek B, Sill&#x000f3; P, Cakir U, Moln&#x000e1;r V, Bencsik A, Mayer B, et al. Melanoma-associated fibroblasts impair CD8+ T cell function and modify expression of immune checkpoint regulators via increased arginase activity. Cell Mol Life Sci. 2021;78:661&#x02013;73.<pub-id pub-id-type="pmid">32328671</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR219"><label>219.</label><citation-alternatives><element-citation id="ec-CR219" publication-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>PF</given-names></name><name><surname>Wei</surname><given-names>W</given-names></name><name><surname>Gupta</surname><given-names>S</given-names></name><name><surname>Smithy</surname><given-names>JW</given-names></name><name><surname>Zelterman</surname><given-names>D</given-names></name><name><surname>Kluger</surname><given-names>HM</given-names></name><etal/></person-group><article-title>Multiplex quantitative analysis of cancer-associated fibroblasts and immunotherapy outcome in metastatic melanoma</article-title><source>J Immunother Cancer</source><year>2019</year><volume>7</volume><fpage>194</fpage><pub-id pub-id-type="doi">10.1186/s40425-019-0675-0</pub-id><pub-id pub-id-type="pmid">31337426</pub-id>
</element-citation><mixed-citation id="mc-CR219" publication-type="journal">Wong PF, Wei W, Gupta S, Smithy JW, Zelterman D, Kluger HM, et al. Multiplex quantitative analysis of cancer-associated fibroblasts and immunotherapy outcome in metastatic melanoma. J Immunother Cancer. 2019;7:194.<pub-id pub-id-type="pmid">31337426</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR220"><label>220.</label><citation-alternatives><element-citation id="ec-CR220" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>F</given-names></name><name><surname>Evans</surname><given-names>K</given-names></name><name><surname>Xiao</surname><given-names>C</given-names></name><name><surname>DeVito</surname><given-names>N</given-names></name><name><surname>Theivanthiran</surname><given-names>B</given-names></name><name><surname>Holtzhausen</surname><given-names>A</given-names></name><etal/></person-group><article-title>Stromal fibroblasts mediate anti-PD-1 resistance via MMP-9 and dictate TGF&#x003b2; inhibitor sequencing in melanoma</article-title><source>Cancer Immunol Res</source><year>2018</year><volume>6</volume><fpage>1459</fpage><lpage>1471</lpage><pub-id pub-id-type="doi">10.1158/2326-6066.CIR-18-0086</pub-id><pub-id pub-id-type="pmid">30209062</pub-id>
</element-citation><mixed-citation id="mc-CR220" publication-type="journal">Zhao F, Evans K, Xiao C, DeVito N, Theivanthiran B, Holtzhausen A, et al. Stromal fibroblasts mediate anti-PD-1 resistance via MMP-9 and dictate TGF&#x003b2; inhibitor sequencing in melanoma. Cancer Immunol Res. 2018;6:1459&#x02013;71.<pub-id pub-id-type="pmid">30209062</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR221"><label>221.</label><citation-alternatives><element-citation id="ec-CR221" publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Zhao</surname><given-names>S</given-names></name><name><surname>Bian</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Lu</surname><given-names>L</given-names></name><name><surname>Pei</surname><given-names>S</given-names></name><etal/></person-group><article-title>Signatures of EMT, immunosuppression, and inflammation in primary and recurrent human cutaneous squamous cell carcinoma at single-cell resolution</article-title><source>Theranostics</source><year>2022</year><volume>12</volume><fpage>7532</fpage><lpage>7549</lpage><pub-id pub-id-type="doi">10.7150/thno.77528</pub-id><pub-id pub-id-type="pmid">36438481</pub-id>
</element-citation><mixed-citation id="mc-CR221" publication-type="journal">Li X, Zhao S, Bian X, Zhang L, Lu L, Pei S, et al. Signatures of EMT, immunosuppression, and inflammation in primary and recurrent human cutaneous squamous cell carcinoma at single-cell resolution. Theranostics. 2022;12:7532&#x02013;49.<pub-id pub-id-type="pmid">36438481</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR222"><label>222.</label><citation-alternatives><element-citation id="ec-CR222" publication-type="journal"><person-group person-group-type="author"><name><surname>Tsang</surname><given-names>M</given-names></name><name><surname>Quesnel</surname><given-names>K</given-names></name><name><surname>Vincent</surname><given-names>K</given-names></name><name><surname>Hutchenreuther</surname><given-names>J</given-names></name><name><surname>Postovit</surname><given-names>LM</given-names></name><name><surname>Leask</surname><given-names>A</given-names></name></person-group><article-title>Insights into fibroblast plasticity: cellular communication network 2 is required for activation of cancer-associated fibroblasts in a murine model of melanoma</article-title><source>Am J Pathol</source><year>2020</year><volume>190</volume><fpage>206</fpage><lpage>221</lpage><pub-id pub-id-type="doi">10.1016/j.ajpath.2019.09.006</pub-id><pub-id pub-id-type="pmid">31610176</pub-id>
</element-citation><mixed-citation id="mc-CR222" publication-type="journal">Tsang M, Quesnel K, Vincent K, Hutchenreuther J, Postovit LM, Leask A. Insights into fibroblast plasticity: cellular communication network 2 is required for activation of cancer-associated fibroblasts in a murine model of melanoma. Am J Pathol. 2020;190:206&#x02013;21.<pub-id pub-id-type="pmid">31610176</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR223"><label>223.</label><citation-alternatives><element-citation id="ec-CR223" publication-type="journal"><person-group person-group-type="author"><name><surname>Novotn&#x000fd;</surname><given-names>J</given-names></name><name><surname>Strnadov&#x000e1;</surname><given-names>K</given-names></name><name><surname>Dvo&#x00159;&#x000e1;nkov&#x000e1;</surname><given-names>B</given-names></name><name><surname>Kocourkov&#x000e1;</surname><given-names>&#x00160;</given-names></name><name><surname>Jak&#x00161;a</surname><given-names>R</given-names></name><name><surname>Dundr</surname><given-names>P</given-names></name><etal/></person-group><article-title>Single-cell RNA sequencing unravels heterogeneity of the stromal niche in cutaneous melanoma heterogeneous spheroids</article-title><source>Cancers (Basel)</source><year>2020</year><volume>12</volume><fpage>3324</fpage><pub-id pub-id-type="doi">10.3390/cancers12113324</pub-id><pub-id pub-id-type="pmid">33182777</pub-id>
</element-citation><mixed-citation id="mc-CR223" publication-type="journal">Novotn&#x000fd; J, Strnadov&#x000e1; K, Dvo&#x00159;&#x000e1;nkov&#x000e1; B, Kocourkov&#x000e1; &#x00160;, Jak&#x00161;a R, Dundr P, et al. Single-cell RNA sequencing unravels heterogeneity of the stromal niche in cutaneous melanoma heterogeneous spheroids. Cancers (Basel). 2020;12:3324.<pub-id pub-id-type="pmid">33182777</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR224"><label>224.</label><citation-alternatives><element-citation id="ec-CR224" publication-type="journal"><person-group person-group-type="author"><name><surname>Lederle</surname><given-names>W</given-names></name><name><surname>Hartenstein</surname><given-names>B</given-names></name><name><surname>Meides</surname><given-names>A</given-names></name><name><surname>Kunzelmann</surname><given-names>H</given-names></name><name><surname>Werb</surname><given-names>Z</given-names></name><name><surname>Angel</surname><given-names>P</given-names></name><etal/></person-group><article-title>MMP13 as a stromal mediator in controlling persistent angiogenesis in skin carcinoma</article-title><source>Carcinogenesis</source><year>2010</year><volume>31</volume><fpage>1175</fpage><lpage>1184</lpage><pub-id pub-id-type="doi">10.1093/carcin/bgp248</pub-id><pub-id pub-id-type="pmid">19892798</pub-id>
</element-citation><mixed-citation id="mc-CR224" publication-type="journal">Lederle W, Hartenstein B, Meides A, Kunzelmann H, Werb Z, Angel P, et al. MMP13 as a stromal mediator in controlling persistent angiogenesis in skin carcinoma. Carcinogenesis. 2010;31:1175&#x02013;84.<pub-id pub-id-type="pmid">19892798</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR225"><label>225.</label><citation-alternatives><element-citation id="ec-CR225" publication-type="journal"><person-group person-group-type="author"><name><surname>Demkova</surname><given-names>L</given-names></name><name><surname>Kucerova</surname><given-names>L</given-names></name></person-group><article-title>Role of the HGF/c-MET tyrosine kinase inhibitors in metastasic melanoma</article-title><source>Mol Cancer</source><year>2018</year><volume>17</volume><fpage>26</fpage><pub-id pub-id-type="doi">10.1186/s12943-018-0795-z</pub-id><pub-id pub-id-type="pmid">29455657</pub-id>
</element-citation><mixed-citation id="mc-CR225" publication-type="journal">Demkova L, Kucerova L. Role of the HGF/c-MET tyrosine kinase inhibitors in metastasic melanoma. Mol Cancer. 2018;17:26.<pub-id pub-id-type="pmid">29455657</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR226"><label>226.</label><citation-alternatives><element-citation id="ec-CR226" publication-type="journal"><person-group person-group-type="author"><name><surname>Kinugasa</surname><given-names>Y</given-names></name><name><surname>Matsui</surname><given-names>T</given-names></name><name><surname>Takakura</surname><given-names>N</given-names></name></person-group><article-title>CD44 expressed on cancer-associated fibroblasts is a functional molecule supporting the stemness and drug resistance of malignant cancer cells in the tumor microenvironment</article-title><source>Stem Cells</source><year>2014</year><volume>32</volume><fpage>145</fpage><lpage>156</lpage><pub-id pub-id-type="doi">10.1002/stem.1556</pub-id><pub-id pub-id-type="pmid">24395741</pub-id>
</element-citation><mixed-citation id="mc-CR226" publication-type="journal">Kinugasa Y, Matsui T, Takakura N. CD44 expressed on cancer-associated fibroblasts is a functional molecule supporting the stemness and drug resistance of malignant cancer cells in the tumor microenvironment. Stem Cells. 2014;32:145&#x02013;56.<pub-id pub-id-type="pmid">24395741</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR227"><label>227.</label><citation-alternatives><element-citation id="ec-CR227" publication-type="journal"><person-group person-group-type="author"><name><surname>Kumamoto</surname><given-names>T</given-names></name><name><surname>Shalhevet</surname><given-names>D</given-names></name><name><surname>Matsue</surname><given-names>H</given-names></name><name><surname>Mummert</surname><given-names>ME</given-names></name><name><surname>Ward</surname><given-names>BR</given-names></name><name><surname>Jester</surname><given-names>JV</given-names></name><etal/></person-group><article-title>Hair follicles serve as local reservoirs of skin mast cell precursors</article-title><source>Blood</source><year>2003</year><volume>102</volume><fpage>1654</fpage><lpage>1660</lpage><pub-id pub-id-type="doi">10.1182/blood-2003-02-0449</pub-id><pub-id pub-id-type="pmid">12738661</pub-id>
</element-citation><mixed-citation id="mc-CR227" publication-type="journal">Kumamoto T, Shalhevet D, Matsue H, Mummert ME, Ward BR, Jester JV, et al. Hair follicles serve as local reservoirs of skin mast cell precursors. Blood. 2003;102:1654&#x02013;60.<pub-id pub-id-type="pmid">12738661</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR228"><label>228.</label><citation-alternatives><element-citation id="ec-CR228" publication-type="journal"><person-group person-group-type="author"><name><surname>Merad</surname><given-names>M</given-names></name><name><surname>Sathe</surname><given-names>P</given-names></name><name><surname>Helft</surname><given-names>J</given-names></name><name><surname>Miller</surname><given-names>J</given-names></name><name><surname>Mortha</surname><given-names>A</given-names></name></person-group><article-title>The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting</article-title><source>Annu Rev Immunol</source><year>2013</year><volume>31</volume><fpage>563</fpage><lpage>604</lpage><pub-id pub-id-type="doi">10.1146/annurev-immunol-020711-074950</pub-id><pub-id pub-id-type="pmid">23516985</pub-id>
</element-citation><mixed-citation id="mc-CR228" publication-type="journal">Merad M, Sathe P, Helft J, Miller J, Mortha A. The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting. Annu Rev Immunol. 2013;31:563&#x02013;604.<pub-id pub-id-type="pmid">23516985</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR229"><label>229.</label><citation-alternatives><element-citation id="ec-CR229" publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>P</given-names></name><name><surname>Gund</surname><given-names>R</given-names></name><name><surname>Dutta</surname><given-names>A</given-names></name><name><surname>Pincha</surname><given-names>N</given-names></name><name><surname>Rana</surname><given-names>I</given-names></name><name><surname>Ghosh</surname><given-names>S</given-names></name><etal/></person-group><article-title>Stimulation of hair follicle stem cell proliferation through an IL-1 dependent activation of &#x003b3;&#x003b4;T-cells</article-title><source>Elife</source><year>2017</year><volume>6</volume><fpage>e28875</fpage><pub-id pub-id-type="doi">10.7554/eLife.28875</pub-id><pub-id pub-id-type="pmid">29199946</pub-id>
</element-citation><mixed-citation id="mc-CR229" publication-type="journal">Lee P, Gund R, Dutta A, Pincha N, Rana I, Ghosh S, et al. Stimulation of hair follicle stem cell proliferation through an IL-1 dependent activation of &#x003b3;&#x003b4;T-cells. Elife. 2017;6: e28875.<pub-id pub-id-type="pmid">29199946</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR230"><label>230.</label><citation-alternatives><element-citation id="ec-CR230" publication-type="journal"><person-group person-group-type="author"><name><surname>Castellana</surname><given-names>D</given-names></name><name><surname>Paus</surname><given-names>R</given-names></name><name><surname>Perez-Moreno</surname><given-names>M</given-names></name></person-group><article-title>Macrophages contribute to the cyclic activation of adult hair follicle stem cells</article-title><source>PLoS Biol</source><year>2014</year><volume>12</volume><fpage>e1002002</fpage><pub-id pub-id-type="doi">10.1371/journal.pbio.1002002</pub-id><pub-id pub-id-type="pmid">25536657</pub-id>
</element-citation><mixed-citation id="mc-CR230" publication-type="journal">Castellana D, Paus R, Perez-Moreno M. Macrophages contribute to the cyclic activation of adult hair follicle stem cells. PLoS Biol. 2014;12: e1002002.<pub-id pub-id-type="pmid">25536657</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR231"><label>231.</label><citation-alternatives><element-citation id="ec-CR231" publication-type="journal"><person-group person-group-type="author"><name><surname>Ali</surname><given-names>N</given-names></name><name><surname>Zirak</surname><given-names>B</given-names></name><name><surname>Rodriguez</surname><given-names>RS</given-names></name><name><surname>Pauli</surname><given-names>ML</given-names></name><name><surname>Truong</surname><given-names>HA</given-names></name><name><surname>Lai</surname><given-names>K</given-names></name><etal/></person-group><article-title>Regulatory T cells in skin facilitate epithelial stem cell differentiation</article-title><source>Cell</source><year>2017</year><volume>169</volume><fpage>1119</fpage><lpage>1129.e11</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2017.05.002</pub-id><pub-id pub-id-type="pmid">28552347</pub-id>
</element-citation><mixed-citation id="mc-CR231" publication-type="journal">Ali N, Zirak B, Rodriguez RS, Pauli ML, Truong HA, Lai K, et al. Regulatory T cells in skin facilitate epithelial stem cell differentiation. Cell. 2017;169:1119-1129.e11.<pub-id pub-id-type="pmid">28552347</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR232"><label>232.</label><citation-alternatives><element-citation id="ec-CR232" publication-type="journal"><person-group person-group-type="author"><name><surname>Rahmani</surname><given-names>W</given-names></name><name><surname>Sinha</surname><given-names>S</given-names></name><name><surname>Biernaskie</surname><given-names>J</given-names></name></person-group><article-title>Immune modulation of hair follicle regeneration</article-title><source>NPJ Regen Med</source><year>2020</year><volume>5</volume><fpage>9</fpage><pub-id pub-id-type="doi">10.1038/s41536-020-0095-2</pub-id><pub-id pub-id-type="pmid">32411394</pub-id>
</element-citation><mixed-citation id="mc-CR232" publication-type="journal">Rahmani W, Sinha S, Biernaskie J. Immune modulation of hair follicle regeneration. NPJ Regen Med. 2020;5:9.<pub-id pub-id-type="pmid">32411394</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR233"><label>233.</label><citation-alternatives><element-citation id="ec-CR233" publication-type="journal"><person-group person-group-type="author"><name><surname>Sanchez Rodriguez</surname><given-names>R</given-names></name><name><surname>Pauli</surname><given-names>ML</given-names></name><name><surname>Neuhaus</surname><given-names>IM</given-names></name><name><surname>Yu</surname><given-names>SS</given-names></name><name><surname>Arron</surname><given-names>ST</given-names></name><name><surname>Harris</surname><given-names>HW</given-names></name><etal/></person-group><article-title>Memory regulatory T cells reside in human skin</article-title><source>J Clin Invest</source><year>2014</year><volume>124</volume><fpage>1027</fpage><lpage>1036</lpage><pub-id pub-id-type="doi">10.1172/JCI72932</pub-id><pub-id pub-id-type="pmid">24509084</pub-id>
</element-citation><mixed-citation id="mc-CR233" publication-type="journal">Sanchez Rodriguez R, Pauli ML, Neuhaus IM, Yu SS, Arron ST, Harris HW, et al. Memory regulatory T cells reside in human skin. J Clin Invest. 2014;124:1027&#x02013;36.<pub-id pub-id-type="pmid">24509084</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR234"><label>234.</label><citation-alternatives><element-citation id="ec-CR234" publication-type="journal"><person-group person-group-type="author"><name><surname>Lui</surname><given-names>PP</given-names></name><name><surname>Xu</surname><given-names>JZ</given-names></name><name><surname>Aziz</surname><given-names>H</given-names></name><name><surname>Sen</surname><given-names>M</given-names></name><name><surname>Ali</surname><given-names>N</given-names></name></person-group><article-title>Jagged-1+ skin Tregs modulate cutaneous wound healing</article-title><source>Sci Rep</source><year>2024</year><volume>14</volume><fpage>20999</fpage><pub-id pub-id-type="doi">10.1038/s41598-024-71512-1</pub-id><pub-id pub-id-type="pmid">39251686</pub-id>
</element-citation><mixed-citation id="mc-CR234" publication-type="journal">Lui PP, Xu JZ, Aziz H, Sen M, Ali N. Jagged-1+ skin Tregs modulate cutaneous wound healing. Sci Rep. 2024;14:20999.<pub-id pub-id-type="pmid">39251686</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR235"><label>235.</label><citation-alternatives><element-citation id="ec-CR235" publication-type="journal"><person-group person-group-type="author"><name><surname>Nosbaum</surname><given-names>A</given-names></name><name><surname>Prevel</surname><given-names>N</given-names></name><name><surname>Truong</surname><given-names>HA</given-names></name><name><surname>Mehta</surname><given-names>P</given-names></name><name><surname>Ettinger</surname><given-names>M</given-names></name><name><surname>Scharschmidt</surname><given-names>TC</given-names></name><etal/></person-group><article-title>Cutting edge: regulatory T cells facilitate cutaneous wound healing</article-title><source>J Immunol</source><year>2016</year><volume>196</volume><fpage>2010</fpage><lpage>2014</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1502139</pub-id><pub-id pub-id-type="pmid">26826250</pub-id>
</element-citation><mixed-citation id="mc-CR235" publication-type="journal">Nosbaum A, Prevel N, Truong HA, Mehta P, Ettinger M, Scharschmidt TC, et al. Cutting edge: regulatory T cells facilitate cutaneous wound healing. J Immunol. 2016;196:2010&#x02013;4.<pub-id pub-id-type="pmid">26826250</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR236"><label>236.</label><citation-alternatives><element-citation id="ec-CR236" publication-type="journal"><person-group person-group-type="author"><name><surname>Agudo</surname><given-names>J</given-names></name><name><surname>Park</surname><given-names>ES</given-names></name><name><surname>Rose</surname><given-names>SA</given-names></name><name><surname>Alibo</surname><given-names>E</given-names></name><name><surname>Sweeney</surname><given-names>R</given-names></name><name><surname>Dhainaut</surname><given-names>M</given-names></name><etal/></person-group><article-title>Quiescent tissue stem cells evade immune surveillance</article-title><source>Immunity</source><year>2018</year><volume>48</volume><fpage>271</fpage><lpage>285.e5</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2018.02.001</pub-id><pub-id pub-id-type="pmid">29466757</pub-id>
</element-citation><mixed-citation id="mc-CR236" publication-type="journal">Agudo J, Park ES, Rose SA, Alibo E, Sweeney R, Dhainaut M, et al. Quiescent tissue stem cells evade immune surveillance. Immunity. 2018;48:271-285.e5.<pub-id pub-id-type="pmid">29466757</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR237"><label>237.</label><mixed-citation publication-type="other">Mani V, Bromley SK, &#x000c4;ij&#x000f6; T, Mora-Buch R, Carrizosa E, Warner RD, et al. Migratory DCs activate TGF-&#x003b2; to precondition na&#x000ef;ve CD8(+) T cells for tissue-resident memory fate<italic>.</italic> Science. 2019; 366:eaav5728.</mixed-citation></ref><ref id="CR238"><label>238.</label><citation-alternatives><element-citation id="ec-CR238" publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>SL</given-names></name><name><surname>Buzzai</surname><given-names>A</given-names></name><name><surname>Rautela</surname><given-names>J</given-names></name><name><surname>Hor</surname><given-names>JL</given-names></name><name><surname>Hochheiser</surname><given-names>K</given-names></name><name><surname>Effern</surname><given-names>M</given-names></name><etal/></person-group><article-title>Tissue-resident memory CD8+ T cells promote melanoma&#x02013;immune equilibrium in skin</article-title><source>Nature</source><year>2019</year><volume>565</volume><fpage>366</fpage><lpage>371</lpage><pub-id pub-id-type="doi">10.1038/s41586-018-0812-9</pub-id><pub-id pub-id-type="pmid">30598548</pub-id>
</element-citation><mixed-citation id="mc-CR238" publication-type="journal">Park SL, Buzzai A, Rautela J, Hor JL, Hochheiser K, Effern M, et al. Tissue-resident memory CD8+ T cells promote melanoma&#x02013;immune equilibrium in skin. Nature. 2019;565:366&#x02013;71.<pub-id pub-id-type="pmid">30598548</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR239"><label>239.</label><citation-alternatives><element-citation id="ec-CR239" publication-type="journal"><person-group person-group-type="author"><name><surname>Rosenblum</surname><given-names>MD</given-names></name><name><surname>Olasz</surname><given-names>EB</given-names></name><name><surname>Yancey</surname><given-names>KB</given-names></name><name><surname>Woodliff</surname><given-names>JE</given-names></name><name><surname>Lazarova</surname><given-names>Z</given-names></name><name><surname>Gerber</surname><given-names>KA</given-names></name><etal/></person-group><article-title>Expression of CD200 on epithelial cells of the murine hair follicle: a role in tissue-specific immune tolerance?</article-title><source>J Invest Dermatol</source><year>2004</year><volume>123</volume><fpage>880</fpage><lpage>887</lpage><pub-id pub-id-type="doi">10.1111/j.0022-202X.2004.23461.x</pub-id><pub-id pub-id-type="pmid">15482475</pub-id>
</element-citation><mixed-citation id="mc-CR239" publication-type="journal">Rosenblum MD, Olasz EB, Yancey KB, Woodliff JE, Lazarova Z, Gerber KA, et al. Expression of CD200 on epithelial cells of the murine hair follicle: a role in tissue-specific immune tolerance? J Invest Dermatol. 2004;123:880&#x02013;7.<pub-id pub-id-type="pmid">15482475</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR240"><label>240.</label><citation-alternatives><element-citation id="ec-CR240" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>ECE</given-names></name><name><surname>Dai</surname><given-names>Z</given-names></name><name><surname>Ferrante</surname><given-names>AW</given-names></name><name><surname>Drake</surname><given-names>CG</given-names></name><name><surname>Christiano</surname><given-names>AM</given-names></name></person-group><article-title>A subset of TREM2(+) dermal macrophages secretes Oncostatin M to maintain hair follicle stem cell quiescence and inhibit hair growth</article-title><source>Cell Stem Cell</source><year>2019</year><volume>24</volume><fpage>654</fpage><lpage>669.e6</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2019.01.011</pub-id><pub-id pub-id-type="pmid">30930146</pub-id>
</element-citation><mixed-citation id="mc-CR240" publication-type="journal">Wang ECE, Dai Z, Ferrante AW, Drake CG, Christiano AM. A subset of TREM2(+) dermal macrophages secretes Oncostatin M to maintain hair follicle stem cell quiescence and inhibit hair growth. Cell Stem Cell. 2019;24:654-669.e6.<pub-id pub-id-type="pmid">30930146</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR241"><label>241.</label><citation-alternatives><element-citation id="ec-CR241" publication-type="journal"><person-group person-group-type="author"><name><surname>Passarelli</surname><given-names>A</given-names></name><name><surname>Mannavola</surname><given-names>F</given-names></name><name><surname>Stucci</surname><given-names>LS</given-names></name><name><surname>Tucci</surname><given-names>M</given-names></name><name><surname>Silvestris</surname><given-names>F</given-names></name></person-group><article-title>Immune system and melanoma biology: a balance between immunosurveillance and immune escape</article-title><source>Oncotarget</source><year>2017</year><volume>8</volume><fpage>106132</fpage><lpage>106142</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.22190</pub-id><pub-id pub-id-type="pmid">29285320</pub-id>
</element-citation><mixed-citation id="mc-CR241" publication-type="journal">Passarelli A, Mannavola F, Stucci LS, Tucci M, Silvestris F. Immune system and melanoma biology: a balance between immunosurveillance and immune escape. Oncotarget. 2017;8:106132&#x02013;42.<pub-id pub-id-type="pmid">29285320</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR242"><label>242.</label><citation-alternatives><element-citation id="ec-CR242" publication-type="journal"><person-group person-group-type="author"><name><surname>Benboubker</surname><given-names>V</given-names></name><name><surname>Boivin</surname><given-names>F</given-names></name><name><surname>Dalle</surname><given-names>S</given-names></name><name><surname>Caramel</surname><given-names>J</given-names></name></person-group><article-title>Cancer cell phenotype plasticity as a driver of immune escape in melanoma</article-title><source>Front Immunol</source><year>2022</year><volume>13</volume><fpage>873116</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2022.873116</pub-id><pub-id pub-id-type="pmid">35432344</pub-id>
</element-citation><mixed-citation id="mc-CR242" publication-type="journal">Benboubker V, Boivin F, Dalle S, Caramel J. Cancer cell phenotype plasticity as a driver of immune escape in melanoma. Front Immunol. 2022;13: 873116.<pub-id pub-id-type="pmid">35432344</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR243"><label>243.</label><citation-alternatives><element-citation id="ec-CR243" publication-type="journal"><person-group person-group-type="author"><name><surname>Habib</surname><given-names>S</given-names></name><name><surname>Osborn</surname><given-names>G</given-names></name><name><surname>Willsmore</surname><given-names>Z</given-names></name><name><surname>Chew</surname><given-names>MW</given-names></name><name><surname>Jakubow</surname><given-names>S</given-names></name><name><surname>Fitzpatrick</surname><given-names>A</given-names></name><etal/></person-group><article-title>Tumor associated macrophages as key contributors and targets in current and future therapies for melanoma</article-title><source>Expert Rev Clin Immunol</source><year>2024</year><volume>20</volume><fpage>895</fpage><lpage>911</lpage><pub-id pub-id-type="doi">10.1080/1744666X.2024.2326626</pub-id><pub-id pub-id-type="pmid">38533720</pub-id>
</element-citation><mixed-citation id="mc-CR243" publication-type="journal">Habib S, Osborn G, Willsmore Z, Chew MW, Jakubow S, Fitzpatrick A, et al. Tumor associated macrophages as key contributors and targets in current and future therapies for melanoma. Expert Rev Clin Immunol. 2024;20:895&#x02013;911.<pub-id pub-id-type="pmid">38533720</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR244"><label>244.</label><citation-alternatives><element-citation id="ec-CR244" publication-type="journal"><person-group person-group-type="author"><name><surname>Saeidi</surname><given-names>V</given-names></name><name><surname>Doudican</surname><given-names>N</given-names></name><name><surname>Carucci</surname><given-names>JA</given-names></name></person-group><article-title>Understanding the squamous cell carcinoma immune microenvironment</article-title><source>Front Immunol</source><year>2023</year><volume>14</volume><fpage>1084873</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2023.1084873</pub-id><pub-id pub-id-type="pmid">36793738</pub-id>
</element-citation><mixed-citation id="mc-CR244" publication-type="journal">Saeidi V, Doudican N, Carucci JA. Understanding the squamous cell carcinoma immune microenvironment. Front Immunol. 2023;14:1084873.<pub-id pub-id-type="pmid">36793738</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR245"><label>245.</label><citation-alternatives><element-citation id="ec-CR245" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Wan</surname><given-names>Q</given-names></name><name><surname>Jin</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>Cheng</surname><given-names>Y</given-names></name><etal/></person-group><article-title>The integrative analysis identifies three cancer subtypes and stemness features in cutaneous melanoma</article-title><source>Front Mol Biosci</source><year>2020</year><volume>7</volume><fpage>598725</fpage><pub-id pub-id-type="doi">10.3389/fmolb.2020.598725</pub-id><pub-id pub-id-type="pmid">33665205</pub-id>
</element-citation><mixed-citation id="mc-CR245" publication-type="journal">Wang X, Wan Q, Jin L, Liu C, Liu C, Cheng Y, et al. The integrative analysis identifies three cancer subtypes and stemness features in cutaneous melanoma. Front Mol Biosci. 2020;7: 598725.<pub-id pub-id-type="pmid">33665205</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR246"><label>246.</label><citation-alternatives><element-citation id="ec-CR246" publication-type="journal"><person-group person-group-type="author"><name><surname>Moussai</surname><given-names>D</given-names></name><name><surname>Mitsui</surname><given-names>H</given-names></name><name><surname>Pettersen</surname><given-names>JS</given-names></name><name><surname>Pierson</surname><given-names>KC</given-names></name><name><surname>Shah</surname><given-names>KR</given-names></name><name><surname>Su&#x000e1;rez-Farinas</surname><given-names>M</given-names></name><etal/></person-group><article-title>The human cutaneous squamous cell carcinoma microenvironment is characterized by increased lymphatic density and enhanced expression of macrophage-derived VEGF-C</article-title><source>J Invest Dermatol</source><year>2011</year><volume>131</volume><fpage>229</fpage><lpage>236</lpage><pub-id pub-id-type="doi">10.1038/jid.2010.266</pub-id><pub-id pub-id-type="pmid">20827282</pub-id>
</element-citation><mixed-citation id="mc-CR246" publication-type="journal">Moussai D, Mitsui H, Pettersen JS, Pierson KC, Shah KR, Su&#x000e1;rez-Farinas M, et al. The human cutaneous squamous cell carcinoma microenvironment is characterized by increased lymphatic density and enhanced expression of macrophage-derived VEGF-C. J Invest Dermatol. 2011;131:229&#x02013;36.<pub-id pub-id-type="pmid">20827282</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR247"><label>247.</label><citation-alternatives><element-citation id="ec-CR247" publication-type="journal"><person-group person-group-type="author"><name><surname>Migden</surname><given-names>MR</given-names></name><name><surname>Rischin</surname><given-names>D</given-names></name><name><surname>Schmults</surname><given-names>CD</given-names></name><name><surname>Guminski</surname><given-names>A</given-names></name><name><surname>Hauschild</surname><given-names>A</given-names></name><name><surname>Lewis</surname><given-names>KD</given-names></name><etal/></person-group><article-title>PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma</article-title><source>N Engl J Med</source><year>2018</year><volume>379</volume><fpage>341</fpage><lpage>351</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1805131</pub-id><pub-id pub-id-type="pmid">29863979</pub-id>
</element-citation><mixed-citation id="mc-CR247" publication-type="journal">Migden MR, Rischin D, Schmults CD, Guminski A, Hauschild A, Lewis KD, et al. PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma. N Engl J Med. 2018;379:341&#x02013;51.<pub-id pub-id-type="pmid">29863979</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR248"><label>248.</label><citation-alternatives><element-citation id="ec-CR248" publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>DS</given-names></name><name><surname>Mellman</surname><given-names>I</given-names></name></person-group><article-title>Oncology meets immunology: the cancer-immunity cycle</article-title><source>Immunity</source><year>2013</year><volume>39</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2013.07.012</pub-id><pub-id pub-id-type="pmid">23890059</pub-id>
</element-citation><mixed-citation id="mc-CR248" publication-type="journal">Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39:1&#x02013;10.<pub-id pub-id-type="pmid">23890059</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR249"><label>249.</label><citation-alternatives><element-citation id="ec-CR249" publication-type="journal"><person-group person-group-type="author"><name><surname>Schatton</surname><given-names>T</given-names></name><name><surname>Sch&#x000fc;tte</surname><given-names>U</given-names></name><name><surname>Frank</surname><given-names>NY</given-names></name><name><surname>Zhan</surname><given-names>Q</given-names></name><name><surname>Hoerning</surname><given-names>A</given-names></name><name><surname>Robles</surname><given-names>SC</given-names></name><etal/></person-group><article-title>Modulation of T-cell activation by malignant melanoma initiating cells</article-title><source>Cancer Res</source><year>2010</year><volume>70</volume><fpage>697</fpage><lpage>708</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-09-1592</pub-id><pub-id pub-id-type="pmid">20068175</pub-id>
</element-citation><mixed-citation id="mc-CR249" publication-type="journal">Schatton T, Sch&#x000fc;tte U, Frank NY, Zhan Q, Hoerning A, Robles SC, et al. Modulation of T-cell activation by malignant melanoma initiating cells. Cancer Res. 2010;70:697&#x02013;708.<pub-id pub-id-type="pmid">20068175</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR250"><label>250.</label><citation-alternatives><element-citation id="ec-CR250" publication-type="journal"><person-group person-group-type="author"><name><surname>Reynolds</surname><given-names>SR</given-names></name><name><surname>Celis</surname><given-names>E</given-names></name><name><surname>Sette</surname><given-names>A</given-names></name><name><surname>Oratz</surname><given-names>R</given-names></name><name><surname>Shapiro</surname><given-names>RL</given-names></name><name><surname>Johnston</surname><given-names>D</given-names></name><etal/></person-group><article-title>HLA-independent heterogeneity of CD8+ T cell responses to MAGE-3, Melan-A/MART-1, gp100, tyrosinase, MC1R, and TRP-2 in vaccine-treated melanoma patients</article-title><source>J Immunol</source><year>1998</year><volume>161</volume><fpage>6970</fpage><lpage>6976</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.161.12.6970</pub-id><pub-id pub-id-type="pmid">9862732</pub-id>
</element-citation><mixed-citation id="mc-CR250" publication-type="journal">Reynolds SR, Celis E, Sette A, Oratz R, Shapiro RL, Johnston D, et al. HLA-independent heterogeneity of CD8+ T cell responses to MAGE-3, Melan-A/MART-1, gp100, tyrosinase, MC1R, and TRP-2 in vaccine-treated melanoma patients. J Immunol. 1998;161:6970&#x02013;6.<pub-id pub-id-type="pmid">9862732</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR251"><label>251.</label><citation-alternatives><element-citation id="ec-CR251" publication-type="journal"><person-group person-group-type="author"><name><surname>Gedye</surname><given-names>C</given-names></name><name><surname>Quirk</surname><given-names>J</given-names></name><name><surname>Browning</surname><given-names>J</given-names></name><name><surname>Svobodov&#x000e1;</surname><given-names>S</given-names></name><name><surname>John</surname><given-names>T</given-names></name><name><surname>Sluka</surname><given-names>P</given-names></name><etal/></person-group><article-title>Cancer/testis antigens can be immunological targets in clonogenic CD133+ melanoma cells</article-title><source>Cancer Immunol Immunother</source><year>2009</year><volume>58</volume><fpage>1635</fpage><lpage>1646</lpage><pub-id pub-id-type="doi">10.1007/s00262-009-0672-0</pub-id><pub-id pub-id-type="pmid">19221743</pub-id>
</element-citation><mixed-citation id="mc-CR251" publication-type="journal">Gedye C, Quirk J, Browning J, Svobodov&#x000e1; S, John T, Sluka P, et al. Cancer/testis antigens can be immunological targets in clonogenic CD133+ melanoma cells. Cancer Immunol Immunother. 2009;58:1635&#x02013;46.<pub-id pub-id-type="pmid">19221743</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR252"><label>252.</label><citation-alternatives><element-citation id="ec-CR252" publication-type="journal"><person-group person-group-type="author"><name><surname>Boiko</surname><given-names>AD</given-names></name><name><surname>Razorenova</surname><given-names>OV</given-names></name><name><surname>van de Rijn</surname><given-names>M</given-names></name><name><surname>Swetter</surname><given-names>SM</given-names></name><name><surname>Johnson</surname><given-names>DL</given-names></name><name><surname>Ly</surname><given-names>DP</given-names></name><etal/></person-group><article-title>Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271</article-title><source>Nature</source><year>2010</year><volume>466</volume><fpage>133</fpage><lpage>137</lpage><pub-id pub-id-type="doi">10.1038/nature09161</pub-id><pub-id pub-id-type="pmid">20596026</pub-id>
</element-citation><mixed-citation id="mc-CR252" publication-type="journal">Boiko AD, Razorenova OV, van de Rijn M, Swetter SM, Johnson DL, Ly DP, et al. Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271. Nature. 2010;466:133&#x02013;7.<pub-id pub-id-type="pmid">20596026</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR253"><label>253.</label><citation-alternatives><element-citation id="ec-CR253" publication-type="journal"><person-group person-group-type="author"><name><surname>Schatton</surname><given-names>T</given-names></name><name><surname>Frank</surname><given-names>MH</given-names></name></person-group><article-title>Antitumor immunity and cancer stem cells</article-title><source>Ann N Y Acad Sci</source><year>2009</year><volume>1176</volume><fpage>154</fpage><lpage>169</lpage><pub-id pub-id-type="doi">10.1111/j.1749-6632.2009.04568.x</pub-id><pub-id pub-id-type="pmid">19796244</pub-id>
</element-citation><mixed-citation id="mc-CR253" publication-type="journal">Schatton T, Frank MH. Antitumor immunity and cancer stem cells. Ann N Y Acad Sci. 2009;1176:154&#x02013;69.<pub-id pub-id-type="pmid">19796244</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR254"><label>254.</label><citation-alternatives><element-citation id="ec-CR254" publication-type="journal"><person-group person-group-type="author"><name><surname>Landsberg</surname><given-names>J</given-names></name><name><surname>Kohlmeyer</surname><given-names>J</given-names></name><name><surname>Renn</surname><given-names>M</given-names></name><name><surname>Bald</surname><given-names>T</given-names></name><name><surname>Rogava</surname><given-names>M</given-names></name><name><surname>Cron</surname><given-names>M</given-names></name><etal/></person-group><article-title>Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation</article-title><source>Nature</source><year>2012</year><volume>490</volume><fpage>412</fpage><lpage>416</lpage><pub-id pub-id-type="doi">10.1038/nature11538</pub-id><pub-id pub-id-type="pmid">23051752</pub-id>
</element-citation><mixed-citation id="mc-CR254" publication-type="journal">Landsberg J, Kohlmeyer J, Renn M, Bald T, Rogava M, Cron M, et al. Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation. Nature. 2012;490:412&#x02013;6.<pub-id pub-id-type="pmid">23051752</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR255"><label>255.</label><citation-alternatives><element-citation id="ec-CR255" publication-type="journal"><person-group person-group-type="author"><name><surname>Mehta</surname><given-names>A</given-names></name><name><surname>Kim</surname><given-names>YJ</given-names></name><name><surname>Robert</surname><given-names>L</given-names></name><name><surname>Tsoi</surname><given-names>J</given-names></name><name><surname>Comin-Anduix</surname><given-names>B</given-names></name><name><surname>Berent-Maoz</surname><given-names>B</given-names></name><etal/></person-group><article-title>Immunotherapy resistance by inflammation-induced dedifferentiation</article-title><source>Cancer Discov</source><year>2018</year><volume>8</volume><fpage>935</fpage><lpage>943</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-17-1178</pub-id><pub-id pub-id-type="pmid">29899062</pub-id>
</element-citation><mixed-citation id="mc-CR255" publication-type="journal">Mehta A, Kim YJ, Robert L, Tsoi J, Comin-Anduix B, Berent-Maoz B, et al. Immunotherapy resistance by inflammation-induced dedifferentiation. Cancer Discov. 2018;8:935&#x02013;43.<pub-id pub-id-type="pmid">29899062</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR256"><label>256.</label><citation-alternatives><element-citation id="ec-CR256" publication-type="journal"><person-group person-group-type="author"><name><surname>Boshuizen</surname><given-names>J</given-names></name><name><surname>Vredevoogd</surname><given-names>DW</given-names></name><name><surname>Krijgsman</surname><given-names>O</given-names></name><name><surname>Ligtenberg</surname><given-names>MA</given-names></name><name><surname>Blankenstein</surname><given-names>S</given-names></name><name><surname>de Bruijn</surname><given-names>B</given-names></name><etal/></person-group><article-title>Reversal of pre-existing NGFR-driven tumor and immune therapy resistance</article-title><source>Nat Commun</source><year>2020</year><volume>11</volume><fpage>3946</fpage><pub-id pub-id-type="doi">10.1038/s41467-020-17739-8</pub-id><pub-id pub-id-type="pmid">32770055</pub-id>
</element-citation><mixed-citation id="mc-CR256" publication-type="journal">Boshuizen J, Vredevoogd DW, Krijgsman O, Ligtenberg MA, Blankenstein S, de Bruijn B, et al. Reversal of pre-existing NGFR-driven tumor and immune therapy resistance. Nat Commun. 2020;11:3946.<pub-id pub-id-type="pmid">32770055</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR257"><label>257.</label><citation-alternatives><element-citation id="ec-CR257" publication-type="journal"><person-group person-group-type="author"><name><surname>Greenwald</surname><given-names>RJ</given-names></name><name><surname>Freeman</surname><given-names>GJ</given-names></name><name><surname>Sharpe</surname><given-names>AH</given-names></name></person-group><article-title>The B7 family revisited</article-title><source>Annu Rev Immunol</source><year>2005</year><volume>23</volume><fpage>515</fpage><lpage>548</lpage><pub-id pub-id-type="doi">10.1146/annurev.immunol.23.021704.115611</pub-id><pub-id pub-id-type="pmid">15771580</pub-id>
</element-citation><mixed-citation id="mc-CR257" publication-type="journal">Greenwald RJ, Freeman GJ, Sharpe AH. The B7 family revisited. Annu Rev Immunol. 2005;23:515&#x02013;48.<pub-id pub-id-type="pmid">15771580</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR258"><label>258.</label><citation-alternatives><element-citation id="ec-CR258" publication-type="journal"><person-group person-group-type="author"><name><surname>Clarkson</surname><given-names>MR</given-names></name><name><surname>Sayegh</surname><given-names>MH</given-names></name></person-group><article-title>T-cell costimulatory pathways in allograft rejection and tolerance</article-title><source>Transplantation</source><year>2005</year><volume>80</volume><fpage>555</fpage><lpage>563</lpage><pub-id pub-id-type="doi">10.1097/01.tp.0000168432.60022.99</pub-id><pub-id pub-id-type="pmid">16177624</pub-id>
</element-citation><mixed-citation id="mc-CR258" publication-type="journal">Clarkson MR, Sayegh MH. T-cell costimulatory pathways in allograft rejection and tolerance. Transplantation. 2005;80:555&#x02013;63.<pub-id pub-id-type="pmid">16177624</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR259"><label>259.</label><citation-alternatives><element-citation id="ec-CR259" publication-type="journal"><person-group person-group-type="author"><name><surname>Lai</surname><given-names>C</given-names></name><name><surname>August</surname><given-names>S</given-names></name><name><surname>Albibas</surname><given-names>A</given-names></name><name><surname>Behar</surname><given-names>R</given-names></name><name><surname>Cho</surname><given-names>SY</given-names></name><name><surname>Polak</surname><given-names>ME</given-names></name><etal/></person-group><article-title>OX40+ regulatory T cells in cutaneous squamous cell carcinoma suppress effector T cell responses and associate with metastatic potential</article-title><source>Clin Cancer Res</source><year>2016</year><volume>22</volume><fpage>4236</fpage><lpage>4248</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-15-2614</pub-id><pub-id pub-id-type="pmid">27034329</pub-id>
</element-citation><mixed-citation id="mc-CR259" publication-type="journal">Lai C, August S, Albibas A, Behar R, Cho SY, Polak ME, et al. OX40+ regulatory T cells in cutaneous squamous cell carcinoma suppress effector T cell responses and associate with metastatic potential. Clin Cancer Res. 2016;22:4236&#x02013;48.<pub-id pub-id-type="pmid">27034329</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR260"><label>260.</label><citation-alternatives><element-citation id="ec-CR260" publication-type="journal"><person-group person-group-type="author"><name><surname>Kosmidis</surname><given-names>M</given-names></name><name><surname>Dziunycz</surname><given-names>P</given-names></name><name><surname>Su&#x000e1;rez-Fari&#x000f1;as</surname><given-names>M</given-names></name><name><surname>M&#x000fc;hleisen</surname><given-names>B</given-names></name><name><surname>Sch&#x000e4;rer</surname><given-names>L</given-names></name><name><surname>L&#x000e4;uchli</surname><given-names>S</given-names></name><etal/></person-group><article-title>Immunosuppression affects CD4+ mRNA expression and induces Th2 dominance in the microenvironment of cutaneous squamous cell carcinoma in organ transplant recipients</article-title><source>J Immunother</source><year>2010</year><volume>33</volume><fpage>538</fpage><lpage>546</lpage><pub-id pub-id-type="doi">10.1097/CJI.0b013e3181cc2615</pub-id><pub-id pub-id-type="pmid">20463594</pub-id>
</element-citation><mixed-citation id="mc-CR260" publication-type="journal">Kosmidis M, Dziunycz P, Su&#x000e1;rez-Fari&#x000f1;as M, M&#x000fc;hleisen B, Sch&#x000e4;rer L, L&#x000e4;uchli S, et al. Immunosuppression affects CD4+ mRNA expression and induces Th2 dominance in the microenvironment of cutaneous squamous cell carcinoma in organ transplant recipients. J Immunother. 2010;33:538&#x02013;46.<pub-id pub-id-type="pmid">20463594</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR261"><label>261.</label><citation-alternatives><element-citation id="ec-CR261" publication-type="journal"><person-group person-group-type="author"><name><surname>Miao</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>H</given-names></name><name><surname>Levorse</surname><given-names>J</given-names></name><name><surname>Yuan</surname><given-names>S</given-names></name><name><surname>Polak</surname><given-names>L</given-names></name><name><surname>Sribour</surname><given-names>M</given-names></name><etal/></person-group><article-title>Adaptive immune resistance emerges from tumor-initiating stem cells</article-title><source>Cell</source><year>2019</year><volume>177</volume><fpage>1172</fpage><lpage>1186.e14</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2019.03.025</pub-id><pub-id pub-id-type="pmid">31031009</pub-id>
</element-citation><mixed-citation id="mc-CR261" publication-type="journal">Miao Y, Yang H, Levorse J, Yuan S, Polak L, Sribour M, et al. Adaptive immune resistance emerges from tumor-initiating stem cells. Cell. 2019;177:1172-1186.e14.<pub-id pub-id-type="pmid">31031009</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR262"><label>262.</label><citation-alternatives><element-citation id="ec-CR262" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Fujita</surname><given-names>H</given-names></name><name><surname>Mitsui</surname><given-names>H</given-names></name><name><surname>Yanofsky</surname><given-names>VR</given-names></name><name><surname>Fuentes-Duculan</surname><given-names>J</given-names></name><name><surname>Pettersen</surname><given-names>JS</given-names></name><etal/></person-group><article-title>Increased Tc22 and Treg/CD8 ratio contribute to aggressive growth of transplant associated squamous cell carcinoma</article-title><source>PLoS ONE</source><year>2013</year><volume>8</volume><fpage>e62154</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0062154</pub-id><pub-id pub-id-type="pmid">23667456</pub-id>
</element-citation><mixed-citation id="mc-CR262" publication-type="journal">Zhang S, Fujita H, Mitsui H, Yanofsky VR, Fuentes-Duculan J, Pettersen JS, et al. Increased Tc22 and Treg/CD8 ratio contribute to aggressive growth of transplant associated squamous cell carcinoma. PLoS ONE. 2013;8: e62154.<pub-id pub-id-type="pmid">23667456</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR263"><label>263.</label><citation-alternatives><element-citation id="ec-CR263" publication-type="journal"><person-group person-group-type="author"><name><surname>Frazzette</surname><given-names>N</given-names></name><name><surname>Khodadadi-Jamayran</surname><given-names>A</given-names></name><name><surname>Doudican</surname><given-names>N</given-names></name><name><surname>Santana</surname><given-names>A</given-names></name><name><surname>Felsen</surname><given-names>D</given-names></name><name><surname>Pavlick</surname><given-names>AC</given-names></name><etal/></person-group><article-title>Decreased cytotoxic T cells and TCR clonality in organ transplant recipients with squamous cell carcinoma</article-title><source>NPJ Precis Onc</source><year>2020</year><volume>4</volume><fpage>13</fpage><pub-id pub-id-type="doi">10.1038/s41698-020-0119-9</pub-id></element-citation><mixed-citation id="mc-CR263" publication-type="journal">Frazzette N, Khodadadi-Jamayran A, Doudican N, Santana A, Felsen D, Pavlick AC, et al. Decreased cytotoxic T cells and TCR clonality in organ transplant recipients with squamous cell carcinoma. NPJ Precis Onc. 2020;4:13.</mixed-citation></citation-alternatives></ref><ref id="CR264"><label>264.</label><citation-alternatives><element-citation id="ec-CR264" publication-type="journal"><person-group person-group-type="author"><name><surname>Clark</surname><given-names>RA</given-names></name><name><surname>Huang</surname><given-names>SJ</given-names></name><name><surname>Murphy</surname><given-names>GF</given-names></name><name><surname>Mollet</surname><given-names>IG</given-names></name><name><surname>Hijnen</surname><given-names>D</given-names></name><name><surname>Muthukuru</surname><given-names>M</given-names></name><etal/></person-group><article-title>Human squamous cell carcinomas evade the immune response by down-regulation of vascular E-selectin and recruitment of regulatory T cells</article-title><source>J Exp Med</source><year>2008</year><volume>205</volume><fpage>2221</fpage><lpage>2234</lpage><pub-id pub-id-type="doi">10.1084/jem.20071190</pub-id><pub-id pub-id-type="pmid">18794336</pub-id>
</element-citation><mixed-citation id="mc-CR264" publication-type="journal">Clark RA, Huang SJ, Murphy GF, Mollet IG, Hijnen D, Muthukuru M, et al. Human squamous cell carcinomas evade the immune response by down-regulation of vascular E-selectin and recruitment of regulatory T cells. J Exp Med. 2008;205:2221&#x02013;34.<pub-id pub-id-type="pmid">18794336</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR265"><label>265.</label><citation-alternatives><element-citation id="ec-CR265" publication-type="journal"><person-group person-group-type="author"><name><surname>Kakizaki</surname><given-names>A</given-names></name><name><surname>Fujimura</surname><given-names>T</given-names></name><name><surname>Furudate</surname><given-names>S</given-names></name><name><surname>Kambayashi</surname><given-names>Y</given-names></name><name><surname>Yamauchi</surname><given-names>T</given-names></name><name><surname>Yagita</surname><given-names>H</given-names></name><etal/></person-group><article-title>Immunomodulatory effect of peritumorally administered interferon-beta on melanoma through tumor-associated macrophages</article-title><source>Oncoimmunology</source><year>2015</year><volume>4</volume><fpage>e1047584</fpage><pub-id pub-id-type="doi">10.1080/2162402X.2015.1047584</pub-id><pub-id pub-id-type="pmid">26451326</pub-id>
</element-citation><mixed-citation id="mc-CR265" publication-type="journal">Kakizaki A, Fujimura T, Furudate S, Kambayashi Y, Yamauchi T, Yagita H, et al. Immunomodulatory effect of peritumorally administered interferon-beta on melanoma through tumor-associated macrophages. Oncoimmunology. 2015;4: e1047584.<pub-id pub-id-type="pmid">26451326</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR266"><label>266.</label><citation-alternatives><element-citation id="ec-CR266" publication-type="journal"><person-group person-group-type="author"><name><surname>Pettersen</surname><given-names>JS</given-names></name><name><surname>Fuentes-Duculan</surname><given-names>J</given-names></name><name><surname>Su&#x000e1;rez-Fari&#x000f1;as</surname><given-names>M</given-names></name><name><surname>Pierson</surname><given-names>KC</given-names></name><name><surname>Pitts-Kiefer</surname><given-names>A</given-names></name><name><surname>Fan</surname><given-names>L</given-names></name><etal/></person-group><article-title>Tumor-associated macrophages in the cutaneous SCC microenvironment are heterogeneously activated</article-title><source>J Invest Dermatol</source><year>2011</year><volume>131</volume><fpage>1322</fpage><lpage>1330</lpage><pub-id pub-id-type="doi">10.1038/jid.2011.9</pub-id><pub-id pub-id-type="pmid">21307877</pub-id>
</element-citation><mixed-citation id="mc-CR266" publication-type="journal">Pettersen JS, Fuentes-Duculan J, Su&#x000e1;rez-Fari&#x000f1;as M, Pierson KC, Pitts-Kiefer A, Fan L, et al. Tumor-associated macrophages in the cutaneous SCC microenvironment are heterogeneously activated. J Invest Dermatol. 2011;131:1322&#x02013;30.<pub-id pub-id-type="pmid">21307877</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR267"><label>267.</label><citation-alternatives><element-citation id="ec-CR267" publication-type="journal"><person-group person-group-type="author"><name><surname>Kambayashi</surname><given-names>Y</given-names></name><name><surname>Fujimura</surname><given-names>T</given-names></name><name><surname>Aiba</surname><given-names>S</given-names></name></person-group><article-title>Comparison of immunosuppressive and immunomodulatory cells in keratoacanthoma and cutaneous squamous cell carcinoma</article-title><source>Acta Derm Venereol</source><year>2013</year><volume>93</volume><fpage>663</fpage><lpage>668</lpage><pub-id pub-id-type="doi">10.2340/00015555-1597</pub-id><pub-id pub-id-type="pmid">23572151</pub-id>
</element-citation><mixed-citation id="mc-CR267" publication-type="journal">Kambayashi Y, Fujimura T, Aiba S. Comparison of immunosuppressive and immunomodulatory cells in keratoacanthoma and cutaneous squamous cell carcinoma. Acta Derm Venereol. 2013;93:663&#x02013;8.<pub-id pub-id-type="pmid">23572151</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR268"><label>268.</label><citation-alternatives><element-citation id="ec-CR268" publication-type="journal"><person-group person-group-type="author"><name><surname>Tjiu</surname><given-names>J-W</given-names></name><name><surname>Chen</surname><given-names>J-S</given-names></name><name><surname>Shun</surname><given-names>C-T</given-names></name><name><surname>Lin</surname><given-names>S-J</given-names></name><name><surname>Liao</surname><given-names>Y-H</given-names></name><name><surname>Chu</surname><given-names>C-Y</given-names></name><etal/></person-group><article-title>Tumor-associated macrophage-induced invasion and angiogenesis of human basal cell carcinoma cells by cyclooxygenase-2 induction</article-title><source>J Invest Dermatol</source><year>2009</year><volume>129</volume><fpage>1016</fpage><lpage>1025</lpage><pub-id pub-id-type="doi">10.1038/jid.2008.310</pub-id><pub-id pub-id-type="pmid">18843292</pub-id>
</element-citation><mixed-citation id="mc-CR268" publication-type="journal">Tjiu J-W, Chen J-S, Shun C-T, Lin S-J, Liao Y-H, Chu C-Y, et al. Tumor-associated macrophage-induced invasion and angiogenesis of human basal cell carcinoma cells by cyclooxygenase-2 induction. J Invest Dermatol. 2009;129:1016&#x02013;25.<pub-id pub-id-type="pmid">18843292</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR269"><label>269.</label><citation-alternatives><element-citation id="ec-CR269" publication-type="journal"><person-group person-group-type="author"><name><surname>Fujimura</surname><given-names>T</given-names></name><name><surname>Kakizaki</surname><given-names>A</given-names></name><name><surname>Furudate</surname><given-names>S</given-names></name><name><surname>Kambayashi</surname><given-names>Y</given-names></name><name><surname>Aiba</surname><given-names>S</given-names></name></person-group><article-title>Tumor-associated macrophages in skin: How to treat their heterogeneity and plasticity</article-title><source>J Dermatol Sci</source><year>2016</year><volume>83</volume><fpage>167</fpage><lpage>173</lpage><pub-id pub-id-type="doi">10.1016/j.jdermsci.2016.05.015</pub-id><pub-id pub-id-type="pmid">27291068</pub-id>
</element-citation><mixed-citation id="mc-CR269" publication-type="journal">Fujimura T, Kakizaki A, Furudate S, Kambayashi Y, Aiba S. Tumor-associated macrophages in skin: How to treat their heterogeneity and plasticity. J Dermatol Sci. 2016;83:167&#x02013;73.<pub-id pub-id-type="pmid">27291068</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR270"><label>270.</label><citation-alternatives><element-citation id="ec-CR270" publication-type="journal"><person-group person-group-type="author"><name><surname>Yamada</surname><given-names>K</given-names></name><name><surname>Uchiyama</surname><given-names>A</given-names></name><name><surname>Uehara</surname><given-names>A</given-names></name><name><surname>Perera</surname><given-names>B</given-names></name><name><surname>Ogino</surname><given-names>S</given-names></name><name><surname>Yokoyama</surname><given-names>Y</given-names></name><etal/></person-group><article-title>MFG-E8 drives melanoma growth by stimulating mesenchymal stromal cell-induced angiogenesis and M2 polarization of tumor-associated macrophages</article-title><source>Cancer Res</source><year>2016</year><volume>76</volume><fpage>4283</fpage><lpage>4292</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-15-2812</pub-id><pub-id pub-id-type="pmid">27197197</pub-id>
</element-citation><mixed-citation id="mc-CR270" publication-type="journal">Yamada K, Uchiyama A, Uehara A, Perera B, Ogino S, Yokoyama Y, et al. MFG-E8 drives melanoma growth by stimulating mesenchymal stromal cell-induced angiogenesis and M2 polarization of tumor-associated macrophages. Cancer Res. 2016;76:4283&#x02013;92.<pub-id pub-id-type="pmid">27197197</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR271"><label>271.</label><citation-alternatives><element-citation id="ec-CR271" publication-type="journal"><person-group person-group-type="author"><name><surname>Beksa&#x000e7;</surname><given-names>B</given-names></name><name><surname>&#x00130;lter</surname><given-names>N</given-names></name><name><surname>Erdem</surname><given-names>&#x000d6;</given-names></name><name><surname>&#x000c7;akmak</surname><given-names>P</given-names></name><name><surname>&#x000c7;eneto&#x0011f;lu</surname><given-names>S</given-names></name><name><surname>Yapar</surname><given-names>D</given-names></name></person-group><article-title>Sparsity of dendritic cells and cytotoxic T cells in tumor microenvironment may lead to recurrence in basal cell carcinoma</article-title><source>Int J Dermatol</source><year>2020</year><volume>59</volume><fpage>1258</fpage><lpage>1263</lpage><pub-id pub-id-type="doi">10.1111/ijd.15065</pub-id><pub-id pub-id-type="pmid">32686125</pub-id>
</element-citation><mixed-citation id="mc-CR271" publication-type="journal">Beksa&#x000e7; B, &#x00130;lter N, Erdem &#x000d6;, &#x000c7;akmak P, &#x000c7;eneto&#x0011f;lu S, Yapar D. Sparsity of dendritic cells and cytotoxic T cells in tumor microenvironment may lead to recurrence in basal cell carcinoma. Int J Dermatol. 2020;59:1258&#x02013;63.<pub-id pub-id-type="pmid">32686125</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR272"><label>272.</label><citation-alternatives><element-citation id="ec-CR272" publication-type="journal"><person-group person-group-type="author"><name><surname>Linde</surname><given-names>N</given-names></name><name><surname>Lederle</surname><given-names>W</given-names></name><name><surname>Depner</surname><given-names>S</given-names></name><name><surname>van Rooijen</surname><given-names>N</given-names></name><name><surname>Gutschalk</surname><given-names>CM</given-names></name><name><surname>Mueller</surname><given-names>MM</given-names></name></person-group><article-title>Vascular endothelial growth factor-induced skin carcinogenesis depends on recruitment and alternative activation of macrophages</article-title><source>J Pathol</source><year>2012</year><volume>227</volume><fpage>17</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1002/path.3989</pub-id><pub-id pub-id-type="pmid">22262122</pub-id>
</element-citation><mixed-citation id="mc-CR272" publication-type="journal">Linde N, Lederle W, Depner S, van Rooijen N, Gutschalk CM, Mueller MM. Vascular endothelial growth factor-induced skin carcinogenesis depends on recruitment and alternative activation of macrophages. J Pathol. 2012;227:17&#x02013;28.<pub-id pub-id-type="pmid">22262122</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR273"><label>273.</label><citation-alternatives><element-citation id="ec-CR273" publication-type="journal"><person-group person-group-type="author"><name><surname>Falleni</surname><given-names>M</given-names></name><name><surname>Savi</surname><given-names>F</given-names></name><name><surname>Tosi</surname><given-names>D</given-names></name><name><surname>Agape</surname><given-names>E</given-names></name><name><surname>Cerri</surname><given-names>A</given-names></name><name><surname>Moneghini</surname><given-names>L</given-names></name><etal/></person-group><article-title>M1 and M2 macrophages&#x02019; clinicopathological significance in cutaneous melanoma</article-title><source>Melanoma Res</source><year>2017</year><volume>27</volume><fpage>200</fpage><lpage>210</lpage><pub-id pub-id-type="doi">10.1097/CMR.0000000000000352</pub-id><pub-id pub-id-type="pmid">28272106</pub-id>
</element-citation><mixed-citation id="mc-CR273" publication-type="journal">Falleni M, Savi F, Tosi D, Agape E, Cerri A, Moneghini L, et al. M1 and M2 macrophages&#x02019; clinicopathological significance in cutaneous melanoma. Melanoma Res. 2017;27:200&#x02013;10.<pub-id pub-id-type="pmid">28272106</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR274"><label>274.</label><citation-alternatives><element-citation id="ec-CR274" publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>N</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Yin</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><etal/></person-group><article-title>Inhibition of xCT suppresses the efficacy of anti-PD-1/L1 melanoma treatment through exosomal PD-L1-induced macrophage M2 polarization</article-title><source>Mol Ther</source><year>2021</year><volume>29</volume><fpage>2321</fpage><lpage>2334</lpage><pub-id pub-id-type="doi">10.1016/j.ymthe.2021.03.013</pub-id><pub-id pub-id-type="pmid">33744468</pub-id>
</element-citation><mixed-citation id="mc-CR274" publication-type="journal">Liu N, Zhang J, Yin M, Liu H, Zhang X, Li J, et al. Inhibition of xCT suppresses the efficacy of anti-PD-1/L1 melanoma treatment through exosomal PD-L1-induced macrophage M2 polarization. Mol Ther. 2021;29:2321&#x02013;34.<pub-id pub-id-type="pmid">33744468</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR275"><label>275.</label><citation-alternatives><element-citation id="ec-CR275" publication-type="journal"><person-group person-group-type="author"><name><surname>Kale</surname><given-names>S</given-names></name><name><surname>Raja</surname><given-names>R</given-names></name><name><surname>Thorat</surname><given-names>D</given-names></name><name><surname>Soundararajan</surname><given-names>G</given-names></name><name><surname>Patil</surname><given-names>TV</given-names></name><name><surname>Kundu</surname><given-names>GC</given-names></name></person-group><article-title>Osteopontin signaling upregulates cyclooxygenase-2 expression in tumor-associated macrophages leading to enhanced angiogenesis and melanoma growth via &#x003b1;9&#x003b2;1 integrin</article-title><source>Oncogene</source><year>2014</year><volume>33</volume><fpage>2295</fpage><lpage>2306</lpage><pub-id pub-id-type="doi">10.1038/onc.2013.184</pub-id><pub-id pub-id-type="pmid">23728342</pub-id>
</element-citation><mixed-citation id="mc-CR275" publication-type="journal">Kale S, Raja R, Thorat D, Soundararajan G, Patil TV, Kundu GC. Osteopontin signaling upregulates cyclooxygenase-2 expression in tumor-associated macrophages leading to enhanced angiogenesis and melanoma growth via &#x003b1;9&#x003b2;1 integrin. Oncogene. 2014;33:2295&#x02013;306.<pub-id pub-id-type="pmid">23728342</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR276"><label>276.</label><citation-alternatives><element-citation id="ec-CR276" publication-type="journal"><person-group person-group-type="author"><name><surname>Gehrke</surname><given-names>S</given-names></name><name><surname>Otsuka</surname><given-names>A</given-names></name><name><surname>Huber</surname><given-names>R</given-names></name><name><surname>Meier</surname><given-names>B</given-names></name><name><surname>Kistowska</surname><given-names>M</given-names></name><name><surname>Fenini</surname><given-names>G</given-names></name><etal/></person-group><article-title>Metastatic melanoma cell lines do not secrete IL-1&#x003b2; but promote IL-1&#x003b2; production from macrophages</article-title><source>J Dermatol Sci</source><year>2014</year><volume>74</volume><fpage>167</fpage><lpage>169</lpage><pub-id pub-id-type="doi">10.1016/j.jdermsci.2014.01.006</pub-id><pub-id pub-id-type="pmid">24581590</pub-id>
</element-citation><mixed-citation id="mc-CR276" publication-type="journal">Gehrke S, Otsuka A, Huber R, Meier B, Kistowska M, Fenini G, et al. Metastatic melanoma cell lines do not secrete IL-1&#x003b2; but promote IL-1&#x003b2; production from macrophages. J Dermatol Sci. 2014;74:167&#x02013;9.<pub-id pub-id-type="pmid">24581590</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR277"><label>277.</label><citation-alternatives><element-citation id="ec-CR277" publication-type="journal"><person-group person-group-type="author"><name><surname>Sevko</surname><given-names>A</given-names></name><name><surname>Michels</surname><given-names>T</given-names></name><name><surname>Vrohlings</surname><given-names>M</given-names></name><name><surname>Umansky</surname><given-names>L</given-names></name><name><surname>Beckhove</surname><given-names>P</given-names></name><name><surname>Kato</surname><given-names>M</given-names></name><etal/></person-group><article-title>Antitumor effect of paclitaxel is mediated by inhibition of myeloid-derived suppressor cells and chronic inflammation in the spontaneous melanoma model</article-title><source>J Immunol</source><year>2013</year><volume>190</volume><fpage>2464</fpage><lpage>2471</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1202781</pub-id><pub-id pub-id-type="pmid">23359505</pub-id>
</element-citation><mixed-citation id="mc-CR277" publication-type="journal">Sevko A, Michels T, Vrohlings M, Umansky L, Beckhove P, Kato M, et al. Antitumor effect of paclitaxel is mediated by inhibition of myeloid-derived suppressor cells and chronic inflammation in the spontaneous melanoma model. J Immunol. 2013;190:2464&#x02013;71.<pub-id pub-id-type="pmid">23359505</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR278"><label>278.</label><citation-alternatives><element-citation id="ec-CR278" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name></person-group><article-title>Pro-tumor activities of macrophages in the progression of melanoma</article-title><source>Hum Vaccin Immunother</source><year>2017</year><volume>13</volume><fpage>1556</fpage><lpage>1562</lpage><pub-id pub-id-type="doi">10.1080/21645515.2017.1312043</pub-id><pub-id pub-id-type="pmid">28441072</pub-id>
</element-citation><mixed-citation id="mc-CR278" publication-type="journal">Wang H, Yang L, Wang D, Zhang Q, Zhang L. Pro-tumor activities of macrophages in the progression of melanoma. Hum Vaccin Immunother. 2017;13:1556&#x02013;62.<pub-id pub-id-type="pmid">28441072</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR279"><label>279.</label><citation-alternatives><element-citation id="ec-CR279" publication-type="journal"><person-group person-group-type="author"><name><surname>Furudate</surname><given-names>S</given-names></name><name><surname>Fujimura</surname><given-names>T</given-names></name><name><surname>Kambayashi</surname><given-names>Y</given-names></name><name><surname>Kakizaki</surname><given-names>A</given-names></name><name><surname>Hidaka</surname><given-names>T</given-names></name><name><surname>Aiba</surname><given-names>S</given-names></name></person-group><article-title>Immunomodulatory effect of imiquimod through CCL22 produced by tumor-associated macrophages in B16F10 melanomas</article-title><source>Anticancer Res</source><year>2017</year><volume>37</volume><fpage>3461</fpage><lpage>3471</lpage><pub-id pub-id-type="pmid">28668835</pub-id>
</element-citation><mixed-citation id="mc-CR279" publication-type="journal">Furudate S, Fujimura T, Kambayashi Y, Kakizaki A, Hidaka T, Aiba S. Immunomodulatory effect of imiquimod through CCL22 produced by tumor-associated macrophages in B16F10 melanomas. Anticancer Res. 2017;37:3461&#x02013;71.<pub-id pub-id-type="pmid">28668835</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR280"><label>280.</label><citation-alternatives><element-citation id="ec-CR280" publication-type="journal"><person-group person-group-type="author"><name><surname>Guti&#x000e9;rrez-Seijo</surname><given-names>A</given-names></name><name><surname>Garc&#x000ed;a-Mart&#x000ed;nez</surname><given-names>E</given-names></name><name><surname>Barrio-Alonso</surname><given-names>C</given-names></name><name><surname>Pareja-Malag&#x000f3;n</surname><given-names>M</given-names></name><name><surname>Acosta-Ocampo</surname><given-names>A</given-names></name><name><surname>Fern&#x000e1;ndez-Santos</surname><given-names>ME</given-names></name><etal/></person-group><article-title>CCL20/TNF/VEGFA cytokine secretory phenotype of tumor-associated macrophages is a negative prognostic factor in cutaneous melanoma</article-title><source>Cancers</source><year>2021</year><volume>13</volume><fpage>3943</fpage><pub-id pub-id-type="doi">10.3390/cancers13163943</pub-id><pub-id pub-id-type="pmid">34439098</pub-id>
</element-citation><mixed-citation id="mc-CR280" publication-type="journal">Guti&#x000e9;rrez-Seijo A, Garc&#x000ed;a-Mart&#x000ed;nez E, Barrio-Alonso C, Pareja-Malag&#x000f3;n M, Acosta-Ocampo A, Fern&#x000e1;ndez-Santos ME, et al. CCL20/TNF/VEGFA cytokine secretory phenotype of tumor-associated macrophages is a negative prognostic factor in cutaneous melanoma. Cancers. 2021;13:3943.<pub-id pub-id-type="pmid">34439098</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR281"><label>281.</label><citation-alternatives><element-citation id="ec-CR281" publication-type="journal"><person-group person-group-type="author"><name><surname>Young</surname><given-names>HL</given-names></name><name><surname>Rowling</surname><given-names>EJ</given-names></name><name><surname>Bugatti</surname><given-names>M</given-names></name><name><surname>Giurisato</surname><given-names>E</given-names></name><name><surname>Luheshi</surname><given-names>N</given-names></name><name><surname>Arozarena</surname><given-names>I</given-names></name><etal/></person-group><article-title>An adaptive signaling network in melanoma inflammatory niches confers tolerance to MAPK signaling inhibition</article-title><source>J Exp Med</source><year>2017</year><volume>214</volume><fpage>1691</fpage><lpage>1710</lpage><pub-id pub-id-type="doi">10.1084/jem.20160855</pub-id><pub-id pub-id-type="pmid">28450382</pub-id>
</element-citation><mixed-citation id="mc-CR281" publication-type="journal">Young HL, Rowling EJ, Bugatti M, Giurisato E, Luheshi N, Arozarena I, et al. An adaptive signaling network in melanoma inflammatory niches confers tolerance to MAPK signaling inhibition. J Exp Med. 2017;214:1691&#x02013;710.<pub-id pub-id-type="pmid">28450382</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR282"><label>282.</label><citation-alternatives><element-citation id="ec-CR282" publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>V</given-names></name><name><surname>Donthireddy</surname><given-names>L</given-names></name><name><surname>Marvel</surname><given-names>D</given-names></name><name><surname>Condamine</surname><given-names>T</given-names></name><name><surname>Wang</surname><given-names>F</given-names></name><name><surname>Lavilla-Alonso</surname><given-names>S</given-names></name><etal/></person-group><article-title>Cancer-associated fibroblasts neutralize the anti-tumor effect of CSF1 receptor blockade by inducing PMN-MDSC infiltration of tumors</article-title><source>Cancer Cell</source><year>2017</year><volume>32</volume><fpage>654</fpage><lpage>668.e5</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2017.10.005</pub-id><pub-id pub-id-type="pmid">29136508</pub-id>
</element-citation><mixed-citation id="mc-CR282" publication-type="journal">Kumar V, Donthireddy L, Marvel D, Condamine T, Wang F, Lavilla-Alonso S, et al. Cancer-associated fibroblasts neutralize the anti-tumor effect of CSF1 receptor blockade by inducing PMN-MDSC infiltration of tumors. Cancer Cell. 2017;32:654-668.e5.<pub-id pub-id-type="pmid">29136508</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR283"><label>283.</label><mixed-citation publication-type="other">Hu-Lieskovan S, Mok S, Homet Moreno B, Tsoi J, Robert L, Goedert L, et al. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma<italic>.</italic> Sci Transl Med. 2015; 7:279ra41.</mixed-citation></ref><ref id="CR284"><label>284.</label><citation-alternatives><element-citation id="ec-CR284" publication-type="journal"><person-group person-group-type="author"><name><surname>Fujimura</surname><given-names>T</given-names></name><name><surname>Kambayashi</surname><given-names>Y</given-names></name><name><surname>Furudate</surname><given-names>S</given-names></name><name><surname>Kakizaki</surname><given-names>A</given-names></name><name><surname>Haga</surname><given-names>T</given-names></name><name><surname>Hashimoto</surname><given-names>A</given-names></name><etal/></person-group><article-title>Immunomodulatory effects of peplomycin on immunosuppressive and cytotoxic cells in the lesional skin of cutaneous squamous cell carcinoma</article-title><source>Dermatology</source><year>2015</year><volume>230</volume><fpage>250</fpage><lpage>255</lpage><pub-id pub-id-type="doi">10.1159/000369166</pub-id><pub-id pub-id-type="pmid">25678188</pub-id>
</element-citation><mixed-citation id="mc-CR284" publication-type="journal">Fujimura T, Kambayashi Y, Furudate S, Kakizaki A, Haga T, Hashimoto A, et al. Immunomodulatory effects of peplomycin on immunosuppressive and cytotoxic cells in the lesional skin of cutaneous squamous cell carcinoma. Dermatology. 2015;230:250&#x02013;5.<pub-id pub-id-type="pmid">25678188</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR285"><label>285.</label><citation-alternatives><element-citation id="ec-CR285" publication-type="journal"><person-group person-group-type="author"><name><surname>Tarhini</surname><given-names>AA</given-names></name><name><surname>Zahoor</surname><given-names>H</given-names></name><name><surname>Yearley</surname><given-names>JH</given-names></name><name><surname>Gibson</surname><given-names>C</given-names></name><name><surname>Rahman</surname><given-names>Z</given-names></name><name><surname>Dubner</surname><given-names>R</given-names></name><etal/></person-group><article-title>Tumor associated PD-L1 expression pattern in microscopically tumor positive sentinel lymph nodes in patients with melanoma</article-title><source>J Transl Med</source><year>2015</year><volume>13</volume><fpage>319</fpage><pub-id pub-id-type="doi">10.1186/s12967-015-0678-7</pub-id><pub-id pub-id-type="pmid">26419843</pub-id>
</element-citation><mixed-citation id="mc-CR285" publication-type="journal">Tarhini AA, Zahoor H, Yearley JH, Gibson C, Rahman Z, Dubner R, et al. Tumor associated PD-L1 expression pattern in microscopically tumor positive sentinel lymph nodes in patients with melanoma. J Transl Med. 2015;13:319.<pub-id pub-id-type="pmid">26419843</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR286"><label>286.</label><citation-alternatives><element-citation id="ec-CR286" publication-type="journal"><person-group person-group-type="author"><name><surname>Gordon</surname><given-names>SR</given-names></name><name><surname>Maute</surname><given-names>RL</given-names></name><name><surname>Dulken</surname><given-names>BW</given-names></name><name><surname>Hutter</surname><given-names>G</given-names></name><name><surname>George</surname><given-names>BM</given-names></name><name><surname>McCracken</surname><given-names>MN</given-names></name><etal/></person-group><article-title>PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity</article-title><source>Nature</source><year>2017</year><volume>545</volume><fpage>495</fpage><lpage>499</lpage><pub-id pub-id-type="doi">10.1038/nature22396</pub-id><pub-id pub-id-type="pmid">28514441</pub-id>
</element-citation><mixed-citation id="mc-CR286" publication-type="journal">Gordon SR, Maute RL, Dulken BW, Hutter G, George BM, McCracken MN, et al. PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity. Nature. 2017;545:495&#x02013;9.<pub-id pub-id-type="pmid">28514441</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR287"><label>287.</label><citation-alternatives><element-citation id="ec-CR287" publication-type="journal"><person-group person-group-type="author"><name><surname>Fujimura</surname><given-names>T</given-names></name><name><surname>Kakizaki</surname><given-names>A</given-names></name><name><surname>Kambayashi</surname><given-names>Y</given-names></name><name><surname>Sato</surname><given-names>Y</given-names></name><name><surname>Tanita</surname><given-names>K</given-names></name><name><surname>Lyu</surname><given-names>C</given-names></name><etal/></person-group><article-title>Cytotoxic antimelanoma drugs suppress the activation of M2 macrophages</article-title><source>Exp Dermatol</source><year>2018</year><volume>27</volume><fpage>64</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1111/exd.13417</pub-id><pub-id pub-id-type="pmid">28833504</pub-id>
</element-citation><mixed-citation id="mc-CR287" publication-type="journal">Fujimura T, Kakizaki A, Kambayashi Y, Sato Y, Tanita K, Lyu C, et al. Cytotoxic antimelanoma drugs suppress the activation of M2 macrophages. Exp Dermatol. 2018;27:64&#x02013;70.<pub-id pub-id-type="pmid">28833504</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR288"><label>288.</label><citation-alternatives><element-citation id="ec-CR288" publication-type="journal"><person-group person-group-type="author"><name><surname>Tsuruta</surname><given-names>A</given-names></name><name><surname>Shiiba</surname><given-names>Y</given-names></name><name><surname>Matsunaga</surname><given-names>N</given-names></name><name><surname>Fujimoto</surname><given-names>M</given-names></name><name><surname>Yoshida</surname><given-names>Y</given-names></name><name><surname>Koyanagi</surname><given-names>S</given-names></name><etal/></person-group><article-title>Diurnal expression of PD-1 on tumor-associated macrophages underlies the dosing time-dependent antitumor effects of the PD-1/PD-L1 Inhibitor BMS-1 in B16/BL6 melanoma-bearing mice</article-title><source>Mol Cancer Res</source><year>2022</year><volume>20</volume><fpage>972</fpage><lpage>982</lpage><pub-id pub-id-type="doi">10.1158/1541-7786.MCR-21-0786</pub-id><pub-id pub-id-type="pmid">35190830</pub-id>
</element-citation><mixed-citation id="mc-CR288" publication-type="journal">Tsuruta A, Shiiba Y, Matsunaga N, Fujimoto M, Yoshida Y, Koyanagi S, et al. Diurnal expression of PD-1 on tumor-associated macrophages underlies the dosing time-dependent antitumor effects of the PD-1/PD-L1 Inhibitor BMS-1 in B16/BL6 melanoma-bearing mice. Mol Cancer Res. 2022;20:972&#x02013;82.<pub-id pub-id-type="pmid">35190830</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR289"><label>289.</label><citation-alternatives><element-citation id="ec-CR289" publication-type="journal"><person-group person-group-type="author"><name><surname>Tham</surname><given-names>M</given-names></name><name><surname>Tan</surname><given-names>KW</given-names></name><name><surname>Keeble</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Hubert</surname><given-names>S</given-names></name><name><surname>Barron</surname><given-names>L</given-names></name><etal/></person-group><article-title>Melanoma-initiating cells exploit M2 macrophage TGF&#x003b2; and arginase pathway for survival and proliferation</article-title><source>Oncotarget</source><year>2014</year><volume>5</volume><fpage>12027</fpage><pub-id pub-id-type="doi">10.18632/oncotarget.2482</pub-id><pub-id pub-id-type="pmid">25294815</pub-id>
</element-citation><mixed-citation id="mc-CR289" publication-type="journal">Tham M, Tan KW, Keeble J, Wang X, Hubert S, Barron L, et al. Melanoma-initiating cells exploit M2 macrophage TGF&#x003b2; and arginase pathway for survival and proliferation. Oncotarget. 2014;5:12027.<pub-id pub-id-type="pmid">25294815</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR290"><label>290.</label><citation-alternatives><element-citation id="ec-CR290" publication-type="journal"><person-group person-group-type="author"><name><surname>Ghosh</surname><given-names>S</given-names></name><name><surname>Juin</surname><given-names>SK</given-names></name><name><surname>Bhattacharyya Majumdar</surname><given-names>S</given-names></name><name><surname>Majumdar</surname><given-names>S</given-names></name></person-group><article-title>Crucial role of glucosylceramide synthase in the regulation of stem cell-like cancer cells in B16F10 murine melanoma</article-title><source>Mol Carcinog</source><year>2021</year><volume>60</volume><fpage>840</fpage><lpage>858</lpage><pub-id pub-id-type="doi">10.1002/mc.23347</pub-id><pub-id pub-id-type="pmid">34516706</pub-id>
</element-citation><mixed-citation id="mc-CR290" publication-type="journal">Ghosh S, Juin SK, Bhattacharyya Majumdar S, Majumdar S. Crucial role of glucosylceramide synthase in the regulation of stem cell-like cancer cells in B16F10 murine melanoma. Mol Carcinog. 2021;60:840&#x02013;58.<pub-id pub-id-type="pmid">34516706</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR291"><label>291.</label><citation-alternatives><element-citation id="ec-CR291" publication-type="journal"><person-group person-group-type="author"><name><surname>Ohanna</surname><given-names>M</given-names></name><name><surname>Giuliano</surname><given-names>S</given-names></name><name><surname>Bonet</surname><given-names>C</given-names></name><name><surname>Imbert</surname><given-names>V</given-names></name><name><surname>Hofman</surname><given-names>V</given-names></name><name><surname>Zangari</surname><given-names>J</given-names></name><etal/></person-group><article-title>Senescent cells develop a PARP-1 and nuclear factor-{kappa}B-associated secretome (PNAS)</article-title><source>Genes Dev</source><year>2011</year><volume>25</volume><fpage>1245</fpage><lpage>1261</lpage><pub-id pub-id-type="doi">10.1101/gad.625811</pub-id><pub-id pub-id-type="pmid">21646373</pub-id>
</element-citation><mixed-citation id="mc-CR291" publication-type="journal">Ohanna M, Giuliano S, Bonet C, Imbert V, Hofman V, Zangari J, et al. Senescent cells develop a PARP-1 and nuclear factor-{kappa}B-associated secretome (PNAS). Genes Dev. 2011;25:1245&#x02013;61.<pub-id pub-id-type="pmid">21646373</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR292"><label>292.</label><citation-alternatives><element-citation id="ec-CR292" publication-type="journal"><person-group person-group-type="author"><name><surname>Modestino</surname><given-names>L</given-names></name><name><surname>Cristinziano</surname><given-names>L</given-names></name><name><surname>Trocchia</surname><given-names>M</given-names></name><name><surname>Ventrici</surname><given-names>A</given-names></name><name><surname>Capone</surname><given-names>M</given-names></name><name><surname>Madonna</surname><given-names>G</given-names></name><etal/></person-group><article-title>Melanoma-derived soluble mediators modulate neutrophil biological properties and the release of neutrophil extracellular traps</article-title><source>Cancer Immunol Immunother</source><year>2023</year><volume>72</volume><fpage>3363</fpage><lpage>3376</lpage><pub-id pub-id-type="doi">10.1007/s00262-023-03493-5</pub-id><pub-id pub-id-type="pmid">37525065</pub-id>
</element-citation><mixed-citation id="mc-CR292" publication-type="journal">Modestino L, Cristinziano L, Trocchia M, Ventrici A, Capone M, Madonna G, et al. Melanoma-derived soluble mediators modulate neutrophil biological properties and the release of neutrophil extracellular traps. Cancer Immunol Immunother. 2023;72:3363&#x02013;76.<pub-id pub-id-type="pmid">37525065</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR293"><label>293.</label><citation-alternatives><element-citation id="ec-CR293" publication-type="journal"><person-group person-group-type="author"><name><surname>Ferrucci</surname><given-names>PF</given-names></name><name><surname>Ascierto</surname><given-names>PA</given-names></name><name><surname>Pigozzo</surname><given-names>J</given-names></name><name><surname>Del Vecchio</surname><given-names>M</given-names></name><name><surname>Maio</surname><given-names>M</given-names></name><name><surname>Cappellini</surname><given-names>GA</given-names></name><etal/></person-group><article-title>Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab</article-title><source>Ann Oncol</source><year>2016</year><volume>27</volume><fpage>732</fpage><lpage>738</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdw016</pub-id><pub-id pub-id-type="pmid">26802161</pub-id>
</element-citation><mixed-citation id="mc-CR293" publication-type="journal">Ferrucci PF, Ascierto PA, Pigozzo J, Del Vecchio M, Maio M, Cappellini GA, et al. Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab. Ann Oncol. 2016;27:732&#x02013;8.<pub-id pub-id-type="pmid">26802161</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR294"><label>294.</label><citation-alternatives><element-citation id="ec-CR294" publication-type="journal"><person-group person-group-type="author"><name><surname>Seddon</surname><given-names>A</given-names></name><name><surname>Hock</surname><given-names>B</given-names></name><name><surname>Miller</surname><given-names>A</given-names></name><name><surname>Frei</surname><given-names>L</given-names></name><name><surname>Pearson</surname><given-names>J</given-names></name><name><surname>McKenzie</surname><given-names>J</given-names></name><etal/></person-group><article-title>Cutaneous squamous cell carcinomas with markers of increased metastatic risk are associated with elevated numbers of neutrophils and/or granulocytic myeloid derived suppressor cells</article-title><source>J Dermatol Sci</source><year>2016</year><volume>83</volume><fpage>124</fpage><lpage>130</lpage><pub-id pub-id-type="doi">10.1016/j.jdermsci.2016.04.013</pub-id><pub-id pub-id-type="pmid">27160951</pub-id>
</element-citation><mixed-citation id="mc-CR294" publication-type="journal">Seddon A, Hock B, Miller A, Frei L, Pearson J, McKenzie J, et al. Cutaneous squamous cell carcinomas with markers of increased metastatic risk are associated with elevated numbers of neutrophils and/or granulocytic myeloid derived suppressor cells. J Dermatol Sci. 2016;83:124&#x02013;30.<pub-id pub-id-type="pmid">27160951</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR295"><label>295.</label><citation-alternatives><element-citation id="ec-CR295" publication-type="journal"><person-group person-group-type="author"><name><surname>Anselmi</surname><given-names>M</given-names></name><name><surname>Fontana</surname><given-names>F</given-names></name><name><surname>Marzagalli</surname><given-names>M</given-names></name><name><surname>Gagliano</surname><given-names>N</given-names></name><name><surname>Sommariva</surname><given-names>M</given-names></name><name><surname>Limonta</surname><given-names>P</given-names></name></person-group><article-title>Melanoma stem cells educate neutrophils to support cancer progression</article-title><source>Cancers</source><year>2022</year><volume>14</volume><fpage>3391</fpage><pub-id pub-id-type="doi">10.3390/cancers14143391</pub-id><pub-id pub-id-type="pmid">35884452</pub-id>
</element-citation><mixed-citation id="mc-CR295" publication-type="journal">Anselmi M, Fontana F, Marzagalli M, Gagliano N, Sommariva M, Limonta P. Melanoma stem cells educate neutrophils to support cancer progression. Cancers. 2022;14:3391.<pub-id pub-id-type="pmid">35884452</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR296"><label>296.</label><citation-alternatives><element-citation id="ec-CR296" publication-type="journal"><person-group person-group-type="author"><name><surname>Festa</surname><given-names>E</given-names></name><name><surname>Fretz</surname><given-names>J</given-names></name><name><surname>Berry</surname><given-names>R</given-names></name><name><surname>Schmidt</surname><given-names>B</given-names></name><name><surname>Rodeheffer</surname><given-names>M</given-names></name><name><surname>Horowitz</surname><given-names>M</given-names></name><etal/></person-group><article-title>Adipocyte lineage cells contribute to the skin stem cell niche to drive hair cycling</article-title><source>Cell</source><year>2011</year><volume>146</volume><fpage>761</fpage><lpage>771</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2011.07.019</pub-id><pub-id pub-id-type="pmid">21884937</pub-id>
</element-citation><mixed-citation id="mc-CR296" publication-type="journal">Festa E, Fretz J, Berry R, Schmidt B, Rodeheffer M, Horowitz M, et al. Adipocyte lineage cells contribute to the skin stem cell niche to drive hair cycling. Cell. 2011;146:761&#x02013;71.<pub-id pub-id-type="pmid">21884937</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR297"><label>297.</label><citation-alternatives><element-citation id="ec-CR297" publication-type="journal"><person-group person-group-type="author"><name><surname>Guerrero-Juarez</surname><given-names>CF</given-names></name><name><surname>Plikus</surname><given-names>MV</given-names></name></person-group><article-title>Emerging nonmetabolic functions of skin fat</article-title><source>Nat Rev Endocrinol</source><year>2018</year><volume>14</volume><fpage>163</fpage><lpage>173</lpage><pub-id pub-id-type="doi">10.1038/nrendo.2017.162</pub-id><pub-id pub-id-type="pmid">29327704</pub-id>
</element-citation><mixed-citation id="mc-CR297" publication-type="journal">Guerrero-Juarez CF, Plikus MV. Emerging nonmetabolic functions of skin fat. Nat Rev Endocrinol. 2018;14:163&#x02013;73.<pub-id pub-id-type="pmid">29327704</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR298"><label>298.</label><citation-alternatives><element-citation id="ec-CR298" publication-type="journal"><person-group person-group-type="author"><name><surname>Plikus</surname><given-names>MV</given-names></name><name><surname>Mayer</surname><given-names>JA</given-names></name><name><surname>de la Cruz</surname><given-names>D</given-names></name><name><surname>Baker</surname><given-names>RE</given-names></name><name><surname>Maini</surname><given-names>PK</given-names></name><name><surname>Maxson</surname><given-names>R</given-names></name><etal/></person-group><article-title>Cyclic dermal BMP signalling regulates stem cell activation during hair regeneration</article-title><source>Nature</source><year>2008</year><volume>451</volume><fpage>340</fpage><lpage>344</lpage><pub-id pub-id-type="doi">10.1038/nature06457</pub-id><pub-id pub-id-type="pmid">18202659</pub-id>
</element-citation><mixed-citation id="mc-CR298" publication-type="journal">Plikus MV, Mayer JA, de la Cruz D, Baker RE, Maini PK, Maxson R, et al. Cyclic dermal BMP signalling regulates stem cell activation during hair regeneration. Nature. 2008;451:340&#x02013;4.<pub-id pub-id-type="pmid">18202659</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR299"><label>299.</label><citation-alternatives><element-citation id="ec-CR299" publication-type="journal"><person-group person-group-type="author"><name><surname>Kandyba</surname><given-names>E</given-names></name><name><surname>Leung</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>YB</given-names></name><name><surname>Widelitz</surname><given-names>R</given-names></name><name><surname>Chuong</surname><given-names>CM</given-names></name><name><surname>Kobielak</surname><given-names>K</given-names></name></person-group><article-title>Competitive balance of intrabulge BMP/Wnt signaling reveals a robust gene network ruling stem cell homeostasis and cyclic activation</article-title><source>Proc Natl Acad Sci U S A</source><year>2013</year><volume>110</volume><fpage>1351</fpage><lpage>1356</lpage><pub-id pub-id-type="doi">10.1073/pnas.1121312110</pub-id><pub-id pub-id-type="pmid">23292934</pub-id>
</element-citation><mixed-citation id="mc-CR299" publication-type="journal">Kandyba E, Leung Y, Chen YB, Widelitz R, Chuong CM, Kobielak K. Competitive balance of intrabulge BMP/Wnt signaling reveals a robust gene network ruling stem cell homeostasis and cyclic activation. Proc Natl Acad Sci U S A. 2013;110:1351&#x02013;6.<pub-id pub-id-type="pmid">23292934</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR300"><label>300.</label><citation-alternatives><element-citation id="ec-CR300" publication-type="journal"><person-group person-group-type="author"><name><surname>Donati</surname><given-names>G</given-names></name><name><surname>Proserpio</surname><given-names>V</given-names></name><name><surname>Lichtenberger</surname><given-names>BM</given-names></name><name><surname>Natsuga</surname><given-names>K</given-names></name><name><surname>Sinclair</surname><given-names>R</given-names></name><name><surname>Fujiwara</surname><given-names>H</given-names></name><etal/></person-group><article-title>Epidermal Wnt/&#x003b2;-catenin signaling regulates adipocyte differentiation via secretion of adipogenic factors</article-title><source>Proc Natl Acad Sci U S A</source><year>2014</year><volume>111</volume><fpage>E1501</fpage><lpage>E1509</lpage><pub-id pub-id-type="doi">10.1073/pnas.1312880111</pub-id><pub-id pub-id-type="pmid">24706781</pub-id>
</element-citation><mixed-citation id="mc-CR300" publication-type="journal">Donati G, Proserpio V, Lichtenberger BM, Natsuga K, Sinclair R, Fujiwara H, et al. Epidermal Wnt/&#x003b2;-catenin signaling regulates adipocyte differentiation via secretion of adipogenic factors. Proc Natl Acad Sci U S A. 2014;111:E1501&#x02013;9.<pub-id pub-id-type="pmid">24706781</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR301"><label>301.</label><citation-alternatives><element-citation id="ec-CR301" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>B</given-names></name><name><surname>Tsai</surname><given-names>PC</given-names></name><name><surname>Gonzalez-Celeiro</surname><given-names>M</given-names></name><name><surname>Chung</surname><given-names>O</given-names></name><name><surname>Boumard</surname><given-names>B</given-names></name><name><surname>Perdigoto</surname><given-names>CN</given-names></name><etal/></person-group><article-title>Hair follicles&#x02019; transit-amplifying cells govern concurrent dermal adipocyte production through Sonic Hedgehog</article-title><source>Genes Dev</source><year>2016</year><volume>30</volume><fpage>2325</fpage><lpage>2338</lpage><pub-id pub-id-type="doi">10.1101/gad.285429.116</pub-id><pub-id pub-id-type="pmid">27807033</pub-id>
</element-citation><mixed-citation id="mc-CR301" publication-type="journal">Zhang B, Tsai PC, Gonzalez-Celeiro M, Chung O, Boumard B, Perdigoto CN, et al. Hair follicles&#x02019; transit-amplifying cells govern concurrent dermal adipocyte production through Sonic Hedgehog. Genes Dev. 2016;30:2325&#x02013;38.<pub-id pub-id-type="pmid">27807033</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR302"><label>302.</label><citation-alternatives><element-citation id="ec-CR302" publication-type="journal"><person-group person-group-type="author"><name><surname>Wagner</surname><given-names>M</given-names></name><name><surname>Bjerkvig</surname><given-names>R</given-names></name><name><surname>Wiig</surname><given-names>H</given-names></name><name><surname>Melero-Martin</surname><given-names>JM</given-names></name><name><surname>Lin</surname><given-names>RZ</given-names></name><name><surname>Klagsbrun</surname><given-names>M</given-names></name><etal/></person-group><article-title>Inflamed tumor-associated adipose tissue is a depot for macrophages that stimulate tumor growth and angiogenesis</article-title><source>Angiogenesis</source><year>2012</year><volume>15</volume><fpage>481</fpage><lpage>495</lpage><pub-id pub-id-type="doi">10.1007/s10456-012-9276-y</pub-id><pub-id pub-id-type="pmid">22614697</pub-id>
</element-citation><mixed-citation id="mc-CR302" publication-type="journal">Wagner M, Bjerkvig R, Wiig H, Melero-Martin JM, Lin RZ, Klagsbrun M, et al. Inflamed tumor-associated adipose tissue is a depot for macrophages that stimulate tumor growth and angiogenesis. Angiogenesis. 2012;15:481&#x02013;95.<pub-id pub-id-type="pmid">22614697</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR303"><label>303.</label><citation-alternatives><element-citation id="ec-CR303" publication-type="journal"><person-group person-group-type="author"><name><surname>Jung</surname><given-names>JI</given-names></name><name><surname>Cho</surname><given-names>HJ</given-names></name><name><surname>Jung</surname><given-names>YJ</given-names></name><name><surname>Kwon</surname><given-names>SH</given-names></name><name><surname>Her</surname><given-names>S</given-names></name><name><surname>Choi</surname><given-names>SS</given-names></name><etal/></person-group><article-title>High-fat diet-induced obesity increases lymphangiogenesis and lymph node metastasis in the B16F10 melanoma allograft model: roles of adipocytes and M2-macrophages</article-title><source>Int J Cancer</source><year>2015</year><volume>136</volume><fpage>258</fpage><lpage>270</lpage><pub-id pub-id-type="doi">10.1002/ijc.28983</pub-id><pub-id pub-id-type="pmid">24844408</pub-id>
</element-citation><mixed-citation id="mc-CR303" publication-type="journal">Jung JI, Cho HJ, Jung YJ, Kwon SH, Her S, Choi SS, et al. High-fat diet-induced obesity increases lymphangiogenesis and lymph node metastasis in the B16F10 melanoma allograft model: roles of adipocytes and M2-macrophages. Int J Cancer. 2015;136:258&#x02013;70.<pub-id pub-id-type="pmid">24844408</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR304"><label>304.</label><citation-alternatives><element-citation id="ec-CR304" publication-type="journal"><person-group person-group-type="author"><name><surname>Buruian&#x00103;</surname><given-names>A</given-names></name><name><surname>Gheban</surname><given-names>BA</given-names></name><name><surname>Gheban-Ro&#x00219;ca</surname><given-names>IA</given-names></name><name><surname>Georgiu</surname><given-names>C</given-names></name><name><surname>Cri&#x00219;an</surname><given-names>D</given-names></name><name><surname>Cri&#x00219;an</surname><given-names>M</given-names></name></person-group><article-title>The tumor stroma of squamous cell carcinoma: a complex environment that fuels cancer progression</article-title><source>Cancers (Basel)</source><year>2024</year><volume>16</volume><fpage>1727</fpage><pub-id pub-id-type="doi">10.3390/cancers16091727</pub-id><pub-id pub-id-type="pmid">38730679</pub-id>
</element-citation><mixed-citation id="mc-CR304" publication-type="journal">Buruian&#x00103; A, Gheban BA, Gheban-Ro&#x00219;ca IA, Georgiu C, Cri&#x00219;an D, Cri&#x00219;an M. The tumor stroma of squamous cell carcinoma: a complex environment that fuels cancer progression. Cancers (Basel). 2024;16:1727.<pub-id pub-id-type="pmid">38730679</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR305"><label>305.</label><citation-alternatives><element-citation id="ec-CR305" publication-type="journal"><person-group person-group-type="author"><name><surname>Iwata</surname><given-names>T</given-names></name><name><surname>Kuwajima</surname><given-names>M</given-names></name><name><surname>Sukeno</surname><given-names>A</given-names></name><name><surname>Ishimaru</surname><given-names>N</given-names></name><name><surname>Hayashi</surname><given-names>Y</given-names></name><name><surname>Wabitsch</surname><given-names>M</given-names></name><etal/></person-group><article-title>YKL-40 secreted from adipose tissue inhibits degradation of type I collagen</article-title><source>Biochem Biophys Res Commun</source><year>2009</year><volume>388</volume><fpage>511</fpage><lpage>516</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2009.08.024</pub-id><pub-id pub-id-type="pmid">19666003</pub-id>
</element-citation><mixed-citation id="mc-CR305" publication-type="journal">Iwata T, Kuwajima M, Sukeno A, Ishimaru N, Hayashi Y, Wabitsch M, et al. YKL-40 secreted from adipose tissue inhibits degradation of type I collagen. Biochem Biophys Res Commun. 2009;388:511&#x02013;6.<pub-id pub-id-type="pmid">19666003</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR306"><label>306.</label><citation-alternatives><element-citation id="ec-CR306" publication-type="journal"><person-group person-group-type="author"><name><surname>Clement</surname><given-names>E</given-names></name><name><surname>Lazar</surname><given-names>I</given-names></name><name><surname>Muller</surname><given-names>C</given-names></name><name><surname>Nieto</surname><given-names>L</given-names></name></person-group><article-title>Obesity and melanoma: could fat be fueling malignancy?</article-title><source>Pigment Cell Melanoma Res</source><year>2017</year><volume>30</volume><fpage>294</fpage><lpage>306</lpage><pub-id pub-id-type="doi">10.1111/pcmr.12584</pub-id><pub-id pub-id-type="pmid">28222242</pub-id>
</element-citation><mixed-citation id="mc-CR306" publication-type="journal">Clement E, Lazar I, Muller C, Nieto L. Obesity and melanoma: could fat be fueling malignancy? Pigment Cell Melanoma Res. 2017;30:294&#x02013;306.<pub-id pub-id-type="pmid">28222242</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR307"><label>307.</label><citation-alternatives><element-citation id="ec-CR307" publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>B</given-names></name><name><surname>Herzog</surname><given-names>EL</given-names></name><name><surname>Moore</surname><given-names>M</given-names></name><name><surname>Lee</surname><given-names>C-M</given-names></name><name><surname>Na</surname><given-names>SH</given-names></name><name><surname>Lee</surname><given-names>CG</given-names></name><etal/></person-group><article-title>RIG-like helicase regulation of chitinase 3-like 1 axis and pulmonary metastasis</article-title><source>Sci Rep</source><year>2016</year><volume>6</volume><fpage>26299</fpage><pub-id pub-id-type="doi">10.1038/srep26299</pub-id><pub-id pub-id-type="pmid">27198666</pub-id>
</element-citation><mixed-citation id="mc-CR307" publication-type="journal">Ma B, Herzog EL, Moore M, Lee C-M, Na SH, Lee CG, et al. RIG-like helicase regulation of chitinase 3-like 1 axis and pulmonary metastasis. Sci Rep. 2016;6:26299.<pub-id pub-id-type="pmid">27198666</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR308"><label>308.</label><citation-alternatives><element-citation id="ec-CR308" publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Du</surname><given-names>JX</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Shi</surname><given-names>MT</given-names></name><name><surname>Jin</surname><given-names>MW</given-names></name><etal/></person-group><article-title>Adipocytes promote tumor progression and induce PD-L1 expression via TNF-&#x003b1;/IL-6 signaling</article-title><source>Cancer Cell Int</source><year>2020</year><volume>20</volume><fpage>179</fpage><pub-id pub-id-type="doi">10.1186/s12935-020-01269-w</pub-id><pub-id pub-id-type="pmid">32477009</pub-id>
</element-citation><mixed-citation id="mc-CR308" publication-type="journal">Li Z, Zhang C, Du JX, Zhao J, Shi MT, Jin MW, et al. Adipocytes promote tumor progression and induce PD-L1 expression via TNF-&#x003b1;/IL-6 signaling. Cancer Cell Int. 2020;20:179.<pub-id pub-id-type="pmid">32477009</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR309"><label>309.</label><citation-alternatives><element-citation id="ec-CR309" publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Lodish</surname><given-names>HF</given-names></name></person-group><article-title>Adiponectin deficiency promotes tumor growth in mice by reducing macrophage infiltration</article-title><source>PLoS ONE</source><year>2010</year><volume>5</volume><fpage>e11987</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0011987</pub-id><pub-id pub-id-type="pmid">20700533</pub-id>
</element-citation><mixed-citation id="mc-CR309" publication-type="journal">Sun Y, Lodish HF. Adiponectin deficiency promotes tumor growth in mice by reducing macrophage infiltration. PLoS ONE. 2010;5: e11987.<pub-id pub-id-type="pmid">20700533</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR310"><label>310.</label><citation-alternatives><element-citation id="ec-CR310" publication-type="journal"><person-group person-group-type="author"><name><surname>Bouche</surname><given-names>C</given-names></name><name><surname>Quail</surname><given-names>DF</given-names></name></person-group><article-title>Fueling the tumor microenvironment with cancer-associated adipocytes</article-title><source>Cancer Res</source><year>2023</year><volume>83</volume><fpage>1170</fpage><lpage>1172</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-23-0505</pub-id><pub-id pub-id-type="pmid">37057599</pub-id>
</element-citation><mixed-citation id="mc-CR310" publication-type="journal">Bouche C, Quail DF. Fueling the tumor microenvironment with cancer-associated adipocytes. Cancer Res. 2023;83:1170&#x02013;2.<pub-id pub-id-type="pmid">37057599</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR311"><label>311.</label><citation-alternatives><element-citation id="ec-CR311" publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>KN</given-names></name><name><surname>Jain</surname><given-names>P</given-names></name><name><surname>He</surname><given-names>CH</given-names></name><name><surname>Eun</surname><given-names>FC</given-names></name><name><surname>Kang</surname><given-names>S</given-names></name><name><surname>Tumbar</surname><given-names>T</given-names></name></person-group><article-title>Skin vasculature and hair follicle cross-talking associated with stem cell activation and tissue homeostasis</article-title><source>Elife</source><year>2019</year><volume>8</volume><fpage>e45977</fpage><pub-id pub-id-type="doi">10.7554/eLife.45977</pub-id><pub-id pub-id-type="pmid">31343406</pub-id>
</element-citation><mixed-citation id="mc-CR311" publication-type="journal">Li KN, Jain P, He CH, Eun FC, Kang S, Tumbar T. Skin vasculature and hair follicle cross-talking associated with stem cell activation and tissue homeostasis. Elife. 2019;8: e45977.<pub-id pub-id-type="pmid">31343406</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR312"><label>312.</label><citation-alternatives><element-citation id="ec-CR312" publication-type="journal"><person-group person-group-type="author"><name><surname>Xiao</surname><given-names>Y</given-names></name><name><surname>Woo</surname><given-names>WM</given-names></name><name><surname>Nagao</surname><given-names>K</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Terunuma</surname><given-names>A</given-names></name><name><surname>Mukouyama</surname><given-names>YS</given-names></name><etal/></person-group><article-title>Perivascular hair follicle stem cells associate with a venule annulus</article-title><source>J Invest Dermatol</source><year>2013</year><volume>133</volume><fpage>2324</fpage><lpage>2331</lpage><pub-id pub-id-type="doi">10.1038/jid.2013.167</pub-id><pub-id pub-id-type="pmid">23558405</pub-id>
</element-citation><mixed-citation id="mc-CR312" publication-type="journal">Xiao Y, Woo WM, Nagao K, Li W, Terunuma A, Mukouyama YS, et al. Perivascular hair follicle stem cells associate with a venule annulus. J Invest Dermatol. 2013;133:2324&#x02013;31.<pub-id pub-id-type="pmid">23558405</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR313"><label>313.</label><citation-alternatives><element-citation id="ec-CR313" publication-type="journal"><person-group person-group-type="author"><name><surname>Mecklenburg</surname><given-names>L</given-names></name><name><surname>Tobin</surname><given-names>DJ</given-names></name><name><surname>M&#x000fc;ller-R&#x000f6;ver</surname><given-names>S</given-names></name><name><surname>Handjiski</surname><given-names>B</given-names></name><name><surname>Wendt</surname><given-names>G</given-names></name><name><surname>Peters</surname><given-names>EM</given-names></name><etal/></person-group><article-title>Active hair growth (anagen) is associated with angiogenesis</article-title><source>J Invest Dermatol</source><year>2000</year><volume>114</volume><fpage>909</fpage><lpage>916</lpage><pub-id pub-id-type="doi">10.1046/j.1523-1747.2000.00954.x</pub-id><pub-id pub-id-type="pmid">10771470</pub-id>
</element-citation><mixed-citation id="mc-CR313" publication-type="journal">Mecklenburg L, Tobin DJ, M&#x000fc;ller-R&#x000f6;ver S, Handjiski B, Wendt G, Peters EM, et al. Active hair growth (anagen) is associated with angiogenesis. J Invest Dermatol. 2000;114:909&#x02013;16.<pub-id pub-id-type="pmid">10771470</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR314"><label>314.</label><citation-alternatives><element-citation id="ec-CR314" publication-type="journal"><person-group person-group-type="author"><name><surname>Botchkarev</surname><given-names>VA</given-names></name><name><surname>Sharov</surname><given-names>AA</given-names></name></person-group><article-title>BMP signaling in the control of skin development and hair follicle growth</article-title><source>Differentiation</source><year>2004</year><volume>72</volume><fpage>512</fpage><lpage>526</lpage><pub-id pub-id-type="doi">10.1111/j.1432-0436.2004.07209005.x</pub-id><pub-id pub-id-type="pmid">15617562</pub-id>
</element-citation><mixed-citation id="mc-CR314" publication-type="journal">Botchkarev VA, Sharov AA. BMP signaling in the control of skin development and hair follicle growth. Differentiation. 2004;72:512&#x02013;26.<pub-id pub-id-type="pmid">15617562</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR315"><label>315.</label><citation-alternatives><element-citation id="ec-CR315" publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>Z</given-names></name><name><surname>Bian</surname><given-names>Y</given-names></name><name><surname>Chu</surname><given-names>T</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Man</surname><given-names>S</given-names></name><name><surname>Song</surname><given-names>Y</given-names></name><etal/></person-group><article-title>The role of angiogenesis in melanoma: Clinical treatments and future expectations</article-title><source>Front Pharmacol</source><year>2022</year><volume>13</volume><fpage>1028647</fpage><pub-id pub-id-type="doi">10.3389/fphar.2022.1028647</pub-id><pub-id pub-id-type="pmid">36588679</pub-id>
</element-citation><mixed-citation id="mc-CR315" publication-type="journal">Wu Z, Bian Y, Chu T, Wang Y, Man S, Song Y, et al. The role of angiogenesis in melanoma: Clinical treatments and future expectations. Front Pharmacol. 2022;13:1028647.<pub-id pub-id-type="pmid">36588679</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR316"><label>316.</label><citation-alternatives><element-citation id="ec-CR316" publication-type="journal"><person-group person-group-type="author"><name><surname>Fania</surname><given-names>L</given-names></name><name><surname>Didona</surname><given-names>D</given-names></name><name><surname>Di Pietro</surname><given-names>FR</given-names></name><name><surname>Verkhovskaia</surname><given-names>S</given-names></name><name><surname>Morese</surname><given-names>R</given-names></name><name><surname>Paolino</surname><given-names>G</given-names></name><etal/></person-group><article-title>Cutaneous squamous cell carcinoma: from pathophysiology to novel therapeutic approaches</article-title><source>Biomedicines</source><year>2021</year><volume>9</volume><fpage>171</fpage><pub-id pub-id-type="doi">10.3390/biomedicines9020171</pub-id><pub-id pub-id-type="pmid">33572373</pub-id>
</element-citation><mixed-citation id="mc-CR316" publication-type="journal">Fania L, Didona D, Di Pietro FR, Verkhovskaia S, Morese R, Paolino G, et al. Cutaneous squamous cell carcinoma: from pathophysiology to novel therapeutic approaches. Biomedicines. 2021;9:171.<pub-id pub-id-type="pmid">33572373</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR317"><label>317.</label><citation-alternatives><element-citation id="ec-CR317" publication-type="journal"><person-group person-group-type="author"><name><surname>Bowden</surname><given-names>J</given-names></name><name><surname>Brennan</surname><given-names>PA</given-names></name><name><surname>Umar</surname><given-names>T</given-names></name><name><surname>Cronin</surname><given-names>A</given-names></name></person-group><article-title>Expression of vascular endothelial growth factor in basal cell carcinoma and cutaneous squamous cell carcinoma of the head and neck</article-title><source>J Cutan Pathol</source><year>2002</year><volume>29</volume><fpage>585</fpage><lpage>589</lpage><pub-id pub-id-type="doi">10.1034/j.1600-0560.2002.291003.x</pub-id><pub-id pub-id-type="pmid">12453295</pub-id>
</element-citation><mixed-citation id="mc-CR317" publication-type="journal">Bowden J, Brennan PA, Umar T, Cronin A. Expression of vascular endothelial growth factor in basal cell carcinoma and cutaneous squamous cell carcinoma of the head and neck. J Cutan Pathol. 2002;29:585&#x02013;9.<pub-id pub-id-type="pmid">12453295</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR318"><label>318.</label><citation-alternatives><element-citation id="ec-CR318" publication-type="journal"><person-group person-group-type="author"><name><surname>Malekan</surname><given-names>M</given-names></name><name><surname>Haass</surname><given-names>NK</given-names></name><name><surname>Rokni</surname><given-names>GR</given-names></name><name><surname>Gholizadeh</surname><given-names>N</given-names></name><name><surname>Ebrahimzadeh</surname><given-names>MA</given-names></name><name><surname>Kazeminejad</surname><given-names>A</given-names></name></person-group><article-title>VEGF/VEGFR axis and its signaling in melanoma: Current knowledge toward therapeutic targeting agents and future perspectives</article-title><source>Life Sci</source><year>2024</year><volume>345</volume><fpage>122563</fpage><pub-id pub-id-type="doi">10.1016/j.lfs.2024.122563</pub-id><pub-id pub-id-type="pmid">38508233</pub-id>
</element-citation><mixed-citation id="mc-CR318" publication-type="journal">Malekan M, Haass NK, Rokni GR, Gholizadeh N, Ebrahimzadeh MA, Kazeminejad A. VEGF/VEGFR axis and its signaling in melanoma: Current knowledge toward therapeutic targeting agents and future perspectives. Life Sci. 2024;345: 122563.<pub-id pub-id-type="pmid">38508233</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR319"><label>319.</label><mixed-citation publication-type="other">L&#x000f3;pez de Andr&#x000e9;s J, Ruiz-Toranzo M, Antich C, Chocarro-Wrona C, L&#x000f3;pez-Ru&#x000ed;z E, Jim&#x000e9;nez G, et al. Biofabrication of a tri-layered 3D-bioprinted CSC-based malignant melanoma model for personalized cancer treatment<italic>.</italic> Biofabrication. 2023; 15:035016.</mixed-citation></ref><ref id="CR320"><label>320.</label><citation-alternatives><element-citation id="ec-CR320" publication-type="journal"><person-group person-group-type="author"><name><surname>Monzani</surname><given-names>E</given-names></name><name><surname>Facchetti</surname><given-names>F</given-names></name><name><surname>Galmozzi</surname><given-names>E</given-names></name><name><surname>Corsini</surname><given-names>E</given-names></name><name><surname>Benetti</surname><given-names>A</given-names></name><name><surname>Cavazzin</surname><given-names>C</given-names></name><etal/></person-group><article-title>Melanoma contains CD133 and ABCG2 positive cells with enhanced tumourigenic potential</article-title><source>Eur J Cancer</source><year>2007</year><volume>43</volume><fpage>935</fpage><lpage>946</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2007.01.017</pub-id><pub-id pub-id-type="pmid">17320377</pub-id>
</element-citation><mixed-citation id="mc-CR320" publication-type="journal">Monzani E, Facchetti F, Galmozzi E, Corsini E, Benetti A, Cavazzin C, et al. Melanoma contains CD133 and ABCG2 positive cells with enhanced tumourigenic potential. Eur J Cancer. 2007;43:935&#x02013;46.<pub-id pub-id-type="pmid">17320377</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR321"><label>321.</label><citation-alternatives><element-citation id="ec-CR321" publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>D</given-names></name><name><surname>Kumar</surname><given-names>S</given-names></name><name><surname>Gorain</surname><given-names>M</given-names></name><name><surname>Tomar</surname><given-names>D</given-names></name><name><surname>Patil</surname><given-names>HS</given-names></name><name><surname>Radharani</surname><given-names>NN</given-names></name><etal/></person-group><article-title>Notch1-MAPK signaling axis regulates CD133+ cancer stem cell-mediated melanoma growth and angiogenesis</article-title><source>J Invest Dermatol</source><year>2016</year><volume>136</volume><fpage>2462</fpage><lpage>2474</lpage><pub-id pub-id-type="doi">10.1016/j.jid.2016.07.024</pub-id><pub-id pub-id-type="pmid">27476721</pub-id>
</element-citation><mixed-citation id="mc-CR321" publication-type="journal">Kumar D, Kumar S, Gorain M, Tomar D, Patil HS, Radharani NN, et al. Notch1-MAPK signaling axis regulates CD133+ cancer stem cell-mediated melanoma growth and angiogenesis. J Invest Dermatol. 2016;136:2462&#x02013;74.<pub-id pub-id-type="pmid">27476721</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR322"><label>322.</label><citation-alternatives><element-citation id="ec-CR322" publication-type="journal"><person-group person-group-type="author"><name><surname>Frank</surname><given-names>NY</given-names></name><name><surname>Schatton</surname><given-names>T</given-names></name><name><surname>Kim</surname><given-names>S</given-names></name><name><surname>Zhan</surname><given-names>Q</given-names></name><name><surname>Wilson</surname><given-names>BJ</given-names></name><name><surname>Ma</surname><given-names>J</given-names></name><etal/></person-group><article-title>VEGFR-1 expressed by malignant melanoma-initiating cells is required for tumor growth</article-title><source>Cancer Res</source><year>2011</year><volume>71</volume><fpage>1474</fpage><lpage>1485</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-10-1660</pub-id><pub-id pub-id-type="pmid">21212411</pub-id>
</element-citation><mixed-citation id="mc-CR322" publication-type="journal">Frank NY, Schatton T, Kim S, Zhan Q, Wilson BJ, Ma J, et al. VEGFR-1 expressed by malignant melanoma-initiating cells is required for tumor growth. Cancer Res. 2011;71:1474&#x02013;85.<pub-id pub-id-type="pmid">21212411</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR323"><label>323.</label><citation-alternatives><element-citation id="ec-CR323" publication-type="journal"><person-group person-group-type="author"><name><surname>Zimmerer</surname><given-names>RM</given-names></name><name><surname>Matthiesen</surname><given-names>P</given-names></name><name><surname>Kreher</surname><given-names>F</given-names></name><name><surname>Kampmann</surname><given-names>A</given-names></name><name><surname>Spalthoff</surname><given-names>S</given-names></name><name><surname>Jehn</surname><given-names>P</given-names></name><etal/></person-group><article-title>Putative CD133+ melanoma cancer stem cells induce initial angiogenesis in vivo</article-title><source>Microvasc Res</source><year>2016</year><volume>104</volume><fpage>46</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1016/j.mvr.2015.12.001</pub-id><pub-id pub-id-type="pmid">26656667</pub-id>
</element-citation><mixed-citation id="mc-CR323" publication-type="journal">Zimmerer RM, Matthiesen P, Kreher F, Kampmann A, Spalthoff S, Jehn P, et al. Putative CD133+ melanoma cancer stem cells induce initial angiogenesis in vivo. Microvasc Res. 2016;104:46&#x02013;54.<pub-id pub-id-type="pmid">26656667</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR324"><label>324.</label><citation-alternatives><element-citation id="ec-CR324" publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Abdeen</surname><given-names>AA</given-names></name><name><surname>Hedhli</surname><given-names>J</given-names></name><name><surname>Wycislo</surname><given-names>KL</given-names></name><name><surname>Dobrucka</surname><given-names>IT</given-names></name><name><surname>Fan</surname><given-names>TM</given-names></name><etal/></person-group><article-title>Melanoma topology reveals a stem-like phenotype that promotes angiogenesis</article-title><source>Sci Adv</source><year>2017</year><volume>3</volume><fpage>e1701350</fpage><pub-id pub-id-type="doi">10.1126/sciadv.1701350</pub-id><pub-id pub-id-type="pmid">29075670</pub-id>
</element-citation><mixed-citation id="mc-CR324" publication-type="journal">Lee J, Abdeen AA, Hedhli J, Wycislo KL, Dobrucka IT, Fan TM, et al. Melanoma topology reveals a stem-like phenotype that promotes angiogenesis. Sci Adv. 2017;3: e1701350.<pub-id pub-id-type="pmid">29075670</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR325"><label>325.</label><citation-alternatives><element-citation id="ec-CR325" publication-type="journal"><person-group person-group-type="author"><name><surname>Ciccone</surname><given-names>V</given-names></name><name><surname>Terzuoli</surname><given-names>E</given-names></name><name><surname>Ristori</surname><given-names>E</given-names></name><name><surname>Filippelli</surname><given-names>A</given-names></name><name><surname>Ziche</surname><given-names>M</given-names></name><name><surname>Morbidelli</surname><given-names>L</given-names></name><etal/></person-group><article-title>ALDH1A1 overexpression in melanoma cells promotes tumor angiogenesis by activating the IL-8/Notch signaling cascade</article-title><source>Int J Mol Med</source><year>2022</year><volume>50</volume><fpage>99</fpage><pub-id pub-id-type="doi">10.3892/ijmm.2022.5155</pub-id><pub-id pub-id-type="pmid">35656893</pub-id>
</element-citation><mixed-citation id="mc-CR325" publication-type="journal">Ciccone V, Terzuoli E, Ristori E, Filippelli A, Ziche M, Morbidelli L, et al. ALDH1A1 overexpression in melanoma cells promotes tumor angiogenesis by activating the IL-8/Notch signaling cascade. Int J Mol Med. 2022;50:99.<pub-id pub-id-type="pmid">35656893</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR326"><label>326.</label><citation-alternatives><element-citation id="ec-CR326" publication-type="journal"><person-group person-group-type="author"><name><surname>Hendrix</surname><given-names>MJC</given-names></name><name><surname>Seftor</surname><given-names>EA</given-names></name><name><surname>Hess</surname><given-names>AR</given-names></name><name><surname>Seftor</surname><given-names>REB</given-names></name></person-group><article-title>Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma</article-title><source>Nat Rev Cancer</source><year>2003</year><volume>3</volume><fpage>411</fpage><lpage>421</lpage><pub-id pub-id-type="doi">10.1038/nrc1092</pub-id><pub-id pub-id-type="pmid">12778131</pub-id>
</element-citation><mixed-citation id="mc-CR326" publication-type="journal">Hendrix MJC, Seftor EA, Hess AR, Seftor REB. Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma. Nat Rev Cancer. 2003;3:411&#x02013;21.<pub-id pub-id-type="pmid">12778131</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR327"><label>327.</label><citation-alternatives><element-citation id="ec-CR327" publication-type="journal"><person-group person-group-type="author"><name><surname>Lai</surname><given-names>CY</given-names></name><name><surname>Schwartz</surname><given-names>BE</given-names></name><name><surname>Hsu</surname><given-names>MY</given-names></name></person-group><article-title>CD133+ melanoma subpopulations contribute to perivascular niche morphogenesis and tumorigenicity through vasculogenic mimicry</article-title><source>Cancer Res</source><year>2012</year><volume>72</volume><fpage>5111</fpage><lpage>5118</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-12-0624</pub-id><pub-id pub-id-type="pmid">22865455</pub-id>
</element-citation><mixed-citation id="mc-CR327" publication-type="journal">Lai CY, Schwartz BE, Hsu MY. CD133+ melanoma subpopulations contribute to perivascular niche morphogenesis and tumorigenicity through vasculogenic mimicry. Cancer Res. 2012;72:5111&#x02013;8.<pub-id pub-id-type="pmid">22865455</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR328"><label>328.</label><citation-alternatives><element-citation id="ec-CR328" publication-type="journal"><person-group person-group-type="author"><name><surname>Spinella</surname><given-names>F</given-names></name><name><surname>Caprara</surname><given-names>V</given-names></name><name><surname>Cianfrocca</surname><given-names>R</given-names></name><name><surname>Rosan&#x000f2;</surname><given-names>L</given-names></name><name><surname>Di Castro</surname><given-names>V</given-names></name><name><surname>Garrafa</surname><given-names>E</given-names></name><etal/></person-group><article-title>The interplay between hypoxia, endothelial and melanoma cells regulates vascularization and cell motility through endothelin-1 and vascular endothelial growth factor</article-title><source>Carcinogenesis</source><year>2014</year><volume>35</volume><fpage>840</fpage><lpage>848</lpage><pub-id pub-id-type="doi">10.1093/carcin/bgu018</pub-id><pub-id pub-id-type="pmid">24473118</pub-id>
</element-citation><mixed-citation id="mc-CR328" publication-type="journal">Spinella F, Caprara V, Cianfrocca R, Rosan&#x000f2; L, Di Castro V, Garrafa E, et al. The interplay between hypoxia, endothelial and melanoma cells regulates vascularization and cell motility through endothelin-1 and vascular endothelial growth factor. Carcinogenesis. 2014;35:840&#x02013;8.<pub-id pub-id-type="pmid">24473118</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR329"><label>329.</label><citation-alternatives><element-citation id="ec-CR329" publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>N</given-names></name><name><surname>Barthel</surname><given-names>SR</given-names></name><name><surname>Schatton</surname><given-names>T</given-names></name></person-group><article-title>Melanoma stem cells and metastasis: mimicking hematopoietic cell trafficking?</article-title><source>Lab Invest</source><year>2014</year><volume>94</volume><fpage>13</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1038/labinvest.2013.116</pub-id><pub-id pub-id-type="pmid">24126889</pub-id>
</element-citation><mixed-citation id="mc-CR329" publication-type="journal">Lee N, Barthel SR, Schatton T. Melanoma stem cells and metastasis: mimicking hematopoietic cell trafficking? Lab Invest. 2014;94:13&#x02013;30.<pub-id pub-id-type="pmid">24126889</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR330"><label>330.</label><citation-alternatives><element-citation id="ec-CR330" publication-type="journal"><person-group person-group-type="author"><name><surname>Beck</surname><given-names>B</given-names></name><name><surname>Driessens</surname><given-names>G</given-names></name><name><surname>Goossens</surname><given-names>S</given-names></name><name><surname>Youssef</surname><given-names>KK</given-names></name><name><surname>Kuchnio</surname><given-names>A</given-names></name><name><surname>Caauwe</surname><given-names>A</given-names></name><etal/></person-group><article-title>A vascular niche and a VEGF-Nrp1 loop regulate the initiation and stemness of skin tumours</article-title><source>Nature</source><year>2011</year><volume>478</volume><fpage>399</fpage><lpage>403</lpage><pub-id pub-id-type="doi">10.1038/nature10525</pub-id><pub-id pub-id-type="pmid">22012397</pub-id>
</element-citation><mixed-citation id="mc-CR330" publication-type="journal">Beck B, Driessens G, Goossens S, Youssef KK, Kuchnio A, Caauwe A, et al. A vascular niche and a VEGF-Nrp1 loop regulate the initiation and stemness of skin tumours. Nature. 2011;478:399&#x02013;403.<pub-id pub-id-type="pmid">22012397</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR331"><label>331.</label><citation-alternatives><element-citation id="ec-CR331" publication-type="journal"><person-group person-group-type="author"><name><surname>Tzoutzos</surname><given-names>K</given-names></name><name><surname>Batistatou</surname><given-names>A</given-names></name><name><surname>Kitsos</surname><given-names>G</given-names></name><name><surname>Liasko</surname><given-names>R</given-names></name><name><surname>Stefanou</surname><given-names>D</given-names></name></person-group><article-title>Study of microvascular density and expression of vascular endothelial growth factor and its receptors in cancerous and precancerous lesions of the eyelids</article-title><source>Anticancer Res</source><year>2014</year><volume>34</volume><fpage>4977</fpage><lpage>4983</lpage><pub-id pub-id-type="pmid">25202080</pub-id>
</element-citation><mixed-citation id="mc-CR331" publication-type="journal">Tzoutzos K, Batistatou A, Kitsos G, Liasko R, Stefanou D. Study of microvascular density and expression of vascular endothelial growth factor and its receptors in cancerous and precancerous lesions of the eyelids. Anticancer Res. 2014;34:4977&#x02013;83.<pub-id pub-id-type="pmid">25202080</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR332"><label>332.</label><citation-alternatives><element-citation id="ec-CR332" publication-type="journal"><person-group person-group-type="author"><name><surname>Benwell</surname><given-names>CJ</given-names></name><name><surname>Johnson</surname><given-names>RT</given-names></name><name><surname>Taylor</surname><given-names>J</given-names></name><name><surname>Price</surname><given-names>CA</given-names></name><name><surname>Robinson</surname><given-names>SD</given-names></name></person-group><article-title>Endothelial VEGFR coreceptors neuropilin-1 and neuropilin-2 are essential for tumor angiogenesis</article-title><source>Cancer Res Commun</source><year>2022</year><volume>2</volume><fpage>1626</fpage><lpage>1640</lpage><pub-id pub-id-type="doi">10.1158/2767-9764.CRC-22-0250</pub-id><pub-id pub-id-type="pmid">36970722</pub-id>
</element-citation><mixed-citation id="mc-CR332" publication-type="journal">Benwell CJ, Johnson RT, Taylor J, Price CA, Robinson SD. Endothelial VEGFR coreceptors neuropilin-1 and neuropilin-2 are essential for tumor angiogenesis. Cancer Res Commun. 2022;2:1626&#x02013;40.<pub-id pub-id-type="pmid">36970722</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR333"><label>333.</label><mixed-citation publication-type="other">Wang X, Liu Y, He J, Wang J, Chen X, and Yang R. Regulation of signaling pathways in hair follicle stem cells. Burns Trauma. 2022; 10:tkac022.</mixed-citation></ref><ref id="CR334"><label>334.</label><mixed-citation publication-type="other">Park HL, Bai C, Platt KA, Matise MP, Beeghly A, Hui Cc, et al. Mouse Gli1 mutants are viable but have defects in SHH signaling in combination with a Gli2 mutation<italic>.</italic> Development. 2000; 127:1593&#x02013;1605.</mixed-citation></ref><ref id="CR335"><label>335.</label><citation-alternatives><element-citation id="ec-CR335" publication-type="journal"><person-group person-group-type="author"><name><surname>Mill</surname><given-names>P</given-names></name><name><surname>Mo</surname><given-names>R</given-names></name><name><surname>Hu</surname><given-names>MC</given-names></name><name><surname>Dagnino</surname><given-names>L</given-names></name><name><surname>Rosenblum</surname><given-names>ND</given-names></name><name><surname>Hui</surname><given-names>CC</given-names></name></person-group><article-title>Shh controls epithelial proliferation via independent pathways that converge on N-Myc</article-title><source>Dev Cell</source><year>2005</year><volume>9</volume><fpage>293</fpage><lpage>303</lpage><pub-id pub-id-type="doi">10.1016/j.devcel.2005.05.009</pub-id><pub-id pub-id-type="pmid">16054035</pub-id>
</element-citation><mixed-citation id="mc-CR335" publication-type="journal">Mill P, Mo R, Hu MC, Dagnino L, Rosenblum ND, Hui CC. Shh controls epithelial proliferation via independent pathways that converge on N-Myc. Dev Cell. 2005;9:293&#x02013;303.<pub-id pub-id-type="pmid">16054035</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR336"><label>336.</label><citation-alternatives><element-citation id="ec-CR336" publication-type="journal"><person-group person-group-type="author"><name><surname>Driskell</surname><given-names>RR</given-names></name><name><surname>Giangreco</surname><given-names>A</given-names></name><name><surname>Jensen</surname><given-names>KB</given-names></name><name><surname>Mulder</surname><given-names>KW</given-names></name><name><surname>Watt</surname><given-names>FM</given-names></name></person-group><article-title>Sox2-positive dermal papilla cells specify hair follicle type in mammalian epidermis</article-title><source>Development</source><year>2009</year><volume>136</volume><fpage>2815</fpage><lpage>2823</lpage><pub-id pub-id-type="doi">10.1242/dev.038620</pub-id><pub-id pub-id-type="pmid">19605494</pub-id>
</element-citation><mixed-citation id="mc-CR336" publication-type="journal">Driskell RR, Giangreco A, Jensen KB, Mulder KW, Watt FM. Sox2-positive dermal papilla cells specify hair follicle type in mammalian epidermis. Development. 2009;136:2815&#x02013;23.<pub-id pub-id-type="pmid">19605494</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR337"><label>337.</label><citation-alternatives><element-citation id="ec-CR337" publication-type="journal"><person-group person-group-type="author"><name><surname>Duman-Scheel</surname><given-names>M</given-names></name><name><surname>Weng</surname><given-names>L</given-names></name><name><surname>Xin</surname><given-names>S</given-names></name><name><surname>Du</surname><given-names>W</given-names></name></person-group><article-title>Hedgehog regulates cell growth and proliferation by inducing Cyclin D and Cyclin E</article-title><source>Nature</source><year>2002</year><volume>417</volume><fpage>299</fpage><lpage>304</lpage><pub-id pub-id-type="doi">10.1038/417299a</pub-id><pub-id pub-id-type="pmid">12015606</pub-id>
</element-citation><mixed-citation id="mc-CR337" publication-type="journal">Duman-Scheel M, Weng L, Xin S, Du W. Hedgehog regulates cell growth and proliferation by inducing Cyclin D and Cyclin E. Nature. 2002;417:299&#x02013;304.<pub-id pub-id-type="pmid">12015606</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR338"><label>338.</label><mixed-citation publication-type="other">Adolphe C, Nieuwenhuis E, Villani R, Li ZJ, Kaur P, Hui C-c, et al. Patched 1 and patched 2 redundancy has a key role in regulating epidermal differentiation<italic>.</italic> J Invest Dermatol. 2014; 134:1981&#x02013;1990.</mixed-citation></ref><ref id="CR339"><label>339.</label><citation-alternatives><element-citation id="ec-CR339" publication-type="journal"><person-group person-group-type="author"><name><surname>Jeong</surname><given-names>J</given-names></name><name><surname>McMahon</surname><given-names>AP</given-names></name></person-group><article-title>Growth and pattern of the mammalian neural tube are governed by partially overlapping feedback activities of the hedgehog antagonists patched 1 and Hhip1</article-title><source>Development</source><year>2005</year><volume>132</volume><fpage>143</fpage><lpage>154</lpage><pub-id pub-id-type="doi">10.1242/dev.01566</pub-id><pub-id pub-id-type="pmid">15576403</pub-id>
</element-citation><mixed-citation id="mc-CR339" publication-type="journal">Jeong J, McMahon AP. Growth and pattern of the mammalian neural tube are governed by partially overlapping feedback activities of the hedgehog antagonists patched 1 and Hhip1. Development. 2005;132:143&#x02013;54.<pub-id pub-id-type="pmid">15576403</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR340"><label>340.</label><citation-alternatives><element-citation id="ec-CR340" publication-type="journal"><person-group person-group-type="author"><name><surname>Adolphe</surname><given-names>C</given-names></name><name><surname>Junker</surname><given-names>JP</given-names></name><name><surname>Lyubimova</surname><given-names>A</given-names></name><name><surname>van Oudenaarden</surname><given-names>A</given-names></name><name><surname>Wainwright</surname><given-names>B</given-names></name></person-group><article-title>Patched receptors sense, interpret, and establish an epidermal hedgehog signaling gradient</article-title><source>J Invest Dermatol</source><year>2017</year><volume>137</volume><fpage>179</fpage><lpage>186</lpage><pub-id pub-id-type="doi">10.1016/j.jid.2016.06.632</pub-id><pub-id pub-id-type="pmid">27498049</pub-id>
</element-citation><mixed-citation id="mc-CR340" publication-type="journal">Adolphe C, Junker JP, Lyubimova A, van Oudenaarden A, Wainwright B. Patched receptors sense, interpret, and establish an epidermal hedgehog signaling gradient. J Invest Dermatol. 2017;137:179&#x02013;86.<pub-id pub-id-type="pmid">27498049</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR341"><label>341.</label><citation-alternatives><element-citation id="ec-CR341" publication-type="journal"><person-group person-group-type="author"><name><surname>Celso</surname><given-names>CL</given-names></name><name><surname>Prowse</surname><given-names>DM</given-names></name><name><surname>Watt</surname><given-names>FM</given-names></name></person-group><article-title>Transient activation of &#x003b2;-catenin signalling in adult mouse epidermis is sufficient to induce new hair follicles but continuous activation is required to maintain hair follicle tumours</article-title><source>Development</source><year>2004</year><volume>131</volume><fpage>1787</fpage><lpage>1799</lpage><pub-id pub-id-type="doi">10.1242/dev.01052</pub-id><pub-id pub-id-type="pmid">15084463</pub-id>
</element-citation><mixed-citation id="mc-CR341" publication-type="journal">Celso CL, Prowse DM, Watt FM. Transient activation of &#x003b2;-catenin signalling in adult mouse epidermis is sufficient to induce new hair follicles but continuous activation is required to maintain hair follicle tumours. Development. 2004;131:1787&#x02013;99.<pub-id pub-id-type="pmid">15084463</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR342"><label>342.</label><citation-alternatives><element-citation id="ec-CR342" publication-type="journal"><person-group person-group-type="author"><name><surname>Suen</surname><given-names>WJ</given-names></name><name><surname>Li</surname><given-names>ST</given-names></name><name><surname>Yang</surname><given-names>LT</given-names></name></person-group><article-title>Hes1 regulates anagen initiation and hair follicle regeneration through modulation of hedgehog signaling</article-title><source>Stem Cells</source><year>2020</year><volume>38</volume><fpage>301</fpage><lpage>314</lpage><pub-id pub-id-type="doi">10.1002/stem.3117</pub-id><pub-id pub-id-type="pmid">31721388</pub-id>
</element-citation><mixed-citation id="mc-CR342" publication-type="journal">Suen WJ, Li ST, Yang LT. Hes1 regulates anagen initiation and hair follicle regeneration through modulation of hedgehog signaling. Stem Cells. 2020;38:301&#x02013;14.<pub-id pub-id-type="pmid">31721388</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR343"><label>343.</label><citation-alternatives><element-citation id="ec-CR343" publication-type="journal"><person-group person-group-type="author"><name><surname>Reddy</surname><given-names>S</given-names></name><name><surname>Andl</surname><given-names>T</given-names></name><name><surname>Bagasra</surname><given-names>A</given-names></name><name><surname>Lu</surname><given-names>MM</given-names></name><name><surname>Epstein</surname><given-names>DJ</given-names></name><name><surname>Morrisey</surname><given-names>EE</given-names></name><etal/></person-group><article-title>Characterization of Wnt gene expression in developing and postnatal hair follicles and identification of Wnt5a as a target of Sonic hedgehog in hair follicle morphogenesis</article-title><source>Mech Dev</source><year>2001</year><volume>107</volume><fpage>69</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1016/S0925-4773(01)00452-X</pub-id><pub-id pub-id-type="pmid">11520664</pub-id>
</element-citation><mixed-citation id="mc-CR343" publication-type="journal">Reddy S, Andl T, Bagasra A, Lu MM, Epstein DJ, Morrisey EE, et al. Characterization of Wnt gene expression in developing and postnatal hair follicles and identification of Wnt5a as a target of Sonic hedgehog in hair follicle morphogenesis. Mech Dev. 2001;107:69&#x02013;82.<pub-id pub-id-type="pmid">11520664</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR344"><label>344.</label><citation-alternatives><element-citation id="ec-CR344" publication-type="journal"><person-group person-group-type="author"><name><surname>Kwack</surname><given-names>MH</given-names></name><name><surname>Kim</surname><given-names>MK</given-names></name><name><surname>Kim</surname><given-names>JC</given-names></name><name><surname>Sung</surname><given-names>YK</given-names></name></person-group><article-title>Wnt5a attenuates Wnt/&#x003b2;-catenin signalling in human dermal papilla cells</article-title><source>Exp Dermatol</source><year>2013</year><volume>22</volume><fpage>229</fpage><lpage>231</lpage><pub-id pub-id-type="doi">10.1111/exd.12101</pub-id><pub-id pub-id-type="pmid">23489428</pub-id>
</element-citation><mixed-citation id="mc-CR344" publication-type="journal">Kwack MH, Kim MK, Kim JC, Sung YK. Wnt5a attenuates Wnt/&#x003b2;-catenin signalling in human dermal papilla cells. Exp Dermatol. 2013;22:229&#x02013;31.<pub-id pub-id-type="pmid">23489428</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR345"><label>345.</label><citation-alternatives><element-citation id="ec-CR345" publication-type="journal"><person-group person-group-type="author"><name><surname>Clevers</surname><given-names>H</given-names></name><name><surname>Loh</surname><given-names>KM</given-names></name><name><surname>Nusse</surname><given-names>R</given-names></name></person-group><article-title>An integral program for tissue renewal and regeneration: Wnt signaling and stem cell control</article-title><source>Science</source><year>2014</year><volume>346</volume><fpage>1248012</fpage><pub-id pub-id-type="doi">10.1126/science.1248012</pub-id><pub-id pub-id-type="pmid">25278615</pub-id>
</element-citation><mixed-citation id="mc-CR345" publication-type="journal">Clevers H, Loh KM, Nusse R. An integral program for tissue renewal and regeneration: Wnt signaling and stem cell control. Science. 2014;346:1248012.<pub-id pub-id-type="pmid">25278615</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR346"><label>346.</label><citation-alternatives><element-citation id="ec-CR346" publication-type="journal"><person-group person-group-type="author"><name><surname>Lim</surname><given-names>X</given-names></name><name><surname>Tan</surname><given-names>SH</given-names></name><name><surname>Koh</surname><given-names>WLC</given-names></name><name><surname>Chau</surname><given-names>RMW</given-names></name><name><surname>Yan</surname><given-names>KS</given-names></name><name><surname>Kuo</surname><given-names>CJ</given-names></name><etal/></person-group><article-title>Interfollicular epidermal stem cells self-renew via autocrine Wnt signaling</article-title><source>Science</source><year>2013</year><volume>342</volume><fpage>1226</fpage><lpage>1230</lpage><pub-id pub-id-type="doi">10.1126/science.1239730</pub-id><pub-id pub-id-type="pmid">24311688</pub-id>
</element-citation><mixed-citation id="mc-CR346" publication-type="journal">Lim X, Tan SH, Koh WLC, Chau RMW, Yan KS, Kuo CJ, et al. Interfollicular epidermal stem cells self-renew via autocrine Wnt signaling. Science. 2013;342:1226&#x02013;30.<pub-id pub-id-type="pmid">24311688</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR347"><label>347.</label><citation-alternatives><element-citation id="ec-CR347" publication-type="journal"><person-group person-group-type="author"><name><surname>Leng</surname><given-names>L</given-names></name><name><surname>Ma</surname><given-names>J</given-names></name><name><surname>Lv</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Gao</surname><given-names>D</given-names></name><name><surname>Zhu</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Both Wnt signaling and epidermal stem cell-derived extracellular vesicles are involved in epidermal cell growth</article-title><source>Stem Cell Res Ther</source><year>2020</year><volume>11</volume><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1186/s13287-020-01933-y</pub-id><pub-id pub-id-type="pmid">31900237</pub-id>
</element-citation><mixed-citation id="mc-CR347" publication-type="journal">Leng L, Ma J, Lv L, Wang W, Gao D, Zhu Y, et al. Both Wnt signaling and epidermal stem cell-derived extracellular vesicles are involved in epidermal cell growth. Stem Cell Res Ther. 2020;11:1&#x02013;11.<pub-id pub-id-type="pmid">31900237</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR348"><label>348.</label><citation-alternatives><element-citation id="ec-CR348" publication-type="journal"><person-group person-group-type="author"><name><surname>Lim</surname><given-names>X</given-names></name><name><surname>Tan</surname><given-names>SH</given-names></name><name><surname>Yu</surname><given-names>KL</given-names></name><name><surname>Lim</surname><given-names>SB</given-names></name><name><surname>Nusse</surname><given-names>R</given-names></name></person-group><article-title>Axin2 marks quiescent hair follicle bulge stem cells that are maintained by autocrine Wnt/&#x003b2;-catenin signaling</article-title><source>Proc Natl Acad Sci U S A</source><year>2016</year><volume>113</volume><fpage>E1498</fpage><lpage>E1505</lpage><pub-id pub-id-type="doi">10.1073/pnas.1601599113</pub-id><pub-id pub-id-type="pmid">26903625</pub-id>
</element-citation><mixed-citation id="mc-CR348" publication-type="journal">Lim X, Tan SH, Yu KL, Lim SB, Nusse R. Axin2 marks quiescent hair follicle bulge stem cells that are maintained by autocrine Wnt/&#x003b2;-catenin signaling. Proc Natl Acad Sci U S A. 2016;113:E1498&#x02013;1505.<pub-id pub-id-type="pmid">26903625</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR349"><label>349.</label><citation-alternatives><element-citation id="ec-CR349" publication-type="journal"><person-group person-group-type="author"><name><surname>Vance</surname><given-names>KW</given-names></name><name><surname>Goding</surname><given-names>CR</given-names></name></person-group><article-title>The transcription network regulating melanocyte development and melanoma</article-title><source>Pigment Cell Res</source><year>2004</year><volume>17</volume><fpage>318</fpage><lpage>325</lpage><pub-id pub-id-type="doi">10.1111/j.1600-0749.2004.00164.x</pub-id><pub-id pub-id-type="pmid">15250933</pub-id>
</element-citation><mixed-citation id="mc-CR349" publication-type="journal">Vance KW, Goding CR. The transcription network regulating melanocyte development and melanoma. Pigment Cell Res. 2004;17:318&#x02013;25.<pub-id pub-id-type="pmid">15250933</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR350"><label>350.</label><citation-alternatives><element-citation id="ec-CR350" publication-type="journal"><person-group person-group-type="author"><name><surname>Totaro</surname><given-names>A</given-names></name><name><surname>Castellan</surname><given-names>M</given-names></name><name><surname>Battilana</surname><given-names>G</given-names></name><name><surname>Zanconato</surname><given-names>F</given-names></name><name><surname>Azzolin</surname><given-names>L</given-names></name><name><surname>Giulitti</surname><given-names>S</given-names></name><etal/></person-group><article-title>YAP/TAZ link cell mechanics to Notch signalling to control epidermal stem cell fate</article-title><source>Nat Commun</source><year>2017</year><volume>8</volume><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1038/ncomms15206</pub-id><pub-id pub-id-type="pmid">28232747</pub-id>
</element-citation><mixed-citation id="mc-CR350" publication-type="journal">Totaro A, Castellan M, Battilana G, Zanconato F, Azzolin L, Giulitti S, et al. YAP/TAZ link cell mechanics to Notch signalling to control epidermal stem cell fate. Nat Commun. 2017;8:1&#x02013;13.<pub-id pub-id-type="pmid">28232747</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR351"><label>351.</label><citation-alternatives><element-citation id="ec-CR351" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Pasolli</surname><given-names>HA</given-names></name><name><surname>Fuchs</surname><given-names>E</given-names></name></person-group><article-title>Yes-associated protein (YAP) transcriptional coactivator functions in balancing growth and differentiation in skin</article-title><source>Proc Natl Acad Sci U S A</source><year>2011</year><volume>108</volume><fpage>2270</fpage><lpage>2275</lpage><pub-id pub-id-type="doi">10.1073/pnas.1019603108</pub-id><pub-id pub-id-type="pmid">21262812</pub-id>
</element-citation><mixed-citation id="mc-CR351" publication-type="journal">Zhang H, Pasolli HA, Fuchs E. Yes-associated protein (YAP) transcriptional coactivator functions in balancing growth and differentiation in skin. Proc Natl Acad Sci U S A. 2011;108:2270&#x02013;5.<pub-id pub-id-type="pmid">21262812</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR352"><label>352.</label><citation-alternatives><element-citation id="ec-CR352" publication-type="journal"><person-group person-group-type="author"><name><surname>De Rosa</surname><given-names>L</given-names></name><name><surname>Seconetti</surname><given-names>AS</given-names></name><name><surname>De Santis</surname><given-names>G</given-names></name><name><surname>Pellacani</surname><given-names>G</given-names></name><name><surname>Hirsch</surname><given-names>T</given-names></name><name><surname>Rothoeft</surname><given-names>T</given-names></name><etal/></person-group><article-title>Laminin 332-dependent YAP dysregulation depletes epidermal stem cells in junctional epidermolysis bullosa</article-title><source>Cell Rep</source><year>2019</year><volume>27</volume><fpage>2036</fpage><lpage>2049.e6</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2019.04.055</pub-id><pub-id pub-id-type="pmid">31091444</pub-id>
</element-citation><mixed-citation id="mc-CR352" publication-type="journal">De Rosa L, Seconetti AS, De Santis G, Pellacani G, Hirsch T, Rothoeft T, et al. Laminin 332-dependent YAP dysregulation depletes epidermal stem cells in junctional epidermolysis bullosa. Cell Rep. 2019;27:2036-2049.e6.<pub-id pub-id-type="pmid">31091444</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR353"><label>353.</label><mixed-citation publication-type="other">Kenny FN, Drymoussi Z, Delaine-Smith R, Kao AP, Laly AC, Knight MM, et al. Tissue stiffening promotes keratinocyte proliferation through activation of epidermal growth factor signaling<italic>.</italic> J Cell Sci. 2018; 131:jcs215780.</mixed-citation></ref><ref id="CR354"><label>354.</label><citation-alternatives><element-citation id="ec-CR354" publication-type="journal"><person-group person-group-type="author"><name><surname>Benham-Pyle</surname><given-names>BW</given-names></name><name><surname>Pruitt</surname><given-names>BL</given-names></name><name><surname>Nelson</surname><given-names>WJ</given-names></name></person-group><article-title>Mechanical strain induces E-cadherin&#x02013;dependent Yap1 and &#x003b2;-catenin activation to drive cell cycle entry</article-title><source>Science</source><year>2015</year><volume>348</volume><fpage>1024</fpage><lpage>1027</lpage><pub-id pub-id-type="doi">10.1126/science.aaa4559</pub-id><pub-id pub-id-type="pmid">26023140</pub-id>
</element-citation><mixed-citation id="mc-CR354" publication-type="journal">Benham-Pyle BW, Pruitt BL, Nelson WJ. Mechanical strain induces E-cadherin&#x02013;dependent Yap1 and &#x003b2;-catenin activation to drive cell cycle entry. Science. 2015;348:1024&#x02013;7.<pub-id pub-id-type="pmid">26023140</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR355"><label>355.</label><citation-alternatives><element-citation id="ec-CR355" publication-type="journal"><person-group person-group-type="author"><name><surname>Ya</surname><given-names>C</given-names></name><name><surname>Carranc&#x000e1;</surname><given-names>M</given-names></name><name><surname>Sigaudo-Roussel</surname><given-names>D</given-names></name><name><surname>Faure</surname><given-names>P</given-names></name><name><surname>Fromy</surname><given-names>B</given-names></name><name><surname>Debret</surname><given-names>R</given-names></name></person-group><article-title>Substrate softness promotes terminal differentiation of human keratinocytes without altering their ability to proliferate back into a rigid environment</article-title><source>Arch Dermatol Res</source><year>2019</year><volume>311</volume><fpage>741</fpage><lpage>751</lpage><pub-id pub-id-type="doi">10.1007/s00403-019-01962-5</pub-id><pub-id pub-id-type="pmid">31392392</pub-id>
</element-citation><mixed-citation id="mc-CR355" publication-type="journal">Ya C, Carranc&#x000e1; M, Sigaudo-Roussel D, Faure P, Fromy B, Debret R. Substrate softness promotes terminal differentiation of human keratinocytes without altering their ability to proliferate back into a rigid environment. Arch Dermatol Res. 2019;311:741&#x02013;51.<pub-id pub-id-type="pmid">31392392</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR356"><label>356.</label><citation-alternatives><element-citation id="ec-CR356" publication-type="journal"><person-group person-group-type="author"><name><surname>Elbediwy</surname><given-names>A</given-names></name><name><surname>Vincent-Mistiaen</surname><given-names>ZI</given-names></name><name><surname>Spencer-Dene</surname><given-names>B</given-names></name><name><surname>Stone</surname><given-names>RK</given-names></name><name><surname>Boeing</surname><given-names>S</given-names></name><name><surname>Wculek</surname><given-names>SK</given-names></name><etal/></person-group><article-title>Integrin signalling regulates YAP and TAZ to control skin homeostasis</article-title><source>Development</source><year>2016</year><volume>143</volume><fpage>1674</fpage><lpage>1687</lpage><pub-id pub-id-type="pmid">26989177</pub-id>
</element-citation><mixed-citation id="mc-CR356" publication-type="journal">Elbediwy A, Vincent-Mistiaen ZI, Spencer-Dene B, Stone RK, Boeing S, Wculek SK, et al. Integrin signalling regulates YAP and TAZ to control skin homeostasis. Development. 2016;143:1674&#x02013;87.<pub-id pub-id-type="pmid">26989177</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR357"><label>357.</label><citation-alternatives><element-citation id="ec-CR357" publication-type="journal"><person-group person-group-type="author"><name><surname>Sambandam</surname><given-names>SA</given-names></name><name><surname>Kasetti</surname><given-names>RB</given-names></name><name><surname>Xue</surname><given-names>L</given-names></name><name><surname>Dean</surname><given-names>DC</given-names></name><name><surname>Lu</surname><given-names>Q</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name></person-group><article-title>14-3-3&#x003c3; regulates keratinocyte proliferation and differentiation by modulating Yap1 cellular localization</article-title><source>J Invest Dermatol</source><year>2015</year><volume>135</volume><fpage>1621</fpage><lpage>1628</lpage><pub-id pub-id-type="doi">10.1038/jid.2015.42</pub-id><pub-id pub-id-type="pmid">25668240</pub-id>
</element-citation><mixed-citation id="mc-CR357" publication-type="journal">Sambandam SA, Kasetti RB, Xue L, Dean DC, Lu Q, Li Q. 14-3-3&#x003c3; regulates keratinocyte proliferation and differentiation by modulating Yap1 cellular localization. J Invest Dermatol. 2015;135:1621&#x02013;8.<pub-id pub-id-type="pmid">25668240</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR358"><label>358.</label><citation-alternatives><element-citation id="ec-CR358" publication-type="journal"><person-group person-group-type="author"><name><surname>Akladios</surname><given-names>B</given-names></name><name><surname>Mendoza Reinoso</surname><given-names>V</given-names></name><name><surname>Cain</surname><given-names>JE</given-names></name><name><surname>Wang</surname><given-names>T</given-names></name><name><surname>Lambie</surname><given-names>DL</given-names></name><name><surname>Watkins</surname><given-names>DN</given-names></name><etal/></person-group><article-title>Positive regulatory interactions between YAP and Hedgehog signalling in skin homeostasis and BCC development in mouse skin in vivo</article-title><source>PLoS ONE</source><year>2017</year><volume>12</volume><fpage>e0183178</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0183178</pub-id><pub-id pub-id-type="pmid">28820907</pub-id>
</element-citation><mixed-citation id="mc-CR358" publication-type="journal">Akladios B, Mendoza Reinoso V, Cain JE, Wang T, Lambie DL, Watkins DN, et al. Positive regulatory interactions between YAP and Hedgehog signalling in skin homeostasis and BCC development in mouse skin in vivo. PLoS ONE. 2017;12: e0183178.<pub-id pub-id-type="pmid">28820907</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR359"><label>359.</label><citation-alternatives><element-citation id="ec-CR359" publication-type="journal"><person-group person-group-type="author"><name><surname>Mendoza-Reinoso</surname><given-names>V</given-names></name><name><surname>Beverdam</surname><given-names>A</given-names></name></person-group><article-title>Epidermal YAP activity drives canonical WNT16/&#x003b2;-catenin signaling to promote keratinocyte proliferation in vitro and in the murine skin</article-title><source>Stem Cell Res</source><year>2018</year><volume>29</volume><fpage>15</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1016/j.scr.2018.03.005</pub-id><pub-id pub-id-type="pmid">29562208</pub-id>
</element-citation><mixed-citation id="mc-CR359" publication-type="journal">Mendoza-Reinoso V, Beverdam A. Epidermal YAP activity drives canonical WNT16/&#x003b2;-catenin signaling to promote keratinocyte proliferation in vitro and in the murine skin. Stem Cell Res. 2018;29:15&#x02013;23.<pub-id pub-id-type="pmid">29562208</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR360"><label>360.</label><citation-alternatives><element-citation id="ec-CR360" publication-type="journal"><person-group person-group-type="author"><name><surname>Akladios</surname><given-names>B</given-names></name><name><surname>Mendoza-Reinoso</surname><given-names>V</given-names></name><name><surname>Samuel</surname><given-names>MS</given-names></name><name><surname>Hardeman</surname><given-names>EC</given-names></name><name><surname>Khosrotehrani</surname><given-names>K</given-names></name><name><surname>Key</surname><given-names>B</given-names></name><etal/></person-group><article-title>Epidermal YAP2-5SA-&#x00394;C drives &#x003b2;-catenin activation to promote keratinocyte proliferation in mouse skin in vivo</article-title><source>J Invest Dermatol</source><year>2017</year><volume>137</volume><fpage>716</fpage><lpage>726</lpage><pub-id pub-id-type="doi">10.1016/j.jid.2016.10.029</pub-id><pub-id pub-id-type="pmid">27816394</pub-id>
</element-citation><mixed-citation id="mc-CR360" publication-type="journal">Akladios B, Mendoza-Reinoso V, Samuel MS, Hardeman EC, Khosrotehrani K, Key B, et al. Epidermal YAP2-5SA-&#x00394;C drives &#x003b2;-catenin activation to promote keratinocyte proliferation in mouse skin in vivo. J Invest Dermatol. 2017;137:716&#x02013;26.<pub-id pub-id-type="pmid">27816394</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR361"><label>361.</label><citation-alternatives><element-citation id="ec-CR361" publication-type="journal"><person-group person-group-type="author"><name><surname>Rangarajan</surname><given-names>A</given-names></name><name><surname>Talora</surname><given-names>C</given-names></name><name><surname>Okuyama</surname><given-names>R</given-names></name><name><surname>Nicolas</surname><given-names>M</given-names></name><name><surname>Mammucari</surname><given-names>C</given-names></name><name><surname>Oh</surname><given-names>H</given-names></name><etal/></person-group><article-title>Notch signaling is a direct determinant of keratinocyte growth arrest and entry into differentiation</article-title><source>EMBO J</source><year>2001</year><volume>20</volume><fpage>3427</fpage><lpage>3436</lpage><pub-id pub-id-type="doi">10.1093/emboj/20.13.3427</pub-id><pub-id pub-id-type="pmid">11432830</pub-id>
</element-citation><mixed-citation id="mc-CR361" publication-type="journal">Rangarajan A, Talora C, Okuyama R, Nicolas M, Mammucari C, Oh H, et al. Notch signaling is a direct determinant of keratinocyte growth arrest and entry into differentiation. EMBO J. 2001;20:3427&#x02013;36.<pub-id pub-id-type="pmid">11432830</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR362"><label>362.</label><citation-alternatives><element-citation id="ec-CR362" publication-type="journal"><person-group person-group-type="author"><name><surname>Devgan</surname><given-names>V</given-names></name><name><surname>Mammucari</surname><given-names>C</given-names></name><name><surname>Millar</surname><given-names>SE</given-names></name><name><surname>Brisken</surname><given-names>C</given-names></name><name><surname>Dotto</surname><given-names>GP</given-names></name></person-group><article-title>p21WAF1/Cip1 is a negative transcriptional regulator of Wnt4 expression downstream of Notch1 activation</article-title><source>Genes Dev</source><year>2005</year><volume>19</volume><fpage>1485</fpage><lpage>1495</lpage><pub-id pub-id-type="doi">10.1101/gad.341405</pub-id><pub-id pub-id-type="pmid">15964998</pub-id>
</element-citation><mixed-citation id="mc-CR362" publication-type="journal">Devgan V, Mammucari C, Millar SE, Brisken C, Dotto GP. p21WAF1/Cip1 is a negative transcriptional regulator of Wnt4 expression downstream of Notch1 activation. Genes Dev. 2005;19:1485&#x02013;95.<pub-id pub-id-type="pmid">15964998</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR363"><label>363.</label><citation-alternatives><element-citation id="ec-CR363" publication-type="journal"><person-group person-group-type="author"><name><surname>Negri</surname><given-names>VA</given-names></name><name><surname>Logtenberg</surname><given-names>MEW</given-names></name><name><surname>Renz</surname><given-names>LM</given-names></name><name><surname>Oules</surname><given-names>B</given-names></name><name><surname>Walko</surname><given-names>G</given-names></name><name><surname>Watt</surname><given-names>FM</given-names></name></person-group><article-title>Delta-like 1-mediated cis-inhibition of Jagged1/2 signalling inhibits differentiation of human epidermal cells in culture</article-title><source>Sci Rep</source><year>2019</year><volume>9</volume><fpage>10825</fpage><pub-id pub-id-type="doi">10.1038/s41598-019-47232-2</pub-id><pub-id pub-id-type="pmid">31346203</pub-id>
</element-citation><mixed-citation id="mc-CR363" publication-type="journal">Negri VA, Logtenberg MEW, Renz LM, Oules B, Walko G, Watt FM. Delta-like 1-mediated cis-inhibition of Jagged1/2 signalling inhibits differentiation of human epidermal cells in culture. Sci Rep. 2019;9:10825.<pub-id pub-id-type="pmid">31346203</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR364"><label>364.</label><citation-alternatives><element-citation id="ec-CR364" publication-type="journal"><person-group person-group-type="author"><name><surname>Negri</surname><given-names>VA</given-names></name><name><surname>Louis</surname><given-names>B</given-names></name><name><surname>Zijl</surname><given-names>S</given-names></name><name><surname>Ganier</surname><given-names>C</given-names></name><name><surname>Philippeos</surname><given-names>C</given-names></name><name><surname>Ali</surname><given-names>S</given-names></name><etal/></person-group><article-title>Single-cell RNA sequencing of human epidermis identifies Lunatic fringe as a novel regulator of the stem cell compartment</article-title><source>Stem Cell Reports</source><year>2023</year><volume>18</volume><fpage>2047</fpage><lpage>2055</lpage><pub-id pub-id-type="doi">10.1016/j.stemcr.2023.09.007</pub-id><pub-id pub-id-type="pmid">37832539</pub-id>
</element-citation><mixed-citation id="mc-CR364" publication-type="journal">Negri VA, Louis B, Zijl S, Ganier C, Philippeos C, Ali S, et al. Single-cell RNA sequencing of human epidermis identifies Lunatic fringe as a novel regulator of the stem cell compartment. Stem Cell Reports. 2023;18:2047&#x02013;55.<pub-id pub-id-type="pmid">37832539</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR365"><label>365.</label><citation-alternatives><element-citation id="ec-CR365" publication-type="journal"><person-group person-group-type="author"><name><surname>Watt</surname><given-names>FM</given-names></name><name><surname>Estrach</surname><given-names>S</given-names></name><name><surname>Ambler</surname><given-names>CA</given-names></name></person-group><article-title>Epidermal Notch signalling: differentiation, cancer and adhesion</article-title><source>Curr Opin Cell Biol</source><year>2008</year><volume>20</volume><fpage>171</fpage><lpage>179</lpage><pub-id pub-id-type="doi">10.1016/j.ceb.2008.01.010</pub-id><pub-id pub-id-type="pmid">18342499</pub-id>
</element-citation><mixed-citation id="mc-CR365" publication-type="journal">Watt FM, Estrach S, Ambler CA. Epidermal Notch signalling: differentiation, cancer and adhesion. Curr Opin Cell Biol. 2008;20:171&#x02013;9.<pub-id pub-id-type="pmid">18342499</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR366"><label>366.</label><citation-alternatives><element-citation id="ec-CR366" publication-type="journal"><person-group person-group-type="author"><name><surname>Lefort</surname><given-names>K</given-names></name><name><surname>Mandinova</surname><given-names>A</given-names></name><name><surname>Ostano</surname><given-names>P</given-names></name><name><surname>Kolev</surname><given-names>V</given-names></name><name><surname>Calpini</surname><given-names>V</given-names></name><name><surname>Kolfschoten</surname><given-names>I</given-names></name><etal/></person-group><article-title>Notch1 is a p53 target gene involved in human keratinocyte tumor suppression through negative regulation of ROCK1/2 and MRCK&#x003b1; kinases</article-title><source>Genes Dev</source><year>2007</year><volume>21</volume><fpage>562</fpage><lpage>577</lpage><pub-id pub-id-type="doi">10.1101/gad.1484707</pub-id><pub-id pub-id-type="pmid">17344417</pub-id>
</element-citation><mixed-citation id="mc-CR366" publication-type="journal">Lefort K, Mandinova A, Ostano P, Kolev V, Calpini V, Kolfschoten I, et al. Notch1 is a p53 target gene involved in human keratinocyte tumor suppression through negative regulation of ROCK1/2 and MRCK&#x003b1; kinases. Genes Dev. 2007;21:562&#x02013;77.<pub-id pub-id-type="pmid">17344417</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR367"><label>367.</label><citation-alternatives><element-citation id="ec-CR367" publication-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>B-C</given-names></name><name><surname>Lefort</surname><given-names>K</given-names></name><name><surname>Mandinova</surname><given-names>A</given-names></name><name><surname>Antonini</surname><given-names>D</given-names></name><name><surname>Devgan</surname><given-names>V</given-names></name><name><surname>Della Gatta</surname><given-names>G</given-names></name><etal/></person-group><article-title>Cross-regulation between Notch and p63 in keratinocyte commitment to differentiation</article-title><source>Genes Dev</source><year>2006</year><volume>20</volume><fpage>1028</fpage><lpage>1042</lpage><pub-id pub-id-type="doi">10.1101/gad.1406006</pub-id><pub-id pub-id-type="pmid">16618808</pub-id>
</element-citation><mixed-citation id="mc-CR367" publication-type="journal">Nguyen B-C, Lefort K, Mandinova A, Antonini D, Devgan V, Della Gatta G, et al. Cross-regulation between Notch and p63 in keratinocyte commitment to differentiation. Genes Dev. 2006;20:1028&#x02013;42.<pub-id pub-id-type="pmid">16618808</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR368"><label>368.</label><citation-alternatives><element-citation id="ec-CR368" publication-type="journal"><person-group person-group-type="author"><name><surname>Restivo</surname><given-names>G</given-names></name><name><surname>Nguyen</surname><given-names>BC</given-names></name><name><surname>Dziunycz</surname><given-names>P</given-names></name><name><surname>Ristorcelli</surname><given-names>E</given-names></name><name><surname>Ryan</surname><given-names>RJ</given-names></name><name><surname>&#x000d6;zuysal</surname><given-names>&#x000d6;Y</given-names></name><etal/></person-group><article-title>IRF6 is a mediator of Notch pro-differentiation and tumour suppressive function in keratinocytes</article-title><source>EMBO J</source><year>2011</year><volume>30</volume><fpage>4571</fpage><lpage>4585</lpage><pub-id pub-id-type="doi">10.1038/emboj.2011.325</pub-id><pub-id pub-id-type="pmid">21909072</pub-id>
</element-citation><mixed-citation id="mc-CR368" publication-type="journal">Restivo G, Nguyen BC, Dziunycz P, Ristorcelli E, Ryan RJ, &#x000d6;zuysal &#x000d6;Y, et al. IRF6 is a mediator of Notch pro-differentiation and tumour suppressive function in keratinocytes. EMBO J. 2011;30:4571&#x02013;85.<pub-id pub-id-type="pmid">21909072</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR369"><label>369.</label><citation-alternatives><element-citation id="ec-CR369" publication-type="journal"><person-group person-group-type="author"><name><surname>Moriyama</surname><given-names>M</given-names></name><name><surname>Osawa</surname><given-names>M</given-names></name><name><surname>Mak</surname><given-names>S-S</given-names></name><name><surname>Ohtsuka</surname><given-names>T</given-names></name><name><surname>Yamamoto</surname><given-names>N</given-names></name><name><surname>Han</surname><given-names>H</given-names></name><etal/></person-group><article-title>Notch signaling via Hes1 transcription factor maintains survival of melanoblasts and melanocyte stem cells</article-title><source>J Cell Biol</source><year>2006</year><volume>173</volume><fpage>333</fpage><lpage>339</lpage><pub-id pub-id-type="doi">10.1083/jcb.200509084</pub-id><pub-id pub-id-type="pmid">16651378</pub-id>
</element-citation><mixed-citation id="mc-CR369" publication-type="journal">Moriyama M, Osawa M, Mak S-S, Ohtsuka T, Yamamoto N, Han H, et al. Notch signaling via Hes1 transcription factor maintains survival of melanoblasts and melanocyte stem cells. J Cell Biol. 2006;173:333&#x02013;9.<pub-id pub-id-type="pmid">16651378</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR370"><label>370.</label><citation-alternatives><element-citation id="ec-CR370" publication-type="journal"><person-group person-group-type="author"><name><surname>Kakuda</surname><given-names>S</given-names></name><name><surname>Haltiwanger</surname><given-names>RS</given-names></name></person-group><article-title>Deciphering the fringe-mediated Notch code: identification of activating and inhibiting sites allowing discrimination between ligands</article-title><source>Dev Cell</source><year>2017</year><volume>40</volume><fpage>193</fpage><lpage>201</lpage><pub-id pub-id-type="doi">10.1016/j.devcel.2016.12.013</pub-id><pub-id pub-id-type="pmid">28089369</pub-id>
</element-citation><mixed-citation id="mc-CR370" publication-type="journal">Kakuda S, Haltiwanger RS. Deciphering the fringe-mediated Notch code: identification of activating and inhibiting sites allowing discrimination between ligands. Dev Cell. 2017;40:193&#x02013;201.<pub-id pub-id-type="pmid">28089369</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR371"><label>371.</label><citation-alternatives><element-citation id="ec-CR371" publication-type="journal"><person-group person-group-type="author"><name><surname>Lowell</surname><given-names>S</given-names></name><name><surname>Jones</surname><given-names>P</given-names></name><name><surname>Le Roux</surname><given-names>I</given-names></name><name><surname>Dunne</surname><given-names>J</given-names></name><name><surname>Watt</surname><given-names>FM</given-names></name></person-group><article-title>Stimulation of human epidermal differentiation by Delta-Notch signalling at the boundaries of stem-cell clusters</article-title><source>Curr Biol</source><year>2000</year><volume>10</volume><fpage>491</fpage><lpage>500</lpage><pub-id pub-id-type="doi">10.1016/S0960-9822(00)00451-6</pub-id><pub-id pub-id-type="pmid">10801437</pub-id>
</element-citation><mixed-citation id="mc-CR371" publication-type="journal">Lowell S, Jones P, Le Roux I, Dunne J, Watt FM. Stimulation of human epidermal differentiation by Delta-Notch signalling at the boundaries of stem-cell clusters. Curr Biol. 2000;10:491&#x02013;500.<pub-id pub-id-type="pmid">10801437</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR372"><label>372.</label><citation-alternatives><element-citation id="ec-CR372" publication-type="journal"><person-group person-group-type="author"><name><surname>Calautti</surname><given-names>E</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Saoncella</surname><given-names>S</given-names></name><name><surname>Brissette</surname><given-names>JL</given-names></name><name><surname>Goetinck</surname><given-names>PF</given-names></name></person-group><article-title>Phosphoinositide 3-kinase signaling to Akt promotes keratinocyte differentiation versus death</article-title><source>J Biol Chem</source><year>2005</year><volume>280</volume><fpage>32856</fpage><lpage>32865</lpage><pub-id pub-id-type="doi">10.1074/jbc.M506119200</pub-id><pub-id pub-id-type="pmid">16036919</pub-id>
</element-citation><mixed-citation id="mc-CR372" publication-type="journal">Calautti E, Li J, Saoncella S, Brissette JL, Goetinck PF. Phosphoinositide 3-kinase signaling to Akt promotes keratinocyte differentiation versus death. J Biol Chem. 2005;280:32856&#x02013;65.<pub-id pub-id-type="pmid">16036919</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR373"><label>373.</label><citation-alternatives><element-citation id="ec-CR373" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Tian</surname><given-names>R</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Drutskaya</surname><given-names>MS</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><etal/></person-group><article-title>Macrophages induce AKT/&#x003b2;-catenin-dependent Lgr5(+) stem cell activation and hair follicle regeneration through TNF</article-title><source>Nat Commun</source><year>2017</year><volume>8</volume><fpage>14091</fpage><pub-id pub-id-type="doi">10.1038/ncomms14091</pub-id><pub-id pub-id-type="pmid">28345588</pub-id>
</element-citation><mixed-citation id="mc-CR373" publication-type="journal">Wang X, Chen H, Tian R, Zhang Y, Drutskaya MS, Wang C, et al. Macrophages induce AKT/&#x003b2;-catenin-dependent Lgr5(+) stem cell activation and hair follicle regeneration through TNF. Nat Commun. 2017;8:14091.<pub-id pub-id-type="pmid">28345588</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR374"><label>374.</label><citation-alternatives><element-citation id="ec-CR374" publication-type="journal"><person-group person-group-type="author"><name><surname>Murayama</surname><given-names>K</given-names></name><name><surname>Kimura</surname><given-names>T</given-names></name><name><surname>Tarutani</surname><given-names>M</given-names></name><name><surname>Tomooka</surname><given-names>M</given-names></name><name><surname>Hayashi</surname><given-names>R</given-names></name><name><surname>Okabe</surname><given-names>M</given-names></name><etal/></person-group><article-title>Akt activation induces epidermal hyperplasia and proliferation of epidermal progenitors</article-title><source>Oncogene</source><year>2007</year><volume>26</volume><fpage>4882</fpage><lpage>4888</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1210274</pub-id><pub-id pub-id-type="pmid">17297448</pub-id>
</element-citation><mixed-citation id="mc-CR374" publication-type="journal">Murayama K, Kimura T, Tarutani M, Tomooka M, Hayashi R, Okabe M, et al. Akt activation induces epidermal hyperplasia and proliferation of epidermal progenitors. Oncogene. 2007;26:4882&#x02013;8.<pub-id pub-id-type="pmid">17297448</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR375"><label>375.</label><citation-alternatives><element-citation id="ec-CR375" publication-type="journal"><person-group person-group-type="author"><name><surname>Sano</surname><given-names>S</given-names></name><name><surname>Itami</surname><given-names>S</given-names></name><name><surname>Takeda</surname><given-names>K</given-names></name><name><surname>Tarutani</surname><given-names>M</given-names></name><name><surname>Yamaguchi</surname><given-names>Y</given-names></name><name><surname>Miura</surname><given-names>H</given-names></name><etal/></person-group><article-title>Keratinocyte-specific ablation of Stat3 exhibits impaired skin remodeling, but does not affect skin morphogenesis</article-title><source>EMBO J</source><year>1999</year><volume>18</volume><fpage>4657</fpage><lpage>4668</lpage><pub-id pub-id-type="doi">10.1093/emboj/18.17.4657</pub-id><pub-id pub-id-type="pmid">10469645</pub-id>
</element-citation><mixed-citation id="mc-CR375" publication-type="journal">Sano S, Itami S, Takeda K, Tarutani M, Yamaguchi Y, Miura H, et al. Keratinocyte-specific ablation of Stat3 exhibits impaired skin remodeling, but does not affect skin morphogenesis. EMBO J. 1999;18:4657&#x02013;68.<pub-id pub-id-type="pmid">10469645</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR376"><label>376.</label><citation-alternatives><element-citation id="ec-CR376" publication-type="journal"><person-group person-group-type="author"><name><surname>Sano</surname><given-names>S</given-names></name><name><surname>Chan</surname><given-names>KS</given-names></name><name><surname>DiGiovanni</surname><given-names>J</given-names></name></person-group><article-title>Impact of Stat3 activation upon skin biology: a dichotomy of its role between homeostasis and diseases</article-title><source>J Dermatol Sci</source><year>2008</year><volume>50</volume><fpage>1</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1016/j.jdermsci.2007.05.016</pub-id><pub-id pub-id-type="pmid">17601706</pub-id>
</element-citation><mixed-citation id="mc-CR376" publication-type="journal">Sano S, Chan KS, DiGiovanni J. Impact of Stat3 activation upon skin biology: a dichotomy of its role between homeostasis and diseases. J Dermatol Sci. 2008;50:1&#x02013;14.<pub-id pub-id-type="pmid">17601706</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR377"><label>377.</label><citation-alternatives><element-citation id="ec-CR377" publication-type="journal"><person-group person-group-type="author"><name><surname>Miettinen</surname><given-names>PJ</given-names></name><name><surname>Berger</surname><given-names>JE</given-names></name><name><surname>Meneses</surname><given-names>J</given-names></name><name><surname>Phung</surname><given-names>Y</given-names></name><name><surname>Pedersen</surname><given-names>RA</given-names></name><name><surname>Werb</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Epithelial immaturity and multiorgan failure in mice lacking epidermal growth factor receptor</article-title><source>Nature</source><year>1995</year><volume>376</volume><fpage>337</fpage><lpage>341</lpage><pub-id pub-id-type="doi">10.1038/376337a0</pub-id><pub-id pub-id-type="pmid">7630400</pub-id>
</element-citation><mixed-citation id="mc-CR377" publication-type="journal">Miettinen PJ, Berger JE, Meneses J, Phung Y, Pedersen RA, Werb Z, et al. Epithelial immaturity and multiorgan failure in mice lacking epidermal growth factor receptor. Nature. 1995;376:337&#x02013;41.<pub-id pub-id-type="pmid">7630400</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR378"><label>378.</label><citation-alternatives><element-citation id="ec-CR378" publication-type="journal"><person-group person-group-type="author"><name><surname>Davies</surname><given-names>MA</given-names></name></person-group><article-title>The role of the PI3K-AKT pathway in melanoma</article-title><source>Cancer J</source><year>2012</year><volume>18</volume><fpage>142</fpage><lpage>147</lpage><pub-id pub-id-type="doi">10.1097/PPO.0b013e31824d448c</pub-id><pub-id pub-id-type="pmid">22453015</pub-id>
</element-citation><mixed-citation id="mc-CR378" publication-type="journal">Davies MA. The role of the PI3K-AKT pathway in melanoma. Cancer J. 2012;18:142&#x02013;7.<pub-id pub-id-type="pmid">22453015</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR379"><label>379.</label><citation-alternatives><element-citation id="ec-CR379" publication-type="journal"><person-group person-group-type="author"><name><surname>Chamcheu</surname><given-names>JC</given-names></name><name><surname>Roy</surname><given-names>T</given-names></name><name><surname>Uddin</surname><given-names>MB</given-names></name><name><surname>Banang-Mbeumi</surname><given-names>S</given-names></name><name><surname>Chamcheu</surname><given-names>RN</given-names></name><name><surname>Walker</surname><given-names>AL</given-names></name><etal/></person-group><article-title>Role and therapeutic targeting of the PI3K/Akt/mTOR signaling pathway in skin cancer: a review of current status and future trends on natural and synthetic agents therapy</article-title><source>Cells</source><year>2019</year><volume>8</volume><fpage>803</fpage><pub-id pub-id-type="doi">10.3390/cells8080803</pub-id><pub-id pub-id-type="pmid">31370278</pub-id>
</element-citation><mixed-citation id="mc-CR379" publication-type="journal">Chamcheu JC, Roy T, Uddin MB, Banang-Mbeumi S, Chamcheu RN, Walker AL, et al. Role and therapeutic targeting of the PI3K/Akt/mTOR signaling pathway in skin cancer: a review of current status and future trends on natural and synthetic agents therapy. Cells. 2019;8:803.<pub-id pub-id-type="pmid">31370278</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR380"><label>380.</label><citation-alternatives><element-citation id="ec-CR380" publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>KK</given-names></name><name><surname>Chudova</surname><given-names>D</given-names></name><name><surname>Hatfield</surname><given-names>GW</given-names></name><name><surname>Smyth</surname><given-names>P</given-names></name><name><surname>Andersen</surname><given-names>B</given-names></name></person-group><article-title>Identification of hair cycle-associated genes from time-course gene expression profile data by using replicate variance</article-title><source>Proc Natl Acad Sci U S A</source><year>2004</year><volume>101</volume><fpage>15955</fpage><lpage>15960</lpage><pub-id pub-id-type="doi">10.1073/pnas.0407114101</pub-id><pub-id pub-id-type="pmid">15520371</pub-id>
</element-citation><mixed-citation id="mc-CR380" publication-type="journal">Lin KK, Chudova D, Hatfield GW, Smyth P, Andersen B. Identification of hair cycle-associated genes from time-course gene expression profile data by using replicate variance. Proc Natl Acad Sci U S A. 2004;101:15955&#x02013;60.<pub-id pub-id-type="pmid">15520371</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR381"><label>381.</label><citation-alternatives><element-citation id="ec-CR381" publication-type="journal"><person-group person-group-type="author"><name><surname>Doles</surname><given-names>J</given-names></name><name><surname>Storer</surname><given-names>M</given-names></name><name><surname>Cozzuto</surname><given-names>L</given-names></name><name><surname>Roma</surname><given-names>G</given-names></name><name><surname>Keyes</surname><given-names>WM</given-names></name></person-group><article-title>Age-associated inflammation inhibits epidermal stem cell function</article-title><source>Genes Dev</source><year>2012</year><volume>26</volume><fpage>2144</fpage><lpage>2153</lpage><pub-id pub-id-type="doi">10.1101/gad.192294.112</pub-id><pub-id pub-id-type="pmid">22972935</pub-id>
</element-citation><mixed-citation id="mc-CR381" publication-type="journal">Doles J, Storer M, Cozzuto L, Roma G, Keyes WM. Age-associated inflammation inhibits epidermal stem cell function. Genes Dev. 2012;26:2144&#x02013;53.<pub-id pub-id-type="pmid">22972935</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR382"><label>382.</label><citation-alternatives><element-citation id="ec-CR382" publication-type="journal"><person-group person-group-type="author"><name><surname>Morris</surname><given-names>R</given-names></name><name><surname>Kershaw</surname><given-names>NJ</given-names></name><name><surname>Babon</surname><given-names>JJ</given-names></name></person-group><article-title>The molecular details of cytokine signaling via the JAK/STAT pathway</article-title><source>Protein Sci</source><year>2018</year><volume>27</volume><fpage>1984</fpage><lpage>2009</lpage><pub-id pub-id-type="doi">10.1002/pro.3519</pub-id><pub-id pub-id-type="pmid">30267440</pub-id>
</element-citation><mixed-citation id="mc-CR382" publication-type="journal">Morris R, Kershaw NJ, Babon JJ. The molecular details of cytokine signaling via the JAK/STAT pathway. Protein Sci. 2018;27:1984&#x02013;2009.<pub-id pub-id-type="pmid">30267440</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR383"><label>383.</label><citation-alternatives><element-citation id="ec-CR383" publication-type="journal"><person-group person-group-type="author"><name><surname>R&#x000e9;b&#x000e9;</surname><given-names>C</given-names></name><name><surname>V&#x000e9;gran</surname><given-names>F</given-names></name><name><surname>Berger</surname><given-names>H</given-names></name><name><surname>Ghiringhelli</surname><given-names>F</given-names></name></person-group><article-title>STAT3 activation: A key factor in tumor immunoescape</article-title><source>Jakstat</source><year>2013</year><volume>2</volume><fpage>e23010</fpage><pub-id pub-id-type="pmid">24058791</pub-id>
</element-citation><mixed-citation id="mc-CR383" publication-type="journal">R&#x000e9;b&#x000e9; C, V&#x000e9;gran F, Berger H, Ghiringhelli F. STAT3 activation: A key factor in tumor immunoescape. Jakstat. 2013;2: e23010.<pub-id pub-id-type="pmid">24058791</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR384"><label>384.</label><citation-alternatives><element-citation id="ec-CR384" publication-type="journal"><person-group person-group-type="author"><name><surname>Gu</surname><given-names>D</given-names></name><name><surname>Fan</surname><given-names>Q</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Xie</surname><given-names>J</given-names></name></person-group><article-title>A role for transcription factor STAT3 signaling in oncogene smoothened-driven carcinogenesis</article-title><source>J Biol Chem</source><year>2012</year><volume>287</volume><fpage>38356</fpage><lpage>38366</lpage><pub-id pub-id-type="doi">10.1074/jbc.M112.377382</pub-id><pub-id pub-id-type="pmid">22992748</pub-id>
</element-citation><mixed-citation id="mc-CR384" publication-type="journal">Gu D, Fan Q, Zhang X, Xie J. A role for transcription factor STAT3 signaling in oncogene smoothened-driven carcinogenesis. J Biol Chem. 2012;287:38356&#x02013;66.<pub-id pub-id-type="pmid">22992748</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR385"><label>385.</label><citation-alternatives><element-citation id="ec-CR385" publication-type="journal"><person-group person-group-type="author"><name><surname>Hauser</surname><given-names>PJ</given-names></name><name><surname>Agrawal</surname><given-names>D</given-names></name><name><surname>Hackney</surname><given-names>J</given-names></name><name><surname>Pledger</surname><given-names>WJ</given-names></name></person-group><article-title>STAT3 activation accompanies keratinocyte differentiation</article-title><source>Cell Growth Differ</source><year>1998</year><volume>9</volume><fpage>847</fpage><lpage>855</lpage><pub-id pub-id-type="pmid">9790496</pub-id>
</element-citation><mixed-citation id="mc-CR385" publication-type="journal">Hauser PJ, Agrawal D, Hackney J, Pledger WJ. STAT3 activation accompanies keratinocyte differentiation. Cell Growth Differ. 1998;9:847&#x02013;55.<pub-id pub-id-type="pmid">9790496</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR386"><label>386.</label><citation-alternatives><element-citation id="ec-CR386" publication-type="journal"><person-group person-group-type="author"><name><surname>Kira</surname><given-names>M</given-names></name><name><surname>Sano</surname><given-names>S</given-names></name><name><surname>Takagi</surname><given-names>S</given-names></name><name><surname>Yoshikawa</surname><given-names>K</given-names></name><name><surname>Takeda</surname><given-names>J</given-names></name><name><surname>Itami</surname><given-names>S</given-names></name></person-group><article-title>STAT3 deficiency in keratinocytes leads to compromised cell migration through hyperphosphorylation of p130(cas)</article-title><source>J Biol Chem</source><year>2002</year><volume>277</volume><fpage>12931</fpage><lpage>12936</lpage><pub-id pub-id-type="doi">10.1074/jbc.M110795200</pub-id><pub-id pub-id-type="pmid">11812786</pub-id>
</element-citation><mixed-citation id="mc-CR386" publication-type="journal">Kira M, Sano S, Takagi S, Yoshikawa K, Takeda J, Itami S. STAT3 deficiency in keratinocytes leads to compromised cell migration through hyperphosphorylation of p130(cas). J Biol Chem. 2002;277:12931&#x02013;6.<pub-id pub-id-type="pmid">11812786</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR387"><label>387.</label><citation-alternatives><element-citation id="ec-CR387" publication-type="journal"><person-group person-group-type="author"><name><surname>Rao</surname><given-names>D</given-names></name><name><surname>Macias</surname><given-names>E</given-names></name><name><surname>Carbajal</surname><given-names>S</given-names></name><name><surname>Kiguchi</surname><given-names>K</given-names></name><name><surname>DiGiovanni</surname><given-names>J</given-names></name></person-group><article-title>Constitutive Stat3 activation alters behavior of hair follicle stem and progenitor cell populations</article-title><source>Mol Carcinog</source><year>2015</year><volume>54</volume><fpage>121</fpage><lpage>133</lpage><pub-id pub-id-type="doi">10.1002/mc.22080</pub-id><pub-id pub-id-type="pmid">24038534</pub-id>
</element-citation><mixed-citation id="mc-CR387" publication-type="journal">Rao D, Macias E, Carbajal S, Kiguchi K, DiGiovanni J. Constitutive Stat3 activation alters behavior of hair follicle stem and progenitor cell populations. Mol Carcinog. 2015;54:121&#x02013;33.<pub-id pub-id-type="pmid">24038534</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR388"><label>388.</label><citation-alternatives><element-citation id="ec-CR388" publication-type="journal"><person-group person-group-type="author"><name><surname>Santini</surname><given-names>R</given-names></name><name><surname>Vinci</surname><given-names>MC</given-names></name><name><surname>Pandolfi</surname><given-names>S</given-names></name><name><surname>Penachioni</surname><given-names>JY</given-names></name><name><surname>Montagnani</surname><given-names>V</given-names></name><name><surname>Olivito</surname><given-names>B</given-names></name><etal/></person-group><article-title>Hedgehog-GLI signaling drives self-renewal and tumorigenicity of human melanoma-initiating cells</article-title><source>Stem Cells</source><year>2012</year><volume>30</volume><fpage>1808</fpage><lpage>1818</lpage><pub-id pub-id-type="doi">10.1002/stem.1160</pub-id><pub-id pub-id-type="pmid">22730244</pub-id>
</element-citation><mixed-citation id="mc-CR388" publication-type="journal">Santini R, Vinci MC, Pandolfi S, Penachioni JY, Montagnani V, Olivito B, et al. Hedgehog-GLI signaling drives self-renewal and tumorigenicity of human melanoma-initiating cells. Stem Cells. 2012;30:1808&#x02013;18.<pub-id pub-id-type="pmid">22730244</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR389"><label>389.</label><citation-alternatives><element-citation id="ec-CR389" publication-type="journal"><person-group person-group-type="author"><name><surname>Pandolfi</surname><given-names>S</given-names></name><name><surname>Montagnani</surname><given-names>V</given-names></name><name><surname>Penachioni</surname><given-names>J</given-names></name><name><surname>Vinci</surname><given-names>M</given-names></name><name><surname>Olivito</surname><given-names>B</given-names></name><name><surname>Borgognoni</surname><given-names>L</given-names></name><etal/></person-group><article-title>WIP1 phosphatase modulates the Hedgehog signaling by enhancing GLI1 function</article-title><source>Oncogene</source><year>2013</year><volume>32</volume><fpage>4737</fpage><lpage>4747</lpage><pub-id pub-id-type="doi">10.1038/onc.2012.502</pub-id><pub-id pub-id-type="pmid">23146903</pub-id>
</element-citation><mixed-citation id="mc-CR389" publication-type="journal">Pandolfi S, Montagnani V, Penachioni J, Vinci M, Olivito B, Borgognoni L, et al. WIP1 phosphatase modulates the Hedgehog signaling by enhancing GLI1 function. Oncogene. 2013;32:4737&#x02013;47.<pub-id pub-id-type="pmid">23146903</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR390"><label>390.</label><citation-alternatives><element-citation id="ec-CR390" publication-type="journal"><person-group person-group-type="author"><name><surname>Epstein</surname><given-names>EH</given-names></name></person-group><article-title>Basal cell carcinomas: attack of the hedgehog</article-title><source>Nat Rev Cancer</source><year>2008</year><volume>8</volume><fpage>743</fpage><lpage>754</lpage><pub-id pub-id-type="doi">10.1038/nrc2503</pub-id><pub-id pub-id-type="pmid">18813320</pub-id>
</element-citation><mixed-citation id="mc-CR390" publication-type="journal">Epstein EH. Basal cell carcinomas: attack of the hedgehog. Nat Rev Cancer. 2008;8:743&#x02013;54.<pub-id pub-id-type="pmid">18813320</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR391"><label>391.</label><citation-alternatives><element-citation id="ec-CR391" publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>HS</given-names></name><name><surname>Kim</surname><given-names>YS</given-names></name><name><surname>Lee</surname><given-names>C</given-names></name><name><surname>Shin</surname><given-names>MS</given-names></name><name><surname>Kim</surname><given-names>JW</given-names></name><name><surname>Jang</surname><given-names>BG</given-names></name></person-group><article-title>Expression profile of sonic hedgehog signaling-related molecules in basal cell carcinoma</article-title><source>PLoS ONE</source><year>2019</year><volume>14</volume><fpage>e0225511</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0225511</pub-id><pub-id pub-id-type="pmid">31756206</pub-id>
</element-citation><mixed-citation id="mc-CR391" publication-type="journal">Kim HS, Kim YS, Lee C, Shin MS, Kim JW, Jang BG. Expression profile of sonic hedgehog signaling-related molecules in basal cell carcinoma. PLoS ONE. 2019;14: e0225511.<pub-id pub-id-type="pmid">31756206</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR392"><label>392.</label><citation-alternatives><element-citation id="ec-CR392" publication-type="journal"><person-group person-group-type="author"><name><surname>Barker</surname><given-names>N</given-names></name><name><surname>Van Es</surname><given-names>J</given-names></name><name><surname>Jaks</surname><given-names>V</given-names></name><name><surname>Kasper</surname><given-names>M</given-names></name><name><surname>Snippert</surname><given-names>H</given-names></name><name><surname>Toftg&#x000e5;rd</surname><given-names>R</given-names></name><etal/></person-group><article-title>Very long-term self-renewal of small intestine, colon, and hair follicles from cycling Lgr5+ ve stem cells</article-title><source>Cold Spring Harb Symp Quant Biol</source><year>2008</year><volume>73</volume><fpage>351</fpage><lpage>356</lpage><pub-id pub-id-type="doi">10.1101/sqb.2008.72.003</pub-id><pub-id pub-id-type="pmid">19478326</pub-id>
</element-citation><mixed-citation id="mc-CR392" publication-type="journal">Barker N, Van Es J, Jaks V, Kasper M, Snippert H, Toftg&#x000e5;rd R, et al. Very long-term self-renewal of small intestine, colon, and hair follicles from cycling Lgr5+ ve stem cells. Cold Spring Harb Symp Quant Biol. 2008;73:351&#x02013;6.<pub-id pub-id-type="pmid">19478326</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR393"><label>393.</label><citation-alternatives><element-citation id="ec-CR393" publication-type="journal"><person-group person-group-type="author"><name><surname>Malanchi</surname><given-names>I</given-names></name><name><surname>Peinado</surname><given-names>H</given-names></name><name><surname>Kassen</surname><given-names>D</given-names></name><name><surname>Hussenet</surname><given-names>T</given-names></name><name><surname>Metzger</surname><given-names>D</given-names></name><name><surname>Chambon</surname><given-names>P</given-names></name><etal/></person-group><article-title>Cutaneous cancer stem cell maintenance is dependent on &#x003b2;-catenin signalling</article-title><source>Nature</source><year>2008</year><volume>452</volume><fpage>650</fpage><lpage>653</lpage><pub-id pub-id-type="doi">10.1038/nature06835</pub-id><pub-id pub-id-type="pmid">18385740</pub-id>
</element-citation><mixed-citation id="mc-CR393" publication-type="journal">Malanchi I, Peinado H, Kassen D, Hussenet T, Metzger D, Chambon P, et al. Cutaneous cancer stem cell maintenance is dependent on &#x003b2;-catenin signalling. Nature. 2008;452:650&#x02013;3.<pub-id pub-id-type="pmid">18385740</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR394"><label>394.</label><mixed-citation publication-type="other">Yang GN, Strudwick XL, Bonder CS, Kopecki Z, and Cowin AJ. Increased expression of flightless I in cutaneous squamous cell carcinoma affects Wnt/&#x003b2;-catenin signaling pathway<italic>.</italic> Int J Mol Sci. 2021; 22.</mixed-citation></ref><ref id="CR395"><label>395.</label><citation-alternatives><element-citation id="ec-CR395" publication-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>CY</given-names></name><name><surname>Zhu</surname><given-names>MX</given-names></name><name><surname>Yang</surname><given-names>YW</given-names></name><name><surname>Zhang</surname><given-names>PF</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Peng</surname><given-names>R</given-names></name><etal/></person-group><article-title>Downregulation of RNF128 activates Wnt/&#x003b2;-catenin signaling to induce cellular EMT and stemness via CD44 and CTTN ubiquitination in melanoma</article-title><source>J Hematol Oncol</source><year>2019</year><volume>12</volume><fpage>21</fpage><pub-id pub-id-type="doi">10.1186/s13045-019-0711-z</pub-id><pub-id pub-id-type="pmid">30832692</pub-id>
</element-citation><mixed-citation id="mc-CR395" publication-type="journal">Wei CY, Zhu MX, Yang YW, Zhang PF, Yang X, Peng R, et al. Downregulation of RNF128 activates Wnt/&#x003b2;-catenin signaling to induce cellular EMT and stemness via CD44 and CTTN ubiquitination in melanoma. J Hematol Oncol. 2019;12:21.<pub-id pub-id-type="pmid">30832692</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR396"><label>396.</label><citation-alternatives><element-citation id="ec-CR396" publication-type="journal"><person-group person-group-type="author"><name><surname>Rappa</surname><given-names>G</given-names></name><name><surname>Mercapide</surname><given-names>J</given-names></name><name><surname>Anzanello</surname><given-names>F</given-names></name><name><surname>Le</surname><given-names>TT</given-names></name><name><surname>Johlfs</surname><given-names>MG</given-names></name><name><surname>Fiscus</surname><given-names>RR</given-names></name><etal/></person-group><article-title>Wnt interaction and extracellular release of prominin-1/CD133 in human malignant melanoma cells</article-title><source>Exp Cell Res</source><year>2013</year><volume>319</volume><fpage>810</fpage><lpage>819</lpage><pub-id pub-id-type="doi">10.1016/j.yexcr.2013.01.003</pub-id><pub-id pub-id-type="pmid">23318676</pub-id>
</element-citation><mixed-citation id="mc-CR396" publication-type="journal">Rappa G, Mercapide J, Anzanello F, Le TT, Johlfs MG, Fiscus RR, et al. Wnt interaction and extracellular release of prominin-1/CD133 in human malignant melanoma cells. Exp Cell Res. 2013;319:810&#x02013;9.<pub-id pub-id-type="pmid">23318676</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR397"><label>397.</label><citation-alternatives><element-citation id="ec-CR397" publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Fang</surname><given-names>R</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Si</surname><given-names>Y</given-names></name><name><surname>Bai</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name></person-group><article-title>The NOP14 nucleolar protein suppresses the function and stemness of melanoma stem-like cells through Wnt/beta-catenin signaling inactivation</article-title><source>Bioengineered</source><year>2022</year><volume>13</volume><fpage>7648</fpage><lpage>7658</lpage><pub-id pub-id-type="doi">10.1080/21655979.2022.2050491</pub-id><pub-id pub-id-type="pmid">35282769</pub-id>
</element-citation><mixed-citation id="mc-CR397" publication-type="journal">Li J, Fang R, Wu J, Si Y, Bai J, Wang Q. The NOP14 nucleolar protein suppresses the function and stemness of melanoma stem-like cells through Wnt/beta-catenin signaling inactivation. Bioengineered. 2022;13:7648&#x02013;58.<pub-id pub-id-type="pmid">35282769</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR398"><label>398.</label><citation-alternatives><element-citation id="ec-CR398" publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>PT</given-names></name><name><surname>Anastas</surname><given-names>JN</given-names></name><name><surname>Toroni</surname><given-names>RA</given-names></name><name><surname>Shinohara</surname><given-names>MM</given-names></name><name><surname>Goodson</surname><given-names>JM</given-names></name><name><surname>Bosserhoff</surname><given-names>AK</given-names></name><etal/></person-group><article-title>WLS inhibits melanoma cell proliferation through the &#x003b2;-catenin signalling pathway and induces spontaneous metastasis</article-title><source>EMBO Mol Med</source><year>2012</year><volume>4</volume><fpage>1294</fpage><lpage>1307</lpage><pub-id pub-id-type="doi">10.1002/emmm.201201486</pub-id><pub-id pub-id-type="pmid">23129487</pub-id>
</element-citation><mixed-citation id="mc-CR398" publication-type="journal">Yang PT, Anastas JN, Toroni RA, Shinohara MM, Goodson JM, Bosserhoff AK, et al. WLS inhibits melanoma cell proliferation through the &#x003b2;-catenin signalling pathway and induces spontaneous metastasis. EMBO Mol Med. 2012;4:1294&#x02013;307.<pub-id pub-id-type="pmid">23129487</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR399"><label>399.</label><citation-alternatives><element-citation id="ec-CR399" publication-type="journal"><person-group person-group-type="author"><name><surname>Dissanayake</surname><given-names>SK</given-names></name><name><surname>Wade</surname><given-names>M</given-names></name><name><surname>Johnson</surname><given-names>CE</given-names></name><name><surname>O&#x02019;Connell</surname><given-names>MP</given-names></name><name><surname>Leotlela</surname><given-names>PD</given-names></name><name><surname>French</surname><given-names>AD</given-names></name><etal/></person-group><article-title>The Wnt5A/protein kinase C pathway mediates motility in melanoma cells via the inhibition of metastasis suppressors and initiation of an epithelial to mesenchymal transition</article-title><source>J Biol Chem</source><year>2007</year><volume>282</volume><fpage>17259</fpage><lpage>17271</lpage><pub-id pub-id-type="doi">10.1074/jbc.M700075200</pub-id><pub-id pub-id-type="pmid">17426020</pub-id>
</element-citation><mixed-citation id="mc-CR399" publication-type="journal">Dissanayake SK, Wade M, Johnson CE, O&#x02019;Connell MP, Leotlela PD, French AD, et al. The Wnt5A/protein kinase C pathway mediates motility in melanoma cells via the inhibition of metastasis suppressors and initiation of an epithelial to mesenchymal transition. J Biol Chem. 2007;282:17259&#x02013;71.<pub-id pub-id-type="pmid">17426020</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR400"><label>400.</label><citation-alternatives><element-citation id="ec-CR400" publication-type="journal"><person-group person-group-type="author"><name><surname>Medici</surname><given-names>D</given-names></name><name><surname>Hay</surname><given-names>ED</given-names></name><name><surname>Olsen</surname><given-names>BR</given-names></name></person-group><article-title>Snail and Slug promote epithelial-mesenchymal transition through beta-catenin-T-cell factor-4-dependent expression of transforming growth factor-beta3</article-title><source>Mol Biol Cell</source><year>2008</year><volume>19</volume><fpage>4875</fpage><lpage>4887</lpage><pub-id pub-id-type="doi">10.1091/mbc.e08-05-0506</pub-id><pub-id pub-id-type="pmid">18799618</pub-id>
</element-citation><mixed-citation id="mc-CR400" publication-type="journal">Medici D, Hay ED, Olsen BR. Snail and Slug promote epithelial-mesenchymal transition through beta-catenin-T-cell factor-4-dependent expression of transforming growth factor-beta3. Mol Biol Cell. 2008;19:4875&#x02013;87.<pub-id pub-id-type="pmid">18799618</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR401"><label>401.</label><citation-alternatives><element-citation id="ec-CR401" publication-type="journal"><person-group person-group-type="author"><name><surname>Ryu</surname><given-names>HJ</given-names></name><name><surname>Kim</surname><given-names>C</given-names></name><name><surname>Jang</surname><given-names>H</given-names></name><name><surname>Kim</surname><given-names>SI</given-names></name><name><surname>Shin</surname><given-names>SJ</given-names></name><name><surname>Chung</surname><given-names>KY</given-names></name><etal/></person-group><article-title>Nuclear localization of yes-associated protein is associated with tumor progression in cutaneous melanoma</article-title><source>Lab Invest</source><year>2024</year><volume>104</volume><fpage>102048</fpage><pub-id pub-id-type="doi">10.1016/j.labinv.2024.102048</pub-id><pub-id pub-id-type="pmid">38490470</pub-id>
</element-citation><mixed-citation id="mc-CR401" publication-type="journal">Ryu HJ, Kim C, Jang H, Kim SI, Shin SJ, Chung KY, et al. Nuclear localization of yes-associated protein is associated with tumor progression in cutaneous melanoma. Lab Invest. 2024;104: 102048.<pub-id pub-id-type="pmid">38490470</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR402"><label>402.</label><citation-alternatives><element-citation id="ec-CR402" publication-type="journal"><person-group person-group-type="author"><name><surname>Jia</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Luo</surname><given-names>S</given-names></name><name><surname>Liu-Smith</surname><given-names>F</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><etal/></person-group><article-title>Yes-associated protein contributes to the development of human cutaneous squamous cell carcinoma via activation of RAS</article-title><source>J Invest Dermatol</source><year>2016</year><volume>136</volume><fpage>1267</fpage><lpage>1277</lpage><pub-id pub-id-type="doi">10.1016/j.jid.2016.02.005</pub-id><pub-id pub-id-type="pmid">26902922</pub-id>
</element-citation><mixed-citation id="mc-CR402" publication-type="journal">Jia J, Li C, Luo S, Liu-Smith F, Yang J, Wang X, et al. Yes-associated protein contributes to the development of human cutaneous squamous cell carcinoma via activation of RAS. J Invest Dermatol. 2016;136:1267&#x02013;77.<pub-id pub-id-type="pmid">26902922</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR403"><label>403.</label><citation-alternatives><element-citation id="ec-CR403" publication-type="journal"><person-group person-group-type="author"><name><surname>Maglic</surname><given-names>D</given-names></name><name><surname>Schlegelmilch</surname><given-names>K</given-names></name><name><surname>Dost</surname><given-names>AF</given-names></name><name><surname>Panero</surname><given-names>R</given-names></name><name><surname>Dill</surname><given-names>MT</given-names></name><name><surname>Calogero</surname><given-names>RA</given-names></name><etal/></person-group><article-title>YAP-TEAD signaling promotes basal cell carcinoma development via ac-JUN/AP1 axis</article-title><source>EMBO J</source><year>2018</year><volume>37</volume><fpage>e98642</fpage><pub-id pub-id-type="doi">10.15252/embj.201798642</pub-id><pub-id pub-id-type="pmid">30037824</pub-id>
</element-citation><mixed-citation id="mc-CR403" publication-type="journal">Maglic D, Schlegelmilch K, Dost AF, Panero R, Dill MT, Calogero RA, et al. YAP-TEAD signaling promotes basal cell carcinoma development via ac-JUN/AP1 axis. EMBO J. 2018;37: e98642.<pub-id pub-id-type="pmid">30037824</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR404"><label>404.</label><citation-alternatives><element-citation id="ec-CR404" publication-type="journal"><person-group person-group-type="author"><name><surname>Quan</surname><given-names>T</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Qin</surname><given-names>Z</given-names></name><name><surname>Robichaud</surname><given-names>P</given-names></name><name><surname>Betcher</surname><given-names>S</given-names></name><name><surname>Calderone</surname><given-names>K</given-names></name><etal/></person-group><article-title>Elevated YAP and its downstream targets CCN1 and CCN2 in basal cell carcinoma: impact on keratinocyte proliferation and stromal cell activation</article-title><source>Am J Pathol</source><year>2014</year><volume>184</volume><fpage>937</fpage><lpage>943</lpage><pub-id pub-id-type="doi">10.1016/j.ajpath.2013.12.017</pub-id><pub-id pub-id-type="pmid">24485923</pub-id>
</element-citation><mixed-citation id="mc-CR404" publication-type="journal">Quan T, Xu Y, Qin Z, Robichaud P, Betcher S, Calderone K, et al. Elevated YAP and its downstream targets CCN1 and CCN2 in basal cell carcinoma: impact on keratinocyte proliferation and stromal cell activation. Am J Pathol. 2014;184:937&#x02013;43.<pub-id pub-id-type="pmid">24485923</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR405"><label>405.</label><citation-alternatives><element-citation id="ec-CR405" publication-type="journal"><person-group person-group-type="author"><name><surname>Miskolczi</surname><given-names>Z</given-names></name><name><surname>Smith</surname><given-names>MP</given-names></name><name><surname>Rowling</surname><given-names>EJ</given-names></name><name><surname>Ferguson</surname><given-names>J</given-names></name><name><surname>Barriuso</surname><given-names>J</given-names></name><name><surname>Wellbrock</surname><given-names>C</given-names></name></person-group><article-title>Collagen abundance controls melanoma phenotypes through lineage-specific microenvironment sensing</article-title><source>Oncogene</source><year>2018</year><volume>37</volume><fpage>3166</fpage><lpage>3182</lpage><pub-id pub-id-type="doi">10.1038/s41388-018-0209-0</pub-id><pub-id pub-id-type="pmid">29545604</pub-id>
</element-citation><mixed-citation id="mc-CR405" publication-type="journal">Miskolczi Z, Smith MP, Rowling EJ, Ferguson J, Barriuso J, Wellbrock C. Collagen abundance controls melanoma phenotypes through lineage-specific microenvironment sensing. Oncogene. 2018;37:3166&#x02013;82.<pub-id pub-id-type="pmid">29545604</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR406"><label>406.</label><citation-alternatives><element-citation id="ec-CR406" publication-type="journal"><person-group person-group-type="author"><name><surname>Manderfield</surname><given-names>LJ</given-names></name><name><surname>Engleka</surname><given-names>KA</given-names></name><name><surname>Aghajanian</surname><given-names>H</given-names></name><name><surname>Gupta</surname><given-names>M</given-names></name><name><surname>Yang</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><etal/></person-group><article-title>Pax3 and hippo signaling coordinate melanocyte gene expression in neural crest</article-title><source>Cell Rep</source><year>2014</year><volume>9</volume><fpage>1885</fpage><lpage>1895</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2014.10.061</pub-id><pub-id pub-id-type="pmid">25466249</pub-id>
</element-citation><mixed-citation id="mc-CR406" publication-type="journal">Manderfield LJ, Engleka KA, Aghajanian H, Gupta M, Yang S, Li L, et al. Pax3 and hippo signaling coordinate melanocyte gene expression in neural crest. Cell Rep. 2014;9:1885&#x02013;95.<pub-id pub-id-type="pmid">25466249</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR407"><label>407.</label><citation-alternatives><element-citation id="ec-CR407" publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>G</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Nishimura</surname><given-names>EK</given-names></name><name><surname>Xin</surname><given-names>H</given-names></name><name><surname>Zhou</surname><given-names>A</given-names></name><name><surname>Guo</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Inhibition of PAX3 by TGF-beta modulates melanocyte viability</article-title><source>Mol Cell</source><year>2008</year><volume>32</volume><fpage>554</fpage><lpage>563</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2008.11.002</pub-id><pub-id pub-id-type="pmid">19026785</pub-id>
</element-citation><mixed-citation id="mc-CR407" publication-type="journal">Yang G, Li Y, Nishimura EK, Xin H, Zhou A, Guo Y, et al. Inhibition of PAX3 by TGF-beta modulates melanocyte viability. Mol Cell. 2008;32:554&#x02013;63.<pub-id pub-id-type="pmid">19026785</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR408"><label>408.</label><citation-alternatives><element-citation id="ec-CR408" publication-type="journal"><person-group person-group-type="author"><name><surname>Braig</surname><given-names>S</given-names></name><name><surname>Wallner</surname><given-names>S</given-names></name><name><surname>Junglas</surname><given-names>B</given-names></name><name><surname>Fuchshofer</surname><given-names>R</given-names></name><name><surname>Bosserhoff</surname><given-names>AK</given-names></name></person-group><article-title>CTGF is overexpressed in malignant melanoma and promotes cell invasion and migration</article-title><source>Br J Cancer</source><year>2011</year><volume>105</volume><fpage>231</fpage><lpage>238</lpage><pub-id pub-id-type="doi">10.1038/bjc.2011.226</pub-id><pub-id pub-id-type="pmid">21673687</pub-id>
</element-citation><mixed-citation id="mc-CR408" publication-type="journal">Braig S, Wallner S, Junglas B, Fuchshofer R, Bosserhoff AK. CTGF is overexpressed in malignant melanoma and promotes cell invasion and migration. Br J Cancer. 2011;105:231&#x02013;8.<pub-id pub-id-type="pmid">21673687</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR409"><label>409.</label><citation-alternatives><element-citation id="ec-CR409" publication-type="journal"><person-group person-group-type="author"><name><surname>Al-Rohil</surname><given-names>RN</given-names></name><name><surname>Tarasen</surname><given-names>AJ</given-names></name><name><surname>Carlson</surname><given-names>JA</given-names></name><name><surname>Wang</surname><given-names>K</given-names></name><name><surname>Johnson</surname><given-names>A</given-names></name><name><surname>Yelensky</surname><given-names>R</given-names></name><etal/></person-group><article-title>Evaluation of 122 advanced-stage cutaneous squamous cell carcinomas by comprehensive genomic profiling opens the door for new routes to targeted therapies</article-title><source>Cancer</source><year>2016</year><volume>122</volume><fpage>249</fpage><lpage>257</lpage><pub-id pub-id-type="doi">10.1002/cncr.29738</pub-id><pub-id pub-id-type="pmid">26479420</pub-id>
</element-citation><mixed-citation id="mc-CR409" publication-type="journal">Al-Rohil RN, Tarasen AJ, Carlson JA, Wang K, Johnson A, Yelensky R, et al. Evaluation of 122 advanced-stage cutaneous squamous cell carcinomas by comprehensive genomic profiling opens the door for new routes to targeted therapies. Cancer. 2016;122:249&#x02013;57.<pub-id pub-id-type="pmid">26479420</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR410"><label>410.</label><citation-alternatives><element-citation id="ec-CR410" publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>D</given-names></name><name><surname>Shain</surname><given-names>AH</given-names></name></person-group><article-title>The landscape of driver mutations in cutaneous squamous cell carcinoma</article-title><source>NPJ Genom Med</source><year>2021</year><volume>6</volume><fpage>61</fpage><pub-id pub-id-type="doi">10.1038/s41525-021-00226-4</pub-id><pub-id pub-id-type="pmid">34272401</pub-id>
</element-citation><mixed-citation id="mc-CR410" publication-type="journal">Chang D, Shain AH. The landscape of driver mutations in cutaneous squamous cell carcinoma. NPJ Genom Med. 2021;6:61.<pub-id pub-id-type="pmid">34272401</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR411"><label>411.</label><citation-alternatives><element-citation id="ec-CR411" publication-type="journal"><person-group person-group-type="author"><name><surname>Bonilla</surname><given-names>X</given-names></name><name><surname>Parmentier</surname><given-names>L</given-names></name><name><surname>King</surname><given-names>B</given-names></name><name><surname>Bezrukov</surname><given-names>F</given-names></name><name><surname>Kaya</surname><given-names>G</given-names></name><name><surname>Zoete</surname><given-names>V</given-names></name><etal/></person-group><article-title>Genomic analysis identifies new drivers and progression pathways in skin basal cell carcinoma</article-title><source>Nat Genet</source><year>2016</year><volume>48</volume><fpage>398</fpage><lpage>406</lpage><pub-id pub-id-type="doi">10.1038/ng.3525</pub-id><pub-id pub-id-type="pmid">26950094</pub-id>
</element-citation><mixed-citation id="mc-CR411" publication-type="journal">Bonilla X, Parmentier L, King B, Bezrukov F, Kaya G, Zoete V, et al. Genomic analysis identifies new drivers and progression pathways in skin basal cell carcinoma. Nat Genet. 2016;48:398&#x02013;406.<pub-id pub-id-type="pmid">26950094</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR412"><label>412.</label><citation-alternatives><element-citation id="ec-CR412" publication-type="journal"><person-group person-group-type="author"><name><surname>Nicolas</surname><given-names>M</given-names></name><name><surname>Wolfer</surname><given-names>A</given-names></name><name><surname>Raj</surname><given-names>K</given-names></name><name><surname>Kummer</surname><given-names>JA</given-names></name><name><surname>Mill</surname><given-names>P</given-names></name><name><surname>van Noort</surname><given-names>M</given-names></name><etal/></person-group><article-title>Notch1 functions as a tumor suppressor in mouse skin</article-title><source>Nat Genet</source><year>2003</year><volume>33</volume><fpage>416</fpage><lpage>421</lpage><pub-id pub-id-type="doi">10.1038/ng1099</pub-id><pub-id pub-id-type="pmid">12590261</pub-id>
</element-citation><mixed-citation id="mc-CR412" publication-type="journal">Nicolas M, Wolfer A, Raj K, Kummer JA, Mill P, van Noort M, et al. Notch1 functions as a tumor suppressor in mouse skin. Nat Genet. 2003;33:416&#x02013;21.<pub-id pub-id-type="pmid">12590261</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR413"><label>413.</label><citation-alternatives><element-citation id="ec-CR413" publication-type="journal"><person-group person-group-type="author"><name><surname>Pickering</surname><given-names>CR</given-names></name><name><surname>Zhou</surname><given-names>JH</given-names></name><name><surname>Lee</surname><given-names>JJ</given-names></name><name><surname>Drummond</surname><given-names>JA</given-names></name><name><surname>Peng</surname><given-names>SA</given-names></name><name><surname>Saade</surname><given-names>RE</given-names></name><etal/></person-group><article-title>Mutational landscape of aggressive cutaneous squamous cell carcinoma</article-title><source>Clin Cancer Res</source><year>2014</year><volume>20</volume><fpage>6582</fpage><lpage>6592</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-14-1768</pub-id><pub-id pub-id-type="pmid">25303977</pub-id>
</element-citation><mixed-citation id="mc-CR413" publication-type="journal">Pickering CR, Zhou JH, Lee JJ, Drummond JA, Peng SA, Saade RE, et al. Mutational landscape of aggressive cutaneous squamous cell carcinoma. Clin Cancer Res. 2014;20:6582&#x02013;92.<pub-id pub-id-type="pmid">25303977</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR414"><label>414.</label><citation-alternatives><element-citation id="ec-CR414" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>NJ</given-names></name><name><surname>Sanborn</surname><given-names>Z</given-names></name><name><surname>Arnett</surname><given-names>KL</given-names></name><name><surname>Bayston</surname><given-names>LJ</given-names></name><name><surname>Liao</surname><given-names>W</given-names></name><name><surname>Proby</surname><given-names>CM</given-names></name><etal/></person-group><article-title>Loss-of-function mutations in Notch receptors in cutaneous and lung squamous cell carcinoma</article-title><source>Proc Natl Acad Sci U S A</source><year>2011</year><volume>108</volume><fpage>17761</fpage><lpage>17766</lpage><pub-id pub-id-type="doi">10.1073/pnas.1114669108</pub-id><pub-id pub-id-type="pmid">22006338</pub-id>
</element-citation><mixed-citation id="mc-CR414" publication-type="journal">Wang NJ, Sanborn Z, Arnett KL, Bayston LJ, Liao W, Proby CM, et al. Loss-of-function mutations in Notch receptors in cutaneous and lung squamous cell carcinoma. Proc Natl Acad Sci U S A. 2011;108:17761&#x02013;6.<pub-id pub-id-type="pmid">22006338</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR415"><label>415.</label><citation-alternatives><element-citation id="ec-CR415" publication-type="journal"><person-group person-group-type="author"><name><surname>Cordle</surname><given-names>J</given-names></name><name><surname>Redfieldz</surname><given-names>C</given-names></name><name><surname>Stacey</surname><given-names>M</given-names></name><name><surname>van der Merwe</surname><given-names>PA</given-names></name><name><surname>Willis</surname><given-names>AC</given-names></name><name><surname>Champion</surname><given-names>BR</given-names></name><etal/></person-group><article-title>Localization of the delta-like-1-binding site in human Notch-1 and its modulation by calcium affinity</article-title><source>J Biol Chem</source><year>2008</year><volume>283</volume><fpage>11785</fpage><lpage>11793</lpage><pub-id pub-id-type="doi">10.1074/jbc.M708424200</pub-id><pub-id pub-id-type="pmid">18296446</pub-id>
</element-citation><mixed-citation id="mc-CR415" publication-type="journal">Cordle J, Redfieldz C, Stacey M, van der Merwe PA, Willis AC, Champion BR, et al. Localization of the delta-like-1-binding site in human Notch-1 and its modulation by calcium affinity. J Biol Chem. 2008;283:11785&#x02013;93.<pub-id pub-id-type="pmid">18296446</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR416"><label>416.</label><citation-alternatives><element-citation id="ec-CR416" publication-type="journal"><person-group person-group-type="author"><name><surname>Nam</surname><given-names>Y</given-names></name><name><surname>Sliz</surname><given-names>P</given-names></name><name><surname>Song</surname><given-names>L</given-names></name><name><surname>Aster</surname><given-names>JC</given-names></name><name><surname>Blacklow</surname><given-names>SC</given-names></name></person-group><article-title>Structural basis for cooperativity in recruitment of MAML coactivators to Notch transcription complexes</article-title><source>Cell</source><year>2006</year><volume>124</volume><fpage>973</fpage><lpage>983</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2005.12.037</pub-id><pub-id pub-id-type="pmid">16530044</pub-id>
</element-citation><mixed-citation id="mc-CR416" publication-type="journal">Nam Y, Sliz P, Song L, Aster JC, Blacklow SC. Structural basis for cooperativity in recruitment of MAML coactivators to Notch transcription complexes. Cell. 2006;124:973&#x02013;83.<pub-id pub-id-type="pmid">16530044</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR417"><label>417.</label><citation-alternatives><element-citation id="ec-CR417" publication-type="journal"><person-group person-group-type="author"><name><surname>Oswald</surname><given-names>F</given-names></name><name><surname>T&#x000e4;uber</surname><given-names>B</given-names></name><name><surname>Dobner</surname><given-names>T</given-names></name><name><surname>Bourteele</surname><given-names>S</given-names></name><name><surname>Kostezka</surname><given-names>U</given-names></name><name><surname>Adler</surname><given-names>G</given-names></name><etal/></person-group><article-title>p300 acts as a transcriptional coactivator for mammalian Notch-1</article-title><source>Mol Cell Biol</source><year>2001</year><volume>21</volume><fpage>7761</fpage><lpage>7774</lpage><pub-id pub-id-type="doi">10.1128/MCB.21.22.7761-7774.2001</pub-id><pub-id pub-id-type="pmid">11604511</pub-id>
</element-citation><mixed-citation id="mc-CR417" publication-type="journal">Oswald F, T&#x000e4;uber B, Dobner T, Bourteele S, Kostezka U, Adler G, et al. p300 acts as a transcriptional coactivator for mammalian Notch-1. Mol Cell Biol. 2001;21:7761&#x02013;74.<pub-id pub-id-type="pmid">11604511</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR418"><label>418.</label><citation-alternatives><element-citation id="ec-CR418" publication-type="journal"><person-group person-group-type="author"><name><surname>Quan</surname><given-names>XX</given-names></name><name><surname>Hawk</surname><given-names>NV</given-names></name><name><surname>Chen</surname><given-names>W</given-names></name><name><surname>Coupar</surname><given-names>J</given-names></name><name><surname>Lee</surname><given-names>SK</given-names></name><name><surname>Petersen</surname><given-names>DW</given-names></name><etal/></person-group><article-title>Targeting notch1 and IKK&#x003b1; enhanced NF-&#x003ba;B activation in CD133+ skin cancer stem cells</article-title><source>Mol Cancer Ther</source><year>2018</year><volume>17</volume><fpage>2034</fpage><lpage>2048</lpage><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-17-0421</pub-id><pub-id pub-id-type="pmid">29959199</pub-id>
</element-citation><mixed-citation id="mc-CR418" publication-type="journal">Quan XX, Hawk NV, Chen W, Coupar J, Lee SK, Petersen DW, et al. Targeting notch1 and IKK&#x003b1; enhanced NF-&#x003ba;B activation in CD133+ skin cancer stem cells. Mol Cancer Ther. 2018;17:2034&#x02013;48.<pub-id pub-id-type="pmid">29959199</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR419"><label>419.</label><citation-alternatives><element-citation id="ec-CR419" publication-type="journal"><person-group person-group-type="author"><name><surname>Bedogni</surname><given-names>B</given-names></name><name><surname>Warneke</surname><given-names>JA</given-names></name><name><surname>Nickoloff</surname><given-names>BJ</given-names></name><name><surname>Giaccia</surname><given-names>AJ</given-names></name><name><surname>Powell</surname><given-names>MB</given-names></name></person-group><article-title>Notch1 is an effector of Akt and hypoxia in melanoma development</article-title><source>J Clin Invest</source><year>2008</year><volume>118</volume><fpage>3660</fpage><lpage>3670</lpage><pub-id pub-id-type="doi">10.1172/JCI36157</pub-id><pub-id pub-id-type="pmid">18924608</pub-id>
</element-citation><mixed-citation id="mc-CR419" publication-type="journal">Bedogni B, Warneke JA, Nickoloff BJ, Giaccia AJ, Powell MB. Notch1 is an effector of Akt and hypoxia in melanoma development. J Clin Invest. 2008;118:3660&#x02013;70.<pub-id pub-id-type="pmid">18924608</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR420"><label>420.</label><citation-alternatives><element-citation id="ec-CR420" publication-type="journal"><person-group person-group-type="author"><name><surname>Kaushik</surname><given-names>G</given-names></name><name><surname>Venugopal</surname><given-names>A</given-names></name><name><surname>Ramamoorthy</surname><given-names>P</given-names></name><name><surname>Standing</surname><given-names>D</given-names></name><name><surname>Subramaniam</surname><given-names>D</given-names></name><name><surname>Umar</surname><given-names>S</given-names></name><etal/></person-group><article-title>Honokiol inhibits melanoma stem cells by targeting Notch signaling</article-title><source>Mol Carcinog</source><year>2015</year><volume>54</volume><fpage>1710</fpage><lpage>1721</lpage><pub-id pub-id-type="doi">10.1002/mc.22242</pub-id><pub-id pub-id-type="pmid">25491779</pub-id>
</element-citation><mixed-citation id="mc-CR420" publication-type="journal">Kaushik G, Venugopal A, Ramamoorthy P, Standing D, Subramaniam D, Umar S, et al. Honokiol inhibits melanoma stem cells by targeting Notch signaling. Mol Carcinog. 2015;54:1710&#x02013;21.<pub-id pub-id-type="pmid">25491779</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR421"><label>421.</label><citation-alternatives><element-citation id="ec-CR421" publication-type="journal"><person-group person-group-type="author"><name><surname>Ronchini</surname><given-names>C</given-names></name><name><surname>Capobianco</surname><given-names>AJ</given-names></name></person-group><article-title>Induction of cyclin D1 transcription and CDK2 activity by Notch(ic): implication for cell cycle disruption in transformation by Notch(ic)</article-title><source>Mol Cell Biol</source><year>2001</year><volume>21</volume><fpage>5925</fpage><lpage>5934</lpage><pub-id pub-id-type="doi">10.1128/MCB.21.17.5925-5934.2001</pub-id><pub-id pub-id-type="pmid">11486031</pub-id>
</element-citation><mixed-citation id="mc-CR421" publication-type="journal">Ronchini C, Capobianco AJ. Induction of cyclin D1 transcription and CDK2 activity by Notch(ic): implication for cell cycle disruption in transformation by Notch(ic). Mol Cell Biol. 2001;21:5925&#x02013;34.<pub-id pub-id-type="pmid">11486031</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR422"><label>422.</label><citation-alternatives><element-citation id="ec-CR422" publication-type="journal"><person-group person-group-type="author"><name><surname>Gustafsson</surname><given-names>MV</given-names></name><name><surname>Zheng</surname><given-names>X</given-names></name><name><surname>Pereira</surname><given-names>T</given-names></name><name><surname>Gradin</surname><given-names>K</given-names></name><name><surname>Jin</surname><given-names>S</given-names></name><name><surname>Lundkvist</surname><given-names>J</given-names></name><etal/></person-group><article-title>Hypoxia requires notch signaling to maintain the undifferentiated cell state</article-title><source>Dev Cell</source><year>2005</year><volume>9</volume><fpage>617</fpage><lpage>628</lpage><pub-id pub-id-type="doi">10.1016/j.devcel.2005.09.010</pub-id><pub-id pub-id-type="pmid">16256737</pub-id>
</element-citation><mixed-citation id="mc-CR422" publication-type="journal">Gustafsson MV, Zheng X, Pereira T, Gradin K, Jin S, Lundkvist J, et al. Hypoxia requires notch signaling to maintain the undifferentiated cell state. Dev Cell. 2005;9:617&#x02013;28.<pub-id pub-id-type="pmid">16256737</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR423"><label>423.</label><citation-alternatives><element-citation id="ec-CR423" publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>X</given-names></name><name><surname>Sun</surname><given-names>B</given-names></name><name><surname>Zhu</surname><given-names>D</given-names></name><name><surname>Zhao</surname><given-names>X</given-names></name><name><surname>Sun</surname><given-names>R</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Notch4+ cancer stem-like cells promote the metastatic and invasive ability of melanoma</article-title><source>Cancer Sci</source><year>2016</year><volume>107</volume><fpage>1079</fpage><lpage>1091</lpage><pub-id pub-id-type="doi">10.1111/cas.12978</pub-id><pub-id pub-id-type="pmid">27234159</pub-id>
</element-citation><mixed-citation id="mc-CR423" publication-type="journal">Lin X, Sun B, Zhu D, Zhao X, Sun R, Zhang Y, et al. Notch4+ cancer stem-like cells promote the metastatic and invasive ability of melanoma. Cancer Sci. 2016;107:1079&#x02013;91.<pub-id pub-id-type="pmid">27234159</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR424"><label>424.</label><citation-alternatives><element-citation id="ec-CR424" publication-type="journal"><person-group person-group-type="author"><name><surname>Hsu</surname><given-names>M-Y</given-names></name><name><surname>Yang</surname><given-names>MH</given-names></name><name><surname>Schnegg</surname><given-names>CI</given-names></name><name><surname>Hwang</surname><given-names>S</given-names></name><name><surname>Ryu</surname><given-names>B</given-names></name><name><surname>Alani</surname><given-names>RM</given-names></name></person-group><article-title>Notch3 signaling-mediated melanoma&#x02013;endothelial crosstalk regulates melanoma stem-like cell homeostasis and niche morphogenesis</article-title><source>Lab Invest</source><year>2017</year><volume>97</volume><fpage>725</fpage><lpage>736</lpage><pub-id pub-id-type="doi">10.1038/labinvest.2017.1</pub-id><pub-id pub-id-type="pmid">28165469</pub-id>
</element-citation><mixed-citation id="mc-CR424" publication-type="journal">Hsu M-Y, Yang MH, Schnegg CI, Hwang S, Ryu B, Alani RM. Notch3 signaling-mediated melanoma&#x02013;endothelial crosstalk regulates melanoma stem-like cell homeostasis and niche morphogenesis. Lab Invest. 2017;97:725&#x02013;36.<pub-id pub-id-type="pmid">28165469</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR425"><label>425.</label><citation-alternatives><element-citation id="ec-CR425" publication-type="journal"><person-group person-group-type="author"><name><surname>Hardy</surname><given-names>KM</given-names></name><name><surname>Kirschmann</surname><given-names>DA</given-names></name><name><surname>Seftor</surname><given-names>EA</given-names></name><name><surname>Margaryan</surname><given-names>NV</given-names></name><name><surname>Postovit</surname><given-names>LM</given-names></name><name><surname>Strizzi</surname><given-names>L</given-names></name><etal/></person-group><article-title>Regulation of the embryonic morphogen Nodal by Notch4 facilitates manifestation of the aggressive melanoma phenotype</article-title><source>Cancer Res</source><year>2010</year><volume>70</volume><fpage>10340</fpage><lpage>10350</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-10-0705</pub-id><pub-id pub-id-type="pmid">21159651</pub-id>
</element-citation><mixed-citation id="mc-CR425" publication-type="journal">Hardy KM, Kirschmann DA, Seftor EA, Margaryan NV, Postovit LM, Strizzi L, et al. Regulation of the embryonic morphogen Nodal by Notch4 facilitates manifestation of the aggressive melanoma phenotype. Cancer Res. 2010;70:10340&#x02013;50.<pub-id pub-id-type="pmid">21159651</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR426"><label>426.</label><citation-alternatives><element-citation id="ec-CR426" publication-type="journal"><person-group person-group-type="author"><name><surname>Kakadia</surname><given-names>S</given-names></name><name><surname>Yarlagadda</surname><given-names>N</given-names></name><name><surname>Awad</surname><given-names>R</given-names></name><name><surname>Kundranda</surname><given-names>M</given-names></name><name><surname>Niu</surname><given-names>J</given-names></name><name><surname>Naraev</surname><given-names>B</given-names></name><etal/></person-group><article-title>Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanoma</article-title><source>Onco Targets Ther</source><year>2018</year><volume>11</volume><fpage>7095</fpage><lpage>7107</lpage><pub-id pub-id-type="doi">10.2147/OTT.S182721</pub-id><pub-id pub-id-type="pmid">30410366</pub-id>
</element-citation><mixed-citation id="mc-CR426" publication-type="journal">Kakadia S, Yarlagadda N, Awad R, Kundranda M, Niu J, Naraev B, et al. Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanoma. Onco Targets Ther. 2018;11:7095&#x02013;107.<pub-id pub-id-type="pmid">30410366</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR427"><label>427.</label><citation-alternatives><element-citation id="ec-CR427" publication-type="journal"><person-group person-group-type="author"><name><surname>Segrelles</surname><given-names>C</given-names></name><name><surname>Garc&#x000ed;a-Escudero</surname><given-names>R</given-names></name><name><surname>Gar&#x000ed;n</surname><given-names>MI</given-names></name><name><surname>Aranda</surname><given-names>JF</given-names></name><name><surname>Hern&#x000e1;ndez</surname><given-names>P</given-names></name><name><surname>Ariza</surname><given-names>JM</given-names></name><etal/></person-group><article-title>Akt signaling leads to stem cell activation and promotes tumor development in epidermis</article-title><source>Stem Cells</source><year>2014</year><volume>32</volume><fpage>1917</fpage><lpage>1928</lpage><pub-id pub-id-type="doi">10.1002/stem.1669</pub-id><pub-id pub-id-type="pmid">24504902</pub-id>
</element-citation><mixed-citation id="mc-CR427" publication-type="journal">Segrelles C, Garc&#x000ed;a-Escudero R, Gar&#x000ed;n MI, Aranda JF, Hern&#x000e1;ndez P, Ariza JM, et al. Akt signaling leads to stem cell activation and promotes tumor development in epidermis. Stem Cells. 2014;32:1917&#x02013;28.<pub-id pub-id-type="pmid">24504902</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR428"><label>428.</label><citation-alternatives><element-citation id="ec-CR428" publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>KS</given-names></name><name><surname>Carbajal</surname><given-names>S</given-names></name><name><surname>Kiguchi</surname><given-names>K</given-names></name><name><surname>Clifford</surname><given-names>J</given-names></name><name><surname>Sano</surname><given-names>S</given-names></name><name><surname>DiGiovanni</surname><given-names>J</given-names></name></person-group><article-title>Epidermal growth factor receptor-mediated activation of Stat3 during multistage skin carcinogenesis</article-title><source>Cancer Res</source><year>2004</year><volume>64</volume><fpage>2382</fpage><lpage>2389</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-03-3197</pub-id><pub-id pub-id-type="pmid">15059889</pub-id>
</element-citation><mixed-citation id="mc-CR428" publication-type="journal">Chan KS, Carbajal S, Kiguchi K, Clifford J, Sano S, DiGiovanni J. Epidermal growth factor receptor-mediated activation of Stat3 during multistage skin carcinogenesis. Cancer Res. 2004;64:2382&#x02013;9.<pub-id pub-id-type="pmid">15059889</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR429"><label>429.</label><citation-alternatives><element-citation id="ec-CR429" publication-type="journal"><person-group person-group-type="author"><name><surname>Niu</surname><given-names>G</given-names></name><name><surname>Bowman</surname><given-names>T</given-names></name><name><surname>Huang</surname><given-names>M</given-names></name><name><surname>Shivers</surname><given-names>S</given-names></name><name><surname>Reintgen</surname><given-names>D</given-names></name><name><surname>Daud</surname><given-names>A</given-names></name><etal/></person-group><article-title>Roles of activated Src and Stat3 signaling in melanoma tumor cell growth</article-title><source>Oncogene</source><year>2002</year><volume>21</volume><fpage>7001</fpage><lpage>7010</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1205859</pub-id><pub-id pub-id-type="pmid">12370822</pub-id>
</element-citation><mixed-citation id="mc-CR429" publication-type="journal">Niu G, Bowman T, Huang M, Shivers S, Reintgen D, Daud A, et al. Roles of activated Src and Stat3 signaling in melanoma tumor cell growth. Oncogene. 2002;21:7001&#x02013;10.<pub-id pub-id-type="pmid">12370822</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR430"><label>430.</label><citation-alternatives><element-citation id="ec-CR430" publication-type="journal"><person-group person-group-type="author"><name><surname>Waterman</surname><given-names>EA</given-names></name><name><surname>Sakai</surname><given-names>N</given-names></name><name><surname>Nguyen</surname><given-names>NT</given-names></name><name><surname>Horst</surname><given-names>BA</given-names></name><name><surname>Veitch</surname><given-names>DP</given-names></name><name><surname>Dey</surname><given-names>CN</given-names></name><etal/></person-group><article-title>A laminin-collagen complex drives human epidermal carcinogenesis through phosphoinositol-3-kinase activation</article-title><source>Cancer Res</source><year>2007</year><volume>67</volume><fpage>4264</fpage><lpage>4270</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-06-4141</pub-id><pub-id pub-id-type="pmid">17483338</pub-id>
</element-citation><mixed-citation id="mc-CR430" publication-type="journal">Waterman EA, Sakai N, Nguyen NT, Horst BA, Veitch DP, Dey CN, et al. A laminin-collagen complex drives human epidermal carcinogenesis through phosphoinositol-3-kinase activation. Cancer Res. 2007;67:4264&#x02013;70.<pub-id pub-id-type="pmid">17483338</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR431"><label>431.</label><citation-alternatives><element-citation id="ec-CR431" publication-type="journal"><person-group person-group-type="author"><name><surname>Yuan</surname><given-names>S</given-names></name><name><surname>Stewart</surname><given-names>KS</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Abdusselamoglu</surname><given-names>MD</given-names></name><name><surname>Parigi</surname><given-names>SM</given-names></name><name><surname>Feinberg</surname><given-names>TY</given-names></name><etal/></person-group><article-title>Ras drives malignancy through stem cell crosstalk with the microenvironment</article-title><source>Nature</source><year>2022</year><volume>612</volume><fpage>555</fpage><lpage>563</lpage><pub-id pub-id-type="doi">10.1038/s41586-022-05475-6</pub-id><pub-id pub-id-type="pmid">36450983</pub-id>
</element-citation><mixed-citation id="mc-CR431" publication-type="journal">Yuan S, Stewart KS, Yang Y, Abdusselamoglu MD, Parigi SM, Feinberg TY, et al. Ras drives malignancy through stem cell crosstalk with the microenvironment. Nature. 2022;612:555&#x02013;63.<pub-id pub-id-type="pmid">36450983</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR432"><label>432.</label><citation-alternatives><element-citation id="ec-CR432" publication-type="journal"><person-group person-group-type="author"><name><surname>Jamal</surname><given-names>SME</given-names></name><name><surname>Alamodi</surname><given-names>A</given-names></name><name><surname>Wahl</surname><given-names>RU</given-names></name><name><surname>Grada</surname><given-names>Z</given-names></name><name><surname>Shareef</surname><given-names>MA</given-names></name><name><surname>Hassan</surname><given-names>S-Y</given-names></name><etal/></person-group><article-title>Melanoma stem cell maintenance and chemo-resistance are mediated by CD133 signal to PI3K-dependent pathways</article-title><source>Oncogene</source><year>2020</year><volume>39</volume><fpage>5468</fpage><lpage>5478</lpage><pub-id pub-id-type="doi">10.1038/s41388-020-1373-6</pub-id><pub-id pub-id-type="pmid">32616888</pub-id>
</element-citation><mixed-citation id="mc-CR432" publication-type="journal">Jamal SME, Alamodi A, Wahl RU, Grada Z, Shareef MA, Hassan S-Y, et al. Melanoma stem cell maintenance and chemo-resistance are mediated by CD133 signal to PI3K-dependent pathways. Oncogene. 2020;39:5468&#x02013;78.<pub-id pub-id-type="pmid">32616888</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR433"><label>433.</label><citation-alternatives><element-citation id="ec-CR433" publication-type="journal"><person-group person-group-type="author"><name><surname>Murai</surname><given-names>T</given-names></name><name><surname>Matsuda</surname><given-names>S</given-names></name></person-group><article-title>Targeting the PI3K-Akt-mTOR signaling pathway involved in vasculogenic mimicry promoted by cancer stem cells</article-title><source>Am J Cancer Res</source><year>2023</year><volume>13</volume><fpage>5039</fpage><lpage>5046</lpage><pub-id pub-id-type="pmid">38058805</pub-id>
</element-citation><mixed-citation id="mc-CR433" publication-type="journal">Murai T, Matsuda S. Targeting the PI3K-Akt-mTOR signaling pathway involved in vasculogenic mimicry promoted by cancer stem cells. Am J Cancer Res. 2023;13:5039&#x02013;46.<pub-id pub-id-type="pmid">38058805</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR434"><label>434.</label><citation-alternatives><element-citation id="ec-CR434" publication-type="journal"><person-group person-group-type="author"><name><surname>De Andrea</surname><given-names>M</given-names></name><name><surname>Ritt&#x000e0;</surname><given-names>M</given-names></name><name><surname>Landini</surname><given-names>MM</given-names></name><name><surname>Borgogna</surname><given-names>C</given-names></name><name><surname>Mondini</surname><given-names>M</given-names></name><name><surname>Kern</surname><given-names>F</given-names></name><etal/></person-group><article-title>Keratinocyte-specific stat3 heterozygosity impairs development of skin tumors in human papillomavirus 8 transgenic mice</article-title><source>Cancer Res</source><year>2010</year><volume>70</volume><fpage>7938</fpage><lpage>7948</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-10-1128</pub-id><pub-id pub-id-type="pmid">20876801</pub-id>
</element-citation><mixed-citation id="mc-CR434" publication-type="journal">De Andrea M, Ritt&#x000e0; M, Landini MM, Borgogna C, Mondini M, Kern F, et al. Keratinocyte-specific stat3 heterozygosity impairs development of skin tumors in human papillomavirus 8 transgenic mice. Cancer Res. 2010;70:7938&#x02013;48.<pub-id pub-id-type="pmid">20876801</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR435"><label>435.</label><citation-alternatives><element-citation id="ec-CR435" publication-type="journal"><person-group person-group-type="author"><name><surname>Kataoka</surname><given-names>K</given-names></name><name><surname>Kim</surname><given-names>DJ</given-names></name><name><surname>Carbajal</surname><given-names>S</given-names></name><name><surname>Clifford</surname><given-names>JL</given-names></name><name><surname>DiGiovanni</surname><given-names>J</given-names></name></person-group><article-title>Stage-specific disruption of Stat3 demonstrates a direct requirement during both the initiation and promotion stages of mouse skin tumorigenesis</article-title><source>Carcinogenesis</source><year>2008</year><volume>29</volume><fpage>1108</fpage><lpage>1114</lpage><pub-id pub-id-type="doi">10.1093/carcin/bgn061</pub-id><pub-id pub-id-type="pmid">18453544</pub-id>
</element-citation><mixed-citation id="mc-CR435" publication-type="journal">Kataoka K, Kim DJ, Carbajal S, Clifford JL, DiGiovanni J. Stage-specific disruption of Stat3 demonstrates a direct requirement during both the initiation and promotion stages of mouse skin tumorigenesis. Carcinogenesis. 2008;29:1108&#x02013;14.<pub-id pub-id-type="pmid">18453544</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR436"><label>436.</label><citation-alternatives><element-citation id="ec-CR436" publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>DJ</given-names></name><name><surname>Kataoka</surname><given-names>K</given-names></name><name><surname>Rao</surname><given-names>D</given-names></name><name><surname>Kiguchi</surname><given-names>K</given-names></name><name><surname>Cotsarelis</surname><given-names>G</given-names></name><name><surname>Digiovanni</surname><given-names>J</given-names></name></person-group><article-title>Targeted disruption of Stat3 reveals a major role for follicular stem cells in skin tumor initiation</article-title><source>Cancer Res</source><year>2009</year><volume>69</volume><fpage>7587</fpage><lpage>7594</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-09-1180</pub-id><pub-id pub-id-type="pmid">19738054</pub-id>
</element-citation><mixed-citation id="mc-CR436" publication-type="journal">Kim DJ, Kataoka K, Rao D, Kiguchi K, Cotsarelis G, Digiovanni J. Targeted disruption of Stat3 reveals a major role for follicular stem cells in skin tumor initiation. Cancer Res. 2009;69:7587&#x02013;94.<pub-id pub-id-type="pmid">19738054</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR437"><label>437.</label><citation-alternatives><element-citation id="ec-CR437" publication-type="journal"><person-group person-group-type="author"><name><surname>Suiqing</surname><given-names>C</given-names></name><name><surname>Min</surname><given-names>Z</given-names></name><name><surname>Lirong</surname><given-names>C</given-names></name></person-group><article-title>Overexpression of phosphorylated-STAT3 correlated with the invasion and metastasis of cutaneous squamous cell carcinoma</article-title><source>J Dermatol</source><year>2005</year><volume>32</volume><fpage>354</fpage><lpage>360</lpage><pub-id pub-id-type="doi">10.1111/j.1346-8138.2005.tb00906.x</pub-id><pub-id pub-id-type="pmid">16043897</pub-id>
</element-citation><mixed-citation id="mc-CR437" publication-type="journal">Suiqing C, Min Z, Lirong C. Overexpression of phosphorylated-STAT3 correlated with the invasion and metastasis of cutaneous squamous cell carcinoma. J Dermatol. 2005;32:354&#x02013;60.<pub-id pub-id-type="pmid">16043897</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR438"><label>438.</label><citation-alternatives><element-citation id="ec-CR438" publication-type="journal"><person-group person-group-type="author"><name><surname>Clifford</surname><given-names>JL</given-names></name><name><surname>Walch</surname><given-names>E</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Xu</surname><given-names>X</given-names></name><name><surname>Alberts</surname><given-names>DS</given-names></name><name><surname>Clayman</surname><given-names>GL</given-names></name><etal/></person-group><article-title>Suppression of type I interferon signaling proteins is an early event in squamous skin carcinogenesis</article-title><source>Clin Cancer Res</source><year>2002</year><volume>8</volume><fpage>2067</fpage><lpage>2072</lpage><pub-id pub-id-type="pmid">12114405</pub-id>
</element-citation><mixed-citation id="mc-CR438" publication-type="journal">Clifford JL, Walch E, Yang X, Xu X, Alberts DS, Clayman GL, et al. Suppression of type I interferon signaling proteins is an early event in squamous skin carcinogenesis. Clin Cancer Res. 2002;8:2067&#x02013;72.<pub-id pub-id-type="pmid">12114405</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR439"><label>439.</label><citation-alternatives><element-citation id="ec-CR439" publication-type="journal"><person-group person-group-type="author"><name><surname>Syed</surname><given-names>ZA</given-names></name><name><surname>Yin</surname><given-names>W</given-names></name><name><surname>Hughes</surname><given-names>K</given-names></name><name><surname>Gill</surname><given-names>JN</given-names></name><name><surname>Shi</surname><given-names>R</given-names></name><name><surname>Clifford</surname><given-names>JL</given-names></name></person-group><article-title>HGF/c-met/Stat3 signaling during skin tumor cell invasion: indications for a positive feedback loop</article-title><source>BMC Cancer</source><year>2011</year><volume>11</volume><fpage>180</fpage><pub-id pub-id-type="doi">10.1186/1471-2407-11-180</pub-id><pub-id pub-id-type="pmid">21595927</pub-id>
</element-citation><mixed-citation id="mc-CR439" publication-type="journal">Syed ZA, Yin W, Hughes K, Gill JN, Shi R, Clifford JL. HGF/c-met/Stat3 signaling during skin tumor cell invasion: indications for a positive feedback loop. BMC Cancer. 2011;11:180.<pub-id pub-id-type="pmid">21595927</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR440"><label>440.</label><citation-alternatives><element-citation id="ec-CR440" publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>SY</given-names></name><name><surname>Takeuchi</surname><given-names>S</given-names></name><name><surname>Moroi</surname><given-names>Y</given-names></name><name><surname>Hayashida</surname><given-names>S</given-names></name><name><surname>Kido</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>SJ</given-names></name><etal/></person-group><article-title>Overexpression of phosphorylated-ATF2 and STAT3 in cutaneous squamous cell carcinoma, Bowen&#x02019;s disease and basal cell carcinoma</article-title><source>J Dermatol Sci</source><year>2008</year><volume>51</volume><fpage>210</fpage><lpage>215</lpage><pub-id pub-id-type="doi">10.1016/j.jdermsci.2008.04.008</pub-id><pub-id pub-id-type="pmid">18547788</pub-id>
</element-citation><mixed-citation id="mc-CR440" publication-type="journal">Chen SY, Takeuchi S, Moroi Y, Hayashida S, Kido M, Chen SJ, et al. Overexpression of phosphorylated-ATF2 and STAT3 in cutaneous squamous cell carcinoma, Bowen&#x02019;s disease and basal cell carcinoma. J Dermatol Sci. 2008;51:210&#x02013;5.<pub-id pub-id-type="pmid">18547788</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR441"><label>441.</label><citation-alternatives><element-citation id="ec-CR441" publication-type="journal"><person-group person-group-type="author"><name><surname>Cai</surname><given-names>SQ</given-names></name><name><surname>Chen</surname><given-names>LR</given-names></name><name><surname>Wang</surname><given-names>HJ</given-names></name><name><surname>Yao</surname><given-names>LF</given-names></name><name><surname>Zheng</surname><given-names>M</given-names></name></person-group><article-title>Effect of STAT3 phosphorylation and p53 expression on human epidermal non melanoma cutaneous tumors</article-title><source>Zhejiang Da Xue Xue Bao Yi Xue Ban</source><year>2004</year><volume>33</volume><fpage>331</fpage><lpage>334</lpage><pub-id pub-id-type="pmid">15269985</pub-id>
</element-citation><mixed-citation id="mc-CR441" publication-type="journal">Cai SQ, Chen LR, Wang HJ, Yao LF, Zheng M. Effect of STAT3 phosphorylation and p53 expression on human epidermal non melanoma cutaneous tumors. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2004;33:331&#x02013;4.<pub-id pub-id-type="pmid">15269985</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR442"><label>442.</label><citation-alternatives><element-citation id="ec-CR442" publication-type="journal"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>TX</given-names></name><name><surname>Wei</surname><given-names>D</given-names></name><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Gao</surname><given-names>AC</given-names></name><name><surname>Ali-Osman</surname><given-names>F</given-names></name><name><surname>Sawaya</surname><given-names>R</given-names></name><etal/></person-group><article-title>Stat3 activation regulates the expression of matrix metalloproteinase-2 and tumor invasion and metastasis</article-title><source>Oncogene</source><year>2004</year><volume>23</volume><fpage>3550</fpage><lpage>3560</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1207383</pub-id><pub-id pub-id-type="pmid">15116091</pub-id>
</element-citation><mixed-citation id="mc-CR442" publication-type="journal">Xie TX, Wei D, Liu M, Gao AC, Ali-Osman F, Sawaya R, et al. Stat3 activation regulates the expression of matrix metalloproteinase-2 and tumor invasion and metastasis. Oncogene. 2004;23:3550&#x02013;60.<pub-id pub-id-type="pmid">15116091</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR443"><label>443.</label><citation-alternatives><element-citation id="ec-CR443" publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>ZS</given-names></name><name><surname>Cheng</surname><given-names>XW</given-names></name><name><surname>Wang</surname><given-names>XN</given-names></name><name><surname>Song</surname><given-names>NJ</given-names></name></person-group><article-title>Prognostic significance of phosphorylated signal transducer and activator of transcription 3 and suppressor of cytokine signaling 3 expression in human cutaneous melanoma</article-title><source>Melanoma Res</source><year>2011</year><volume>21</volume><fpage>483</fpage><lpage>490</lpage><pub-id pub-id-type="doi">10.1097/CMR.0b013e32834acc37</pub-id><pub-id pub-id-type="pmid">21876460</pub-id>
</element-citation><mixed-citation id="mc-CR443" publication-type="journal">Wu ZS, Cheng XW, Wang XN, Song NJ. Prognostic significance of phosphorylated signal transducer and activator of transcription 3 and suppressor of cytokine signaling 3 expression in human cutaneous melanoma. Melanoma Res. 2011;21:483&#x02013;90.<pub-id pub-id-type="pmid">21876460</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR444"><label>444.</label><citation-alternatives><element-citation id="ec-CR444" publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>KS</given-names></name><name><surname>Sano</surname><given-names>S</given-names></name><name><surname>Kataoka</surname><given-names>K</given-names></name><name><surname>Abel</surname><given-names>E</given-names></name><name><surname>Carbajal</surname><given-names>S</given-names></name><name><surname>Beltran</surname><given-names>L</given-names></name><etal/></person-group><article-title>Forced expression of a constitutively active form of Stat3 in mouse epidermis enhances malignant progression of skin tumors induced by two-stage carcinogenesis</article-title><source>Oncogene</source><year>2008</year><volume>27</volume><fpage>1087</fpage><lpage>1094</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1210726</pub-id><pub-id pub-id-type="pmid">17700521</pub-id>
</element-citation><mixed-citation id="mc-CR444" publication-type="journal">Chan KS, Sano S, Kataoka K, Abel E, Carbajal S, Beltran L, et al. Forced expression of a constitutively active form of Stat3 in mouse epidermis enhances malignant progression of skin tumors induced by two-stage carcinogenesis. Oncogene. 2008;27:1087&#x02013;94.<pub-id pub-id-type="pmid">17700521</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR445"><label>445.</label><citation-alternatives><element-citation id="ec-CR445" publication-type="journal"><person-group person-group-type="author"><name><surname>Yin</surname><given-names>W</given-names></name><name><surname>Cheepala</surname><given-names>S</given-names></name><name><surname>Roberts</surname><given-names>JN</given-names></name><name><surname>Syson-Chan</surname><given-names>K</given-names></name><name><surname>DiGiovanni</surname><given-names>J</given-names></name><name><surname>Clifford</surname><given-names>JL</given-names></name></person-group><article-title>Active Stat3 is required for survival of human squamous cell carcinoma cells in serum-free conditions</article-title><source>Mol Cancer</source><year>2006</year><volume>5</volume><fpage>15</fpage><pub-id pub-id-type="doi">10.1186/1476-4598-5-15</pub-id><pub-id pub-id-type="pmid">16603078</pub-id>
</element-citation><mixed-citation id="mc-CR445" publication-type="journal">Yin W, Cheepala S, Roberts JN, Syson-Chan K, DiGiovanni J, Clifford JL. Active Stat3 is required for survival of human squamous cell carcinoma cells in serum-free conditions. Mol Cancer. 2006;5:15.<pub-id pub-id-type="pmid">16603078</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR446"><label>446.</label><citation-alternatives><element-citation id="ec-CR446" publication-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>Y</given-names></name><name><surname>Massagu&#x000e9;</surname><given-names>J</given-names></name></person-group><article-title>Epithelial-mesenchymal transitions: Twist in development and metastasis</article-title><source>Cell</source><year>2004</year><volume>118</volume><fpage>277</fpage><lpage>279</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2004.07.011</pub-id><pub-id pub-id-type="pmid">15294153</pub-id>
</element-citation><mixed-citation id="mc-CR446" publication-type="journal">Kang Y, Massagu&#x000e9; J. Epithelial-mesenchymal transitions: Twist in development and metastasis. Cell. 2004;118:277&#x02013;9.<pub-id pub-id-type="pmid">15294153</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR447"><label>447.</label><citation-alternatives><element-citation id="ec-CR447" publication-type="journal"><person-group person-group-type="author"><name><surname>Badarinath</surname><given-names>K</given-names></name><name><surname>Dam</surname><given-names>B</given-names></name><name><surname>Kataria</surname><given-names>S</given-names></name><name><surname>Zirmire</surname><given-names>RK</given-names></name><name><surname>Dey</surname><given-names>R</given-names></name><name><surname>Kansagara</surname><given-names>G</given-names></name><etal/></person-group><article-title>Snail maintains the stem/progenitor state of skin epithelial cells and carcinomas through the autocrine effect of matricellular protein Mindin</article-title><source>Cell Rep</source><year>2022</year><volume>40</volume><fpage>111390</fpage><pub-id pub-id-type="doi">10.1016/j.celrep.2022.111390</pub-id><pub-id pub-id-type="pmid">36130502</pub-id>
</element-citation><mixed-citation id="mc-CR447" publication-type="journal">Badarinath K, Dam B, Kataria S, Zirmire RK, Dey R, Kansagara G, et al. Snail maintains the stem/progenitor state of skin epithelial cells and carcinomas through the autocrine effect of matricellular protein Mindin. Cell Rep. 2022;40: 111390.<pub-id pub-id-type="pmid">36130502</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR448"><label>448.</label><citation-alternatives><element-citation id="ec-CR448" publication-type="journal"><person-group person-group-type="author"><name><surname>Du</surname><given-names>F</given-names></name><name><surname>Nakamura</surname><given-names>Y</given-names></name><name><surname>Tan</surname><given-names>TL</given-names></name><name><surname>Lee</surname><given-names>P</given-names></name><name><surname>Lee</surname><given-names>R</given-names></name><name><surname>Yu</surname><given-names>B</given-names></name><etal/></person-group><article-title>Expression of Snail in epidermal keratinocytes promotes cutaneous inflammation and hyperplasia conducive to tumor formation</article-title><source>Cancer Res</source><year>2010</year><volume>70</volume><fpage>10080</fpage><lpage>10089</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-10-0324</pub-id><pub-id pub-id-type="pmid">21159631</pub-id>
</element-citation><mixed-citation id="mc-CR448" publication-type="journal">Du F, Nakamura Y, Tan TL, Lee P, Lee R, Yu B, et al. Expression of Snail in epidermal keratinocytes promotes cutaneous inflammation and hyperplasia conducive to tumor formation. Cancer Res. 2010;70:10080&#x02013;9.<pub-id pub-id-type="pmid">21159631</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR449"><label>449.</label><citation-alternatives><element-citation id="ec-CR449" publication-type="journal"><person-group person-group-type="author"><name><surname>Rana</surname><given-names>I</given-names></name><name><surname>Kataria</surname><given-names>S</given-names></name><name><surname>Tan</surname><given-names>TL</given-names></name><name><surname>Hajam</surname><given-names>EY</given-names></name><name><surname>Kashyap</surname><given-names>DK</given-names></name><name><surname>Saha</surname><given-names>D</given-names></name><etal/></person-group><article-title>Mindin (SPON2) Is essential for cutaneous fibrogenesis in a mouse model of systemic sclerosis</article-title><source>J Invest Dermatol</source><year>2023</year><volume>143</volume><fpage>699</fpage><lpage>710.e10</lpage><pub-id pub-id-type="doi">10.1016/j.jid.2022.10.011</pub-id><pub-id pub-id-type="pmid">36528128</pub-id>
</element-citation><mixed-citation id="mc-CR449" publication-type="journal">Rana I, Kataria S, Tan TL, Hajam EY, Kashyap DK, Saha D, et al. Mindin (SPON2) Is essential for cutaneous fibrogenesis in a mouse model of systemic sclerosis. J Invest Dermatol. 2023;143:699-710.e10.<pub-id pub-id-type="pmid">36528128</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR450"><label>450.</label><mixed-citation publication-type="other">Mullor JL, Dahmane N, Sun T, and Ruiz i Altaba A. Wnt signals are targets and mediators of Gli function. Curr Biol. 2001; 11:769&#x02013;773.</mixed-citation></ref><ref id="CR451"><label>451.</label><citation-alternatives><element-citation id="ec-CR451" publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>SH</given-names></name><name><surname>Andl</surname><given-names>T</given-names></name><name><surname>Grachtchouk</surname><given-names>V</given-names></name><name><surname>Wang</surname><given-names>A</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Syu</surname><given-names>LJ</given-names></name><etal/></person-group><article-title>Pathological responses to oncogenic Hedgehog signaling in skin are dependent on canonical Wnt/beta3-catenin signaling</article-title><source>Nat Genet</source><year>2008</year><volume>40</volume><fpage>1130</fpage><lpage>1135</lpage><pub-id pub-id-type="doi">10.1038/ng.192</pub-id><pub-id pub-id-type="pmid">19165927</pub-id>
</element-citation><mixed-citation id="mc-CR451" publication-type="journal">Yang SH, Andl T, Grachtchouk V, Wang A, Liu J, Syu LJ, et al. Pathological responses to oncogenic Hedgehog signaling in skin are dependent on canonical Wnt/beta3-catenin signaling. Nat Genet. 2008;40:1130&#x02013;5.<pub-id pub-id-type="pmid">19165927</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR452"><label>452.</label><citation-alternatives><element-citation id="ec-CR452" publication-type="journal"><person-group person-group-type="author"><name><surname>Kuphal</surname><given-names>S</given-names></name><name><surname>Lodermeyer</surname><given-names>S</given-names></name><name><surname>Bataille</surname><given-names>F</given-names></name><name><surname>Schuierer</surname><given-names>M</given-names></name><name><surname>Hoang</surname><given-names>BH</given-names></name><name><surname>Bosserhoff</surname><given-names>AK</given-names></name></person-group><article-title>Expression of Dickkopf genes is strongly reduced in malignant melanoma</article-title><source>Oncogene</source><year>2006</year><volume>25</volume><fpage>5027</fpage><lpage>5036</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1209508</pub-id><pub-id pub-id-type="pmid">16568085</pub-id>
</element-citation><mixed-citation id="mc-CR452" publication-type="journal">Kuphal S, Lodermeyer S, Bataille F, Schuierer M, Hoang BH, Bosserhoff AK. Expression of Dickkopf genes is strongly reduced in malignant melanoma. Oncogene. 2006;25:5027&#x02013;36.<pub-id pub-id-type="pmid">16568085</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR453"><label>453.</label><citation-alternatives><element-citation id="ec-CR453" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>JP</given-names></name><name><surname>Li</surname><given-names>N</given-names></name><name><surname>Bai</surname><given-names>WZ</given-names></name><name><surname>Qiu</surname><given-names>XC</given-names></name><name><surname>Ma</surname><given-names>BA</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Notch ligand Delta-like 1 promotes the metastasis of melanoma by enhancing tumor adhesion</article-title><source>Braz J Med Biol Res</source><year>2014</year><volume>47</volume><fpage>299</fpage><lpage>306</lpage><pub-id pub-id-type="doi">10.1590/1414-431X20143368</pub-id><pub-id pub-id-type="pmid">24714813</pub-id>
</element-citation><mixed-citation id="mc-CR453" publication-type="journal">Zhang JP, Li N, Bai WZ, Qiu XC, Ma BA, Zhou Y, et al. Notch ligand Delta-like 1 promotes the metastasis of melanoma by enhancing tumor adhesion. Braz J Med Biol Res. 2014;47:299&#x02013;306.<pub-id pub-id-type="pmid">24714813</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR454"><label>454.</label><citation-alternatives><element-citation id="ec-CR454" publication-type="journal"><person-group person-group-type="author"><name><surname>Nusse</surname><given-names>R</given-names></name></person-group><article-title>Patching up hedgehog</article-title><source>Nature</source><year>1996</year><volume>384</volume><fpage>119</fpage><lpage>120</lpage><pub-id pub-id-type="doi">10.1038/384119a0</pub-id><pub-id pub-id-type="pmid">8906783</pub-id>
</element-citation><mixed-citation id="mc-CR454" publication-type="journal">Nusse R. Patching up hedgehog. Nature. 1996;384:119&#x02013;20.<pub-id pub-id-type="pmid">8906783</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR455"><label>455.</label><citation-alternatives><element-citation id="ec-CR455" publication-type="journal"><person-group person-group-type="author"><name><surname>Webster</surname><given-names>MR</given-names></name><name><surname>Kugel</surname><given-names>CH</given-names></name><name><surname>Weeraratna</surname><given-names>AT</given-names></name></person-group><article-title>The Wnts of change: how Wnts regulate phenotype switching in melanoma</article-title><source>Biochim Biophys Acta</source><year>2015</year><volume>1856</volume><fpage>244</fpage><lpage>251</lpage><pub-id pub-id-type="pmid">26546268</pub-id>
</element-citation><mixed-citation id="mc-CR455" publication-type="journal">Webster MR, Kugel CH, Weeraratna AT. The Wnts of change: how Wnts regulate phenotype switching in melanoma. Biochim Biophys Acta. 2015;1856:244&#x02013;51.<pub-id pub-id-type="pmid">26546268</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR456"><label>456.</label><mixed-citation publication-type="other">Grossmann AH, Yoo JH, Clancy J, Sorensen LK, Sedgwick A, Tong Z, et al. The small GTPase ARF6 stimulates &#x003b2;-catenin transcriptional activity during WNT5A-mediated melanoma invasion and metastasis<italic>.</italic> Sci Signal. 2013; 6:ra14.</mixed-citation></ref><ref id="CR457"><label>457.</label><citation-alternatives><element-citation id="ec-CR457" publication-type="journal"><person-group person-group-type="author"><name><surname>Jobe</surname><given-names>NP</given-names></name><name><surname>&#x000c5;sberg</surname><given-names>L</given-names></name><name><surname>Andersson</surname><given-names>T</given-names></name></person-group><article-title>Reduced WNT5A signaling in melanoma cells favors an amoeboid mode of invasion</article-title><source>Mol Oncol</source><year>2021</year><volume>15</volume><fpage>1835</fpage><lpage>1848</lpage><pub-id pub-id-type="doi">10.1002/1878-0261.12974</pub-id><pub-id pub-id-type="pmid">33969605</pub-id>
</element-citation><mixed-citation id="mc-CR457" publication-type="journal">Jobe NP, &#x000c5;sberg L, Andersson T. Reduced WNT5A signaling in melanoma cells favors an amoeboid mode of invasion. Mol Oncol. 2021;15:1835&#x02013;48.<pub-id pub-id-type="pmid">33969605</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR458"><label>458.</label><citation-alternatives><element-citation id="ec-CR458" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>T</given-names></name><name><surname>Yang</surname><given-names>K</given-names></name><name><surname>Wang</surname><given-names>R</given-names></name><etal/></person-group><article-title>Wnt5a inhibits the proliferation and melanogenesis of melanocytes</article-title><source>Int J Med Sci</source><year>2013</year><volume>10</volume><fpage>699</fpage><lpage>706</lpage><pub-id pub-id-type="doi">10.7150/ijms.5664</pub-id><pub-id pub-id-type="pmid">23569434</pub-id>
</element-citation><mixed-citation id="mc-CR458" publication-type="journal">Zhang J, Li Y, Wu Y, Yang T, Yang K, Wang R, et al. Wnt5a inhibits the proliferation and melanogenesis of melanocytes. Int J Med Sci. 2013;10:699&#x02013;706.<pub-id pub-id-type="pmid">23569434</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR459"><label>459.</label><citation-alternatives><element-citation id="ec-CR459" publication-type="journal"><person-group person-group-type="author"><name><surname>Nomachi</surname><given-names>A</given-names></name><name><surname>Nishita</surname><given-names>M</given-names></name><name><surname>Inaba</surname><given-names>D</given-names></name><name><surname>Enomoto</surname><given-names>M</given-names></name><name><surname>Hamasaki</surname><given-names>M</given-names></name><name><surname>Minami</surname><given-names>Y</given-names></name></person-group><article-title>Receptor tyrosine kinase Ror2 mediates Wnt5a-induced polarized cell migration by activating c-Jun N-terminal kinase via actin-binding protein filamin A</article-title><source>J Biol Chem</source><year>2008</year><volume>283</volume><fpage>27973</fpage><lpage>27981</lpage><pub-id pub-id-type="doi">10.1074/jbc.M802325200</pub-id><pub-id pub-id-type="pmid">18667433</pub-id>
</element-citation><mixed-citation id="mc-CR459" publication-type="journal">Nomachi A, Nishita M, Inaba D, Enomoto M, Hamasaki M, Minami Y. Receptor tyrosine kinase Ror2 mediates Wnt5a-induced polarized cell migration by activating c-Jun N-terminal kinase via actin-binding protein filamin A. J Biol Chem. 2008;283:27973&#x02013;81.<pub-id pub-id-type="pmid">18667433</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR460"><label>460.</label><citation-alternatives><element-citation id="ec-CR460" publication-type="journal"><person-group person-group-type="author"><name><surname>Kasper</surname><given-names>M</given-names></name><name><surname>Jaks</surname><given-names>V</given-names></name><name><surname>Are</surname><given-names>A</given-names></name><name><surname>Bergstr&#x000f6;m</surname><given-names>&#x000c5;</given-names></name><name><surname>Schw&#x000e4;ger</surname><given-names>A</given-names></name><name><surname>Sv&#x000e4;rd</surname><given-names>J</given-names></name><etal/></person-group><article-title>Wounding enhances epidermal tumorigenesis by recruiting hair follicle keratinocytes</article-title><source>Proc Natl Acad Sci U S A</source><year>2011</year><volume>108</volume><fpage>4099</fpage><lpage>4104</lpage><pub-id pub-id-type="doi">10.1073/pnas.1014489108</pub-id><pub-id pub-id-type="pmid">21321199</pub-id>
</element-citation><mixed-citation id="mc-CR460" publication-type="journal">Kasper M, Jaks V, Are A, Bergstr&#x000f6;m &#x000c5;, Schw&#x000e4;ger A, Sv&#x000e4;rd J, et al. Wounding enhances epidermal tumorigenesis by recruiting hair follicle keratinocytes. Proc Natl Acad Sci U S A. 2011;108:4099&#x02013;104.<pub-id pub-id-type="pmid">21321199</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR461"><label>461.</label><citation-alternatives><element-citation id="ec-CR461" publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Deng</surname><given-names>W</given-names></name><name><surname>Lobo-Ruppert</surname><given-names>S</given-names></name><name><surname>Ruppert</surname><given-names>J</given-names></name></person-group><article-title>Gli1 acts through Snail and E-cadherin to promote nuclear signaling by &#x003b2;-catenin</article-title><source>Oncogene</source><year>2007</year><volume>26</volume><fpage>4489</fpage><lpage>4498</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1210241</pub-id><pub-id pub-id-type="pmid">17297467</pub-id>
</element-citation><mixed-citation id="mc-CR461" publication-type="journal">Li X, Deng W, Lobo-Ruppert S, Ruppert J. Gli1 acts through Snail and E-cadherin to promote nuclear signaling by &#x003b2;-catenin. Oncogene. 2007;26:4489&#x02013;98.<pub-id pub-id-type="pmid">17297467</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR462"><label>462.</label><citation-alternatives><element-citation id="ec-CR462" publication-type="journal"><person-group person-group-type="author"><name><surname>Samuel</surname><given-names>MS</given-names></name><name><surname>Lopez</surname><given-names>JI</given-names></name><name><surname>McGhee</surname><given-names>EJ</given-names></name><name><surname>Croft</surname><given-names>DR</given-names></name><name><surname>Strachan</surname><given-names>D</given-names></name><name><surname>Timpson</surname><given-names>P</given-names></name><etal/></person-group><article-title>Actomyosin-mediated cellular tension drives increased tissue stiffness and &#x003b2;-catenin activation to induce epidermal hyperplasia and tumor growth</article-title><source>Cancer Cell</source><year>2011</year><volume>19</volume><fpage>776</fpage><lpage>791</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2011.05.008</pub-id><pub-id pub-id-type="pmid">21665151</pub-id>
</element-citation><mixed-citation id="mc-CR462" publication-type="journal">Samuel MS, Lopez JI, McGhee EJ, Croft DR, Strachan D, Timpson P, et al. Actomyosin-mediated cellular tension drives increased tissue stiffness and &#x003b2;-catenin activation to induce epidermal hyperplasia and tumor growth. Cancer Cell. 2011;19:776&#x02013;91.<pub-id pub-id-type="pmid">21665151</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR463"><label>463.</label><citation-alternatives><element-citation id="ec-CR463" publication-type="journal"><person-group person-group-type="author"><name><surname>Ibbetson</surname><given-names>SJ</given-names></name><name><surname>Pyne</surname><given-names>NT</given-names></name><name><surname>Pollard</surname><given-names>AN</given-names></name><name><surname>Olson</surname><given-names>MF</given-names></name><name><surname>Samuel</surname><given-names>MS</given-names></name></person-group><article-title>Mechanotransduction pathways promoting tumor progression are activated in invasive human squamous cell carcinoma</article-title><source>Am J Pathol</source><year>2013</year><volume>183</volume><fpage>930</fpage><lpage>937</lpage><pub-id pub-id-type="doi">10.1016/j.ajpath.2013.05.014</pub-id><pub-id pub-id-type="pmid">23830873</pub-id>
</element-citation><mixed-citation id="mc-CR463" publication-type="journal">Ibbetson SJ, Pyne NT, Pollard AN, Olson MF, Samuel MS. Mechanotransduction pathways promoting tumor progression are activated in invasive human squamous cell carcinoma. Am J Pathol. 2013;183:930&#x02013;7.<pub-id pub-id-type="pmid">23830873</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR464"><label>464.</label><citation-alternatives><element-citation id="ec-CR464" publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Aria</surname><given-names>AB</given-names></name><name><surname>Silapunt</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>HH</given-names></name><name><surname>Migden</surname><given-names>MR</given-names></name></person-group><article-title>Treatment of advanced basal cell carcinoma with sonidegib: perspective from the 30-month update of the BOLT trial</article-title><source>Future Oncol</source><year>2018</year><volume>14</volume><fpage>515</fpage><lpage>525</lpage><pub-id pub-id-type="doi">10.2217/fon-2017-0457</pub-id><pub-id pub-id-type="pmid">29119833</pub-id>
</element-citation><mixed-citation id="mc-CR464" publication-type="journal">Chen L, Aria AB, Silapunt S, Lee HH, Migden MR. Treatment of advanced basal cell carcinoma with sonidegib: perspective from the 30-month update of the BOLT trial. Future Oncol. 2018;14:515&#x02013;25.<pub-id pub-id-type="pmid">29119833</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR465"><label>465.</label><citation-alternatives><element-citation id="ec-CR465" publication-type="journal"><person-group person-group-type="author"><name><surname>Sekulic</surname><given-names>A</given-names></name><name><surname>Migden</surname><given-names>MR</given-names></name><name><surname>Oro</surname><given-names>AE</given-names></name><name><surname>Dirix</surname><given-names>L</given-names></name><name><surname>Lewis</surname><given-names>KD</given-names></name><name><surname>Hainsworth</surname><given-names>JD</given-names></name><etal/></person-group><article-title>Efficacy and safety of vismodegib in advanced basal-cell carcinoma</article-title><source>N Engl J Med</source><year>2012</year><volume>366</volume><fpage>2171</fpage><lpage>2179</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1113713</pub-id><pub-id pub-id-type="pmid">22670903</pub-id>
</element-citation><mixed-citation id="mc-CR465" publication-type="journal">Sekulic A, Migden MR, Oro AE, Dirix L, Lewis KD, Hainsworth JD, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med. 2012;366:2171&#x02013;9.<pub-id pub-id-type="pmid">22670903</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR466"><label>466.</label><citation-alternatives><element-citation id="ec-CR466" publication-type="journal"><person-group person-group-type="author"><name><surname>Von Hoff</surname><given-names>DD</given-names></name><name><surname>LoRusso</surname><given-names>PM</given-names></name><name><surname>Rudin</surname><given-names>CM</given-names></name><name><surname>Reddy</surname><given-names>JC</given-names></name><name><surname>Yauch</surname><given-names>RL</given-names></name><name><surname>Tibes</surname><given-names>R</given-names></name><etal/></person-group><article-title>Inhibition of the hedgehog pathway in advanced basal-cell carcinoma</article-title><source>N Engl J Med</source><year>2009</year><volume>361</volume><fpage>1164</fpage><lpage>1172</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa0905360</pub-id><pub-id pub-id-type="pmid">19726763</pub-id>
</element-citation><mixed-citation id="mc-CR466" publication-type="journal">Von Hoff DD, LoRusso PM, Rudin CM, Reddy JC, Yauch RL, Tibes R, et al. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med. 2009;361:1164&#x02013;72.<pub-id pub-id-type="pmid">19726763</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR467"><label>467.</label><mixed-citation publication-type="other">Chang ALS, Solomon JA, Hainsworth JD, Goldberg L, McKenna E, Day B-m, et al. Expanded access study of patients with advanced basal&#x000a0;cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib<italic>.</italic> J Am Acad Dermatol. 2014; 70:60&#x02013;69.</mixed-citation></ref><ref id="CR468"><label>468.</label><citation-alternatives><element-citation id="ec-CR468" publication-type="journal"><person-group person-group-type="author"><name><surname>Axelson</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>K</given-names></name><name><surname>Jiang</surname><given-names>X</given-names></name><name><surname>He</surname><given-names>K</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Zhao</surname><given-names>H</given-names></name><etal/></person-group><article-title>US Food and Drug Administration approval: vismodegib for recurrent, locally advanced, or metastatic basal cell carcinoma</article-title><source>Clin Cancer Res</source><year>2013</year><volume>19</volume><fpage>2289</fpage><lpage>2293</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-12-1956</pub-id><pub-id pub-id-type="pmid">23515405</pub-id>
</element-citation><mixed-citation id="mc-CR468" publication-type="journal">Axelson M, Liu K, Jiang X, He K, Wang J, Zhao H, et al. US Food and Drug Administration approval: vismodegib for recurrent, locally advanced, or metastatic basal cell carcinoma. Clin Cancer Res. 2013;19:2289&#x02013;93.<pub-id pub-id-type="pmid">23515405</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR469"><label>469.</label><citation-alternatives><element-citation id="ec-CR469" publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>JY</given-names></name><name><surname>Mackay-Wiggan</surname><given-names>JM</given-names></name><name><surname>Aszterbaum</surname><given-names>M</given-names></name><name><surname>Yauch</surname><given-names>RL</given-names></name><name><surname>Lindgren</surname><given-names>J</given-names></name><name><surname>Chang</surname><given-names>K</given-names></name><etal/></person-group><article-title>Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome</article-title><source>N Engl J Med</source><year>2012</year><volume>366</volume><fpage>2180</fpage><lpage>2188</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1113538</pub-id><pub-id pub-id-type="pmid">22670904</pub-id>
</element-citation><mixed-citation id="mc-CR469" publication-type="journal">Tang JY, Mackay-Wiggan JM, Aszterbaum M, Yauch RL, Lindgren J, Chang K, et al. Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome. N Engl J Med. 2012;366:2180&#x02013;8.<pub-id pub-id-type="pmid">22670904</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR470"><label>470.</label><citation-alternatives><element-citation id="ec-CR470" publication-type="journal"><person-group person-group-type="author"><name><surname>Dummer</surname><given-names>R</given-names></name><name><surname>Guminksi</surname><given-names>A</given-names></name><name><surname>Gutzmer</surname><given-names>R</given-names></name><name><surname>Lear</surname><given-names>J</given-names></name><name><surname>Lewis</surname><given-names>K</given-names></name><name><surname>Chang</surname><given-names>A</given-names></name><etal/></person-group><article-title>Long-term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42-month analysis of the phase II randomized, double-blind BOLT study</article-title><source>Br J Dermatol</source><year>2020</year><volume>182</volume><fpage>1369</fpage><lpage>1378</lpage><pub-id pub-id-type="doi">10.1111/bjd.18552</pub-id><pub-id pub-id-type="pmid">31545507</pub-id>
</element-citation><mixed-citation id="mc-CR470" publication-type="journal">Dummer R, Guminksi A, Gutzmer R, Lear J, Lewis K, Chang A, et al. Long-term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42-month analysis of the phase II randomized, double-blind BOLT study. Br J Dermatol. 2020;182:1369&#x02013;78.<pub-id pub-id-type="pmid">31545507</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR471"><label>471.</label><citation-alternatives><element-citation id="ec-CR471" publication-type="journal"><person-group person-group-type="author"><name><surname>Papastefanou</surname><given-names>VP</given-names></name><name><surname>Ren&#x000e9;</surname><given-names>C</given-names></name></person-group><article-title>Secondary resistance to vismodegib after initial successful treatment of extensive recurrent periocular basal cell carcinoma with orbital invasion</article-title><source>Ophthalmic Plast Reconstr Surg</source><year>2017</year><volume>33</volume><fpage>S68</fpage><lpage>S70</lpage><pub-id pub-id-type="doi">10.1097/IOP.0000000000000565</pub-id><pub-id pub-id-type="pmid">26398246</pub-id>
</element-citation><mixed-citation id="mc-CR471" publication-type="journal">Papastefanou VP, Ren&#x000e9; C. Secondary resistance to vismodegib after initial successful treatment of extensive recurrent periocular basal cell carcinoma with orbital invasion. Ophthalmic Plast Reconstr Surg. 2017;33:S68&#x02013;70.<pub-id pub-id-type="pmid">26398246</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR472"><label>472.</label><citation-alternatives><element-citation id="ec-CR472" publication-type="journal"><person-group person-group-type="author"><name><surname>Meani</surname><given-names>RE</given-names></name><name><surname>Lim</surname><given-names>SW</given-names></name><name><surname>Chang</surname><given-names>ALS</given-names></name><name><surname>Kelly</surname><given-names>JW</given-names></name></person-group><article-title>Emergence of chemoresistance in a metastatic basal cell carcinoma patient after complete response to hedgehog pathway inhibitor vismodegib (GDC-0449)</article-title><source>Australas J Dermatol</source><year>2014</year><volume>55</volume><fpage>218</fpage><lpage>221</lpage><pub-id pub-id-type="doi">10.1111/ajd.12196</pub-id><pub-id pub-id-type="pmid">25117162</pub-id>
</element-citation><mixed-citation id="mc-CR472" publication-type="journal">Meani RE, Lim SW, Chang ALS, Kelly JW. Emergence of chemoresistance in a metastatic basal cell carcinoma patient after complete response to hedgehog pathway inhibitor vismodegib (GDC-0449). Australas J Dermatol. 2014;55:218&#x02013;21.<pub-id pub-id-type="pmid">25117162</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR473"><label>473.</label><citation-alternatives><element-citation id="ec-CR473" publication-type="journal"><person-group person-group-type="author"><name><surname>Chmiel</surname><given-names>P</given-names></name><name><surname>K&#x00142;osi&#x00144;ska</surname><given-names>M</given-names></name><name><surname>Forma</surname><given-names>A</given-names></name><name><surname>Pelc</surname><given-names>Z</given-names></name><name><surname>G&#x00119;ca</surname><given-names>K</given-names></name><name><surname>Sk&#x000f3;rzewska</surname><given-names>M</given-names></name></person-group><article-title>Novel approaches in non-melanoma skin cancers&#x02014;a focus on hedgehog pathway in basal cell carcinoma (BCC)</article-title><source>Cells</source><year>2022</year><volume>11</volume><fpage>3210</fpage><pub-id pub-id-type="doi">10.3390/cells11203210</pub-id><pub-id pub-id-type="pmid">36291078</pub-id>
</element-citation><mixed-citation id="mc-CR473" publication-type="journal">Chmiel P, K&#x00142;osi&#x00144;ska M, Forma A, Pelc Z, G&#x00119;ca K, Sk&#x000f3;rzewska M. Novel approaches in non-melanoma skin cancers&#x02014;a focus on hedgehog pathway in basal cell carcinoma (BCC). Cells. 2022;11:3210.<pub-id pub-id-type="pmid">36291078</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR474"><label>474.</label><citation-alternatives><element-citation id="ec-CR474" publication-type="journal"><person-group person-group-type="author"><name><surname>Frampton</surname><given-names>JE</given-names></name><name><surname>Basset-S&#x000e9;guin</surname><given-names>N</given-names></name></person-group><article-title>Vismodegib: a review in advanced basal cell carcinoma</article-title><source>Drugs</source><year>2018</year><volume>78</volume><fpage>1145</fpage><lpage>1156</lpage><pub-id pub-id-type="doi">10.1007/s40265-018-0948-9</pub-id><pub-id pub-id-type="pmid">30030732</pub-id>
</element-citation><mixed-citation id="mc-CR474" publication-type="journal">Frampton JE, Basset-S&#x000e9;guin N. Vismodegib: a review in advanced basal cell carcinoma. Drugs. 2018;78:1145&#x02013;56.<pub-id pub-id-type="pmid">30030732</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR475"><label>475.</label><citation-alternatives><element-citation id="ec-CR475" publication-type="journal"><person-group person-group-type="author"><name><surname>Sharpe</surname><given-names>HJ</given-names></name><name><surname>Pau</surname><given-names>G</given-names></name><name><surname>Dijkgraaf</surname><given-names>GJ</given-names></name><name><surname>Basset-Seguin</surname><given-names>N</given-names></name><name><surname>Modrusan</surname><given-names>Z</given-names></name><name><surname>Januario</surname><given-names>T</given-names></name><etal/></person-group><article-title>Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma</article-title><source>Cancer Cell</source><year>2015</year><volume>27</volume><fpage>327</fpage><lpage>341</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2015.02.001</pub-id><pub-id pub-id-type="pmid">25759019</pub-id>
</element-citation><mixed-citation id="mc-CR475" publication-type="journal">Sharpe HJ, Pau G, Dijkgraaf GJ, Basset-Seguin N, Modrusan Z, Januario T, et al. Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma. Cancer Cell. 2015;27:327&#x02013;41.<pub-id pub-id-type="pmid">25759019</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR476"><label>476.</label><citation-alternatives><element-citation id="ec-CR476" publication-type="journal"><person-group person-group-type="author"><name><surname>Atwood</surname><given-names>SX</given-names></name><name><surname>Sarin</surname><given-names>KY</given-names></name><name><surname>Whitson</surname><given-names>RJ</given-names></name><name><surname>Li</surname><given-names>JR</given-names></name><name><surname>Kim</surname><given-names>G</given-names></name><name><surname>Rezaee</surname><given-names>M</given-names></name><etal/></person-group><article-title>Smoothened variants explain the majority of drug resistance in basal cell carcinoma</article-title><source>Cancer Cell</source><year>2015</year><volume>27</volume><fpage>342</fpage><lpage>353</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2015.02.002</pub-id><pub-id pub-id-type="pmid">25759020</pub-id>
</element-citation><mixed-citation id="mc-CR476" publication-type="journal">Atwood SX, Sarin KY, Whitson RJ, Li JR, Kim G, Rezaee M, et al. Smoothened variants explain the majority of drug resistance in basal cell carcinoma. Cancer Cell. 2015;27:342&#x02013;53.<pub-id pub-id-type="pmid">25759020</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR477"><label>477.</label><citation-alternatives><element-citation id="ec-CR477" publication-type="journal"><person-group person-group-type="author"><name><surname>Sekulic</surname><given-names>A</given-names></name><name><surname>Migden</surname><given-names>MR</given-names></name><name><surname>Basset-Seguin</surname><given-names>N</given-names></name><name><surname>Garbe</surname><given-names>C</given-names></name><name><surname>Gesierich</surname><given-names>A</given-names></name><name><surname>Lao</surname><given-names>CD</given-names></name><etal/></person-group><article-title>Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study</article-title><source>BMC Cancer</source><year>2017</year><volume>17</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1186/s12885-017-3286-5</pub-id><pub-id pub-id-type="pmid">28049525</pub-id>
</element-citation><mixed-citation id="mc-CR477" publication-type="journal">Sekulic A, Migden MR, Basset-Seguin N, Garbe C, Gesierich A, Lao CD, et al. Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study. BMC Cancer. 2017;17:1&#x02013;10.<pub-id pub-id-type="pmid">28049525</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR478"><label>478.</label><citation-alternatives><element-citation id="ec-CR478" publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>AL</given-names></name><name><surname>Oro</surname><given-names>AE</given-names></name></person-group><article-title>Initial assessment of tumor regrowth after vismodegib in advanced basal cell carcinoma</article-title><source>Arch Dermatol</source><year>2012</year><volume>148</volume><fpage>1324</fpage><lpage>1325</lpage><pub-id pub-id-type="doi">10.1001/archdermatol.2012.2354</pub-id><pub-id pub-id-type="pmid">22910979</pub-id>
</element-citation><mixed-citation id="mc-CR478" publication-type="journal">Chang AL, Oro AE. Initial assessment of tumor regrowth after vismodegib in advanced basal cell carcinoma. Arch Dermatol. 2012;148:1324&#x02013;5.<pub-id pub-id-type="pmid">22910979</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR479"><label>479.</label><citation-alternatives><element-citation id="ec-CR479" publication-type="journal"><person-group person-group-type="author"><name><surname>Lear</surname><given-names>JT</given-names></name><name><surname>Migden</surname><given-names>MR</given-names></name><name><surname>Lewis</surname><given-names>KD</given-names></name><name><surname>Chang</surname><given-names>ALS</given-names></name><name><surname>Guminski</surname><given-names>A</given-names></name><name><surname>Gutzmer</surname><given-names>R</given-names></name><etal/></person-group><article-title>Long-term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30-month analysis of the randomized phase 2 BOLT study</article-title><source>J Eur Acad Dermatol Venereol</source><year>2018</year><volume>32</volume><fpage>372</fpage><lpage>381</lpage><pub-id pub-id-type="doi">10.1111/jdv.14542</pub-id><pub-id pub-id-type="pmid">28846163</pub-id>
</element-citation><mixed-citation id="mc-CR479" publication-type="journal">Lear JT, Migden MR, Lewis KD, Chang ALS, Guminski A, Gutzmer R, et al. Long-term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30-month analysis of the randomized phase 2 BOLT study. J Eur Acad Dermatol Venereol. 2018;32:372&#x02013;81.<pub-id pub-id-type="pmid">28846163</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR480"><label>480.</label><citation-alternatives><element-citation id="ec-CR480" publication-type="journal"><person-group person-group-type="author"><name><surname>Danial</surname><given-names>C</given-names></name><name><surname>Sarin</surname><given-names>KY</given-names></name><name><surname>Oro</surname><given-names>AE</given-names></name><name><surname>Chang</surname><given-names>AL</given-names></name></person-group><article-title>An investigator-initiated open-label trial of sonidegib in advanced basal cell carcinoma patients resistant to vismodegib</article-title><source>Clin Cancer Res</source><year>2016</year><volume>22</volume><fpage>1325</fpage><lpage>1329</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-15-1588</pub-id><pub-id pub-id-type="pmid">26546616</pub-id>
</element-citation><mixed-citation id="mc-CR480" publication-type="journal">Danial C, Sarin KY, Oro AE, Chang AL. An investigator-initiated open-label trial of sonidegib in advanced basal cell carcinoma patients resistant to vismodegib. Clin Cancer Res. 2016;22:1325&#x02013;9.<pub-id pub-id-type="pmid">26546616</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR481"><label>481.</label><citation-alternatives><element-citation id="ec-CR481" publication-type="journal"><person-group person-group-type="author"><name><surname>Mohan</surname><given-names>SV</given-names></name><name><surname>Chang</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Henry</surname><given-names>AS</given-names></name><name><surname>Wood</surname><given-names>DJ</given-names></name><name><surname>Chang</surname><given-names>AL</given-names></name></person-group><article-title>Increased risk of cutaneous squamous cell carcinoma after vismodegib therapy for basal cell carcinoma</article-title><source>JAMA Dermatol</source><year>2016</year><volume>152</volume><fpage>527</fpage><lpage>532</lpage><pub-id pub-id-type="doi">10.1001/jamadermatol.2015.4330</pub-id><pub-id pub-id-type="pmid">26914338</pub-id>
</element-citation><mixed-citation id="mc-CR481" publication-type="journal">Mohan SV, Chang J, Li S, Henry AS, Wood DJ, Chang AL. Increased risk of cutaneous squamous cell carcinoma after vismodegib therapy for basal cell carcinoma. JAMA Dermatol. 2016;152:527&#x02013;32.<pub-id pub-id-type="pmid">26914338</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR482"><label>482.</label><citation-alternatives><element-citation id="ec-CR482" publication-type="journal"><person-group person-group-type="author"><name><surname>R&#x000fc;bben</surname><given-names>A</given-names></name><name><surname>Hilgers</surname><given-names>R-D</given-names></name><name><surname>Leverkus</surname><given-names>M</given-names></name></person-group><article-title>Hedgehog blockade for basal cell carcinoma: Coming at a (secondary neoplastic) price</article-title><source>JAMA Dermatol</source><year>2016</year><volume>152</volume><fpage>521</fpage><lpage>523</lpage><pub-id pub-id-type="doi">10.1001/jamadermatol.2015.5239</pub-id><pub-id pub-id-type="pmid">26913776</pub-id>
</element-citation><mixed-citation id="mc-CR482" publication-type="journal">R&#x000fc;bben A, Hilgers R-D, Leverkus M. Hedgehog blockade for basal cell carcinoma: Coming at a (secondary neoplastic) price. JAMA Dermatol. 2016;152:521&#x02013;3.<pub-id pub-id-type="pmid">26913776</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR483"><label>483.</label><citation-alternatives><element-citation id="ec-CR483" publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Tang</surname><given-names>JY</given-names></name><name><surname>Gong</surname><given-names>R</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Lee</surname><given-names>JJ</given-names></name><name><surname>Clemons</surname><given-names>KV</given-names></name><etal/></person-group><article-title>Itraconazole, a commonly used antifungal that inhibits Hedgehog pathway activity and cancer growth</article-title><source>Cancer Cell</source><year>2010</year><volume>17</volume><fpage>388</fpage><lpage>399</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2010.02.027</pub-id><pub-id pub-id-type="pmid">20385363</pub-id>
</element-citation><mixed-citation id="mc-CR483" publication-type="journal">Kim J, Tang JY, Gong R, Kim J, Lee JJ, Clemons KV, et al. Itraconazole, a commonly used antifungal that inhibits Hedgehog pathway activity and cancer growth. Cancer Cell. 2010;17:388&#x02013;99.<pub-id pub-id-type="pmid">20385363</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR484"><label>484.</label><citation-alternatives><element-citation id="ec-CR484" publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Aftab</surname><given-names>B</given-names></name><name><surname>Tang</surname><given-names>J</given-names></name><name><surname>Kim</surname><given-names>D</given-names></name><name><surname>Lee</surname><given-names>A</given-names></name><name><surname>Rezaee</surname><given-names>M</given-names></name><etal/></person-group><article-title>Itraconazole and arsenic trioxide inhibit Hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonists</article-title><source>Cancer Cell</source><year>2013</year><volume>23</volume><fpage>23</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2012.11.017</pub-id><pub-id pub-id-type="pmid">23291299</pub-id>
</element-citation><mixed-citation id="mc-CR484" publication-type="journal">Kim J, Aftab B, Tang J, Kim D, Lee A, Rezaee M, et al. Itraconazole and arsenic trioxide inhibit Hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonists. Cancer Cell. 2013;23:23&#x02013;34.<pub-id pub-id-type="pmid">23291299</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR485"><label>485.</label><citation-alternatives><element-citation id="ec-CR485" publication-type="journal"><person-group person-group-type="author"><name><surname>Jimeno</surname><given-names>A</given-names></name><name><surname>Weiss</surname><given-names>GJ</given-names></name><name><surname>Miller</surname><given-names>WH</given-names><suffix>Jr</suffix></name><name><surname>Gettinger</surname><given-names>S</given-names></name><name><surname>Eigl</surname><given-names>BJC</given-names></name><name><surname>Chang</surname><given-names>ALS</given-names></name><etal/></person-group><article-title>Phase I study of the hedgehog pathway inhibitor IPI-926 in adult patients with solid tumors</article-title><source>Clin Cancer Res</source><year>2013</year><volume>19</volume><fpage>2766</fpage><lpage>2774</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-12-3654</pub-id><pub-id pub-id-type="pmid">23575478</pub-id>
</element-citation><mixed-citation id="mc-CR485" publication-type="journal">Jimeno A, Weiss GJ, Miller WH Jr, Gettinger S, Eigl BJC, Chang ALS, et al. Phase I study of the hedgehog pathway inhibitor IPI-926 in adult patients with solid tumors. Clin Cancer Res. 2013;19:2766&#x02013;74.<pub-id pub-id-type="pmid">23575478</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR486"><label>486.</label><mixed-citation publication-type="other">Cosio T, Di Prete M, Di Raimondo C, Garofalo V, Lozzi F, Lanna C, et al. Clinical trial of patidegib gel 2%, 4%, and vehicle applied once or twice daily to decrease the GLI1 biomarker in sporadic nodular basal cell carcinomas (BCC). Available from: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/study/NCT02828111">https://clinicaltrials.gov/study/NCT02828111</ext-link>.&#x000a0;Accessed 20 Feb 2025.</mixed-citation></ref><ref id="CR487"><label>487.</label><citation-alternatives><element-citation id="ec-CR487" publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>DJ</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Spaunhurst</surname><given-names>K</given-names></name><name><surname>Montoya</surname><given-names>J</given-names></name><name><surname>Khodosh</surname><given-names>R</given-names></name><name><surname>Chandra</surname><given-names>K</given-names></name><etal/></person-group><article-title>Open-label, exploratory phase II trial of oral itraconazole for the treatment of basal cell carcinoma</article-title><source>J Clin Oncol</source><year>2014</year><volume>32</volume><fpage>745</fpage><lpage>751</lpage><pub-id pub-id-type="doi">10.1200/JCO.2013.49.9525</pub-id><pub-id pub-id-type="pmid">24493717</pub-id>
</element-citation><mixed-citation id="mc-CR487" publication-type="journal">Kim DJ, Kim J, Spaunhurst K, Montoya J, Khodosh R, Chandra K, et al. Open-label, exploratory phase II trial of oral itraconazole for the treatment of basal cell carcinoma. J Clin Oncol. 2014;32:745&#x02013;51.<pub-id pub-id-type="pmid">24493717</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR488"><label>488.</label><citation-alternatives><element-citation id="ec-CR488" publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>AC</given-names></name><name><surname>Martin</surname><given-names>AJ</given-names></name><name><surname>Choy</surname><given-names>B</given-names></name><name><surname>Fern&#x000e1;ndez-Pe&#x000f1;as</surname><given-names>P</given-names></name><name><surname>Dalziell</surname><given-names>RA</given-names></name><name><surname>McKenzie</surname><given-names>CA</given-names></name><etal/></person-group><article-title>A phase 3 randomized trial of nicotinamide for skin-cancer chemoprevention</article-title><source>N Engl J Med</source><year>2015</year><volume>373</volume><fpage>1618</fpage><lpage>1626</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1506197</pub-id><pub-id pub-id-type="pmid">26488693</pub-id>
</element-citation><mixed-citation id="mc-CR488" publication-type="journal">Chen AC, Martin AJ, Choy B, Fern&#x000e1;ndez-Pe&#x000f1;as P, Dalziell RA, McKenzie CA, et al. A phase 3 randomized trial of nicotinamide for skin-cancer chemoprevention. N Engl J Med. 2015;373:1618&#x02013;26.<pub-id pub-id-type="pmid">26488693</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR489"><label>489.</label><citation-alternatives><element-citation id="ec-CR489" publication-type="journal"><person-group person-group-type="author"><name><surname>O&#x02019;Callaghan</surname><given-names>C</given-names></name><name><surname>Vassilopoulos</surname><given-names>A</given-names></name></person-group><article-title>Sirtuins at the crossroads of stemness, aging, and cancer</article-title><source>Aging Cell</source><year>2017</year><volume>16</volume><fpage>1208</fpage><lpage>1218</lpage><pub-id pub-id-type="doi">10.1111/acel.12685</pub-id><pub-id pub-id-type="pmid">28994177</pub-id>
</element-citation><mixed-citation id="mc-CR489" publication-type="journal">O&#x02019;Callaghan C, Vassilopoulos A. Sirtuins at the crossroads of stemness, aging, and cancer. Aging Cell. 2017;16:1208&#x02013;18.<pub-id pub-id-type="pmid">28994177</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR490"><label>490.</label><citation-alternatives><element-citation id="ec-CR490" publication-type="journal"><person-group person-group-type="author"><name><surname>Bubna</surname><given-names>AK</given-names></name></person-group><article-title>Imiquimod - Its role in the treatment of cutaneous malignancies</article-title><source>Indian J Pharmacol</source><year>2015</year><volume>47</volume><fpage>354</fpage><lpage>359</lpage><pub-id pub-id-type="doi">10.4103/0253-7613.161249</pub-id><pub-id pub-id-type="pmid">26288465</pub-id>
</element-citation><mixed-citation id="mc-CR490" publication-type="journal">Bubna AK. Imiquimod - Its role in the treatment of cutaneous malignancies. Indian J Pharmacol. 2015;47:354&#x02013;9.<pub-id pub-id-type="pmid">26288465</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR491"><label>491.</label><citation-alternatives><element-citation id="ec-CR491" publication-type="journal"><person-group person-group-type="author"><name><surname>Rodon</surname><given-names>J</given-names></name><name><surname>Argil&#x000e9;s</surname><given-names>G</given-names></name><name><surname>Connolly</surname><given-names>RM</given-names></name><name><surname>Vaishampayan</surname><given-names>U</given-names></name><name><surname>de Jonge</surname><given-names>M</given-names></name><name><surname>Garralda</surname><given-names>E</given-names></name><etal/></person-group><article-title>Phase 1 study of single-agent WNT974, a first-in-class Porcupine inhibitor, in patients with advanced solid tumours</article-title><source>Br J Cancer</source><year>2021</year><volume>125</volume><fpage>28</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1038/s41416-021-01389-8</pub-id><pub-id pub-id-type="pmid">33941878</pub-id>
</element-citation><mixed-citation id="mc-CR491" publication-type="journal">Rodon J, Argil&#x000e9;s G, Connolly RM, Vaishampayan U, de Jonge M, Garralda E, et al. Phase 1 study of single-agent WNT974, a first-in-class Porcupine inhibitor, in patients with advanced solid tumours. Br J Cancer. 2021;125:28&#x02013;37.<pub-id pub-id-type="pmid">33941878</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR492"><label>492.</label><citation-alternatives><element-citation id="ec-CR492" publication-type="journal"><person-group person-group-type="author"><name><surname>Plummer</surname><given-names>R</given-names></name><name><surname>Dua</surname><given-names>D</given-names></name><name><surname>Cresti</surname><given-names>N</given-names></name><name><surname>Drew</surname><given-names>Y</given-names></name><name><surname>Stephens</surname><given-names>P</given-names></name><name><surname>Foegh</surname><given-names>M</given-names></name><etal/></person-group><article-title>First-in-human study of the PARP/tankyrase inhibitor E7449 in patients with advanced solid tumours and evaluation of a novel drug-response predictor</article-title><source>Br J Cancer</source><year>2020</year><volume>123</volume><fpage>525</fpage><lpage>533</lpage><pub-id pub-id-type="doi">10.1038/s41416-020-0916-5</pub-id><pub-id pub-id-type="pmid">32523090</pub-id>
</element-citation><mixed-citation id="mc-CR492" publication-type="journal">Plummer R, Dua D, Cresti N, Drew Y, Stephens P, Foegh M, et al. First-in-human study of the PARP/tankyrase inhibitor E7449 in patients with advanced solid tumours and evaluation of a novel drug-response predictor. Br J Cancer. 2020;123:525&#x02013;33.<pub-id pub-id-type="pmid">32523090</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR493"><label>493.</label><citation-alternatives><element-citation id="ec-CR493" publication-type="journal"><person-group person-group-type="author"><name><surname>Dihlmann</surname><given-names>S</given-names></name><name><surname>von Knebel</surname><given-names>DM</given-names></name></person-group><article-title>Wnt/&#x003b2;-catenin-pathway as a molecular target for future anti-cancer therapeutics</article-title><source>Int J Cancer</source><year>2005</year><volume>113</volume><fpage>515</fpage><lpage>524</lpage><pub-id pub-id-type="doi">10.1002/ijc.20609</pub-id><pub-id pub-id-type="pmid">15472907</pub-id>
</element-citation><mixed-citation id="mc-CR493" publication-type="journal">Dihlmann S, von Knebel DM. Wnt/&#x003b2;-catenin-pathway as a molecular target for future anti-cancer therapeutics. Int J Cancer. 2005;113:515&#x02013;24.<pub-id pub-id-type="pmid">15472907</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR494"><label>494.</label><citation-alternatives><element-citation id="ec-CR494" publication-type="journal"><person-group person-group-type="author"><name><surname>Gala</surname><given-names>MK</given-names></name><name><surname>Chan</surname><given-names>AT</given-names></name></person-group><article-title>Molecular pathways: aspirin and Wnt signaling&#x02014;a molecularly targeted approach to cancer prevention and treatment</article-title><source>Clin Cancer Res</source><year>2015</year><volume>21</volume><fpage>1543</fpage><lpage>1548</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-14-0877</pub-id><pub-id pub-id-type="pmid">25501125</pub-id>
</element-citation><mixed-citation id="mc-CR494" publication-type="journal">Gala MK, Chan AT. Molecular pathways: aspirin and Wnt signaling&#x02014;a molecularly targeted approach to cancer prevention and treatment. Clin Cancer Res. 2015;21:1543&#x02013;8.<pub-id pub-id-type="pmid">25501125</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR495"><label>495.</label><citation-alternatives><element-citation id="ec-CR495" publication-type="journal"><person-group person-group-type="author"><name><surname>Algazi</surname><given-names>A</given-names></name><name><surname>Weber</surname><given-names>J</given-names></name><name><surname>Andrews</surname><given-names>S</given-names></name><name><surname>Urbas</surname><given-names>P</given-names></name><name><surname>Munster</surname><given-names>P</given-names></name><name><surname>DeConti</surname><given-names>R</given-names></name><etal/></person-group><article-title>Phase I clinical trial of the Src inhibitor dasatinib with dacarbazine in metastatic melanoma</article-title><source>Br J Cancer</source><year>2012</year><volume>106</volume><fpage>85</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1038/bjc.2011.514</pub-id><pub-id pub-id-type="pmid">22127285</pub-id>
</element-citation><mixed-citation id="mc-CR495" publication-type="journal">Algazi A, Weber J, Andrews S, Urbas P, Munster P, DeConti R, et al. Phase I clinical trial of the Src inhibitor dasatinib with dacarbazine in metastatic melanoma. Br J Cancer. 2012;106:85&#x02013;91.<pub-id pub-id-type="pmid">22127285</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR496"><label>496.</label><citation-alternatives><element-citation id="ec-CR496" publication-type="journal"><person-group person-group-type="author"><name><surname>Kalinsky</surname><given-names>K</given-names></name><name><surname>Lee</surname><given-names>S</given-names></name><name><surname>Rubin</surname><given-names>KM</given-names></name><name><surname>Lawrence</surname><given-names>DP</given-names></name><name><surname>Iafrarte</surname><given-names>AJ</given-names></name><name><surname>Borger</surname><given-names>DR</given-names></name><etal/></person-group><article-title>A phase 2 trial of dasatinib in patients with locally advanced or stage IV mucosal, acral, or vulvovaginal melanoma: A trial of the ECOG-ACRIN Cancer Research Group (E2607)</article-title><source>Cancer</source><year>2017</year><volume>123</volume><fpage>2688</fpage><lpage>2697</lpage><pub-id pub-id-type="doi">10.1002/cncr.30663</pub-id><pub-id pub-id-type="pmid">28334439</pub-id>
</element-citation><mixed-citation id="mc-CR496" publication-type="journal">Kalinsky K, Lee S, Rubin KM, Lawrence DP, Iafrarte AJ, Borger DR, et al. A phase 2 trial of dasatinib in patients with locally advanced or stage IV mucosal, acral, or vulvovaginal melanoma: A trial of the ECOG-ACRIN Cancer Research Group (E2607). Cancer. 2017;123:2688&#x02013;97.<pub-id pub-id-type="pmid">28334439</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR497"><label>497.</label><citation-alternatives><element-citation id="ec-CR497" publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>J</given-names></name><name><surname>Carvajal</surname><given-names>RD</given-names></name><name><surname>Dummer</surname><given-names>R</given-names></name><name><surname>Hauschild</surname><given-names>A</given-names></name><name><surname>Daud</surname><given-names>A</given-names></name><name><surname>Bastian</surname><given-names>BC</given-names></name><etal/></person-group><article-title>Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial</article-title><source>Ann Oncol</source><year>2017</year><volume>28</volume><fpage>1380</fpage><lpage>1387</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdx079</pub-id><pub-id pub-id-type="pmid">28327988</pub-id>
</element-citation><mixed-citation id="mc-CR497" publication-type="journal">Guo J, Carvajal RD, Dummer R, Hauschild A, Daud A, Bastian BC, et al. Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial. Ann Oncol. 2017;28:1380&#x02013;7.<pub-id pub-id-type="pmid">28327988</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR498"><label>498.</label><citation-alternatives><element-citation id="ec-CR498" publication-type="journal"><person-group person-group-type="author"><name><surname>Kluger</surname><given-names>HM</given-names></name><name><surname>Dudek</surname><given-names>AZ</given-names></name><name><surname>McCann</surname><given-names>C</given-names></name><name><surname>Ritacco</surname><given-names>J</given-names></name><name><surname>Southard</surname><given-names>N</given-names></name><name><surname>Jilaveanu</surname><given-names>LB</given-names></name><etal/></person-group><article-title>A phase 2 trial of dasatinib in advanced melanoma</article-title><source>Cancer</source><year>2011</year><volume>117</volume><fpage>2202</fpage><lpage>2208</lpage><pub-id pub-id-type="doi">10.1002/cncr.25766</pub-id><pub-id pub-id-type="pmid">21523734</pub-id>
</element-citation><mixed-citation id="mc-CR498" publication-type="journal">Kluger HM, Dudek AZ, McCann C, Ritacco J, Southard N, Jilaveanu LB, et al. A phase 2 trial of dasatinib in advanced melanoma. Cancer. 2011;117:2202&#x02013;8.<pub-id pub-id-type="pmid">21523734</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR499"><label>499.</label><citation-alternatives><element-citation id="ec-CR499" publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>H</given-names></name><name><surname>Yang</surname><given-names>B</given-names></name><name><surname>Nakaoka</surname><given-names>HJ</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Le Nguyen</surname><given-names>K</given-names></name><etal/></person-group><article-title>Hippo signaling dysfunction induces cancer cell addiction to YAP</article-title><source>Oncogene</source><year>2018</year><volume>37</volume><fpage>6414</fpage><lpage>6424</lpage><pub-id pub-id-type="doi">10.1038/s41388-018-0419-5</pub-id><pub-id pub-id-type="pmid">30068939</pub-id>
</element-citation><mixed-citation id="mc-CR499" publication-type="journal">Han H, Yang B, Nakaoka HJ, Yang J, Zhao Y, Le Nguyen K, et al. Hippo signaling dysfunction induces cancer cell addiction to YAP. Oncogene. 2018;37:6414&#x02013;24.<pub-id pub-id-type="pmid">30068939</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR500"><label>500.</label><citation-alternatives><element-citation id="ec-CR500" publication-type="journal"><person-group person-group-type="author"><name><surname>Munster</surname><given-names>PN</given-names></name><name><surname>Marchion</surname><given-names>D</given-names></name><name><surname>Thomas</surname><given-names>S</given-names></name><name><surname>Egorin</surname><given-names>M</given-names></name><name><surname>Minton</surname><given-names>S</given-names></name><name><surname>Springett</surname><given-names>G</given-names></name><etal/></person-group><article-title>Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker</article-title><source>Br J Cancer</source><year>2009</year><volume>101</volume><fpage>1044</fpage><lpage>1050</lpage><pub-id pub-id-type="doi">10.1038/sj.bjc.6605293</pub-id><pub-id pub-id-type="pmid">19738609</pub-id>
</element-citation><mixed-citation id="mc-CR500" publication-type="journal">Munster PN, Marchion D, Thomas S, Egorin M, Minton S, Springett G, et al. Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker. Br J Cancer. 2009;101:1044&#x02013;50.<pub-id pub-id-type="pmid">19738609</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR501"><label>501.</label><citation-alternatives><element-citation id="ec-CR501" publication-type="journal"><person-group person-group-type="author"><name><surname>Fruehauf</surname><given-names>JP</given-names></name><name><surname>El-Masry</surname><given-names>M</given-names></name><name><surname>Osann</surname><given-names>K</given-names></name><name><surname>Parmakhtiar</surname><given-names>B</given-names></name><name><surname>Yamamoto</surname><given-names>M</given-names></name><name><surname>Jakowatz</surname><given-names>JG</given-names></name></person-group><article-title>Phase II study of pazopanib in combination with paclitaxel in patients with metastatic melanoma</article-title><source>Cancer Chemother Pharmacol</source><year>2018</year><volume>82</volume><fpage>353</fpage><lpage>360</lpage><pub-id pub-id-type="doi">10.1007/s00280-018-3624-6</pub-id><pub-id pub-id-type="pmid">29943192</pub-id>
</element-citation><mixed-citation id="mc-CR501" publication-type="journal">Fruehauf JP, El-Masry M, Osann K, Parmakhtiar B, Yamamoto M, Jakowatz JG. Phase II study of pazopanib in combination with paclitaxel in patients with metastatic melanoma. Cancer Chemother Pharmacol. 2018;82:353&#x02013;60.<pub-id pub-id-type="pmid">29943192</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR502"><label>502.</label><citation-alternatives><element-citation id="ec-CR502" publication-type="journal"><person-group person-group-type="author"><name><surname>Tolcher</surname><given-names>AW</given-names></name><name><surname>Messersmith</surname><given-names>WA</given-names></name><name><surname>Mikulski</surname><given-names>SM</given-names></name><name><surname>Papadopoulos</surname><given-names>KP</given-names></name><name><surname>Kwak</surname><given-names>EL</given-names></name><name><surname>Gibbon</surname><given-names>DG</given-names></name><etal/></person-group><article-title>Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors</article-title><source>J Clin Oncol</source><year>2012</year><volume>30</volume><fpage>2348</fpage><pub-id pub-id-type="doi">10.1200/JCO.2011.36.8282</pub-id><pub-id pub-id-type="pmid">22529266</pub-id>
</element-citation><mixed-citation id="mc-CR502" publication-type="journal">Tolcher AW, Messersmith WA, Mikulski SM, Papadopoulos KP, Kwak EL, Gibbon DG, et al. Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors. J Clin Oncol. 2012;30:2348.<pub-id pub-id-type="pmid">22529266</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR503"><label>503.</label><citation-alternatives><element-citation id="ec-CR503" publication-type="journal"><person-group person-group-type="author"><name><surname>Schram</surname><given-names>AM</given-names></name><name><surname>Gandhi</surname><given-names>L</given-names></name><name><surname>Mita</surname><given-names>MM</given-names></name><name><surname>Damstrup</surname><given-names>L</given-names></name><name><surname>Campana</surname><given-names>F</given-names></name><name><surname>Hidalgo</surname><given-names>M</given-names></name><etal/></person-group><article-title>A phase Ib dose-escalation and expansion study of the oral MEK inhibitor pimasertib and PI3K/MTOR inhibitor voxtalisib in patients with advanced solid tumours</article-title><source>Br J Cancer</source><year>2018</year><volume>119</volume><fpage>1471</fpage><lpage>1476</lpage><pub-id pub-id-type="doi">10.1038/s41416-018-0322-4</pub-id><pub-id pub-id-type="pmid">30425349</pub-id>
</element-citation><mixed-citation id="mc-CR503" publication-type="journal">Schram AM, Gandhi L, Mita MM, Damstrup L, Campana F, Hidalgo M, et al. A phase Ib dose-escalation and expansion study of the oral MEK inhibitor pimasertib and PI3K/MTOR inhibitor voxtalisib in patients with advanced solid tumours. Br J Cancer. 2018;119:1471&#x02013;6.<pub-id pub-id-type="pmid">30425349</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR504"><label>504.</label><citation-alternatives><element-citation id="ec-CR504" publication-type="journal"><person-group person-group-type="author"><name><surname>Dummer</surname><given-names>R</given-names></name><name><surname>Sandhu</surname><given-names>SK</given-names></name><name><surname>Miller</surname><given-names>WH</given-names></name><name><surname>Butler</surname><given-names>MO</given-names></name><name><surname>Blank</surname><given-names>CU</given-names></name><name><surname>Mu&#x000f1;oz-Couselo</surname><given-names>E</given-names></name><etal/></person-group><article-title>A phase II, multicenter study of encorafenib/binimetinib followed by a rational triple-combination after progression in patients with advanced BRAF V600-mutated melanoma (LOGIC2)</article-title><source>J Clin Oncol</source><year>2020</year><volume>38</volume><fpage>10022</fpage><lpage>10022</lpage><pub-id pub-id-type="doi">10.1200/JCO.2020.38.15_suppl.10022</pub-id></element-citation><mixed-citation id="mc-CR504" publication-type="journal">Dummer R, Sandhu SK, Miller WH, Butler MO, Blank CU, Mu&#x000f1;oz-Couselo E, et al. A phase II, multicenter study of encorafenib/binimetinib followed by a rational triple-combination after progression in patients with advanced BRAF V600-mutated melanoma (LOGIC2). J Clin Oncol. 2020;38:10022&#x02013;10022.</mixed-citation></citation-alternatives></ref><ref id="CR505"><label>505.</label><citation-alternatives><element-citation id="ec-CR505" publication-type="journal"><person-group person-group-type="author"><name><surname>Algazi</surname><given-names>AP</given-names></name><name><surname>Rotow</surname><given-names>J</given-names></name><name><surname>Posch</surname><given-names>C</given-names></name><name><surname>Ortiz-Urda</surname><given-names>S</given-names></name><name><surname>Pelayo</surname><given-names>A</given-names></name><name><surname>Munster</surname><given-names>PN</given-names></name><etal/></person-group><article-title>A dual pathway inhibition strategy using BKM120 combined with vemurafenib is poorly tolerated in BRAF V600(E/K) mutant advanced melanoma</article-title><source>Pigment Cell Melanoma Res</source><year>2019</year><volume>32</volume><fpage>603</fpage><lpage>606</lpage><pub-id pub-id-type="doi">10.1111/pcmr.12777</pub-id><pub-id pub-id-type="pmid">30801911</pub-id>
</element-citation><mixed-citation id="mc-CR505" publication-type="journal">Algazi AP, Rotow J, Posch C, Ortiz-Urda S, Pelayo A, Munster PN, et al. A dual pathway inhibition strategy using BKM120 combined with vemurafenib is poorly tolerated in BRAF V600(E/K) mutant advanced melanoma. Pigment Cell Melanoma Res. 2019;32:603&#x02013;6.<pub-id pub-id-type="pmid">30801911</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR506"><label>506.</label><citation-alternatives><element-citation id="ec-CR506" publication-type="journal"><person-group person-group-type="author"><name><surname>Tolcher</surname><given-names>AW</given-names></name><name><surname>Kurzrock</surname><given-names>R</given-names></name><name><surname>Valero</surname><given-names>V</given-names></name><name><surname>Gonzalez</surname><given-names>R</given-names></name><name><surname>Heist</surname><given-names>RS</given-names></name><name><surname>Tan</surname><given-names>AR</given-names></name><etal/></person-group><article-title>Phase I dose-escalation trial of the oral AKT inhibitor uprosertib in combination with the oral MEK1/MEK2 inhibitor trametinib in patients with solid tumors</article-title><source>Cancer Chemother Pharmacol</source><year>2020</year><volume>85</volume><fpage>673</fpage><lpage>683</lpage><pub-id pub-id-type="doi">10.1007/s00280-020-04038-8</pub-id><pub-id pub-id-type="pmid">32062691</pub-id>
</element-citation><mixed-citation id="mc-CR506" publication-type="journal">Tolcher AW, Kurzrock R, Valero V, Gonzalez R, Heist RS, Tan AR, et al. Phase I dose-escalation trial of the oral AKT inhibitor uprosertib in combination with the oral MEK1/MEK2 inhibitor trametinib in patients with solid tumors. Cancer Chemother Pharmacol. 2020;85:673&#x02013;83.<pub-id pub-id-type="pmid">32062691</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR507"><label>507.</label><citation-alternatives><element-citation id="ec-CR507" publication-type="journal"><person-group person-group-type="author"><name><surname>Algazi</surname><given-names>AP</given-names></name><name><surname>Esteve-Puig</surname><given-names>R</given-names></name><name><surname>Nosrati</surname><given-names>A</given-names></name><name><surname>Hinds</surname><given-names>B</given-names></name><name><surname>Hobbs-Muthukumar</surname><given-names>A</given-names></name><name><surname>Nandoskar</surname><given-names>P</given-names></name><etal/></person-group><article-title>Dual MEK/AKT inhibition with trametinib and GSK2141795 does not yield clinical benefit in metastatic NRAS-mutant and wild-type melanoma</article-title><source>Pigment Cell Melanoma Res</source><year>2018</year><volume>31</volume><fpage>110</fpage><lpage>114</lpage><pub-id pub-id-type="doi">10.1111/pcmr.12644</pub-id><pub-id pub-id-type="pmid">28921907</pub-id>
</element-citation><mixed-citation id="mc-CR507" publication-type="journal">Algazi AP, Esteve-Puig R, Nosrati A, Hinds B, Hobbs-Muthukumar A, Nandoskar P, et al. Dual MEK/AKT inhibition with trametinib and GSK2141795 does not yield clinical benefit in metastatic NRAS-mutant and wild-type melanoma. Pigment Cell Melanoma Res. 2018;31:110&#x02013;4.<pub-id pub-id-type="pmid">28921907</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR508"><label>508.</label><mixed-citation publication-type="other">Algazi AP, Moon J, Chmielowski B, Lo R, Kendra KL, Lao CD, et al. SWOG S1221: A phase 1 dose escalation study co-targeting MAPK-dependent and MAPK-independent BRAF inhibitor resistance in BRAF mutant advanced solid tumors with dabrafenib, trametinib, and GSK2141795 (ClinicalTrials. gov NCT01902173). J Clin Oncol. 2017; 35:2578.</mixed-citation></ref><ref id="CR509"><label>509.</label><citation-alternatives><element-citation id="ec-CR509" publication-type="journal"><person-group person-group-type="author"><name><surname>Molife</surname><given-names>L</given-names></name><name><surname>Yan</surname><given-names>L</given-names></name><name><surname>Vitfell-Rasmussen</surname><given-names>J</given-names></name><name><surname>Zernhelt</surname><given-names>AM</given-names></name><name><surname>Sullivan</surname><given-names>DM</given-names></name><name><surname>Cassier</surname><given-names>PA</given-names></name><etal/></person-group><article-title>Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors</article-title><source>J Hematol Oncol</source><year>2014</year><volume>7</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1186/1756-8722-7-1</pub-id><pub-id pub-id-type="pmid">24387695</pub-id>
</element-citation><mixed-citation id="mc-CR509" publication-type="journal">Molife L, Yan L, Vitfell-Rasmussen J, Zernhelt AM, Sullivan DM, Cassier PA, et al. Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors. J Hematol Oncol. 2014;7:1&#x02013;12.<pub-id pub-id-type="pmid">24387695</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR510"><label>510.</label><citation-alternatives><element-citation id="ec-CR510" publication-type="journal"><person-group person-group-type="author"><name><surname>Tolcher</surname><given-names>AW</given-names></name><name><surname>Patnaik</surname><given-names>A</given-names></name><name><surname>Papadopoulos</surname><given-names>KP</given-names></name><name><surname>Rasco</surname><given-names>DW</given-names></name><name><surname>Becerra</surname><given-names>CR</given-names></name><name><surname>Allred</surname><given-names>AJ</given-names></name><etal/></person-group><article-title>Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma</article-title><source>Cancer Chemother Pharmacol</source><year>2015</year><volume>75</volume><fpage>183</fpage><lpage>189</lpage><pub-id pub-id-type="doi">10.1007/s00280-014-2615-5</pub-id><pub-id pub-id-type="pmid">25417902</pub-id>
</element-citation><mixed-citation id="mc-CR510" publication-type="journal">Tolcher AW, Patnaik A, Papadopoulos KP, Rasco DW, Becerra CR, Allred AJ, et al. Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma. Cancer Chemother Pharmacol. 2015;75:183&#x02013;9.<pub-id pub-id-type="pmid">25417902</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR511"><label>511.</label><citation-alternatives><element-citation id="ec-CR511" publication-type="journal"><person-group person-group-type="author"><name><surname>Bhutani</surname><given-names>T</given-names></name><name><surname>Abrouk</surname><given-names>M</given-names></name><name><surname>Sima</surname><given-names>CS</given-names></name><name><surname>Sadetsky</surname><given-names>N</given-names></name><name><surname>Hou</surname><given-names>J</given-names></name><name><surname>Caro</surname><given-names>I</given-names></name><etal/></person-group><article-title>Risk of cutaneous squamous cell carcinoma after treatment of basal cell carcinoma with vismodegib</article-title><source>J Am Acad Dermatol</source><year>2017</year><volume>77</volume><fpage>713</fpage><lpage>718</lpage><pub-id pub-id-type="doi">10.1016/j.jaad.2017.03.038</pub-id><pub-id pub-id-type="pmid">28780365</pub-id>
</element-citation><mixed-citation id="mc-CR511" publication-type="journal">Bhutani T, Abrouk M, Sima CS, Sadetsky N, Hou J, Caro I, et al. Risk of cutaneous squamous cell carcinoma after treatment of basal cell carcinoma with vismodegib. J Am Acad Dermatol. 2017;77:713&#x02013;8.<pub-id pub-id-type="pmid">28780365</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR512"><label>512.</label><citation-alternatives><element-citation id="ec-CR512" publication-type="journal"><person-group person-group-type="author"><name><surname>Sekulic</surname><given-names>A</given-names></name><name><surname>Yoo</surname><given-names>S</given-names></name><name><surname>Kudchadkar</surname><given-names>R</given-names></name><name><surname>Guillen</surname><given-names>J</given-names></name><name><surname>Rogers</surname><given-names>G</given-names></name><name><surname>Chang</surname><given-names>ALS</given-names></name><etal/></person-group><article-title>Real-world assessment and treatment of locally advanced basal cell carcinoma: Findings from the RegiSONIC disease registry</article-title><source>PLoS ONE</source><year>2022</year><volume>17</volume><fpage>e0262151</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0262151</pub-id><pub-id pub-id-type="pmid">35030185</pub-id>
</element-citation><mixed-citation id="mc-CR512" publication-type="journal">Sekulic A, Yoo S, Kudchadkar R, Guillen J, Rogers G, Chang ALS, et al. Real-world assessment and treatment of locally advanced basal cell carcinoma: Findings from the RegiSONIC disease registry. PLoS ONE. 2022;17: e0262151.<pub-id pub-id-type="pmid">35030185</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR513"><label>513.</label><citation-alternatives><element-citation id="ec-CR513" publication-type="journal"><person-group person-group-type="author"><name><surname>Ransohoff</surname><given-names>KJ</given-names></name><name><surname>Tang</surname><given-names>JY</given-names></name><name><surname>Sarin</surname><given-names>KY</given-names></name></person-group><article-title>Squamous change in basal-cell carcinoma with drug resistance</article-title><source>N Engl J Med</source><year>2015</year><volume>373</volume><fpage>1079</fpage><lpage>1082</lpage><pub-id pub-id-type="doi">10.1056/NEJMc1504261</pub-id><pub-id pub-id-type="pmid">26352826</pub-id>
</element-citation><mixed-citation id="mc-CR513" publication-type="journal">Ransohoff KJ, Tang JY, Sarin KY. Squamous change in basal-cell carcinoma with drug resistance. N Engl J Med. 2015;373:1079&#x02013;82.<pub-id pub-id-type="pmid">26352826</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR514"><label>514.</label><citation-alternatives><element-citation id="ec-CR514" publication-type="journal"><person-group person-group-type="author"><name><surname>Ingrassia</surname><given-names>J</given-names></name><name><surname>Maher</surname><given-names>J</given-names></name><name><surname>Cline</surname><given-names>A</given-names></name></person-group><article-title>A review of the risk of cutaneous squamous cell carcinoma after Vismodegib therapy</article-title><source>J of Skin</source><year>2022</year><volume>6</volume><fpage>453</fpage><lpage>457</lpage><pub-id pub-id-type="doi">10.25251/skin.6.6.1</pub-id></element-citation><mixed-citation id="mc-CR514" publication-type="journal">Ingrassia J, Maher J, Cline A. A review of the risk of cutaneous squamous cell carcinoma after Vismodegib therapy. J of Skin. 2022;6:453&#x02013;7.</mixed-citation></citation-alternatives></ref><ref id="CR515"><label>515.</label><citation-alternatives><element-citation id="ec-CR515" publication-type="journal"><person-group person-group-type="author"><name><surname>Yilmaz</surname><given-names>AS</given-names></name><name><surname>Ozer</surname><given-names>HG</given-names></name><name><surname>Gillespie</surname><given-names>JL</given-names></name><name><surname>Allain</surname><given-names>DC</given-names></name><name><surname>Bernhardt</surname><given-names>MN</given-names></name><name><surname>Furlan</surname><given-names>KC</given-names></name><etal/></person-group><article-title>Differential mutation frequencies in metastatic cutaneous squamous cell carcinomas versus primary tumors</article-title><source>Cancer</source><year>2017</year><volume>123</volume><fpage>1184</fpage><lpage>1193</lpage><pub-id pub-id-type="doi">10.1002/cncr.30459</pub-id><pub-id pub-id-type="pmid">27906449</pub-id>
</element-citation><mixed-citation id="mc-CR515" publication-type="journal">Yilmaz AS, Ozer HG, Gillespie JL, Allain DC, Bernhardt MN, Furlan KC, et al. Differential mutation frequencies in metastatic cutaneous squamous cell carcinomas versus primary tumors. Cancer. 2017;123:1184&#x02013;93.<pub-id pub-id-type="pmid">27906449</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR516"><label>516.</label><citation-alternatives><element-citation id="ec-CR516" publication-type="journal"><person-group person-group-type="author"><name><surname>Bancalari</surname><given-names>B</given-names></name><name><surname>Llombart</surname><given-names>B</given-names></name><name><surname>Serra-Guill&#x000e9;n</surname><given-names>C</given-names></name><name><surname>Bernia</surname><given-names>E</given-names></name><name><surname>Requena</surname><given-names>C</given-names></name><name><surname>Nagore</surname><given-names>E</given-names></name><etal/></person-group><article-title>Histologic changes during treatment with vismodegib in locally advanced basal cell carcinoma: a series of 19 cases</article-title><source>Am J Dermatopathol</source><year>2019</year><volume>41</volume><fpage>711</fpage><lpage>717</lpage><pub-id pub-id-type="doi">10.1097/DAD.0000000000001384</pub-id><pub-id pub-id-type="pmid">31436575</pub-id>
</element-citation><mixed-citation id="mc-CR516" publication-type="journal">Bancalari B, Llombart B, Serra-Guill&#x000e9;n C, Bernia E, Requena C, Nagore E, et al. Histologic changes during treatment with vismodegib in locally advanced basal cell carcinoma: a series of 19 cases. Am J Dermatopathol. 2019;41:711&#x02013;7.<pub-id pub-id-type="pmid">31436575</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR517"><label>517.</label><citation-alternatives><element-citation id="ec-CR517" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>X</given-names></name><name><surname>Ponomaryov</surname><given-names>T</given-names></name><name><surname>Ornell</surname><given-names>KJ</given-names></name><name><surname>Zhou</surname><given-names>P</given-names></name><name><surname>Dabral</surname><given-names>SK</given-names></name><name><surname>Pak</surname><given-names>E</given-names></name><etal/></person-group><article-title>RAS/MAPK activation drives resistance to SMO inhibition, metastasis, and tumor evolution in shh pathway-dependent tumors</article-title><source>Cancer Res</source><year>2015</year><volume>75</volume><fpage>3623</fpage><lpage>3635</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-14-2999-T</pub-id><pub-id pub-id-type="pmid">26130651</pub-id>
</element-citation><mixed-citation id="mc-CR517" publication-type="journal">Zhao X, Ponomaryov T, Ornell KJ, Zhou P, Dabral SK, Pak E, et al. RAS/MAPK activation drives resistance to SMO inhibition, metastasis, and tumor evolution in shh pathway-dependent tumors. Cancer Res. 2015;75:3623&#x02013;35.<pub-id pub-id-type="pmid">26130651</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR518"><label>518.</label><citation-alternatives><element-citation id="ec-CR518" publication-type="journal"><person-group person-group-type="author"><name><surname>Kuonen</surname><given-names>F</given-names></name><name><surname>Huskey</surname><given-names>NE</given-names></name><name><surname>Shankar</surname><given-names>G</given-names></name><name><surname>Jaju</surname><given-names>P</given-names></name><name><surname>Whitson</surname><given-names>RJ</given-names></name><name><surname>Rieger</surname><given-names>KE</given-names></name><etal/></person-group><article-title>Loss of primary cilia drives switching from hedgehog to Ras/MAPK pathway in resistant basal cell carcinoma</article-title><source>J Invest Dermatol</source><year>2019</year><volume>139</volume><fpage>1439</fpage><lpage>1448</lpage><pub-id pub-id-type="doi">10.1016/j.jid.2018.11.035</pub-id><pub-id pub-id-type="pmid">30707899</pub-id>
</element-citation><mixed-citation id="mc-CR518" publication-type="journal">Kuonen F, Huskey NE, Shankar G, Jaju P, Whitson RJ, Rieger KE, et al. Loss of primary cilia drives switching from hedgehog to Ras/MAPK pathway in resistant basal cell carcinoma. J Invest Dermatol. 2019;139:1439&#x02013;48.<pub-id pub-id-type="pmid">30707899</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR519"><label>519.</label><citation-alternatives><element-citation id="ec-CR519" publication-type="journal"><person-group person-group-type="author"><name><surname>Pite&#x00161;a</surname><given-names>N</given-names></name><name><surname>Kurtovi&#x00107;</surname><given-names>M</given-names></name><name><surname>Bartoni&#x0010d;ek</surname><given-names>N</given-names></name><name><surname>Gkotsi</surname><given-names>DS</given-names></name><name><surname>&#x0010c;onka&#x00161;</surname><given-names>J</given-names></name><name><surname>Petri&#x00107;</surname><given-names>T</given-names></name><etal/></person-group><article-title>Signaling switching from hedgehog-GLI to MAPK signaling potentially serves as a compensatory mechanism in melanoma cell lines resistant to GANT-61</article-title><source>Biomedicines</source><year>2023</year><volume>11</volume><fpage>1353</fpage><pub-id pub-id-type="doi">10.3390/biomedicines11051353</pub-id><pub-id pub-id-type="pmid">37239024</pub-id>
</element-citation><mixed-citation id="mc-CR519" publication-type="journal">Pite&#x00161;a N, Kurtovi&#x00107; M, Bartoni&#x0010d;ek N, Gkotsi DS, &#x0010c;onka&#x00161; J, Petri&#x00107; T, et al. Signaling switching from hedgehog-GLI to MAPK signaling potentially serves as a compensatory mechanism in melanoma cell lines resistant to GANT-61. Biomedicines. 2023;11:1353.<pub-id pub-id-type="pmid">37239024</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR520"><label>520.</label><citation-alternatives><element-citation id="ec-CR520" publication-type="journal"><person-group person-group-type="author"><name><surname>Patil</surname><given-names>K</given-names></name><name><surname>Khan</surname><given-names>AQ</given-names></name><name><surname>Ahmad</surname><given-names>F</given-names></name><name><surname>Kuttikrishnan</surname><given-names>S</given-names></name><name><surname>Anver</surname><given-names>R</given-names></name><name><surname>Mateo</surname><given-names>JM</given-names></name><etal/></person-group><article-title>Sanguinarine triggers apoptosis in cutaneous squamous cell carcinoma cells through reactive oxygen species-dependent c-Jun N-terminal kinase signaling pathway</article-title><source>Front Biosci (Landmark Ed)</source><year>2024</year><volume>29</volume><fpage>40</fpage><pub-id pub-id-type="doi">10.31083/j.fbl2901040</pub-id><pub-id pub-id-type="pmid">38287817</pub-id>
</element-citation><mixed-citation id="mc-CR520" publication-type="journal">Patil K, Khan AQ, Ahmad F, Kuttikrishnan S, Anver R, Mateo JM, et al. Sanguinarine triggers apoptosis in cutaneous squamous cell carcinoma cells through reactive oxygen species-dependent c-Jun N-terminal kinase signaling pathway. Front Biosci (Landmark Ed). 2024;29:40.<pub-id pub-id-type="pmid">38287817</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR521"><label>521.</label><citation-alternatives><element-citation id="ec-CR521" publication-type="journal"><person-group person-group-type="author"><name><surname>Neill</surname><given-names>GW</given-names></name><name><surname>Harrison</surname><given-names>WJ</given-names></name><name><surname>Ikram</surname><given-names>MS</given-names></name><name><surname>Williams</surname><given-names>TDL</given-names></name><name><surname>Bianchi</surname><given-names>LS</given-names></name><name><surname>Nadendla</surname><given-names>SK</given-names></name><etal/></person-group><article-title>GLI1 repression of ERK activity correlates with colony formation and impaired migration in human epidermal keratinocytes</article-title><source>Carcinogenesis</source><year>2008</year><volume>29</volume><fpage>738</fpage><lpage>746</lpage><pub-id pub-id-type="doi">10.1093/carcin/bgn037</pub-id><pub-id pub-id-type="pmid">18281251</pub-id>
</element-citation><mixed-citation id="mc-CR521" publication-type="journal">Neill GW, Harrison WJ, Ikram MS, Williams TDL, Bianchi LS, Nadendla SK, et al. GLI1 repression of ERK activity correlates with colony formation and impaired migration in human epidermal keratinocytes. Carcinogenesis. 2008;29:738&#x02013;46.<pub-id pub-id-type="pmid">18281251</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR522"><label>522.</label><citation-alternatives><element-citation id="ec-CR522" publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>SM</given-names></name><name><surname>Moon</surname><given-names>J</given-names></name><name><surname>Redman</surname><given-names>BG</given-names></name><name><surname>Chidiac</surname><given-names>T</given-names></name><name><surname>Flaherty</surname><given-names>LE</given-names></name><name><surname>Zha</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Phase 2 study of RO 4929097, a gamma-secretase inhibitor, in metastatic melanoma: SWOG 0933</article-title><source>Cancer</source><year>2015</year><volume>121</volume><fpage>432</fpage><lpage>440</lpage><pub-id pub-id-type="doi">10.1002/cncr.29055</pub-id><pub-id pub-id-type="pmid">25250858</pub-id>
</element-citation><mixed-citation id="mc-CR522" publication-type="journal">Lee SM, Moon J, Redman BG, Chidiac T, Flaherty LE, Zha Y, et al. Phase 2 study of RO 4929097, a gamma-secretase inhibitor, in metastatic melanoma: SWOG 0933. Cancer. 2015;121:432&#x02013;40.<pub-id pub-id-type="pmid">25250858</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR523"><label>523.</label><citation-alternatives><element-citation id="ec-CR523" publication-type="journal"><person-group person-group-type="author"><name><surname>Bonyadi Rad</surname><given-names>E</given-names></name><name><surname>Hammerlindl</surname><given-names>H</given-names></name><name><surname>Wels</surname><given-names>C</given-names></name><name><surname>Popper</surname><given-names>U</given-names></name><name><surname>Ravindran Menon</surname><given-names>D</given-names></name><name><surname>Breiteneder</surname><given-names>H</given-names></name><etal/></person-group><article-title>Notch4 signaling induces a mesenchymal-epithelial-like transition in melanoma cells to suppress malignant behaviors</article-title><source>Cancer Res</source><year>2016</year><volume>76</volume><fpage>1690</fpage><lpage>1697</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-15-1722</pub-id><pub-id pub-id-type="pmid">26801977</pub-id>
</element-citation><mixed-citation id="mc-CR523" publication-type="journal">Bonyadi Rad E, Hammerlindl H, Wels C, Popper U, Ravindran Menon D, Breiteneder H, et al. Notch4 signaling induces a mesenchymal-epithelial-like transition in melanoma cells to suppress malignant behaviors. Cancer Res. 2016;76:1690&#x02013;7.<pub-id pub-id-type="pmid">26801977</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR524"><label>524.</label><citation-alternatives><element-citation id="ec-CR524" publication-type="journal"><person-group person-group-type="author"><name><surname>Vasilaki</surname><given-names>E</given-names></name><name><surname>Kanaki</surname><given-names>Z</given-names></name><name><surname>Stravopodis</surname><given-names>DJ</given-names></name><name><surname>Klinakis</surname><given-names>A</given-names></name></person-group><article-title>Dll1 marks cells of origin of Ras-induced cancer in mouse squamous epithelia</article-title><source>Transl Oncol</source><year>2018</year><volume>11</volume><fpage>1213</fpage><lpage>1219</lpage><pub-id pub-id-type="doi">10.1016/j.tranon.2018.07.011</pub-id><pub-id pub-id-type="pmid">30081298</pub-id>
</element-citation><mixed-citation id="mc-CR524" publication-type="journal">Vasilaki E, Kanaki Z, Stravopodis DJ, Klinakis A. Dll1 marks cells of origin of Ras-induced cancer in mouse squamous epithelia. Transl Oncol. 2018;11:1213&#x02013;9.<pub-id pub-id-type="pmid">30081298</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR525"><label>525.</label><citation-alternatives><element-citation id="ec-CR525" publication-type="journal"><person-group person-group-type="author"><name><surname>Golan</surname><given-names>T</given-names></name><name><surname>Messer</surname><given-names>AR</given-names></name><name><surname>Amitai-Lange</surname><given-names>A</given-names></name><name><surname>Melamed</surname><given-names>Z</given-names></name><name><surname>Ohana</surname><given-names>R</given-names></name><name><surname>Bell</surname><given-names>RE</given-names></name><etal/></person-group><article-title>Interactions of melanoma cells with distal keratinocytes trigger metastasis via Notch signaling inhibition of MITF</article-title><source>Mol Cell</source><year>2015</year><volume>59</volume><fpage>664</fpage><lpage>676</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2015.06.028</pub-id><pub-id pub-id-type="pmid">26236014</pub-id>
</element-citation><mixed-citation id="mc-CR525" publication-type="journal">Golan T, Messer AR, Amitai-Lange A, Melamed Z, Ohana R, Bell RE, et al. Interactions of melanoma cells with distal keratinocytes trigger metastasis via Notch signaling inhibition of MITF. Mol Cell. 2015;59:664&#x02013;76.<pub-id pub-id-type="pmid">26236014</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR526"><label>526.</label><citation-alternatives><element-citation id="ec-CR526" publication-type="journal"><person-group person-group-type="author"><name><surname>Del Castillo</surname><given-names>V-H</given-names></name><name><surname>van der Weyden</surname><given-names>L</given-names></name><name><surname>Nsengimana</surname><given-names>J</given-names></name><name><surname>Speak</surname><given-names>AO</given-names></name><name><surname>Sj&#x000f6;berg</surname><given-names>MK</given-names></name><name><surname>Bishop</surname><given-names>DT</given-names></name><etal/></person-group><article-title>Comparative genomics reveals that loss of lunatic fringe (LFNG) promotes melanoma metastasis</article-title><source>Mol Oncol</source><year>2018</year><volume>12</volume><fpage>239</fpage><lpage>255</lpage><pub-id pub-id-type="doi">10.1002/1878-0261.12161</pub-id><pub-id pub-id-type="pmid">29193607</pub-id>
</element-citation><mixed-citation id="mc-CR526" publication-type="journal">Del Castillo V-H, van der Weyden L, Nsengimana J, Speak AO, Sj&#x000f6;berg MK, Bishop DT, et al. Comparative genomics reveals that loss of lunatic fringe (LFNG) promotes melanoma metastasis. Mol Oncol. 2018;12:239&#x02013;55.<pub-id pub-id-type="pmid">29193607</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR527"><label>527.</label><citation-alternatives><element-citation id="ec-CR527" publication-type="journal"><person-group person-group-type="author"><name><surname>Hiratochi</surname><given-names>M</given-names></name><name><surname>Nagase</surname><given-names>H</given-names></name><name><surname>Kuramochi</surname><given-names>Y</given-names></name><name><surname>Koh</surname><given-names>C-S</given-names></name><name><surname>Ohkawara</surname><given-names>T</given-names></name><name><surname>Nakayama</surname><given-names>K</given-names></name></person-group><article-title>The Delta intracellular domain mediates TGF-&#x003b2;/Activin signaling through binding to Smads and has an important bi-directional function in the Notch-Delta signaling pathway</article-title><source>Nucleic Acids Res</source><year>2007</year><volume>35</volume><fpage>912</fpage><lpage>922</lpage><pub-id pub-id-type="doi">10.1093/nar/gkl1128</pub-id><pub-id pub-id-type="pmid">17251195</pub-id>
</element-citation><mixed-citation id="mc-CR527" publication-type="journal">Hiratochi M, Nagase H, Kuramochi Y, Koh C-S, Ohkawara T, Nakayama K. The Delta intracellular domain mediates TGF-&#x003b2;/Activin signaling through binding to Smads and has an important bi-directional function in the Notch-Delta signaling pathway. Nucleic Acids Res. 2007;35:912&#x02013;22.<pub-id pub-id-type="pmid">17251195</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR528"><label>528.</label><citation-alternatives><element-citation id="ec-CR528" publication-type="journal"><person-group person-group-type="author"><name><surname>Atkinson</surname><given-names>JM</given-names></name><name><surname>Rank</surname><given-names>KB</given-names></name><name><surname>Zeng</surname><given-names>Y</given-names></name><name><surname>Capen</surname><given-names>A</given-names></name><name><surname>Yadav</surname><given-names>V</given-names></name><name><surname>Manro</surname><given-names>JR</given-names></name><etal/></person-group><article-title>Activating the Wnt/&#x003b2;-catenin pathway for the treatment of melanoma&#x02013;application of LY2090314, a novel selective inhibitor of glycogen synthase kinase-3</article-title><source>PLoS ONE</source><year>2015</year><volume>10</volume><fpage>e0125028</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0125028</pub-id><pub-id pub-id-type="pmid">25915038</pub-id>
</element-citation><mixed-citation id="mc-CR528" publication-type="journal">Atkinson JM, Rank KB, Zeng Y, Capen A, Yadav V, Manro JR, et al. Activating the Wnt/&#x003b2;-catenin pathway for the treatment of melanoma&#x02013;application of LY2090314, a novel selective inhibitor of glycogen synthase kinase-3. PLoS ONE. 2015;10: e0125028.<pub-id pub-id-type="pmid">25915038</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR529"><label>529.</label><citation-alternatives><element-citation id="ec-CR529" publication-type="journal"><person-group person-group-type="author"><name><surname>Zimmerman</surname><given-names>ZF</given-names></name><name><surname>Kulikauskas</surname><given-names>RM</given-names></name><name><surname>Bomsztyk</surname><given-names>K</given-names></name><name><surname>Moon</surname><given-names>RT</given-names></name><name><surname>Chien</surname><given-names>AJ</given-names></name></person-group><article-title>Activation of Wnt/&#x003b2;-catenin signaling increases apoptosis in melanoma cells treated with trail</article-title><source>PLoS ONE</source><year>2013</year><volume>8</volume><fpage>e69593</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0069593</pub-id><pub-id pub-id-type="pmid">23869245</pub-id>
</element-citation><mixed-citation id="mc-CR529" publication-type="journal">Zimmerman ZF, Kulikauskas RM, Bomsztyk K, Moon RT, Chien AJ. Activation of Wnt/&#x003b2;-catenin signaling increases apoptosis in melanoma cells treated with trail. PLoS ONE. 2013;8: e69593.<pub-id pub-id-type="pmid">23869245</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR530"><label>530.</label><citation-alternatives><element-citation id="ec-CR530" publication-type="journal"><person-group person-group-type="author"><name><surname>Sato</surname><given-names>A</given-names></name><name><surname>Yamamoto</surname><given-names>H</given-names></name><name><surname>Sakane</surname><given-names>H</given-names></name><name><surname>Koyama</surname><given-names>H</given-names></name><name><surname>Kikuchi</surname><given-names>A</given-names></name></person-group><article-title>Wnt5a regulates distinct signalling pathways by binding to Frizzled2</article-title><source>EMBO J</source><year>2010</year><volume>29</volume><fpage>41</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1038/emboj.2009.322</pub-id><pub-id pub-id-type="pmid">19910923</pub-id>
</element-citation><mixed-citation id="mc-CR530" publication-type="journal">Sato A, Yamamoto H, Sakane H, Koyama H, Kikuchi A. Wnt5a regulates distinct signalling pathways by binding to Frizzled2. EMBO J. 2010;29:41&#x02013;54.<pub-id pub-id-type="pmid">19910923</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR531"><label>531.</label><citation-alternatives><element-citation id="ec-CR531" publication-type="journal"><person-group person-group-type="author"><name><surname>van Amerongen</surname><given-names>R</given-names></name><name><surname>Fuerer</surname><given-names>C</given-names></name><name><surname>Mizutani</surname><given-names>M</given-names></name><name><surname>Nusse</surname><given-names>R</given-names></name></person-group><article-title>Wnt5a can both activate and repress Wnt/&#x003b2;-catenin signaling during mouse embryonic development</article-title><source>Dev Biol</source><year>2012</year><volume>369</volume><fpage>101</fpage><lpage>114</lpage><pub-id pub-id-type="doi">10.1016/j.ydbio.2012.06.020</pub-id><pub-id pub-id-type="pmid">22771246</pub-id>
</element-citation><mixed-citation id="mc-CR531" publication-type="journal">van Amerongen R, Fuerer C, Mizutani M, Nusse R. Wnt5a can both activate and repress Wnt/&#x003b2;-catenin signaling during mouse embryonic development. Dev Biol. 2012;369:101&#x02013;14.<pub-id pub-id-type="pmid">22771246</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR532"><label>532.</label><citation-alternatives><element-citation id="ec-CR532" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>K</given-names></name><name><surname>Ma</surname><given-names>F</given-names></name><name><surname>Arai</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Varkaris</surname><given-names>A</given-names></name><name><surname>Poluben</surname><given-names>L</given-names></name><etal/></person-group><article-title>WNT5a signaling through ROR2 activates the Hippo pathway to suppress YAP1 activity and tumor growth</article-title><source>Cancer Res</source><year>2023</year><volume>83</volume><fpage>1016</fpage><lpage>1030</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-22-3003</pub-id><pub-id pub-id-type="pmid">36622276</pub-id>
</element-citation><mixed-citation id="mc-CR532" publication-type="journal">Wang K, Ma F, Arai S, Wang Y, Varkaris A, Poluben L, et al. WNT5a signaling through ROR2 activates the Hippo pathway to suppress YAP1 activity and tumor growth. Cancer Res. 2023;83:1016&#x02013;30.<pub-id pub-id-type="pmid">36622276</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR533"><label>533.</label><citation-alternatives><element-citation id="ec-CR533" publication-type="journal"><person-group person-group-type="author"><name><surname>Ploper</surname><given-names>D</given-names></name><name><surname>Taelman</surname><given-names>VF</given-names></name><name><surname>Robert</surname><given-names>L</given-names></name><name><surname>Perez</surname><given-names>BS</given-names></name><name><surname>Titz</surname><given-names>B</given-names></name><name><surname>Chen</surname><given-names>HW</given-names></name><etal/></person-group><article-title>MITF drives endolysosomal biogenesis and potentiates Wnt signaling in melanoma cells</article-title><source>Proc Natl Acad Sci U S A</source><year>2015</year><volume>112</volume><fpage>E420</fpage><lpage>429</lpage><pub-id pub-id-type="doi">10.1073/pnas.1424576112</pub-id><pub-id pub-id-type="pmid">25605940</pub-id>
</element-citation><mixed-citation id="mc-CR533" publication-type="journal">Ploper D, Taelman VF, Robert L, Perez BS, Titz B, Chen HW, et al. MITF drives endolysosomal biogenesis and potentiates Wnt signaling in melanoma cells. Proc Natl Acad Sci U S A. 2015;112:E420-429.<pub-id pub-id-type="pmid">25605940</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR534"><label>534.</label><citation-alternatives><element-citation id="ec-CR534" publication-type="journal"><person-group person-group-type="author"><name><surname>Arozarena</surname><given-names>I</given-names></name><name><surname>Bischof</surname><given-names>H</given-names></name><name><surname>Gilby</surname><given-names>D</given-names></name><name><surname>Belloni</surname><given-names>B</given-names></name><name><surname>Dummer</surname><given-names>R</given-names></name><name><surname>Wellbrock</surname><given-names>C</given-names></name></person-group><article-title>In melanoma, beta-catenin is a suppressor of invasion</article-title><source>Oncogene</source><year>2011</year><volume>30</volume><fpage>4531</fpage><lpage>4543</lpage><pub-id pub-id-type="doi">10.1038/onc.2011.162</pub-id><pub-id pub-id-type="pmid">21577209</pub-id>
</element-citation><mixed-citation id="mc-CR534" publication-type="journal">Arozarena I, Bischof H, Gilby D, Belloni B, Dummer R, Wellbrock C. In melanoma, beta-catenin is a suppressor of invasion. Oncogene. 2011;30:4531&#x02013;43.<pub-id pub-id-type="pmid">21577209</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR535"><label>535.</label><citation-alternatives><element-citation id="ec-CR535" publication-type="journal"><person-group person-group-type="author"><name><surname>Hess</surname><given-names>AR</given-names></name><name><surname>Seftor</surname><given-names>EA</given-names></name><name><surname>Seftor</surname><given-names>RE</given-names></name><name><surname>Hendrix</surname><given-names>MJ</given-names></name></person-group><article-title>Phosphoinositide 3-kinase regulates membrane type 1-matrix metalloproteinase (MMP) and MMP-2 activity during melanoma cell vasculogenic mimicry</article-title><source>Cancer Res</source><year>2003</year><volume>63</volume><fpage>4757</fpage><lpage>4762</lpage><pub-id pub-id-type="pmid">12941789</pub-id>
</element-citation><mixed-citation id="mc-CR535" publication-type="journal">Hess AR, Seftor EA, Seftor RE, Hendrix MJ. Phosphoinositide 3-kinase regulates membrane type 1-matrix metalloproteinase (MMP) and MMP-2 activity during melanoma cell vasculogenic mimicry. Cancer Res. 2003;63:4757&#x02013;62.<pub-id pub-id-type="pmid">12941789</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR536"><label>536.</label><citation-alternatives><element-citation id="ec-CR536" publication-type="journal"><person-group person-group-type="author"><name><surname>Hess</surname><given-names>AR</given-names></name><name><surname>Margaryan</surname><given-names>NV</given-names></name><name><surname>Seftor</surname><given-names>EA</given-names></name><name><surname>Hendrix</surname><given-names>MJ</given-names></name></person-group><article-title>Deciphering the signaling events that promote melanoma tumor cell vasculogenic mimicry and their link to embryonic vasculogenesis: role of the Eph receptors</article-title><source>Dev Dyn</source><year>2007</year><volume>236</volume><fpage>3283</fpage><lpage>3296</lpage><pub-id pub-id-type="doi">10.1002/dvdy.21190</pub-id><pub-id pub-id-type="pmid">17557303</pub-id>
</element-citation><mixed-citation id="mc-CR536" publication-type="journal">Hess AR, Margaryan NV, Seftor EA, Hendrix MJ. Deciphering the signaling events that promote melanoma tumor cell vasculogenic mimicry and their link to embryonic vasculogenesis: role of the Eph receptors. Dev Dyn. 2007;236:3283&#x02013;96.<pub-id pub-id-type="pmid">17557303</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR537"><label>537.</label><citation-alternatives><element-citation id="ec-CR537" publication-type="journal"><person-group person-group-type="author"><name><surname>Lacaria</surname><given-names>L</given-names></name><name><surname>Lange</surname><given-names>JR</given-names></name><name><surname>Goldmann</surname><given-names>WH</given-names></name><name><surname>Rico</surname><given-names>F</given-names></name><name><surname>Alonso</surname><given-names>JL</given-names></name></person-group><article-title>&#x003b1;v&#x003b2;3 integrin expression increases elasticity in human melanoma cells</article-title><source>Biochem Biophys Res Commun</source><year>2020</year><volume>525</volume><fpage>836</fpage><lpage>840</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2020.02.156</pub-id><pub-id pub-id-type="pmid">32164941</pub-id>
</element-citation><mixed-citation id="mc-CR537" publication-type="journal">Lacaria L, Lange JR, Goldmann WH, Rico F, Alonso JL. &#x003b1;v&#x003b2;3 integrin expression increases elasticity in human melanoma cells. Biochem Biophys Res Commun. 2020;525:836&#x02013;40.<pub-id pub-id-type="pmid">32164941</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR538"><label>538.</label><citation-alternatives><element-citation id="ec-CR538" publication-type="journal"><person-group person-group-type="author"><name><surname>Minaei</surname><given-names>E</given-names></name><name><surname>Mueller</surname><given-names>SA</given-names></name><name><surname>Ashford</surname><given-names>B</given-names></name><name><surname>Thind</surname><given-names>AS</given-names></name><name><surname>Mitchell</surname><given-names>J</given-names></name><name><surname>Perry</surname><given-names>JR</given-names></name><etal/></person-group><article-title>Cancer progression gene expression profiling identifies the urokinase plasminogen activator receptor as a biomarker of metastasis in cutaneous squamous cell carcinoma</article-title><source>Front Oncol</source><year>2022</year><volume>12</volume><fpage>835929</fpage><pub-id pub-id-type="doi">10.3389/fonc.2022.835929</pub-id><pub-id pub-id-type="pmid">35480116</pub-id>
</element-citation><mixed-citation id="mc-CR538" publication-type="journal">Minaei E, Mueller SA, Ashford B, Thind AS, Mitchell J, Perry JR, et al. Cancer progression gene expression profiling identifies the urokinase plasminogen activator receptor as a biomarker of metastasis in cutaneous squamous cell carcinoma. Front Oncol. 2022;12: 835929.<pub-id pub-id-type="pmid">35480116</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR539"><label>539.</label><citation-alternatives><element-citation id="ec-CR539" publication-type="journal"><person-group person-group-type="author"><name><surname>Vizkeleti</surname><given-names>L</given-names></name><name><surname>Kiss</surname><given-names>T</given-names></name><name><surname>Koroknai</surname><given-names>V</given-names></name><name><surname>Ecsedi</surname><given-names>S</given-names></name><name><surname>Papp</surname><given-names>O</given-names></name><name><surname>Szasz</surname><given-names>I</given-names></name><etal/></person-group><article-title>Altered integrin expression patterns shown by microarray in human cutaneous melanoma</article-title><source>Melanoma Res</source><year>2017</year><volume>27</volume><fpage>180</fpage><lpage>188</lpage><pub-id pub-id-type="doi">10.1097/CMR.0000000000000322</pub-id><pub-id pub-id-type="pmid">28234767</pub-id>
</element-citation><mixed-citation id="mc-CR539" publication-type="journal">Vizkeleti L, Kiss T, Koroknai V, Ecsedi S, Papp O, Szasz I, et al. Altered integrin expression patterns shown by microarray in human cutaneous melanoma. Melanoma Res. 2017;27:180&#x02013;8.<pub-id pub-id-type="pmid">28234767</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR540"><label>540.</label><mixed-citation publication-type="other">Baart VM, van Duijn C, van Egmond SL, Dijckmeester WA, Jansen JC, Vahrmeijer AL, et al. EGFR and &#x003b1;v&#x003b2;6 as promising targets for molecular imaging of cutaneous and mucosal squamous cell carcinoma of the head and neck region. Cancers (Basel). 2020; 12.</mixed-citation></ref><ref id="CR541"><label>541.</label><citation-alternatives><element-citation id="ec-CR541" publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Abdeen</surname><given-names>AA</given-names></name><name><surname>Wycislo</surname><given-names>KL</given-names></name><name><surname>Fan</surname><given-names>TM</given-names></name><name><surname>Kilian</surname><given-names>KA</given-names></name></person-group><article-title>Interfacial geometry dictates cancer cell tumorigenicity</article-title><source>Nat Mater</source><year>2016</year><volume>15</volume><fpage>856</fpage><lpage>862</lpage><pub-id pub-id-type="doi">10.1038/nmat4610</pub-id><pub-id pub-id-type="pmid">27043781</pub-id>
</element-citation><mixed-citation id="mc-CR541" publication-type="journal">Lee J, Abdeen AA, Wycislo KL, Fan TM, Kilian KA. Interfacial geometry dictates cancer cell tumorigenicity. Nat Mater. 2016;15:856&#x02013;62.<pub-id pub-id-type="pmid">27043781</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR542"><label>542.</label><citation-alternatives><element-citation id="ec-CR542" publication-type="journal"><person-group person-group-type="author"><name><surname>Sil</surname><given-names>H</given-names></name><name><surname>Sen</surname><given-names>T</given-names></name><name><surname>Chatterjee</surname><given-names>A</given-names></name></person-group><article-title>Fibronectin-integrin (alpha5beta1) modulates migration and invasion of murine melanoma cell line B16F10 by involving MMP-9</article-title><source>Oncol Res</source><year>2011</year><volume>19</volume><fpage>335</fpage><lpage>348</lpage><pub-id pub-id-type="doi">10.3727/096504011X13079697132925</pub-id><pub-id pub-id-type="pmid">21936403</pub-id>
</element-citation><mixed-citation id="mc-CR542" publication-type="journal">Sil H, Sen T, Chatterjee A. Fibronectin-integrin (alpha5beta1) modulates migration and invasion of murine melanoma cell line B16F10 by involving MMP-9. Oncol Res. 2011;19:335&#x02013;48.<pub-id pub-id-type="pmid">21936403</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR543"><label>543.</label><citation-alternatives><element-citation id="ec-CR543" publication-type="journal"><person-group person-group-type="author"><name><surname>Mitra</surname><given-names>A</given-names></name><name><surname>Chakrabarti</surname><given-names>J</given-names></name><name><surname>Chatterjee</surname><given-names>A</given-names></name></person-group><article-title>Binding of alpha5 monoclonal antibody to cell surface alpha5beta1 integrin modulates MMP-2 and MMP-7 activity in B16F10 melanoma cells</article-title><source>J Environ Pathol Toxicol Oncol</source><year>2003</year><volume>22</volume><fpage>167</fpage><lpage>178</lpage><pub-id pub-id-type="doi">10.1615/JEnvPathToxOncol.v22.i3.20</pub-id><pub-id pub-id-type="pmid">14529092</pub-id>
</element-citation><mixed-citation id="mc-CR543" publication-type="journal">Mitra A, Chakrabarti J, Chatterjee A. Binding of alpha5 monoclonal antibody to cell surface alpha5beta1 integrin modulates MMP-2 and MMP-7 activity in B16F10 melanoma cells. J Environ Pathol Toxicol Oncol. 2003;22:167&#x02013;78.<pub-id pub-id-type="pmid">14529092</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR544"><label>544.</label><citation-alternatives><element-citation id="ec-CR544" publication-type="journal"><person-group person-group-type="author"><name><surname>Jiao</surname><given-names>Y</given-names></name><name><surname>Feng</surname><given-names>X</given-names></name><name><surname>Zhan</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>R</given-names></name><name><surname>Zheng</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>W</given-names></name><etal/></person-group><article-title>Matrix metalloproteinase-2 promotes &#x003b1;v&#x003b2;3 integrin-mediated adhesion and migration of human melanoma cells by cleaving fibronectin</article-title><source>PLoS ONE</source><year>2012</year><volume>7</volume><fpage>e41591</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0041591</pub-id><pub-id pub-id-type="pmid">22848537</pub-id>
</element-citation><mixed-citation id="mc-CR544" publication-type="journal">Jiao Y, Feng X, Zhan Y, Wang R, Zheng S, Liu W, et al. Matrix metalloproteinase-2 promotes &#x003b1;v&#x003b2;3 integrin-mediated adhesion and migration of human melanoma cells by cleaving fibronectin. PLoS ONE. 2012;7: e41591.<pub-id pub-id-type="pmid">22848537</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR545"><label>545.</label><citation-alternatives><element-citation id="ec-CR545" publication-type="journal"><person-group person-group-type="author"><name><surname>Mahabeleshwar</surname><given-names>GH</given-names></name><name><surname>Byzova</surname><given-names>TV</given-names></name></person-group><article-title>Angiogenesis in melanoma</article-title><source>Semin Oncol</source><year>2007</year><volume>34</volume><fpage>555</fpage><lpage>565</lpage><pub-id pub-id-type="doi">10.1053/j.seminoncol.2007.09.009</pub-id><pub-id pub-id-type="pmid">18083379</pub-id>
</element-citation><mixed-citation id="mc-CR545" publication-type="journal">Mahabeleshwar GH, Byzova TV. Angiogenesis in melanoma. Semin Oncol. 2007;34:555&#x02013;65.<pub-id pub-id-type="pmid">18083379</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR546"><label>546.</label><citation-alternatives><element-citation id="ec-CR546" publication-type="journal"><person-group person-group-type="author"><name><surname>Tebcherani</surname><given-names>AJ</given-names></name><name><surname>de Andrade</surname><given-names>HF</given-names></name><name><surname>Jr., and Sotto MN. </surname></name></person-group><article-title>Diagnostic utility of immunohistochemistry in distinguishing trichoepithelioma and basal cell carcinoma: evaluation using tissue microarray samples</article-title><source>Mod Pathol</source><year>2012</year><volume>25</volume><fpage>1345</fpage><lpage>1353</lpage><pub-id pub-id-type="doi">10.1038/modpathol.2012.96</pub-id><pub-id pub-id-type="pmid">22684216</pub-id>
</element-citation><mixed-citation id="mc-CR546" publication-type="journal">Tebcherani AJ, de Andrade HF, Jr., and Sotto MN. Diagnostic utility of immunohistochemistry in distinguishing trichoepithelioma and basal cell carcinoma: evaluation using tissue microarray samples. Mod Pathol. 2012;25:1345&#x02013;53.<pub-id pub-id-type="pmid">22684216</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR547"><label>547.</label><citation-alternatives><element-citation id="ec-CR547" publication-type="journal"><person-group person-group-type="author"><name><surname>Ke</surname><given-names>H</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Lin</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Sun</surname><given-names>J</given-names></name><name><surname>Massoumi</surname><given-names>R</given-names></name></person-group><article-title>High expression of CD34 and &#x003b1;6-integrin contributes to the cancer-initiating cell behaviour in ultraviolet-induced mouse skin squamous cell carcinoma</article-title><source>J Cancer</source><year>2020</year><volume>11</volume><fpage>6760</fpage><lpage>6767</lpage><pub-id pub-id-type="doi">10.7150/jca.45819</pub-id><pub-id pub-id-type="pmid">33123267</pub-id>
</element-citation><mixed-citation id="mc-CR547" publication-type="journal">Ke H, Yang Y, Lin Y, Liu L, Sun J, Massoumi R. High expression of CD34 and &#x003b1;6-integrin contributes to the cancer-initiating cell behaviour in ultraviolet-induced mouse skin squamous cell carcinoma. J Cancer. 2020;11:6760&#x02013;7.<pub-id pub-id-type="pmid">33123267</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR548"><label>548.</label><citation-alternatives><element-citation id="ec-CR548" publication-type="journal"><person-group person-group-type="author"><name><surname>Breza</surname><given-names>TS</given-names></name><name><surname>Magro</surname><given-names>CM</given-names></name></person-group><article-title>CD34 expression in primary cutaneous malignant melanoma: apropos of a case and review of the aberrant melanoma phenotype</article-title><source>J Cutan Pathol</source><year>2005</year><volume>32</volume><fpage>685</fpage><lpage>689</lpage><pub-id pub-id-type="doi">10.1111/j.0303-6987.2005.00367.x</pub-id><pub-id pub-id-type="pmid">16293181</pub-id>
</element-citation><mixed-citation id="mc-CR548" publication-type="journal">Breza TS, Magro CM. CD34 expression in primary cutaneous malignant melanoma: apropos of a case and review of the aberrant melanoma phenotype. J Cutan Pathol. 2005;32:685&#x02013;9.<pub-id pub-id-type="pmid">16293181</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR549"><label>549.</label><citation-alternatives><element-citation id="ec-CR549" publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Q</given-names></name><name><surname>Nie</surname><given-names>R</given-names></name><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Zhou</surname><given-names>H</given-names></name><name><surname>Lu</surname><given-names>H</given-names></name><etal/></person-group><article-title>Identification of subtypes correlated with tumor immunity and immunotherapy in cutaneous melanoma</article-title><source>Comput Struct Biotechnol J</source><year>2021</year><volume>19</volume><fpage>4472</fpage><lpage>4485</lpage><pub-id pub-id-type="doi">10.1016/j.csbj.2021.08.005</pub-id><pub-id pub-id-type="pmid">34471493</pub-id>
</element-citation><mixed-citation id="mc-CR549" publication-type="journal">Liu Q, Nie R, Li M, Li L, Zhou H, Lu H, et al. Identification of subtypes correlated with tumor immunity and immunotherapy in cutaneous melanoma. Comput Struct Biotechnol J. 2021;19:4472&#x02013;85.<pub-id pub-id-type="pmid">34471493</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR550"><label>550.</label><citation-alternatives><element-citation id="ec-CR550" publication-type="journal"><person-group person-group-type="author"><name><surname>Hoek</surname><given-names>KS</given-names></name><name><surname>Goding</surname><given-names>CR</given-names></name></person-group><article-title>Cancer stem cells versus phenotype-switching in melanoma</article-title><source>Pigment Cell Melanoma Res</source><year>2010</year><volume>23</volume><fpage>746</fpage><lpage>759</lpage><pub-id pub-id-type="doi">10.1111/j.1755-148X.2010.00757.x</pub-id><pub-id pub-id-type="pmid">20726948</pub-id>
</element-citation><mixed-citation id="mc-CR550" publication-type="journal">Hoek KS, Goding CR. Cancer stem cells versus phenotype-switching in melanoma. Pigment Cell Melanoma Res. 2010;23:746&#x02013;59.<pub-id pub-id-type="pmid">20726948</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR551"><label>551.</label><citation-alternatives><element-citation id="ec-CR551" publication-type="journal"><person-group person-group-type="author"><name><surname>Ennen</surname><given-names>M</given-names></name><name><surname>Keime</surname><given-names>C</given-names></name><name><surname>Gambi</surname><given-names>G</given-names></name><name><surname>Kieny</surname><given-names>A</given-names></name><name><surname>Coassolo</surname><given-names>S</given-names></name><name><surname>Thibault-Carpentier</surname><given-names>C</given-names></name><etal/></person-group><article-title>MITF-high and MITF-low cells and a novel subpopulation expressing genes of both cell states contribute to intra- and intertumoral heterogeneity of primary melanoma</article-title><source>Clin Cancer Res</source><year>2017</year><volume>23</volume><fpage>7097</fpage><lpage>7107</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-17-0010</pub-id><pub-id pub-id-type="pmid">28855355</pub-id>
</element-citation><mixed-citation id="mc-CR551" publication-type="journal">Ennen M, Keime C, Gambi G, Kieny A, Coassolo S, Thibault-Carpentier C, et al. MITF-high and MITF-low cells and a novel subpopulation expressing genes of both cell states contribute to intra- and intertumoral heterogeneity of primary melanoma. Clin Cancer Res. 2017;23:7097&#x02013;107.<pub-id pub-id-type="pmid">28855355</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR552"><label>552.</label><citation-alternatives><element-citation id="ec-CR552" publication-type="journal"><person-group person-group-type="author"><name><surname>Pozniak</surname><given-names>J</given-names></name><name><surname>Pedri</surname><given-names>D</given-names></name><name><surname>Landeloos</surname><given-names>E</given-names></name><name><surname>Van Herck</surname><given-names>Y</given-names></name><name><surname>Antoranz</surname><given-names>A</given-names></name><name><surname>Vanwynsberghe</surname><given-names>L</given-names></name><etal/></person-group><article-title>A TCF4-dependent gene regulatory network confers resistance to immunotherapy in melanoma</article-title><source>Cell</source><year>2024</year><volume>187</volume><fpage>166</fpage><lpage>183.e25</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2023.11.037</pub-id><pub-id pub-id-type="pmid">38181739</pub-id>
</element-citation><mixed-citation id="mc-CR552" publication-type="journal">Pozniak J, Pedri D, Landeloos E, Van Herck Y, Antoranz A, Vanwynsberghe L, et al. A TCF4-dependent gene regulatory network confers resistance to immunotherapy in melanoma. Cell. 2024;187:166-183.e25.<pub-id pub-id-type="pmid">38181739</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR553"><label>553.</label><mixed-citation publication-type="other">Zeng Z, Veitch M, Kelly GA, Tuong ZK, Cruz JG, Frazer IH, et al. IFN-&#x003b3; critically enables the intratumoural infiltration of CXCR3(+) CD8(+) T cells to drive squamous cell carcinoma regression<italic>.</italic> Cancers (Basel). 2021; 13.</mixed-citation></ref><ref id="CR554"><label>554.</label><citation-alternatives><element-citation id="ec-CR554" publication-type="journal"><person-group person-group-type="author"><name><surname>Toyoda</surname><given-names>H</given-names></name><name><surname>Ido</surname><given-names>M</given-names></name><name><surname>Nakanishi</surname><given-names>K</given-names></name><name><surname>Nakano</surname><given-names>T</given-names></name><name><surname>Kamiya</surname><given-names>H</given-names></name><name><surname>Matsumine</surname><given-names>A</given-names></name><etal/></person-group><article-title>Multiple cutaneous squamous cell carcinomas in a patient with interferon gamma receptor 2 (IFN gamma R2) deficiency</article-title><source>J Med Genet</source><year>2010</year><volume>47</volume><fpage>631</fpage><lpage>634</lpage><pub-id pub-id-type="doi">10.1136/jmg.2009.072108</pub-id><pub-id pub-id-type="pmid">20587411</pub-id>
</element-citation><mixed-citation id="mc-CR554" publication-type="journal">Toyoda H, Ido M, Nakanishi K, Nakano T, Kamiya H, Matsumine A, et al. Multiple cutaneous squamous cell carcinomas in a patient with interferon gamma receptor 2 (IFN gamma R2) deficiency. J Med Genet. 2010;47:631&#x02013;4.<pub-id pub-id-type="pmid">20587411</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR555"><label>555.</label><citation-alternatives><element-citation id="ec-CR555" publication-type="journal"><person-group person-group-type="author"><name><surname>Herwig-Carl</surname><given-names>MC</given-names></name><name><surname>Loeffler</surname><given-names>KU</given-names></name></person-group><article-title>Regression of periocular basal cell carcinoma: a report of four cases with clinicopathologic correlation</article-title><source>Ocul Oncol Pathol</source><year>2020</year><volume>6</volume><fpage>107</fpage><lpage>114</lpage><pub-id pub-id-type="doi">10.1159/000501370</pub-id><pub-id pub-id-type="pmid">32258018</pub-id>
</element-citation><mixed-citation id="mc-CR555" publication-type="journal">Herwig-Carl MC, Loeffler KU. Regression of periocular basal cell carcinoma: a report of four cases with clinicopathologic correlation. Ocul Oncol Pathol. 2020;6:107&#x02013;14.<pub-id pub-id-type="pmid">32258018</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR556"><label>556.</label><citation-alternatives><element-citation id="ec-CR556" publication-type="journal"><person-group person-group-type="author"><name><surname>Propper</surname><given-names>DJ</given-names></name><name><surname>Chao</surname><given-names>D</given-names></name><name><surname>Braybrooke</surname><given-names>JP</given-names></name><name><surname>Bahl</surname><given-names>P</given-names></name><name><surname>Thavasu</surname><given-names>P</given-names></name><name><surname>Balkwill</surname><given-names>F</given-names></name><etal/></person-group><article-title>Low-dose IFN-gamma induces tumor MHC expression in metastatic malignant melanoma</article-title><source>Clin Cancer Res</source><year>2003</year><volume>9</volume><fpage>84</fpage><lpage>92</lpage><pub-id pub-id-type="pmid">12538455</pub-id>
</element-citation><mixed-citation id="mc-CR556" publication-type="journal">Propper DJ, Chao D, Braybrooke JP, Bahl P, Thavasu P, Balkwill F, et al. Low-dose IFN-gamma induces tumor MHC expression in metastatic malignant melanoma. Clin Cancer Res. 2003;9:84&#x02013;92.<pub-id pub-id-type="pmid">12538455</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR557"><label>557.</label><mixed-citation publication-type="other">Davar D, Wang H, Chauvin JM, Pagliano O, Fourcade JJ, Ka M, et al. Phase Ib/II study of pembrolizumab and pegylated-interferon alfa-2b in advanced melanoma<italic>.</italic> J Clin Oncol. 2018; 36:Jco1800632.</mixed-citation></ref><ref id="CR558"><label>558.</label><citation-alternatives><element-citation id="ec-CR558" publication-type="journal"><person-group person-group-type="author"><name><surname>Donia</surname><given-names>M</given-names></name><name><surname>Hansen</surname><given-names>M</given-names></name><name><surname>Sendrup</surname><given-names>SL</given-names></name><name><surname>Iversen</surname><given-names>TZ</given-names></name><name><surname>Elleb&#x000e6;k</surname><given-names>E</given-names></name><name><surname>Andersen</surname><given-names>MH</given-names></name><etal/></person-group><article-title>Methods to improve adoptive T-cell therapy for melanoma: IFN-&#x003b3; enhances anticancer responses of cell products for infusion</article-title><source>J Invest Dermatol</source><year>2013</year><volume>133</volume><fpage>545</fpage><lpage>552</lpage><pub-id pub-id-type="doi">10.1038/jid.2012.336</pub-id><pub-id pub-id-type="pmid">23014345</pub-id>
</element-citation><mixed-citation id="mc-CR558" publication-type="journal">Donia M, Hansen M, Sendrup SL, Iversen TZ, Elleb&#x000e6;k E, Andersen MH, et al. Methods to improve adoptive T-cell therapy for melanoma: IFN-&#x003b3; enhances anticancer responses of cell products for infusion. J Invest Dermatol. 2013;133:545&#x02013;52.<pub-id pub-id-type="pmid">23014345</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR559"><label>559.</label><citation-alternatives><element-citation id="ec-CR559" publication-type="journal"><person-group person-group-type="author"><name><surname>Buferne</surname><given-names>M</given-names></name><name><surname>Chasson</surname><given-names>L</given-names></name><name><surname>Grange</surname><given-names>M</given-names></name><name><surname>Mas</surname><given-names>A</given-names></name><name><surname>Arnoux</surname><given-names>F</given-names></name><name><surname>Bertuzzi</surname><given-names>M</given-names></name><etal/></person-group><article-title>IFN&#x003b3; producing CD8(+) T cells modified to resist major immune checkpoints induce regression of MHC class I-deficient melanomas</article-title><source>Oncoimmunology</source><year>2015</year><volume>4</volume><fpage>e974959</fpage><pub-id pub-id-type="doi">10.4161/2162402X.2014.974959</pub-id><pub-id pub-id-type="pmid">25949872</pub-id>
</element-citation><mixed-citation id="mc-CR559" publication-type="journal">Buferne M, Chasson L, Grange M, Mas A, Arnoux F, Bertuzzi M, et al. IFN&#x003b3; producing CD8(+) T cells modified to resist major immune checkpoints induce regression of MHC class I-deficient melanomas. Oncoimmunology. 2015;4: e974959.<pub-id pub-id-type="pmid">25949872</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR560"><label>560.</label><citation-alternatives><element-citation id="ec-CR560" publication-type="journal"><person-group person-group-type="author"><name><surname>Subhadarshini</surname><given-names>S</given-names></name><name><surname>Sahoo</surname><given-names>S</given-names></name><name><surname>Debnath</surname><given-names>S</given-names></name><name><surname>Somarelli</surname><given-names>JA</given-names></name><name><surname>Jolly</surname><given-names>MK</given-names></name></person-group><article-title>Dynamical modeling of proliferative-invasive plasticity and IFN&#x003b3; signaling in melanoma reveals mechanisms of PD-L1 expression heterogeneity</article-title><source>J Immunother Cancer</source><year>2023</year><volume>11</volume><fpage>e006766</fpage><pub-id pub-id-type="doi">10.1136/jitc-2023-006766</pub-id><pub-id pub-id-type="pmid">37678920</pub-id>
</element-citation><mixed-citation id="mc-CR560" publication-type="journal">Subhadarshini S, Sahoo S, Debnath S, Somarelli JA, Jolly MK. Dynamical modeling of proliferative-invasive plasticity and IFN&#x003b3; signaling in melanoma reveals mechanisms of PD-L1 expression heterogeneity. J Immunother Cancer. 2023;11: e006766.<pub-id pub-id-type="pmid">37678920</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR561"><label>561.</label><citation-alternatives><element-citation id="ec-CR561" publication-type="journal"><person-group person-group-type="author"><name><surname>S&#x000e6;varsson</surname><given-names>T</given-names></name><name><surname>de Lomana</surname><given-names>ALG</given-names></name><name><surname>S&#x000e1;nchez</surname><given-names>&#x000d3;</given-names></name><name><surname>van Esch</surname><given-names>V</given-names></name><name><surname>Ragnarsson</surname><given-names>GB</given-names></name><name><surname>Brynj&#x000f3;lfsson</surname><given-names>SF</given-names></name><etal/></person-group><article-title>Differentiation status determines the effects of IFN&#x003b3; on the expression of PD-L1 and immunomodulatory genes in melanoma</article-title><source>Cell Commun Signal</source><year>2024</year><volume>22</volume><fpage>618</fpage><pub-id pub-id-type="doi">10.1186/s12964-024-01963-6</pub-id><pub-id pub-id-type="pmid">39736644</pub-id>
</element-citation><mixed-citation id="mc-CR561" publication-type="journal">S&#x000e6;varsson T, de Lomana ALG, S&#x000e1;nchez &#x000d3;, van Esch V, Ragnarsson GB, Brynj&#x000f3;lfsson SF, et al. Differentiation status determines the effects of IFN&#x003b3; on the expression of PD-L1 and immunomodulatory genes in melanoma. Cell Commun Signal. 2024;22:618.<pub-id pub-id-type="pmid">39736644</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR562"><label>562.</label><citation-alternatives><element-citation id="ec-CR562" publication-type="journal"><person-group person-group-type="author"><name><surname>Otsuka</surname><given-names>A</given-names></name><name><surname>Dreier</surname><given-names>J</given-names></name><name><surname>Cheng</surname><given-names>PF</given-names></name><name><surname>N&#x000e4;geli</surname><given-names>M</given-names></name><name><surname>Lehmann</surname><given-names>H</given-names></name><name><surname>Felderer</surname><given-names>L</given-names></name><etal/></person-group><article-title>Hedgehog pathway inhibitors promote adaptive immune responses in basal cell carcinoma</article-title><source>Clin Cancer Res</source><year>2015</year><volume>21</volume><fpage>1289</fpage><lpage>1297</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-14-2110</pub-id><pub-id pub-id-type="pmid">25593302</pub-id>
</element-citation><mixed-citation id="mc-CR562" publication-type="journal">Otsuka A, Dreier J, Cheng PF, N&#x000e4;geli M, Lehmann H, Felderer L, et al. Hedgehog pathway inhibitors promote adaptive immune responses in basal cell carcinoma. Clin Cancer Res. 2015;21:1289&#x02013;97.<pub-id pub-id-type="pmid">25593302</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR563"><label>563.</label><citation-alternatives><element-citation id="ec-CR563" publication-type="journal"><person-group person-group-type="author"><name><surname>Dessinioti</surname><given-names>C</given-names></name><name><surname>Stratigos</surname><given-names>AJ</given-names></name></person-group><article-title>Immunotherapy and its timing in advanced basal cell carcinoma treatment</article-title><source>Dermatol Pract Concept</source><year>2023</year><volume>13</volume><fpage>e2023252</fpage><pub-id pub-id-type="doi">10.5826/dpc.1304a252</pub-id><pub-id pub-id-type="pmid">37992360</pub-id>
</element-citation><mixed-citation id="mc-CR563" publication-type="journal">Dessinioti C, Stratigos AJ. Immunotherapy and its timing in advanced basal cell carcinoma treatment. Dermatol Pract Concept. 2023;13: e2023252.<pub-id pub-id-type="pmid">37992360</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR564"><label>564.</label><citation-alternatives><element-citation id="ec-CR564" publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>J</given-names></name><name><surname>Zhu</surname><given-names>GA</given-names></name><name><surname>Cheung</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Chang</surname><given-names>AL</given-names></name></person-group><article-title>Association between programmed death ligand 1 expression in patients with basal cell carcinomas and the number of treatment modalities</article-title><source>JAMA Dermatol</source><year>2017</year><volume>153</volume><fpage>285</fpage><lpage>290</lpage><pub-id pub-id-type="doi">10.1001/jamadermatol.2016.5062</pub-id><pub-id pub-id-type="pmid">28259105</pub-id>
</element-citation><mixed-citation id="mc-CR564" publication-type="journal">Chang J, Zhu GA, Cheung C, Li S, Kim J, Chang AL. Association between programmed death ligand 1 expression in patients with basal cell carcinomas and the number of treatment modalities. JAMA Dermatol. 2017;153:285&#x02013;90.<pub-id pub-id-type="pmid">28259105</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR565"><label>565.</label><mixed-citation publication-type="other">FDA approves cemiplimab-rwlc for locally advanced and metastatic basal cell carcinoma. FDA. 2022. <ext-link ext-link-type="uri" xlink:href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-cemiplimab-rwlc-locally-advanced-and-metastatic-basal-cell-carcinoma">https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-cemiplimab-rwlc-locally-advanced-and-metastatic-basal-cell-carcinoma</ext-link>.</mixed-citation></ref><ref id="CR566"><label>566.</label><citation-alternatives><element-citation id="ec-CR566" publication-type="journal"><person-group person-group-type="author"><name><surname>Stratigos</surname><given-names>AJ</given-names></name><name><surname>Sekulic</surname><given-names>A</given-names></name><name><surname>Peris</surname><given-names>K</given-names></name><name><surname>Bechter</surname><given-names>O</given-names></name><name><surname>Prey</surname><given-names>S</given-names></name><name><surname>Kaatz</surname><given-names>M</given-names></name><etal/></person-group><article-title>Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial</article-title><source>Lancet Oncol</source><year>2021</year><volume>22</volume><fpage>848</fpage><lpage>857</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(21)00126-1</pub-id><pub-id pub-id-type="pmid">34000246</pub-id>
</element-citation><mixed-citation id="mc-CR566" publication-type="journal">Stratigos AJ, Sekulic A, Peris K, Bechter O, Prey S, Kaatz M, et al. Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial. Lancet Oncol. 2021;22:848&#x02013;57.<pub-id pub-id-type="pmid">34000246</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR567"><label>567.</label><citation-alternatives><element-citation id="ec-CR567" publication-type="journal"><person-group person-group-type="author"><name><surname>Lewis</surname><given-names>KD</given-names></name><name><surname>Peris</surname><given-names>K</given-names></name><name><surname>Sekulic</surname><given-names>A</given-names></name><name><surname>Stratigos</surname><given-names>AJ</given-names></name><name><surname>Dunn</surname><given-names>L</given-names></name><name><surname>Eroglu</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Final analysis of phase II results with cemiplimab in metastatic basal cell carcinoma after hedgehog pathway inhibitors</article-title><source>Ann Oncol</source><year>2024</year><volume>35</volume><fpage>221</fpage><lpage>228</lpage><pub-id pub-id-type="doi">10.1016/j.annonc.2023.10.123</pub-id><pub-id pub-id-type="pmid">38072158</pub-id>
</element-citation><mixed-citation id="mc-CR567" publication-type="journal">Lewis KD, Peris K, Sekulic A, Stratigos AJ, Dunn L, Eroglu Z, et al. Final analysis of phase II results with cemiplimab in metastatic basal cell carcinoma after hedgehog pathway inhibitors. Ann Oncol. 2024;35:221&#x02013;8.<pub-id pub-id-type="pmid">38072158</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR568"><label>568.</label><citation-alternatives><element-citation id="ec-CR568" publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>ALS</given-names></name><name><surname>Tran</surname><given-names>DC</given-names></name><name><surname>Cannon</surname><given-names>JGD</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Jeng</surname><given-names>M</given-names></name><name><surname>Patel</surname><given-names>R</given-names></name><etal/></person-group><article-title>Pembrolizumab for advanced basal cell carcinoma: An investigator-initiated, proof-of-concept study</article-title><source>J Am Acad Dermatol</source><year>2019</year><volume>80</volume><fpage>564</fpage><lpage>566</lpage><pub-id pub-id-type="doi">10.1016/j.jaad.2018.08.017</pub-id><pub-id pub-id-type="pmid">30145186</pub-id>
</element-citation><mixed-citation id="mc-CR568" publication-type="journal">Chang ALS, Tran DC, Cannon JGD, Li S, Jeng M, Patel R, et al. Pembrolizumab for advanced basal cell carcinoma: An investigator-initiated, proof-of-concept study. J Am Acad Dermatol. 2019;80:564&#x02013;6.<pub-id pub-id-type="pmid">30145186</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR569"><label>569.</label><citation-alternatives><element-citation id="ec-CR569" publication-type="journal"><person-group person-group-type="author"><name><surname>Quandt</surname><given-names>Z</given-names></name><name><surname>Jacob</surname><given-names>S</given-names></name><name><surname>Fadlullah</surname><given-names>MZH</given-names></name><name><surname>Wu</surname><given-names>C</given-names></name><name><surname>Wu</surname><given-names>C</given-names></name><name><surname>Huppert</surname><given-names>L</given-names></name><etal/></person-group><article-title>Phase II trial of pembrolizumab, ipilimumab, and aspirin in melanoma: clinical outcomes and translational predictors of response</article-title><source>BJC Reports</source><year>2024</year><volume>2</volume><fpage>46</fpage><pub-id pub-id-type="doi">10.1038/s44276-024-00057-7</pub-id><pub-id pub-id-type="pmid">39516257</pub-id>
</element-citation><mixed-citation id="mc-CR569" publication-type="journal">Quandt Z, Jacob S, Fadlullah MZH, Wu C, Wu C, Huppert L, et al. Phase II trial of pembrolizumab, ipilimumab, and aspirin in melanoma: clinical outcomes and translational predictors of response. BJC Reports. 2024;2:46.<pub-id pub-id-type="pmid">39516257</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR570"><label>570.</label><citation-alternatives><element-citation id="ec-CR570" publication-type="journal"><person-group person-group-type="author"><name><surname>Spranger</surname><given-names>S</given-names></name><name><surname>Bao</surname><given-names>R</given-names></name><name><surname>Gajewski</surname><given-names>TF</given-names></name></person-group><article-title>Melanoma-intrinsic &#x003b2;-catenin signalling prevents anti-tumour immunity</article-title><source>Nature</source><year>2015</year><volume>523</volume><fpage>231</fpage><lpage>235</lpage><pub-id pub-id-type="doi">10.1038/nature14404</pub-id><pub-id pub-id-type="pmid">25970248</pub-id>
</element-citation><mixed-citation id="mc-CR570" publication-type="journal">Spranger S, Bao R, Gajewski TF. Melanoma-intrinsic &#x003b2;-catenin signalling prevents anti-tumour immunity. Nature. 2015;523:231&#x02013;5.<pub-id pub-id-type="pmid">25970248</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR571"><label>571.</label><citation-alternatives><element-citation id="ec-CR571" publication-type="journal"><person-group person-group-type="author"><name><surname>DeVito</surname><given-names>NC</given-names></name><name><surname>Sturdivant</surname><given-names>M</given-names></name><name><surname>Thievanthiran</surname><given-names>B</given-names></name><name><surname>Xiao</surname><given-names>C</given-names></name><name><surname>Plebanek</surname><given-names>MP</given-names></name><name><surname>Salama</surname><given-names>AKS</given-names></name><etal/></person-group><article-title>Pharmacological Wnt ligand inhibition overcomes key tumor-mediated resistance pathways to anti-PD-1 immunotherapy</article-title><source>Cell Rep</source><year>2021</year><volume>35</volume><fpage>109071</fpage><pub-id pub-id-type="doi">10.1016/j.celrep.2021.109071</pub-id><pub-id pub-id-type="pmid">33951424</pub-id>
</element-citation><mixed-citation id="mc-CR571" publication-type="journal">DeVito NC, Sturdivant M, Thievanthiran B, Xiao C, Plebanek MP, Salama AKS, et al. Pharmacological Wnt ligand inhibition overcomes key tumor-mediated resistance pathways to anti-PD-1 immunotherapy. Cell Rep. 2021;35: 109071.<pub-id pub-id-type="pmid">33951424</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR572"><label>572.</label><citation-alternatives><element-citation id="ec-CR572" publication-type="journal"><person-group person-group-type="author"><name><surname>Fukuda</surname><given-names>Y</given-names></name><name><surname>Kim</surname><given-names>SH</given-names></name><name><surname>Bustos</surname><given-names>MA</given-names></name><name><surname>Cho</surname><given-names>SN</given-names></name><name><surname>Roszik</surname><given-names>J</given-names></name><name><surname>Burks</surname><given-names>JK</given-names></name><etal/></person-group><article-title>Inhibition of microsomal prostaglandin E2 synthase reduces collagen deposition in melanoma tumors and may improve immunotherapy efficacy by reducing T-cell exhaustion</article-title><source>Cancer Res Commun</source><year>2023</year><volume>3</volume><fpage>1397</fpage><lpage>1408</lpage><pub-id pub-id-type="doi">10.1158/2767-9764.CRC-23-0210</pub-id><pub-id pub-id-type="pmid">37529399</pub-id>
</element-citation><mixed-citation id="mc-CR572" publication-type="journal">Fukuda Y, Kim SH, Bustos MA, Cho SN, Roszik J, Burks JK, et al. Inhibition of microsomal prostaglandin E2 synthase reduces collagen deposition in melanoma tumors and may improve immunotherapy efficacy by reducing T-cell exhaustion. Cancer Res Commun. 2023;3:1397&#x02013;408.<pub-id pub-id-type="pmid">37529399</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR573"><label>573.</label><mixed-citation publication-type="other">Wang SJ, Khullar K, Kim S, Yegya-Raman N, Malhotra J, Groisberg R, et al. Effect of cyclo-oxygenase inhibitor use during checkpoint blockade immunotherapy in patients with metastatic melanoma and non-small cell lung cancer. J Immunother Cancer. 2020;8:e000889.</mixed-citation></ref><ref id="CR574"><label>574.</label><citation-alternatives><element-citation id="ec-CR574" publication-type="journal"><person-group person-group-type="author"><name><surname>Long</surname><given-names>GV</given-names></name><name><surname>Robert</surname><given-names>C</given-names></name><name><surname>Butler</surname><given-names>MO</given-names></name><name><surname>Couture</surname><given-names>F</given-names></name><name><surname>Carlino</surname><given-names>MS</given-names></name><name><surname>O&#x02019;Day</surname><given-names>S</given-names></name><etal/></person-group><article-title>Standard-dose pembrolizumab plus alternate-dose ipilimumab in advanced melanoma: KEYNOTE-029 cohort 1C, a phase 2 randomized study of two dosing schedules</article-title><source>Clin Cancer Res</source><year>2021</year><volume>27</volume><fpage>5280</fpage><lpage>5288</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-21-0793</pub-id><pub-id pub-id-type="pmid">34210681</pub-id>
</element-citation><mixed-citation id="mc-CR574" publication-type="journal">Long GV, Robert C, Butler MO, Couture F, Carlino MS, O&#x02019;Day S, et al. Standard-dose pembrolizumab plus alternate-dose ipilimumab in advanced melanoma: KEYNOTE-029 cohort 1C, a phase 2 randomized study of two dosing schedules. Clin Cancer Res. 2021;27:5280&#x02013;8.<pub-id pub-id-type="pmid">34210681</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR575"><label>575.</label><citation-alternatives><element-citation id="ec-CR575" publication-type="journal"><person-group person-group-type="author"><name><surname>Kakavand</surname><given-names>H</given-names></name><name><surname>Rawson</surname><given-names>RV</given-names></name><name><surname>Pupo</surname><given-names>GM</given-names></name><name><surname>Yang</surname><given-names>JY</given-names></name><name><surname>Menzies</surname><given-names>AM</given-names></name><name><surname>Carlino</surname><given-names>MS</given-names></name><etal/></person-group><article-title>PD-L1 expression and immune escape in melanoma resistance to MAPK inhibitors</article-title><source>Clin Cancer Res</source><year>2017</year><volume>23</volume><fpage>6054</fpage><lpage>6061</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-16-1688</pub-id><pub-id pub-id-type="pmid">28724663</pub-id>
</element-citation><mixed-citation id="mc-CR575" publication-type="journal">Kakavand H, Rawson RV, Pupo GM, Yang JY, Menzies AM, Carlino MS, et al. PD-L1 expression and immune escape in melanoma resistance to MAPK inhibitors. Clin Cancer Res. 2017;23:6054&#x02013;61.<pub-id pub-id-type="pmid">28724663</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR576"><label>576.</label><citation-alternatives><element-citation id="ec-CR576" publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>MH</given-names></name><name><surname>Kim</surname><given-names>CG</given-names></name><name><surname>Kim</surname><given-names>S-K</given-names></name><name><surname>Shin</surname><given-names>SJ</given-names></name><name><surname>Choe</surname><given-names>EA</given-names></name><name><surname>Park</surname><given-names>S-H</given-names></name><etal/></person-group><article-title>YAP-Induced PD-L1 expression drives immune evasion in BRAFi-resistant melanoma YAP promotes immune evasion by PD-L1 upregulation</article-title><source>Cancer Immunol Res</source><year>2018</year><volume>6</volume><fpage>255</fpage><lpage>266</lpage><pub-id pub-id-type="doi">10.1158/2326-6066.CIR-17-0320</pub-id><pub-id pub-id-type="pmid">29382670</pub-id>
</element-citation><mixed-citation id="mc-CR576" publication-type="journal">Kim MH, Kim CG, Kim S-K, Shin SJ, Choe EA, Park S-H, et al. YAP-Induced PD-L1 expression drives immune evasion in BRAFi-resistant melanoma YAP promotes immune evasion by PD-L1 upregulation. Cancer Immunol Res. 2018;6:255&#x02013;66.<pub-id pub-id-type="pmid">29382670</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR577"><label>577.</label><citation-alternatives><element-citation id="ec-CR577" publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>KB</given-names></name><name><surname>Prieto</surname><given-names>V</given-names></name><name><surname>Joseph</surname><given-names>RW</given-names></name><name><surname>Diwan</surname><given-names>AH</given-names></name><name><surname>Gallick</surname><given-names>GE</given-names></name><name><surname>Papadopoulos</surname><given-names>NE</given-names></name><etal/></person-group><article-title>A randomized phase II study of cilengitide (EMD 121974) in patients with metastatic melanoma</article-title><source>Melanoma Res</source><year>2012</year><volume>22</volume><fpage>294</fpage><lpage>301</lpage><pub-id pub-id-type="doi">10.1097/CMR.0b013e32835312e4</pub-id><pub-id pub-id-type="pmid">22668797</pub-id>
</element-citation><mixed-citation id="mc-CR577" publication-type="journal">Kim KB, Prieto V, Joseph RW, Diwan AH, Gallick GE, Papadopoulos NE, et al. A randomized phase II study of cilengitide (EMD 121974) in patients with metastatic melanoma. Melanoma Res. 2012;22:294&#x02013;301.<pub-id pub-id-type="pmid">22668797</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR578"><label>578.</label><citation-alternatives><element-citation id="ec-CR578" publication-type="journal"><person-group person-group-type="author"><name><surname>Su</surname><given-names>X</given-names></name><name><surname>Esser</surname><given-names>AK</given-names></name><name><surname>Amend</surname><given-names>SR</given-names></name><name><surname>Xiang</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Ross</surname><given-names>MH</given-names></name><etal/></person-group><article-title>Antagonizing integrin &#x003b2;3 increases immunosuppression in cancer</article-title><source>Cancer Res</source><year>2016</year><volume>76</volume><fpage>3484</fpage><lpage>3495</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-15-2663</pub-id><pub-id pub-id-type="pmid">27216180</pub-id>
</element-citation><mixed-citation id="mc-CR578" publication-type="journal">Su X, Esser AK, Amend SR, Xiang J, Xu Y, Ross MH, et al. Antagonizing integrin &#x003b2;3 increases immunosuppression in cancer. Cancer Res. 2016;76:3484&#x02013;95.<pub-id pub-id-type="pmid">27216180</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR579"><label>579.</label><citation-alternatives><element-citation id="ec-CR579" publication-type="journal"><person-group person-group-type="author"><name><surname>Du</surname><given-names>Y</given-names></name><name><surname>Shao</surname><given-names>H</given-names></name><name><surname>Moller</surname><given-names>M</given-names></name><name><surname>Prokupets</surname><given-names>R</given-names></name><name><surname>Tse</surname><given-names>YT</given-names></name><name><surname>Liu</surname><given-names>ZJ</given-names></name></person-group><article-title>Intracellular Notch1 signaling in cancer-associated fibroblasts dictates the plasticity and stemness of melanoma stem/initiating cells</article-title><source>Stem Cells</source><year>2019</year><volume>37</volume><fpage>865</fpage><lpage>875</lpage><pub-id pub-id-type="doi">10.1002/stem.3013</pub-id><pub-id pub-id-type="pmid">30941836</pub-id>
</element-citation><mixed-citation id="mc-CR579" publication-type="journal">Du Y, Shao H, Moller M, Prokupets R, Tse YT, Liu ZJ. Intracellular Notch1 signaling in cancer-associated fibroblasts dictates the plasticity and stemness of melanoma stem/initiating cells. Stem Cells. 2019;37:865&#x02013;75.<pub-id pub-id-type="pmid">30941836</pub-id>
</mixed-citation></citation-alternatives></ref></ref-list></back></article>